<SEC-DOCUMENT>0000200406-21-000036.txt : 20210430
<SEC-HEADER>0000200406-21-000036.hdr.sgml : 20210430
<ACCEPTANCE-DATETIME>20210430160402
ACCESSION NUMBER:		0000200406-21-000036
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20210404
FILED AS OF DATE:		20210430
DATE AS OF CHANGE:		20210430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		21877749

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>jnj-20210404.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:1a2ac66c-2667-4890-bd3c-b889272a48e4,g:4415be36-51dc-414c-a907-a89d836331d3,d:0699d70253b44b9fbc20ae5610df4e69--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:jnj="http://www.jnj.com/20210404" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jnj-20210404</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83L2ZyYWc6MjIwZjM1MDAyNDRlNDBjOThjNDEzYTIyNTA5MWIzN2YvdGFibGU6NzkyMDY4MGViM2ZhNDMyMDkwZTc2ODYzZWZkMTBjODEvdGFibGVyYW5nZTo3OTIwNjgwZWIzZmE0MzIwOTBlNzY4NjNlZmQxMGM4MV80LTEtMS0xLTA_4b902f60-716e-4910-a918-92b6db47126a">0000200406</ix:nonNumeric><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83L2ZyYWc6MjIwZjM1MDAyNDRlNDBjOThjNDEzYTIyNTA5MWIzN2YvdGFibGU6NzkyMDY4MGViM2ZhNDMyMDkwZTc2ODYzZWZkMTBjODEvdGFibGVyYW5nZTo3OTIwNjgwZWIzZmE0MzIwOTBlNzY4NjNlZmQxMGM4MV81LTEtMS0xLTA_108187ad-57a2-43d9-9e30-ea4afb331f66">1/2</ix:nonNumeric><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83L2ZyYWc6MjIwZjM1MDAyNDRlNDBjOThjNDEzYTIyNTA5MWIzN2YvdGFibGU6NzkyMDY4MGViM2ZhNDMyMDkwZTc2ODYzZWZkMTBjODEvdGFibGVyYW5nZTo3OTIwNjgwZWIzZmE0MzIwOTBlNzY4NjNlZmQxMGM4MV85LTEtMS0xLTA_8874e416-d5d7-4e80-a4ec-f426e59921b6">2021</ix:nonNumeric><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83L2ZyYWc6MjIwZjM1MDAyNDRlNDBjOThjNDEzYTIyNTA5MWIzN2YvdGFibGU6NzkyMDY4MGViM2ZhNDMyMDkwZTc2ODYzZWZkMTBjODEvdGFibGVyYW5nZTo3OTIwNjgwZWIzZmE0MzIwOTBlNzY4NjNlZmQxMGM4MV8xMC0xLTEtMS0w_7b92d37e-ecd9-4b9b-bee4-74032abf94f9">Q1</ix:nonNumeric><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83L2ZyYWc6MjIwZjM1MDAyNDRlNDBjOThjNDEzYTIyNTA5MWIzN2YvdGFibGU6NzkyMDY4MGViM2ZhNDMyMDkwZTc2ODYzZWZkMTBjODEvdGFibGVyYW5nZTo3OTIwNjgwZWIzZmE0MzIwOTBlNzY4NjNlZmQxMGM4MV8xMS0xLTEtMS0w_515b572f-0a58-4cd8-a709-5be06ec17e32">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jnj-20210404.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0aa473acf8a4d8fab6230244556c8da_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic746560139dc41349deb2325633b7ea4_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2783afe2aa264bce937ed802ab36bb6f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i143b4f489f304a75aa99c0136cd5ebff_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b2ac8bef704242b9043de1cdfb6053_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i224f75bae26342ffb97488937c270d87_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ifde8fdc6f153456891b3a67798d76d3f_I20210423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic8bf9ed56e84446385347cf261ab52e6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i554ccf5c7c5d4082a647db172a33ff5e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45b058f1e15f44aea2e4af4460a4bbeb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4622c24078884c9b85a313f0376a062f_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5bf68e42813419189d9d5ff49143138_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie77099172951473bbab56c32e4583bd4_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb70055ec76a478fb6bd6838dbc2aeaa_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90694bac6fa841438f930b207399b28a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c6da1c0265643db83e0afcdaa488d07_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3029d43aa1d647acbb02dc5cdfe3bd78_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5337f7aeb8794921aa62a3f210452e64_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9d7acadaebe4196a88b514c7f9d15cb_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57b90fcac8194c0c83439d028eb794fa_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81a1c011ad384c69babb9ebc86eb4a3a_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6b4922887c94a5e974f74b0748d2716_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb9aaa3bb3c148dea235f3a41f284cfa_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic07ec8e0b215404d950899c6b10f4fbc_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie740235dd54d4a0ea8cbd91b22b8ba76_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f57ab699b4e44729a17b2ccc22e7648_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d8ed8a180c4d6fb9225796febd9cbc_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f9f433686145c29000c017762e5f79_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d880e598230476c96c6eb9db808e92c_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e28a2034ae84b938a05edbccc78058c_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f5d1f228aa9422383b1640228e75524_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08ed9aabae5243eab0507179e5521406_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i938fd3f47216423db6add422786e33d8_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38454aa367154112bb15da46777db708_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0082d9cc376345feb045a0d2dc22b630_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57d42da3fc7e4a9c8e74db6c49bd6a30_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe502bb02104e159d70555125632c61_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i377d715a6bfa41408e72610b259d73ff_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc8848a62dcb4452a2fc843002a09302_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40f64fb8b6794e99af54c94ba64590f2_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i388de1b5762e4c0fb0d8bbd78e4af41a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide5b19ddfb3441d99114a1bb6fd6c98c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6244cbbe09374700aeac1db74a330aae_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cb654a681744cccadb2bf5b36aa0112_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0bb046f4ee745b8a6a3a214d7610a6d_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i765e60a738e846889a642c75a5734d75_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e47fb2653614b9fb11a7cb9230babba_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id62f882886ab4b96929fde2ec8b4ad23_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd17c512c40140ec8ea55845257d1f58_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30217af13d8d4037a36480117a2ddbe0_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b0bf4ce3bd940f0b30c1308159ff8a6_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie72107b2f41048608d40b52f7842ac46_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19e2c42c0f614e9b9a6645e5624ab2fb_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d3517c75cc34f07baec1683d55a7bd2_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c6b3c3cbf0f47ce9e5cbd3982f08fa7_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie01d964788264049a7b9adb01bd01ac5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a02c0a42a74896bf7be48d3b1027e1_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i874f30e6f0c8448b864fdca3e1298a1f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie68b3ac552404011acaedf92944e753a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a9a259f20724c67beb3b788b0f25057_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342418f455914456a29f58d87b451c6d_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b1bec5d96714b3eba498d07a965ad79_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72b8cfc3f21b47e1a9083977bf9e2a88_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fca4d1476a349df850a392206294580_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9619cfd7a6d6418e84ba17ca620027fe_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbc060006e064bbca9524dae843e6335_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a18315fb614992b5e5d355a07e9360_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0906ba73795343c2a2e180261f092582_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26027c48bade4ff7acf52354b330290d_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1341509a716f4cf7adb94b1d81181765_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3cc70b838c74057a0eddbcc40f06c72_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i878350a72ee146ab880ae401386a353d_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822c73144e3a487798d589465af318e5_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b9dc30fa88d4596b1e3378aeddbe13f_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if38820cb50084fd0a8928b4fff09c1b2_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad3b2a712b0e498c9cafbdd3bdc0628b_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i140d1f4f250d42e78b3172103a09a2c9_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dd389ffc711425dad2694706f9e91f0_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf315858f46544fda7be3aa113c4fe5e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0216e83e61184ac5a91bab7c9e89040e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i204355d7d9a948e5a652a98e8a346114_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22bf2da4717d42ec8e7363aaabf9331c_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadca5d6789ff4116b0dce69a9dfc7267_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2257a4164c24da4808f08e7779edb63_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf3c269c11bd42aea7263d884b1eb127_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b228055f3cd41bb8574ba5091b477ab_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea3523edfc54b9795f412328fb8cc54_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d3a64af1b114e0faba3662a1c101141_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40ee10e36a6846f9a154a6a47b79529a_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14fe7f8132004082bcb935f2f27f8655_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35bdc996add34d468a13b2fe99d899e7_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87420fbb466e4d8f880a94561a21e400_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i946eb5aeb32245f6be05dc48e566fa0b_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i232b3bcc9db9455c814fc452f8315a6d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bc1a06bc0d240b8852a2c4d4a71d78a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7bd67d98bc44c14b76b19b4583f853b_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia18cccc27ae74f93a145a0bb576d9145_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idac7648f2ee14ded909ba25b98704f30_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3db46d4c79c4830b0ea1b74ee41714e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic55cbe2969894f10bd11012937cb3cdd_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddd05909aea443d3b6e90c5026e77987_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i750ed2565a694c9c819af99b440bccb0_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3281569ca4124bab9a05c92d04b015b3_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee80bb4dedc94292864c36970f859808_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic246ecfdb3484602b3397443c4ae0302_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cca5da5737441298ed9e781c444cab4_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c58449914d342049beb19957b06dcd4_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6112627e2fe7456bbf10241a8ee92b8e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62b449f24e1840a188eeaea7b64de5c5_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i087920326dbc4003933caee61ef1d032_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9081f2f0d3934ae7b2f8a1376e4c854c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1d3968138264974924b828c7a733b2e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b53ffb9394c4a118127e114b531b8f2_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fef9ce1b1c94e7baad55d8c2f003ca8_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9108e0198f1454fbc22f7c1d46a4ac8_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06eb83c93424fc38c8f74e769309ab0_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ee15e9e3be0451c9104456ede3ce154_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6c3f15ce4ab427d911866506af070e3_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7915bfce2cf46dca29a5703af986b2e_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfdfbb11f0c04c20a79df23a07ba5ecc_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bde608450a04e129af5ff3ed4538b5d_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e402b3caab4da7802a67171676c4f0_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2aae0ebe6c54209a9f723970cc996ab_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">jnj:OtherReverseRepurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21d02a87aab8433eb31b762adf895c58_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53522da16d414a2cbe5ee063bc15169e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c13e647c3264f6d9f7597704bbc8077_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id34dd034a8ce44d78c8d013272369235_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55ad5b35a58e4a549a452417ff62e50f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia551774380104d5a9cb2e81ed84e5fbc_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6527580553d4feaa0905f4262bf370f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if362b20960c24710b7e9131a1f050ad8_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f92bb8177d4d7b8cd1179e1735f8d6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i080bcda1e8fc49b9b3b8f7f21d977c2e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4db85c50deb4321b0098f8ccf20b46a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cc61c2b232f40b88208ae48fe534d86_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffab5554feae486aaf2e6e43a90b37e5_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bcc1b72d9204d9fb6b0776f239845df_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d1395460274475eb8aec4f946ce6846_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c7696b31ef458dbdebd3465124db85_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i232ebe15fffe4208ae8fe01bb810d201_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ecca6252ec6440ab50478e4522c9cb9_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b9cda0ccb141c2b49c9bbf460578e8_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01bc079fc7af4d169035bc9957d09c9d_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17306623a4594a4599e905c0006aa969_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb973d605fa44eeba1302fbb97d677fa_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7218d516a3fa4b1a991bda3b84a3972b_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02515bdf715434b91522300dc22073a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50dd314f98bc4ea585b34a6ef22d88bd_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85a39dbd593546cb8669a44bf5ba1f36_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib067ee5fb75e4a41a8dd5a32a4fc5baf_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida015c71d6964ba4b2e11a562c29b0eb_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5af5af1c6e1541e99b3ea8ce7066da11_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0514f7f1d16f40e0b128088ad9ec2a66_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c97765733f04d0ab64e6cc604f9feaf_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9fca91959a44bc99f389c8604972d5a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ab9b12aba8443be862462c8b208e6ff_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e9d564117274a81b671fc45094fcb9d_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i885f427d1f254de2a0594cd4499d4276_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib87c8983a8b144e0a0b7a8d79fd69370_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i641f9be9a5ad45c5b83f607f6d1f3eda_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79896030d67642908f3083ddc47a69c0_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65d0ffe736bd4dcfbd632eed9b5f65e0_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20ee57fedc3544d9bd6c9bd722f91f29_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7487f3b4696241b19abfcd01b9537fbf_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a6737fe6b814f04816f11baa77695f0_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88bd89b0cd024d28be4458c01e872c39_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd0df51e9f6e40ed9d88e684d9499266_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68d584c5a1bd4ff0b1a6d41603dd3b08_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65e137191bb04b98bfcb88e12baff57b_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9d444d344a4100a0391cef4739483c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5388981f8dd34003b44bcdbb65f1e543_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d20b300aee54da4b4d3efd6dc870a65_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d5f6e95714e4bae9c1e910ae22b802f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ecc979877e4f0e8a892f8c76441de8_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb5caa2a14204d6898789b7e13ec13e5_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8f2e21bf85c4d6aa21abd973b571c71_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05cd1ceca68a4be7b9e6e339e53f6023_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5d469fc5b8845779a850f71b49f8b62_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i481f371accbb49f5a40e7d7669b9063d_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a96ed3119e94dd8ad5b849b0dfa13af_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb0b9ad2fc354d65944c2a61b639e19f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if558e7c662c6460dbcfc287f05df9a6d_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8522b9e894d4fdcbef8ee00218f96cd_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16824b55647942daa85e7513f921c7ed_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4df43fc8b5ab4339afaf013e8ee480e5_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36ff32f415f941d28b01c0eae65ebd16_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i298a5e31ae074ef2b1abcdecc4c9bd6e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c5519ac2c74223abd4ff4bb596aa99_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i001e8a223ba8491f983e78ad8fa58d53_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41eefdb455ed41d6bb26fb8467d496d7_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib24e4cc519e54204a76fb775b089fea4_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08bc89cac5b142cba9c10b6895ceadba_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66627c055dbf4a0eb408404ce5322e9e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ec5bd94c75b4263b7251abd5a82e702_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b60cd521d53474e8b55300042817025_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7388370141f140dd8d9ec8e9d39c42fb_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1155094efd13425786f2ecdb88995104_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21042b2cd4f347c5865cf57c2a26b8a2_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b2aff0da8e54f4589d4056567f1b3f6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57fe94aa53c54ce5bf1df72bd198dfae_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a5b5475dca04fa0909cd83bb83e1b41_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic90df002b0584aeeb48770c1c328a738_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee3f15e281e4b1c872375fbc9f0e83e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c851c9ae9be4c899817cd64ae156b3f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i520739d470874963ac1889aae3a2cb7a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8b7274f1d224358bbaae38c9f942bb2_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec18e7fe67d455d845353e1a9594d67_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i953edb0e44f84203a69075078f4a87a2_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i630bac5b3b4c4c1ebdb26307f5299f07_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d26316cfec049b1a3d5289265e218b2_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3157c394710c4db09c9733fc27554cec_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7da76c95df1476cbe7abf79df1c0a8e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i552a9d1be5df4fa5b99522a4cbd14464_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i084e71373b7e4ff08ea007b9768f21b0_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d6e2c751f95477baa381dda34964d6d_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2340f88dd3fd42c6881635ed13a8ad1e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a22670a5e304df9807dd47199a4122b_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb901ca38ff742d2b392935788bce117_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd2f5ee051df4ee7affc9c9a72a15930_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34901dc3115b4d80b6bc2c5a322da841_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a5e79fdc705408d96c62523a56dd2c9_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ea6a649ed4a4d8b953110b3f73c6be4_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d3f229defa146f0a98220762a4f2b93_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i830d1be156484a03851fff96315b9dea_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b6b59bed6954d418eb4c5847b9548be_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i423d7e8b4b254413810c2f5c4fda19b5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e622c310144cc8949249a07bf071cc_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154642870660410a90785a135a0fb8f5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4d8262305ed4a808270a6d930b2b201_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c0764f40c2472b8a0a5b59873f1ca3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d76493e48f94dcba8cc74f15393b857_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a475b649b7b482bafe66f589d72289e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia40af87a50514bc5a829dc0dd0888e9e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28d96c7a5b464914b6d3373fefe93b84_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i816f31f509494a34bc7e2cedd91d16d2_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic10284d081934582868002bbf2ed2c0c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1354338217d411997a1333f76f744ea_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e23c8ee5426493fa9a9020a4460a66e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1971251aab8f40e581900d63eac2f931_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10269159ffc3444fbcf1d8e9aa219a53_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7c535299fe9457290a897be433005f5_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b83b2a50512439ea7c32eba157340bc_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ae622fe28cc41748a80fa1570cfe35c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f1ff6fb4d12459fb76b519f3aa064d0_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idffd022b600f4ab19da11eb4a92bbea7_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaba9b1b928784fbca8eb92f74ca624c0_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d7961dbf5348efbc49acaf2aed16bd_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i723bca619dee4d77adbb0ace89cf793c_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25dc22f2e2bd45de940fef17d3860c93_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1a0e1bfa74b499eaf41e73bfbea7789_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50e3695fe3ad4d6397fe1681cee71dbb_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i166260d97d024b4da59529851700b260_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b585d84ee0b4c8e899f4c0c52424cb1_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d9e5272e1d64d9291f65425f7a17561_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddfeadcc4c9f4c14b150e5ed0df1edc8_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i906fd8e56b88496dad9f6b80d29a44da_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3854ce9adfd64c2682550767fe397150_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib661f1c760ad44e9b55754282fa57e3c_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8faa580354e043dfaf23f1f42fb88960_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32385508ea6d4658b01bac013205426a_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92ebcd0a77d74afaa4aef8e33703f1b2_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a5cd00fdb24916a240b612026b1e93_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67c2a0954d344c4bb590b8e16e9b3919_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9058a80fcd945bd954291432adf44b8_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bae718df24b4f13951655bc41d7bf96_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i983c24aea97b44299332fe0f8a655f72_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44787243fb164e10b42245b3160597dd_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95a750086de9495a8afc776a19ad7a9a_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42bf8dca10bb48398b2f3f163ed419bf_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fa60389107541e38de00816279454bf_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i331b3b92b0b34bafa98699f766892580_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i964cf45dd1db45268ef9917e50464450_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60d3b975b16e4b83a8d7a02ed320e405_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf40698a4cb8405c9ebbbf461d299a30_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d7ab27284c405ca2762880403e8d9e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic71b279765044852900c44013574acce_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied69986251ca49af95c8ab2e38acfc45_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26bfd85decb944d8a5ff899f4f8b8a85_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ebdcc3eb7548edaa2a797dcee28eb1_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b4f194c8d2948e682ea7750ae9e4ae0_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i289737a850a54d0cbb70e8bba2e95d4a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0432cb1fa6fe47fbbcfad08028e0cc71_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc8d5d21439a44449fe0a777201e9ce6_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff567a96444d40aaaaee5e54bec7304e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib06bac64a0724d9ea69537ebd326bdd3_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d625febf4bb4703b403d98d5ce8c57b_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia82ae2d3a5a249beac2043ef02e2f433_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6171f8ab5dda4d0c9faa7382c2f231b3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d1f27f9c7334c3f9ad28edfbf7dcaa1_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69ea8e5d1357498b955cea3a65e70a42_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61d81d5483f04c2ea8808ff914905c50_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd8ce529fd4e489ca217b53ba112079a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f8e51a1f6cb449ea7ff42d6f4948b73_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i136d588a998d4a2da83c088f3e0ce2d7_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ef18e066a7d417b8a7dedcd9680329b_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf4afeb424b42099ca0595af209f4c9_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29009a53b5dc403aa2843d2d81dd1cdc_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6114f587788a46509aa693a877fbec65_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d2ad3a676074fd39646dd2b42a1a394_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ec26a4598846aa90c13dbf69fee0e6_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib369d313870f4e40bcae5f48dbba9156_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49f387a41d284ee49ce4f7ab58e64040_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i146ce49a479f4a72b766a6152145d2db_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d35b2d6abf46dabb281f94354a317e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie48b966b3ecb41279941f7e8cedc781e_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5832713827f49e68a1d9256b8db22f8_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cbb2403d3fa48e6a6c860006059dbbb_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36c510944ae54934a1107ef6d1ded6a8_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd6ad0e6e1643d381813d989c2cec70_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32aca65dc81d4c26ac1e08379d1ef4bb_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i148fd285f2164e8b84b5f919df795949_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06e61e62b4724e93ae93816c2f3192f8_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80770d9508b2437f8389e28b2b941a02_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fbc72131dcb4cfb8a2b4aefd58180c0_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529ed72788a0459399f52e3044b3e2ec_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia66fb5605b064618a2816914b2ab7bfa_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac8d1c045b4547659ceadd21ec5dcc69_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i093cfc8901c7491da04dfd1a8c00c997_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idac706fc6d814cd3b02325aac9a6a583_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e51d8457af2428d92fb1a6f3d416b27_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7477ed6ae844839a6a17c6320a1490a_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bee09b00e4e4176b4a2035aa5f68b99_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f88fa52f8b64198a27db57dc8f3446d_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i433a9d857de442baa6ab86474c907a9e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf7597b20ee4154a38d35f8a5783413_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e6b6d91108495abc61b13e632ed5e5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafed813fd0b0453992e024335f1146fd_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80ed82867cff4a2a90aaf86dabd6f75a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36f05bd8bedc483e9e416de970f7e815_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f4e287198db4e008b203874b5cc8f67_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cedc93843e0405aa3fa264e1182e575_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8276bebcd3646be90506d64f62c9552_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0a5e29a43049de90706107caedb36e_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i361f978e79cb45ce9e204e867cf6632d_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad6a0b3794e4083b20fb16dbb34c231_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifad881d92a614ae4a72edef7e338e323_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20adde6886944d06ab57d875198dab9d_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59f953f7b8304173993dce91c2663860_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c4623cb45a4be88936c830cca8137d_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60a0def5e08a4ad8961fabcaa36ce515_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1cdd7d8723049d19609b00fa9d90353_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i831167bcd06748238ad090de986cb792_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia20e73715a764fab811e562e85895b43_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fa7ccc867e0451d8c3472534acc0afe_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8be1c5255c4b4a188392c9c769c5191a_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a0dc7a2446b402d88958e72d228822f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf0bee74b66411f86595a8d281104e2_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b10e6ae68dd44b5aa1f27dc3875bf97_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i988753d50e764ca9a7c00a80520f3048_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a9e5fed8d614670826d46986af440a1_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife89528554c54fccbdf65c21b5a431c8_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8754c3942af4f6d99cc04b08b970f18_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i176baa8660424665898357a803f03887_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d57014634294477bf7002a25123153e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2265d889108547338b832b208684da7d_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c291b0634924a55bacc7238c574ac85_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b68654dad44b8cba983ed66dcf3568_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i902b036bad4646c3acfbaa6a61042bcd_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64d06d5b850a4229a8ead53a9c9ba9e8_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c130fa5cebe472c9176470dc88dbbb5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c030aed94064ab6a76b0da185985ac9_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e4e92c9d6c74bb2895cb6659afe4aec_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08530f48301640e2a981713098e61fde_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b34fffac82440368445497712324317_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4bdee0e174a46a0b8c038d4489acc40_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i686fb29be97940259a0115fdd23a57e4_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63eeae9617e4445594405644c82b4ae2_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58449ca63dee493eb4a627122847148a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibba918ab4a4549e78a7dbbe69cf89f5e_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcab1dd336244969a3214dd17843013a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieee11dbbba0341acad84e21d44b66cb0_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcb7c0f2ea9d4046a2c03e628109123a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1561310f3be0405d937bd6b471583f21_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifab1d64419004688bb06b6ce8e08f292_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if345aeec465f40d3988084e400c97b4e_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a80582d773f48a88dd91b183eca0b21_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b3b072e6a9b4111a82aad6be86d93c6_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22f5c3eb00ca4f86a05c633b971c6262_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c42bc98065a4fcba4fa265b813a01b1_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f35f4e601b0404393243d21e82cb121_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7c978b217504b4e97c5a3da905e7be6_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i215e664def914a8f8dae6cdfc6d30664_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad1e1a3f79d44f43a2ae8c994d019ed7_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6cfc8b3edfc4a0ea32dd87a1d6bfe83_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864c9546ca1845cea37de582336593f0_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92f4c2b4bc544bb9938f19f240de842b_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91610b7c00884714803dc8fef0f20607_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2ac86b2ad464bea9af64abe75679432_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec972b10c7b0493883f2bd7563ffbd99_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cfbea1e8ef24573bc5a395f4dc46921_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0afc2d9300442c481f53a34f4d5eadf_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cee6a4e627d4c4281ce1b29360ea956_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3511302b1ae41809e6440adaa75a4b8_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69417898b97a46fbb70d8ba92644a167_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac5940573a824aea9b11c62a69e8e3fe_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a54ac8edede45ddbaab8f1db84179d2_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2ad067eaffd4f1391d0486fc4161840_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if080c4dd59e944648097620649b8fb6f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b2d16f32fba47f09eaaea5712a0b4fa_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9de68fe20a54bb3938d8f34bc55a8a9_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa43d68970b74de495b2ce1d7600846a_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idebe2f3e24dc4867b6dc012fde3f09fd_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f3f4cd739b446e89e809b5ac4d5df4_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a98910058dc499f9afafc26d4f8d7a2_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c52fe15105d49e18829d0a70625bdad_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cf69631e6a64a778cb06aa103ea457a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25d01b70ce6a4d158b8e85edb95cab4a_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic10b7e28bcf94b0f8cf1550242af73c0_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ccc8d4aa3944fc9a6f5d46048c4e46b_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a43fa091bd04904af477b8da882ccc9_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ca74a38d344c029cb03ec16c2adf4e_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1056e17dd9d4f2cac9bf0fbd592a173_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0278ad7c322f4c488129c6b911f43d45_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d4763b134be49d4b30da01bf1ba44e0_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b19e46a75b4847a0c6f53f552cfbc8_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie48200892c424f87b7edda0ba0409c96_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c5442217af4f099da88cd8d2d16584_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i769a39b459364823ac7bbeb1e988ee9a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d972234fcd4ba498f466945a9c4cc4_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f07da4bc71140e69f2cd469df1ff0a4_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1c7abf55c7f4cd1825fbdb35e87d736_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i871b3677375a4491991a21ca121e6485_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic19c69b6d1454567bbf90da51c867584_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i712cec174e7a4562b67a334df7885636_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6cb98336e1146a28b4c4b2c51be0b43_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c23981dbe7c474d94010c344d4e9738_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eaafeabe91c4ea48c2ad1d1f12dba58_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24a8dc58bc5a4da4ad5d964b5437e8b6_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f8096a899854fcf930ca0cea72e522b_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf849323318a42d78e841021176dc0db_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3881e94557524789a9ff7fc5efb2d29a_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id087d3cf08544d0e8465c05939e54c06_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f4ecbbe64184af588dc9aa7b93d8f9c_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90325c74593949fc87a8cc588c4f9fee_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794c9a7bb0c54961a3e9869aa082ba42_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i123f5966e05a44d085563e3eeb9a895f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide5f1afa7b3f4d9c86ef358c4ed464c0_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12bbf63564d04cae9ff269c9f4bbb527_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfc39cb498d44439a78cc49f5f336acd_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b9a89680513428485a34f3f48c896f6_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7783e4e0f34f45f8b3873d934bac73a8_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ca9de72471f4144afc322742d3ee277_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87786ad4f32e48449a1996e1153a6164_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe0a5b0064547b1a5b98fe08aa407bf_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i782d96754043498593d177ed7e9d7435_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ad2d868e8f94f1ea0241239aa8abf8a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia564284c6bec4f09a465f098bbfaf35b_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2237e862843c453cba68d7ee3d286ba2_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06dac5d761d243b8861130b807832ca5_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d2cab6e4a2f4243aff50d87fb678757_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56e25388aba946e39f461155f1e66bb3_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ed7f86f44840468b3a6ca64ad69b92_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac1b72498c54651b9f3390eaf7bc4a4_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78be76eb6d4c4d7297a4bf4093369453_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic869379c2ad541c399cbf3c1fb6a954e_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9c30797b0cf4d2cb47f26f7a4501b8c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibedf86a241dc4b5bbb19ba292a60a3fa_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b64f045460a4ca8858056eef80e48c5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf5f96085f349f4b87d2aa43da1a71b_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c259fa6ac434248908eaf1d9085cbae_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab22b59ea5b8436eb6d4e323ffdb8113_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie92f35e3cc8049518e4c913312f61c94_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75a7e770b127440794059c8ec0d770e5_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if67e32a6ba574c4bb1df1943ab8a91c6_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib935f1d5a67d445e8d777642f2400a7a_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3db4b7b2b9104e8aa81ffe56c63244b3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c6a9d00e90848c58e88acd8954635ae_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9387bd1d4a9542529ff61ba379041ef5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedc20ebf5bd042ad896ae4efdc519047_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65d5eedb28a4d1fac8ffba1883d31d7_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ee165c65f3448d9fd58f57b88afb73_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a203809cc6644f48256490ae13f0ab3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i438067415c5c4f5985d9ae849a5e2a71_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id10068aaaa974a5aa7d0db7ddb857b8a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b613e89c6de4696b5f46fb3913eb864_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdca448a11c64bc48442f40fa88d4ce3_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eda2d70fc65473fa36d660afce9a681_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f0decb1dd364c8da7e609d042602990_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d9df6ec7e15475b80a0ddd952dd424b_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f8f49e166a42308c773c330db2cdac_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c9c51f138064f7693ff21bd0cbc01dd_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80a728efc7c4431185d2257b26f2c766_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i046c37ec387d418792e0b7796ecad6b5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3aa1d5138aa4eef99d2d397be8bb5a9_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04925e843e58499d8cb79ab41d517312_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i311fa4ee096d498cb9fc15d6e2eac138_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5de8902fb1d64e47b0f656f4518cc948_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1b6bee78af44dfb8c09e1d37795edec_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eed8f3fd6bb4026b042b674919fe034_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6edb3ee83adb4242bda5469bdac2cd58_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f6c8b86b7546149befa4e5f3fca4d5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idebb01df50a34ff1b884a2077e7460a5_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8154d1203f304af6adf50d35bf4f7880_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8740a5ae1646469f9c8fd93ba62467bc_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06f962900d174483a2d8ef350b1d7647_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a878e7d9cdf44f8a0e5b960ec217e8b_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id864ff961e674fb1b62f80b8c6932ea9_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2c551cbda52435687542e1e45b23fd4_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67be5d04e3c440f888ad9161a9e5eda7_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9037030323674d438622ead7d2365cee_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03bec226c4414b32b21f05d00c95bd73_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1806bc88b23744e38bf7a4a18ee82827_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4fc05c968db431dafa927a4b29febff_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib713a362c12a4e0f8c0fdb3f559dd81d_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0230b4c2f04f45c08018028261942d70_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da6efb5d0a745239d6361465c0a8cf7_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59adb5a67adb476b8ee2fd372e3f1de0_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d6ab8313ed7411fb9fcccd2fb2fc054_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70464af74e1244fe971e0ce8df9c1139_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87c7441a2ff64814bc9edd9ebb11379a_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f75cbd2f3e44e86b3159f06713cea79_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46794c3f5f7641c28479e5843b966ae4_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbbac775d46c4b0caf203e09c5683d11_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73332a11822c4dfab9561d066cb74b28_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i381d0ba83d1f41bdb53476e56a42a36e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icae9f5809e1e453ca62e9f4b2040f4f4_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee3f3e37530b4bc5bc81e9b8b73ec767_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i373fb25b6ac74376b24f1838469cdc56_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d757ba0d9b54fa8a6d3b798835d364a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib89e19ebfa6741fab1ef7e4ccb9bce83_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i829ccedf81764d70b896a39ffc2b8d95_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia475a9342c1549239a4b78261b9b833c_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia646bd76b4f54d908a6d0888a0bab427_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc399b9993724391a7b071eb85f26048_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc92d2e4cf8a4de7b8c3172a78c2d8ff_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab081c7294c94dacb3f3da911787176a_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id694df27cb364c85abe72911f2a4f74b_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee0751bab8e4f7b823728d29fc3a815_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i309da13ba23248d2bbd4befdd7ec001c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52d6c8b409ec42199210aa34c876fc99_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf3ceb4f65cc4b228df4f27cfee4babf_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ae566a0efc441eb0fb6ea1cc2e1608_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idae5fbf3821e4b25b63bbfb4f1173093_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fa44b2106d7456086d7300b833a26cc_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i173c358b9082487dacc6b62f9414e27e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d24994a8ef4424b6c1f77a1a7134a4_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44aeed20d86c44c5b5a4ebeafec47aed_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51883c3c4f5f4d9989d8ea8605f231dd_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d094f0fc9b241f89a961261247144f3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3abe5bb0d9c4e3298e7a1b39eb3e953_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1952414febe4c02a498725387577ba4_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f37539b91d45b7b48a375afd131b53_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8585c10f5564b039e486807c6255230_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e06d38a4dbb4397aa56a49e80a320af_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i317a97ccb069420ab772ab1f52d977ba_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied6815bd7b754e4a902dee41b3bff0ac_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2ac2702e3294ccc936243e7e77b3337_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d9f04a32215495f8fb5d9251c0b8172_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0effaa8d4d19429294ebb6baadb91fe8_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dba1ed2af8443a0a29e304aa9362c9e_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27ba1a98c3ed46fea5a3c71020abc7e5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eeba07dc96844578537afa4da1d4909_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88511d277635488580602c5f2d2efbe9_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc1d3ef8e82b4cab9d2f209a70930bad_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia49cb056ac9642fab13eb3c45dd7beb7_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61df9a2348d5485696295a61a5f0b0ba_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dc14d98635140cf98a64f0c2425a440_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8774a60d6f6649268ae5cf40efca6063_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f824bef77534b77acea435e4bcf50ed_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id645f8a91fb54b40adfd453cef0dbd05_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia347c7ffc8b448789de799026384d1b8_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46b22e45743641e680c31d8beb794e56_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfce5280afb34c08b7d2df0de5af45e1_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4237eb3d9454518b7d9808794278432_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6730cd63c2644e6b98a2fca79af18d2_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7090787364da465d986409e41cdb9e8e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic00b4438aac54f08b9632ab4416202d2_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67972ac0db9340ad9d3acaa558c457e3_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aeec3665cb149868af31f13c90e99f3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cff44da9a7a458490003f90a4b032fa_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e19dfed28af47909fc2e122d61ba3e1_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3d17e0cdb3e4dc9a51f76c0b873f000_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia707285795354a909320047e9adde65b_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d72ee63d68e465c9fb647ef821fca86_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f4c6a54630d423ab63d36db8db32449_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d9f14bc65a147d0b6ffd1245515b56e_D20191230-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8daceaf8ad2943238f7e0666635677be_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ebc13e73dd24d8bbb4f49c2c087c1ff_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VerbSurgicalInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>jnj:claimant</xbrli:measure></xbrli:unit><xbrli:context id="ic5b57e148881429fbffa7b15c1969483_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32c65ab8cb634ad9bd5a0e2f7d30a359_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd5cde0149284609a90fe89bccf88fe6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08582f9cef4d4567a55ffdc339dd9b58_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4720b5ba970c4ae58eeca3720feaa0b3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaeacf387226456196518be5d4285e6c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6fb78dabc7c431c8db3fa456cae770d_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41413d437f794ec3a9f045f6a27f2722_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>jnj:patient</xbrli:measure></xbrli:unit><xbrli:context id="ifd2cd7a8594949e083f88b8b79935b39_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b1fe073177c4b3ab83e3d3452139524_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13f02d9a0d3b4b66a1c40f110cbc1e1e_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9b48d0973f493eb3ab6b9a6476c385_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i709811f027d74897b86c8f1d12b504ed_D20200601-20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62bf76445bd948c38790ffcd119476a4_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db493405e0444d89bf7eaab26517bde_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e04dd168b1041b3919b1a56f47b4ecf_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f0753d19d5149c091394208cbea890d_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i851c9cc374994813ad167606b1ea44ed_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id807403c46b245c9bd8b6055a4d42cef_D20200120-20200120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-20</xbrli:startDate><xbrli:endDate>2020-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic02f715544ff4105bfd2a3c2d151ac0c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b908089cc6a4f068612a9b2d5d34ca1_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96add54e896749258f1ad0c9536687a7_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a22a8f09eac408299c442ea44cab0af_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1552e8f8c0724beea6478ac55c3106db_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95abcc6431244e8a90f59ff7792cfc79_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e03a943b1aa425496029ce0733bd863_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0290e1c992b748a9908d71498dc82a4e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aabc22a7d5a4aa597cd7da431d465a3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f3ba126d47a4b5a846574f6d9d31fa6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b5e6d446af4a1ca2c03a629dbf4eae_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009c62493dd242ae928d25a27ed97197_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36ee9965a40148bda5e997a88d5d4930_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52afe008fb4f4c819028d3daabd32602_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50377f6db9174c48a6ce24be02ba8d60_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca084b4733440fcbbf545f29821a06d_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0856470384d143029d8218bb9189e71f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1cbff6b8f7d426ab49cc6dad88e6c0f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i378ddce2634145fcb6a28fcfb5b8592e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10eefa077224d8094f6feb17315c535_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d58eb1fecdb4c148121d9d91c2a78c6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0699d70253b44b9fbc20ae5610df4e69_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDY2_380bdbdf-6110-46b4-9de3-152364cadc13">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6NDU3MzAyYWFlYTFlNGJkNmI0NWU1ZGU0MDUyMzFjNGUvdGFibGVyYW5nZTo0NTczMDJhYWVhMWU0YmQ2YjQ1ZTVkZTQwNTIzMWM0ZV8xLTAtMS0xLTA_74ec096b-2878-44bd-9e59-6360e720eac7">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarterly Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">for the quarterly period ended <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8xMjI_6190eb87-ce2f-4611-abaa-ee4ea1842f55">April 4, 2021</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6OWQ3Njc4OTRjMzQ4NGIxZGJkYWU4MDIwOTNjYWYyOWIvdGFibGVyYW5nZTo5ZDc2Nzg5NGMzNDg0YjFkYmRhZTgwMjA5M2NhZjI5Yl8xLTAtMS0xLTA_aa5313a5-809d-4374-89ea-af8e991536e1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934<br/>for the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDY3_5eaf7f5c-5c4c-4648-a129-02dffe2629f2">1-3215</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDcy_9ef1b45c-4c23-42b2-b109-c77153b8b92d">Johnson &amp; Johnson</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MDcxMjQzZmQ2M2I2NGEyYjhmMWFjYzBjOGEyYWJmODIvdGFibGVyYW5nZTowNzEyNDNmZDYzYjY0YTJiOGYxYWNjMGM4YTJhYmY4Ml8wLTAtMS0xLTA_9b6599ad-7861-4e1f-8fb4-138975df9df4">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MDcxMjQzZmQ2M2I2NGEyYjhmMWFjYzBjOGEyYWJmODIvdGFibGVyYW5nZTowNzEyNDNmZDYzYjY0YTJiOGYxYWNjMGM4YTJhYmY4Ml8wLTItMS0xLTA_984958d1-67eb-4f33-876c-75e2d91401e3">22-1024240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDcz_1852a8bc-b74b-4034-bba8-064a30007846">One Johnson &amp; Johnson Plaza</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDY4_bfc42653-6e7b-4e14-8a50-17f3331a578d">New Brunswick</ix:nonNumeric>, <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDY5_86f58ff8-2160-48b9-ac73-f323d5ff80da">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDYy_8ee14754-bfe3-4a8d-a3be-1c7bddfbf7d6">08933</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDYz_dda649d0-4db1-4d3a-9342-cc8552070302">732</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDY0_688efaa1-5cc1-475a-a976-fd5436b4e606">524-0400</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDY1_acafa34e-81ef-4abc-afaf-d3b6eae42952">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDcw_11afba81-9d4b-42ca-ace9-cc496872247e">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6OTAzNmZlMzVjYmQ1NGY0NmE4Y2M3M2MxMWQ1NDcxZWMvdGFibGVyYW5nZTo5MDM2ZmUzNWNiZDU0ZjQ2YThjYzczYzExZDU0NzFlY18wLTEtMS0xLTA_9cb2d50b-5b54-437d-ad00-d36164e00291">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6OTAzNmZlMzVjYmQ1NGY0NmE4Y2M3M2MxMWQ1NDcxZWMvdGFibGVyYW5nZTo5MDM2ZmUzNWNiZDU0ZjQ2YThjYzczYzExZDU0NzFlY18xLTQtMS0xLTA_d37983b8-0aea-450a-b01c-4409a238ec78">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6OTAzNmZlMzVjYmQ1NGY0NmE4Y2M3M2MxMWQ1NDcxZWMvdGFibGVyYW5nZTo5MDM2ZmUzNWNiZDU0ZjQ2YThjYzczYzExZDU0NzFlY18yLTItMS0xLTA_62e07e17-79ef-4395-b0a7-e732cd57a2df">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If&#160;an&#160;emerging&#160;growth&#160;company,&#160;indicated&#160;by&#160;check&#160;mark&#160;if&#160;the&#160;registrant&#160;has&#160;elected&#160;not&#160;to&#160;use&#160;the&#160;extended&#160;transition period&#160;for&#160;complying with&#160;any&#160;new&#160;or&#160;revised&#160;financial&#160;accounting&#160;standards&#160;provided pursuant&#160;to&#160;Section&#160;13(a)&#160;of&#160;the&#160;Exchange&#160;Act. &#9744;</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDcx_b8bb9d7f-a4f4-4ee1-be8d-afa187b7fa3f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(b) OF THE ACT</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0aa473acf8a4d8fab6230244556c8da_D20210104-20210404" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8xLTAtMS0xLTA_33543ead-4582-433a-831e-0be89d9bb73b">Common Stock, Par Value $1.00</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0aa473acf8a4d8fab6230244556c8da_D20210104-20210404" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8xLTEtMS0xLTA_a280448c-34f4-432a-987e-a4f8ad5f7c3f">JNJ</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0aa473acf8a4d8fab6230244556c8da_D20210104-20210404" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8xLTItMS0xLTA_f09e4dc0-1692-4185-bc71-ab83330176a1">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic746560139dc41349deb2325633b7ea4_D20210104-20210404" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8yLTAtMS0xLTA_61352186-6f7a-4a1a-88d5-9eb1aae8b98b">0.250% Notes Due January 2022</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic746560139dc41349deb2325633b7ea4_D20210104-20210404" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8yLTEtMS0xLTA_8d45afcc-1390-4a95-8f71-c8a1c6b9db19">JNJ22</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic746560139dc41349deb2325633b7ea4_D20210104-20210404" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8yLTItMS0xLTA_ace9fe1e-c77c-4058-938d-e188e1c4aa9e">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2783afe2aa264bce937ed802ab36bb6f_D20210104-20210404" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8zLTAtMS0xLTA_8dba46a4-7f3d-4f32-8c1e-ab12ecc0a90e">0.650% Notes Due May 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2783afe2aa264bce937ed802ab36bb6f_D20210104-20210404" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8zLTEtMS0xLTA_392efad8-a0fc-4ec2-b3b2-0a769e2d293c">JNJ24C</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2783afe2aa264bce937ed802ab36bb6f_D20210104-20210404" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8zLTItMS0xLTA_7eabcecc-d52e-4b5d-bd8b-bdb34c2a65c3">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i143b4f489f304a75aa99c0136cd5ebff_D20210104-20210404" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl80LTAtMS0xLTA_ffdb027b-a238-4557-91d3-4fc0793a291a">5.50% Notes Due November 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i143b4f489f304a75aa99c0136cd5ebff_D20210104-20210404" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl80LTEtMS0xLTA_33a3f6af-82db-422d-bc1a-7bf84a24e187">JNJ24BP</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i143b4f489f304a75aa99c0136cd5ebff_D20210104-20210404" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl80LTItMS0xLTA_fac92212-edd9-43d9-b305-e5a0ff46652f">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i11b2ac8bef704242b9043de1cdfb6053_D20210104-20210404" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl81LTAtMS0xLTA_15ee8d1c-7ddb-40fe-8cd9-3b6efca9c395">1.150% Notes Due November 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i11b2ac8bef704242b9043de1cdfb6053_D20210104-20210404" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl81LTEtMS0xLTA_7faa71d6-0e3b-4b86-87dc-212e19634166">JNJ28</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i11b2ac8bef704242b9043de1cdfb6053_D20210104-20210404" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl81LTItMS0xLTA_735c1bbf-c86b-409d-a9d8-13c244d891cb">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i224f75bae26342ffb97488937c270d87_D20210104-20210404" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl82LTAtMS0xLTA_23a4a3c8-7d69-4582-a552-3e99caca8318">1.650% Notes Due May 2035</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i224f75bae26342ffb97488937c270d87_D20210104-20210404" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl82LTEtMS0xLTA_1e988b86-de5a-4219-b9ab-af6c6084003c">JNJ35</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i224f75bae26342ffb97488937c270d87_D20210104-20210404" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl82LTItMS0xLTA_b34759eb-c837-4d80-bab7-fd2e8d088d1e">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2021, <ix:nonFraction unitRef="shares" contextRef="ifde8fdc6f153456891b3a67798d76d3f_I20210423" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDAx_5186a535-3b8f-4295-9281-a494dadcf715">2,633,396,003</ix:nonFraction> shares of Common Stock, $1.00 par value, were outstanding.</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_10"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_16">Part I &#8212; Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_19">Item&#160;1. Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22">Consolidated Balance Sheets &#8212; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22">April</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22">January</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22">21</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_28">Consolidated Statements of Earnings for the Fiscal First Quarter Ended April 4, 2021 and March 29, 2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_28">2</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_34">Consolidated Statements of Comprehensive Income for the Fiscal First Quarter Ended April 4, 2021 and March 29, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_34">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_40">Consolidated Statements of Equity for the Fiscal First Quarter Ended April 4, 2021 and March 29, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_40">4</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_46">Consolidated Statements of Cash Flows for the Fiscal Three Months Ended April 4, 2021 and March 29, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_46">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_49">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_49">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_100">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_100">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_103">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_103">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_106">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_106">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_109">Part II &#8212; Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_109">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_112">Item&#160;1 - Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_112">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_115">Item&#160;2 - Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_115">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_118">Item&#160;6 - Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_118">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_121">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0699d70253b44b9fbc20ae5610df4e69_121">55</a></span></div></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Johnson &amp; Johnson's other publicly available documents contain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forward-looking statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.&#160;Management and representatives of Johnson &amp; Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements do not relate strictly to historical or current facts and reflect management&#8217;s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Company's strategy for growth; product development activities; regulatory approvals; market position and expenditures.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company&#8217;s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Development, Market Success and Competition</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company&#8217;s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;  </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges to the Company&#8217;s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of patent expirations, typically followed by the introduction of competing biosimilars and generics and resulting revenue and market share losses;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increasingly aggressive and frequent challenges to the Company&#8217;s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allegations that the Company&#8217;s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company&#8217;s ability to sell the products in question and require the payment of money damages and future royalties.</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Liability, Litigation and Regulatory Activity</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased scrutiny of the health care industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to meet compliance obligations in the McNEIL-PPC, Inc. Consent Decree or any other compliance agreements with governments or government agencies, which could result in significant sanctions;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential changes to applicable laws and regulations affecting United States&#160;and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of health care products; access to, and reimbursement and pricing for, health care products and services; environmental protection and sourcing of raw materials;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with local regulations and laws that may restrict the Company&#8217;s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union's Medical Devices Regulation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in domestic and international tax laws and regulations, including changes related to the Tax Cuts and Jobs Act in the United States, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Company&#8217;s Strategic Initiatives and Healthcare Market Trends</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pricing pressures resulting from trends toward health care cost containment, including the continued consolidation among health care providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of health care expenses, significant new entrants to the health care markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restricted spending patterns of individual, institutional and governmental purchasers of health care products and services due to economic hardship and budgetary constraints; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges to the Company&#8217;s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Economic Conditions, Financial Markets and Operating Internationally</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of global public health crises and pandemics, including the outbreak of the novel coronavirus (COVID-19) pandemic;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes to global climate, extreme weather and natural disasters that could affect demand for the Company's products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company's products and operations; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of armed conflicts and terrorist attacks in the United States and other parts of the world including social and economic disruptions and instability of financial and other markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Supply Chain and Operations </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulties and delays in manufacturing, internally, through third party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interruptions and breaches of the Company's information technology systems or those of the Company's vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company&#8217;s products; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. Disruptions associated with the announced global supply chain actions may adversely affect supply and sourcing of materials used in the Company's products.</span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021, for a description of certain risks that could, among other things, cause the Company&#8217;s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;I &#8212; FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1 &#8212; FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions Except Share and Per Share Data)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:69.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMy0yLTEtMS0w_ea04587e-bd63-46e4-bede-da1bacd96200">12,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMy00LTEtMS0w_336a3158-5e08-4840-8b4f-1e7e6e81ec76">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNC0yLTEtMS0w_1e4e83ab-140a-4759-8fa0-862474fba010">11,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNC00LTEtMS0w_829e900b-6232-46a0-b806-cd5143f2bf90">11,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, trade, less allowances for doubtful accounts and credit losses $<ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNS0wLTEtMS0wL3RleHRyZWdpb246YTk2ZmUwNDMyMmQzNGYwZDk0MTE4NWZhNzQ3NDQ0MDJfODg_7ae82640-fbad-42d8-9430-3d12c644f034">270</ix:nonFraction> (2020, $<ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNS0wLTEtMS0wL3RleHRyZWdpb246YTk2ZmUwNDMyMmQzNGYwZDk0MTE4NWZhNzQ3NDQ0MDJfOTg_9fcb06a7-d47b-4e95-b3b8-6678e10daf18">293</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNS0yLTEtMS0w_a5d1eedf-5d0e-4b75-a6a8-fc932b618c1f">14,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNS00LTEtMS0w_49c35633-e6c1-475f-a730-8f347780e4ad">13,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNi0yLTEtMS0w_c23ea3a2-7e2b-4add-b893-1724671a7007">9,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNi00LTEtMS0w_29d969fe-f9b5-47dd-aba7-7d76e1673b3d">9,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNy0yLTEtMS0w_607021da-3797-4839-ad8d-f2083a2f3a8a">3,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNy00LTEtMS0w_ea4d4f5e-863e-422e-b656-cd17bf38d565">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfOS0yLTEtMS0w_58694b0d-22d7-4102-ba45-a8af0235ceb0">52,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfOS00LTEtMS0w_cba32ba1-10e6-4cdc-8509-1013c38cdcad">51,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTAtMi0xLTEtMA_794b1671-2e06-4650-8a41-ca9b88ab388b">46,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTAtNC0xLTEtMA_636da5bd-e4e0-4b4f-b134-59db45ef400e">46,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTEtMi0xLTEtMA_0351379a-da93-4c25-b61c-b5f8b609ae25">28,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTEtNC0xLTEtMA_e0e4c0c8-6058-4dee-a234-2a1cffb71711">28,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTItMi0xLTEtMA_c7f0c2b8-a662-4ffd-a213-4f5ec7e9227f">18,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTItNC0xLTEtMA_d1bb90a1-f2c1-4381-a59d-12364cdeb49d">18,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTMtMi0xLTEtMA_daea7e21-ae5f-45d2-8ec3-41b0081f615e">51,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTMtNC0xLTEtMA_425539fa-0fe3-40c5-9132-b52611586896">53,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTQtMi0xLTEtMA_d86e8e04-e3a9-42e6-9cce-bc77d199a354">35,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTQtNC0xLTEtMA_f1d23e80-7247-4f59-9945-0668104946e5">36,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTUtMi0xLTEtMA_6e13c0a1-a806-4bac-90f9-d2c67d17abbf">8,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTUtNC0xLTEtMA_362a25d0-a1c1-4c45-833e-aa8415279689">8,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTYtMi0xLTEtMA_e2045ade-8de0-42e5-8623-bc53abf526d0">6,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTYtNC0xLTEtMA_5f926787-3856-44bf-8510-8cedb4b3be79">6,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTctMi0xLTEtMA_e83ed07a-0e96-4119-a5fd-d8eddb802d22">172,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTctNC0xLTEtMA_6c35b75b-b232-4408-9355-efa92733c2cd">174,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans and notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjAtMi0xLTEtMA_8a48e019-4e53-4b82-b49d-61c5e815e403">3,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjAtNC0xLTEtMA_74106587-7c47-4b0b-b1e0-209e9e13e0b9">2,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjEtMi0xLTEtMA_7f7160a2-dce0-4bd2-99cd-833bfbc38abb">8,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjEtNC0xLTEtMA_db67bcf7-f045-477b-9264-bf42baf3ebcd">9,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjItMi0xLTEtMA_249c0b30-951e-4ed8-b088-abfd37f7600d">13,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjItNC0xLTEtMA_bb9081f4-f860-490c-8b6d-e0379415990b">13,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, returns and promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="jnj:AccruedRebatesReturnsAndPromotions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjMtMi0xLTEtMA_d6e46dfb-b47e-47a7-bb15-ed7aa0a42e24">11,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="jnj:AccruedRebatesReturnsAndPromotions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjMtNC0xLTEtMA_01ff0c08-8e26-43cb-a252-5b962bbbf1e7">11,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjQtMi0xLTEtMA_18964d22-3cf9-4594-ab4e-de0a9cf0958c">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjQtNC0xLTEtMA_17672ee2-83a1-4437-8935-651439e8e081">3,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjUtMi0xLTEtMA_9f5678a3-bca9-41e4-8ad8-9a43b7f22503">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjUtNC0xLTEtMA_a9b64bbf-2db0-4bf9-8be0-d4b4ab7e1253">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjYtMi0xLTEtMA_4ac95e2b-6329-4a18-8763-a565c419675c">40,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjYtNC0xLTEtMA_05dd8e3b-cbb4-4f50-93b0-6d946516ff2d">42,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjctMi0xLTEtMA_22e26871-1b12-41f0-bed1-ca2d755ad6bc">30,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjctNC0xLTEtMA_ceeafa0b-9dc0-48d4-a9a8-3c8f2414687e">32,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjgtMi0xLTEtMA_cf54771d-88de-4caa-8a55-02aaae2d1588">6,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjgtNC0xLTEtMA_270d791a-f9b7-4ce5-8dd2-d4095cc001ed">7,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjktMi0xLTEtMA_97c833b7-8e66-4c3e-8e4d-b64fa7190e7e">10,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjktNC0xLTEtMA_ffec4349-80fa-402d-8501-3705ef82895c">10,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term taxes payable (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzAtMi0xLTEtMA_2748a117-6605-402b-b683-595c7729930b">6,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzAtNC0xLTEtMA_42b62ad8-d3b3-44e1-93cc-93f0744c2e7d">6,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzEtMi0xLTEtMA_4f8d73fb-0d15-47e0-bbdd-52506543e329">11,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzEtNC0xLTEtMA_baa51517-ebbb-444c-a325-72b8254bf88a">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzItMi0xLTEtMA_e72dce38-6f55-49ad-8652-751fb85567ae">106,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzItNC0xLTEtMA_3af66a18-cc5d-411e-9371-98ca0622ad70">111,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzMtMi0xLTEtMA_328524da-db51-4234-9787-54e372ad0d92"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzMtNC0xLTEtMA_7379be89-5ef2-4919-b3f5-7f38eb3e1db1"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock &#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmRkNzgyYWEzODY0MDRjZmU5NDJjYTY1NDUwNmIyODAyXzI5_0ca6ae09-e13d-40f9-b9f2-55fb006d6bf5"><ix:nonFraction unitRef="usdPerShare" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmRkNzgyYWEzODY0MDRjZmU5NDJjYTY1NDUwNmIyODAyXzI5_bc2dc826-1e43-4730-94d2-32e853d97db2">1.00</ix:nonFraction></ix:nonFraction> per share (authorized <ix:nonFraction unitRef="shares" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmRkNzgyYWEzODY0MDRjZmU5NDJjYTY1NDUwNmIyODAyXzU0_c834f35d-eeb2-4647-9e55-4aaebf079641"><ix:nonFraction unitRef="shares" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmRkNzgyYWEzODY0MDRjZmU5NDJjYTY1NDUwNmIyODAyXzU0_f7b540eb-d02d-431b-ad86-2ebca88486f0">4,320,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmRkNzgyYWEzODY0MDRjZmU5NDJjYTY1NDUwNmIyODAyXzcy_0580e30a-ab04-4b41-89bf-f227c0b7efa0"><ix:nonFraction unitRef="shares" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmRkNzgyYWEzODY0MDRjZmU5NDJjYTY1NDUwNmIyODAyXzcy_a446190b-29ca-41d3-988b-92287ab4c07a">3,119,843,000</ix:nonFraction></ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMi0xLTEtMA_2e157177-aba6-4d8e-9e54-986f349c9558">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtNC0xLTEtMA_4ddfa7dd-d3e1-4180-938a-cf52d0a527cf">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss) (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzYtMi0xLTEtMA_c651fb06-6e84-4722-9483-d28f56148b7e">15,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzYtNC0xLTEtMA_6a443f6c-0189-4a66-b672-f3b6a94cba3e">15,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzctMi0xLTEtMA_09b7a172-f14d-4df1-b43c-6c080c8fce89">116,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzctNC0xLTEtMA_ef0894c9-5097-4572-b727-02369a5b7ac3">113,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: common stock held in treasury, at cost (<ix:nonFraction unitRef="shares" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjI2NWI0ODllN2VkYjQ5YTc5OTdmZjliYTI0MmEzZjYxXzUw_c07bdcc4-17f9-4912-8d16-b9381b06d511">487,141,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjI2NWI0ODllN2VkYjQ5YTc5OTdmZjliYTI0MmEzZjYxXzU3_872a6eb4-af20-42d8-bc00-c670a7ab42a7">487,331,000</ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzgtMi0xLTEtMA_0ddca983-962f-4c73-9d16-09c0a5c51c5b">38,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzgtNC0xLTEtMA_00da024f-edf2-41f0-89b7-60264326aa06">38,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzktMi0xLTEtMA_9ce76a0e-2a87-40bc-b8b6-1c423cbba6c6">65,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzktNC0xLTEtMA_fa5baab5-afd1-41ed-aca1-1f4acdb50814">63,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNDAtMi0xLTEtMA_83664fe0-9eeb-4b02-a017-61f10f7c7ba8">172,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNDAtNC0xLTEtMA_1aa17da0-36b7-4c70-9ebf-e7171ab1c15e">174,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EARNINGS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars &amp; Shares in Millions Except Per Share Amounts)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:54.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMi0yLTEtMS0w_693445e8-5fad-4081-8e52-9525cb735422">22,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMi00LTEtMS0w_3de7e9e5-0b2f-451c-abe4-ea0e305ec0b6">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMi02LTEtMS0w_3f6de200-8518-42cc-85cd-a423aeffc68f">20,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMi04LTEtMS0w_0cbe3fc5-e24d-4086-ae08-d4c664b6d70a">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMy0yLTEtMS0w_37b28962-4cf3-4aeb-ac0a-652e4386c685">7,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMy00LTEtMS0w_fd2cc3b9-da17-46d9-8ce0-c6e473c06cd1">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMy02LTEtMS0w_cd579375-342e-4463-bcc2-f32dc24fefe9">7,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMy04LTEtMS0w_0bf4a40b-2518-4691-b00f-6490464ed4bf">34.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNC0yLTEtMS0w_36180ef9-52b2-43c0-960d-3c73dfe42017">15,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNC00LTEtMS0w_4b84f74d-3d16-4c0a-b7e0-d0317e5caeb2">68.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNC02LTEtMS0w_7d9cb2b4-d1af-4713-9f1a-d8b2dcd2de19">13,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNC04LTEtMS0w_da9273f1-d3f1-41c0-8bf1-684c34433a9c">65.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNS0yLTEtMS0w_eb144445-c6ba-49ac-8e10-b7850856785e">5,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNS00LTEtMS0w_faf2cca0-9501-408b-b90e-c271df75cc3d">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNS02LTEtMS0w_84ea302b-a9a2-402b-bcea-9d8a0ffcf099">5,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNS04LTEtMS0w_5198d0e7-52e2-408b-86ce-b21040207e01">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNi0yLTEtMS0w_48f99fe5-64dd-4ac8-9bc2-f15b4952b3ea">3,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNi00LTEtMS0w_5d67763b-5c56-4326-9b31-62a88d63ca0e">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNi02LTEtMS0w_c5142440-af0c-43f1-8602-6dd73a82de5a">2,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNi04LTEtMS0w_a0922dd6-edf9-4327-b8f8-49b8154a74b2">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOC0yLTEtMS0w_cef3aa6e-966a-4d3b-a49a-8a129a7d0517">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOC00LTEtMS0w_ff51be7b-a958-4801-aa2a-6060029eec6d">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOC02LTEtMS0w_e43026a3-b9b2-4926-9550-d9e41351a261">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOC04LTEtMS0w_2a0df218-f06c-400f-8247-05b0f30baba5">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOS0yLTEtMS0w_219eb7ff-2023-43de-8f27-cf09a9460f56">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOS00LTEtMS0w_26cf0c2e-2c6d-42b2-82a3-fa321050a166">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOS02LTEtMS0w_3b0db69f-f049-457a-b74c-a31a670d8d3b">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOS04LTEtMS0w_272b8240-bb08-41a5-ad2a-8bb78dfb1bd9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTAtMi0xLTEtMA_fcddb69c-5acc-4293-ab67-46caed4996da">882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" sign="-" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTAtNC0xLTEtMA_17e96aa0-98b1-4a95-81b9-28caec2b314f">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTAtNi0xLTEtMA_cbffe618-b0f6-4265-95a6-e203cec17a9b">679</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" sign="-" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTAtOC0xLTEtMA_98ecc5c8-e108-4919-b49e-23c6e8269fd5">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring (Note 12)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTEtMi0xLTEtMA_2a5c2a16-285b-4953-b72a-ded6d1b59bcc">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTEtNC0xLTEtMA_c19b613c-87ea-403b-bcb0-f60e5f22c1a2">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTEtNi0xLTEtMA_c0044e62-eb06-4ac8-828b-77e7f19044ee">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTEtOC0xLTEtMA_e3f7f33d-307d-4eaa-bd37-78b64b080c98">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTItMi0xLTEtMA_3f24c895-214a-42c7-9f3e-1d34a2574709">7,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTItNC0xLTEtMA_e4ca10b9-b491-47cc-ad7b-f815609b61a6">33.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTItNi0xLTEtMA_6b0e8a0b-ac6f-4453-a39d-d360d425466f">6,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTItOC0xLTEtMA_f29dbfe9-ddee-4b33-8396-aaa7c35db61a">31.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTMtMi0xLTEtMA_f0f46f37-e5f4-4eda-8dea-d99ad15e1b19">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTMtNC0xLTEtMA_f22a34da-7c58-4b37-b66e-a269ec40d0ab">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTMtNi0xLTEtMA_872ab4e6-71c8-49fd-9ab7-73b420ff6228">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTMtOC0xLTEtMA_626fe3ca-cd88-4c3d-80e7-02526570961d">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTQtMi0xLTEtMA_73cb9704-9606-48b1-9abe-ea41152a085c">6,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTQtNC0xLTEtMA_d7452376-ad0e-442e-a05a-ef28497b508b">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTQtNi0xLTEtMA_c925264e-2eb9-4c56-ab93-3b4a51c69965">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTQtOC0xLTEtMA_dec551e5-19c2-43fe-b2f5-619dcda58e57">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS PER SHARE (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTctMi0xLTEtMA_4daa789b-5f57-4f12-a810-d65ebd199bd1">2.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTctNi0xLTEtMA_05c7cd87-af6a-4ce0-9330-23a4ed0502ad">2.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTgtMi0xLTEtMA_d4eb09af-6ead-4a7f-9688-001ae6085f22">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTgtNi0xLTEtMA_0f8c0543-ffde-4a34-809e-8b2fbbb7e1b9">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVG. SHARES OUTSTANDING</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMjEtMi0xLTEtMA_12a060e4-6274-48ed-ab9b-5d050bac36ad">2,631.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMjEtNi0xLTEtMA_d18e89a9-682b-4972-a002-d8e404f1e428">2,633.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMjItMi0xLTEtMA_46cfaa17-4e51-49e4-9250-f28b5a3d5a0f">2,672.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMjItNi0xLTEtMA_11b26d3c-3c13-4ad8-bf29-f5bf6960897a">2,671.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.730%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.242%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMy0xLTEtMS0w_9bce3874-c2ed-4921-a4fd-3131459a84ca">6,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMy0zLTEtMS0w_de2ccbd1-b556-433d-b553-ef2f3589674e">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfNi0xLTEtMS0w_9dd2eece-278a-458d-85cc-9be768b292dd">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfNi0zLTEtMS0w_72112c89-6949-45f2-854d-e2a445e4f0d2">1,519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized holding gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfOS0xLTEtMS0w_db6636f8-b4f6-49c7-884a-be49aa26d5d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfOS0zLTEtMS0w_32d6a916-2fc3-4609-8a25-5bd983b812a2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTAtMS0xLTEtMA_00643a45-d25b-4dec-8878-c84e03ec6e72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTAtMy0xLTEtMA_3a467431-322e-4255-959b-3cc8f9e658cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTItMS0xLTEtMA_c1c3f887-9d94-4138-a428-2be89d1c29b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTItMy0xLTEtMA_cf81322b-7b77-4e63-8a03-237735384680">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Prior service cost amortization during period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTUtMS0xLTEtMA_f19d0260-8511-4b92-b7a3-867465effd51">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTUtMy0xLTEtMA_af17ff20-6c2d-42a3-82d3-4b38749bc316">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Gain (loss) amortization during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTYtMS0xLTEtMA_5abd5e74-de03-4bcb-9d57-ecb4f0155633">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTYtMy0xLTEtMA_3f1514d0-23a6-45ee-a6bb-0ffb001c89d4">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTgtMS0xLTEtMA_b4c2cc52-c681-4b91-881a-cfe97a52e13b">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTgtMy0xLTEtMA_3769d2fd-978e-4c03-bc59-1a82f1d2e1c1">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives &amp; hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjEtMS0xLTEtMA_b1a79861-fd7a-47e3-82ca-5aef2b05a61c">522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjEtMy0xLTEtMA_6838842d-00d1-42be-9e38-dd33aaa9a637">832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjItMS0xLTEtMA_59b619ad-e438-4e7d-b590-549370080574">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjItMy0xLTEtMA_9a20e7fc-5bc1-427b-8d68-ccbebe1e61e2">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjMtMS0xLTEtMA_d75d2299-b572-4078-ac46-55e2de3d330b">595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjMtMy0xLTEtMA_c9589383-f4f8-40cf-b396-e05169e2f972">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjUtMS0xLTEtMA_951bfad8-3de5-4167-9b2b-835dcd1f58fc">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjUtMy0xLTEtMA_65f65337-f87b-451b-bc90-83f0205f6740">352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjctMS0xLTEtMA_f06f2b0a-8f5a-4fd6-9b01-10025773d940">6,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjctMy0xLTEtMA_9026541a-3fcb-43e9-85aa-3222e8d5a254">5,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The tax effects in other comprehensive income for the fiscal first quarter were as follows for 2021 and 2020, respectively: Foreign Currency Translation: $<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMTU5_326d438a-c338-420f-929b-30e589c1807b">319</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMTc1_69aaab6b-2848-4185-8c0b-ec5656e19dab">46</ix:nonFraction> million; Securities: $<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMjE5OTAyMzI1NTkwOQ_22754afe-3da8-458a-ad40-855978903121">1</ix:nonFraction> million in 2020; Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMjEy_23805f73-df91-4bac-a9ec-35ad9e12431b">66</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMjI4_93289742-c4a5-43a5-ae53-213f9ddfe5ec">56</ix:nonFraction> million; Derivatives &amp; Hedges: $<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMjYz_fe97683b-c906-4b06-b403-03cc3580ce39">157</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMjc5_52efb6ff-ad3b-40c6-84d2-e983118c25b4">256</ix:nonFraction> million.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal First Quarter Ended April&#160;4, 2021 </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMS0xLTEtMS0w_35fb2b56-5422-4053-835c-b09dcce381cd">63,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ccf5c7c5d4082a647db172a33ff5e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMS0zLTEtMS0w_24981763-49f5-4f70-b0a3-3aed28d4f2fe">113,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45b058f1e15f44aea2e4af4460a4bbeb_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMS01LTEtMS0w_95a2dcc5-8913-4f04-8e9f-c0f15ee66063">15,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4622c24078884c9b85a313f0376a062f_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMS03LTEtMS0w_2016793f-73f5-496c-a19d-36a495086b4b">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5bf68e42813419189d9d5ff49143138_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMS05LTEtMS0w_1b4b22ae-0c39-4fdf-8a81-251706094f9e">38,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMi0xLTEtMS0w_8535544e-8122-40f6-abc3-5a2f28636070">6,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77099172951473bbab56c32e4583bd4_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMi0zLTEtMS0w_23cb91b4-1825-42ed-a343-630dc84386c0">6,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMy0wLTEtMS0wL3RleHRyZWdpb246ZThmYmZiMGM2NDZiNDQ2MGExMjQzZTg5NDY4YWE4NzhfMjY_ead893e5-296b-4a01-91c7-a9e1935331c7">1.01</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMy0xLTEtMS0w_4c6f12bb-c6ef-41a1-9bfa-da69b18fe94e">2,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie77099172951473bbab56c32e4583bd4_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMy0zLTEtMS0w_9b2d7010-3351-4027-9eeb-636b779688ae">2,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNC0xLTEtMS0w_cd67cc8e-bdf9-40b8-bb6f-5f2204849d29">542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie77099172951473bbab56c32e4583bd4_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNC0zLTEtMS0w_87c9dd0f-31ee-4412-816c-75a2bb3c3de5">920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb70055ec76a478fb6bd6838dbc2aeaa_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNC05LTEtMS0w_01bd3da7-c04d-4fd1-9840-0b44159cd697">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNS0xLTEtMS0w_6d904187-919e-4efe-a7a7-176145fc33d3">1,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb70055ec76a478fb6bd6838dbc2aeaa_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNS05LTEtMS0w_4b65325c-5bd0-4afa-86a0-0f23d02d2514">1,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNy0xLTEtMS0w_c79f442d-518b-4123-93a3-d5d32620f9a0">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90694bac6fa841438f930b207399b28a_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNy01LTEtMS0w_41678c89-8cca-432f-b7c5-ab6633398953">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, April 4, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfOC0xLTEtMS0w_b44db08c-2fee-4745-a164-ead11939f448">65,834</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6da1c0265643db83e0afcdaa488d07_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfOC0zLTEtMS0w_68338751-2622-48ef-9ed5-e191bf96cbae">116,508</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3029d43aa1d647acbb02dc5cdfe3bd78_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfOC01LTEtMS0w_3bce0a9a-c8ba-4b64-a743-a7c7dbb2105c">15,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5337f7aeb8794921aa62a3f210452e64_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfOC03LTEtMS0w_0a2903f7-e071-4c9d-97d5-dd087a8aef04">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9d7acadaebe4196a88b514c7f9d15cb_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfOC05LTEtMS0w_f6f979a9-3614-4e1c-b768-4d9986d5b0f7">38,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.037%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal First Quarter Ended March&#160;29, 2020 </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:37.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 29, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b90fcac8194c0c83439d028eb794fa_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMS0xLTEtMS0w_403baab9-5493-4ea2-b962-2d522154720f">59,471</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a1c011ad384c69babb9ebc86eb4a3a_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMS0zLTEtMS0w_ebdb8c4e-6fd8-43c1-a531-2027d16fd9f2">110,659</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6b4922887c94a5e974f74b0748d2716_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMS01LTEtMS0w_959cdf4d-c1ce-4d80-b859-8a67d733d07f">15,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9aaa3bb3c148dea235f3a41f284cfa_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMS03LTEtMS0w_1c657a40-8b01-4dfd-9895-e42e62a5d8b1">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic07ec8e0b215404d950899c6b10f4fbc_I20191229" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMS05LTEtMS0w_3239ff59-48ff-46eb-a330-07886a3c9d2e">38,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMy0xLTEtMS0w_95a7a5c1-467d-4a7f-ab43-eba7ddf16d22">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie740235dd54d4a0ea8cbd91b22b8ba76_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMy0zLTEtMS0w_85f1167f-d902-44b7-a9e4-253c55d2bb95">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNC0wLTEtMS0wL3RleHRyZWdpb246OGI5ZDYwZGM3YjFlNDdjYzk0Zjc2OTNjODgxZDhmZGJfMjY_4b05a36d-ea7d-401e-831a-2933c1605642">0.95</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNC0xLTEtMS0w_cfaa4a64-e634-499b-99aa-85e11bf1aa5e">2,505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie740235dd54d4a0ea8cbd91b22b8ba76_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNC0zLTEtMS0w_6dc9644b-90b6-4849-ba02-d83fee86813d">2,505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNS0xLTEtMS0w_17cf6645-0c04-486d-8cdf-ea1260e245a7">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie740235dd54d4a0ea8cbd91b22b8ba76_D20191230-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNS0zLTEtMS0w_4e150652-4c38-40d8-beae-3f1ad4435247">1,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f57ab699b4e44729a17b2ccc22e7648_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNS05LTEtMS0w_b9362970-de11-4a29-8cdf-00c690572edb">1,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNi0xLTEtMS0w_4ae8a18a-6b64-4a8e-a20d-fc15a34ebc81">1,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f57ab699b4e44729a17b2ccc22e7648_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNi05LTEtMS0w_7225c99d-0c93-472e-8c91-b98d60964404">1,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOC0xLTEtMS0w_50d20366-29b4-4815-95de-a13e58eb476e">352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74d8ed8a180c4d6fb9225796febd9cbc_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOC01LTEtMS0w_3e96f5a2-6cad-4b0a-9e44-d20aa60e8867">352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 29, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f9f433686145c29000c017762e5f79_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOS0xLTEtMS0w_2e7f96b8-f9df-48d5-a924-d1a2e07ff811">61,294</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d880e598230476c96c6eb9db808e92c_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOS0zLTEtMS0w_0669d414-cae6-498b-81d1-7829190a8fe5">112,901</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e28a2034ae84b938a05edbccc78058c_I20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOS01LTEtMS0w_c99b5979-568c-4da4-9ceb-dd7e7aadad0d">16,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5d1f228aa9422383b1640228e75524_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOS03LTEtMS0w_69710fe6-5231-467f-9993-9768d7dc3244">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08ed9aabae5243eab0507179e5521406_I20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOS05LTEtMS0w_06aee904-78f3-419b-bda3-bb05e83b7c0e">38,484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:37.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.081%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_46"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMy0yLTEtMS0w_f432f2c9-f397-4c07-8a36-f429596a6974">6,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMy00LTEtMS0w_c7d5b1ed-cb12-473b-9c97-3553208519d9">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNS0yLTEtMS0w_bf262e89-f0c4-497e-ba46-ecd2113dd2f4">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNS00LTEtMS0w_43606439-96c8-4036-a94b-f8eaa78d6d59">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNi0yLTEtMS0w_b60cf351-e80e-4d40-91f8-a62a72633c90">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNi00LTEtMS0w_642169f3-c827-42b4-93a5-4cbea8a606bd">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write-downs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfOS0yLTEtMS0w_b0170fe1-f10d-42ed-9668-56975d025f2b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfOS00LTEtMS0w_d0ff1bc3-4e96-451a-a4e8-8879b5f9ada3">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Contingent consideration reversal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTAtMi0xLTEtMA_6bfd3c74-efbf-40cc-a740-ea136567bcc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTAtNC0xLTEtMA_71686bd4-75a7-4345-8ce4-32603ddbe68e">983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets/businesses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTEtMi0xLTEtMA_0fdd416e-aff2-481f-9293-13932b4baa13">580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTEtNC0xLTEtMA_825c2df9-7de9-4bb1-b426-cb6df6479a62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTMtMi0xLTEtMA_947ae293-4a04-4ddb-b09b-f9f34e387ed5">730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTMtNC0xLTEtMA_8fa13225-c351-4ebe-95f8-e6ba0f643443">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit losses and accounts receivable allowances </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTQtMi0xLTEtMA_d2025d03-1560-4b92-819d-51c12473bf0e">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTQtNC0xLTEtMA_97c58c0e-3a08-416b-a73b-334043fb8a1d">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTYtMi0xLTEtMA_e5f63a45-bdaf-479b-9754-6583736875ca">1,604</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTYtNC0xLTEtMA_602216fc-e7fa-40a6-83b0-9f60a725f545">812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTctMi0xLTEtMA_ca161d4d-78a7-4db6-a4bc-d65a3ba61f75">695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTctNC0xLTEtMA_8648032f-97d0-4282-a562-a75819cbd9b1">159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTgtMi0xLTEtMA_2d9e36f5-622d-4331-b598-7ff2a133ea31">2,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTgtNC0xLTEtMA_a397ea54-9266-43bf-9b28-aa8d5c6ccf87">2,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in other current and non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTktMi0xLTEtMA_f9979034-16b0-4c5c-9988-50036b5cd999">2,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTktNC0xLTEtMA_517851c8-2d6a-4db7-a3cc-566604466e2e">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in other current and non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjAtMi0xLTEtMA_1e11e725-2caf-4b86-8879-aa48d4010432">902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjAtNC0xLTEtMA_28489545-63d9-43f4-bde8-9e067d57782e">329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjItMi0xLTEtMA_3375905a-b1bb-47a7-a291-e9062f86c7f0">4,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjItNC0xLTEtMA_781829e7-d745-4a35-b92b-d0ffc8a3994d">3,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjUtMi0xLTEtMA_b9895d5e-8dfd-4a11-959a-c0d274eb7727">677</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjUtNC0xLTEtMA_bc54747e-98c3-496d-bd97-997c720c008f">625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the disposal of assets/businesses, net (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjYtMi0xLTEtMA_2d4f12b8-ea8f-4cc3-88b1-edb40fd4a5c5">603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjYtNC0xLTEtMA_a7a5b59c-402e-410a-87bd-3ed508aeaa2d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired (Note 10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjctMi0xLTEtMA_c81b2b33-39d9-41c4-bb0a-75685813caa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjctNC0xLTEtMA_6b297692-23cd-4546-a660-e1e9110973ec">939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjgtMi0xLTEtMA_82452388-01ef-487a-b99c-d4370bf8cddb">5,994</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjgtNC0xLTEtMA_af1a8299-7528-45c8-8036-2f0df482f882">2,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjktMi0xLTEtMA_62da906c-62cc-4eb8-8dde-b917af52d7fc">5,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjktNC0xLTEtMA_50e25502-1028-4e14-9529-d1882d3e0aa3">1,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzAtMi0xLTEtMA_6a6db6ec-c42d-4615-b339-f053d3098a23">751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzAtNC0xLTEtMA_920809c0-63a2-4e86-8854-f2bdb4f84c1d">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (primarily licenses and milestones)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzEtMi0xLTEtMA_dfd97aaf-ff5c-422f-9921-41a7d1a78670">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzEtNC0xLTEtMA_0aa4f718-4d28-47b5-ba77-f1a0c68d1654">257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH USED BY INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzMtMi0xLTEtMA_84184de7-61eb-4c1e-97ff-ea099543ac8e">185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzMtNC0xLTEtMA_b958e0a5-b00a-4deb-b4cb-324723645d38">581</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzYtMi0xLTEtMA_fca1e0b8-e081-4b29-b793-d5a30ebf7e4a">2,659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzYtNC0xLTEtMA_91d0ab8f-c37b-4eae-8be8-b7cbd2c4b779">2,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzctMi0xLTEtMA_81ef23cd-4ad7-4344-8082-fee7574d3293">1,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzctNC0xLTEtMA_d8e3d41b-0b73-4592-9c9c-ef3eeb866ee0">1,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzgtMi0xLTEtMA_5007839d-d7ec-4ef8-bab9-8dc86ff073d3">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzgtNC0xLTEtMA_94ddf51a-bc87-47de-81f4-7162cc6d03d8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzktMi0xLTEtMA_46eec95d-232c-46e9-972a-3c84807736b0">475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzktNC0xLTEtMA_6ba672bd-78e2-4721-b6b5-348dab268641">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDAtMi0xLTEtMA_98c694df-a02c-4671-9455-bf94049fe089">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDAtNC0xLTEtMA_7dff3b0e-b2c5-4c4d-824a-3cdb36411fb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDEtMi0xLTEtMA_44d49a14-0de3-4c58-8ff5-6f930f1b2af8">1,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDEtNC0xLTEtMA_768ca66a-5d3d-4000-a7e7-e86d1628090e">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDItMi0xLTEtMA_f9b7d0c4-9956-4d17-ae4c-9aa844a39793">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDItNC0xLTEtMA_24290ff3-1444-48af-9105-1b234ce33fdb">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDMtMi0xLTEtMjg0NA_4e3facf3-7060-4091-8fc3-6580be18aab2">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDMtNC0xLTEtMjg0NA_fab56371-101b-4950-a408-cb6b2c61262a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDMtMi0xLTEtMA_5f0c33d1-3377-4ca0-8097-5d68756a4681">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDMtNC0xLTEtMA_40894ebb-bc4f-4fe2-af76-b7ae8b9ee92d">412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH USED BY FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDUtMi0xLTEtMA_28a1fcb4-4ae6-4c35-b5c2-e9471d8d5385">5,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDUtNC0xLTEtMA_7c65c8d3-ef88-4e0a-abc1-c82f35d07479">4,315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDctMi0xLTEtMA_6e1266db-07d5-45a2-97d5-780e6002d100">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDctNC0xLTEtMA_71256e5b-8083-41ce-b889-8ca87872da4c">237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDgtMi0xLTEtMA_f8307e20-37fd-4323-9121-dda911261776">1,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDgtNC0xLTEtMA_07b7d412-bef6-428e-a4a7-d22df7d4a42e">1,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash equivalents, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDktMi0xLTEtMA_8dcfb7d2-5754-43e6-a3bf-557aa22abf29">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b90fcac8194c0c83439d028eb794fa_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDktNC0xLTEtMA_5b6fd381-0d7a-437c-adf2-ffd82da8181c">17,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH AND CASH EQUIVALENTS, END OF PERIOD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTAtMi0xLTEtMA_4431e89d-ca3b-4ea2-9174-bf094e435d1f">12,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f9f433686145c29000c017762e5f79_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTAtNC0xLTEtMA_8f4af21c-ce78-4087-be55-298b52db2cbf">15,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTctMi0xLTEtMA_902335d5-e7b5-4d0c-ad7c-8322b499054c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTctNC0xLTEtMA_62cdf1b4-f427-4501-80cd-71dffd9e6ba7">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed and noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTgtMi0xLTEtMA_fbaebbc1-d09c-4d99-b835-e636894e622d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTgtNC0xLTEtMA_f261fe5b-2bcc-4f08-b5af-d752e361ae84">197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTktMi0xLTEtMA_19b5e58e-d9fe-43fb-ae79-c5d04a63a31d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTktNC0xLTEtMA_e66c96aa-d589-42dd-8345-fe97f2c6c91a">939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NOTE 1 &#8212; <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81Mi9mcmFnOmFmZDMwM2QzNDhjMjRmZGFhMDE5OWUxNzM0YWNiNmFjL3RleHRyZWdpb246YWZkMzAzZDM0OGMyNGZkYWEwMTk5ZTE3MzRhY2I2YWNfMjc3NQ_f8f71753-f6ce-4995-800d-d1b42de1245b" continuedAt="ic6a59bcc42014eb9926aaecf37bfbadb" escape="true">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic6a59bcc42014eb9926aaecf37bfbadb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81Mi9mcmFnOmFmZDMwM2QzNDhjMjRmZGFhMDE5OWUxNzM0YWNiNmFjL3RleHRyZWdpb246YWZkMzAzZDM0OGMyNGZkYWEwMTk5ZTE3MzRhY2I2YWNfMjc3Nw_1b24cab2-600f-4d9d-9364-75a044a482c7" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April 4, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#8217;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended April 4, 2021, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div></ix:nonNumeric><div style="margin-top:3pt"><span><br/></span></div><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81Mi9mcmFnOmFmZDMwM2QzNDhjMjRmZGFhMDE5OWUxNzM0YWNiNmFjL3RleHRyZWdpb246YWZkMzAzZDM0OGMyNGZkYWEwMTk5ZTE3MzRhY2I2YWNfMjc3OA_2162a6c7-8f9d-411f-ac34-3550b724f46f" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in the fiscal first quarter of 2021 that impacted the Company.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal first quarter of 2021.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81Mi9mcmFnOmFmZDMwM2QzNDhjMjRmZGFhMDE5OWUxNzM0YWNiNmFjL3RleHRyZWdpb246YWZkMzAzZDM0OGMyNGZkYWEwMTk5ZTE3MzRhY2I2YWNfMjc3OQ_7c84d726-a219-437b-83db-98d9b68a5efa" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_55"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 2 &#8212; <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RleHRyZWdpb246NzljNDJjMzBkY2RiNDY3Y2IyYjRmNjdiOTk2MzE5MmFfMTY5_c79418e2-dd8a-46da-8918-69b17bcc1f68" continuedAt="i66ab624e9e9e41e3a4241c6ab8abfbba" escape="true">INVENTORIES </ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i66ab624e9e9e41e3a4241c6ab8abfbba"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RleHRyZWdpb246NzljNDJjMzBkY2RiNDY3Y2IyYjRmNjdiOTk2MzE5MmFfMTU0_1ff89537-7479-436f-9e7f-7ea1af08da5b" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.070%"><tr><td style="width:1.0%"></td><td style="width:51.896%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfMS0yLTEtMS0w_8c48bfdd-8656-49d7-b3a3-0641f1ac4c85">1,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfMS00LTEtMS0w_62072658-a68e-4a67-b57a-32d15213af79">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfMi0yLTEtMS0w_0b610c55-2f10-476f-8b4d-1c43c403569d">2,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfMi00LTEtMS0w_2fe90940-2b94-4b2c-8e33-d4c171c60692">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfMy0yLTEtMS0w_886dc1cd-4692-4afb-9a0e-12505d0b0b94">6,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfMy00LTEtMS0w_0123a106-6bc2-4339-a0bf-8528502ce0a4">5,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfNC0yLTEtMS0w_5c47ce52-3607-4bfb-b450-137a5edfe34e">9,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfNC00LTEtMS0w_997c59fe-52cb-4b56-a471-75cba1adea6c">9,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 3 &#8212; <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTY3Nw_6df017a2-5a5a-46bc-a9dd-7bbdfc4028ee" continuedAt="i98772ab808c44063ba5ae68092a92010" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i98772ab808c44063ba5ae68092a92010"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2020. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.</span></div><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTY5Mg_3eeb7493-af4e-48a6-ba8f-8b01a6838a3a" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:61.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938fd3f47216423db6add422786e33d8_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMi0yLTEtMS0w_ffa375b4-9651-4187-95b4-d85ae715f082">39,505</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38454aa367154112bb15da46777db708_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMi00LTEtMS0w_8e7c7362-7830-4232-88a5-1c892845907d">39,990</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938fd3f47216423db6add422786e33d8_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMy0yLTEtMS0w_7093b024-d933-4f7c-a360-a5cf1bac623a">18,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38454aa367154112bb15da46777db708_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMy00LTEtMS0w_2562d416-f6c9-4b17-8b19-d693cba24a7b">17,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938fd3f47216423db6add422786e33d8_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNC0yLTEtMS0w_a331f7d9-b96e-4146-ab61-fea2aada30a1">21,499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38454aa367154112bb15da46777db708_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNC00LTEtMS0w_a14c92ab-9a9f-4d3f-a7f1-219725b7e8f4">22,372</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0082d9cc376345feb045a0d2dc22b630_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNS0yLTEtMS0w_26a7c575-5178-45e0-ac70-0bb77831f9b8">22,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d42da3fc7e4a9c8e74db6c49bd6a30_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNS00LTEtMS0w_0c7dfe36-efdb-43bd-81c0-b52387b81692">22,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0082d9cc376345feb045a0d2dc22b630_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNi0yLTEtMS0w_ea7bfc49-8fa1-4cd4-b14e-e1547626053b">11,031</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d42da3fc7e4a9c8e74db6c49bd6a30_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNi00LTEtMS0w_d7ece31e-2058-4f47-b662-0a4c4dee3272">10,912</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0082d9cc376345feb045a0d2dc22b630_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNy0yLTEtMS0w_7b557916-561f-4350-8567-cee10967a986">11,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d42da3fc7e4a9c8e74db6c49bd6a30_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNy00LTEtMS0w_1e4b34df-8497-4fc9-866c-15d0c14587c4">11,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe502bb02104e159d70555125632c61_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfOS0yLTEtMS0w_1dce76ab-6f98-4923-8ff6-afffb5af8c81">7,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377d715a6bfa41408e72610b259d73ff_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfOS00LTEtMS0w_df6bab6e-4c66-47f7-b7ac-8f512de52562">7,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc8848a62dcb4452a2fc843002a09302_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMTAtMi0xLTEtMA_911dab9b-8d92-49bc-8a56-55f03b1492be">10,788</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40f64fb8b6794e99af54c94ba64590f2_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMTAtNC0xLTEtMA_3d1b8e6e-2b51-4812-8460-bba815efe828">11,849</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMTEtMi0xLTEtMA_cfc7d1b1-b685-4af3-9f2c-cd6df9416a29">17,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMTEtNC0xLTEtMA_1169ff8c-f44d-42ae-9a33-90adfe53cf29">19,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMTItMi0xLTEtMA_b4268bfe-9187-413f-b498-621d869d648c">51,110</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMTItNC0xLTEtMA_6529e7ab-86c4-4b91-8ea8-895ce4e3f429">53,402</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*The majority is comprised of customer relationships</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTY3OA_fb3814eb-085a-479f-b9c7-08eee4b57af0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of April&#160;4, 2021 was allocated by segment of business as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:39.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388de1b5762e4c0fb0d8bbd78e4af41a_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMS0yLTEtMS0w_f5f4e0ec-d0d5-4305-9a84-8ed25d27a38b">10,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5b19ddfb3441d99114a1bb6fd6c98c_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMS00LTEtMS0w_105787c3-92e0-4f00-a105-3945f37cd8f9">11,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6244cbbe09374700aeac1db74a330aae_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMS02LTEtMS0w_2675cb9c-dc3c-4547-9106-2e40cdc284e2">15,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMS04LTEtMS0w_1ef23048-50b0-461f-8b43-6efcbe4ee04b">36,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions and divestitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb654a681744cccadb2bf5b36aa0112_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMi0yLTEtMS0w_0fd9f022-57ee-4594-8d8e-b72bc70e4bed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bb046f4ee745b8a6a3a214d7610a6d_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMi00LTEtMS0w_0cd06d0b-99b9-4391-a605-67a703f324cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765e60a738e846889a642c75a5734d75_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMi02LTEtMS0w_ab7cf6ed-821d-4632-8c0d-4a4db706f0fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMi04LTEtMS0w_d7c595a9-7eaa-4f32-b6b7-2ae35b8a26f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cb654a681744cccadb2bf5b36aa0112_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNC0yLTEtMS0w_5f2da9a6-4a53-48b4-ac5a-f51165acbc1f">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bb046f4ee745b8a6a3a214d7610a6d_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNC00LTEtMS0w_37ede2be-4677-44d6-8408-d3714a138690">262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i765e60a738e846889a642c75a5734d75_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNC02LTEtMS0w_bfc0a89d-3587-4c7f-b008-1207b2a4098b">133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNC04LTEtMS0w_79ca4d34-cda6-4052-a591-e7a1db6f25a7">705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at April 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e47fb2653614b9fb11a7cb9230babba_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNS0yLTEtMS0w_8a620bdf-98c6-49dd-9441-8f80ff4de56f">10,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62f882886ab4b96929fde2ec8b4ad23_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNS00LTEtMS0w_3fbd1081-6b67-4256-aaf6-f38526609159">10,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd17c512c40140ec8ea55845257d1f58_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNS02LTEtMS0w_274d1d0e-c445-4857-bcec-9e09068b396b">14,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNS04LTEtMS0w_c2123615-b1b5-4d6c-902d-0cadf373fff0">35,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is <ix:nonNumeric contextRef="i30217af13d8d4037a36480117a2ddbe0_D20210104-20210404" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfOTUy_342b9e45-da01-4406-a1c0-5a5be0c6196b">12</ix:nonNumeric> years. The weighted average amortization period for customer relationships and other intangible assets is <ix:nonNumeric contextRef="i9b0bf4ce3bd940f0b30c1308159ff8a6_D20210104-20210404" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTA2MQ_648b1415-2132-45ee-9064-fc4cec135b8f">21</ix:nonNumeric> years. The amortization expense of amortizable intangible assets included in cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTE2Nw_0e6702bc-eeda-4582-b8f1-12249e75cc24">1.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTE3NA_5e5db372-f7ab-4fa5-8d59-49584193c357">1.1</ix:nonFraction>&#160;billion for the fiscal first quarters ended April&#160;4, 2021 and March&#160;29, 2020, respectively. Intangible asset write-downs are included in Other (income) expense, net. </span></div><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTY4MQ_14208d82-2b7a-44ee-9459-956af8ce1f13" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.760%"><tr><td style="width:1.0%"></td><td style="width:18.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjE4MWZhZTJiOTVhNTQwOTlhMmIwZTU0MDAxODRlNzkxL3RhYmxlcmFuZ2U6MTgxZmFlMmI5NWE1NDA5OWEyYjBlNTQwMDE4NGU3OTFfMi0wLTEtMS0w_a7bb5c6a-079a-472e-aed2-9d6e9bba0622">4,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjE4MWZhZTJiOTVhNTQwOTlhMmIwZTU0MDAxODRlNzkxL3RhYmxlcmFuZ2U6MTgxZmFlMmI5NWE1NDA5OWEyYjBlNTQwMDE4NGU3OTFfMi0yLTEtMS0w_681122ad-e75a-4ceb-b208-306ed376393a">4,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjE4MWZhZTJiOTVhNTQwOTlhMmIwZTU0MDAxODRlNzkxL3RhYmxlcmFuZ2U6MTgxZmFlMmI5NWE1NDA5OWEyYjBlNTQwMDE4NGU3OTFfMi00LTEtMS0w_62cf4862-ff34-4582-a367-dba69ae72a60">4,300</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjE4MWZhZTJiOTVhNTQwOTlhMmIwZTU0MDAxODRlNzkxL3RhYmxlcmFuZ2U6MTgxZmFlMmI5NWE1NDA5OWEyYjBlNTQwMDE4NGU3OTFfMi02LTEtMS0w_703876a6-86a6-4759-9344-75cd06d2e73e">4,100</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjE4MWZhZTJiOTVhNTQwOTlhMmIwZTU0MDAxODRlNzkxL3RhYmxlcmFuZ2U6MTgxZmFlMmI5NWE1NDA5OWEyYjBlNTQwMDE4NGU3OTFfMi04LTEtMS0w_530b93d8-f5a7-47e8-94f9-df3bff063c62">3,300</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div></ix:continuation><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 4 &#8212; <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwMDU_b92663fe-031f-4da0-a156-2c4d33a9f32e" continuedAt="i83db1be946b84a33aaaa543cd35913f1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i83db1be946b84a33aaaa543cd35913f1" continuedAt="ic8d64692a7bc40febc5f3632e16beacb">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. </ix:continuation></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ic8d64692a7bc40febc5f3632e16beacb" continuedAt="i85ad07fce5954cdc9c41273565bd473e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges.  Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of April&#160;4, 2021, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $<ix:nonFraction unitRef="usd" contextRef="ie72107b2f41048608d40b52f7842ac46_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTY0Mw_557aaed6-21f0-41f5-9785-4a4e7a892251">102</ix:nonFraction> million net, primarily related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April&#160;4, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="ie72107b2f41048608d40b52f7842ac46_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMjI0MA_3b9238f6-196d-48dd-8eba-71504b8b7a12">41.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i19e2c42c0f614e9b9a6645e5624ab2fb_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMjI0Nw_67ebdcba-81e4-4186-8264-e522c6621440">31.2</ix:nonFraction>&#160;billion, respectively. As of January&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="i6d3517c75cc34f07baec1683d55a7bd2_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMjQwMg_d394032a-d2eb-4887-95ae-6c0a3b3b7d8f">37.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i8c6b3c3cbf0f47ce9e5cbd3982f08fa7_I20210103" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMjQwOQ_52c8f306-ccb8-4caa-99cd-5693c4986957">30.6</ix:nonFraction> billion, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;4, 2021, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $<ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfNDU0MA_cc88f8da-d74e-4bff-ab6b-aaa6fec3a70d">57</ix:nonFraction>&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfNDc5OA_930788ce-7edf-4500-ad0b-fab0660c5355">next 12 months</ix:nonNumeric> as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" format="ixt-sec:durmonth" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfNDk1OQ_f8a72e3a-a7f6-462c-9dac-0c65bcb6569f">18</ix:nonNumeric> months, excluding interest rate contracts and </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investment hedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwNjI_1336a9a0-e05a-44a1-ae2c-f951f899b350" continuedAt="id09e95dee3584917b553681e239f4bda" escape="true">The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2021 and 2020, net of tax:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i85ad07fce5954cdc9c41273565bd473e" continuedAt="idaade545d3614087ab2eaa624380da5f"><ix:continuation id="id09e95dee3584917b553681e239f4bda" continuedAt="icdda76bf017340e9886c40d7cb5330f7"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d964788264049a7b9adb01bd01ac5_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtMS0xLTEtMA_54cc2b87-95a1-4b60-a4d9-6589aa303b19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a02c0a42a74896bf7be48d3b1027e1_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtMi0xLTEtMA_45c0ebd0-8c36-47e0-8391-36fd5bbc43b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874f30e6f0c8448b864fdca3e1298a1f_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtMy0xLTEtMA_716823bc-3cff-4333-9391-7f57b8af5ef7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie68b3ac552404011acaedf92944e753a_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtNC0xLTEtMA_f8cef261-da30-44e4-85a8-18dae22814d0">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9a259f20724c67beb3b788b0f25057_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtNS0xLTEtMA_8b779a8f-a367-4c39-9e5e-c68e669574fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342418f455914456a29f58d87b451c6d_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtNi0xLTEtMA_f2a52962-2c01-498a-8e72-868f16bbdc9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1bec5d96714b3eba498d07a965ad79_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtNy0xLTEtMA_709cb0dc-58ff-4b96-ab76-8b43374dbdf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b8cfc3f21b47e1a9083977bf9e2a88_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtOC0xLTEtMA_cc2f4aa7-86bc-4e19-802a-11d8ada4a379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fca4d1476a349df850a392206294580_D20191230-20200329" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtOS0xLTEtMA_31141bca-702e-4603-96e9-cc817706d3b6">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9619cfd7a6d6418e84ba17ca620027fe_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtMTAtMS0xLTA_889ab2a3-7473-44ab-89a9-66e5cd19de05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01d964788264049a7b9adb01bd01ac5_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtMS0xLTEtMA_a7d2cdac-b2ea-4da2-94a5-599ca29fdd8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a02c0a42a74896bf7be48d3b1027e1_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtMi0xLTEtMA_110018ad-8cbe-4ce5-bb86-9cfc45f7f484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874f30e6f0c8448b864fdca3e1298a1f_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtMy0xLTEtMA_f5964462-1156-41c8-972e-4783f0e175b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie68b3ac552404011acaedf92944e753a_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtNC0xLTEtMA_1d886092-1002-4c45-909d-9201f5c880b1">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9a259f20724c67beb3b788b0f25057_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtNS0xLTEtMA_b9d1d1f0-f52b-4019-83d2-8af52627925a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342418f455914456a29f58d87b451c6d_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtNi0xLTEtMA_274470e3-7274-4ae7-ad29-87a008df893a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1bec5d96714b3eba498d07a965ad79_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtNy0xLTEtMA_10bde833-0f87-44ca-9b15-2b99c9599c5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b8cfc3f21b47e1a9083977bf9e2a88_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtOC0xLTEtMA_a5b3937d-9226-4711-8a23-90940982fc89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fca4d1476a349df850a392206294580_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtOS0xLTEtMA_cda92364-7492-453a-85cd-5369d671fc48">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9619cfd7a6d6418e84ba17ca620027fe_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtMTAtMS0xLTA_2437c9d9-af8a-4a0d-8e20-250e613666bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbc060006e064bbca9524dae843e6335_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtMS0xLTEtMA_85a72590-b24e-459f-976e-e27559e957f5">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a18315fb614992b5e5d355a07e9360_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtMi0xLTEtMA_4fc4fbf9-c8d2-42be-be1f-751868218a12">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0906ba73795343c2a2e180261f092582_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtMy0xLTEtMA_002b0504-9e0f-475d-8e13-44b691f5e4a4">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26027c48bade4ff7acf52354b330290d_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtNC0xLTEtMA_71965bdd-e6dd-4c5e-b99a-99759019b49a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1341509a716f4cf7adb94b1d81181765_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtNS0xLTEtMA_8ced4e44-f782-4c1a-a11e-4ac6a16e9c52">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3cc70b838c74057a0eddbcc40f06c72_D20191230-20200329" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtNi0xLTEtMA_bd8ddd1e-0118-4001-b7eb-2d9c7999babb">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i878350a72ee146ab880ae401386a353d_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtNy0xLTEtMA_0a75e830-54fe-43fb-ba20-1e617c657f43">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i822c73144e3a487798d589465af318e5_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtOC0xLTEtMA_029e6fe9-a255-419b-a75e-37f4b2276801">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b9dc30fa88d4596b1e3378aeddbe13f_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtOS0xLTEtMA_43f24a08-9610-42d3-83b9-3ec551de7100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if38820cb50084fd0a8928b4fff09c1b2_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtMTAtMS0xLTA_bacce9a5-0ea4-4d4d-8f18-01ac5a6cb57e">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbc060006e064bbca9524dae843e6335_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItMS0xLTEtMA_6a9d7a29-765b-4f3e-8e2d-494551ae833a">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a18315fb614992b5e5d355a07e9360_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItMi0xLTEtMA_2c13e3bc-92f0-4e18-8573-166b35683e42">193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0906ba73795343c2a2e180261f092582_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItMy0xLTEtMA_a3b9ca3c-81a7-45ad-932a-ebabf802d333">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26027c48bade4ff7acf52354b330290d_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItNC0xLTEtMA_15bcf6f1-1d7e-48d9-9399-64990999806e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1341509a716f4cf7adb94b1d81181765_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItNS0xLTEtMA_8fa10cd3-1fbe-4c08-a36a-6b3a8828a9db">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3cc70b838c74057a0eddbcc40f06c72_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItNi0xLTEtMA_a70a4779-e647-470e-bb15-16278f1cc02f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878350a72ee146ab880ae401386a353d_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItNy0xLTEtMA_2e7becf4-56e8-4727-9314-50ef4e203d6d">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i822c73144e3a487798d589465af318e5_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItOC0xLTEtMA_e9a5a336-de2f-422f-8a90-1aea08157745">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b9dc30fa88d4596b1e3378aeddbe13f_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItOS0xLTEtMA_2897bdba-a740-43c4-b342-e79abbbd72a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if38820cb50084fd0a8928b4fff09c1b2_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItMTAtMS0xLTA_eed336aa-cedb-42f3-b88f-30f9243ddb15">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad3b2a712b0e498c9cafbdd3bdc0628b_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtMS0xLTEtMA_7e494537-6ef2-447e-acb9-e93e7c7f7071">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140d1f4f250d42e78b3172103a09a2c9_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtMi0xLTEtMA_e30bcf32-95e8-4c65-9d7c-44e03747462a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd389ffc711425dad2694706f9e91f0_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtMy0xLTEtMA_98cf980b-e61b-4ae5-b621-d27ef460f7c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf315858f46544fda7be3aa113c4fe5e_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtNC0xLTEtMA_9ba0a6cd-2358-4c1c-99a4-d110b2f70e8d">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0216e83e61184ac5a91bab7c9e89040e_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtNS0xLTEtMA_53a7ea57-cf45-4ae2-889a-916594c2ad93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204355d7d9a948e5a652a98e8a346114_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtNi0xLTEtMA_2e73e88c-ee5c-42cd-b874-d1db6c285133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i22bf2da4717d42ec8e7363aaabf9331c_D20191230-20200329" xsi:nil="true" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtNy0xLTEtMA_05956402-96c0-4a5b-bca4-d125bca5b642"></ix:nonFraction></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadca5d6789ff4116b0dce69a9dfc7267_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtOC0xLTEtMA_06e2ba67-0dcd-437d-8b71-a54020f27727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2257a4164c24da4808f08e7779edb63_D20191230-20200329" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtOS0xLTEtMA_4a446925-4a8a-45d9-b1a1-db3b07adb8da">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf3c269c11bd42aea7263d884b1eb127_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtMTAtMS0xLTA_5aee254b-6764-484d-86ee-188b82fe82d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad3b2a712b0e498c9cafbdd3bdc0628b_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctMS0xLTEtMA_998c0d52-1fa6-4f05-a808-75765e774521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140d1f4f250d42e78b3172103a09a2c9_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctMi0xLTEtMA_5131542d-2a2c-48c5-9a94-580aa8bdd6d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd389ffc711425dad2694706f9e91f0_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctMy0xLTEtMA_845de5ed-ca6e-4fbe-a09b-fd7673638bcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf315858f46544fda7be3aa113c4fe5e_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctNC0xLTEtMA_4a9ace5c-0690-4848-84b0-d8966fe48a97">307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0216e83e61184ac5a91bab7c9e89040e_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctNS0xLTEtMA_28ca5345-524a-48b2-b6b4-1b4eda34cd18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204355d7d9a948e5a652a98e8a346114_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctNi0xLTEtMA_3aa5a1d5-b254-486a-8b7d-7f82494a4023">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22bf2da4717d42ec8e7363aaabf9331c_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctNy0xLTEtMA_ad62edd5-6e56-45f0-a844-c13c691c8b31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadca5d6789ff4116b0dce69a9dfc7267_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctOC0xLTEtMA_0bcd7a0f-dda3-4f6c-9b28-4a96f5e9775d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2257a4164c24da4808f08e7779edb63_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctOS0xLTEtMA_b21eb616-1da4-4977-a1a2-ba1525ca8f72">625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf3c269c11bd42aea7263d884b1eb127_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctMTAtMS0xLTA_812d466d-12c7-433f-bebc-74cb8632e8cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><ix:continuation id="idaade545d3614087ab2eaa624380da5f" continuedAt="i6fb1d938605e457d893f4649fec4a175"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters 2021 and 2020: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwMjg_c4e933cb-99f3-41cd-9548-6cde4a3f8145" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.532%"><tr><td style="width:1.0%"></td><td style="width:34.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.896%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b228055f3cd41bb8574ba5091b477ab_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRjNzAwNDM1YjcxMjQwNmVhYmIwOTJiNzUzY2UyODE3L3RhYmxlcmFuZ2U6NGM3MDA0MzViNzEyNDA2ZWFiYjA5MmI3NTNjZTI4MTdfNC00LTEtMS0w_d6cf8ec7-75de-42a9-b66a-228daae1081b">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea3523edfc54b9795f412328fb8cc54_D20191230-20200329" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRjNzAwNDM1YjcxMjQwNmVhYmIwOTJiNzUzY2UyODE3L3RhYmxlcmFuZ2U6NGM3MDA0MzViNzEyNDA2ZWFiYjA5MmI3NTNjZTI4MTdfNC02LTEtMS0w_61efab88-8f74-4d85-9c7e-6383cb17ba2f">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="icdda76bf017340e9886c40d7cb5330f7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal first quarters ended in 2021 and 2020</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfMy0yLTEtMS0w_5ebac5d3-9cf1-449a-b277-a04b068a4ea2">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfMy00LTEtMS0w_325fe074-4a31-4a63-b66c-9ec302c56fae">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d3a64af1b114e0faba3662a1c101141_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfMy04LTEtMS0w_aa6dedf3-362e-49d1-99b0-7f6267d2d402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ee10e36a6846f9a154a6a47b79529a_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfMy0xMC0xLTEtMA_6e5a7768-5292-4224-8916-37dda8967262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14fe7f8132004082bcb935f2f27f8655_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfNC0yLTEtMS0w_12625a20-fa56-4c84-ab90-7c0416dfc1b3">361</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bdc996add34d468a13b2fe99d899e7_D20191230-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfNC00LTEtMS0w_740c5d80-854b-429d-a5d8-8c228d49190e">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87420fbb466e4d8f880a94561a21e400_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfNC04LTEtMS0w_5ade0b11-93c9-4c3a-8eba-4e185e2ffcd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i946eb5aeb32245f6be05dc48e566fa0b_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfNC0xMC0xLTEtMA_522f389e-ee31-48ef-b55e-ac6dc8b88775">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.791%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwMTY_404d638d-c71f-4fb0-801c-e8b476ac4490" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:25.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.464%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i232b3bcc9db9455c814fc452f8315a6d_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfMi0yLTEtMS0w_da3f2d7c-1b7e-44d9-88ea-9e47275149b8">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bc1a06bc0d240b8852a2c4d4a71d78a_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfMi00LTEtMS0w_131e8248-62fd-4a3f-a46a-c53cb610e355">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc1a06bc0d240b8852a2c4d4a71d78a_D20210104-20210404" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfMi02LTEtMS0w_9702c491-ca3c-4b05-8910-c12afcef2a89">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7bd67d98bc44c14b76b19b4583f853b_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfMi04LTEtMS0w_3e07f81c-5db7-4825-92d7-35f66d549cfc">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7bd67d98bc44c14b76b19b4583f853b_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfMi0xMC0xLTEtMA_fffaadf0-8a65-4001-8041-17463de5f436">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18cccc27ae74f93a145a0bb576d9145_I20210103" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfNC0yLTEtMS0w_4be66762-d261-4845-9813-2e757530f54b">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idac7648f2ee14ded909ba25b98704f30_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfNC00LTEtMS0w_90b80eaa-2577-4ab0-a1d4-dbb7da6bebaf">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac7648f2ee14ded909ba25b98704f30_D20210104-20210404" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfNC02LTEtMS0w_f70ccd22-5a6e-4248-92c4-7f36fdd0155e">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3db46d4c79c4830b0ea1b74ee41714e_I20210404" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfNC04LTEtMS0w_bb264466-f9ac-41a7-b55c-6abbf5b97d6c">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3db46d4c79c4830b0ea1b74ee41714e_I20210404" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfNC0xMC0xLTEtMA_558a3d71-6897-439f-9a0c-cb9899730b34">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity investments without readily determinable market values, $<ix:nonFraction unitRef="usd" contextRef="idac7648f2ee14ded909ba25b98704f30_D20210104-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="jnj:EquityFairValueAdjustmentImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfNjQ4NA_689e17ca-555e-4b07-bd65-c88bbbbb25c9">55</ix:nonFraction> million of the decrease in the fair value reflected in net income were the result of impairments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i6fb1d938605e457d893f4649fec4a175" continuedAt="i95ef4f5f8d654cbebea9f749679105be"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Significant unobservable inputs.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwNTM_d874a7e5-bdbf-4e65-8515-d3af6db4f447" continuedAt="i2faf7e09dc7f4a78ae43aec5c10e5c20" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of April&#160;4, 2021 and January&#160;3, 2021 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:48.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55cbe2969894f10bd11012937cb3cdd_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNC0yLTEtMS0w_51d11691-f095-457c-8aac-3aa153700d04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd05909aea443d3b6e90c5026e77987_I20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNC00LTEtMS0w_9d8b16aa-5974-4909-b949-2934fdb8195a">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i750ed2565a694c9c819af99b440bccb0_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNC02LTEtMS0w_32ec99e6-1b98-477e-a1e5-cf6d95138d35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72107b2f41048608d40b52f7842ac46_I20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNC04LTEtMS0w_0c22250c-f22b-4ee2-8669-e6a7256b6c77">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3281569ca4124bab9a05c92d04b015b3_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNC0xMC0xLTEtMA_80de9269-77f9-4378-9c33-867d1a028896">849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee80bb4dedc94292864c36970f859808_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNS0yLTEtMS0w_51a95925-1d92-42e9-9ceb-c7942ed6bc58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic246ecfdb3484602b3397443c4ae0302_I20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNS00LTEtMS0w_bc3aed2a-4983-4365-be45-4055d7fa66c6">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cca5da5737441298ed9e781c444cab4_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNS02LTEtMS0w_94f969b7-6fc9-400c-a5bc-b8d4b4abe275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c58449914d342049beb19957b06dcd4_I20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNS04LTEtMS0w_0203435e-58ab-46d2-a2ca-3c050233c414">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6112627e2fe7456bbf10241a8ee92b8e_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNS0xMC0xLTEtMA_30ea51a4-a6a0-4cf3-bad6-9f28b973cc93">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b449f24e1840a188eeaea7b64de5c5_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNy0yLTEtMS0w_d95e7617-0db2-4af4-8905-719ef8ee76d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087920326dbc4003933caee61ef1d032_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNy00LTEtMS0w_4524ad2e-7a4f-436e-9661-0e0bc5845586">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9081f2f0d3934ae7b2f8a1376e4c854c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNy02LTEtMS0w_b881775b-347b-4389-bdf5-aeb7d052bbc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNy04LTEtMS0w_0b95cd1c-953b-4bef-9dfe-b438931dd296">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1d3968138264974924b828c7a733b2e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNy0xMC0xLTEtMA_386a8e9d-4fe4-42a2-a763-1e107f94ecb2">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55cbe2969894f10bd11012937cb3cdd_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfOS0yLTEtMS0w_f33875ec-8f74-43e9-a1d5-12b75366394c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd05909aea443d3b6e90c5026e77987_I20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfOS00LTEtMS0w_a9681353-e1e5-4e63-9cc5-9cbc95f9016c">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i750ed2565a694c9c819af99b440bccb0_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfOS02LTEtMS0w_277d5e22-6c0d-4920-a434-2919ebd0515f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72107b2f41048608d40b52f7842ac46_I20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfOS04LTEtMS0w_c9263a66-9e4b-4ef7-bd83-8299edc944b8">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3281569ca4124bab9a05c92d04b015b3_I20210103" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfOS0xMC0xLTEtMA_adb78f11-a9a3-4aac-801c-11c3e5f5ae7f">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee80bb4dedc94292864c36970f859808_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTAtMi0xLTEtMA_dc0d73c5-f016-49ad-b0e7-83044275be2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic246ecfdb3484602b3397443c4ae0302_I20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTAtNC0xLTEtMA_1429cd9c-9b9a-4472-8679-b41d51b2daf9">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cca5da5737441298ed9e781c444cab4_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTAtNi0xLTEtMA_8cec1566-e142-4291-996c-dff0ee5f47dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c58449914d342049beb19957b06dcd4_I20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTAtOC0xLTEtMA_860cca82-3b68-4be0-a254-631f4d3196a3">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6112627e2fe7456bbf10241a8ee92b8e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTAtMTAtMS0xLTA_80b62337-ac43-4282-a89e-a5fdd469dbc1">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b449f24e1840a188eeaea7b64de5c5_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTItMi0xLTEtMA_5d36fb7b-0821-40c6-a0dd-45d906f78e3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087920326dbc4003933caee61ef1d032_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTItNC0xLTEtMA_1b876ec7-68ec-4809-ab21-e55ffdfbfae9">1,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9081f2f0d3934ae7b2f8a1376e4c854c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTItNi0xLTEtMA_a7dfe8cc-2a7a-4b8a-8864-637d6501b979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTItOC0xLTEtMA_4aad8ff7-af33-4a2e-bd63-e6c6898e4806">1,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1d3968138264974924b828c7a733b2e_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTItMTAtMS0xLTA_23c32018-3a61-4463-a174-c5ca37b914d2">2,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55cbe2969894f10bd11012937cb3cdd_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTUtMi0xLTEtMA_cfbf59ae-c18d-416e-8184-f1e0ac8c3a98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd05909aea443d3b6e90c5026e77987_I20210404" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTUtNC0xLTEtMA_b96f38a6-6895-4840-bd28-69a2ef40d8ef">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i750ed2565a694c9c819af99b440bccb0_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTUtNi0xLTEtMA_29219705-7d9b-4e02-a3ce-35c0f4b302de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72107b2f41048608d40b52f7842ac46_I20210404" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTUtOC0xLTEtMA_e13c84d5-4846-4beb-a8f2-cd66b3d45de3">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3281569ca4124bab9a05c92d04b015b3_I20210103" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTUtMTAtMS0xLTA_f553b083-2263-476c-a49b-b033a592ab12">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55cbe2969894f10bd11012937cb3cdd_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTctMi0xLTEtMA_c9f7fff4-3e6b-4020-915f-33bed5a5ff57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd05909aea443d3b6e90c5026e77987_I20210404" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTctNC0xLTEtMA_54728e7b-520b-48b1-bc58-ad44efffae0b">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i750ed2565a694c9c819af99b440bccb0_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTctNi0xLTEtMA_297f5073-b9ca-4535-a6d1-5826cfd4a4f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72107b2f41048608d40b52f7842ac46_I20210404" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTctOC0xLTEtMA_0c8f6e6e-da0f-47c4-bdcc-5350681801e7">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3281569ca4124bab9a05c92d04b015b3_I20210103" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTctMTAtMS0xLTA_529fa54d-0f65-477b-9941-77b3228cd727">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b449f24e1840a188eeaea7b64de5c5_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTktMi0xLTEtMA_909c5866-e728-43d6-9689-2c322dacb004">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087920326dbc4003933caee61ef1d032_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTktNC0xLTEtMA_4f722440-56ff-4344-805b-b42d95ea2cab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9081f2f0d3934ae7b2f8a1376e4c854c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTktNi0xLTEtMA_83078432-01a1-421b-85f5-80e8f47c579e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTktOC0xLTEtMA_c03cda27-83ba-4492-80e5-eb2c2a7c1338">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTktMTAtMS0xLTA_7922ff22-60f8-4d99-a2cb-a7b37306a597">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b449f24e1840a188eeaea7b64de5c5_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjAtMi0xLTEtMA_896348aa-e62d-43b8-a2b7-27fcf34d635f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087920326dbc4003933caee61ef1d032_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjAtNC0xLTEtMA_acaf40e0-ee4f-45a5-b532-57e07342c723">14,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9081f2f0d3934ae7b2f8a1376e4c854c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjAtNi0xLTEtMA_c2cdde8f-00f4-4f1c-beff-3a5f9535c8be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjAtOC0xLTEtMA_b5f23008-9c8d-4c37-891f-f815dc3a0a5e">14,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjAtMTAtMS0xLTA_3795a3f8-451e-48aa-8b1d-1a5f86c98f9d">14,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b449f24e1840a188eeaea7b64de5c5_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjItMi0xLTEtMA_c4eff1eb-ddf9-4f34-b1d5-4806d755421c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087920326dbc4003933caee61ef1d032_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjItNC0xLTEtMA_e26dfa9f-516b-49b6-aedf-26035bccc32d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9081f2f0d3934ae7b2f8a1376e4c854c_I20210404" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjItNi0xLTEtMA_a20ab512-a7a4-4a46-9f2c-e593c3bc237e">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjItOC0xLTEtMA_9ff31e47-0c60-439b-b8ed-91523c867404">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjItMTAtMS0xLTA_65c8737b-7e66-4c02-83ac-53d29052198e">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfMi0yLTEtMS0w_fce27494-7991-41dc-886a-c3a5d546a6b4">1,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfMi00LTEtMS0w_9572a46a-81e2-4438-9ec7-6a4607c79428">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfMy0yLTEtMS0w_5c41c60e-2267-4a09-8bcd-fde465fab492">1,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfMy00LTEtMS0w_7f47f689-42a8-4cf1-9195-7a6906657265">1,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfNC0yLTEtMS0w_afff9db5-e259-427a-903f-c778e41e021f">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfNC00LTEtMS0w_485ec7d7-8549-4fa0-8037-cac2dad8c88e">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfNi0yLTEtMS0w_4aeba229-9be2-4437-879b-494cd3c85579">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfNi00LTEtMS0w_1ebfa0ef-a05b-4923-b8a1-3d8d7ea9d84e">2,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfNy0yLTEtMS0w_5feca86a-1f27-4859-b248-f1f2ae6146a5">1,130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfNy00LTEtMS0w_ac9ac62c-0ae9-4389-a35e-92ce1f4fb996">2,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfOC0yLTEtMS0w_9190a406-e942-4a8f-b5e3-2f7ce677a4ee">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfOC00LTEtMS0w_593e1c5a-c1d3-4cb3-94e2-0e19d7619903">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><ix:continuation id="i95ef4f5f8d654cbebea9f749679105be" continuedAt="i089450ed47674d329970b219c0e510f5"><ix:continuation id="i2faf7e09dc7f4a78ae43aec5c10e5c20" continuedAt="if2f59dd6eb6541299a11efe5741c299f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.807%"><tr><td style="width:1.0%"></td><td style="width:41.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.606%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfMy0yLTEtMS0w_fb112e04-5add-49cf-b70f-c75956f57d18">633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b90fcac8194c0c83439d028eb794fa_I20191229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfMy00LTEtMS0w_dddb08fd-52d7-40d4-8e09-58eb75bc4e94">1,715</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNC0yLTEtMS0w_8911c985-fde3-4510-842b-d6c8e726168e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" sign="-" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNC00LTEtMS0w_5c643d5a-983c-46a8-b51e-04bd6f2f2977">977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNS0yLTEtMS0w_c7010fcd-c5ea-473d-84fa-b941d8ae0641">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNS00LTEtMS0w_38c1205c-cb7f-4940-92d0-d18efd1d2ce5">106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNi0yLTEtMS0w_52517cfb-dd05-44cb-8e11-809fdb8f9742">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNi00LTEtMS0w_727d6ea5-bc0b-4725-8009-32771fafdabf">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNy0yLTEtMS0w_7f0ee57a-9113-4612-bc6d-5293285e127a">600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f9f433686145c29000c017762e5f79_I20200329" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNy00LTEtMS0w_77896037-ee71-48df-b2ab-edb34bf9c98d">784</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $<ix:nonFraction unitRef="usd" contextRef="i4b53ffb9394c4a118127e114b531b8f2_I20210103" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfODg1OA_d4304775-786a-44cd-9c38-646259256e06">1,481</ix:nonFraction> million, which are classified as Level 1 and contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i8fef9ce1b1c94e7baad55d8c2f003ca8_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfODkyNg_c7fa5f3b-7f00-48f5-996a-f6c5e14b38a2">633</ix:nonFraction> million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $<ix:nonFraction unitRef="usd" contextRef="if9108e0198f1454fbc22f7c1d46a4ac8_I20210404" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfOTIzMg_4ff583cb-a855-434d-b11b-be9eadac9aec">589</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie06eb83c93424fc38c8f74e769309ab0_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfOTI0Nw_1d9664ab-2d8d-480a-b5f1-6c9363926e4c">594</ix:nonFraction> million, classified as non-current other liabilities as of April&#160;4, 2021 and January&#160;3, 2021, respectively.  Includes $<ix:nonFraction unitRef="usd" contextRef="i2ee15e9e3be0451c9104456ede3ce154_I20210404" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfOTQwMQ_927376cb-7179-450f-9afb-6122bf1331cb">11</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic6c3f15ce4ab427d911866506af070e3_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfOTQxNg_7aa08f04-c57c-4452-9f8b-f3fd2c3fd8a1">39</ix:nonFraction> million classified as current liabilities as of April&#160;4, 2021 and January&#160;3, 2021, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. </span></div></ix:continuation><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if2f59dd6eb6541299a11efe5741c299f">The Company recorded a contingent consideration reversal of $<ix:nonFraction unitRef="usd" contextRef="ib7915bfce2cf46dca29a5703af986b2e_D20191230-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfOTY2OQ_73cdb12d-f29d-46fa-820c-ea2435c8cf6a">983</ix:nonFraction> million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense, net.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i089450ed47674d329970b219c0e510f5" continuedAt="i57c11d54d579463dbc58105bd310a271"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwNTY_db0125ef-ece1-43b2-8f93-3c260893d10b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of April&#160;4, 2021 comprised:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:22.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Gain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdfbb11f0c04c20a79df23a07ba5ecc_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMS0xLTEtMS0w_afee55ae-7e5f-4c05-9707-9f430cd4f3e7">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdfbb11f0c04c20a79df23a07ba5ecc_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMS0zLTEtMS0w_9fa09481-5be9-42a9-b957-a5a8f1bacd4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdfbb11f0c04c20a79df23a07ba5ecc_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMS01LTEtMS0w_78223eb1-8f38-4e93-91c9-3db961b21234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdfbb11f0c04c20a79df23a07ba5ecc_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMS03LTEtMS0w_d5ad262a-cb6b-4007-b8d7-0b701ba11390">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdfbb11f0c04c20a79df23a07ba5ecc_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMS05LTEtMS0w_7e604f23-74f3-4d4f-b7fd-963332536371">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bde608450a04e129af5ff3ed4538b5d_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMy0xLTEtMS0w_329ff2ca-df99-4cd4-b738-d96a97ea8535">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bde608450a04e129af5ff3ed4538b5d_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMy0zLTEtMS0w_53756f1f-116d-46dc-a1f2-add8cc70c127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bde608450a04e129af5ff3ed4538b5d_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMy01LTEtMS0w_c0e5dad7-3fb9-42eb-985d-b845ef51a589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bde608450a04e129af5ff3ed4538b5d_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMy03LTEtMS0w_c7241049-f67c-408a-87b0-37064f76e439">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bde608450a04e129af5ff3ed4538b5d_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMy05LTEtMS0w_886839ca-fd84-4b8c-9083-2fd1b037958e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bde608450a04e129af5ff3ed4538b5d_I20210404" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMy0xMS0xLTEtMA_1886fcb5-eae6-4afd-ade8-2b18d1004c72">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e402b3caab4da7802a67171676c4f0_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNC0xLTEtMS0w_88746f53-254c-4b2c-8f9e-765ef3d10e98">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e402b3caab4da7802a67171676c4f0_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNC0zLTEtMS0w_e7f62a14-0e80-41e5-8b10-ec8736a9b6eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e402b3caab4da7802a67171676c4f0_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNC01LTEtMS0w_a24c071b-1b62-49d7-8396-949c14dc3ab6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e402b3caab4da7802a67171676c4f0_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNC03LTEtMS0w_f52175db-0220-46d9-8e8b-711bbb75ff2f">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e402b3caab4da7802a67171676c4f0_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNC05LTEtMS0w_081636ee-bf76-4d73-bf54-dc5322231740">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e402b3caab4da7802a67171676c4f0_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNC0xMS0xLTEtMA_91330a3c-6f39-4298-b2d2-6ccf24cfe33f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other reverse repurchase agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2aae0ebe6c54209a9f723970cc996ab_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNS0xLTEtMS0w_c79cdde4-a6a3-49de-b297-2ea2de77f7dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2aae0ebe6c54209a9f723970cc996ab_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNS0zLTEtMS0w_34d8ff91-26c1-4a7f-ac10-2b0267397583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2aae0ebe6c54209a9f723970cc996ab_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNS01LTEtMS0w_fa0ddbf1-ec36-4efc-b92c-158bfe5852a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2aae0ebe6c54209a9f723970cc996ab_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNS03LTEtMS0w_a634630a-6cb5-4bd5-be87-7d7a8eeda567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2aae0ebe6c54209a9f723970cc996ab_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNS05LTEtMS0w_6b767675-9ed8-45cb-b4c7-df38eb285ef2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d02a87aab8433eb31b762adf895c58_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNi0xLTEtMS0w_695980ef-a952-45ac-b59d-25ba251a2ab4">3,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d02a87aab8433eb31b762adf895c58_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNi0zLTEtMS0w_c664ed98-d187-49d9-b3d2-e35c38b8cecf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d02a87aab8433eb31b762adf895c58_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNi01LTEtMS0w_7694df9e-d818-46c0-8a9f-0c6db97ee097">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d02a87aab8433eb31b762adf895c58_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNi03LTEtMS0w_56fa1aa6-b198-4ac4-ae5c-fea4785efe5c">3,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d02a87aab8433eb31b762adf895c58_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNi05LTEtMS0w_8d8737c5-7162-4553-9b2f-eb1e2e106e3f">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d02a87aab8433eb31b762adf895c58_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNi0xMS0xLTEtMA_79ce4a37-9f95-4b83-b69a-eed5bf9a89e4">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53522da16d414a2cbe5ee063bc15169e_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNy0xLTEtMS0w_07c2a595-c43f-4228-88d7-f43ad057ac2c">2,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53522da16d414a2cbe5ee063bc15169e_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNy0zLTEtMS0w_b09891ef-d9fe-4c28-9e2b-0cc626113799">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53522da16d414a2cbe5ee063bc15169e_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNy01LTEtMS0w_1a21bff0-ba43-43dd-a10d-215f2bd603c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53522da16d414a2cbe5ee063bc15169e_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNy03LTEtMS0w_07a60311-4628-40be-8185-e1e97086d0c8">2,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53522da16d414a2cbe5ee063bc15169e_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNy05LTEtMS0w_281f2699-963e-415c-b822-005c9b56adb7">2,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c13e647c3264f6d9f7597704bbc8077_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOC0xLTEtMS0w_37d0e769-a18c-4b68-8cde-5c44964bc988">947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c13e647c3264f6d9f7597704bbc8077_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOC0zLTEtMS0w_abc5eb17-067c-4912-8f51-68af46fe9ca3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c13e647c3264f6d9f7597704bbc8077_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOC01LTEtMS0w_395e80fd-a01c-4cb5-a11b-9d412cb1bb02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c13e647c3264f6d9f7597704bbc8077_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOC03LTEtMS0w_ccb15e9d-964f-4f9f-ab3a-4e1fe33f6746">947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c13e647c3264f6d9f7597704bbc8077_I20210404" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOC05LTEtMS0w_7b3f6462-5abf-47b0-ac0d-1284f2f6e4df">947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOS0xLTEtMS0w_09767cb7-0348-4a4e-8ade-a44c58997779">10,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOS0zLTEtMS0w_c55d50b9-9047-4209-9b4c-ee67af86bd29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOS01LTEtMS0w_6c1d7071-d686-4b71-92ea-06ff889e1af8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOS03LTEtMS0w_df171a7f-a531-4e02-b843-6df6be7c34a6">10,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOS05LTEtMS0w_31626505-311f-4efc-a560-2f240239ba5e">8,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOS0xMS0xLTEtMA_bd041861-c0f5-4371-bc1d-143291089580">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTItMS0xLTEtMA_5ff05e1f-a2ac-464b-965b-44b09739ffea">14,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTItMy0xLTEtMA_49195c19-166a-42bb-8704-0edcee5e9653">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTItNS0xLTEtMA_f5e6e0fb-745b-4796-805d-e44f1a013b8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTItNy0xLTEtMA_b03bb212-59b2-47da-b85d-f7b408ea42ef">14,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTItOS0xLTEtMA_87699035-aa74-481f-908e-049468ed98d3">4,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTItMTEtMS0xLTA_6d9e42dd-f704-412f-a0f6-2e73877b1d5a">9,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other sovereign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34dd034a8ce44d78c8d013272369235_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtMS0xLTEtMA_3d3d7013-7a1d-413b-8ff3-3dea5db91cee">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34dd034a8ce44d78c8d013272369235_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtMy0xLTEtMA_b8ae70f2-e5cc-4c0a-8249-0d245eda5601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34dd034a8ce44d78c8d013272369235_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtNS0xLTEtMA_9e175d92-aafa-44c7-bbde-538ef8899377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34dd034a8ce44d78c8d013272369235_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtNy0xLTEtMA_db48f2f1-9593-4f4e-86b0-f9aea0fd141f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34dd034a8ce44d78c8d013272369235_I20210404" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtOS0xLTEtMA_12763ac6-d3b5-4ba9-8135-ef6fdd422748">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34dd034a8ce44d78c8d013272369235_I20210404" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtMTEtMS0xLTA_03e1e097-8210-4609-8fb6-3cd14f7b771b"><ix:nonFraction unitRef="usd" contextRef="id34dd034a8ce44d78c8d013272369235_I20210404" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtMTEtMS0xLTA_f3342731-7ef2-4aa3-a68c-fbb891477940">7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTQtMS0xLTEtMA_f00762ae-8fcf-41a4-b57e-3509028ce775">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTQtMy0xLTEtMA_0affdfa5-e76d-4def-b7e2-db02ac7aa7eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTQtNS0xLTEtMA_eb35b467-1110-4960-8f25-2cb7e74fe5dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTQtNy0xLTEtMA_8e75b115-df1a-4ac3-b02a-965d2ce8acb0">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTQtOS0xLTEtMA_0fdd4fef-c1a3-4f4e-a5d7-fb1daa23d96c">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTQtMTEtMS0xLTA_63a2bd60-b071-4c3b-9842-61ee57056082">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ad5b35a58e4a549a452417ff62e50f_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTUtMS0xLTEtMA_fb4d8fb1-704a-42d9-8c30-ae9e727dae39">14,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ad5b35a58e4a549a452417ff62e50f_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTUtMy0xLTEtMA_c9764e61-e615-4547-a04f-9f25418d3591">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ad5b35a58e4a549a452417ff62e50f_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTUtNS0xLTEtMA_d667a7a3-d93a-4270-8679-4304b103713b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ad5b35a58e4a549a452417ff62e50f_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTUtNy0xLTEtMA_42613c0e-cff9-4bac-abd9-c0a5f322ba1b">14,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ad5b35a58e4a549a452417ff62e50f_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTUtOS0xLTEtMA_bae475a9-fbef-44f2-8db9-dd7bd40d59f4">4,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ad5b35a58e4a549a452417ff62e50f_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTUtMTEtMS0xLTA_e6a6c966-f696-4881-bae6-835a192517e1">10,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTYtMS0xLTEtMA_0b8df3ef-36ea-425b-8570-d2f93a82780a">24,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" name="jnj:CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTYtMy0xLTEtMA_60e731c9-e697-43e6-a48a-b0f13f1bcf6e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:zerodash" name="jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTYtNS0xLTEtMA_22a232b5-cdb5-4829-8486-390211359f8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTYtNy0xLTEtMA_42a079b9-8e01-4606-a4db-11a978af6a21">24,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTYtOS0xLTEtMA_add481dd-71fe-4a66-88bc-e34e32e1144d">12,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTYtMTEtMS0xLTA_5db65d5f-5eba-4d81-a98a-5a611a9b5a98">11,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal year ended January&#160;3, 2021 the carrying amount was approximately the same as the estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwMTk_413df230-255c-4149-a5eb-1634cfa5f8cc" escape="true">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwNzA_b1424772-6bf0-4bf4-8a09-bb85f690f52c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of April&#160;4, 2021 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.415%"><tr><td style="width:1.0%"></td><td style="width:43.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfMS0yLTEtMS0w_154c2ec9-01bd-4b8d-abdf-1f31a5367d24">14,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfMS00LTEtMS0w_09a3188e-72d0-44d7-97b2-8b8e61fba3b2">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfMi0yLTEtMS0w_a34a3787-7152-4313-831a-80e59c61b4cd">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfMi00LTEtMS0w_aa85ce27-e14d-42a5-9be5-53fc6d84d744">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfMy0yLTEtMS0w_4bf92425-44ad-48e0-9be7-551fd1f6d9a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfMy00LTEtMS0w_e3774998-4a8e-446b-8ece-62345fbd6bea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfNC0yLTEtMS0w_61d47383-8ad3-4de4-a8e8-96c7a1a143ce">14,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfNC00LTEtMS0w_ef0db8fc-2fcd-412a-8154-cbac0883b21b">14,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i57c11d54d579463dbc58105bd310a271" continuedAt="id22baa04529c4fcbaa690e001293c90e"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwMTE_3efa5c98-2907-41d1-821b-1f4679c0a675" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;4, 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.259%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia551774380104d5a9cb2e81ed84e5fbc_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNC0yLTEtMS0w_256989e6-dd3a-491f-8de3-e0dec3d89054">3,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6527580553d4feaa0905f4262bf370f_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNC00LTEtMS0w_3562b329-a56a-40ad-962c-38c27523f6d7">3,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if362b20960c24710b7e9131a1f050ad8_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOmUwZmU0N2Y2M2IwZTRmNjFhOWNkYWVmYzU3ZWVhM2Y2XzQ_d976cb9d-4822-4900-bcf6-35332ba89b04">6.73</ix:nonFraction>% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f92bb8177d4d7b8cd1179e1735f8d6_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTEtMi0xLTEtMA_e506c04b-7338-499b-9d6c-79880b669ad4">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i080bcda1e8fc49b9b3b8f7f21d977c2e_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTEtNC0xLTEtMA_5713b8c0-eab2-4ec9-b8bb-0cb240b9f87f">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4db85c50deb4321b0098f8ccf20b46a_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTItMC0xLTEtMC90ZXh0cmVnaW9uOmM2MTdhMTc0NmViYjQ4ZGZiNDQyMjc3MTk5Mjk4YTZiXzQ_c5eca0a1-4d12-45da-ba40-21508a35ab6a">3.375</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc61c2b232f40b88208ae48fe534d86_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTItMi0xLTEtMA_7c9df107-c7a7-4015-adde-aae655391972">802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffab5554feae486aaf2e6e43a90b37e5_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTItNC0xLTEtMA_216a95d5-9ad3-4c3f-ac8d-0ef16542fdc7">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9bcc1b72d9204d9fb6b0776f239845df_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOmYyYzkxYjMxMzA3MjRjZjNiYzJmMTU2NmVmM2VlMDU5XzQ_7ab135a9-a56a-47e4-a65a-85d17a34c47f">2.05</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d1395460274475eb8aec4f946ce6846_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTMtMi0xLTEtMA_a90a730e-607b-41e2-8505-8e6d2f6908bf">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c7696b31ef458dbdebd3465124db85_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTMtNC0xLTEtMA_9e51fae6-fb38-49e5-8a38-451bf0e50f2e">515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i232ebe15fffe4208ae8fe01bb810d201_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOmJkNTgwNGNiNmY3YzRiYTg4ZTA5M2ZhMDZkODg2NTNkXzQ_fef2c663-44ed-4dc3-adc4-6afb6d92c3ef">0.650</ix:nonFraction>% Notes due 2024 (750MM Euro 1.1757)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ecca6252ec6440ab50478e4522c9cb9_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTQtMi0xLTEtMA_9da87d8d-144c-46af-ad9c-dc7670c7347f">880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b9cda0ccb141c2b49c9bbf460578e8_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTQtNC0xLTEtMA_f8eb896e-6e00-4235-b478-3f4f89249631">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01bc079fc7af4d169035bc9957d09c9d_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTUtMC0xLTEtMC90ZXh0cmVnaW9uOjJmNDFmMWViNjAwYjRmNzM4M2U3YzY0YWQ5ZGQ3Y2I1XzQ_197f7f2d-d31c-44ec-afe8-234ba5598797">5.50</ix:nonFraction>% Notes due 2024 (500 MM GBP 1.3799)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17306623a4594a4599e905c0006aa969_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTUtMi0xLTEtMA_a02680c2-c47c-4c92-8ee2-187c21431db2">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb973d605fa44eeba1302fbb97d677fa_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTUtNC0xLTEtMA_614be717-2412-4d4e-8881-86ca5327f0b1">808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7218d516a3fa4b1a991bda3b84a3972b_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTYtMC0xLTEtMC90ZXh0cmVnaW9uOjk3OTFlYzUzMTY0OTQ3Y2NhZTA1Yjc5NWZhMjRjMGYzXzQ_081d53f3-351a-4cea-a16e-b5225564b1cd">2.625</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02515bdf715434b91522300dc22073a_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTYtMi0xLTEtMA_55dbb6c8-4a29-4824-8c97-6f160837d4d3">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50dd314f98bc4ea585b34a6ef22d88bd_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTYtNC0xLTEtMA_69661ebd-b2ba-49a8-926c-b127a5c28cf8">797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i85a39dbd593546cb8669a44bf5ba1f36_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTgtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YWZhNDk1N2UzMDQ3ZGZiMTIwNDZhMjQ1NjliODE2XzQ_aaebb5fc-09b2-48a0-9015-a75c3bacb635">0.55</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib067ee5fb75e4a41a8dd5a32a4fc5baf_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTgtMi0xLTEtMA_38df0697-a459-4b9f-a0e2-45cbcc853bba">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida015c71d6964ba4b2e11a562c29b0eb_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTgtNC0xLTEtMA_8d2ccae3-d919-40c8-94e8-d2fd0de0424b">982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5af5af1c6e1541e99b3ea8ce7066da11_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTktMC0xLTEtMC90ZXh0cmVnaW9uOjQ5MjgzODNjNTk0NjQxNzI5ZTY1ODAwNGQ3NzI4YTc1XzQ_b7999144-1d78-4157-9e51-c5a03fa78e55">2.45</ix:nonFraction>% Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0514f7f1d16f40e0b128088ad9ec2a66_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTktMi0xLTEtMA_2de91aaf-750d-48cc-befe-8ff347b27256">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c97765733f04d0ab64e6cc604f9feaf_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTktNC0xLTEtMA_2ead5f22-29bf-4a17-87fe-d0204d869ce8">2,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9fca91959a44bc99f389c8604972d5a_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0ODcwZDA4MjdkNjQyNzU5ZTVmNTRiMjZiMmU3ZDQ4XzQ_6ccc0691-395d-418f-8d20-8282f6d27369">2.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab9b12aba8443be862462c8b208e6ff_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjAtMi0xLTEtMA_45220b42-3488-4aaa-80c0-b19cc9df467b">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9d564117274a81b671fc45094fcb9d_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjAtNC0xLTEtMA_396a815a-bd43-437d-9875-4f92e1365286">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i885f427d1f254de2a0594cd4499d4276_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjItMC0xLTEtMC90ZXh0cmVnaW9uOmJhNGQ1MmYyYjI3YjRiNjQ5ODQyOTgxNDRjM2I0NDFlXzQ_5f8336f2-05e3-4165-a7cb-c9476c408400">0.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87c8983a8b144e0a0b7a8d79fd69370_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjItMi0xLTEtMA_ca6dcbea-fc47-4b38-91f2-13baf924e001">1,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641f9be9a5ad45c5b83f607f6d1f3eda_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjItNC0xLTEtMA_3af012f1-4465-44dd-886f-6e19009be2b4">1,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79896030d67642908f3083ddc47a69c0_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmQwOTRlMTJhYWExOTRkN2Q4YzE4MmMzMmEwZjMxNGUyXzQ_2a3053c6-d1cd-4fa4-b358-7843d4669c9e">2.90</ix:nonFraction>%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d0ffe736bd4dcfbd632eed9b5f65e0_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjMtMi0xLTEtMA_642d1520-9212-44d8-b374-8479c1b7dd33">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20ee57fedc3544d9bd6c9bd722f91f29_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjMtNC0xLTEtMA_fb5da0fa-770a-4032-a787-3a540f15a2e2">1,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7487f3b4696241b19abfcd01b9537fbf_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOjhmNWIyZGNhMmFlZTRjYTRhMmE3NjI4YTQwNTMxOTZkXzQ_ea751742-eb8b-498b-9673-d952a4e4de1c">1.150</ix:nonFraction>% Notes due 2028 (750MM Euro 1.1757)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a6737fe6b814f04816f11baa77695f0_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjQtMi0xLTEtMA_6894b3a7-9d3c-41be-a963-1748ba9118a9">876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd89b0cd024d28be4458c01e872c39_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjQtNC0xLTEtMA_fa4cea81-dd73-475d-9df4-7d975a8c426c">955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd0df51e9f6e40ed9d88e684d9499266_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmUxOWFhODMyZjk4NDQ4ZWFiYTBlYWExYWE5YTYzNWRlXzQ_3240fa43-b72e-4728-a299-2a2bd52cdaa4">6.95</ix:nonFraction>% Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d584c5a1bd4ff0b1a6d41603dd3b08_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjUtMi0xLTEtMA_e38a9ebd-865e-4310-a82d-25f7ebc45228">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65e137191bb04b98bfcb88e12baff57b_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjUtNC0xLTEtMA_fe5dc06e-82ea-45db-baaa-439327c1cd9b">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a9d444d344a4100a0391cef4739483c_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjM1MzYzZmM4YjA0ZTQzYjA5NTFkN2JlNDlhYWRiZTM0XzQ_a9175747-2789-4e47-9e0d-009158306b54">1.30</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5388981f8dd34003b44bcdbb65f1e543_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjctMi0xLTEtMA_3e5e8924-ff4d-4ba4-8138-35506d44122e">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d20b300aee54da4b4d3efd6dc870a65_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjctNC0xLTEtMA_d1d68f8b-5ed2-40ce-ad7e-b7046ce46bc9">1,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d5f6e95714e4bae9c1e910ae22b802f_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmM2MTcxOGYzYWQzNjQ2NDZhMGU5ZDkzYjQ4MWNiZDAwXzQ_064d5b23-d848-4fd5-9ec3-e48e6a91b687">4.95</ix:nonFraction>% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ecc979877e4f0e8a892f8c76441de8_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjgtMi0xLTEtMA_b2210f1b-b833-4f91-8978-3365fd4b4227">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5caa2a14204d6898789b7e13ec13e5_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjgtNC0xLTEtMA_a302d277-3de6-47a3-b128-e26f7d1238d0">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8f2e21bf85c4d6aa21abd973b571c71_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBlYTIyMzRiNWMxMzRhYTY5NjkzZWQ3ZjBjYTU5MjA3XzQ_3be28e57-ca52-44a3-9311-dfa75441d346">4.375</ix:nonFraction>% Notes due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05cd1ceca68a4be7b9e6e339e53f6023_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjktMi0xLTEtMA_489501a7-cba4-4f6f-a735-ec69a582b4f7">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d469fc5b8845779a850f71b49f8b62_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjktNC0xLTEtMA_2a94c776-6f3b-444e-b374-18e88541ea55">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i481f371accbb49f5a40e7d7669b9063d_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjA0YmFjOGNjNDRiN2U4OTA3ODQzYTRjMTFjYzFlXzQ_eadffe87-2043-4142-a4af-c2afa277dbb0">1.650</ix:nonFraction>% Notes due 2035 (1.5B Euro 1.1757)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a96ed3119e94dd8ad5b849b0dfa13af_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzAtMi0xLTEtMA_a4ba431c-88e1-4ff6-bf30-7705d552f69f">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb0b9ad2fc354d65944c2a61b639e19f_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzAtNC0xLTEtMA_1cfed088-ef26-4975-9a7d-7f46a4a2c664">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if558e7c662c6460dbcfc287f05df9a6d_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEzM2QxZGM2Y2M3MTRhMjc4ODNjMjE0OTc3YjM5Y2ZkXzQ_83e819f9-8f21-4965-99cf-96b2e34e06f1">3.55</ix:nonFraction>% Notes due 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8522b9e894d4fdcbef8ee00218f96cd_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzEtMi0xLTEtMA_34e6871f-4f9d-4f4d-a901-c2ae32a2dfa5">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16824b55647942daa85e7513f921c7ed_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzEtNC0xLTEtMA_f76dddb1-e17b-4d36-aa64-7f3557d74b21">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4df43fc8b5ab4339afaf013e8ee480e5_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmEwYjA2ZGE4Y2IzMDQ1NTQ4ZTA2NWVkMTE3ZjA2NzU2XzQ_1d8e3106-a50d-48c9-b85c-8fea7487ad29">5.95</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ff32f415f941d28b01c0eae65ebd16_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzItMi0xLTEtMA_0e9a4c51-ea5e-47ab-9c37-f4d6e1722fd2">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298a5e31ae074ef2b1abcdecc4c9bd6e_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzItNC0xLTEtMA_b462efd2-f83e-48c0-a4aa-67dfe5f48999">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i85c5519ac2c74223abd4ff4bb596aa99_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjg5ODFmZTgzNzhhOTRjM2M4MmE2Yjg0ZTk4YWIyOTUzXzQ_f59ffb5d-4948-4981-b3a8-f7d7eb2d7c55">3.625</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001e8a223ba8491f983e78ad8fa58d53_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzMtMi0xLTEtMA_9d663b95-373c-4823-a162-105d54106c79">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41eefdb455ed41d6bb26fb8467d496d7_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzMtNC0xLTEtMA_da95143e-0d1e-45d4-a48b-2065d087cd2e">1,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib24e4cc519e54204a76fb775b089fea4_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ3NmFkNTBhM2U4MDQ2MTQ4OTBjYTljM2FlY2UxNjA4XzQ_194a3d97-9c7b-4062-b219-4d7260619878">3.40</ix:nonFraction>%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08bc89cac5b142cba9c10b6895ceadba_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzQtMi0xLTEtMA_85a7563c-45d5-484a-83f0-4fb800e71012">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66627c055dbf4a0eb408404ce5322e9e_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzQtNC0xLTEtMA_37aed6b5-4d6c-4b26-95a8-767ef9af2fad">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ec5bd94c75b4263b7251abd5a82e702_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjI1NDY1MTRlMTVjYjRlM2ZhMGQ1YmQ3OTFkYTdhOGU1XzQ_09722fee-109d-4d59-acf6-47a92e0213d9">5.85</ix:nonFraction>% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b60cd521d53474e8b55300042817025_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzUtMi0xLTEtMA_f6a64138-3418-4710-a1f0-81075f948908">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7388370141f140dd8d9ec8e9d39c42fb_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzUtNC0xLTEtMA_e1b43cfb-64b1-4d02-bda5-62d79be0d591">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1155094efd13425786f2ecdb88995104_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjM1MDhhNWMxZTY2MzQ2ZTZiZGM3ZTBmMTI2NDAxY2Q4XzQ_8d5daf91-36c1-4283-b491-d9c42ca799ae">4.50</ix:nonFraction>% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21042b2cd4f347c5865cf57c2a26b8a2_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzYtMi0xLTEtMA_5c3c3c4f-e629-4e69-8454-d7da0f67af3e">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2aff0da8e54f4589d4056567f1b3f6_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzYtNC0xLTEtMA_593150eb-df7e-4768-a498-94221673c7be">676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57fe94aa53c54ce5bf1df72bd198dfae_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjA2MjkyOWIyZWRjODQwZWY4ZmZlYjQzZmY2NDEwNDE2XzQ_0efe28c1-29ec-465b-80ff-e916db04f4d6">2.10</ix:nonFraction>% Notes due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5b5475dca04fa0909cd83bb83e1b41_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzgtMi0xLTEtMA_ada3754b-a260-4179-88c5-86c581e5392b">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90df002b0584aeeb48770c1c328a738_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzgtNC0xLTEtMA_24150865-eb78-478c-a6ab-55cfbcada028">907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieee3f15e281e4b1c872375fbc9f0e83e_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjNlZTJhNTUwZmQ0MTQ4Y2U5NTNlN2I3N2E5NzM3Y2I5XzQ_4d454889-82ac-4185-bdef-79e828466861">4.85</ix:nonFraction>% Notes due 2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c851c9ae9be4c899817cd64ae156b3f_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzktMi0xLTEtMA_2736334d-a0f4-4713-ab62-d8ab92e331c1">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i520739d470874963ac1889aae3a2cb7a_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzktNC0xLTEtMA_e55566ea-5a37-4110-8c1b-376098b69069">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8b7274f1d224358bbaae38c9f942bb2_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOmIyYjY5NmY3YTNkZjQyNzRhZTcxNzU2NGVhNzVhMzBhXzQ_5f3f8073-7af6-491f-8d67-7509645d7d10">4.50</ix:nonFraction>% Notes due 2043</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec18e7fe67d455d845353e1a9594d67_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDAtMi0xLTEtMA_804f9c57-d0d2-43fd-b4a0-2a04b9dd7aaa">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953edb0e44f84203a69075078f4a87a2_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDAtNC0xLTEtMA_2e7415c7-be7e-4314-8b90-78a6e8b282d0">628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i630bac5b3b4c4c1ebdb26307f5299f07_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlYWFlYTMwNmU5NDQwOWQ5YzcyM2E5MGNmY2U0NTgyXzQ_0defde2d-98e8-4878-888f-c226e9886e54">3.70</ix:nonFraction>% Notes due 2046</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d26316cfec049b1a3d5289265e218b2_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDEtMi0xLTEtMA_4e75d4fe-b918-4b08-8e09-7ab9e12f69bb">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3157c394710c4db09c9733fc27554cec_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDEtNC0xLTEtMA_b2000dea-bdcb-4150-8c52-3f7fd2079031">2,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7da76c95df1476cbe7abf79df1c0a8e_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmE4ZmY4YTFhN2MzMDRhYWU5ZmY4OTA3ZDNjNzQ1NjRmXzQ_b15ff602-5eb0-47bc-8081-6796d7559f32">3.75</ix:nonFraction>% Notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552a9d1be5df4fa5b99522a4cbd14464_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDItMi0xLTEtMA_5856caff-6a04-4450-90c8-07081b0166d1">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084e71373b7e4ff08ea007b9768f21b0_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDItNC0xLTEtMA_f4528e4e-a754-49c7-92b8-85fbebba0bee">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d6e2c751f95477baa381dda34964d6d_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjFjZWVmOWYxODU1NDQyNjVhMzRmNDA5N2I5OWE1NjVmXzQ_801810a8-f27b-46c0-adb9-7d4729b03050">3.50</ix:nonFraction>% Notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2340f88dd3fd42c6881635ed13a8ad1e_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDMtMi0xLTEtMA_ad8ea7f7-3452-468f-b3db-a1aa5b9ff93f">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a22670a5e304df9807dd47199a4122b_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDMtNC0xLTEtMA_70e08a85-2212-4ba5-9a80-0dbbf081614a">827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb901ca38ff742d2b392935788bce117_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDQtMC0xLTEtMC90ZXh0cmVnaW9uOmQyNzFkMzBmMTA3YTQ0NjRiZWJiM2U0MzI5NDI0YzQzXzQ_b5b1a1e0-9dee-4d82-bcd0-ca2240154002">2.25</ix:nonFraction>% Notes due 2050</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd2f5ee051df4ee7affc9c9a72a15930_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDQtMi0xLTEtMA_0acc9be2-1a67-4b31-8e19-e7a3b0214493">984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34901dc3115b4d80b6bc2c5a322da841_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDQtNC0xLTEtMA_fe25f69c-c1cb-414c-a00f-b100e4d1cc5f">883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a5e79fdc705408d96c62523a56dd2c9_I20210404" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDUtMC0xLTEtMC90ZXh0cmVnaW9uOmVhODA1MWRiZmJhYTQ4NzA4ZTc3YWRmYjM2NDBjYTFjXzQ_449cec2a-6488-4948-bad5-188879a0aafb">2.45</ix:nonFraction>% Notes due 2060</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ea6a649ed4a4d8b953110b3f73c6be4_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDUtMi0xLTEtMA_982f628f-bd98-4a94-af66-cbcc6118159b">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3f229defa146f0a98220762a4f2b93_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDUtNC0xLTEtMA_be7e6aa6-3a7a-49d6-b9c3-d6c557ddad36">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830d1be156484a03851fff96315b9dea_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDYtMi0xLTEtMA_1e17ddab-9024-44e9-9625-e1c9dfc1cc97">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b6b59bed6954d418eb4c5847b9548be_I20210404" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDYtNC0xLTEtMA_d8eb3b2e-4004-46b1-9e0b-30093121c65c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia551774380104d5a9cb2e81ed84e5fbc_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDctMi0xLTEtMA_82bc48d4-5812-48e8-bf39-2368a70be388">30,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6527580553d4feaa0905f4262bf370f_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDctNC0xLTEtMA_4eb6a328-2555-4165-887a-9cc5f772b46d">33,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average effective interest rate on non-current debt is <ix:nonFraction unitRef="number" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTEzODY_bebdd250-2cc6-4439-b3b4-56db4af028d6">2.98</ix:nonFraction>%.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the estimated fair value over the carrying value of debt was $<ix:nonFraction unitRef="usd" contextRef="i423d7e8b4b254413810c2f5c4fda19b5_D20191230-20210103" decimals="-8" format="ixt:numdotdecimal" name="jnj:ExcessOfFairValueOverCarryingValueOfDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTE0NjY_416cc8d7-dd96-4e09-a439-70b7b6e8de6b">5.4</ix:nonFraction> billion at January 4, 2021.</span></div></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="id22baa04529c4fcbaa690e001293c90e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current debt balance as of April 4, 2021 includes $<ix:nonFraction unitRef="usd" contextRef="i70e622c310144cc8949249a07bf071cc_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTE1NTE_1b41ed78-e3cb-44e7-80ee-300e182b3880">0.3</ix:nonFraction>&#160;billion of commercial paper which has a weighted average interest rate of <ix:nonFraction unitRef="number" contextRef="i70e622c310144cc8949249a07bf071cc_I20210404" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTE2MjA_7b102070-9a41-443d-abbf-4a02f0359605">0.12</ix:nonFraction>% and a weighted average maturity of <ix:nonNumeric contextRef="i154642870660410a90785a135a0fb8f5_D20210104-20210404" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfNjA0NzMxMzk2NzQ4NA_3926ee6c-80ee-4aec-8a30-5f8eebb49b0e">two months</ix:nonNumeric>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div></ix:continuation><div id="i0699d70253b44b9fbc20ae5610df4e69_73"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 5 &#8212; <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfNTE0Nw_54547cd9-e82c-4ca9-bab5-c7b79f3fcb72" continuedAt="i97270dd36e864bc6a2db9ee30a5dc6a5" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i97270dd36e864bc6a2db9ee30a5dc6a5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rates for the fiscal first quarters of 2021 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2020 were <ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfMTE1_f4bdc827-bd69-4141-b3e2-63722db25df0">16.6</ix:nonFraction>% an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">d <ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfMTIy_27e01967-a57c-48bb-ba6f-59fc488bf12e">11.0</ix:nonFraction>%, respectively. In 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF), which became effective on January 1, 2020. More information on the provisions of TRAF can be found in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. During the fiscal first quarter of 2020, the final canton where the Company maintains significant operations enacted TRAF legislation and, accordingly, the Company recorded an estimated deferred tax benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-8" format="ixt:numdotdecimal" name="jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfNjk4_368986b4-5072-4a1f-96e9-21e3a5e90aaf">0.3</ix:nonFraction> billion for the remeasurement of existing deferred tax liabilities offset by a related $<ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-8" format="ixt:numdotdecimal" name="jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfNzgw_4719de9b-c893-4247-b2e7-8c6e77df3b79">0.2</ix:nonFraction> billion increase in U.S. GILTI deferred taxes (<ix:nonFraction unitRef="number" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="3" name="jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfMjc0ODc3OTA3NDgyNA_cfb1aef0-0f69-4600-8b89-2cee18c44600">1.3</ix:nonFraction>% net benefit to the effective tax rate).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the first fiscal quarter of 2020, the Company reversed a contingent consideration liability related to the 2019 Auris Health acquisition that benefited the effective tax rate by <ix:nonFraction unitRef="number" contextRef="ib7915bfce2cf46dca29a5703af986b2e_D20191230-20200329" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfMjc0ODc3OTA3NTM5MA_5d42e6b1-295d-48f9-ab1b-dd062b111a91">1.9</ix:nonFraction>% (for additional details see Note 18 to the Consolidated Financial Statements in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January 3, 2021). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additionally, the Company had more income in higher tax jurisdictions relative to lower tax jurisdictions, as compared to the same period in the prior fiscal year. The Company also had additional tax benefits received from stock-based compensation that were either exercised or vested during each of the fiscal first quarters. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;4, 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfMzY0NQ_2628e2ba-5fe4-4599-a7e1-29f1522dfaf7">3.3</ix:nonFraction> billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 6 &#8212; <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RleHRyZWdpb246NTZjODlkYjVkNWQ1NGI4ZTlkZmJhYjhlNDVmZGUyY2RfOTQz_5af0fa03-46df-4f60-8803-48663d31900a" continuedAt="i4d2e2a691dd8461e962d3b9c2fe40423" escape="true">PENSIONS AND OTHER BENEFIT PLANS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4d2e2a691dd8461e962d3b9c2fe40423"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RleHRyZWdpb246NTZjODlkYjVkNWQ1NGI4ZTlkZmJhYjhlNDVmZGUyY2RfOTM2_4deb34b5-067f-4042-844b-a7479b9f1a98" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.187%"><tr><td style="width:1.0%"></td><td style="width:43.891%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.035%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMy0yLTEtMS0w_132ee049-7081-499b-9198-731e988c1d0c">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMy00LTEtMS0w_1f03b99a-be05-47b2-bd6b-a9c129c881fb">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMy02LTEtMS0w_6459926a-0053-4e3a-bfc0-eb61ef2e5b8e">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMy04LTEtMS0w_87fc4b78-ff0c-45bb-a068-c33bcaeeeee4">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNC0yLTEtMS0w_b83ee590-346f-4261-95af-b4a62b9aa835">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNC00LTEtMS0w_5d822e21-e03e-4490-8948-74768553cb30">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNC02LTEtMS0w_67696a6b-c86a-47ae-8b23-73797490b123">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNC04LTEtMS0w_22f3fa71-5b36-4e9e-89dc-5bb2142afd2c">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNS0yLTEtMS0w_e7b73706-0223-488c-9340-7f1c5985db37">680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNS00LTEtMS0w_10d48b65-9cbe-4ccd-a0ac-74df2d9d6c25">614</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNS02LTEtMS0w_5e880b2f-305b-462c-aa52-08c2c340ac00">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNS04LTEtMS0w_58471107-48aa-4171-a52b-43e90205564a">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNi0yLTEtMS0w_9a954959-9ad2-4768-9acb-49e707752afb">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNi00LTEtMS0w_469bc91b-0fc8-4acf-82c3-f4bcebb1baae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNi02LTEtMS0w_fcd3b6dc-7b93-48ac-826f-4c11b2ed524e">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNi04LTEtMS0w_74d83080-53ad-4a63-b981-78be0b0f793b">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOC0yLTEtMS0w_6ce0e9db-ff6d-4529-b811-a03f71800e6f">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOC00LTEtMS0w_fb61d6a0-efe2-48c3-bf5e-3d7d32ab3d92">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOC02LTEtMS0w_3cb7261a-2ea3-40be-80e6-6d6cd775850d">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOC04LTEtMS0w_8a061323-435b-417a-af30-e5b8d5022d68">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOS0yLTEtMS0w_cd32a7ae-5dad-40af-82fe-3c5a74e13d95">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOS00LTEtMS0w_51d4c4b2-de50-454c-9c9a-d41832d19d28">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOS02LTEtMS0w_d4250ea2-a33d-41c2-9054-5942345f98d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOS04LTEtMS0w_c1ea82a4-9640-45c7-b2fe-c7ba7890ae1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMTAtMi0xLTEtMA_db0c8578-3a9e-4006-837d-a165fff8a117">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMTAtNC0xLTEtMA_452625f5-5aac-4998-80f4-4607231d5ee4">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMTAtNi0xLTEtMA_84a4807f-36ac-4da9-ba58-cd34485faa82">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMTAtOC0xLTEtMA_bbbc8832-b5bc-4b43-a554-90b0ea059834">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company Contributions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Three Months Ended April&#160;4, 2021, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="ib4d8262305ed4a808270a6d930b2b201_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RleHRyZWdpb246NTZjODlkYjVkNWQ1NGI4ZTlkZmJhYjhlNDVmZGUyY2RfNjcx_06a52131-4040-4838-a9d8-2e0cd31f7254">24</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic5c0764f40c2472b8a0a5b59873f1ca3_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PensionContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RleHRyZWdpb246NTZjODlkYjVkNWQ1NGI4ZTlkZmJhYjhlNDVmZGUyY2RfNjc4_c1cd8ec4-66db-489e-8524-e3bf5175c872">10</ix:nonFraction> million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.</span></div></ix:continuation><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_79"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 7 &#8212; <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RleHRyZWdpb246ODE0Yjg3MGIzYzIxNDI0Y2I0NzY5N2JkMWU2ZjE5YzRfOTMw_05f6e2d7-8e7a-47d0-80bb-db92348738eb" continuedAt="ie17b890151ba427685a8ad6a84a016a5" escape="true">ACCUMULATED OTHER COMPREHENSIVE INCOME</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie17b890151ba427685a8ad6a84a016a5"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RleHRyZWdpb246ODE0Yjg3MGIzYzIxNDI0Y2I0NzY5N2JkMWU2ZjE5YzRfOTIz_4be41d42-72c4-47c9-acfa-bba9146d6c80" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:34.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.991%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d76493e48f94dcba8cc74f15393b857_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNC0yLTEtMS0w_03187aff-6a5f-46d4-a6f5-a9667480dd5a">8,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a475b649b7b482bafe66f589d72289e_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNC00LTEtMS0w_8d6fff22-87c9-43fd-829c-9583bc03c3ac">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia40af87a50514bc5a829dc0dd0888e9e_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNC02LTEtMS0w_7d9cb251-7000-41ed-bde9-f223bf30bc5a">6,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d96c7a5b464914b6d3373fefe93b84_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNC04LTEtMS0w_504c074c-2700-4ad0-b5fa-e50dd7a3b853">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45b058f1e15f44aea2e4af4460a4bbeb_I20210103" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNC0xMC0xLTEtMA_e23ca465-e397-4aa1-bf97-144d6afcd074">15,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816f31f509494a34bc7e2cedd91d16d2_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNS0yLTEtMS0w_abad06c2-7e2d-4ac8-a3a2-e112a03c5b63">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10284d081934582868002bbf2ed2c0c_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNS00LTEtMS0w_20c82f95-46a0-4ad7-a2af-a015071abb75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1354338217d411997a1333f76f744ea_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNS02LTEtMS0w_cbdcac5a-6ff8-44c8-bb5b-e53996f11e04">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e23c8ee5426493fa9a9020a4460a66e_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNS04LTEtMS0w_e0a85925-8042-4fcf-a974-a9140a808e16">595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90694bac6fa841438f930b207399b28a_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNS0xMC0xLTEtMA_ba7f3659-6087-4650-80f5-9f56ad516c4b">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1971251aab8f40e581900d63eac2f931_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNy0yLTEtMS0w_22ca9afb-6a73-4eed-91a5-77911db0d6f7">8,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10269159ffc3444fbcf1d8e9aa219a53_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNy00LTEtMS0w_3ccd9628-29e9-4f07-a231-b97e8084a8ba">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7c535299fe9457290a897be433005f5_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNy02LTEtMS0w_9ac65755-e3af-4b47-8496-f245be99b8dd">6,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b83b2a50512439ea7c32eba157340bc_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNy04LTEtMS0w_0d7b0b65-2c41-49d1-a231-a74029f2bb7c">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3029d43aa1d647acbb02dc5cdfe3bd78_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNy0xMC0xLTEtMA_7528ad39-b53b-471c-92fb-0621910c210d">15,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 8 &#8212; <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RleHRyZWdpb246MGZhNzA5OGE0NGMxNGU0OWEzZDdjZjhlODg5NDFmNjRfMTU4Mw_9fc350ee-43c0-449f-a3e1-1fd3f98b8000" continuedAt="i1c80540d4be2492586f558b1eb9050ce" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i1c80540d4be2492586f558b1eb9050ce" continuedAt="i83db4e831aec446cafe4cb0d16f23c7a"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RleHRyZWdpb246MGZhNzA5OGE0NGMxNGU0OWEzZDdjZjhlODg5NDFmNjRfMTU4OA_80d62745-8def-4a83-b082-97c356267c98" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.344%"><tr><td style="width:1.0%"></td><td style="width:63.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.645%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfMi0yLTEtMS0w_94b74e6a-f559-4866-bd62-48a9f0e73304">2.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfMi00LTEtMS0w_3c8be7cd-0db8-4894-add6-96636627d4e3">2.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfMy0yLTEtMS0w_acb0e7df-a695-44f6-bc2c-ecb19bbb8d79">2,631.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfMy00LTEtMS0w_70e28837-a6dd-4616-a090-17266a3dd145">2,633.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNC0yLTEtMS0w_1e884a63-1e84-4d4f-ab25-db80b3627806">128.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNC00LTEtMS0w_290543f4-0a17-446b-b3d0-0edb019dea55">126.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNS0yLTEtMS0w_2804459d-911f-4c8c-972c-0f36b5c0ed4c">87.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNS00LTEtMS0w_2ba36315-643c-413b-9554-7ae122299dff">89.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNi0yLTEtMS0w_03cb9a36-7bc1-4182-8d06-658093371773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNi00LTEtMS0w_8813c43d-c0d3-4885-8511-298d2bd78a07">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNy0yLTEtMS0w_b8f2ffbb-fe36-4cc0-9bc3-aa3b95fea5fa">2,672.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNy00LTEtMS0w_e1a4307d-f203-4fff-bfc9-ee7614f556ff">2,671.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfOC0yLTEtMS0w_3fde75df-7c22-496b-98a0-5b0f17a39073">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfOC00LTEtMS0w_fa867ac8-fed2-469d-8b14-b6c938327b31">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The diluted net earnings per share calculation for the fiscal first quarter ended April&#160;4, 2021 excluded <ix:nonFraction unitRef="shares" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RleHRyZWdpb246MGZhNzA5OGE0NGMxNGU0OWEzZDdjZjhlODg5NDFmNjRfMjgx_ed96c58f-3037-44cc-b378-05b3f21b0e0d">9</ix:nonFraction> million shares related to stock options, as the exercise price of these options was greater than their average market value. In the fiscal first quarter ended April&#160;4, 2021, the Company did not have convertible debt.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i83db4e831aec446cafe4cb0d16f23c7a">The diluted net earnings per share calculation for the fiscal first quarter ended March&#160;29, 2020 excluded <ix:nonFraction unitRef="shares" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RleHRyZWdpb246MGZhNzA5OGE0NGMxNGU0OWEzZDdjZjhlODg5NDFmNjRfNTg2_1b77898c-3a25-4555-907c-324d875ea157">10</ix:nonFraction>&#160;million shares related to stock options, as the exercise price of these options was greater than their average market value. The diluted net earnings per share calculation for the fiscal first quarter ended March&#160;29, 2020 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:57.327%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 9 &#8212; <ix:nonNumeric contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzg4OA_b6c0672b-fce8-4aa3-b3b0-4a46c47869b3" continuedAt="icbfebf35a5fa4d2aa06b3427defad0e1" escape="true">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="icbfebf35a5fa4d2aa06b3427defad0e1" continuedAt="ibf27a59dc5b94a7fb807aa34fca70fe6"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="jnj:SalesBySegmentOfBusinessTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzg4OQ_b5cdd07c-ba0f-4c3a-a910-98adb2561a25" continuedAt="i0eedb69484a64576b2984276dd38676d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ae622fe28cc41748a80fa1570cfe35c_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNS0yLTEtMS0w_b0781b55-0010-423d-947b-afcd29cd6781">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f1ff6fb4d12459fb76b519f3aa064d0_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNS00LTEtMS0w_48015686-73fe-4fd3-aba7-fe63daecc14e">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2ae622fe28cc41748a80fa1570cfe35c_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNS02LTEtMS0w_8d86b9de-3249-4905-a281-365bf8b0cbf8">13.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idffd022b600f4ab19da11eb4a92bbea7_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNi0yLTEtMS0w_b4389ef4-4423-44ee-b966-893f95c3d197">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba9b1b928784fbca8eb92f74ca624c0_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNi00LTEtMS0w_984cc227-3d81-4816-81c6-021a2aeaed50">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idffd022b600f4ab19da11eb4a92bbea7_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNi02LTEtMS0w_72216938-3298-4aac-b7f2-31c74d779ede">12.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d7961dbf5348efbc49acaf2aed16bd_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNy0yLTEtMS0w_7dc05737-4702-4049-99eb-e289ebfdd40e">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i723bca619dee4d77adbb0ace89cf793c_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNy00LTEtMS0w_6d4a66e5-fb1a-4e65-9828-00ee03e060a5">1,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i92d7961dbf5348efbc49acaf2aed16bd_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNy02LTEtMS0w_2d902666-7e04-4622-93c5-b9e3273d5b73">12.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25dc22f2e2bd45de940fef17d3860c93_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOS0yLTEtMS0w_cae1f0eb-6b6d-40fc-a421-359bbea0db15">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a0e1bfa74b499eaf41e73bfbea7789_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOS00LTEtMS0w_4ce25c43-3cbf-4da6-a304-0f7d1e7c6d6e">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i25dc22f2e2bd45de940fef17d3860c93_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOS02LTEtMS0w_d7bddac8-8e4e-4b8a-b065-ad7fc0b3b644">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e3695fe3ad4d6397fe1681cee71dbb_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAtMi0xLTEtMA_dd36f792-cf40-4dd4-843b-691d155dfacc">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166260d97d024b4da59529851700b260_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAtNC0xLTEtMA_c5222b86-f91f-4e37-b712-e02eb2fa2ed1">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50e3695fe3ad4d6397fe1681cee71dbb_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAtNi0xLTEtMA_bca39e46-acdc-482a-9720-24e4c09db821">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b585d84ee0b4c8e899f4c0c52424cb1_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEtMi0xLTEtMA_6a902f89-1fbe-497a-8af4-5506a8735ea0">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9e5272e1d64d9291f65425f7a17561_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEtNC0xLTEtMA_e9ec91be-a4c0-4315-8008-dfbf31d61178">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b585d84ee0b4c8e899f4c0c52424cb1_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEtNi0xLTEtMA_7e3e3224-036c-4ee4-8a60-6c41a4c159c1">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfeadcc4c9f4c14b150e5ed0df1edc8_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMtMi0xLTEtMA_ad45e8fa-67f9-4c2c-aa9a-a3f775932139">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906fd8e56b88496dad9f6b80d29a44da_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMtNC0xLTEtMA_bcf82a47-22c0-4254-a72a-b6f795f25d14">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iddfeadcc4c9f4c14b150e5ed0df1edc8_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMtNi0xLTEtMA_2911029c-413a-4030-91b6-e51ea2a3d736">7.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3854ce9adfd64c2682550767fe397150_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQtMi0xLTEtMA_fd50486b-7857-4b74-bf70-9f18d933d44c">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib661f1c760ad44e9b55754282fa57e3c_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQtNC0xLTEtMA_3cc5dc0b-24d3-4e33-8cc0-a6a81e4d0066">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3854ce9adfd64c2682550767fe397150_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQtNi0xLTEtMA_54723cce-d3c4-46ec-be66-15ee425fc1fc">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8faa580354e043dfaf23f1f42fb88960_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUtMi0xLTEtMA_0c571cef-7b3f-43eb-98be-21b47692da2e">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32385508ea6d4658b01bac013205426a_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUtNC0xLTEtMA_479abbe7-3f16-4b2c-b3f5-9d85e3194204">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8faa580354e043dfaf23f1f42fb88960_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUtNi0xLTEtMA_6fc43e7b-b8f9-4de0-a4a3-aecbb66806cd">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ebcd0a77d74afaa4aef8e33703f1b2_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTctMi0xLTEtMA_8a9c55e3-c478-4ab2-ac69-2be11d6eaf39">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a5cd00fdb24916a240b612026b1e93_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTctNC0xLTEtMA_d53e54ff-13d4-41e2-9771-64cf35e01bf8">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92ebcd0a77d74afaa4aef8e33703f1b2_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTctNi0xLTEtMA_0f2f802d-c2af-4a06-a839-871428e3e819">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67c2a0954d344c4bb590b8e16e9b3919_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgtMi0xLTEtMA_1d45b148-25b5-442c-a58b-b429940c24ff">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9058a80fcd945bd954291432adf44b8_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgtNC0xLTEtMA_f661432f-e6b7-4401-b165-3cd9f9f68c32">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67c2a0954d344c4bb590b8e16e9b3919_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgtNi0xLTEtMA_98282c5d-2acb-435e-97f2-4efc7b0065d4">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bae718df24b4f13951655bc41d7bf96_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTktMi0xLTEtMA_8256c0da-42ff-49e0-a61c-b73c56262afd">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i983c24aea97b44299332fe0f8a655f72_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTktNC0xLTEtMA_b4dbfdfb-8d08-4aac-8164-1e1fe70129d8">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8bae718df24b4f13951655bc41d7bf96_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTktNi0xLTEtMA_f40fd784-0c37-4e14-8a0e-42c83070067e">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44787243fb164e10b42245b3160597dd_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEtMi0xLTEtMA_8087ac15-5802-4d89-814e-4462039f8f3a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a750086de9495a8afc776a19ad7a9a_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEtNC0xLTEtMA_b18a1594-54fb-402a-8c4c-30a6800f1166">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i44787243fb164e10b42245b3160597dd_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEtNi0xLTEtMA_7e6d20d0-da20-428e-976e-bf769683b4a2">25.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42bf8dca10bb48398b2f3f163ed419bf_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjItMi0xLTEtMA_cb14d10d-861e-4f8d-b76b-372f5e22b601">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa60389107541e38de00816279454bf_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjItNC0xLTEtMA_844ceed6-3911-4ffa-b238-8f9f27d8345e">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i42bf8dca10bb48398b2f3f163ed419bf_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjItNi0xLTEtMA_df274c71-19e0-40a4-a0dd-6d47b73a29c7">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331b3b92b0b34bafa98699f766892580_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMtMi0xLTEtMA_7e7a9579-7dc6-4f31-8b92-aa8ee8942aaf">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964cf45dd1db45268ef9917e50464450_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMtNC0xLTEtMA_0106baf4-ea08-4de8-b006-d4a30c9738a8">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i331b3b92b0b34bafa98699f766892580_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMtNi0xLTEtMA_02ac473e-2f28-4286-b4d5-2df46116bed4">4.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d3b975b16e4b83a8d7a02ed320e405_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjUtMi0xLTEtMA_dd063895-9f3a-4d45-893d-477b6b828ddd">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf40698a4cb8405c9ebbbf461d299a30_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjUtNC0xLTEtMA_5d74c11c-3080-45c7-86d1-e748ca88aca1">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i60d3b975b16e4b83a8d7a02ed320e405_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjUtNi0xLTEtMA_5dfa4892-78a0-4fc5-ada6-c582088efc8f">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d7ab27284c405ca2762880403e8d9e_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjYtMi0xLTEtMA_907b338a-5547-42bc-a869-91163d61e3ca">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic71b279765044852900c44013574acce_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjYtNC0xLTEtMA_ced3ece5-2b9d-4e22-8156-f5f7a733eed2">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9d7ab27284c405ca2762880403e8d9e_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjYtNi0xLTEtMA_e59434c5-da31-460a-b9cf-2b0fcd4385a4">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied69986251ca49af95c8ab2e38acfc45_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjctMi0xLTEtMA_6c95cc7d-719f-419d-8348-b65a4a26f9fb">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26bfd85decb944d8a5ff899f4f8b8a85_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjctNC0xLTEtMA_79cb4bcf-b593-4a4a-9a1d-a18fa02756ea">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied69986251ca49af95c8ab2e38acfc45_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjctNi0xLTEtMA_5fd08b95-f563-49d3-854c-a294150fa0fd">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ebdcc3eb7548edaa2a797dcee28eb1_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjktMi0xLTEtMA_83087310-8cda-4348-8504-3f4c1d954365">1,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b4f194c8d2948e682ea7750ae9e4ae0_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjktNC0xLTEtMA_4654f94b-55bd-46c9-953e-8ca476828aee">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i01ebdcc3eb7548edaa2a797dcee28eb1_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjktNi0xLTEtMA_4efb1a33-64af-4180-b94b-6acf36da84f0">7.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i289737a850a54d0cbb70e8bba2e95d4a_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzAtMi0xLTEtMA_8a3e9348-ef4c-47a3-aac8-711da988ef69">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0432cb1fa6fe47fbbcfad08028e0cc71_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzAtNC0xLTEtMA_273cf440-3771-4076-a9ec-7285353ff569">1,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i289737a850a54d0cbb70e8bba2e95d4a_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzAtNi0xLTEtMA_e2648d7a-51e3-418a-a3d6-37dd416884bb">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb654a681744cccadb2bf5b36aa0112_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzEtMi0xLTEtMA_f30f067e-0093-4b0b-b93a-d22f3719b1ab">3,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8d5d21439a44449fe0a777201e9ce6_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzEtNC0xLTEtMA_bae8d5cb-ee1e-46b7-af75-fa23abadcde6">3,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9cb654a681744cccadb2bf5b36aa0112_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzEtNi0xLTEtMA_42277e78-b178-4427-8f70-bb6776142b60">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="ibf27a59dc5b94a7fb807aa34fca70fe6" continuedAt="i597adde2f10342e4bd62ce045779ff15"><ix:continuation id="i0eedb69484a64576b2984276dd38676d" continuedAt="i30bf09eea77b4f449bca7d76f90b096e"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff567a96444d40aaaaee5e54bec7304e_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzYtMi0xLTEtMA_41888209-3f09-4cb4-8cde-03e563b29d6a">2,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib06bac64a0724d9ea69537ebd326bdd3_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzYtNC0xLTEtMA_b387fd16-d5f4-4bcb-a2db-bd0d9747bbdc">2,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff567a96444d40aaaaee5e54bec7304e_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzYtNi0xLTEtMA_31196ecf-b105-4985-933e-fb2bfcab66db">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d625febf4bb4703b403d98d5ce8c57b_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzctMi0xLTEtMA_334ec2db-6764-4951-86d3-dae0d701c986">1,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82ae2d3a5a249beac2043ef02e2f433_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzctNC0xLTEtMA_67ce7824-995c-42be-8753-107cdaf28c12">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d625febf4bb4703b403d98d5ce8c57b_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzctNi0xLTEtMA_a0aae114-9d50-42b8-9650-a0424655d816">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6171f8ab5dda4d0c9faa7382c2f231b3_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzgtMi0xLTEtMA_47702dcf-3ae1-4d91-90ab-a889ca439178">3,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d1f27f9c7334c3f9ad28edfbf7dcaa1_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzgtNC0xLTEtMA_8ab34dee-1f5c-447b-9da2-1fa4d1dd665a">3,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6171f8ab5dda4d0c9faa7382c2f231b3_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzgtNi0xLTEtMA_87dec6f6-6056-40de-bb57-45d531bfac9a">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ea8e5d1357498b955cea3a65e70a42_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDAtMi0xLTEtMA_f36caee6-6c84-4564-ae48-428925b751ce">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61d81d5483f04c2ea8808ff914905c50_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDAtNC0xLTEtMA_6751486d-efd0-44de-a70e-aa358e892063">625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i69ea8e5d1357498b955cea3a65e70a42_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDAtNi0xLTEtMA_856ac835-0a72-4925-aef5-0b21b77c54e2">21.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd8ce529fd4e489ca217b53ba112079a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDEtMi0xLTEtMA_648e71e4-edd3-4f42-8fb9-2617c1af2c7a">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8e51a1f6cb449ea7ff42d6f4948b73_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDEtNC0xLTEtMA_ad11f361-a2e6-4004-8c6f-46b816563049">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibd8ce529fd4e489ca217b53ba112079a_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDEtNi0xLTEtMA_f3fdbee3-54a0-4cb7-88b2-cbac3e3c4760">48.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136d588a998d4a2da83c088f3e0ce2d7_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDItMi0xLTEtMA_a9dc2bca-220f-4898-824f-40f2bdd1bf3e">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef18e066a7d417b8a7dedcd9680329b_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDItNC0xLTEtMA_c7640747-8f51-4cc4-9525-587b776bbdcc">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i136d588a998d4a2da83c088f3e0ce2d7_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDItNi0xLTEtMA_0c051d17-d62d-4713-9db7-4e1bbae47170">9.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf4afeb424b42099ca0595af209f4c9_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDMtMi0xLTEtMA_0918fb7b-21ec-455e-894d-827e3488d6dd">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29009a53b5dc403aa2843d2d81dd1cdc_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDMtNC0xLTEtMA_6b8cf5f4-33c4-44a5-b569-18ea9219d871">990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icaf4afeb424b42099ca0595af209f4c9_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDMtNi0xLTEtMA_3854af7f-841b-4dd0-8098-5ba4c0d3b5e6">21.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6114f587788a46509aa693a877fbec65_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDUtMi0xLTEtMA_893c5d6f-0b09-4332-b3d8-3119e2cb4658">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d2ad3a676074fd39646dd2b42a1a394_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDUtNC0xLTEtMA_b3d5647a-e5f4-4cdb-9aab-e929ba7d2d03">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6114f587788a46509aa693a877fbec65_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDUtNi0xLTEtMA_1c3912e7-3fdd-4398-92d8-dda50c04937e">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ec26a4598846aa90c13dbf69fee0e6_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDYtMi0xLTEtMA_0ac2ff59-3580-4b54-a27c-7804fdf6bd0e">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib369d313870f4e40bcae5f48dbba9156_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDYtNC0xLTEtMA_39a634e9-5a11-4ee6-9c30-54ed4b1d9c72">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3ec26a4598846aa90c13dbf69fee0e6_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDYtNi0xLTEtMA_dc6337a7-4844-4942-aefa-3050ddcbbeda">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f387a41d284ee49ce4f7ab58e64040_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDctMi0xLTEtMA_05ccaabf-ea59-4ee6-a032-a8febcf1b7fe">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146ce49a479f4a72b766a6152145d2db_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDctNC0xLTEtMA_a79b70a1-627c-4eff-985a-8542029ffc7e">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i49f387a41d284ee49ce4f7ab58e64040_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDctNi0xLTEtMA_7e3f2fab-94a9-4a3d-bb40-9b173c3cbaac">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d35b2d6abf46dabb281f94354a317e_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDktMi0xLTEtMA_268be6d3-8517-481f-ba60-335c8f6ffcbe">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48b966b3ecb41279941f7e8cedc781e_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDktNC0xLTEtMA_4df0950d-a0b3-4198-911b-8c6d3ada4e00">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03d35b2d6abf46dabb281f94354a317e_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDktNi0xLTEtMA_bdf9cb73-66cd-4271-bd61-09b1e6fe7333">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5832713827f49e68a1d9256b8db22f8_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTAtMi0xLTEtMA_78d8a4df-08e9-44f7-860c-f19feac31afb">817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cbb2403d3fa48e6a6c860006059dbbb_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTAtNC0xLTEtMA_3bd7e37b-5a2f-41f7-99b4-966d62bb016c">603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia5832713827f49e68a1d9256b8db22f8_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTAtNi0xLTEtMA_1467ca18-2639-4c7f-92ae-ae52a7ef379b">35.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c510944ae54934a1107ef6d1ded6a8_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTEtMi0xLTEtMA_32d6eec8-20f8-4da7-aadf-52c4aaa05269">2,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd6ad0e6e1643d381813d989c2cec70_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTEtNC0xLTEtMA_d8c93038-b1e8-4c7a-91f9-605a915dedde">1,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36c510944ae54934a1107ef6d1ded6a8_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTEtNi0xLTEtMA_8990c636-4d83-4d85-90e1-1507c81a251c">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32aca65dc81d4c26ac1e08379d1ef4bb_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTMtMi0xLTEtMA_40f901f7-11b2-4026-bc36-f04ead270f9b">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148fd285f2164e8b84b5f919df795949_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTMtNC0xLTEtMA_53fc8710-5254-49fc-aa18-c88367bba01e">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32aca65dc81d4c26ac1e08379d1ef4bb_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTMtNi0xLTEtMA_f9f676f0-ded1-411c-b981-be925eea2b3d">46.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e61e62b4724e93ae93816c2f3192f8_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTQtMi0xLTEtMA_60d9aa04-4f5d-45b6-898c-08d8dc0c1789">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80770d9508b2437f8389e28b2b941a02_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTQtNC0xLTEtMA_b6dda175-5031-4ec0-9aad-c21cfb64bc02">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06e61e62b4724e93ae93816c2f3192f8_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTQtNi0xLTEtMA_59876762-48bb-4233-bca4-a5f845244088">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc72131dcb4cfb8a2b4aefd58180c0_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTUtMi0xLTEtMA_697c9ae2-e494-4fad-8048-0c11136b00f0">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529ed72788a0459399f52e3044b3e2ec_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTUtNC0xLTEtMA_3186e47b-810e-46cd-a14d-95dd4724c589">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fbc72131dcb4cfb8a2b4aefd58180c0_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTUtNi0xLTEtMA_2c2ccf4c-420b-47b2-8b73-ef0c595210ff">41.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66fb5605b064618a2816914b2ab7bfa_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTctMi0xLTEtMA_a2af9239-87ca-4dbc-b8c8-c7ef13865e69">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac8d1c045b4547659ceadd21ec5dcc69_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTctNC0xLTEtMA_1ea1d88f-3264-4da9-9376-5a9a4a32c7ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i093cfc8901c7491da04dfd1a8c00c997_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTgtMi0xLTEtMA_ef4625a9-f159-4e10-a0ec-dde17c7b0121">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac706fc6d814cd3b02325aac9a6a583_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTgtNC0xLTEtMA_9572da52-4a53-4b35-85b2-2c9f7c6b0c05">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i093cfc8901c7491da04dfd1a8c00c997_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTgtNi0xLTEtMA_3df0904b-234d-48d3-ba7e-ba382c0b4079">38.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e51d8457af2428d92fb1a6f3d416b27_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTktMi0xLTEtMA_291cdecc-3beb-4f06-9fa3-e2eceebbf832">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7477ed6ae844839a6a17c6320a1490a_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTktNC0xLTEtMA_e51c8694-e5d3-46c1-b1e5-0591bb287b2d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bee09b00e4e4176b4a2035aa5f68b99_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjItMi0xLTEtMA_e3d3d768-dfa4-4e14-b5fb-4fdd4194225f">512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f88fa52f8b64198a27db57dc8f3446d_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjItNC0xLTEtMA_c967e88b-afd0-43c5-9763-a0a8b1466bfc">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2bee09b00e4e4176b4a2035aa5f68b99_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjItNi0xLTEtMA_3280aa8d-ee69-4edb-8388-df25752d39fa">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i433a9d857de442baa6ab86474c907a9e_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjMtMi0xLTEtMA_3530d519-395d-4267-8031-d2418a492b93">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf7597b20ee4154a38d35f8a5783413_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjMtNC0xLTEtMA_29f192b8-1bac-4ebb-99e6-c604dff9b5c9">483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i433a9d857de442baa6ab86474c907a9e_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjMtNi0xLTEtMA_6e095442-02b0-44e1-b436-4f1fe245c7bf">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e6b6d91108495abc61b13e632ed5e5_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjQtMi0xLTEtMA_045f5b76-929d-4b0d-8a7b-b9ce90d3f5d7">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafed813fd0b0453992e024335f1146fd_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjQtNC0xLTEtMA_60c44534-e0d6-4417-8529-4f631f9ced62">920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1e6b6d91108495abc61b13e632ed5e5_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjQtNi0xLTEtMA_f599c635-6792-4e48-b3a9-0a43c5d3b8f0">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 vaccine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ed82867cff4a2a90aaf86dabd6f75a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjYtMi0xLTEtMTA1Nw_d456ea68-2de4-4586-932c-a1e687c3dbf4">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36f05bd8bedc483e9e416de970f7e815_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjYtNC0xLTEtMTA2Ng_1f77c3b6-0adf-42a9-bf25-f5a08fa9e63f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4e287198db4e008b203874b5cc8f67_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjctMi0xLTEtMTA1Nw_03c9eb0f-b724-4871-bce7-d46898352ee6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cedc93843e0405aa3fa264e1182e575_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjctNC0xLTEtMTA2Ng_c1a029d0-4ea8-479d-ac31-eb2799423fbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8276bebcd3646be90506d64f62c9552_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjgtMi0xLTEtMTA1Nw_8b738e42-3cd2-4842-9b98-8bd0a2fe63a7">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0a5e29a43049de90706107caedb36e_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjgtNC0xLTEtMTA2Ng_f2fcd354-f9fd-4156-b1b2-dbd4022eccf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361f978e79cb45ce9e204e867cf6632d_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjYtMi0xLTEtMA_1635f7a7-07fb-43d3-af3e-f365bbc151be">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad6a0b3794e4083b20fb16dbb34c231_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjYtNC0xLTEtMA_736657d3-b962-444f-9554-56b3b5d4892e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i361f978e79cb45ce9e204e867cf6632d_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjYtNi0xLTEtMA_d3690dbf-a8da-4ad7-ab84-2f9ee105ff64">12.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad881d92a614ae4a72edef7e338e323_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjctMi0xLTEtMA_b297a739-3042-4367-8ee4-f38978ca1064">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20adde6886944d06ab57d875198dab9d_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjctNC0xLTEtMA_9e23e0b5-1ec7-4634-87eb-a54be0fe13fc">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifad881d92a614ae4a72edef7e338e323_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjctNi0xLTEtMA_8c70ad6d-f5dc-4ce9-b8b5-7d24b77f7dd2">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f953f7b8304173993dce91c2663860_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjgtMi0xLTEtMA_b4280720-22b7-4d8b-aed4-4d05819612d9">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c4623cb45a4be88936c830cca8137d_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjgtNC0xLTEtMA_a8041759-6798-4665-a4db-c1cda2fa6393">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i59f953f7b8304173993dce91c2663860_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjgtNi0xLTEtMA_a1406d1a-da45-42c6-b0b0-95ef959d9676">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> /  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                         </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">                     REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0def5e08a4ad8961fabcaa36ce515_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzAtMi0xLTEtMA_423b5f5d-d555-4be3-bf2e-aef41867de1f">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1cdd7d8723049d19609b00fa9d90353_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzAtNC0xLTEtMA_6232ed21-c2e7-4b9b-bb78-938d1a590e90">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i60a0def5e08a4ad8961fabcaa36ce515_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzAtNi0xLTEtMA_ac329665-60de-4e35-881b-7fc7942bdf1c">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i831167bcd06748238ad090de986cb792_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzEtMi0xLTEtMA_41f22702-62b1-4460-bf0f-6ebbb367539f">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia20e73715a764fab811e562e85895b43_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzEtNC0xLTEtMA_942e6b86-e314-4418-a7a8-ea0fb89a4983">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i831167bcd06748238ad090de986cb792_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzEtNi0xLTEtMA_8dcb3fe6-b02e-4374-86ed-19a2a156a2d4">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa7ccc867e0451d8c3472534acc0afe_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzItMi0xLTEtMA_1ea6c284-39ed-419f-9a3a-49fae226a094">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8be1c5255c4b4a188392c9c769c5191a_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzItNC0xLTEtMA_78e3cdc8-be6e-47b2-94e5-f86e47fb89a2">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8fa7ccc867e0451d8c3472534acc0afe_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzItNi0xLTEtMA_ae032613-721f-4a0a-a544-d9f416df6651">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i597adde2f10342e4bd62ce045779ff15" continuedAt="i188efe981cfe4b9eabba62c7a6a39622"><ix:continuation id="i30bf09eea77b4f449bca7d76f90b096e" continuedAt="i2c375a5e737a4105a7f92fa0a8329c03"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a0dc7a2446b402d88958e72d228822f_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzQtMi0xLTEtMA_a2459cd7-ff53-495a-a637-b0a792dfecea">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf0bee74b66411f86595a8d281104e2_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzQtNC0xLTEtMA_edd62b24-e6a6-4966-8766-53246c1ca91f">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9a0dc7a2446b402d88958e72d228822f_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzQtNi0xLTEtMA_d13bb66e-00a7-4ea0-8e9b-2f116d9ed01c">27.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b10e6ae68dd44b5aa1f27dc3875bf97_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzUtMi0xLTEtMA_d6894fa4-6901-4e65-a911-b3ca3116e36a">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i988753d50e764ca9a7c00a80520f3048_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzUtNC0xLTEtMA_1e3fd704-4541-4a5e-8802-ba10dcd2d06c">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b10e6ae68dd44b5aa1f27dc3875bf97_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzUtNi0xLTEtMA_cb34ab30-d11a-4335-bd54-c4b4f743ffed">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9e5fed8d614670826d46986af440a1_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzYtMi0xLTEtMA_4eec6861-7e56-44e9-b5d2-d14afde95169">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife89528554c54fccbdf65c21b5a431c8_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzYtNC0xLTEtMA_77d13760-f209-4ce8-a8b5-b7de5c7a0328">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a9e5fed8d614670826d46986af440a1_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzYtNi0xLTEtMA_332008fa-106f-4467-9226-1e0232c53ee4">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8754c3942af4f6d99cc04b08b970f18_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzktMi0xLTEtMA_1a3ee597-5b50-4d38-b1ba-9e044cd28548">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176baa8660424665898357a803f03887_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzktNC0xLTEtMA_218bf60b-4aac-40e1-ac7e-53c2b9558e73">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8754c3942af4f6d99cc04b08b970f18_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzktNi0xLTEtMA_91db36b2-b762-4577-b80e-762625277c5e">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d57014634294477bf7002a25123153e_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODAtMi0xLTEtMA_91385859-2d81-419e-a543-3b5ae2305fa4">949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2265d889108547338b832b208684da7d_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODAtNC0xLTEtMA_8b65384e-ecc2-4ed7-a233-7eb1c2a701b4">910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6d57014634294477bf7002a25123153e_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODAtNi0xLTEtMA_6f4290fa-6730-4b07-b4b9-49d58ff54700">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c291b0634924a55bacc7238c574ac85_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODEtMi0xLTEtMA_32c721b5-888d-4778-aed6-043275fdcb5d">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22b68654dad44b8cba983ed66dcf3568_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODEtNC0xLTEtMA_469cc0eb-f578-4e41-8b82-a4f6a22176e3">1,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c291b0634924a55bacc7238c574ac85_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODEtNi0xLTEtMA_5cc637f7-d43b-440e-9816-d9bdb125782e">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i902b036bad4646c3acfbaa6a61042bcd_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODMtMi0xLTEtMA_1fd4f930-111f-46b2-8f93-e9244e63e7f8">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64d06d5b850a4229a8ead53a9c9ba9e8_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODMtNC0xLTEtMA_c436ed6b-3eb5-4e98-940c-a0f05e0d9bf7">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i902b036bad4646c3acfbaa6a61042bcd_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODMtNi0xLTEtMA_2fe25a36-1059-4960-a443-f900b5c3486d">9.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c130fa5cebe472c9176470dc88dbbb5_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODQtMi0xLTEtMA_27123bc4-19f3-4012-8046-77a66e1748ef">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c030aed94064ab6a76b0da185985ac9_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODQtNC0xLTEtMA_3d27cbec-9fca-4ff2-9fb8-96a1fed77d6c">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c130fa5cebe472c9176470dc88dbbb5_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODQtNi0xLTEtMA_dad1c41d-0081-4c24-adaf-3731f333fe05">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4e92c9d6c74bb2895cb6659afe4aec_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODUtMi0xLTEtMA_fa168de8-3288-465b-bd71-d057a1d111db">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08530f48301640e2a981713098e61fde_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODUtNC0xLTEtMA_917ba1c0-f4d9-46cd-b80e-f553e645672a">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e4e92c9d6c74bb2895cb6659afe4aec_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODUtNi0xLTEtMA_a11abd5f-3c8b-436d-8c86-325de67e0e8b">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVEGA   TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b34fffac82440368445497712324317_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODctMi0xLTEtMA_d45ac75d-196a-4d53-afea-e36af113dcbe">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bdee0e174a46a0b8c038d4489acc40_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODctNC0xLTEtMA_a4d641a8-6519-468f-bd0b-d94c4d251b23">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b34fffac82440368445497712324317_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODctNi0xLTEtMA_d8806be7-e01e-41b9-996e-d9e9b031d17e">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686fb29be97940259a0115fdd23a57e4_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODgtMi0xLTEtMA_a2277b48-91c2-401c-93d2-7e2ffe2e0188">376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63eeae9617e4445594405644c82b4ae2_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODgtNC0xLTEtMA_0d934b85-617b-4485-b2cd-94c6db890b05">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i686fb29be97940259a0115fdd23a57e4_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODgtNi0xLTEtMA_450a762d-0a04-4ada-86b0-0d85501ed4bd">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58449ca63dee493eb4a627122847148a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODktMi0xLTEtMA_50b90a9a-273f-42fe-943d-40ec2a01683e">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba918ab4a4549e78a7dbbe69cf89f5e_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODktNC0xLTEtMA_96d4562d-5eae-4796-881a-a2fc43723cd6">883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58449ca63dee493eb4a627122847148a_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODktNi0xLTEtMA_f4ac1f5b-d45d-424e-87ef-370922e02e4d">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcab1dd336244969a3214dd17843013a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTEtMi0xLTEtMA_9de003f8-67bc-49a8-a5cc-bacf716b06f8">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieee11dbbba0341acad84e21d44b66cb0_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTEtNC0xLTEtMA_1271b018-0a1c-4615-8ff9-add50a404a18">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibcab1dd336244969a3214dd17843013a_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTEtNi0xLTEtMA_8045f4fe-e6b7-43ff-a1c6-f7dabbbf3ab0">11.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb7c0f2ea9d4046a2c03e628109123a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTItMi0xLTEtMA_529b7cfd-f87a-4cd9-afe6-fb1ad2dc622c">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1561310f3be0405d937bd6b471583f21_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTItNC0xLTEtMA_b1d8503e-d6ce-49ba-a9e0-4ae0d1b02d1c">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifcb7c0f2ea9d4046a2c03e628109123a_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTItNi0xLTEtMA_e3fb350d-136f-4b0d-bb78-04ab48e9ecd6">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab1d64419004688bb06b6ce8e08f292_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTMtMi0xLTEtMA_41a3e873-f7f3-4882-a84e-b8cbc2d6eadf">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if345aeec465f40d3988084e400c97b4e_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTMtNC0xLTEtMA_0ce21107-7e06-4512-a099-28d48e6a26d8">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifab1d64419004688bb06b6ce8e08f292_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTMtNi0xLTEtMA_4879675e-c406-4e10-909f-8309ef87b2f3">7.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a80582d773f48a88dd91b183eca0b21_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTUtMi0xLTEtMA_24d60329-bcf9-4747-bdb6-9a05c5edb64a">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3b072e6a9b4111a82aad6be86d93c6_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTUtNC0xLTEtMA_8764f140-b80c-4e0f-b689-3fba27810ee9">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2a80582d773f48a88dd91b183eca0b21_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTUtNi0xLTEtMA_66a0441d-bf47-4e26-a09f-0aac741827d5">9.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f5c3eb00ca4f86a05c633b971c6262_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTYtMi0xLTEtMA_48acdfeb-d9a0-4520-9b28-fbbe332dc319">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c42bc98065a4fcba4fa265b813a01b1_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTYtNC0xLTEtMA_7a819b8d-2853-4a11-9a4b-605e9ffefed3">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i22f5c3eb00ca4f86a05c633b971c6262_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTYtNi0xLTEtMA_480acf29-24e7-4944-af50-219295e3ebf9">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f35f4e601b0404393243d21e82cb121_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTctMi0xLTEtMA_3f8ff370-0f21-4b3d-bf6b-347e4629a4f7">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7c978b217504b4e97c5a3da905e7be6_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTctNC0xLTEtMA_b5077965-ccf7-4c2e-8eb1-e5b5d4002127">435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8f35f4e601b0404393243d21e82cb121_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTctNi0xLTEtMA_9c08c10e-e7f3-4658-ba69-fadd0c65963a">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i215e664def914a8f8dae6cdfc6d30664_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAwLTItMS0xLTA_a32395a4-ed34-41ea-b7e9-0110e115bfd3">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1e1a3f79d44f43a2ae8c994d019ed7_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAwLTQtMS0xLTA_ad101c5d-c841-437b-9d0a-b2871e338ebf">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i215e664def914a8f8dae6cdfc6d30664_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAwLTYtMS0xLTA_231d8714-1705-4c6c-a0c6-e28dad9bcbda">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6cfc8b3edfc4a0ea32dd87a1d6bfe83_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAxLTItMS0xLTA_31484a45-7f24-437e-b50e-8a5c355c7330">2,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864c9546ca1845cea37de582336593f0_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAxLTQtMS0xLTA_1033518d-85e5-4fae-a72c-d578655d7897">1,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6cfc8b3edfc4a0ea32dd87a1d6bfe83_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAxLTYtMS0xLTA_c0cbc25c-6c52-48a7-bc66-9a0297c2a377">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f4c2b4bc544bb9938f19f240de842b_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAyLTItMS0xLTA_025d774d-3b7c-4e60-a342-947f48bba056">3,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91610b7c00884714803dc8fef0f20607_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAyLTQtMS0xLTA_666d5e16-1cdf-46b1-bace-3644d8f565ae">3,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92f4c2b4bc544bb9938f19f240de842b_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAyLTYtMS0xLTA_8ba72ac3-1eb4-44f6-8dc8-0e1897df1a60">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ac86b2ad464bea9af64abe75679432_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA0LTItMS0xLTA_980b55a0-cc0b-415d-a134-0faefcb98695">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec972b10c7b0493883f2bd7563ffbd99_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA0LTQtMS0xLTA_ae17bcc3-c224-44f1-8179-ed9ef3f15da8">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2ac86b2ad464bea9af64abe75679432_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA0LTYtMS0xLTA_bebb1900-526c-473a-9c3c-5fe25ff369a7">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfbea1e8ef24573bc5a395f4dc46921_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA1LTItMS0xLTA_a97b40ef-c5c4-44f7-9e4b-9c8250b757bf">674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0afc2d9300442c481f53a34f4d5eadf_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA1LTQtMS0xLTA_0f8c15f4-7f48-494b-b6e7-3fb57ccc54a3">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8cfbea1e8ef24573bc5a395f4dc46921_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA1LTYtMS0xLTA_aa2a589d-90b3-453c-a1c8-75328c4737ad">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cee6a4e627d4c4281ce1b29360ea956_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA2LTItMS0xLTA_2715b48f-2f19-4436-b402-d1c627138e3f">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3511302b1ae41809e6440adaa75a4b8_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA2LTQtMS0xLTA_d4fccbab-c222-4653-beb9-8f96cd233b89">937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3cee6a4e627d4c4281ce1b29360ea956_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA2LTYtMS0xLTA_3bab23d8-79e9-47ad-8922-b1ae693805b5">45.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69417898b97a46fbb70d8ba92644a167_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA4LTItMS0xLTA_003e4770-97b7-43ba-abe6-c63fe52aa14e">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5940573a824aea9b11c62a69e8e3fe_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA4LTQtMS0xLTA_28735311-36f8-4474-bb9f-01bf71a90749">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69417898b97a46fbb70d8ba92644a167_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA4LTYtMS0xLTA_c8c67431-7936-42b1-8340-73b7bedef973">44.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a54ac8edede45ddbaab8f1db84179d2_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA5LTItMS0xLTA_9d6d0443-792f-46e0-a5a8-953485529f56">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2ad067eaffd4f1391d0486fc4161840_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA5LTQtMS0xLTA_6e33dffe-beb6-47cd-a92e-3e4a92e319ac">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if080c4dd59e944648097620649b8fb6f_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEwLTItMS0xLTA_4f5cac6d-a44f-4a2d-8846-47d7c9081011">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2d16f32fba47f09eaaea5712a0b4fa_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEwLTQtMS0xLTA_c6bd27a5-418f-4cf6-a861-f906b59d87df">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if080c4dd59e944648097620649b8fb6f_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEwLTYtMS0xLTA_8c513572-2037-4338-a24a-b0ee52c0188a">82.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9de68fe20a54bb3938d8f34bc55a8a9_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEyLTItMS0xLTA_eef5883c-ca32-4b9a-96fc-b704c6b7f9d5">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa43d68970b74de495b2ce1d7600846a_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEyLTQtMS0xLTA_0b4e51bd-ab4a-4551-88af-1237e5078362">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9de68fe20a54bb3938d8f34bc55a8a9_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEyLTYtMS0xLTA_dd434a79-d4f3-42a8-9b78-70d1b6608198">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebe2f3e24dc4867b6dc012fde3f09fd_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEzLTItMS0xLTA_db1d6146-7c16-446a-b504-ef8f1ae01b38">680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f3f4cd739b446e89e809b5ac4d5df4_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEzLTQtMS0xLTA_6ead61e8-c2c1-4bde-965a-f75a0805436c">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idebe2f3e24dc4867b6dc012fde3f09fd_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEzLTYtMS0xLTA_f2695673-025f-44f2-9ee3-187de61d0d56">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a98910058dc499f9afafc26d4f8d7a2_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTE0LTItMS0xLTA_e0339646-0e6c-42d5-8f9d-ce10102a2fc8">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c52fe15105d49e18829d0a70625bdad_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTE0LTQtMS0xLTA_85d919a6-37a3-498d-aad5-9f15092d1487">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a98910058dc499f9afafc26d4f8d7a2_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTE0LTYtMS0xLTA_5e65babf-6f92-45ee-9adc-7bad3d912de9">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf69631e6a64a778cb06aa103ea457a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIwLTItMS0xLTA_ea6eccb3-94a0-41b0-8fb0-c7f7e214c10c">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d01b70ce6a4d158b8e85edb95cab4a_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIwLTQtMS0xLTA_6065269a-b98c-4faf-bec6-be895bba17fc">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9cf69631e6a64a778cb06aa103ea457a_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIwLTYtMS0xLTA_45d1a347-75f9-41c4-adce-58ec8469c2ac">64.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10b7e28bcf94b0f8cf1550242af73c0_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIxLTItMS0xLTA_50bca223-6408-4c25-826c-b68d5cf7d7f4">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ccc8d4aa3944fc9a6f5d46048c4e46b_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIxLTQtMS0xLTA_88b29303-17e1-4b13-a84f-29deda5d4218">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic10b7e28bcf94b0f8cf1550242af73c0_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIxLTYtMS0xLTA_27b6a69b-cd85-4171-a201-07922355042e">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a43fa091bd04904af477b8da882ccc9_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIyLTItMS0xLTA_357f2e3d-6309-4760-a231-aa464dad624d">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ca74a38d344c029cb03ec16c2adf4e_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIyLTQtMS0xLTA_2ad109e9-e6f5-42fb-98a1-32b879a01baf">690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0a43fa091bd04904af477b8da882ccc9_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIyLTYtMS0xLTA_55640c6d-d411-419b-9095-672d57f2502b">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i188efe981cfe4b9eabba62c7a6a39622" continuedAt="ib2145c5f91874cb8a0f761f170cb3529"><ix:continuation id="i2c375a5e737a4105a7f92fa0a8329c03" continuedAt="ic18baf75f4ee4fc59849be4382bc38b3"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1056e17dd9d4f2cac9bf0fbd592a173_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI1LTItMS0xLTA_14ab167c-f2df-4eac-9d2d-d0f38042346f">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0278ad7c322f4c488129c6b911f43d45_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI1LTQtMS0xLTA_a75b566f-44d8-4dae-becf-30a83170d4be">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie1056e17dd9d4f2cac9bf0fbd592a173_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI1LTYtMS0xLTA_3074e3a1-8f5f-4d87-aa04-665ba67529df">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d4763b134be49d4b30da01bf1ba44e0_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI2LTItMS0xLTA_ddf2b520-fce1-4471-a2e8-e3f9c7add957">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b19e46a75b4847a0c6f53f552cfbc8_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI2LTQtMS0xLTA_145ef33f-8bf8-41d1-bf7b-f144d11bec82">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8d4763b134be49d4b30da01bf1ba44e0_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI2LTYtMS0xLTA_4d7a4b2d-38ee-451e-86fa-cad21a6cd225">15.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48200892c424f87b7edda0ba0409c96_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI3LTItMS0xLTA_52958510-d4ea-467c-9f91-de7f61a09c71">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c5442217af4f099da88cd8d2d16584_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI3LTQtMS0xLTA_2dc8283c-ef79-47cb-9a77-106a895d20da">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie48200892c424f87b7edda0ba0409c96_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI3LTYtMS0xLTA_90423ce3-dc8d-4645-975f-f2c47a6f79ad">14.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769a39b459364823ac7bbeb1e988ee9a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMwLTItMS0xLTA_a577d09f-f2db-4be2-ae0b-c1cf250a231c">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3d972234fcd4ba498f466945a9c4cc4_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMwLTQtMS0xLTA_d74854ff-e1cb-4361-88e7-b9defce844e9">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i769a39b459364823ac7bbeb1e988ee9a_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMwLTYtMS0xLTA_ede943e5-cb6c-407a-9eeb-61f0e0ccc359">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f07da4bc71140e69f2cd469df1ff0a4_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMxLTItMS0xLTA_102fc816-a877-4849-ac1a-09675e51a3ca">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c7abf55c7f4cd1825fbdb35e87d736_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMxLTQtMS0xLTA_657baa9a-c721-416b-ab2c-2253ddcff4dc">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f07da4bc71140e69f2cd469df1ff0a4_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMxLTYtMS0xLTA_0ac7f684-1cac-4078-9c07-664fac775722">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871b3677375a4491991a21ca121e6485_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMyLTItMS0xLTA_c06c9223-8cd8-43ef-be83-8a1cd9141d04">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic19c69b6d1454567bbf90da51c867584_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMyLTQtMS0xLTA_f06be2f6-68b9-44b9-a136-7ec84ddb22f3">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i871b3677375a4491991a21ca121e6485_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMyLTYtMS0xLTA_0b7eddf9-fac0-483c-b099-f0cd0749e29a">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i712cec174e7a4562b67a334df7885636_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM0LTItMS0xLTA_fffcfc86-074f-410e-bb64-820d949a5a53">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cb98336e1146a28b4c4b2c51be0b43_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM0LTQtMS0xLTA_376466fc-988c-4c36-b175-4b20d9adb20f">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i712cec174e7a4562b67a334df7885636_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM0LTYtMS0xLTA_4c7c1fc8-76c9-473a-bd6d-60d1f470c068">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c23981dbe7c474d94010c344d4e9738_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM1LTItMS0xLTA_cd30908d-5441-4dc5-ab57-4ebebc948dd2">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eaafeabe91c4ea48c2ad1d1f12dba58_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM1LTQtMS0xLTA_9987de33-2992-44cc-ac7d-939e9f016b25">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c23981dbe7c474d94010c344d4e9738_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM1LTYtMS0xLTA_a9f376e5-0d4a-4599-8d20-647217e4e5e0">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24a8dc58bc5a4da4ad5d964b5437e8b6_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM2LTItMS0xLTA_90e1a9d0-55ad-4d75-94cf-24bac1a339aa">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8096a899854fcf930ca0cea72e522b_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM2LTQtMS0xLTA_3d5a6960-851c-4e4e-9762-ecb7fa751962">389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24a8dc58bc5a4da4ad5d964b5437e8b6_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM2LTYtMS0xLTA_6b793c78-2568-4111-a6a0-c1c47f981584">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf849323318a42d78e841021176dc0db_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM4LTItMS0xLTA_451d23fe-3c72-4c89-837a-6156dac9cefe">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3881e94557524789a9ff7fc5efb2d29a_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM4LTQtMS0xLTA_59db86e4-b31a-4e35-9044-a87d3c4d2ca3">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf849323318a42d78e841021176dc0db_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM4LTYtMS0xLTA_74d43521-e298-4dcd-be21-92345f5a2423">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id087d3cf08544d0e8465c05939e54c06_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM5LTItMS0xLTA_3e53be67-9001-4a03-b7a7-d1b5c1a3e764">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4ecbbe64184af588dc9aa7b93d8f9c_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM5LTQtMS0xLTA_f8f317b6-1f60-4b3a-9c86-d4a8e67236e6">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id087d3cf08544d0e8465c05939e54c06_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM5LTYtMS0xLTA_0d45b7d3-aec0-4f97-9ab4-43c34ded6aed">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90325c74593949fc87a8cc588c4f9fee_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQwLTItMS0xLTA_07d8953e-cb3c-479c-88c9-c358d1625262">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794c9a7bb0c54961a3e9869aa082ba42_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQwLTQtMS0xLTA_9eebc747-a986-453a-8339-9fa8b35f43d0">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i90325c74593949fc87a8cc588c4f9fee_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQwLTYtMS0xLTA_a733ee6c-83d6-4525-91ce-ea54ffca0d67">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123f5966e05a44d085563e3eeb9a895f_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQyLTItMS0xLTA_846b2d31-77af-4dd9-a624-131808db5dc7">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5f1afa7b3f4d9c86ef358c4ed464c0_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQyLTQtMS0xLTA_3ba563c3-cda5-49b1-90c0-7df12abfa63c">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i123f5966e05a44d085563e3eeb9a895f_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQyLTYtMS0xLTA_46872867-258e-4125-bb6e-00e7eab9cb6c">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12bbf63564d04cae9ff269c9f4bbb527_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQzLTItMS0xLTA_5a33ef76-99c1-459b-9b8c-fac2097261a2">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc39cb498d44439a78cc49f5f336acd_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQzLTQtMS0xLTA_14261f4d-bd48-4801-acd7-d68b40090e9f">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12bbf63564d04cae9ff269c9f4bbb527_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQzLTYtMS0xLTA_ed21b6cb-440d-4b09-931b-4bd9a8ea1a21">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b9a89680513428485a34f3f48c896f6_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ0LTItMS0xLTA_01bc2b27-b2d1-4867-9aa8-720f9b102a34">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7783e4e0f34f45f8b3873d934bac73a8_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ0LTQtMS0xLTA_76ff412c-e409-4220-a6a4-b9e5ff96d287">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4b9a89680513428485a34f3f48c896f6_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ0LTYtMS0xLTA_81de60c8-75b2-4f20-8148-8117b6f0cf0a">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca9de72471f4144afc322742d3ee277_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ3LTItMS0xLTA_32106b4d-cce7-4b9a-b21c-74e90f051cbc">799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87786ad4f32e48449a1996e1153a6164_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ3LTQtMS0xLTA_47112f9c-6110-438c-9688-37b54708eeed">806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9ca9de72471f4144afc322742d3ee277_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ3LTYtMS0xLTA_2f95ee30-7bcc-4cac-8268-6070f6fca85f">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe0a5b0064547b1a5b98fe08aa407bf_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ4LTItMS0xLTA_f285e3dc-1673-41f7-aec8-5eeb57523da1">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782d96754043498593d177ed7e9d7435_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ4LTQtMS0xLTA_3e8dba79-5f9d-4ff6-a675-a30071904e6d">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1fe0a5b0064547b1a5b98fe08aa407bf_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ4LTYtMS0xLTA_1b87c1be-a7be-411d-aab1-de51e1c76040">7.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad2d868e8f94f1ea0241239aa8abf8a_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ5LTItMS0xLTA_02afb35b-8af5-4e3a-995e-222381344549">1,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia564284c6bec4f09a465f098bbfaf35b_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ5LTQtMS0xLTA_2738c0b3-0299-4f74-a77d-82aa71c605cf">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8ad2d868e8f94f1ea0241239aa8abf8a_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ5LTYtMS0xLTA_19a8ed99-255a-4807-ba7d-731badbcd07f">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2237e862843c453cba68d7ee3d286ba2_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUxLTItMS0xLTA_7e692dd7-4ebb-4635-8bde-b438d2eeb231">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dac5d761d243b8861130b807832ca5_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUxLTQtMS0xLTA_ad472025-ddcb-4634-8664-1ad6561dda86">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2237e862843c453cba68d7ee3d286ba2_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUxLTYtMS0xLTA_bb66fb17-551e-4ae2-a729-aa7414508f68">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d2cab6e4a2f4243aff50d87fb678757_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUyLTItMS0xLTA_b2ccd9bf-6b8e-417f-a0f6-8eb82bd6a585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e25388aba946e39f461155f1e66bb3_D20191230-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUyLTQtMS0xLTA_d2ec2727-3226-47f5-8259-9ebf44c0de08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d2cab6e4a2f4243aff50d87fb678757_D20210104-20210404" decimals="3" format="ixt:zerodash" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUyLTYtMS0xLTA_ddfa079f-0d9c-455c-a4ff-be65dbefe3ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ed7f86f44840468b3a6ca64ad69b92_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUzLTItMS0xLTA_cd68b7f8-bab8-47ce-976a-551e4c7ecc84">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac1b72498c54651b9f3390eaf7bc4a4_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUzLTQtMS0xLTA_5c49ac34-bb1d-4bf4-bc20-59dfa135d089">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1ed7f86f44840468b3a6ca64ad69b92_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUzLTYtMS0xLTA_eef06c60-bfb3-4fad-807c-ab98bea8b1da">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78be76eb6d4c4d7297a4bf4093369453_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU1LTItMS0xLTA_55ab1949-554a-4066-9d2b-11be04c80be6">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic869379c2ad541c399cbf3c1fb6a954e_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU1LTQtMS0xLTA_58ab7844-c126-4b49-8973-597c5bfdae2e">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i78be76eb6d4c4d7297a4bf4093369453_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU1LTYtMS0xLTA_cc275771-f225-4b9c-a138-039d3670deb0">26.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c30797b0cf4d2cb47f26f7a4501b8c_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU2LTItMS0xLTA_375b2a65-3d26-431f-989e-bc5cb568aa0a">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedf86a241dc4b5bbb19ba292a60a3fa_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU2LTQtMS0xLTA_a2e2d1ff-28fc-47c8-a61e-a1a12b6aa185">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9c30797b0cf4d2cb47f26f7a4501b8c_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU2LTYtMS0xLTA_f6050fee-29a6-459d-8f8f-2d2bbc16eaaa">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b64f045460a4ca8858056eef80e48c5_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU3LTItMS0xLTA_54d7026c-c937-4cb7-9bd0-6fce1f9416f6">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf5f96085f349f4b87d2aa43da1a71b_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU3LTQtMS0xLTA_82194154-c5d2-47de-b597-506ed50b3a8b">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8b64f045460a4ca8858056eef80e48c5_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU3LTYtMS0xLTA_d1bb54e6-192a-4d82-95d9-8f7f9fd5afa3">14.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c259fa6ac434248908eaf1d9085cbae_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU5LTItMS0xLTA_41a51054-e6dc-4f87-9718-41477a3cb6f0">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab22b59ea5b8436eb6d4e323ffdb8113_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU5LTQtMS0xLTA_136e64fc-7b42-46c5-bb83-119c1b3714a3">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4c259fa6ac434248908eaf1d9085cbae_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU5LTYtMS0xLTA_f1cbcf73-a0a8-40ae-a2e9-8ddc4e818213">18.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92f35e3cc8049518e4c913312f61c94_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYwLTItMS0xLTA_b1921521-c9f3-4894-81ff-1e3935c41737">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a7e770b127440794059c8ec0d770e5_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYwLTQtMS0xLTA_8200a8ea-c204-416b-9d19-b3dcf4551c64">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie92f35e3cc8049518e4c913312f61c94_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYwLTYtMS0xLTA_002fa4f8-58ee-47b1-af9a-207d9dd40e8f">18.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67e32a6ba574c4bb1df1943ab8a91c6_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYxLTItMS0xLTA_61eb9e35-8c5b-4c2d-b017-c3df3ff394ab">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib935f1d5a67d445e8d777642f2400a7a_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYxLTQtMS0xLTA_5582d8ef-6c7e-4866-a64c-7ff217df553b">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if67e32a6ba574c4bb1df1943ab8a91c6_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYxLTYtMS0xLTA_f458be3f-ebc3-4496-a914-250d1992a067">18.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3db4b7b2b9104e8aa81ffe56c63244b3_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYzLTItMS0xLTA_ee87855e-4b4a-48fd-9342-8e3fa3e503a8">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c6a9d00e90848c58e88acd8954635ae_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYzLTQtMS0xLTA_76c98275-52a9-45bc-a440-cca2b34380e5">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3db4b7b2b9104e8aa81ffe56c63244b3_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYzLTYtMS0xLTA_acc509b4-21a8-4c56-bcab-56659e327627">28.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9387bd1d4a9542529ff61ba379041ef5_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY0LTItMS0xLTA_da8aab68-a980-4a77-ba01-f70a5e2df78a">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc20ebf5bd042ad896ae4efdc519047_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY0LTQtMS0xLTA_528901dc-9b31-44a1-a86e-19f0eb08daf9">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9387bd1d4a9542529ff61ba379041ef5_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY0LTYtMS0xLTA_dee2f907-a68b-41d8-bd73-2458aa808233">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65d5eedb28a4d1fac8ffba1883d31d7_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY1LTItMS0xLTA_e51ddbf5-544e-44d4-a455-534d16268c1b">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ee165c65f3448d9fd58f57b88afb73_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY1LTQtMS0xLTA_812f3bbb-6638-4bef-bec3-287c6f9cdcaf">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if65d5eedb28a4d1fac8ffba1883d31d7_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY1LTYtMS0xLTA_b3065dfa-b799-4ae4-bccf-12e08b9dd94f">13.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a203809cc6644f48256490ae13f0ab3_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY4LTItMS0xLTA_8762b08f-3dd8-42c2-acb8-6f4d7b85ee8a">6,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438067415c5c4f5985d9ae849a5e2a71_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY4LTQtMS0xLTA_be25a44b-9ec7-43bc-9ba5-4dea13a00ae3">6,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a203809cc6644f48256490ae13f0ab3_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY4LTYtMS0xLTA_e38833ef-6bd7-4ccd-843f-e38354f42ec7">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id10068aaaa974a5aa7d0db7ddb857b8a_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY5LTItMS0xLTA_e3adb20b-4dd8-4b66-a43d-293266ec686e">5,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b613e89c6de4696b5f46fb3913eb864_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY5LTQtMS0xLTA_4cd7b44f-c897-422e-a055-ff576ed2d6a6">5,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id10068aaaa974a5aa7d0db7ddb857b8a_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY5LTYtMS0xLTA_e66e2e65-ad53-4813-b438-26484e04c536">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bb046f4ee745b8a6a3a214d7610a6d_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTcwLTItMS0xLTA_a77961b2-dee7-4f39-a18b-fc9adbd1032c">12,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdca448a11c64bc48442f40fa88d4ce3_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTcwLTQtMS0xLTA_a575ddb4-d3cf-4caa-9138-7bb393f5d15f">11,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0bb046f4ee745b8a6a3a214d7610a6d_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTcwLTYtMS0xLTA_3e42b386-ae7c-425f-9efc-0db89d4f286c">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="ib2145c5f91874cb8a0f761f170cb3529" continuedAt="i15dc188cbced4874bec18bf294f33bec"><ix:continuation id="ic18baf75f4ee4fc59849be4382bc38b3" continuedAt="i8866181c138543928517627913305d6e"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eda2d70fc65473fa36d660afce9a681_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgyLTItMS0xLTA_e9330b7d-5675-46b2-b3f4-ee828b7b954f">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0decb1dd364c8da7e609d042602990_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgyLTQtMS0xLTA_f798be00-0013-49af-8395-faa05c560b1f">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6eda2d70fc65473fa36d660afce9a681_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgyLTYtMS0xLTA_06ad5484-c519-4016-877d-47268e3262d2">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9df6ec7e15475b80a0ddd952dd424b_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgzLTItMS0xLTA_31c7338b-7c43-44e1-9fe5-b42167a2ee06">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f8f49e166a42308c773c330db2cdac_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgzLTQtMS0xLTA_4ecc70e7-cd18-412f-b967-aabf1673b729">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d9df6ec7e15475b80a0ddd952dd424b_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgzLTYtMS0xLTA_8eb9488a-4b34-466e-beb4-56a2c5d079ae">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c9c51f138064f7693ff21bd0cbc01dd_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg0LTItMS0xLTA_909521ad-94bb-4837-bbe2-9411f5386ad2">949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a728efc7c4431185d2257b26f2c766_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg0LTQtMS0xLTA_c1ae7466-2905-4995-89d1-4dfee65f3c61">727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c9c51f138064f7693ff21bd0cbc01dd_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg0LTYtMS0xLTA_be95ad35-1f41-4ae4-a420-9005520a331a">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i046c37ec387d418792e0b7796ecad6b5_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg2LTItMS0xLTA_5de76eb5-138b-4500-b83d-d9c6cdbeb904">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3aa1d5138aa4eef99d2d397be8bb5a9_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg2LTQtMS0xLTA_b60983da-0a24-4d3e-b14d-c4d84c49e649">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i046c37ec387d418792e0b7796ecad6b5_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg2LTYtMS0xLTA_b45c11e0-4591-4e4a-903b-7585dcccc4a9">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04925e843e58499d8cb79ab41d517312_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg3LTItMS0xLTA_5565d148-32e1-4770-ab3f-32b4a8b70f89">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311fa4ee096d498cb9fc15d6e2eac138_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg3LTQtMS0xLTA_11f68887-4c2d-4d70-879d-b6ceeb15e3ad">788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04925e843e58499d8cb79ab41d517312_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg3LTYtMS0xLTA_035af759-0522-4f5d-bf5d-40e392a8ff13">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de8902fb1d64e47b0f656f4518cc948_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg4LTItMS0xLTA_0a4a51dd-6580-4045-aa31-d407696bf01b">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b6bee78af44dfb8c09e1d37795edec_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg4LTQtMS0xLTA_97db0fd5-fa47-4f91-9539-c6e3e7602019">2,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5de8902fb1d64e47b0f656f4518cc948_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg4LTYtMS0xLTA_9062e80c-6c7b-4b2b-8c06-45131e2de16a">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eed8f3fd6bb4026b042b674919fe034_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkwLTItMS0xLTA_7f664b03-5966-4b94-9d4b-998ba5f42c51">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edb3ee83adb4242bda5469bdac2cd58_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkwLTQtMS0xLTA_7ff4aede-80f6-4aef-80a2-5a800ddab8b7">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2eed8f3fd6bb4026b042b674919fe034_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkwLTYtMS0xLTA_435ec634-72fb-40cc-85be-6e3904b441b6">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f6c8b86b7546149befa4e5f3fca4d5_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkxLTItMS0xLTA_787bb719-d360-4a96-8a34-b3f9f1b35c66">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebb01df50a34ff1b884a2077e7460a5_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkxLTQtMS0xLTA_c7aeb1a0-0848-437d-a5b8-72073d7512b0">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51f6c8b86b7546149befa4e5f3fca4d5_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkxLTYtMS0xLTA_49892dbd-9d47-45fd-b63a-8e18c97ebaaf">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8154d1203f304af6adf50d35bf4f7880_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkyLTItMS0xLTA_e4f5db1e-f48c-45d4-b370-0d652537d48a">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8740a5ae1646469f9c8fd93ba62467bc_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkyLTQtMS0xLTA_ee3bdba9-4136-4ff8-a881-e6040032a06e">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8154d1203f304af6adf50d35bf4f7880_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkyLTYtMS0xLTA_6c543bfc-0680-4027-a996-c9848ec5d90c">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f962900d174483a2d8ef350b1d7647_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk0LTItMS0xLTA_d803b7d2-2375-4d6e-8496-d153f0ee42ab">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a878e7d9cdf44f8a0e5b960ec217e8b_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk0LTQtMS0xLTA_fd91a30d-32b4-4c84-b326-1dc5dd4aad7c">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i06f962900d174483a2d8ef350b1d7647_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk0LTYtMS0xLTA_c6d01440-f043-4ced-9211-3f076f2f0591">13.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id864ff961e674fb1b62f80b8c6932ea9_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk1LTItMS0xLTA_87b53229-438e-4ca9-a974-1d091a5d149d">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c551cbda52435687542e1e45b23fd4_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk1LTQtMS0xLTA_f80fffb2-415b-4a92-8ead-93a395368da1">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id864ff961e674fb1b62f80b8c6932ea9_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk1LTYtMS0xLTA_77f8447a-a6ab-47da-89f3-216723d02f55">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67be5d04e3c440f888ad9161a9e5eda7_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk2LTItMS0xLTA_388091b4-79da-4e7c-824a-098caf920502">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9037030323674d438622ead7d2365cee_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk2LTQtMS0xLTA_0fc8e26e-58db-4ce4-ba75-afcdf7e1f85c">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i67be5d04e3c440f888ad9161a9e5eda7_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk2LTYtMS0xLTA_a0eff06c-b84e-41d9-aaf0-bf635a63399d">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bec226c4414b32b21f05d00c95bd73_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk4LTItMS0xLTA_32c359a4-2514-4c32-9fee-ec8d311f1eb3">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1806bc88b23744e38bf7a4a18ee82827_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk4LTQtMS0xLTA_b0b1d51d-6150-40b5-b39b-761685679621">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03bec226c4414b32b21f05d00c95bd73_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk4LTYtMS0xLTA_865fbc34-ed1a-4a74-ab05-2f03124de1f8">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4fc05c968db431dafa927a4b29febff_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk5LTItMS0xLTA_caf3f231-d284-46d3-a764-0719e3300ae6">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib713a362c12a4e0f8c0fdb3f559dd81d_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk5LTQtMS0xLTA_6082de30-20d8-42f3-b012-61fe5ffe9158">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4fc05c968db431dafa927a4b29febff_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk5LTYtMS0xLTA_85da5081-2186-4955-baed-6a2d8ad36682">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0230b4c2f04f45c08018028261942d70_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAwLTItMS0xLTA_736d8963-8b04-440c-9129-eb4db8ae26f7">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da6efb5d0a745239d6361465c0a8cf7_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAwLTQtMS0xLTA_37ccd2ca-be82-4e5e-bc17-ef8ecd55763e">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0230b4c2f04f45c08018028261942d70_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAwLTYtMS0xLTA_e693e8f9-d970-4d06-aa55-5511834fa5dc">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59adb5a67adb476b8ee2fd372e3f1de0_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAyLTItMS0xLTA_5c873a33-c7b0-45d3-86af-44b794435f53">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6ab8313ed7411fb9fcccd2fb2fc054_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAyLTQtMS0xLTA_37b5236d-d6d7-4dcd-b644-1db027b9a776">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i59adb5a67adb476b8ee2fd372e3f1de0_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAyLTYtMS0xLTA_16c686a3-9545-410f-8b60-fb999135500f">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70464af74e1244fe971e0ce8df9c1139_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAzLTItMS0xLTA_583b351e-d62d-49ca-837f-a0473c811276">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87c7441a2ff64814bc9edd9ebb11379a_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAzLTQtMS0xLTA_9ecade36-b3d2-42fa-9f36-d3dd5c205f1e">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70464af74e1244fe971e0ce8df9c1139_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAzLTYtMS0xLTA_b5a05d55-db84-48ff-9f46-bef16396963b">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f75cbd2f3e44e86b3159f06713cea79_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA0LTItMS0xLTA_9e8bd62c-cb5b-499a-9544-f4b936f0e01b">706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46794c3f5f7641c28479e5843b966ae4_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA0LTQtMS0xLTA_ed169ca3-cf9c-4ffe-bc4c-4f73f209dd8b">703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f75cbd2f3e44e86b3159f06713cea79_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA0LTYtMS0xLTA_26d4b00d-9b56-4ede-8630-54155a07ddd7">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbac775d46c4b0caf203e09c5683d11_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA2LTItMS0xLTA_e1a205de-3e1e-4002-afac-ae12766e0a82">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73332a11822c4dfab9561d066cb74b28_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA2LTQtMS0xLTA_18305704-c5c6-486f-afcc-47fb7e542bfb">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifbbac775d46c4b0caf203e09c5683d11_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA2LTYtMS0xLTA_f47474e9-9e7a-4a40-9d20-fbc4e565027f">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381d0ba83d1f41bdb53476e56a42a36e_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA3LTItMS0xLTA_3730f87d-641d-47c9-b96a-fed31a711e62">1,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae9f5809e1e453ca62e9f4b2040f4f4_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA3LTQtMS0xLTA_3c3d42f4-6dc0-48cb-a0b6-40775a853dd9">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i381d0ba83d1f41bdb53476e56a42a36e_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA3LTYtMS0xLTA_091def7a-0116-4c1e-97c4-c8fdc65755ac">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee3f3e37530b4bc5bc81e9b8b73ec767_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA4LTItMS0xLTA_1a6965ba-4261-419c-aba9-66a6a926cec6">2,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i373fb25b6ac74376b24f1838469cdc56_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA4LTQtMS0xLTA_018b5cd5-539b-49d4-904e-9c6f3656de19">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee3f3e37530b4bc5bc81e9b8b73ec767_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA4LTYtMS0xLTA_51f87948-caf0-45ae-875e-5983a1e59a78">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d757ba0d9b54fa8a6d3b798835d364a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEwLTItMS0xLTA_b302708c-fd72-4c30-9c1c-9c8726e50a50">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib89e19ebfa6741fab1ef7e4ccb9bce83_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEwLTQtMS0xLTA_47780b76-1c77-4865-ab3c-490159899eaf">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d757ba0d9b54fa8a6d3b798835d364a_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEwLTYtMS0xLTA_bf4a77b5-d7e4-4cd9-9b87-eea51bbc6666">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i829ccedf81764d70b896a39ffc2b8d95_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjExLTItMS0xLTA_c0263eac-368a-4cfb-a1e9-d02bf3805c70">713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia475a9342c1549239a4b78261b9b833c_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjExLTQtMS0xLTA_dad4870e-5b43-47c0-b7ef-8b89d8e79df5">567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i829ccedf81764d70b896a39ffc2b8d95_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjExLTYtMS0xLTA_6967383f-0a67-4084-9a8a-b4050f8ecfd7">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia646bd76b4f54d908a6d0888a0bab427_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEyLTItMS0xLTA_5eb5bf82-df1c-444a-a9ac-9374006cd11f">1,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc399b9993724391a7b071eb85f26048_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEyLTQtMS0xLTA_92352db5-e00f-4f24-ab70-3043903b968c">948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia646bd76b4f54d908a6d0888a0bab427_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEyLTYtMS0xLTA_59455bb7-dd22-42aa-b5f2-b4d715329054">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc92d2e4cf8a4de7b8c3172a78c2d8ff_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE0LTItMS0xLTA_b1163303-6aaa-4d57-b289-bbf8bf24c11f">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab081c7294c94dacb3f3da911787176a_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE0LTQtMS0xLTA_fa57e02c-51d6-4524-80c3-3bf1bfe6ea2f">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc92d2e4cf8a4de7b8c3172a78c2d8ff_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE0LTYtMS0xLTA_57bc830c-79b9-42bc-9dbf-19a03c3a02bd">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id694df27cb364c85abe72911f2a4f74b_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE1LTItMS0xLTA_3578baff-6bd3-4f74-b890-f9c569f808b6">761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee0751bab8e4f7b823728d29fc3a815_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE1LTQtMS0xLTA_bcc00bd0-196a-4a9b-b1a5-173fd2d96082">690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id694df27cb364c85abe72911f2a4f74b_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE1LTYtMS0xLTA_b0dddba9-994b-46f3-8278-75b41aaff87f">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i309da13ba23248d2bbd4befdd7ec001c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE2LTItMS0xLTA_95beb09a-73d5-460c-b0fa-980af7202188">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d6c8b409ec42199210aa34c876fc99_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE2LTQtMS0xLTA_d8d1d95b-406c-4ae9-baef-e610395d63cf">1,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i309da13ba23248d2bbd4befdd7ec001c_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE2LTYtMS0xLTA_faec0509-a1d4-4dae-9875-c72322d69c9d">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3ceb4f65cc4b228df4f27cfee4babf_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE4LTItMS0xLTA_76f8d282-e7ef-42a3-a8bc-41b775a2a88d">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ae566a0efc441eb0fb6ea1cc2e1608_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE4LTQtMS0xLTA_1747e17b-2002-49cc-8257-938b7a29cd21">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf3ceb4f65cc4b228df4f27cfee4babf_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE4LTYtMS0xLTA_c9507164-e0bb-405c-8138-f15179693181">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae5fbf3821e4b25b63bbfb4f1173093_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE5LTItMS0xLTA_8b83e1ca-9923-4225-a5c4-ad51e6fbbc03">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa44b2106d7456086d7300b833a26cc_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE5LTQtMS0xLTA_cfd0a1e0-44b4-4d26-9acd-b6673fbff7c4">628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idae5fbf3821e4b25b63bbfb4f1173093_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE5LTYtMS0xLTA_aa9e3496-b6f9-47a7-a075-31515a12b820">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i173c358b9082487dacc6b62f9414e27e_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIwLTItMS0xLTA_6ba85d82-6ee5-497e-9e67-f3a30ed7682b">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d24994a8ef4424b6c1f77a1a7134a4_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIwLTQtMS0xLTA_77273cb1-cfed-48b3-83fb-c9d239e2c51e">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i173c358b9082487dacc6b62f9414e27e_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIwLTYtMS0xLTA_5830497d-1731-49d7-a31e-c345ba0f5489">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44aeed20d86c44c5b5a4ebeafec47aed_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIyLTItMS0xLTA_ab972fc8-29f6-4fda-a83d-a1660074bad7">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51883c3c4f5f4d9989d8ea8605f231dd_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIyLTQtMS0xLTA_02932d1c-e82a-4e38-9377-410cec15c4d6">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i44aeed20d86c44c5b5a4ebeafec47aed_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIyLTYtMS0xLTA_a410b469-064c-44a9-933b-131c4184419b">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d094f0fc9b241f89a961261247144f3_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIzLTItMS0xLTA_2229e458-8d6d-4a33-bf5e-f2f5d01e5b1b">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3abe5bb0d9c4e3298e7a1b39eb3e953_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIzLTQtMS0xLTA_99edcb92-c5ee-4841-bdc2-04ade4d00358">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d094f0fc9b241f89a961261247144f3_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIzLTYtMS0xLTA_475df133-d7e5-498f-b012-3d4e83b5dddd">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1952414febe4c02a498725387577ba4_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI0LTItMS0xLTA_c03309fd-7bbd-4f7d-ae54-3568f331ffe2">857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f37539b91d45b7b48a375afd131b53_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI0LTQtMS0xLTA_666b8429-4c21-4b39-a1ae-eb072393b2f2">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1952414febe4c02a498725387577ba4_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI0LTYtMS0xLTA_77ffc643-859c-4240-b0e6-99b00c875fb0">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i15dc188cbced4874bec18bf294f33bec" continuedAt="i81d2d94fb14e48269192f7e63ea16ae1"><ix:continuation id="i8866181c138543928517627913305d6e"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8585c10f5564b039e486807c6255230_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI3LTItMS0xLTA_95c778bc-930d-4ee5-8d5a-16848770eb07">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e06d38a4dbb4397aa56a49e80a320af_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI3LTQtMS0xLTA_b2f5403d-2ae0-4c0a-b759-6a206c492855">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8585c10f5564b039e486807c6255230_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI3LTYtMS0xLTA_3094c735-58a4-4ba3-b395-ef740ff59735">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i317a97ccb069420ab772ab1f52d977ba_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI4LTItMS0xLTA_a5ac1368-b529-40eb-a74a-3aa7f55b342f">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6815bd7b754e4a902dee41b3bff0ac_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI4LTQtMS0xLTA_c47bdc03-291d-4c8a-a3d1-b422c267b08e">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i317a97ccb069420ab772ab1f52d977ba_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI4LTYtMS0xLTA_c203f429-6d7e-413c-85c9-69776532e2b7">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ac2702e3294ccc936243e7e77b3337_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI5LTItMS0xLTA_c0b8286b-3982-444d-9cc0-e46a825282a4">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d9f04a32215495f8fb5d9251c0b8172_D20191230-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI5LTQtMS0xLTA_cfa52845-6ecc-440e-a5e8-788a6abaae08">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2ac2702e3294ccc936243e7e77b3337_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI5LTYtMS0xLTA_83ad7795-7be0-4fdb-9970-1a266f1ec182">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0effaa8d4d19429294ebb6baadb91fe8_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMyLTItMS0xLTA_4a858202-0c88-4918-a62a-73695dac3765">3,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dba1ed2af8443a0a29e304aa9362c9e_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMyLTQtMS0xLTA_c7b15005-59bf-4a28-b192-0c5990369dbc">2,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0effaa8d4d19429294ebb6baadb91fe8_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMyLTYtMS0xLTA_ee3c17af-2eda-4626-95ce-6348e0640988">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27ba1a98c3ed46fea5a3c71020abc7e5_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMzLTItMS0xLTA_fe2794aa-da4b-46dc-8833-ddd2c6b38c6b">3,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eeba07dc96844578537afa4da1d4909_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMzLTQtMS0xLTA_c07eff77-901a-440b-ae26-d48f8bde57d4">3,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i27ba1a98c3ed46fea5a3c71020abc7e5_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMzLTYtMS0xLTA_e63172de-d1a8-496c-9b3d-7ad6b577b224">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765e60a738e846889a642c75a5734d75_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM0LTItMS0xLTA_85cb9114-e3c8-46b1-8e0a-be72133b80d2">6,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88511d277635488580602c5f2d2efbe9_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM0LTQtMS0xLTA_23ef43ec-f92a-4460-a266-3420484e9fbb">5,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i765e60a738e846889a642c75a5734d75_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM0LTYtMS0xLTA_908b3e8a-6ec1-41b1-ae7c-3346e4036cc0">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc1d3ef8e82b4cab9d2f209a70930bad_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM3LTItMS0xLTA_d1dc9425-5faf-4154-a829-67f8821e7a42">11,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia49cb056ac9642fab13eb3c45dd7beb7_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM3LTQtMS0xLTA_00d42dcb-c971-49ed-a8ac-19de20222efe">10,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc1d3ef8e82b4cab9d2f209a70930bad_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM3LTYtMS0xLTA_95332d47-7e09-4332-ba56-cf077f28d452">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61df9a2348d5485696295a61a5f0b0ba_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM4LTItMS0xLTA_819649b4-84c6-43bf-80ca-cec14d625d52">11,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc14d98635140cf98a64f0c2425a440_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM4LTQtMS0xLTA_c77c5d18-1c52-44fc-8b38-3ee4fe899c9a">9,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61df9a2348d5485696295a61a5f0b0ba_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM4LTYtMS0xLTA_224bab76-2bd5-4c6d-a282-b1f3ddd079b1">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM5LTItMS0xLTA_fab7d022-83eb-4095-bfe2-67a825cca2b3">22,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM5LTQtMS0xLTA_b8ce28c9-a574-40de-9116-55ceace52ebc">20,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM5LTYtMS0xLTA_d3cd8a5d-2602-42a6-8bd5-7f6aedd92efa">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzg5Nw_5c21e8fb-647e-4150-be28-42c8dae8dd05" continuedAt="i887c00097b574b94b79e5861a48560e7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT  </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.415%"><tr><td style="width:1.0%"></td><td style="width:55.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.785%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8774a60d6f6649268ae5cf40efca6063_D20210104-20210404" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfMi0yLTEtMS0w_768341d6-65e9-4c38-a47e-2a719b12b0c5">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f824bef77534b77acea435e4bcf50ed_D20191230-20200329" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfMi00LTEtMS0w_210038f7-d99e-430e-b290-469f1fee8f4c">770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8774a60d6f6649268ae5cf40efca6063_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfMi02LTEtMS0w_b7ce9e8e-563c-4867-b0a1-556146baab30">2.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id645f8a91fb54b40adfd453cef0dbd05_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfMy0yLTEtMS0w_8f0c80b6-e658-4794-8cf9-7268b5a28514">5,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia347c7ffc8b448789de799026384d1b8_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfMy00LTEtMS0w_487e5f7a-0cf7-4b42-9be3-383ce9e077a9">3,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id645f8a91fb54b40adfd453cef0dbd05_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfMy02LTEtMS0yMjUy_91765323-107c-46c8-af00-caad9da4aa11">36.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b22e45743641e680c31d8beb794e56_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNC0yLTEtMS0w_132f707c-6b76-4bdf-93f6-11deb7a97605">1,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfce5280afb34c08b7d2df0de5af45e1_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNC00LTEtMS0w_d995db81-3fcc-4562-bd64-97b50c8c6f4d">2,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i46b22e45743641e680c31d8beb794e56_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNC02LTEtMS0w_1efd70d2-44ec-47c2-82b5-8b06a49fabf3">19.6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4237eb3d9454518b7d9808794278432_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNS0yLTEtMS0w_81264be2-0a9c-48a5-b9b3-36d4254768d0">7,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6730cd63c2644e6b98a2fca79af18d2_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNS00LTEtMS0w_4c105f9d-ba85-4dac-819d-36aeeadf0793">6,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if4237eb3d9454518b7d9808794278432_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNS02LTEtMS0w_1e1915bd-c3f7-46e3-95e5-1e5c2bff9d14">15.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7090787364da465d986409e41cdb9e8e_D20210104-20210404" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNi0yLTEtMS0w_121699f2-dedd-4998-befd-f30159655bf6">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00b4438aac54f08b9632ab4416202d2_D20191230-20200329" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNi00LTEtMS0w_c63ac93d-3129-4cb3-ac22-5c7fc78d6f26">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNy0yLTEtMS0w_2a569d01-e538-4b12-88d5-8b33d7971df1">7,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNy00LTEtMS0w_e7e27b85-8e0b-4cab-8186-232be6136181">6,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNy02LTEtMS0w_9e845fbf-2b9a-4431-8e83-4d70fa68af36">14.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Includes amortization expense of  $<ix:nonFraction unitRef="usd" contextRef="i8774a60d6f6649268ae5cf40efca6063_D20210104-20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfNzM1_384461aa-4ffd-4633-9e35-6f00f44b881d"><ix:nonFraction unitRef="usd" contextRef="i6f824bef77534b77acea435e4bcf50ed_D20191230-20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfNzM1_efaefded-8439-45ae-a038-1242cabf91dd">0.1</ix:nonFraction></ix:nonFraction> billion in both the fiscal first quarter of 2021 and 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes divestiture gains of $<ix:nonFraction unitRef="usd" contextRef="id645f8a91fb54b40adfd453cef0dbd05_D20210104-20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMTA5OTUxMTYzNTg5OA_9b1c0938-5e0b-474b-8aa4-f8842920ead9">0.6</ix:nonFraction>&#160;billion in the fiscal first quarter of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes an unrealized loss on securities of $<ix:nonFraction unitRef="usd" contextRef="ia347c7ffc8b448789de799026384d1b8_D20191230-20200329" decimals="-8" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnSecurities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMTQ0OA_12b9148d-b5c8-41c4-823b-2f7ed1d1b21c">0.3</ix:nonFraction>&#160;billion in the fiscal first quarter of 2020. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ibdca448a11c64bc48442f40fa88d4ce3_D20191230-20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMTA5OTUxMTYzNjA0NA_30138cc7-9900-4fc5-a7e8-88baf1157627">0.1</ix:nonFraction>&#160;billion in the fiscal first quarter of 2020.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes amortization expense of $<ix:nonFraction unitRef="usd" contextRef="id645f8a91fb54b40adfd453cef0dbd05_D20210104-20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMjc0ODc3OTA3NjUxNQ_4cfabfec-fbd9-4685-add6-bee28cff7443">0.9</ix:nonFraction>&#160;billion and  $<ix:nonFraction unitRef="usd" contextRef="ia347c7ffc8b448789de799026384d1b8_D20191230-20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMTc2MQ_146d8c3c-7e86-402e-8eb5-6e522a5921f2">0.8</ix:nonFraction> billion in the fiscal first quarter of 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $<ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-8" format="ixt:numdotdecimal" name="jnj:AmountPrepaidAndDueToManufacturers" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMTA5OTUxMTYzNzc4MQ_29b0a5d5-5dbe-48bc-893a-594346a368e3">1.0</ix:nonFraction>&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a contingent consideration reversal of $<ix:nonFraction unitRef="usd" contextRef="i67972ac0db9340ad9d3acaa558c457e3_D20191230-20200329" decimals="-8" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzAwNw_29ff644b-9a1b-40e2-909f-6e01bef3932d">1.0</ix:nonFraction>&#160;billion in the fiscal first quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i88511d277635488580602c5f2d2efbe9_D20191230-20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzQwNA_69d2dfaa-0279-4978-8b3a-1ac0fe40e70e"><ix:nonFraction unitRef="usd" contextRef="i765e60a738e846889a642c75a5734d75_D20210104-20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzQwNA_c92668be-58ea-4d34-bd73-e5e794d0f9bd">0.1</ix:nonFraction></ix:nonFraction> billion in both the fiscal first quarter of 2021 and 2020, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i46b22e45743641e680c31d8beb794e56_D20210104-20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMjc0ODc3OTA3NjgxMg_fc45bde2-7951-4ca4-adcd-f67083e91478">0.3</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="idfce5280afb34c08b7d2df0de5af45e1_D20191230-20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzU2Ng_73dbd80a-eef2-4139-b91f-432e421fb8c0">0.2</ix:nonFraction>&#160;billion in the fiscal first quarter of 2021 and 2020, respectively. </span></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i887c00097b574b94b79e5861a48560e7" continuedAt="i91af2427527f40a8b6ca6b6cd8ddca5f">(4)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i91af2427527f40a8b6ca6b6cd8ddca5f"> Amounts not allocated to segments include interest income/expense and general corporate income/expense.</ix:continuation> </span></div></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:10pt"><span><br/></span></div><ix:continuation id="i81d2d94fb14e48269192f7e63ea16ae1"><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzkxMA_2c5cc55c-1431-4f0a-be44-1398ee490bd2" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.684%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.190%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc1d3ef8e82b4cab9d2f209a70930bad_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfMi0yLTEtMS0w_1bd461ee-4cc4-4f8a-a0b2-7ad3863118a8">11,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia49cb056ac9642fab13eb3c45dd7beb7_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfMi00LTEtMS0w_9aafb702-8253-4e78-a972-07a725322ac2">10,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc1d3ef8e82b4cab9d2f209a70930bad_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfMi02LTEtMS0w_743418e8-088e-4414-8832-60f36c1fdd76">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aeec3665cb149868af31f13c90e99f3_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfMy0yLTEtMS0w_83223f9e-6382-49f2-93d6-89a674d5a92d">5,414</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cff44da9a7a458490003f90a4b032fa_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfMy00LTEtMS0w_66189946-eb52-40eb-9693-1a1ef7868657">4,827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4aeec3665cb149868af31f13c90e99f3_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfMy02LTEtMS0w_6ddf5933-ec76-403a-a32e-675390254d34">12.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e19dfed28af47909fc2e122d61ba3e1_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNC0yLTEtMS0w_51180c91-4373-48d4-9307-6f2f3fc850c8">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d17e0cdb3e4dc9a51f76c0b873f000_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNC00LTEtMS0w_e299f838-cee6-47bd-8a19-d2d055ec4b7c">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e19dfed28af47909fc2e122d61ba3e1_D20210104-20210404" decimals="3" sign="-" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNC02LTEtMS0w_75f751c7-f6d9-483c-85de-ffdf07364681">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia707285795354a909320047e9adde65b_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNS0yLTEtMS0w_a5c23579-d94e-4415-92fc-05177fdee8a3">4,372</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d72ee63d68e465c9fb647ef821fca86_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNS00LTEtMS0w_1aad9ba9-528e-45ab-862f-a6a09710a482">3,663</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia707285795354a909320047e9adde65b_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNS02LTEtMS0w_b2f799ce-dbb4-4c53-b514-a4810fd59757">19.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNi0yLTEtMS0w_4b57aa85-3a47-454e-920c-35a2390d71cd">22,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNi00LTEtMS0w_95b7e7dd-3eec-4b20-ac26-58b373f76d08">20,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNi02LTEtMS0w_2228fd15-bc2b-4025-a11b-f7cd01ba8030">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 10&#8212; <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfNjMzMg_a29ad2c8-4208-47e7-a596-ad52121d78b0" continuedAt="ie025519b14b040fd92e80ad5794490ad" escape="true">ACQUISITIONS AND DIVESTITURES</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ie025519b14b040fd92e80ad5794490ad" continuedAt="ia681e3337dab406ea3ab76272506d1b3">In the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $<ix:nonFraction unitRef="usd" contextRef="i6f4c6a54630d423ab63d36db8db32449_D20210104-20210404" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMTA5OTUxMTY0MDIwOA_5ed6353c-f493-48ad-b96d-03790ae0507f">0.6</ix:nonFraction>&#160;billion. </ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ia681e3337dab406ea3ab76272506d1b3">During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i5d9f14bc65a147d0b6ffd1245515b56e_D20191230-20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMTM4OQ_7e9b6b7f-2c40-4c47-b1a1-a7a60dc2beb9">0.8</ix:nonFraction> billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $<ix:nonFraction unitRef="usd" contextRef="i8daceaf8ad2943238f7e0666635677be_I20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMTUxMA_ec5431d6-f2eb-4055-a46f-be7b18617192">0.8</ix:nonFraction> billion. XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. Additionally, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with world-class robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $<ix:nonFraction unitRef="usd" contextRef="i0ebc13e73dd24d8bbb4f49c2c087c1ff_I20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMjE3Ng_ff246757-6319-4bed-a13c-e1caf1021a94">0.4</ix:nonFraction> billion, goodwill for $<ix:nonFraction unitRef="usd" contextRef="i0ebc13e73dd24d8bbb4f49c2c087c1ff_I20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMjE5Mw_3a4a8126-597d-4c3a-a319-3426c2a68f40">0.2</ix:nonFraction> billion, other assets of $<ix:nonFraction unitRef="usd" contextRef="i0ebc13e73dd24d8bbb4f49c2c087c1ff_I20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMjIxMw_4f628d65-904d-4767-a177-c7358360a04b">0.2</ix:nonFraction> billion and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i0ebc13e73dd24d8bbb4f49c2c087c1ff_I20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMjI0Mw_cd3d5408-4da4-4a2d-8ad1-a261dcf57ecd">0.3</ix:nonFraction> billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $<ix:nonFraction unitRef="usd" contextRef="i0ebc13e73dd24d8bbb4f49c2c087c1ff_I20200329" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMjMzOQ_79369c52-3f6b-4cf2-8c54-892d2c8272e5">0.4</ix:nonFraction> billion.</ix:continuation> </span></div><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 11 &#8212; <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfODc5ODI_28403b38-8c43-44e9-b9eb-d0e748582664" continuedAt="i574e812050224b9cb8c6d02160850cf3" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i574e812050224b9cb8c6d02160850cf3" continuedAt="i4f5129b432f4462f84be5a91a820d9ea"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed.  The Company continues to monitor its legal proceedings as the situation evolves.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of April&#160;4, 2021, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i4f5129b432f4462f84be5a91a820d9ea" continuedAt="i04f302447e39418a9ea1b720e4719d64"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant of these cases include: the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System; pelvic meshes; RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; body powders containing talc, primarily JOHNSONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Baby Powder; INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flexible Composite Mesh. As of April&#160;4, 2021, in the United States there were approximately <ix:nonFraction unitRef="claimant" contextRef="ic5b57e148881429fbffa7b15c1969483_I20210404" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDU3NQ_cc46594a-91e6-4652-943b-b13ca3f87853">300</ix:nonFraction> plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; <ix:nonFraction unitRef="claimant" contextRef="i32c65ab8cb634ad9bd5a0e2f7d30a359_I20210404" decimals="INF" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDczOQ_57dc9e0d-065f-4ea3-a69b-6fe372c1b221">7,000</ix:nonFraction> with respect to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System; <ix:nonFraction unitRef="claimant" contextRef="icd5cde0149284609a90fe89bccf88fe6_I20210404" decimals="INF" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDc5NQ_cd22959a-1aca-44ad-847f-14531c7e3729">12,200</ix:nonFraction> with respect to pelvic meshes; <ix:nonFraction unitRef="claimant" contextRef="i08582f9cef4d4567a55ffdc339dd9b58_I20210404" decimals="INF" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDgyOQ_4cafa555-3418-4bb5-9359-cc343e91a314">9,200</ix:nonFraction> with respect to RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; <ix:nonFraction unitRef="claimant" contextRef="i4720b5ba970c4ae58eeca3720feaa0b3_I20210404" decimals="INF" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDg2MA_d769b5ce-5e42-453c-8486-1b9ea256f607">10,200</ix:nonFraction> with respect to XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; <ix:nonFraction unitRef="claimant" contextRef="ibaeacf387226456196518be5d4285e6c_I20210404" decimals="INF" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDg4OQ_62208040-52e4-4dc0-a82c-9b3e28bbb48b">28,900</ix:nonFraction> with respect to body powders containing talc; <ix:nonFraction unitRef="claimant" contextRef="if6fb78dabc7c431c8db3fa456cae770d_I20210404" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDkzOA_beca68ed-2dcd-4400-9050-e1985be5dc94">300</ix:nonFraction> with respect to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and <ix:nonFraction unitRef="claimant" contextRef="i41413d437f794ec3a9f045f6a27f2722_I20210404" decimals="INF" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDk3Mw_1d36cbec-18b5-499a-b009-01df2a984bad">4,400</ix:nonFraction> with respect to ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Flexible Composite Mesh.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XL Acetabular System and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than <ix:nonFraction unitRef="patient" contextRef="ifd2cd7a8594949e083f88b8b79935b39_I20210404" decimals="0" format="ixt:numdotdecimal" name="jnj:Numberofpatientsinsettlement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODUyOA_c2e1ec14-93f4-4def-8fca-36528c1bb86e">10,000</ix:nonFraction> claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle </span><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the class actions filed in that country</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i04f302447e39418a9ea1b720e4719d64" continuedAt="ia00fed36f82e42d187ec0cb1e9c8ac11"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and class actions in Israel, Australia and Canada,.  In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021. With respect to class members other than the Lead Applicants, the Federal Court will conduct an individual case assessment process that will require proof of use and causally related loss, although the form of that process has not yet been decided. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device.&#160; Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. Discovery is proceeding in these cases and certain of the cases are in preparation for trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Ventral Patch hernia mesh products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. Discovery is underway in these cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Ethicon and Johnson &amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE&#8482; Polypropylene Hernia System (PHS). In September 2019, plaintiffs&#8217; attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PHS cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those cases have also been transferred to an MCL in Atlantic County Superior Court. There are now approximately 304 cases pending in the MCL and discovery is underway in a subset of these cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Flexible Composite Mesh, PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Ventral Patch, and PROLENE&#8482; Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $<ix:nonFraction unitRef="usd" contextRef="i9b1fe073177c4b3ab83e3d3452139524_D20191001-20191031" decimals="-9" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODQ4MA_80f6839f-b504-465b-8bac-f0acc568b365">8.0</ix:nonFraction>&#160;billion of punitive damages related to one plaintiff which the trial judge reduced to $<ix:nonFraction unitRef="usd" contextRef="i13f02d9a0d3b4b66a1c40f110cbc1e1e_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODUwNw_59cfde30-6395-4f39-b489-89815b81c04b">6.8</ix:nonFraction>&#160;million in January 2020. The Company and plaintiff each are appealing this judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson; and JPI&#8217;s collaboration partner for XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson  &amp; Johnson announced an agreement in principle to settle the XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ia00fed36f82e42d187ec0cb1e9c8ac11" continuedAt="id26dd1cc743040dab2519dd07d378235"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Personal injury claims alleging that talc causes cancer have been made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder. The number of pending personal injury lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits primarily have been filed in state courts in Missouri, New Jersey and California, and suits have also been filed outside the United States. The majority of cases are pending in federal court, organized into a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, the parties sought to exclude experts through Daubert motions. In April 2020, the Court issued rulings that limit the scope of testimony, including some theories and testing methods, for certain plaintiff expert witnesses and denied  plaintiffs&#8217; attempt to limit the scope of testimony of certain of the Company&#8217;s witnesses. With this ruling made, case-specific discovery has begun per the Court&#8217;s directive. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $<ix:nonFraction unitRef="usd" contextRef="i6d9b48d0973f493eb3ab6b9a6476c385_D20180701-20180731" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODU0OQ_a4d6a48f-e302-4409-9a47-f8a4a3281c7a">4.7</ix:nonFraction>&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No. ED 207476 (Mo. App.), reducing the overall award to $<ix:nonFraction unitRef="usd" contextRef="i709811f027d74897b86c8f1d12b504ed_D20200601-20200628" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODU3Ng_b6b8bb25-4bda-4cdf-bb6a-2a789bffa15a">2.1</ix:nonFraction>&#160;billion and, with additional interest as of April 4, 2021, as the Company pursues further appeal, is approximately $<ix:nonFraction unitRef="usd" contextRef="i62bf76445bd948c38790ffcd119476a4_D20210104-20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODYwMw_018f0965-e04e-40d4-a9c8-36c825de337e">2.5</ix:nonFraction>&#160;billion (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decision). An application for transfer of the case to the Missouri Supreme Court was subsequently denied. In March 2021, the Company filed a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decision by the United States Supreme Court. In April 2021, the Plaintiffs filed their opposition to the petition. The Company continues to believe that it has strong legal grounds for the appeal of this verdict, as well as other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. The Company has established an accrual for defense costs and reserves for the resolution of certain cases and claims, including the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decision currently on appeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in connection with product liability litigation associated with body powders containing talc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217; potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it alleges it has against the Company for indemnification and rights to joint insurance proceeds. The Company previously proposed to resolve Imerys' (and the Company&#8217;s) obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, waiving the Company&#8217;s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. In May 2020, Imerys and the asbestos claimants&#8217; committee (Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto agreeing to put its North American operations up for auction which was subsequently amended. The Company has objected to the Disclosure Statement and intends to object to the Plan of Reorganization as currently structured. Additionally, in June 2020, Cyprus Mines Corporation and its parent (Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company as well as Imerys seeking a declaration of indemnity under certain contractual agreements.  The Company denies such indemnification is owed and filed a motion to dismiss the adversary complaint arguing, among other things, that the Court does not have subject matter jurisdiction over Cyprus&#8217;s claims against the Company. The Plan Proponents filed numerous amendments to the Plan and Disclosure Statement to which the Company objected. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement for the Ninth Amended Joint Chapter 11 Plan of Reorganization of Imerys Talc America, Inc. and its Debtor Affiliates, allowing Debtors Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Debtors&#8217; Plan and opted out of the consensual releases in the Plan. Discovery with respect to the Debtors&#8217; Plan is ongoing and the Confirmation Hearing is set for August 2021. Relatedly, in February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and Cyprus filed its Disclosure Statement and Plan.  Also, in February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the &#8220;Coverage Action&#8221;) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action.  In March 2021, the Company filed a limited response and reservation of rights with respect to the motion.  The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"> Baby Powder, and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="id26dd1cc743040dab2519dd07d378235" continuedAt="i3b919a92cd0b44799177a234c73b0412"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. In March 2021 briefing on Plaintiffs&#8217; motion for class certification was completed.  Discovery is ongoing.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:99%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:99%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp; Johnson&#8217;s motion to dismiss pending a decision on Plaintiff&#8217;s motion for discovery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"> Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete. In February 2021, the Court granted Defendants&#8217; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings.  In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the Abtahi Law Group filed an action under Proposition 65 against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Inc. as well as a number of other alleged talcum powder manufacturers and distributors, including one California company. In that action, the plaintiff alleges contamination of talcum powder products with unsafe levels of arsenic, hexavalent chromium and lead. The plaintiff seeks civil penalties and injunctive relief. Defendants filed a motion for summary judgment in January 2021, and a hearing on the motion was held in April 2021. Limited informal discovery is continuing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding talc matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company produced documents as required in response and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i3b919a92cd0b44799177a234c73b0412" continuedAt="i887f310561e847c48f32502571accfcf"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a prescription medication  indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including two putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Devices</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent&#8217;s RELIEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Spin and RELIEVEA SpinPlus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products infringe U.S. Patent No. 9,011,412.  Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent&#8217;s U.S. Patent No. 8,414,473. Trial is scheduled to begin in October 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC (collectively, Ethicon) alleging the manufacture and sale of VICRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures, MONOCRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures, PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures, STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Antibacterial Sutures and STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> MONOCRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plus Antibacterial Sutures infringe plaintiffs&#8217; United States Patent Nos. 6,596,296 (&#8217;296) and 7,033,603 (&#8217;603) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UT is seeking damages and an injunction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the USPTO denied institution of the &#8217;296 patent IPR and granted institution of the &#8217;603 patent IPR.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UT dismissed the &#8217;603 patent from the suit and no longer accuses PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures or STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures of infringement. The previously scheduled district court trial has been postponed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#8217;200); 6,491,701 (&#8217;701); 6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447); 8,620,473 (&#8217;473); 8,801,601 (&#8217;601); and 9,452,276 (&#8217;276) based on Auris&#8217; Monarch&#8482; Platform.  Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#8217;200, &#8217;056, &#8217;601 &#8217;701, &#8217;447, &#8217;276 and &#8217;906 patents. Intuitive subsequently dropped the &#8217;200, &#8217;473 and &#8217;701 patents from the suit.  In December 2019, the USPTO instituted review of the &#8217;601 patent and denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the &#8217;200, &#8217;447, &#8217;701 and &#8217;906 patents and denied review of the &#8217;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#8217;601 patent to be invalid.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intuitive has appealed that decision. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris has appealed that decision. The District Court postponed trial until the appeal of the invalidity decision on the &#8217;601 patent is complete. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA&#8482; Spacer, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i887f310561e847c48f32502571accfcf" continuedAt="i4a3d9479c2074b528f78ffdfc75b37e5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ZERO-P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Spacer, ZERO-P NATURAL&#8482; Plate, SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> LR Spacer and SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. In June 2020, the case was stayed pending IPR proceedings filed by the Consolidated Defendants involving the asserted patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and Synthes, Inc. (collectively, DePuy Synthes) in the United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and 9,275,191 based on the PROPLAN CMF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Virtual Surgical Planning Services and the TruMatch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. 9,292,920 for U.S. Patent No. 9,929,920.  Osteoplastics seeks monetary damages and injunctive relief. In June 2020, DePuy Synthes filed a motion to dismiss the complaint. In October 2020, the Court dismissed Medical Device Business Services, Inc. from the case but otherwise denied the motion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trial is scheduled for October 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits pending against generic companies that have filed ANDAs with the FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the third-party companies involved would have the ability, upon approval of the FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Janssen Inc. and Janssen Oncology Inc. (collectively, Janssen) initiated a Notice of Application under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) and the Minister of Health in Canada in response to Apotex&#8217;s filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of Canadian Patent No. 2,661,422 (&#8217;422). The final hearing concluded in May 2019.  In October 2019, the Court issued an order prohibiting the Canadian Minister of Health from approving Apotex&#8217;s ANDS until the expiration of the &#8217;422 patent. In November 2019, Apotex filed an appeal, which was dismissed in March 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in January 2019, Janssen initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex, Pharmascience Inc. (Pharmascience) and Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;422 patent. The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In August 2020, Janssen initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (Jamp) in Canada in response to Jamp&#8217;s filing of an ANDS seeking approval to market a generic version of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> before the expiration of the &#8217;422 patent. In March 2021, the parties entered into a confidential settlement agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen is seeking an order enjoining the defendants from marketing their generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;422 patent.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin) which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i4a3d9479c2074b528f78ffdfc75b37e5" continuedAt="if9a1f173e785490fabb2cf2bcce7f99f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before expiration of U.S. Patent No. 10,828,310 (&#8217;310). In this lawsuit, JPI and Bayer are seeking an order enjoining Lupin from marketing their generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;310 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in July 2017, Janssen Pharmaceuticals, Inc., Janssen Research &amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR before expiration of MTPC&#8217;s United States Patent Nos. 7,943,582 (&#8217;582) and/or 8,513,202 (&#8217;202) relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR. Janssen is the exclusive licensee of the asserted patents. Named defendants include MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc. (MSN); Zydus Pharmaceuticals (USA) Inc. (Zydus). These cases were consolidated into one action (Polymorph Main Action), which has been scheduled for trial starting in July 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In July 2017, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus which filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">and INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">before expiration of MTPC&#8217;s United States Patent No. 7,943,788 (&#8217;788), 8,222,219 (&#8217;219) and/or 8,785,403 (&#8217;403) relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">and INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"> (Compounds Main Action). Janssen is the exclusive licensee of the asserted patents. Trial concluded in October 2020. The Court issued a decision holding that the patents are not invalid and would be infringed by Zydus&#8217; generic products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2019, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;582 patent and &#8217;202 patent relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;788 patent. In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;788 patent. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;582 patent and &#8217;202 patent relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In February 2021, Janssen filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of United States Patent No. 10,617,668 relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. These lawsuits have not been consolidated with the Polymorph Main Action or Compound Main Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">In each of these U.S. lawsuits, Janssen and MTPC are seeking an order enjoining the defendant from marketing their generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"> and/or, INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the Canadian Patent Nos. 2,799,204, 2,534,024 and 2,671,357. Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an order enjoining Sandoz from marketing its generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents. The trial is scheduled to begin in August 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Trial is scheduled to begin in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Trial is scheduled to begin in February 2022.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="if9a1f173e785490fabb2cf2bcce7f99f" continuedAt="i067acb666d7942faaa50b76584793cf0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg before the expiration of the &#8217;770 patent and Canadian Patent No. 2,621,273 (&#8217;273). Trial is scheduled to begin in April 2022.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of United States Patent No. 9,439,906 (&#8217;906).  Trial concluded in October 2020, and closing arguments were made in March 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;906 patent. In February 2020, Mylan filed a Petition for Inter Partes Review with the USPTO seeking to invalidate the &#8217;906 patent. The USPTO denied the Petition in September 2020, and Mylan appealed. Janssen filed a motion to dismiss the appeal, which was granted in March 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, would infringe claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid for obviousness. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.'s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement is scheduled for November 2021. The trial is scheduled to begin in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in response to Apotex's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement is scheduled for December 2021. The trial is scheduled to begin in September 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LCC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before expiration of United States Patent No. 10,143,693 relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i067acb666d7942faaa50b76584793cf0" continuedAt="id448e56447fc481c8358a5c64e45192c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Beginning in January 2018, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies that filed ANDAs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> 140 mg capsules before expiration of Pharmacyclics&#8217;  United States Patent Nos. 8,008,309, 7,514,444, 8,697,711, 8,735,403, 8,957,079, 9,181,257, 8,754,091, 8,497,277, 8,925,015, 8,476,284, 8,754,090, 8,999,999, 9,125,889, 9,801,881, 9,801,883, 9,814,721, 9,795,604, 9,296,753, 9,540,382, 9,713,617 and/or 9,725,455 relating to IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">. JBI is the exclusive licensee of the asserted patents. The named defendants include the following generic companies: Cipla Limited and Cipla USA Inc. (collectively, Cipla); Sandoz Inc. and Lek Pharmaceuticals d.d. (collectively, Sandoz).  In January 2019 and February 2019, Pharmacyclics and JBI amended their complaint against Sandoz and Cipla, respectively, to allege infringement of United States Patent Nos. 10,125,140 and 10,106,548. In May 2019, Pharmacyclics and JBI amended their complaint against Cipla to further allege infringement of United States Patent No. 10,016,435. In August 2019, Pharmacyclics and JBI amended their complaints against Cipla and Sandoz to further allege infringement of U.S. Patent Nos. 10,294,231 and 10,294,232. In August 2019, the Court granted a joint stipulation to stay the litigation against Cipla.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,003,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trial in the foregoing actions against Sandoz and Alvogen took place in October 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen asserting infringement of United States Patent No. 10,478,439. In October 2020, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of U.S. Patent No. 10,653,696. In April 2021, the court entered a joint stipulation dismissing the complaint against Alvogen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Zydus Worldwide DMCC and Cadila Healthcare Limited (collectively, Zydus), which filed an ANDA seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,008,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, 10,125,140, 10,213,386 and 10,478,439. In March 2021, JBI, Pharmacyclics and Zydus entered into a confidential settlement agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of the lawsuits, Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, Actelion Pharmaceuticals Ltd (Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before expiration of Nippon Shinyaku&#8217;s United States Patent Nos. 7,205,302; 8,791,122; and 9,284,280 relating to UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actelion is the exclusive licensee of the asserted patents. The defendants include Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals Inc. (collectively, Alembic); and Zydus Pharmaceuticals (USA), Inc. and Zydus Worldwide DMCC (collectively, Zydus). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actelion and Nippon Shinyaku are seeking an order enjoining the defendants from marketing generic versions of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="id448e56447fc481c8358a5c64e45192c" continuedAt="id825df1392704ac0a5349152211447fc"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial.  In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in more than <ix:nonFraction unitRef="claimant" contextRef="i5db493405e0444d89bf7eaab26517bde_I20210404" decimals="0" format="ixt:numdotdecimal" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNjA0NzMxNDI2Mzg4Ng_05c5045e-705b-45be-8424-e908137b0735">3,200</ix:nonFraction> lawsuits related to the marketing of opioids, including DURAGESIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia and Wisconsin. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are more than 380 cases pending in various state&#160;courts. There are over 2,800 federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio.&#160;In addition, the Province of British Columbia filed suit in Canada. In October 2019, an anti-trust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $<ix:nonFraction unitRef="usd" contextRef="i6e04dd168b1041b3919b1a56f47b4ecf_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODYzNg_8d7638d4-e871-45a5-964c-d2aab6501091">465</ix:nonFraction>&#160;million. Johnson &amp; Johnson and JPI have appealed the judgment. The Company believes that it has strong grounds to overturn this judgment. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial is scheduled to last up to three months. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $<ix:nonFraction unitRef="usd" contextRef="i2f0753d19d5149c091394208cbea890d_I20191031" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODY2MQ_84b1c0d2-5f67-4ba3-a631-35b8e3b20bc8">4</ix:nonFraction>&#160;billion as settlement of these matters. In October 2020, the Company agreed to contribute up to an additional $<ix:nonFraction unitRef="usd" contextRef="i851c9cc374994813ad167606b1ea44ed_I20201031" decimals="-9" format="ixt:numdotdecimal" name="jnj:LossContingencyEstimateOfAdditionalPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODY4NA_b480c3db-cffe-4c1c-8bee-1529f476dea7">1</ix:nonFraction>&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $<ix:nonFraction unitRef="usd" contextRef="i851c9cc374994813ad167606b1ea44ed_I20201031" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODcwNw_4d6c4f1c-51c4-4137-b898-2c0adc600dcc">5</ix:nonFraction>&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing and would resolve opioid lawsuits filed </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="id825df1392704ac0a5349152211447fc" continuedAt="i12a32295d4804dbca194da3502886f3b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and future claims by states, cities and counties. The Company has made progress towards negotiating a final settlement with a coalition of state Attorneys General. The Company cannot predict if or when the agreement will be finalized and individual cases are ongoing. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson &amp; Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums.&#160;In September 2020, the Company learned that NYDFS filed a statement of charges related to this investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In May 2020, the shareholder filed an amended complaint challenging the Board&#8217;s rejection of his demand. In August 2020, Johnson &amp; Johnson moved to dismiss the amended complaint. In February 2021, the Court held oral argument on Johnson &amp; Johnson's motion. In August 2020, another shareholder who sent a demand filed a separate derivative complaint in the same court making similar allegations. In October 2020, the Court granted defendants&#8217; request to reassign the second-filed case to the division where the first-filed case is pending. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, two additional shareholders who sent demands filed two separate derivative complaints making similar allegations against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. In April 2020, the two federal cases were consolidated into a single action captioned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> In re Johnson &amp; Johnson Opioid Stockholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In July 2020, the shareholders filed a consolidated complaint. In September 2020, Johnson &amp; Johnson moved to dismiss the consolidated complaint, and in December 2020, the shareholders opposed Johnson &amp; Johnson&#8217;s motion. Johnson &amp; Johnson filed its reply in February 2021. In July 2020, an additional shareholder who sent a demand filed a derivative complaint in the same federal court making similar allegations against the same defendants named in the consolidated action. In January 2021, pursuant to an order in the consolidated action, the third case was consolidated into the consolidated action. In February 2021, the Court granted the shareholders motion to voluntarily dismiss the consolidated action without prejudice. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney's Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR&#8482; XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. The relators&#8217; remaining claims are now pending before the District Court. In July 2020, the Court ordered the relators to complete discovery by August 2020; the Relators have requested an extension of the August 2020 deadline that DePuy opposed and additional discovery-related motions have been filed by both parties since. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint. In March 2021, the District Court issued an order stating that if DePuy&#8217;s motion to strike and dismiss is denied, the court will hold a conference at which a limited period for remaining discovery will be established.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General's office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson's subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i12a32295d4804dbca194da3502886f3b" continuedAt="i1456e89b0ba8483a8c059f12ada63dc8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson and Ethicon settled the Washington case. The California case started trial in July 2019 and concluded in September 2019. The trial date for the Kentucky case was scheduled for September 2019 but has been adjourned and no new trial date has been scheduled. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $<ix:nonFraction unitRef="usd" contextRef="id807403c46b245c9bd8b6055a4d42cef_D20200120-20200120" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODczMg_76b0567d-cd88-418d-9693-960e5251ae8b">344</ix:nonFraction>&#160;million. In April 2020, the Court in California denied the Company's motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $<ix:nonFraction unitRef="usd" contextRef="id807403c46b245c9bd8b6055a4d42cef_D20200120-20200120" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODc1OQ_c372c557-7e19-42f4-beac-c4a8f7c06de9">344</ix:nonFraction>&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company is appealing the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">penalty judgment. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon.  In November 2020, the Company settled with the Attorney General of Mississippi. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (JJCI).&#160;The complaint alleges that defendants violated the Mississippi Consumer Protection Act by </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failing to disclose alleged health risks associated with female consumers' use of talc contained in JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder and JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The matter is stayed pending interlocutory appeal of a December 2018 denial of Johnson &amp; Johnson and JJCI's motion for summary judgment. The Mississippi Supreme Court granted Johnson &amp; Johnson and JJCI's request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. In April 2021, the Mississippi Supreme Court dismissed the Company&#8217;s interlocutory appeal and remanded the case back to the Hinds County Chancery Court. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. The New Mexico Attorney General has issued requests for documents and the Company anticipates the document production will commence in mid-2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-two states have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has entered into a tolling agreement with the States and has begun to produce responsive documents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Attorney&#8217;s Office for the Southern District of New York related to JPI&#8217;s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI's pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act. The Company has provided documents in response to the demand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, Johnson &amp; Johnson and Janssen Products LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and INTELENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and anti-kickback violations in connection with the promotion of these products.&#160;The complaint was filed under seal in December 2012.&#160;The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators.&#160; In February 2021, the Court stayed the case and ordered mediation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OLYSIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#160;The subpoenas also seek documents relating to&#160;Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney's Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc.(DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i1456e89b0ba8483a8c059f12ada63dc8" continuedAt="ie0d813270a264cb99082100a6b6387eb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospitals. Johnson &amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018 the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2018, a purported class action was filed in the Circuit Court Third Judicial District Madison County, Illinois against Johnson &amp; Johnson Consumer, Inc. (JJCI), alleging violations of state consumer fraud statutes based on nondisclosure of alleged health risks associated with talc contained in JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Baby Powder. The complaint seeks damages but does not allege personal injury. In October 2020, JJCI moved to dismiss the complaint.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2013, Janssen Ortho LLC (Janssen Ortho) sued the United States in the United States Court of International Trade (the Classification Litigation) seeking a determination that darunavir ethanolate (the active pharmaceutical ingredient in PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) is exempt from duties upon importation into the United States.  In August 2014, United States Customs and Border Protection (US CBP) issued a Penalty Notice against Janssen Ortho LLC (Janssen Ortho), assessing penalties for the alleged improper classification of darunavir ethanolate (the active pharmaceutical ingredient in PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) in connection with its importation into the United States. In February 2020, the Court in the Classification Litigation ruled that darunavir ethanolate is eligible for duty free treatment. In April 2020, the United States appealed that ruling to the United States Court of Appeals for the Federal Circuit. In August 2020, US CBP formally rejected Janssen&#8217;s Supplemental Petition challenging the penalties assessment and demanded payment of the mitigated penalty. In October 2020, US CBP agreed to not refer the matter to the Office of Chief Counsel, pending resolution of the related Classification Litigation. In April 2021, the Federal Circuit denied the United States&#8217; appeal in the Classification Litigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. Discovery and pre-trial motion practice are complete. No trial date has been set.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2015, two third-party payors filed a purported class action in the United States District Court for the Eastern District of Louisiana against Janssen Research &amp; Development, LLC, Janssen Ortho LLC, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson (as well as certain Bayer entities), alleging that the defendants improperly marketed and promoted XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as safer and more effective than less expensive alternative medications while failing to fully disclose its risks. The complaint seeks damages. In November 2020, Defendants moved to dismiss the complaint. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Pfizer, Inc. (Pfizer) filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in United States District Court for the Eastern District of Pennsylvania.  Pfizer alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The complaint seeks damages and injunctive relief. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. The consolidated complaint seeks damages and injunctive relief.  Discovery is ongoing.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ie0d813270a264cb99082100a6b6387eb" continuedAt="ie9f6536b25ce4756a2c449dee221cee2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania.  The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson in connection with its investigation of whether Janssen&#8217;s REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act.  The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2021, plaintiffs appealed the District Court&#8217;s decision to the United States Court of Appeals for the District of Columbia Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia.&#160;The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160; TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product.&#160; In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.&#160; In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed on behalf of the United States, 28 states, and the District of Columbia.&#160;The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the government in connection with direct government sales and government-funded drug reimbursement programs.&#160;At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. In September 2019, Janssen moved to dismiss the complaint. In February 2021, the judge has set a renewed schedule for the Company's motion to dismiss, with briefs to be fully submitted by early July 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Blue Cross &amp; Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research &amp; Development, LLC (collectively, Janssen) and BTG International Limited in the United States District Court for the Eastern District of Virginia on behalf of indirect purchasers of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Several additional complaints were filed thereafter in Virginia and New Jersey.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indirect purchaser complaints generally allege that the defendants violated the antitrust and consumer protections laws of several states and the Sherman Act by pursuing patent litigation relating to ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to delay generic entry and seek damages. The Virginia cases have been transferred to the United States District Court for the District of New Jersey and consolidated with the New Jersey case. A consolidated amended complaint was filed in February 2021. In April 2021, Janssen moved to dismiss the Indirect Purchaser Action. In May 2020, a class action complaint was filed against Janssen Biotech Inc., Janssen Oncology, Inc., Janssen Research &amp; Development LLC and BTG International Limited in the United States District Court for the District of New Jersey, on behalf of direct purchasers of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The direct purchaser complaint alleges that defendants violated the Sherman Act by pursuing patent litigation relating to ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in order to delay generic entry, and seek damages and injunctive relief. In April 2021, Janssen moved to compel arbitration of the Direct Purchaser Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss.  Plaintiffs filed an amended complaint in April 2020. Defendants moved to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ie9f6536b25ce4756a2c449dee221cee2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">dismiss the amended complaint.  In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s&#160;business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson, Inc. received a demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between J&amp;J, Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim.  The notices seek indemnification for legal claims related to over-the-counter ZANTAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2020, Ethicon moved to dismiss certain causes of action in the complaint. Oral argument on the motion to dismiss is scheduled for June 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 12&#8212; <ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMjgzMw_bd3d20fb-fe90-4cb3-b6f7-3da7fb5e6536" continuedAt="id9081fefe34e48ae8cb73eb14ec93526" escape="true">RESTRUCTURING</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id9081fefe34e48ae8cb73eb14ec93526"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal first quarter of 2021, the Company recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="ic02f715544ff4105bfd2a3c2d151ac0c_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfNzg0_651cfae2-98e2-4909-a8d3-29297b2d9042">104</ix:nonFraction> million, which is included on the following lines of the Consolidated Statement of Earnings, $<ix:nonFraction unitRef="usd" contextRef="i3b908089cc6a4f068612a9b2d5d34ca1_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfODcy_2ccb7632-7b59-4d81-9ddd-4c769f6bca80">53</ix:nonFraction> million in restructuring, $<ix:nonFraction unitRef="usd" contextRef="i96add54e896749258f1ad0c9536687a7_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfODkz_c5bc46f9-ad98-42c6-93f4-6bc87d4f3643">27</ix:nonFraction> million in cost of products sold and $<ix:nonFraction unitRef="usd" contextRef="i8a22a8f09eac408299c442ea44cab0af_D20210104-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfOTI1_d910f022-b0e3-4dcc-83e3-4733740240a1">24</ix:nonFraction> million in other (income) expense, net.  Total project costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i1552e8f8c0724beea6478ac55c3106db_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTIzOQ_3ce8ce0f-b9c2-486b-bc83-18d07be9c704">1.4</ix:nonFraction> billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company expects the Global Supply Chain actions to generate approximately $<ix:nonFraction unitRef="usd" contextRef="i95abcc6431244e8a90f59ff7792cfc79_I20210404" decimals="-8" format="ixt:numdotdecimal" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTQ2Nw_096036c5-86c8-4445-859f-02dfccee0ba4">0.6</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="i2e03a943b1aa425496029ce0733bd863_I20210404" decimals="-8" format="ixt:numdotdecimal" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTQ3Mw_0db62e5d-1fcb-42b6-8e84-5428632e5a9f">0.8</ix:nonFraction> billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i95abcc6431244e8a90f59ff7792cfc79_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTYzMA_1df48cce-d2da-4a5a-9e9e-3958c95f68b7">1.9</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="i2e03a943b1aa425496029ce0733bd863_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTYzNg_e1d59b39-3e6e-4307-bb27-a02459687fbe">2.3</ix:nonFraction> billion, over the <ix:nonNumeric contextRef="i0290e1c992b748a9908d71498dc82a4e_D20210104-20210404" format="ixt-sec:duryear" name="jnj:RestructuringandRelatedCostDurationofRestructuringPlan" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTY0OQ_3eed4464-20b3-497f-bab4-6c0b75a9dd5b">4</ix:nonNumeric> to <ix:nonNumeric contextRef="i3aabc22a7d5a4aa597cd7da431d465a3_D20210104-20210404" format="ixt-sec:duryear" name="jnj:RestructuringandRelatedCostDurationofRestructuringPlan" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTY1NQ_4a7aeb8a-cf09-4ce6-a5db-ca65e0f37a7f">5</ix:nonNumeric> year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMjgzNg_38006719-e87e-4112-a76c-7c9be5b73aae" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal first quarter of 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:33.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3ba126d47a4b5a846574f6d9d31fa6_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfMS0xLTEtMS0w_29876180-da8d-40a9-8ca0-6dd6a8c35ac9">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0b5e6d446af4a1ca2c03a629dbf4eae_I20210103" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfMS0yLTEtMS0w_888b1133-368d-4cf9-a6ca-db5f4708d9c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009c62493dd242ae928d25a27ed97197_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfMS0zLTEtMS0w_d798b258-1383-462d-9d8a-595e17379cd7">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ee9965a40148bda5e997a88d5d4930_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfMS01LTEtMS0w_2578bfb7-7c92-4762-b327-31ba8831035a">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52afe008fb4f4c819028d3daabd32602_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNC0xLTEtMS0w_fe517f03-b112-44dd-94ed-65b175bef25c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50377f6db9174c48a6ce24be02ba8d60_D20210104-20210404" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNC0yLTEtMS0w_46415dfc-5002-4cb9-a8f7-bb15fbb11413">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca084b4733440fcbbf545f29821a06d_D20210104-20210404" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNC0zLTEtMS0w_7948963f-6cc2-4ac6-8b65-25810ebd3276">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0856470384d143029d8218bb9189e71f_D20210104-20210404" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNC01LTEtMS0w_6d763948-c60d-400d-8ef5-7fc28763f570">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52afe008fb4f4c819028d3daabd32602_D20210104-20210404" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNS0xLTEtMS0w_5bd6b2b5-9933-4756-a226-ccea840cc7f7">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50377f6db9174c48a6ce24be02ba8d60_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNS0yLTEtMS0w_62415707-f853-4019-983c-6c48cf93e0be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idca084b4733440fcbbf545f29821a06d_D20210104-20210404" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNS0zLTEtMS0w_bf9f4a6a-39ba-4be1-b574-53b36270552b">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0856470384d143029d8218bb9189e71f_D20210104-20210404" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNS01LTEtMS0w_39117638-9452-4d30-97e9-cb4538e19ad5">96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52afe008fb4f4c819028d3daabd32602_D20210104-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNi0xLTEtMS0w_29011527-8cc9-4e9a-9a14-e7be16b2c7be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50377f6db9174c48a6ce24be02ba8d60_D20210104-20210404" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNi0yLTEtMS0w_8619354f-74b4-4499-8685-4a5fc6968fe4">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idca084b4733440fcbbf545f29821a06d_D20210104-20210404" sign="-" xsi:nil="true" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNi0zLTEtMS0w_9fde788d-8e51-4a20-b5d7-2c568dc54fbc"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0856470384d143029d8218bb9189e71f_D20210104-20210404" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNi01LTEtMS0w_e8e70170-d0b6-4d62-905b-40d87b06b93f">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, April 4, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cbff6b8f7d426ab49cc6dad88e6c0f_I20210404" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfOS0xLTEtMS0w_4a8781e1-ac47-4a69-b1bf-f58ac604c15b">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378ddce2634145fcb6a28fcfb5b8592e_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfOS0yLTEtMS0w_9fa6c446-95bf-4914-8410-2cbaea64703e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10eefa077224d8094f6feb17315c535_I20210404" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfOS0zLTEtMS0w_2901b60b-c59b-48bb-b4ce-4c6242be10a0">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d58eb1fecdb4c148121d9d91c2a78c6_I20210404" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfOS01LTEtMS0w_9bac5f5e-bf1b-4220-b31e-4557e349e741">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out over the next <ix:nonNumeric contextRef="i0856470384d143029d8218bb9189e71f_D20210104-20210404" format="ixt-sec:durmonth" name="jnj:RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMjAyMg_2df13f9e-9075-414b-8804-dd06c4e493db">18</ix:nonNumeric> months in accordance with the Company's plans and local laws. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_100"></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;2 &#8212; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Consolidated Sales</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal first quarter of 2021, worldwide sales were $22.3 billion, a total increase of 7.9%, which included operational growth of 5.5%  and a positive currency impact of 2.4% as compared to 2020 fiscal first quarter sales of $20.7 billion. In the fiscal first quarter of 2021, the net impact of acquisitions and divestitures on worldwide operational sales growth was a negative 0.5%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by U.S. companies were $11.1 billion in the fiscal first quarter of 2021, which represented an increase of 3.9% as compared to the prior year. In the fiscal first quarter of 2021, the net impact of acquisitions and divestitures on the U.S. operational sales growth was negligible.  Sales by international companies were $11.2 billion, a total increase of 12.2%, which included operational growth of 7.3% and a positive currency impact of 4.9%. In the fiscal first quarter of 2021, the net impact of acquisitions and divestitures on the international operational sales growth was a negative 0.9%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal first quarter of 2021, sales by companies in Europe achieved growth of 12.1%, which included operational growth of 4.7% and a positive currency impact of 7.4%. Sales by companies in the Western Hemisphere, excluding the U.S., experienced a decline of 5.1%, which included a negative currency impact of 5.1%. Sales by companies in the Asia-Pacific, Africa region achieved growth 19.4%, including operational growth of 13.7% and a positive currency impact of 5.7%.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20210404_g1.jpg" alt="jnj-20210404_g1.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/><img src="jnj-20210404_g2.jpg" alt="jnj-20210404_g2.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:310px"/></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: values may have been rounded</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:180pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Sales by Business Segments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health segment sales in the fiscal first quarter of 2021 were $3.5 billion, a decrease of 2.3% as compared to the same period a year ago, including an operational decline of 3.3% and a positive currency impact of 1.0%. U.S. Consumer Health segment sales declined by 7.4%. International Consumer Health segment sales increased by 2.5%, including operational growth of 0.5% and a positive currency impact of 2.0%. In the fiscal first quarter of 2021, the net impact of acquisitions and divestitures on the Consumer Health segment operational sales growth was a negative 0.4%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Consumer Health Franchise Sales &#8212; Fiscal First Quarter Ended</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:43.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Consumer Health Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,543</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OTC franchise experienced an operational decline of 14.8% as compared to the prior year fiscal first quarter. The results reflect negative comparisons due to prior year COVID-19 pantry loading and category declines driven by weaker Cough, Cold and Flu season due to social distancing and lockdowns. Partially offsetting declines were timing of shipments, e-commerce strength, and U.S. share gains primarily in TYLENOL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ZYRTEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PEPCID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as strong international sales of NICORETTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Skin Health/Beauty franchise achieved operational growth of 2.8% as compared to the prior year fiscal first quarter. Growth was primarily attributable to international NEUTROGENA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and DABAO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as worldwide AVEENO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to strength in e-commerce, new product innovations and COVID-19 related recovery. Results were partially offset by U.S. COVID-19 related market contraction in make-up wipes and competitive pressures in NEUTROGENA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oral Care franchise achieved operational growth of 4.5% as compared to the prior year fiscal first quarter primarily due to sales of LISTERINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mouthwash outside the U.S. related to category growth driven by increased consumer focus on oral hygiene and strong promotions partially offset by divestitures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Baby Care franchise achieved operational growth of 9.5% as compared to the prior year fiscal first quarter. Growth was attributable to sales of JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products outside the U.S. primarily in Latin America and Asia Pacific due to increased COVID-19 demand coupled with AVEENO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> baby growth in e-commerce globally. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Women&#8217;s Health franchise experienced an operational decline of 2.6% as compared to the prior year fiscal first quarter primarily driven by internal sanitary protection and liners due to prior year COVID-19 impact comparisons primarily in Europe, partially offset by growth in napkins in Asia Pacific and Latin America.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Wound Care/Other franchise achieved operational growth of 2.2% as compared to the prior year fiscal first quarter. Growth was due to strong performance in hand hygiene primarily due to increased demand and new promotional campaigns coupled with U.S. share gains partially offset by prior year COVID-19 impact comparisons. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment sales in the fiscal first quarter of 2021 were $12.2 billion, an increase of 9.6% as compared to the same period a year ago, with an operational increase of 7.1% and a positive currency impact of 2.5%. U.S. Pharmaceutical sales increased 6.4% as compared to the same period a year ago. International Pharmaceutical sales increased by 13.4%, including operational growth of 7.9% and a positive currency impact of 5.5%. In the fiscal first quarter of 2021, the net impact of acquisitions and divestitures on the Pharmaceutical segment operational sales growth was a negative 0.3%. Adjustments to previous reserve estimates were $0.2 billion in both fiscal first quarters of 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Pharmaceutical Therapeutic Area Sales** &#8212; Fiscal First Quarter Ended</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:47.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,914</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,638</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">920</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;COVID-19 vaccine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,721</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,658</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/ INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,570</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">861</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pharmaceutical Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,134</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunology products achieved operational growth of 5.5% as compared to the same period a year ago driven by strong uptake of STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ustekinumab) in Crohn's disease and Ulcerative Colitis and strength in TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(guselkumab) in Psoriasis and uptake in Psoriatic Arthritis. This was partially offset by lower sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(infliximab) due to biosimilar competition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilar versions of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious disease products achieved operational growth of 7.1% as compared to the same period a year ago primarily due to the contribution of the recently authorized COVID-19 vaccine and uptake of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JULUCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(dolutegravir/rilpivirine).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This was partially offset by lower sales of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (darunavir/cobicistat) due to increased competition and loss of exclusivity of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in certain countries outside the U.S. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience products achieved operational sales growth of 1.6% as compared to the same period a year ago. Paliperidone long-acting injectables growth was driven by sales of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (paliperidone palmitate) and INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from new patient starts and persistence. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology products achieved strong operational sales growth of 14.6% as compared to the same period a year ago. Contributors to the growth were strong sales of DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (daratumumab) driven by continued strong market growth, share gains in all regions and solid uptake from the recent launch of the subcutaneous formulation; the continued global launch uptake of ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (apalutamide) and IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ibrutinib) growth driven by market leading share and increased persistence as patients extend the duration of therapy, partially offset by COVID-19 related market dynamics including new patient starts and longer-term scripts written in the same period a year ago. The growth was negatively impacted by declining sales of  ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(abiraterone acetate) due to generic competition.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonary Hypertension achieved operational sales growth of 13.7% as compared to the same period a year ago. Sales growth of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (macitentan) and UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (selexipag) were due to continued share gains and market growth.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular / Metabolism / Other products experienced an operational decline of 4.1% as compared to the same period a year ago. The decline was primarily attributable to lower sales of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (canagliflozin) due to share erosion partially offset by strong market growth and PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(epoetin alfa) due to biosimilar competition. Additionally, the growth of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(rivaroxaban) was driven by continued demand and a one-time favorable prior period pricing adjustment in the current quarter partially offset by higher rebates. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Devices</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Devices segment sales in the fiscal first quarter of 2021 were $6.6 billion, an increase of 10.9% as compared to the same period a year ago, which included operational growth of 8.0% and a positive currency impact of 2.9%. U.S. Medical Devices sales increased 5.4%. International Medical Devices sales increased by 16.2%, including operational growth of 10.5% and a positive currency impact of 5.7%. In the fiscal first quarter of 2021, the net impact of acquisitions and divestitures on the Medical Devices segment operational sales growth was a negative 0.8%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Medical Devices Franchise Sales &#8212; Fiscal First Quarter Ended</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:235.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,372</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Advanced</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Hips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Knees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trauma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Spine, Sports &amp; Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,067</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contact Lenses/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">949</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medical Devices Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,579</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,932</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Surgery franchise achieved operational sales growth of 9.6% as compared to the prior year fiscal first quarter. The operational growth in Advanced Surgery was primarily driven by market recovery. In addition, growth of Endocutters was due to market expansion and new products primarily in China, which was partially offset by competitive pressure in the U.S. The growth in Biosurgery and Energy products was due to the success of new products and expansion within the China market. The operational growth in General Surgery was primarily driven by market recovery and continued strength of the Suture portfolio in Wound Closure partially offset by the impact of the Advanced Sterilization Products (ASP) divestiture in the prior year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Orthopaedics franchise achieved operational sales growth of 1.2% as compared to the prior year fiscal first quarter. The operational growth in hips was driven by market procedure recovery as well as leadership in the Anterior approach, strong market demand for the ACTIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> stem and enabling technologies &#8211; KINCISE&#8482; and VELYS&#8482; Hip Navigation. The operational decline in knees was driven by the negative impact of COVID-19 on procedure volume and changes in channel mix. The operational growth in Trauma was driven by global market recovery and uptake of new products. The operational decline in Spine, Sports &amp; Other was driven by the negative impact from COVID-19 and China distribution channel changes partially offset by uptake of new products and partnerships in Spine.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vision franchise achieved operational sales growth of 5.4% as compared to the prior year fiscal first quarter. The Contact Lenses/Other operational growth was due to market recovery, new products and channel inventory changes in the U.S. and Japan. The Surgical operational growth was primarily due to market recovery and uptake of recently launched products.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Interventional Solutions franchise achieved operational sales growth of 26.4% as compared to the prior year fiscal first quarter driven by atrial fibrillation market growth coupled with strength from new products.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANALYSIS OF CONSOLIDATED EARNINGS BEFORE PROVISION FOR TAXES ON INCOME </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated earnings before provision for taxes on income for the fiscal first quarter of 2021 was $7.4 billion representing 33.3% of sales as compared to $6.5 billion in the fiscal first quarter of 2020, representing 31.5% of sales. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold </span></div><div style="text-align:center"><img src="jnj-20210404_g3.jpg" alt="jnj-20210404_g3.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:280px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q1 2021 versus Q1 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Favorable product mix and translational currency in the Pharmaceutical business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Favorable volume/mix in the Medical Devices business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The establishment of a COVID-19 inventory reserve in the fiscal first quarter 2020 in the Medical Devices business which did not repeat in 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The intangible asset amortization expense included in cost of products sold for the fiscal first quarters of 2021 and 2020 was $1.2 billion and $1.1 billion, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, Marketing and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                           </span><img src="jnj-20210404_g4.jpg" alt="jnj-20210404_g4.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:280px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q1 2021 versus Q1 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, Marketing and Administrative Expenses decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leveraging in the Medical Devices business resulting from the recovery of sales from the prior years impact of COVID-19</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="text-align:center"><img src="jnj-20210404_g5.jpg" alt="jnj-20210404_g5.jpg" style="height:190px;margin-bottom:5pt;vertical-align:text-bottom;width:260px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q1 2021 versus Q1 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">COVID-19 vaccine expenses, net of governmental reimbursements</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Portfolio progression in the Pharmaceutical business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest (Income) Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest (Income) Expense in the fiscal first quarter of 2021 was a net interest expense of $48 million as compared to income of $42 million in the same period a year ago. This was primarily due to reduced interest income resulting from lower rates of interest earned on cash balances and a higher average debt balance. The balance of cash, cash equivalents and current marketable securities was $24.6&#160;billion at the end of the fiscal first quarter of 2021 as compared to $18.0 billion at the end of the fiscal first quarter of 2020. The Company&#8217;s debt position was $33.6 billion as of April 4, 2021 as compared to $27.6 billion the same period a year ago. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income) Expense, Net*</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q1 2021 versus Q1 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income)&#160;expense, net for the fiscal first quarter of 2021 was favorable by $0.2 billion as compared to the prior year primarily due to the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:49.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal First Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture gains</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration reversal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (gains)/losses on securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Divestiture gains of two pharmaceutical brands outside the U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Related to the timing of certain developmental milestones associated with the Auris Health acquisition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC), unrealized gains and losses on investments, gains and losses on divestitures, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, as well as royalty income.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before tax by segment of business for the fiscal first quarters were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:23.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent of Segment Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,640&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,629&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,691&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expenses not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,691&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consumer Health segment income before tax as a percent of sales in the fiscal first quarter of 2021 was 22.2% versus 21.2% for the same period a year ago. The increase in the income before tax as a percent of sales in the fiscal first quarter of 2021 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Supply chain efficiencies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       Partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased brand marketing expense </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment income before tax as a percent of sales in the fiscal first quarter of 2021 was 42.8% versus 34.4% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal first quarter of 2021 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Favorable product mix</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $0.6 billion related to two pharmaceutical brands outside the U.S. in the fiscal first quarter of 2021</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower unrealized losses on securities ($0.0 billion in 2021 vs. $0.3 billion in 2020)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower litigation expense ($0.0 billion in 2021 vs. $0.1 billion in 2020)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Positive translational currency</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       Partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research &amp; Development investment in the COVID-19 vaccine net of governmental reimbursements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Devices Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Devices segment income before tax as a percent of sales in the fiscal first quarter of 2021 was 24.8% versus 34.1% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal first quarter was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A contingent consideration reversal of approximately $1.0 billion in the fiscal first quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       Partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Incremental inventory reserves recorded in the fiscal first quarter of 2020 associated with the impact of COVID-19, which did not repeat in the fiscal first quarter of 2021</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Overall leveraging in the fiscal first quarter of 2021 resulting from the Medical Devices sales recovery                                                                </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018, the Company announced plans to implement actions across its Global Supply Chain that are intended to enable the Company to focus resources and increase investments in critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio of the future, enhance agility and drive growth. The Company expects these supply chain actions will include expanding its use of strategic collaborations, and bolstering its </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiatives to reduce complexity, improving cost-competitiveness, enhancing capabilities and optimizing its network.&#160;Discussions regarding specific future actions are ongoing and are subject to all relevant consultation requirements before they are finalized. In total, the Company expects these actions to generate approximately $0.6 to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 to $2.3 billion. In the fiscal first quarter of 2021, the Company recorded a pre-tax charge of $104 million, which is included on the following lines of the Consolidated Statement of Earnings, $53 million in restructuring, $27 million in cost of products sold and $24 million in other (income) expense, net. In the fiscal first quarter of 2020, the Company recorded a pre-tax charge of $118 million, which is included on the following lines of the Consolidated Statement of Earnings, $58 million in restructuring, $15 million in cost of products sold and $45 million in other (income) expense, net. Restructuring charges of approximately $1.4 billion have been recorded since the restructuring was announced.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;12 to the Consolidated Financial Statements for additional details related to the restructuring.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Taxes on Income</span></div><div><span><br/></span></div><div style="margin-top:2.7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion related to the fiscal first quarter of 2021 provision for taxes refer to Note&#160;5 to the Consolidated Financial Statements. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:2.7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20210404_g6.jpg" alt="jnj-20210404_g6.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:193px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><img src="jnj-20210404_g7.jpg" alt="jnj-20210404_g7.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><img src="jnj-20210404_g8.jpg" alt="jnj-20210404_g8.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:193px"/></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents were $12.7&#160;billion at the end of the fiscal first quarter of 2021 as compared with $14.0&#160;billion at the end of fiscal year 2020. The primary sources and uses of cash that contributed to the $1.3&#160;billion decrease were:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:21.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2020 Cash and cash equivalents balance</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash generated from operating activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by investing activities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by financing activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">effect of exchange rate and rounding</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2021 Cash and cash equivalents balance</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company had $11.9 billion in marketable securities at the end of the fiscal first quarter of 2021 and $11.2 billion at the end of fiscal year 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operations of $4.1&#160;billion was the result of:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs partially offset by the deferred tax provision, net gain on sale of assets/businesses and credit losses and accounts receivable allowances</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in accounts payable and accrued liabilities and other current and non-current liabilities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in accounts receivable and inventories </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease other current and non-current assets</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow from operations</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities use of $0.2 billion of cash was primarily used for:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">additions to property, plant and equipment</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from the disposal of assets/businesses, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net purchases of investments</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">credit support agreements activity, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for investing activities</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities use of $5.1 billion of cash was primarily used for: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">dividends to shareholders </span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">repurchase of common stock</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net repayment of short and long term debt</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from stock options exercised/employee withholding tax on stock awards, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">credit support agreements activity, net</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other and rounding</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for financing activities</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2020, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10&#160;billion, which expires on September&#160;9, 2021.  Interest charged on borrowings under the credit line agreement is based on either bids provided by banks, the prime rate, London Interbank Offered Rates (LIBOR), Secured Overnight Financing Rate (SOFR) Swap Curve or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreement are not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fiscal first quarter of 2021, the Company's notes payable and long-term debt was in excess of cash, cash equivalents and marketable securities. As of April 4, 2021, the net debt position was $9.0 billion as compared to the prior year of $9.6 billion. Considering recent market conditions and the on-going COVID-19 crisis, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's approximate $1.0 billion in contractual supply commitments associated with its development of the COVID-19 vaccine, the talc litigation and agreement in principle to settle opioid litigation of which the majority may be paid over the next two to three years. In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, as a result of the Tax Cuts and Jobs Act (TCJA), the Company has access to its cash outside the U.S. at a significantly reduced cost.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subsequent to April 4, 2021, the Company paid approximately $1.2 billion to the U.S. Treasury for $0.8 billion related to the current installment due on foreign undistributed earnings as part of the TCJA (see Note 1 to the Consolidated Financial Statements in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January 3, 2021) and $0.4 billion primarily related to the normal estimated payment for the fiscal first quarter of 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, the Board of Directors declared a regular cash dividend of $1.01 per share, payable on March 9, 2021 to shareholders of record as of February 23, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2021, the Board of Directors declared a regular cash dividend of $1.06 per share, payable on June 8, 2021 to shareholders of record as of May 25, 2021. The Company expects to continue the practice of paying regular quarterly cash dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OTHER INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic and Market Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 considerations and business continuity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered various internal and external factors in assessing the potential impact of COVID-19 on its business and financial results based upon information available at this time, as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Operating Model: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a diversified business model across the healthcare industry with flexibility designed into its manufacturing, research and development clinical operations and commercial capabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to leverage its global manufacturing footprint and dual-source capabilities while closely monitoring and maintaining critical inventory at major distribution centers away from high-risk areas to ensure adequate and effective distribution. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Business Continuity: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The robust, active business continuity plans across the Company's network have been instrumental in preparing the Company for events like COVID-19 and the ability to meet the majority of patient and consumer needs remains uninterrupted.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Workforce: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has put procedures in place to protect its essential workforce in manufacturing, distribution, commercial and research operations while ensuring appropriate remote working protocols have been established for other employees. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Liquidity:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's high-quality credit rating allows the Company superior access to the financial capital markets for the foreseeable future. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Domestic and Foreign Legislation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to assess and evaluate the on-going global legislative efforts to combat the COVID-19 impact on economies and the sectors in which it participates. Currently, the recent legislative acts put in place are not expected to have a material impact on the Company&#8217;s operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In fiscal 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.0 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to evaluate and monitor both its internal and external supply arrangements, including its contract with Emergent BioSolutions and related production activities at its Bayview, Maryland facility. The Company  has established a global vaccine supply network, where, in addition to its internal manufacturing site in Leiden, the Netherlands, ten other manufacturing sites will be involved in the production of vaccine across different countries and continents. The Company does not believe that a disruption at a vaccine manufacturing site, or the resulting delay would have a material financial impact on the Company&#8217;s consolidated financial statements or results.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela and Argentina as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. This did not have a material impact on the Company's results in the period. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In June 2016, the United Kingdom (U.K.) held a referendum in which voters approved an exit from the European Union (E.U.), commonly referred to as &#8220;Brexit&#8221;. The U.K. officially exited the E.U. on January 31, 2020, however, there was a transition period  to allow time to agree the terms of a new trade deal. On December 30, 2020, the U.K., E.U. and the European Atomic Energy Community (Euratom) signed the EU&#8211;UK Trade and Cooperation Agreement (TCA). Over the last few years, Brexit has created global political and economic uncertainty and has led to volatility in exchange rates and interest rates, additional cost containment by third-party payors and changes in regulations. While the UK and EU have now agreed on a future trade and cooperation agreement, it is still unclear what the ultimate financial, trade, regulatory and legal implications the withdrawal of the U.K. from the E.U. will have. However, the Company currently does not believe that these and other related effects will have a material impact on the Company&#8217;s consolidated financial position or operating results. As of April&#160;4, 2021, and for the fiscal three months, the business of the Company&#8217;s U.K. subsidiaries represented less than 6% of the Company&#8217;s consolidated assets and less than 3% of the fiscal three months revenues. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governments around the world consider various proposals to make changes to tax laws and regulations, which may include increasing or decreasing existing statutory tax rates. A change in statutory tax rate in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted.&#160; This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings.&#160; The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing health care insurance coverage, may continue to impact the Company&#8217;s businesses.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also operates in an environment increasingly hostile to intellectual property rights. Firms have filed Abbreviated New Drug Applications or Biosimilar Biological Product Applications with the FDA or otherwise challenged the coverage and/or validity of the Company's patents, seeking to market generic or biosimilar forms of many of the Company&#8217;s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue will be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also a risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;3 &#8212; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the Company&#8217;s assessment of its sensitivity to market risk since its presentation set forth in Item&#160;7A, &#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; in its Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;4 &#8212; CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company&#8217;s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Alex Gorsky, Chairman and Chief Executive Officer, and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs.&#160;Gorsky and Wolk concluded that, as of the end of the period covered by this report, the Company&#8217;s disclosure controls and procedures were effective.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Internal control. During the period covered by this report, there were no changes in the Company&#8217;s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company has not experienced any material impact to its internal controls over financial reporting despite the fact that most of its employees are working remotely due to the COVID-19 pandemic. The Company proactively took actions to re-evaluate and refine its financial reporting process through additional monitoring controls to provide reasonable assurance that the financial results are reported accurately and timely. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part II &#8212; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1 &#8212; LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to Note 11 included in Part&#160;I, Item&#160;1, Financial Statements (unaudited) &#8212; Notes to Consolidated Financial Statements.</span></div><div><span><br/></span></div><div id="i0699d70253b44b9fbc20ae5610df4e69_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;2 &#8212; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to Common Stock purchases by the Company during the fiscal first quarter of 2021. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal first quarter.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:497.25pt"><tr><td style="width:1.0pt"></td><td style="width:210.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:84.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:57pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Month Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Avg. Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 4, 2021 through January 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,233,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2021 through February 28, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021 through April 4, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,898,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;During the fiscal first quarter of 2021, the Company repurchased an aggregate of 8,898,542 shares of Johnson &amp; Johnson Common Stock in open-market transactions, all of which were purchased as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;6 &#8212; EXHIBITS</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20211qex311ceocertificati.htm">Exhibit&#160;31.1  </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer under Rule&#160;13a-14(a) of the Securities Exchange Act pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 &#8212; Filed with this document.</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20211qex312cfocertificati.htm">Exhibit&#160;31.2 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Financial Officer under Rule&#160;13a-14(a) of the Securities Exchange Act pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 &#8212; Filed with this document.</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20211qex321ceocertificati.htm">Exhibit&#160;32.1 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 &#8212; Furnished with this document.</span></div><div style="text-indent:11.25pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20211qex322cfocertificati.htm">Exhibit&#160;32.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certification of Chief Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 &#8212; Furnished with this document.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 101: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i0699d70253b44b9fbc20ae5610df4e69_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:51.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JOHNSON &amp; JOHNSON<br/>(Registrant)&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By /s/ J. J. WOLK</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. J. WOLK</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer (Principal Financial Officer)&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By /s/&#160;R. J. DECKER Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. J. DECKER Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controller (Principal Accounting Officer)&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a20211qex311ceocertificati.htm
<DESCRIPTION>EX-31.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ieb300ee0038e46ee8c9828c34076e637_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Alex Gorsky, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended April&#160;4, 2021 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#34;Company&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)  Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.  The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="padding-left:288pt"><font><br></font></div><div style="padding-left:288pt"><font><br></font></div><div style="padding-left:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Alex Gorsky</font></div><div style="padding-left:288pt"><font style="color:#7d7d7d;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">__________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alex Gorsky</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;   April&#160;30, 2021</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a20211qex312cfocertificati.htm
<DESCRIPTION>EX-31.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3dd74c76be1344258b1aba0212c904c1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph J. Wolk, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended April&#160;4, 2021 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#34;Company&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)  Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.  The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Joseph J. Wolk</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">______________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph J. Wolk</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;30, 2021</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a20211qex321ceocertificati.htm
<DESCRIPTION>EX-31.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ice8d432732a54458a56ad647453fa5df_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-right:38.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 32.1</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned, Alex Gorsky, the Chief Executive Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-bottom:5pt;margin-top:11pt;padding-left:22.5pt;padding-right:38.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company's Quarterly Report on Form 10-Q for the quarterly period ended April 4, 2021 (the&#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Alex Gorsky</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alex Gorsky&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;  April&#160;30, 2021</font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification is being furnished to the SEC with this Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.</font></div><div style="margin-top:11.25pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a20211qex322cfocertificati.htm
<DESCRIPTION>EX-31.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1f4fcb5b87274ab3be36ab165548aa68_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-right:38.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 32.2</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company's Quarterly Report on Form 10-Q for the quarterly period ended April 4, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph J. Wolk</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Dated&#58;  April&#160;30, 2021</font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-indent:-20.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification is being furnished to the SEC with this Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.</font></div><div style="margin-top:11.25pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>jnj-20210404.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1a2ac66c-2667-4890-bd3c-b889272a48e4,g:4415be36-51dc-414c-a907-a89d836331d3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20210404" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.jnj.com/20210404">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20210404_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20210404_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20210404_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20210404_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.jnj.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEarnings" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings">
        <link:definition>1003004 - Statement - Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>1405401 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity">
        <link:definition>1006006 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>1007007 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1008008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.jnj.com/role/Inventories">
        <link:definition>2103102 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.jnj.com/role/InventoriesTables">
        <link:definition>2304301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.jnj.com/role/InventoriesDetails">
        <link:definition>2405402 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2106103 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2307302 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>2408403 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillGoodwillBySegmentDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails">
        <link:definition>2409404 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>2410405 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails">
        <link:definition>2411406 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.jnj.com/role/FairValueMeasurements">
        <link:definition>2112104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.jnj.com/role/FairValueMeasurementsTables">
        <link:definition>2313303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2414407 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofDerivativeActivityDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails">
        <link:definition>2415408 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
        <link:definition>2416409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
        <link:definition>2417410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
        <link:definition>2418411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
        <link:definition>2419412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>2420413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails">
        <link:definition>2421414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails">
        <link:definition>2422415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.jnj.com/role/IncomeTaxes">
        <link:definition>2123105 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.jnj.com/role/IncomeTaxesDetails">
        <link:definition>2424416 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlans" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans">
        <link:definition>2125106 - Disclosure - Pensions and Other Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansTables" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables">
        <link:definition>2326304 - Disclosure - Pensions and Other Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>2427417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails">
        <link:definition>2428418 - Disclosure - Pensions and Other Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncome" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome">
        <link:definition>2129107 - Disclosure - Accumulated Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeTables" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables">
        <link:definition>2330305 - Disclosure - Accumulated Other Comprehensive Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>2431419 - Disclosure - Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.jnj.com/role/EarningsPerShare">
        <link:definition>2132108 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.jnj.com/role/EarningsPerShareTables">
        <link:definition>2333306 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.jnj.com/role/EarningsPerShareDetails">
        <link:definition>2434420 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreas" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas">
        <link:definition>2135109 - Disclosure - Segments of Business and Geographic Areas</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasTables" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables">
        <link:definition>2336307 - Disclosure - Segments of Business and Geographic Areas (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails">
        <link:definition>2437421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails">
        <link:definition>2438422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
        <link:definition>2439423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures">
        <link:definition>2140110 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresNarrativeDetails" roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails">
        <link:definition>2441424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails">
        <link:definition>2442425 - Disclosure - Business Combinations and Divestitures - Schedule of Pro Forma Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.jnj.com/role/LegalProceedings">
        <link:definition>2143111 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsDetails" roleURI="http://www.jnj.com/role/LegalProceedingsDetails">
        <link:definition>2444426 - Disclosure - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.jnj.com/role/Restructuring">
        <link:definition>2145112 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.jnj.com/role/RestructuringTables">
        <link:definition>2346308 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails">
        <link:definition>2447427 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofRestructuringReserveDetails" roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails">
        <link:definition>2448428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jnj_RestructuringandRelatedCostExpectedFutureSavings" abstract="false" name="RestructuringandRelatedCostExpectedFutureSavings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_IncomeTaxExpenseBenefitPercentToSales" abstract="false" name="IncomeTaxExpenseBenefitPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_A4.85Notesdue2041Member" abstract="true" name="A4.85Notesdue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OrthopaedicsMember" abstract="true" name="OrthopaedicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A0550NotesDue2025Member" abstract="true" name="A0550NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A4.50Debenturesdue2040Member" abstract="true" name="A4.50Debenturesdue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherIncomeExpenseNetMember" abstract="true" name="OtherIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A3.500Notesdue2048Member" abstract="true" name="A3.500Notesdue2048Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EDURANTrilpivirineMember" abstract="true" name="EDURANTrilpivirineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CONCERTAMethylphenidateMember" abstract="true" name="CONCERTAMethylphenidateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_GrossProfitPercentToSales" abstract="false" name="GrossProfitPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" abstract="false" name="FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_InterestIncomeExpenseNetMember" abstract="true" name="InterestIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PulmonaryHypertensionMember" abstract="true" name="PulmonaryHypertensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_KNEESMember" abstract="true" name="KNEESMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SURGICALMember" abstract="true" name="SURGICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CostOfGoodsSoldPercentToSales" abstract="false" name="CostOfGoodsSoldPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_NotesDuePeriodFifteenMember" abstract="true" name="NotesDuePeriodFifteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesAxis" abstract="true" name="LitigationSettlementByCompaniesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A0.250NotesDue2022Member" abstract="true" name="A0.250NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ConsumerMember" abstract="true" name="ConsumerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2250NotesDue2050Member" abstract="true" name="A2250NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EquityInvestmentswithReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithoutReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_VisionMember" abstract="true" name="VisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ADVANCEDMember" abstract="true" name="ADVANCEDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" abstract="false" name="EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EvraAndDoxilMember" abstract="true" name="EvraAndDoxilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" abstract="false" name="RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_A2.900Notesdue2028Member" abstract="true" name="A2.900Notesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PROCRITEPREXMember" abstract="true" name="PROCRITEPREXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A1300NotesDue2030Member" abstract="true" name="A1300NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SimponiSimponiAriaMember" abstract="true" name="SimponiSimponiAriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TalcMember" abstract="true" name="TalcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SPINEOTHERMember" abstract="true" name="SPINEOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A3.375Notesdue2023Member" abstract="true" name="A3.375Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" abstract="false" name="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" abstract="true" name="OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PatentsAndTrademarksMember" abstract="true" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PinnacleAcetabularCupSystemMember" abstract="false" name="PinnacleAcetabularCupSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_WoundCareandOtherMember" abstract="true" name="WoundCareandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AssetWriteoffMember" abstract="true" name="AssetWriteoffMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_IncomeTaxTextualsAbstract" abstract="true" name="IncomeTaxTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_InfectiousDiseasesMember" abstract="true" name="InfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_Restructuringchargepercenttosales" abstract="false" name="Restructuringchargepercenttosales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_OtherNonOperatingIncomeExpensePercentToSales" abstract="false" name="OtherNonOperatingIncomeExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" abstract="false" name="FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_IMBRUVICAMember" abstract="true" name="IMBRUVICAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OPSUMITMember" abstract="true" name="OPSUMITMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesByGeographicArea" abstract="false" name="PercentageChangeInSalesByGeographicArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SalesRevenueGoodsNetPercentToSales" abstract="false" name="SalesRevenueGoodsNetPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" abstract="true" name="PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentRollForward" abstract="true" name="EquityInvestmentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A5.95Notesdue2037Member" abstract="true" name="A5.95Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A6.95Notesdue2029Member" abstract="true" name="A6.95Notesdue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_VerbSurgicalInc.Member" abstract="true" name="VerbSurgicalInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_LegalProceedingTextualsAbstract" abstract="true" name="LegalProceedingTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A5.85Debenturesdue2038Member" abstract="true" name="A5.85Debenturesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A095NotesDue2027Member" abstract="true" name="A095NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_GENERALMember" abstract="true" name="GENERALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A1.150NotesDue2028Member" abstract="true" name="A1.150NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OralCareMember" abstract="true" name="OralCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AsiaPacificAfricaMember" abstract="true" name="AsiaPacificAfricaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ExcessOfFairValueOverCarryingValueOfDebt" abstract="false" name="ExcessOfFairValueOverCarryingValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_OTCMember" abstract="true" name="OTCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_HIPSMember" abstract="true" name="HIPSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AmountPrepaidAndDueToManufacturers" abstract="false" name="AmountPrepaidAndDueToManufacturers" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_RestructuringandRelatedCostDurationofRestructuringPlan" abstract="false" name="RestructuringandRelatedCostDurationofRestructuringPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_WomensHealthMember" abstract="true" name="WomensHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_INVOKANAINVOKAMETMember" abstract="true" name="INVOKANAINVOKAMETMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_InterestExpensePercentToSales" abstract="false" name="InterestExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesDomain" abstract="true" name="LitigationSettlementByCompaniesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" abstract="false" name="SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_AsrMember" abstract="false" name="AsrMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TRAUMAMember" abstract="true" name="TRAUMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_WesternHemisphereExcludingUSMember" abstract="true" name="WesternHemisphereExcludingUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InvestmentIncomeInterestPercentToSales" abstract="false" name="InvestmentIncomeInterestPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2450NotesDue2060Member" abstract="true" name="A2450NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_RISPERDALCONSTAMember" abstract="true" name="RISPERDALCONSTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_UNITEDSTATESExportsMember" abstract="true" name="UNITEDSTATESExportsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OtherInfectiousDiseasesMember" abstract="true" name="OtherInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A6.73Debenturesdue2023Member" abstract="true" name="A6.73Debenturesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_BabyCareMember" abstract="true" name="BabyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OpioidMember" abstract="true" name="OpioidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2.45Notesdue2026Member" abstract="true" name="A2.45Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A0.650NotesDue2024Member" abstract="true" name="A0.650NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_OTHERNEUROSCIENCEMember" abstract="true" name="OTHERNEUROSCIENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A3.625Notesdue2037Member" abstract="true" name="A3.625Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_BeautyMember" abstract="true" name="BeautyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PelvicMeshesMember" abstract="false" name="PelvicMeshesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A5.50NotesDue2024Member" abstract="true" name="A5.50NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_UPTRAVIMember" abstract="true" name="UPTRAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInOperatingIncomeLoss" abstract="false" name="PercentageChangeInOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_A1.650NotesDue2035Member" abstract="true" name="A1.650NotesDue2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_RisperdalMember" abstract="true" name="RisperdalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_XareltoMember" abstract="true" name="XareltoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A4.95Debenturesdue2033Member" abstract="true" name="A4.95Debenturesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" abstract="true" name="INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A4.50Notesdue2043Member" abstract="true" name="A4.50Notesdue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SupplyChainMember" abstract="true" name="SupplyChainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales" abstract="false" name="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DePuyASRU.S.Member" abstract="true" name="DePuyASRU.S.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_Numberofpatientsinsettlement" abstract="false" name="Numberofpatientsinsettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_A2.95Notesdue2027Member" abstract="true" name="A2.95Notesdue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_LossContingencyEstimateOfAdditionalPossibleLoss" abstract="false" name="LossContingencyEstimateOfAdditionalPossibleLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A2.05Notesdue2023Member" abstract="true" name="A2.05Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_StelaraMember" abstract="true" name="StelaraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesBySegmentOfBusiness" abstract="false" name="PercentageChangeInSalesBySegmentOfBusiness" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_CONTACTLENSESOTHERMember" abstract="true" name="CONTACTLENSESOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ProductLiabilityContingencyNumberOfClaimant" abstract="false" name="ProductLiabilityContingencyNumberOfClaimant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_SellingGeneralAndAdministrativeExpensePercentToSales" abstract="false" name="SellingGeneralAndAdministrativeExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_AccruedRebatesReturnsAndPromotions" abstract="false" name="AccruedRebatesReturnsAndPromotions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_OtherReverseRepurchaseAgreementsMember" abstract="true" name="OtherReverseRepurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_SurgeryMember" abstract="true" name="SurgeryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentImpairmentLoss" abstract="false" name="EquityFairValueAdjustmentImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CardiovascularMetabolismOtherMember" abstract="true" name="CardiovascularMetabolismOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" abstract="false" name="FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_MedicalDevicesMember" abstract="true" name="MedicalDevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_BabyPowderMember" abstract="true" name="BabyPowderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A3.400Notesdue2038Member" abstract="true" name="A3.400Notesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_InterventionalSolutionsMember" abstract="true" name="InterventionalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_BermekimabMember" abstract="true" name="BermekimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A210NotesDue2040Member" abstract="true" name="A210NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ZYTIGAMember" abstract="true" name="ZYTIGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_InvokanaMember" abstract="true" name="InvokanaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A3.55Notesdue2036Member" abstract="true" name="A3.55Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_NetIncomeAttributableToParentPercentToSales" abstract="false" name="NetIncomeAttributableToParentPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" abstract="false" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SalesBySegmentOfBusinessTableTextBlock" abstract="false" name="SalesBySegmentOfBusinessTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="jnj_A4.375Notesdue2033Member" abstract="true" name="A4.375Notesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PhysiomeshMember" abstract="true" name="PhysiomeshMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A3.75Notesdue2047Member" abstract="true" name="A3.75Notesdue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A3.70Notesdue2046Member" abstract="true" name="A3.70Notesdue2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_AurisHealthMember" abstract="true" name="AurisHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_ERLEADAMember" abstract="true" name="ERLEADAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_DARZALEXMember" abstract="true" name="DARZALEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_PurchasedInProcessResearchAndDevelopmentMember" abstract="true" name="PurchasedInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="jnj_A2.625Notesdue2025Member" abstract="true" name="A2.625Notesdue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>jnj-20210404_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1a2ac66c-2667-4890-bd3c-b889272a48e4,g:4415be36-51dc-414c-a907-a89d836331d3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20210404.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f42f8541-ab23-4a74-8c77-f30879d26cee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d83e574a-8ede-45b9-ab6b-152d45a118ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f42f8541-ab23-4a74-8c77-f30879d26cee" xlink:to="loc_us-gaap_LiabilitiesCurrent_d83e574a-8ede-45b9-ab6b-152d45a118ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ff8f699d-62a3-4b97-9024-f0d6ee79e587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f42f8541-ab23-4a74-8c77-f30879d26cee" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ff8f699d-62a3-4b97-9024-f0d6ee79e587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9c17d25a-d032-4a77-aa3d-07c3fef13044" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f42f8541-ab23-4a74-8c77-f30879d26cee" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9c17d25a-d032-4a77-aa3d-07c3fef13044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_f7ac1188-a041-4ff9-bf26-7a947c0ef005" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f42f8541-ab23-4a74-8c77-f30879d26cee" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_f7ac1188-a041-4ff9-bf26-7a947c0ef005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1a5f5ac9-ca91-4dd1-b280-54569a7d8138" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f42f8541-ab23-4a74-8c77-f30879d26cee" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1a5f5ac9-ca91-4dd1-b280-54569a7d8138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f400fe9b-bd8e-4913-96be-da08e310ded8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f42f8541-ab23-4a74-8c77-f30879d26cee" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f400fe9b-bd8e-4913-96be-da08e310ded8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d18fc08b-0615-4631-a1e0-71d60b093f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_5305af94-d9b7-4c73-a93c-a1473b28504f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d18fc08b-0615-4631-a1e0-71d60b093f6a" xlink:to="loc_us-gaap_ShortTermBorrowings_5305af94-d9b7-4c73-a93c-a1473b28504f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2f020d6e-f7e6-4f2f-ae2c-f655e096ae0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d18fc08b-0615-4631-a1e0-71d60b093f6a" xlink:to="loc_us-gaap_AccountsPayableCurrent_2f020d6e-f7e6-4f2f-ae2c-f655e096ae0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_186ca109-e5fc-4e0d-9f9c-761f6281895e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d18fc08b-0615-4631-a1e0-71d60b093f6a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_186ca109-e5fc-4e0d-9f9c-761f6281895e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_37f15bee-7a7a-4636-a0e0-8be46ddbe7bd" xlink:href="jnj-20210404.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d18fc08b-0615-4631-a1e0-71d60b093f6a" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_37f15bee-7a7a-4636-a0e0-8be46ddbe7bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_82220fcf-99a9-4b55-b0a1-febc5e22977a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d18fc08b-0615-4631-a1e0-71d60b093f6a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_82220fcf-99a9-4b55-b0a1-febc5e22977a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_7daa72bf-cb1c-4799-a1e5-b0f47fcbfc63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d18fc08b-0615-4631-a1e0-71d60b093f6a" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_7daa72bf-cb1c-4799-a1e5-b0f47fcbfc63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e515af03-196b-4baa-b226-d0a9732f476b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a123c688-4000-45f8-8392-52f3c850e86a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e515af03-196b-4baa-b226-d0a9732f476b" xlink:to="loc_us-gaap_AssetsCurrent_a123c688-4000-45f8-8392-52f3c850e86a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0a0e33d5-ca51-4285-89ca-30de5e3ccdc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e515af03-196b-4baa-b226-d0a9732f476b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0a0e33d5-ca51-4285-89ca-30de5e3ccdc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ff0f192-75cc-41fc-8c54-4f9cc6e83e65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e515af03-196b-4baa-b226-d0a9732f476b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ff0f192-75cc-41fc-8c54-4f9cc6e83e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_03c06efe-6db1-4a8a-88c0-8ab9a4d6dd72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e515af03-196b-4baa-b226-d0a9732f476b" xlink:to="loc_us-gaap_Goodwill_03c06efe-6db1-4a8a-88c0-8ab9a4d6dd72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_b4cdae88-3d08-4162-b2c0-8580603fbe60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e515af03-196b-4baa-b226-d0a9732f476b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_b4cdae88-3d08-4162-b2c0-8580603fbe60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_916b25b9-f3ad-4a83-a8d9-dfbab6e60655" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e515af03-196b-4baa-b226-d0a9732f476b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_916b25b9-f3ad-4a83-a8d9-dfbab6e60655" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cee598a6-9f7b-43e9-8e7e-127427237485" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cfaf2a84-a873-4785-9348-4a95a374c043" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cee598a6-9f7b-43e9-8e7e-127427237485" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cfaf2a84-a873-4785-9348-4a95a374c043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4899f4fa-b6e8-4802-8048-20c99f263a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_cee598a6-9f7b-43e9-8e7e-127427237485" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4899f4fa-b6e8-4802-8048-20c99f263a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5c35b13e-cefb-4aae-9e0e-f471bdc4bce1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_904cd1a8-cd2c-43dc-9d3c-3655c2b431fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5c35b13e-cefb-4aae-9e0e-f471bdc4bce1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_904cd1a8-cd2c-43dc-9d3c-3655c2b431fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_0db29694-d444-4b1d-99ca-369710a3ec9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5c35b13e-cefb-4aae-9e0e-f471bdc4bce1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_0db29694-d444-4b1d-99ca-369710a3ec9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0aa24088-cde8-48d0-bc66-c85a03524b89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5c35b13e-cefb-4aae-9e0e-f471bdc4bce1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0aa24088-cde8-48d0-bc66-c85a03524b89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_85f97bce-849f-42cc-b33c-ccb18fb03963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5c35b13e-cefb-4aae-9e0e-f471bdc4bce1" xlink:to="loc_us-gaap_InventoryNet_85f97bce-849f-42cc-b33c-ccb18fb03963" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ebc01de8-465e-44fc-a82e-bb597bdef505" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5c35b13e-cefb-4aae-9e0e-f471bdc4bce1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ebc01de8-465e-44fc-a82e-bb597bdef505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c2872fd0-4682-4688-b1b2-1f45104e5379" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9601ee3f-9104-49a0-bd35-284a46e06fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c2872fd0-4682-4688-b1b2-1f45104e5379" xlink:to="loc_us-gaap_Liabilities_9601ee3f-9104-49a0-bd35-284a46e06fd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b12501d1-3280-4c9a-a3b2-15f879760c48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c2872fd0-4682-4688-b1b2-1f45104e5379" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b12501d1-3280-4c9a-a3b2-15f879760c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4707528e-667a-48dc-a7a3-dfb2989d63c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c2872fd0-4682-4688-b1b2-1f45104e5379" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4707528e-667a-48dc-a7a3-dfb2989d63c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_22488f95-3dae-4998-976a-02886351fd22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_26540209-256e-4b34-b828-7f137d86f4c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_22488f95-3dae-4998-976a-02886351fd22" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_26540209-256e-4b34-b828-7f137d86f4c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_39639984-18d9-4ffb-8e1b-7112b7015f69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_22488f95-3dae-4998-976a-02886351fd22" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_39639984-18d9-4ffb-8e1b-7112b7015f69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9bf6f869-8ffe-4b91-bcee-b8443e5333a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_22488f95-3dae-4998-976a-02886351fd22" xlink:to="loc_us-gaap_CommonStockValue_9bf6f869-8ffe-4b91-bcee-b8443e5333a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b65180de-f52c-4fce-8aa8-568fb4720c93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_22488f95-3dae-4998-976a-02886351fd22" xlink:to="loc_us-gaap_TreasuryStockValue_b65180de-f52c-4fce-8aa8-568fb4720c93" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_83eac354-578d-427c-9851-e732969527d0" xlink:href="jnj-20210404.xsd#jnj_GrossProfitPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales_328f16a8-c4dd-4321-822d-af4fa01e57a3" xlink:href="jnj-20210404.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_GrossProfitPercentToSales_83eac354-578d-427c-9851-e732969527d0" xlink:to="loc_jnj_CostOfGoodsSoldPercentToSales_328f16a8-c4dd-4321-822d-af4fa01e57a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales_83d13f94-09c4-436b-aaac-d23e75a10535" xlink:href="jnj-20210404.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_GrossProfitPercentToSales_83eac354-578d-427c-9851-e732969527d0" xlink:to="loc_jnj_SalesRevenueGoodsNetPercentToSales_83d13f94-09c4-436b-aaac-d23e75a10535" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fdb0cbe0-3712-4b29-926f-55946b2a6e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e966e0c4-9ccd-4fcd-974f-78868a4dbd44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fdb0cbe0-3712-4b29-926f-55946b2a6e2e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e966e0c4-9ccd-4fcd-974f-78868a4dbd44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ad4a08e6-0aaf-4ba8-821f-6fb68f40796a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fdb0cbe0-3712-4b29-926f-55946b2a6e2e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ad4a08e6-0aaf-4ba8-821f-6fb68f40796a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_60ac4c5e-4ab9-4971-8d5e-b8589c31f7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fdb0cbe0-3712-4b29-926f-55946b2a6e2e" xlink:to="loc_us-gaap_GrossProfit_60ac4c5e-4ab9-4971-8d5e-b8589c31f7c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3fdf800b-a2a0-4db4-ad62-aceaca0183d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fdb0cbe0-3712-4b29-926f-55946b2a6e2e" xlink:to="loc_us-gaap_RestructuringCharges_3fdf800b-a2a0-4db4-ad62-aceaca0183d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2c3a8ee7-70b0-4d21-ae01-536471b73586" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fdb0cbe0-3712-4b29-926f-55946b2a6e2e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2c3a8ee7-70b0-4d21-ae01-536471b73586" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2a373bf7-0825-4063-b289-a4018415d70b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fdb0cbe0-3712-4b29-926f-55946b2a6e2e" xlink:to="loc_us-gaap_InterestExpense_2a373bf7-0825-4063-b289-a4018415d70b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cf49e5f3-06dd-45a1-87a9-48a89e1c3145" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fdb0cbe0-3712-4b29-926f-55946b2a6e2e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cf49e5f3-06dd-45a1-87a9-48a89e1c3145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_dce35c91-2f89-44d7-8258-6b35f5eef8c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae1f364b-57f1-4823-9878-46ac3c6fcf98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_dce35c91-2f89-44d7-8258-6b35f5eef8c4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae1f364b-57f1-4823-9878-46ac3c6fcf98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1212346f-2e59-4a27-9ada-1fa75e2539e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_dce35c91-2f89-44d7-8258-6b35f5eef8c4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1212346f-2e59-4a27-9ada-1fa75e2539e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_04daa04c-90bf-44e4-9cf5-5c5ed4bec7c2" xlink:href="jnj-20210404.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_ddf9a4f4-74f6-42ac-a6da-e683278f7570" xlink:href="jnj-20210404.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_04daa04c-90bf-44e4-9cf5-5c5ed4bec7c2" xlink:to="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_ddf9a4f4-74f6-42ac-a6da-e683278f7570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_d2905ceb-9205-4146-8a7b-d7b9d25417bd" xlink:href="jnj-20210404.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_04daa04c-90bf-44e4-9cf5-5c5ed4bec7c2" xlink:to="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_d2905ceb-9205-4146-8a7b-d7b9d25417bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_2288027b-035e-4bc4-a332-2e46e87695af" xlink:href="jnj-20210404.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_04daa04c-90bf-44e4-9cf5-5c5ed4bec7c2" xlink:to="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_2288027b-035e-4bc4-a332-2e46e87695af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales_d7028e4d-6b8a-4af0-b25c-5eae5561b7de" xlink:href="jnj-20210404.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_04daa04c-90bf-44e4-9cf5-5c5ed4bec7c2" xlink:to="loc_jnj_InvestmentIncomeInterestPercentToSales_d7028e4d-6b8a-4af0-b25c-5eae5561b7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales_75406728-c90d-475f-86fe-4ba039d3b9c0" xlink:href="jnj-20210404.xsd#jnj_InterestExpensePercentToSales"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_04daa04c-90bf-44e4-9cf5-5c5ed4bec7c2" xlink:to="loc_jnj_InterestExpensePercentToSales_75406728-c90d-475f-86fe-4ba039d3b9c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_c731a097-005f-460f-9747-af5c36615332" xlink:href="jnj-20210404.xsd#jnj_GrossProfitPercentToSales"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_04daa04c-90bf-44e4-9cf5-5c5ed4bec7c2" xlink:to="loc_jnj_GrossProfitPercentToSales_c731a097-005f-460f-9747-af5c36615332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales_ae3d2de0-7876-4507-b661-4a2a2e6351d3" xlink:href="jnj-20210404.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_04daa04c-90bf-44e4-9cf5-5c5ed4bec7c2" xlink:to="loc_jnj_Restructuringchargepercenttosales_ae3d2de0-7876-4507-b661-4a2a2e6351d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales_18abc5e8-450c-4f8a-be7e-4127225cd18c" xlink:href="jnj-20210404.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_4cc19e05-1f0e-4d54-9f18-b36bbb778be1" xlink:href="jnj-20210404.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales_18abc5e8-450c-4f8a-be7e-4127225cd18c" xlink:to="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_4cc19e05-1f0e-4d54-9f18-b36bbb778be1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_18f17873-dd83-44d9-9060-652bab3a8616" xlink:href="jnj-20210404.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales_18abc5e8-450c-4f8a-be7e-4127225cd18c" xlink:to="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_18f17873-dd83-44d9-9060-652bab3a8616" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8fe962e2-c28d-46ec-b12a-cb5647a3057f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3f50ab27-ccf2-4fc6-af63-6050c71c7bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8fe962e2-c28d-46ec-b12a-cb5647a3057f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3f50ab27-ccf2-4fc6-af63-6050c71c7bd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10cc2168-0994-417f-92c4-49a8fc2467f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8fe962e2-c28d-46ec-b12a-cb5647a3057f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10cc2168-0994-417f-92c4-49a8fc2467f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e10d0f63-620e-48d1-8200-9bbe8125a040" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_39337454-5543-423e-ad0a-f37e76e34d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e10d0f63-620e-48d1-8200-9bbe8125a040" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_39337454-5543-423e-ad0a-f37e76e34d3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fdf27ddd-5f2a-4dda-9b11-ba0bec432cab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e10d0f63-620e-48d1-8200-9bbe8125a040" xlink:to="loc_us-gaap_NetIncomeLoss_fdf27ddd-5f2a-4dda-9b11-ba0bec432cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f9a9ed9d-739f-42be-bf64-1c2292b65935" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_ef6b963b-1fc3-483f-b4f0-2872685fd532" xlink:href="jnj-20210404.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f9a9ed9d-739f-42be-bf64-1c2292b65935" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_ef6b963b-1fc3-483f-b4f0-2872685fd532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_51421eeb-6eba-4404-95b7-e4b0ada84a63" xlink:href="jnj-20210404.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f9a9ed9d-739f-42be-bf64-1c2292b65935" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_51421eeb-6eba-4404-95b7-e4b0ada84a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_e3e61a96-c465-484d-8cb1-6986e75a18c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_faa14f9b-2e8f-40bc-aae0-d812df1de4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_e3e61a96-c465-484d-8cb1-6986e75a18c8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_faa14f9b-2e8f-40bc-aae0-d812df1de4c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_c78d7825-e292-457d-ab90-585e24f595bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_e3e61a96-c465-484d-8cb1-6986e75a18c8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_c78d7825-e292-457d-ab90-585e24f595bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_182bf381-7dbb-43cc-b421-caa72e07ace9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_25a94044-42ea-4afd-a13c-48c676c3efda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_182bf381-7dbb-43cc-b421-caa72e07ace9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_25a94044-42ea-4afd-a13c-48c676c3efda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a1dc251b-68be-4afa-b5b4-d369b3df8db5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_182bf381-7dbb-43cc-b421-caa72e07ace9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a1dc251b-68be-4afa-b5b4-d369b3df8db5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9098bed-38ab-4953-b389-6ad57de42731" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_65b44608-29bc-4043-abc3-aa07b62ff3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9098bed-38ab-4953-b389-6ad57de42731" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_65b44608-29bc-4043-abc3-aa07b62ff3a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9ca60ea2-64c2-4954-a56c-4273ef458882" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9098bed-38ab-4953-b389-6ad57de42731" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9ca60ea2-64c2-4954-a56c-4273ef458882" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2c272805-9e2a-4b61-918a-3cab738db785" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9098bed-38ab-4953-b389-6ad57de42731" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2c272805-9e2a-4b61-918a-3cab738db785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_34013373-f9ec-4e7a-9e75-b1e0a8c5f261" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9098bed-38ab-4953-b389-6ad57de42731" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_34013373-f9ec-4e7a-9e75-b1e0a8c5f261" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofEquity"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_756ee0ca-021e-404e-a0b0-6940319f4fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f043bb5f-6730-414b-b6ef-13d3b0a4730d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_756ee0ca-021e-404e-a0b0-6940319f4fbd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f043bb5f-6730-414b-b6ef-13d3b0a4730d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9a0ebb6d-ce83-417f-893c-efcd73d6ee58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_756ee0ca-021e-404e-a0b0-6940319f4fbd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9a0ebb6d-ce83-417f-893c-efcd73d6ee58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2738dafc-9f79-42e5-8759-e8569448c657" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_756ee0ca-021e-404e-a0b0-6940319f4fbd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2738dafc-9f79-42e5-8759-e8569448c657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2f2c108f-a11c-42dc-8309-6cc9f737eaee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_756ee0ca-021e-404e-a0b0-6940319f4fbd" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2f2c108f-a11c-42dc-8309-6cc9f737eaee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_dc8fe0b3-6815-4565-a0af-1459ef1557e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_fb804c04-41e9-49b0-ac8f-74a10319fe99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_dc8fe0b3-6815-4565-a0af-1459ef1557e1" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_fb804c04-41e9-49b0-ac8f-74a10319fe99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ef68c4f1-a7cd-4908-98e5-14700a17c99d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_dc8fe0b3-6815-4565-a0af-1459ef1557e1" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ef68c4f1-a7cd-4908-98e5-14700a17c99d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50b4ab73-488c-42d1-aa7b-31a9d63c084b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_dd09dc87-4c7d-4eb1-a863-822bfb2aeacc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50b4ab73-488c-42d1-aa7b-31a9d63c084b" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_dd09dc87-4c7d-4eb1-a863-822bfb2aeacc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_89a88ace-e2b0-4997-9498-b3c565b30fae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50b4ab73-488c-42d1-aa7b-31a9d63c084b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_89a88ace-e2b0-4997-9498-b3c565b30fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_0a383647-761b-4605-adaf-8b7fa46e1049" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50b4ab73-488c-42d1-aa7b-31a9d63c084b" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_0a383647-761b-4605-adaf-8b7fa46e1049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f68f1235-22f4-4c06-a97e-4689f1b447c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50b4ab73-488c-42d1-aa7b-31a9d63c084b" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f68f1235-22f4-4c06-a97e-4689f1b447c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_0db4e3ea-5c2c-4b24-985e-5a27b8cec2bb" xlink:href="jnj-20210404.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50b4ab73-488c-42d1-aa7b-31a9d63c084b" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_0db4e3ea-5c2c-4b24-985e-5a27b8cec2bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bb8f3caf-60d3-41fd-a2ac-3579519e6cae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50b4ab73-488c-42d1-aa7b-31a9d63c084b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bb8f3caf-60d3-41fd-a2ac-3579519e6cae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5370e2a3-6f93-4ded-acfb-b2823cf559f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50b4ab73-488c-42d1-aa7b-31a9d63c084b" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5370e2a3-6f93-4ded-acfb-b2823cf559f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ce150c08-c553-4d67-9e34-3cc539043899" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_NetIncomeLoss_ce150c08-c553-4d67-9e34-3cc539043899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1521d010-6bd4-45de-8011-e4926cbf27a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1521d010-6bd4-45de-8011-e4926cbf27a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d951bbc7-6acd-478f-b5a6-e5b5db1bbb23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_ShareBasedCompensation_d951bbc7-6acd-478f-b5a6-e5b5db1bbb23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_7cc67969-502f-4d70-82c9-00bb5b20d792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_AssetImpairmentCharges_7cc67969-502f-4d70-82c9-00bb5b20d792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3fc9e757-638b-4db0-9b4b-091eb127c6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3fc9e757-638b-4db0-9b4b-091eb127c6dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8058fd24-1e44-439f-ac37-3c05f3fd3a35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8058fd24-1e44-439f-ac37-3c05f3fd3a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aa24d9b4-eeda-4812-b04e-ad7d7909c70a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aa24d9b4-eeda-4812-b04e-ad7d7909c70a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_fc5ef6da-e981-4ad6-8604-6c9d6d9beae2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_fc5ef6da-e981-4ad6-8604-6c9d6d9beae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3f3fbab8-e970-4d57-a5f1-181b4611ab78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3f3fbab8-e970-4d57-a5f1-181b4611ab78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3a2e193e-37ac-46ae-884b-13e9ca31eac2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3a2e193e-37ac-46ae-884b-13e9ca31eac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6eec4dec-8072-45c7-b8c7-0f7a0a1e8176" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6eec4dec-8072-45c7-b8c7-0f7a0a1e8176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bafa2934-7c66-4d5c-8f3d-21c929b75aec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bafa2934-7c66-4d5c-8f3d-21c929b75aec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d705befa-7b46-4307-8a23-d64c21fce9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab0d1b56-e6ff-42c7-a1fc-4316d9c82013" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d705befa-7b46-4307-8a23-d64c21fce9fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_187119a2-892e-4cb0-94f2-fca635a644c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_69b8ae25-4548-4027-9639-03d8199acc15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_187119a2-892e-4cb0-94f2-fca635a644c1" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_69b8ae25-4548-4027-9639-03d8199acc15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_636c7ad2-2ef0-4f64-8b87-873cb2062327" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_187119a2-892e-4cb0-94f2-fca635a644c1" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_636c7ad2-2ef0-4f64-8b87-873cb2062327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_f1c37ae0-1e84-4bdc-8f37-5a1ce4082a2c" xlink:href="jnj-20210404.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_187119a2-892e-4cb0-94f2-fca635a644c1" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_f1c37ae0-1e84-4bdc-8f37-5a1ce4082a2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_4afb2fc1-a62e-4021-b834-870de42a5efa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_187119a2-892e-4cb0-94f2-fca635a644c1" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_4afb2fc1-a62e-4021-b834-870de42a5efa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_9d52ab73-3308-4d13-9276-56571df0f713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_187119a2-892e-4cb0-94f2-fca635a644c1" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_9d52ab73-3308-4d13-9276-56571df0f713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9ee911ae-00c3-4b8e-968b-fee964c82605" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_187119a2-892e-4cb0-94f2-fca635a644c1" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9ee911ae-00c3-4b8e-968b-fee964c82605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_b55265f5-286e-42a4-82e4-00bc3d9fefae" xlink:href="jnj-20210404.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_187119a2-892e-4cb0-94f2-fca635a644c1" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_b55265f5-286e-42a4-82e4-00bc3d9fefae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_a81ad232-f1d9-4efc-8b49-eb85840085ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_187119a2-892e-4cb0-94f2-fca635a644c1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_a81ad232-f1d9-4efc-8b49-eb85840085ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6987264c-fdea-4b4a-963a-077550efe685" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_187119a2-892e-4cb0-94f2-fca635a644c1" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6987264c-fdea-4b4a-963a-077550efe685" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20210404.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20210404.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20210404.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bb693921-fbcf-4c84-a07b-b83bcf962d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_ff397fc8-24de-4d80-abd8-d6e971e5e230" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_bb693921-fbcf-4c84-a07b-b83bcf962d9c" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_ff397fc8-24de-4d80-abd8-d6e971e5e230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b1c6a938-d678-45d2-bf23-c28b09bb68a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_bb693921-fbcf-4c84-a07b-b83bcf962d9c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b1c6a938-d678-45d2-bf23-c28b09bb68a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d99fc5ed-32af-42fe-bf08-e4ada74f2429" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_bb693921-fbcf-4c84-a07b-b83bcf962d9c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d99fc5ed-32af-42fe-bf08-e4ada74f2429" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwill"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7a57cfa1-47f4-481f-9634-614838333048" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1a61dc1d-50ff-435f-b1bf-267d9e751c11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7a57cfa1-47f4-481f-9634-614838333048" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1a61dc1d-50ff-435f-b1bf-267d9e751c11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b7a17fd1-303f-41bc-b23b-e0f50dd6d627" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7a57cfa1-47f4-481f-9634-614838333048" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b7a17fd1-303f-41bc-b23b-e0f50dd6d627" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_0cdc1b90-afa1-4d6e-8016-8d1226f3c394" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_90caf03d-6090-4e0b-876e-e1066662c0d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_0cdc1b90-afa1-4d6e-8016-8d1226f3c394" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_90caf03d-6090-4e0b-876e-e1066662c0d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_4dda2800-391f-411b-80ba-4da5da72a3b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_0cdc1b90-afa1-4d6e-8016-8d1226f3c394" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_4dda2800-391f-411b-80ba-4da5da72a3b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_a671dd15-b23b-4db8-90fe-ec08a928b22b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_e301021b-2902-406c-a6f5-73477f62ced6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_a671dd15-b23b-4db8-90fe-ec08a928b22b" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_e301021b-2902-406c-a6f5-73477f62ced6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_2b9c5343-81a2-4a20-a34d-446465a3448d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_a671dd15-b23b-4db8-90fe-ec08a928b22b" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_2b9c5343-81a2-4a20-a34d-446465a3448d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_b28cdd23-d6d3-4a75-85a4-652706d253be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_db5cc78c-ee09-47eb-8c31-3e4c13fa99a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_b28cdd23-d6d3-4a75-85a4-652706d253be" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_db5cc78c-ee09-47eb-8c31-3e4c13fa99a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_ae074a04-8a76-4602-958f-70d9a0121f3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_b28cdd23-d6d3-4a75-85a4-652706d253be" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_ae074a04-8a76-4602-958f-70d9a0121f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_fe6b5e3c-a289-43d1-8770-7f91cacc61ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_b28cdd23-d6d3-4a75-85a4-652706d253be" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_fe6b5e3c-a289-43d1-8770-7f91cacc61ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dbcddf55-c6a4-414d-8339-589a78386b90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b66341ec-49d8-457e-aa7c-ec29037debc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dbcddf55-c6a4-414d-8339-589a78386b90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b66341ec-49d8-457e-aa7c-ec29037debc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6f0e756e-e389-43a8-b042-17428f612737" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dbcddf55-c6a4-414d-8339-589a78386b90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6f0e756e-e389-43a8-b042-17428f612737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_913de894-5b02-4e30-8dbf-5979f9aa62ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dbcddf55-c6a4-414d-8339-589a78386b90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_913de894-5b02-4e30-8dbf-5979f9aa62ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_e3547c49-f1eb-4666-bb4c-7ac6d73e8d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_623f8b80-ecb4-4031-bd72-bdf1304a4eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_e3547c49-f1eb-4666-bb4c-7ac6d73e8d3d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_623f8b80-ecb4-4031-bd72-bdf1304a4eb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_825b6765-ac4f-49aa-ad28-d3292e8ad271" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_e3547c49-f1eb-4666-bb4c-7ac6d73e8d3d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_825b6765-ac4f-49aa-ad28-d3292e8ad271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_533d9d99-a3fd-4e85-9d9e-79204fdc7bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_e3547c49-f1eb-4666-bb4c-7ac6d73e8d3d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_533d9d99-a3fd-4e85-9d9e-79204fdc7bc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_a897864d-5349-4374-be34-16c11f6f172b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_dcf713ed-1c82-45b8-9950-2e921896707d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_a897864d-5349-4374-be34-16c11f6f172b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_dcf713ed-1c82-45b8-9950-2e921896707d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_36026f09-5eb8-4b9a-8ac0-56c24def0e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_a897864d-5349-4374-be34-16c11f6f172b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_36026f09-5eb8-4b9a-8ac0-56c24def0e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_c5627431-80be-4ee5-bf9e-eeb562e2cfa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_a897864d-5349-4374-be34-16c11f6f172b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_c5627431-80be-4ee5-bf9e-eeb562e2cfa3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20210404.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20210404.xsd#PensionsandOtherBenefitPlans"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2548be6d-9b86-48d2-bfc6-5c7596345f30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_87f6573f-5dd7-4299-a1a7-650325356832" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2548be6d-9b86-48d2-bfc6-5c7596345f30" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_87f6573f-5dd7-4299-a1a7-650325356832" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_408e2981-463c-40eb-b679-9d51cedb39ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2548be6d-9b86-48d2-bfc6-5c7596345f30" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_408e2981-463c-40eb-b679-9d51cedb39ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_012cd71a-7469-4871-b6c3-09c225c08ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2548be6d-9b86-48d2-bfc6-5c7596345f30" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_012cd71a-7469-4871-b6c3-09c225c08ff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5ed0f976-ea2b-4e1e-9ede-12cec308c883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2548be6d-9b86-48d2-bfc6-5c7596345f30" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5ed0f976-ea2b-4e1e-9ede-12cec308c883" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_79f09b28-9c14-4ff1-b481-0eef86289f33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2548be6d-9b86-48d2-bfc6-5c7596345f30" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_79f09b28-9c14-4ff1-b481-0eef86289f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_7f7b927a-c36d-40c6-bb1a-156aecd767ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2548be6d-9b86-48d2-bfc6-5c7596345f30" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_7f7b927a-c36d-40c6-bb1a-156aecd767ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20210404.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20210404.xsd#EarningsPerShare"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#EarningsPerShareTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0ba0e5ce-9f34-48c7-9075-7865e6e38c54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7219b6e4-be28-407d-b573-7b3eeb3e76b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0ba0e5ce-9f34-48c7-9075-7865e6e38c54" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7219b6e4-be28-407d-b573-7b3eeb3e76b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_b8605d26-44f5-439a-86c3-8f44e3aee739" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0ba0e5ce-9f34-48c7-9075-7865e6e38c54" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_b8605d26-44f5-439a-86c3-8f44e3aee739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0523d9af-a223-4638-9527-4a83a7ee2c16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0ba0e5ce-9f34-48c7-9075-7865e6e38c54" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0523d9af-a223-4638-9527-4a83a7ee2c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_abdc2d35-f31f-4086-972a-50f26582f524" xlink:href="jnj-20210404.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0ba0e5ce-9f34-48c7-9075-7865e6e38c54" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_abdc2d35-f31f-4086-972a-50f26582f524" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20210404.xsd#AcquisitionsandDivestitures"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20210404.xsd#LegalProceedings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#LegalProceedingsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20210404.xsd#Restructuring"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#RestructuringTables"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#RestructuringNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>jnj-20210404_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1a2ac66c-2667-4890-bd3c-b889272a48e4,g:4415be36-51dc-414c-a907-a89d836331d3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20210404.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended" id="i3791416bfd68496d844b496518b50402_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ff4d4451-173f-4af9-bd08-ddb15b8187fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_DocumentType_ff4d4451-173f-4af9-bd08-ddb15b8187fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_3fb5b4ef-0b42-4854-97cd-b4f16df25745" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_DocumentQuarterlyReport_3fb5b4ef-0b42-4854-97cd-b4f16df25745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_70648b3d-cfe5-44f9-9c32-7da6958e38fd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_DocumentPeriodEndDate_70648b3d-cfe5-44f9-9c32-7da6958e38fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_806762a1-7177-42a7-ac6b-591513d0d0d7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_DocumentTransitionReport_806762a1-7177-42a7-ac6b-591513d0d0d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_43a33eb9-c895-4431-b19c-0dc2189512bf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityFileNumber_43a33eb9-c895-4431-b19c-0dc2189512bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c28ba9c0-ba04-4a1a-95be-6cda1327150b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityRegistrantName_c28ba9c0-ba04-4a1a-95be-6cda1327150b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_815c53e5-cc11-41ae-a99f-ddd75c6ed193" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_815c53e5-cc11-41ae-a99f-ddd75c6ed193" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a113127d-f91c-4e82-854c-035bb0f2e576" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityTaxIdentificationNumber_a113127d-f91c-4e82-854c-035bb0f2e576" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c8ca8674-f2a5-4747-b927-934d96f35e89" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityAddressAddressLine1_c8ca8674-f2a5-4747-b927-934d96f35e89" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_228cbba3-f94a-41ca-8074-5c129beb6b4f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityAddressCityOrTown_228cbba3-f94a-41ca-8074-5c129beb6b4f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_be3b8652-0ac0-44d8-98e1-975b9e8cd474" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityAddressStateOrProvince_be3b8652-0ac0-44d8-98e1-975b9e8cd474" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_79d15c4a-3ebe-4bf5-a223-73ed5370dde8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityAddressPostalZipCode_79d15c4a-3ebe-4bf5-a223-73ed5370dde8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0a6b5bdc-c9dc-42e5-8bfa-35f6fcd5e244" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_CityAreaCode_0a6b5bdc-c9dc-42e5-8bfa-35f6fcd5e244" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a1eadc1f-4e6a-4215-9565-5a3191d5779e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_LocalPhoneNumber_a1eadc1f-4e6a-4215-9565-5a3191d5779e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7945e949-0bf2-4557-939a-58705c4ae5c3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityCurrentReportingStatus_7945e949-0bf2-4557-939a-58705c4ae5c3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_80d23260-7ca5-4c43-8b22-0acc15788ba5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityInteractiveDataCurrent_80d23260-7ca5-4c43-8b22-0acc15788ba5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_42f9c72c-a161-403f-86ff-7f4bbe62fa38" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityFilerCategory_42f9c72c-a161-403f-86ff-7f4bbe62fa38" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ca0aecd7-40ec-4c57-8d29-23591d6728d5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntitySmallBusiness_ca0aecd7-40ec-4c57-8d29-23591d6728d5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8b61313b-4743-4c97-9823-86255dc7ac31" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityEmergingGrowthCompany_8b61313b-4743-4c97-9823-86255dc7ac31" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8d9cbc1a-b209-4167-8554-a3b80300627d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityShellCompany_8d9cbc1a-b209-4167-8554-a3b80300627d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6b7bb619-4ea1-46be-8a12-b96a0d1fc7f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_Security12bTitle_6b7bb619-4ea1-46be-8a12-b96a0d1fc7f4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d21ef0f3-1a1d-489c-b543-ed591955c1cc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_TradingSymbol_d21ef0f3-1a1d-489c-b543-ed591955c1cc" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c80127a7-c9c3-4fdb-a07b-24918fe75ee7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_SecurityExchangeName_c80127a7-c9c3-4fdb-a07b-24918fe75ee7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0b05f2ad-791e-48f6-bbb5-0dfa9420f5d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0b05f2ad-791e-48f6-bbb5-0dfa9420f5d8" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d4630cb1-35fe-4f7a-a62f-99cec164b8dc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityCentralIndexKey_d4630cb1-35fe-4f7a-a62f-99cec164b8dc" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7e238b9a-d8c5-4f98-9b69-7388a2c72a7c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_CurrentFiscalYearEndDate_7e238b9a-d8c5-4f98-9b69-7388a2c72a7c" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0934e737-744e-42d7-8d52-e9f5bae5870b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_DocumentFiscalYearFocus_0934e737-744e-42d7-8d52-e9f5bae5870b" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8175de5b-9803-49d6-ae9e-eddfa80a494a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8175de5b-9803-49d6-ae9e-eddfa80a494a" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2a30e3d9-1e7f-45a0-a197-2a227069340a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_AmendmentFlag_2a30e3d9-1e7f-45a0-a197-2a227069340a" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_baee2fbc-d2a7-4962-9722-ddb313cd5f85" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntitiesTable_baee2fbc-d2a7-4962-9722-ddb313cd5f85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_375d938f-a9e8-483e-86b5-3ca3185a765a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_baee2fbc-d2a7-4962-9722-ddb313cd5f85" xlink:to="loc_us-gaap_StatementClassOfStockAxis_375d938f-a9e8-483e-86b5-3ca3185a765a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_375d938f-a9e8-483e-86b5-3ca3185a765a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_375d938f-a9e8-483e-86b5-3ca3185a765a" xlink:to="loc_us-gaap_ClassOfStockDomain_375d938f-a9e8-483e-86b5-3ca3185a765a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_375d938f-a9e8-483e-86b5-3ca3185a765a" xlink:to="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f9e8497f-646e-45e9-867b-52ec13c8ced2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:to="loc_us-gaap_CommonStockMember_f9e8497f-646e-45e9-867b-52ec13c8ced2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member_fd0c36e2-1a82-4f17-acb9-36af50c4ba7c" xlink:href="jnj-20210404.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:to="loc_jnj_A0.250NotesDue2022Member_fd0c36e2-1a82-4f17-acb9-36af50c4ba7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_1fc64329-ed71-4c92-bb78-f7f83304325c" xlink:href="jnj-20210404.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:to="loc_jnj_A0.650NotesDue2024Member_1fc64329-ed71-4c92-bb78-f7f83304325c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_86fe2876-363f-4975-9488-0d8f37e05a99" xlink:href="jnj-20210404.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:to="loc_jnj_A5.50NotesDue2024Member_86fe2876-363f-4975-9488-0d8f37e05a99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_61bc4ca6-cc6c-4491-8155-e01a255d2831" xlink:href="jnj-20210404.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:to="loc_jnj_A1.150NotesDue2028Member_61bc4ca6-cc6c-4491-8155-e01a255d2831" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_7218af75-7c41-4c45-a066-d362c052b869" xlink:href="jnj-20210404.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:to="loc_jnj_A1.650NotesDue2035Member_7218af75-7c41-4c45-a066-d362c052b869" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="ieb652b76342f41dc9990db5473574a51_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ief7ee2d2b17c4ac3b241565e06ed2491_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofEarnings"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended" id="i3397175f55a04fe6807d49604db22371_ConsolidatedStatementsofEarnings"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended" id="i3d29ef320b524bfc9a42ab600abfb584_ConsolidatedStatementsofComprehensiveIncome"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended" id="i61905b7e7a3f426a8961b9e8b6635961_ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="idd16566bef2a415aa8f3a18b008164ce_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3fc10a0a-11fd-4b28-8222-fe761bfa2155" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3fc10a0a-11fd-4b28-8222-fe761bfa2155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_199f17e0-2796-4964-9b02-45f9409d2305" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_NetIncomeLoss_199f17e0-2796-4964-9b02-45f9409d2305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_145d52b6-2288-419b-b786-253cea0147f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_DividendsCommonStockCash_145d52b6-2288-419b-b786-253cea0147f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_e4e7ca42-6bfd-4796-a1e1-29ea0e916bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_e4e7ca42-6bfd-4796-a1e1-29ea0e916bb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_72142805-30f4-485b-9cd4-b15dd7e22e74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_72142805-30f4-485b-9cd4-b15dd7e22e74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e42470d-3d86-457d-a5a1-cca69bd0522e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e42470d-3d86-457d-a5a1-cca69bd0522e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9c0c34a5-f048-4067-88ff-81d2c727562b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bfea3c11-4be7-458e-b824-802e1ed4c741" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_StatementTable_bfea3c11-4be7-458e-b824-802e1ed4c741" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cdfaca74-f589-4161-9e1a-c213cd44b9a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bfea3c11-4be7-458e-b824-802e1ed4c741" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cdfaca74-f589-4161-9e1a-c213cd44b9a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cdfaca74-f589-4161-9e1a-c213cd44b9a8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cdfaca74-f589-4161-9e1a-c213cd44b9a8" xlink:to="loc_us-gaap_EquityComponentDomain_cdfaca74-f589-4161-9e1a-c213cd44b9a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_718bd21b-9a2b-43a2-b279-21fd40e58d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cdfaca74-f589-4161-9e1a-c213cd44b9a8" xlink:to="loc_us-gaap_EquityComponentDomain_718bd21b-9a2b-43a2-b279-21fd40e58d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ce6461c5-6536-438a-9618-a558b033136d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_718bd21b-9a2b-43a2-b279-21fd40e58d9b" xlink:to="loc_us-gaap_RetainedEarningsMember_ce6461c5-6536-438a-9618-a558b033136d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_65b79a2c-64bc-4185-b896-698bd7ff0306" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_718bd21b-9a2b-43a2-b279-21fd40e58d9b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_65b79a2c-64bc-4185-b896-698bd7ff0306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9ffeaf04-aea7-48a7-904b-c3a1df582808" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_718bd21b-9a2b-43a2-b279-21fd40e58d9b" xlink:to="loc_us-gaap_CommonStockMember_9ffeaf04-aea7-48a7-904b-c3a1df582808" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_0a9125e4-3a9e-4203-912d-acf67e4ff653" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_718bd21b-9a2b-43a2-b279-21fd40e58d9b" xlink:to="loc_us-gaap_TreasuryStockMember_0a9125e4-3a9e-4203-912d-acf67e4ff653" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended" id="i6e112a648b604200a8fb454f690b4adc_ConsolidatedStatementsofEquityParenthetical"/>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i6a5d85b9030a4c029b597f3956693710_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20210404.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i1661f31935f04ca0a8fd3aba6dc7cd8a_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20210404.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i29862a917c474ad086d4a0c5f1bf5bdd_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20210404.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended" id="icf82336329a345df8614b2c3a1b29659_Inventories"/>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended" id="i4df27f2dd0fe4444967c951580beb821_InventoriesTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#InventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended" id="i999850d0d0364f688c80ea0af099c293_InventoriesDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwill"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended" id="i7d744c82df3142a0adba6cf89d8b45e3_IntangibleAssetsandGoodwill"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended" id="i46ea06aa3bb649deac6b23a1cffc119e_IntangibleAssetsandGoodwillTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="iffde4b5543f74dae8954ddd655d48251_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_d4103580-c5e6-46a7-afe3-9910e4c9b91e" xlink:href="jnj-20210404.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_019859c5-1433-4bbf-9c04-0de90f8718ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_d4103580-c5e6-46a7-afe3-9910e4c9b91e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_019859c5-1433-4bbf-9c04-0de90f8718ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ea44ccb6-19e1-4d4b-9ae9-a0f30d6bcf1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_019859c5-1433-4bbf-9c04-0de90f8718ee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ea44ccb6-19e1-4d4b-9ae9-a0f30d6bcf1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ec35fab9-ca76-4291-9438-0b714648b058" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ea44ccb6-19e1-4d4b-9ae9-a0f30d6bcf1f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ec35fab9-ca76-4291-9438-0b714648b058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_15c68125-6a56-4406-9afd-7d46452fe878" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ea44ccb6-19e1-4d4b-9ae9-a0f30d6bcf1f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_15c68125-6a56-4406-9afd-7d46452fe878" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d5a0262d-bee1-4dfa-a05c-e9475bab471b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ea44ccb6-19e1-4d4b-9ae9-a0f30d6bcf1f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d5a0262d-bee1-4dfa-a05c-e9475bab471b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ccffe8ca-3d9b-47c9-be7a-e61f619a918e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_019859c5-1433-4bbf-9c04-0de90f8718ee" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ccffe8ca-3d9b-47c9-be7a-e61f619a918e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb47d9c9-1a57-476e-a323-7d5f969c965d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ccffe8ca-3d9b-47c9-be7a-e61f619a918e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb47d9c9-1a57-476e-a323-7d5f969c965d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3b7c64ac-c7fb-488c-ad9e-555d82f7ff07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ccffe8ca-3d9b-47c9-be7a-e61f619a918e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3b7c64ac-c7fb-488c-ad9e-555d82f7ff07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_103ccd1d-115c-49f0-b7a1-c67ce374a8eb" xlink:href="jnj-20210404.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_d4103580-c5e6-46a7-afe3-9910e4c9b91e" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_103ccd1d-115c-49f0-b7a1-c67ce374a8eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fb2bb52-7a45-4beb-9dc2-0cd8b2782a46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_103ccd1d-115c-49f0-b7a1-c67ce374a8eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fb2bb52-7a45-4beb-9dc2-0cd8b2782a46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fb2bb52-7a45-4beb-9dc2-0cd8b2782a46_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fb2bb52-7a45-4beb-9dc2-0cd8b2782a46" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fb2bb52-7a45-4beb-9dc2-0cd8b2782a46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a5256c4-64a4-4c82-a03b-df4ecb90ed6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fb2bb52-7a45-4beb-9dc2-0cd8b2782a46" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a5256c4-64a4-4c82-a03b-df4ecb90ed6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_a00fdf62-69c3-4350-a199-b3f1ea0648a5" xlink:href="jnj-20210404.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a5256c4-64a4-4c82-a03b-df4ecb90ed6f" xlink:to="loc_jnj_PatentsAndTrademarksMember_a00fdf62-69c3-4350-a199-b3f1ea0648a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_3e63ab6e-d4e1-451c-b555-973fa84709d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a5256c4-64a4-4c82-a03b-df4ecb90ed6f" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_3e63ab6e-d4e1-451c-b555-973fa84709d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5f19a0a4-ed8a-4057-9862-692de92ef5d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_103ccd1d-115c-49f0-b7a1-c67ce374a8eb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5f19a0a4-ed8a-4057-9862-692de92ef5d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5f19a0a4-ed8a-4057-9862-692de92ef5d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5f19a0a4-ed8a-4057-9862-692de92ef5d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5f19a0a4-ed8a-4057-9862-692de92ef5d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96931810-6be4-498b-ae23-176a14e3e55d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5f19a0a4-ed8a-4057-9862-692de92ef5d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96931810-6be4-498b-ae23-176a14e3e55d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_cadd8caf-0261-47d9-a6e0-3c4838e8080d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96931810-6be4-498b-ae23-176a14e3e55d" xlink:to="loc_us-gaap_TrademarksMember_cadd8caf-0261-47d9-a6e0-3c4838e8080d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_1d2d1765-01a4-40d4-95cd-b03b53a8630e" xlink:href="jnj-20210404.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96931810-6be4-498b-ae23-176a14e3e55d" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_1d2d1765-01a4-40d4-95cd-b03b53a8630e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended" id="i010dd8dccbe0453a882a5e3802bfab91_IntangibleAssetsandGoodwillGoodwillBySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_219402ed-4eef-42dc-9ff3-7d1e61913eed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_19202ebe-e090-4a3f-a3d5-14a74c42b997" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_219402ed-4eef-42dc-9ff3-7d1e61913eed" xlink:to="loc_us-gaap_GoodwillRollForward_19202ebe-e090-4a3f-a3d5-14a74c42b997" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8141fdb2-595d-46f5-a34c-5685c0afb0c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_19202ebe-e090-4a3f-a3d5-14a74c42b997" xlink:to="loc_us-gaap_Goodwill_8141fdb2-595d-46f5-a34c-5685c0afb0c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_6edfc0e3-d211-4aa5-ac11-c375287efecc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_19202ebe-e090-4a3f-a3d5-14a74c42b997" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_6edfc0e3-d211-4aa5-ac11-c375287efecc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_0f6bc09d-c7f1-44e6-a9d1-f555d55f0370" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_19202ebe-e090-4a3f-a3d5-14a74c42b997" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_0f6bc09d-c7f1-44e6-a9d1-f555d55f0370" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fd3bd095-2e9b-451c-85ef-d69b647edaba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5f15a458-1ce5-4742-bad6-70d034b17841" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_219402ed-4eef-42dc-9ff3-7d1e61913eed" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5f15a458-1ce5-4742-bad6-70d034b17841" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b209e4bc-0879-4f0e-acab-b0614664c1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5f15a458-1ce5-4742-bad6-70d034b17841" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b209e4bc-0879-4f0e-acab-b0614664c1f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b209e4bc-0879-4f0e-acab-b0614664c1f2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b209e4bc-0879-4f0e-acab-b0614664c1f2" xlink:to="loc_us-gaap_SegmentDomain_b209e4bc-0879-4f0e-acab-b0614664c1f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_90dc8320-8d8b-4520-ad98-4c9538975bab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b209e4bc-0879-4f0e-acab-b0614664c1f2" xlink:to="loc_us-gaap_SegmentDomain_90dc8320-8d8b-4520-ad98-4c9538975bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_caa6566b-728e-46ff-a8ca-4bb741fe9a4a" xlink:href="jnj-20210404.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_90dc8320-8d8b-4520-ad98-4c9538975bab" xlink:to="loc_jnj_ConsumerMember_caa6566b-728e-46ff-a8ca-4bb741fe9a4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_4ccea77e-0c64-4a60-9e8b-0d5f432a113b" xlink:href="jnj-20210404.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_90dc8320-8d8b-4520-ad98-4c9538975bab" xlink:to="loc_jnj_PharmaceuticalMember_4ccea77e-0c64-4a60-9e8b-0d5f432a113b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_49c42f1b-8d71-4d4e-bc39-781602f6e5ba" xlink:href="jnj-20210404.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_90dc8320-8d8b-4520-ad98-4c9538975bab" xlink:to="loc_jnj_MedicalDevicesMember_49c42f1b-8d71-4d4e-bc39-781602f6e5ba" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended" id="ida31a958dabd4d0b821938fddd027f11_IntangibleAssetsandGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c05b71a7-d964-4919-aa14-2263a1c2ba80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_be7780ab-c1e1-4240-b5ae-4ffc8b8609c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c05b71a7-d964-4919-aa14-2263a1c2ba80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_be7780ab-c1e1-4240-b5ae-4ffc8b8609c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_351afcce-ec81-49f3-9551-c0de5e37c3d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c05b71a7-d964-4919-aa14-2263a1c2ba80" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_351afcce-ec81-49f3-9551-c0de5e37c3d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02b7f9df-897d-488c-b570-57b4f993cd40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c05b71a7-d964-4919-aa14-2263a1c2ba80" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02b7f9df-897d-488c-b570-57b4f993cd40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_470775d8-e57f-4aea-9fe2-2fde7c79186a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02b7f9df-897d-488c-b570-57b4f993cd40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_470775d8-e57f-4aea-9fe2-2fde7c79186a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_470775d8-e57f-4aea-9fe2-2fde7c79186a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_470775d8-e57f-4aea-9fe2-2fde7c79186a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_470775d8-e57f-4aea-9fe2-2fde7c79186a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7229547-b2e9-4dd4-8995-d391495aa477" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_470775d8-e57f-4aea-9fe2-2fde7c79186a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7229547-b2e9-4dd4-8995-d391495aa477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_7945435f-2244-4d41-a18d-80a7ffdc4e97" xlink:href="jnj-20210404.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7229547-b2e9-4dd4-8995-d391495aa477" xlink:to="loc_jnj_PatentsAndTrademarksMember_7945435f-2244-4d41-a18d-80a7ffdc4e97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_2ffdeaee-ab94-4948-b9ab-2ff54ce01188" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7229547-b2e9-4dd4-8995-d391495aa477" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_2ffdeaee-ab94-4948-b9ab-2ff54ce01188" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="extended" id="i34f8f945a0164d7e9f8003ef30e84ced_IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended" id="icfeef66098734c448c6b96d53eb17f1a_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i2848512bc03b4343bc5e49855cb2e501_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i1083a5c146524216b88a3bba1bd42507_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_9331ebe9-fe48-470a-8229-27a21cfcfef6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_9331ebe9-fe48-470a-8229-27a21cfcfef6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_71a806b0-a0e4-403d-8ee9-c4312f36e22d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_DerivativeNotionalAmount_71a806b0-a0e4-403d-8ee9-c4312f36e22d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_d2a87ca7-98b1-4aa6-9c6f-65e973e8e7af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_d2a87ca7-98b1-4aa6-9c6f-65e973e8e7af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_4e6fd776-25b4-4950-9dea-e811b029062f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_4e6fd776-25b4-4950-9dea-e811b029062f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_79f544f6-4f4f-4e1e-957a-abe7e2a31e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_79f544f6-4f4f-4e1e-957a-abe7e2a31e1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_46242c6e-afe7-4c97-be2b-f60bf1cea675" xlink:href="jnj-20210404.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_46242c6e-afe7-4c97-be2b-f60bf1cea675" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_06e8ffeb-e60e-47c2-a151-1b803f906505" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_06e8ffeb-e60e-47c2-a151-1b803f906505" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_807fd7aa-7039-4051-8e5d-bd2cba501929" xlink:href="jnj-20210404.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_807fd7aa-7039-4051-8e5d-bd2cba501929" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_e0d1fd01-776a-4d8c-9dd1-798ef398d0de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_ShortTermBorrowings_e0d1fd01-776a-4d8c-9dd1-798ef398d0de" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_425e78b8-6ec3-4014-90c9-7e7ea90328ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_425e78b8-6ec3-4014-90c9-7e7ea90328ba" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_1d97f0df-3cc4-4078-a4c0-ba2eff4d4a92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_DebtInstrumentTerm_1d97f0df-3cc4-4078-a4c0-ba2eff4d4a92" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_9ccb600e-107a-4f6c-a49c-d72cd2e8d7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_9ccb600e-107a-4f6c-a49c-d72cd2e8d7ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9ccb600e-107a-4f6c-a49c-d72cd2e8d7ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_9ccb600e-107a-4f6c-a49c-d72cd2e8d7ca" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9ccb600e-107a-4f6c-a49c-d72cd2e8d7ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_916bc0ab-b1db-4a61-b538-6cfbaf9790c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_9ccb600e-107a-4f6c-a49c-d72cd2e8d7ca" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_916bc0ab-b1db-4a61-b538-6cfbaf9790c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_34018127-432c-44f2-a7e9-aef74fbcba1f" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_916bc0ab-b1db-4a61-b538-6cfbaf9790c8" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_34018127-432c-44f2-a7e9-aef74fbcba1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_63be8fc7-59f2-4952-9b1f-4e43a92a2d81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_63be8fc7-59f2-4952-9b1f-4e43a92a2d81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_63be8fc7-59f2-4952-9b1f-4e43a92a2d81_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_63be8fc7-59f2-4952-9b1f-4e43a92a2d81" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_63be8fc7-59f2-4952-9b1f-4e43a92a2d81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bcb4554-cbb6-45c9-9d9b-c7e9b3b013da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_63be8fc7-59f2-4952-9b1f-4e43a92a2d81" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bcb4554-cbb6-45c9-9d9b-c7e9b3b013da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_4e0902a3-7ab4-45bd-8f8e-2a8df4f926d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bcb4554-cbb6-45c9-9d9b-c7e9b3b013da" xlink:to="loc_us-gaap_EquitySecuritiesMember_4e0902a3-7ab4-45bd-8f8e-2a8df4f926d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a1f485b7-e551-49c6-94b4-4d5f6c4d8fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a1f485b7-e551-49c6-94b4-4d5f6c4d8fbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a1f485b7-e551-49c6-94b4-4d5f6c4d8fbe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a1f485b7-e551-49c6-94b4-4d5f6c4d8fbe" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a1f485b7-e551-49c6-94b4-4d5f6c4d8fbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c6f735d4-f5f9-419f-9463-9dd217a5f30f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a1f485b7-e551-49c6-94b4-4d5f6c4d8fbe" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c6f735d4-f5f9-419f-9463-9dd217a5f30f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d458ce2f-82b7-4df9-859e-01bbbb2614f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c6f735d4-f5f9-419f-9463-9dd217a5f30f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d458ce2f-82b7-4df9-859e-01bbbb2614f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_4a4079ac-e8b9-4551-840e-1696008cf50a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c6f735d4-f5f9-419f-9463-9dd217a5f30f" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_4a4079ac-e8b9-4551-840e-1696008cf50a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_255ba6f8-27ac-410f-b7cc-cfc9d5d0c96d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_255ba6f8-27ac-410f-b7cc-cfc9d5d0c96d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_255ba6f8-27ac-410f-b7cc-cfc9d5d0c96d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_255ba6f8-27ac-410f-b7cc-cfc9d5d0c96d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_255ba6f8-27ac-410f-b7cc-cfc9d5d0c96d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_71fdd901-dabe-4f05-8e8c-56654c42dce1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_255ba6f8-27ac-410f-b7cc-cfc9d5d0c96d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_71fdd901-dabe-4f05-8e8c-56654c42dce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c8ad3d85-9302-467e-80b6-cf3ab47c20ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_71fdd901-dabe-4f05-8e8c-56654c42dce1" xlink:to="loc_us-gaap_CommercialPaperMember_c8ad3d85-9302-467e-80b6-cf3ab47c20ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended" id="i67b6be998ed546d8bbee1301cec1ebfc_FairValueMeasurementsSummaryofDerivativeActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_33537c0d-67b7-4b53-a15a-6d32d745faf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_3f3743e4-b2b2-4e00-a5c3-54d1d8d54178" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_33537c0d-67b7-4b53-a15a-6d32d745faf8" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_3f3743e4-b2b2-4e00-a5c3-54d1d8d54178" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_f4b3ee9b-d761-4570-9a66-f8eac03c487b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_33537c0d-67b7-4b53-a15a-6d32d745faf8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_f4b3ee9b-d761-4570-9a66-f8eac03c487b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_dbc92215-4f79-4dd3-8b6f-f70010c439c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_33537c0d-67b7-4b53-a15a-6d32d745faf8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_dbc92215-4f79-4dd3-8b6f-f70010c439c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_61cc2c49-b3ab-4746-a780-e673f988f9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_33537c0d-67b7-4b53-a15a-6d32d745faf8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_61cc2c49-b3ab-4746-a780-e673f988f9cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_de346e05-4dab-4143-b97c-c3e6d8511c1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_61cc2c49-b3ab-4746-a780-e673f988f9cd" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_de346e05-4dab-4143-b97c-c3e6d8511c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_de346e05-4dab-4143-b97c-c3e6d8511c1e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_de346e05-4dab-4143-b97c-c3e6d8511c1e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_de346e05-4dab-4143-b97c-c3e6d8511c1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_814eb8a1-21fe-42e0-a393-7f7072e65506" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_de346e05-4dab-4143-b97c-c3e6d8511c1e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_814eb8a1-21fe-42e0-a393-7f7072e65506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_19bca4a7-23bc-46fb-86a1-637f4228e5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_814eb8a1-21fe-42e0-a393-7f7072e65506" xlink:to="loc_us-gaap_FairValueHedgingMember_19bca4a7-23bc-46fb-86a1-637f4228e5ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_c2bf07dd-33e5-4f18-87a7-e6e425234983" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_814eb8a1-21fe-42e0-a393-7f7072e65506" xlink:to="loc_us-gaap_CashFlowHedgingMember_c2bf07dd-33e5-4f18-87a7-e6e425234983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_47ac3fa5-4d5c-46db-83aa-f1591cc41c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_61cc2c49-b3ab-4746-a780-e673f988f9cd" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_47ac3fa5-4d5c-46db-83aa-f1591cc41c9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_47ac3fa5-4d5c-46db-83aa-f1591cc41c9f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_47ac3fa5-4d5c-46db-83aa-f1591cc41c9f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_47ac3fa5-4d5c-46db-83aa-f1591cc41c9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4a966886-55c3-408e-9da9-65175e75d992" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_47ac3fa5-4d5c-46db-83aa-f1591cc41c9f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4a966886-55c3-408e-9da9-65175e75d992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_4c947897-78a2-4b5e-80de-9f923657388b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4a966886-55c3-408e-9da9-65175e75d992" xlink:to="loc_us-gaap_InterestRateContractMember_4c947897-78a2-4b5e-80de-9f923657388b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_6fa11ae8-d633-4785-934b-08e572c6723c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4a966886-55c3-408e-9da9-65175e75d992" xlink:to="loc_us-gaap_ForeignExchangeContractMember_6fa11ae8-d633-4785-934b-08e572c6723c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_c02009da-7d7f-4231-a4d8-42f57826bb2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4a966886-55c3-408e-9da9-65175e75d992" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_c02009da-7d7f-4231-a4d8-42f57826bb2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_aeb48961-1dde-476c-b1e6-bc1abb241f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_61cc2c49-b3ab-4746-a780-e673f988f9cd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_aeb48961-1dde-476c-b1e6-bc1abb241f7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aeb48961-1dde-476c-b1e6-bc1abb241f7e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_aeb48961-1dde-476c-b1e6-bc1abb241f7e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aeb48961-1dde-476c-b1e6-bc1abb241f7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_aeb48961-1dde-476c-b1e6-bc1abb241f7e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_23c23bb6-ddab-4b17-9c35-35e13d5a5d75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:to="loc_us-gaap_SalesMember_23c23bb6-ddab-4b17-9c35-35e13d5a5d75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_7b95c37b-36d6-49d6-b947-0f31573524ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:to="loc_us-gaap_CostOfSalesMember_7b95c37b-36d6-49d6-b947-0f31573524ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_92645ec9-4abd-4265-b1a4-77bf9cd2ba34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_92645ec9-4abd-4265-b1a4-77bf9cd2ba34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_12eeb092-99fb-4f11-bf4a-1a04b6f9d45e" xlink:href="jnj-20210404.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_12eeb092-99fb-4f11-bf4a-1a04b6f9d45e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_cdb5d93a-c83a-4c57-a432-bd4db4049741" xlink:href="jnj-20210404.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_cdb5d93a-c83a-4c57-a432-bd4db4049741" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="ie8019dda34394edba5437f3d696b3d59_FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5a0b0a65-0f89-411f-aad4-720ba58b89e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_1dd4bbcc-b5a7-414f-8db1-f30225333a79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5a0b0a65-0f89-411f-aad4-720ba58b89e4" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_1dd4bbcc-b5a7-414f-8db1-f30225333a79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99e462ae-fb38-45d2-a0a1-73129207fcfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5a0b0a65-0f89-411f-aad4-720ba58b89e4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99e462ae-fb38-45d2-a0a1-73129207fcfe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_07d310a5-fb80-4704-b16f-31b5c4191588" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99e462ae-fb38-45d2-a0a1-73129207fcfe" xlink:to="loc_us-gaap_HedgingDesignationAxis_07d310a5-fb80-4704-b16f-31b5c4191588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_07d310a5-fb80-4704-b16f-31b5c4191588_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_07d310a5-fb80-4704-b16f-31b5c4191588" xlink:to="loc_us-gaap_HedgingDesignationDomain_07d310a5-fb80-4704-b16f-31b5c4191588_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e13ba3ae-2783-4c78-98f0-095729f1f85c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_07d310a5-fb80-4704-b16f-31b5c4191588" xlink:to="loc_us-gaap_HedgingDesignationDomain_e13ba3ae-2783-4c78-98f0-095729f1f85c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_646d89ea-32d8-43eb-b8b0-4564ab9e7eba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e13ba3ae-2783-4c78-98f0-095729f1f85c" xlink:to="loc_us-gaap_NondesignatedMember_646d89ea-32d8-43eb-b8b0-4564ab9e7eba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f3d46499-d32b-422c-826d-e2843949e710" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99e462ae-fb38-45d2-a0a1-73129207fcfe" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f3d46499-d32b-422c-826d-e2843949e710" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f3d46499-d32b-422c-826d-e2843949e710_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f3d46499-d32b-422c-826d-e2843949e710" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f3d46499-d32b-422c-826d-e2843949e710_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_65d6c88f-0484-4dcc-ac77-7929531c0aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f3d46499-d32b-422c-826d-e2843949e710" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_65d6c88f-0484-4dcc-ac77-7929531c0aa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d5d4366c-f19c-4fb2-860e-3fb45b118dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_65d6c88f-0484-4dcc-ac77-7929531c0aa4" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d5d4366c-f19c-4fb2-860e-3fb45b118dc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_71f7a009-9c3a-4350-b328-9e8c1bb34a43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99e462ae-fb38-45d2-a0a1-73129207fcfe" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_71f7a009-9c3a-4350-b328-9e8c1bb34a43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_71f7a009-9c3a-4350-b328-9e8c1bb34a43_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_71f7a009-9c3a-4350-b328-9e8c1bb34a43" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_71f7a009-9c3a-4350-b328-9e8c1bb34a43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a4ff8a73-f54a-4fa0-b69c-23d38bf7eb67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_71f7a009-9c3a-4350-b328-9e8c1bb34a43" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a4ff8a73-f54a-4fa0-b69c-23d38bf7eb67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_da81ac33-59b8-4095-8607-7f2607cf1b7e" xlink:href="jnj-20210404.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a4ff8a73-f54a-4fa0-b69c-23d38bf7eb67" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_da81ac33-59b8-4095-8607-7f2607cf1b7e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="i11b69dabb8bd483782792345353c99bd_FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b9db5e8c-c73d-41bf-b2b3-270cf609cc7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_5486b5eb-13aa-4370-8361-5484ef18b737" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b9db5e8c-c73d-41bf-b2b3-270cf609cc7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_5486b5eb-13aa-4370-8361-5484ef18b737" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_81ea48a6-1524-4e65-9ae2-c221199c11dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b9db5e8c-c73d-41bf-b2b3-270cf609cc7f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_81ea48a6-1524-4e65-9ae2-c221199c11dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_db3e3616-f8af-469d-b791-63e661db760b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b9db5e8c-c73d-41bf-b2b3-270cf609cc7f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_db3e3616-f8af-469d-b791-63e661db760b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_77521711-e091-4c81-a8a9-0e947b258765" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_db3e3616-f8af-469d-b791-63e661db760b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_77521711-e091-4c81-a8a9-0e947b258765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_77521711-e091-4c81-a8a9-0e947b258765_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_77521711-e091-4c81-a8a9-0e947b258765" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_77521711-e091-4c81-a8a9-0e947b258765_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d6a9f918-564d-4972-bdca-e3023cb1b2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_77521711-e091-4c81-a8a9-0e947b258765" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d6a9f918-564d-4972-bdca-e3023cb1b2c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_48f3be11-3d02-4462-a86b-5e0360c2799f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d6a9f918-564d-4972-bdca-e3023cb1b2c3" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_48f3be11-3d02-4462-a86b-5e0360c2799f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b26c6c75-d2e3-446b-8926-fc66c73e6cc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_db3e3616-f8af-469d-b791-63e661db760b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b26c6c75-d2e3-446b-8926-fc66c73e6cc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b26c6c75-d2e3-446b-8926-fc66c73e6cc8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b26c6c75-d2e3-446b-8926-fc66c73e6cc8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b26c6c75-d2e3-446b-8926-fc66c73e6cc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_48e7e881-4fb9-45db-852f-ad367b8878a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b26c6c75-d2e3-446b-8926-fc66c73e6cc8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_48e7e881-4fb9-45db-852f-ad367b8878a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_12c68a54-99bf-47bb-93f2-89acc63dcbfb" xlink:href="jnj-20210404.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_48e7e881-4fb9-45db-852f-ad367b8878a4" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_12c68a54-99bf-47bb-93f2-89acc63dcbfb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended" id="if33c544653554c04b9a14a6c75dbac99_FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_61a5bb5e-a6bf-4620-8fd6-a4c735302f28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_61a5bb5e-a6bf-4620-8fd6-a4c735302f28" xlink:to="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_42aaea83-2232-459a-a17e-4b69a75373de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_42aaea83-2232-459a-a17e-4b69a75373de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_a625eb2c-e32c-4964-b808-c01662f17a74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_a625eb2c-e32c-4964-b808-c01662f17a74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_025569ba-e2f3-47e5-a168-47e7fe2a6d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:to="loc_us-gaap_EquityFairValueAdjustment_025569ba-e2f3-47e5-a168-47e7fe2a6d7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_5194c16f-355b-4cbc-9d07-0e7adef7294e" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_5194c16f-355b-4cbc-9d07-0e7adef7294e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_c90202cc-e2a0-4ca3-9e56-46a982bd4703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_25cf9d98-7e60-4474-9476-35a4b063acd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e39be03f-170c-4299-a032-dabf8f92f109" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e39be03f-170c-4299-a032-dabf8f92f109" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_0f77481d-d080-469e-9947-d7f6f3d677ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_61a5bb5e-a6bf-4620-8fd6-a4c735302f28" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_0f77481d-d080-469e-9947-d7f6f3d677ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4e2cd9bd-6dbe-42ce-9e78-ce839cf6d4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_0f77481d-d080-469e-9947-d7f6f3d677ce" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4e2cd9bd-6dbe-42ce-9e78-ce839cf6d4d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4e2cd9bd-6dbe-42ce-9e78-ce839cf6d4d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4e2cd9bd-6dbe-42ce-9e78-ce839cf6d4d3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4e2cd9bd-6dbe-42ce-9e78-ce839cf6d4d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_95a9cefd-2934-440f-9df1-83e4d2312110" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4e2cd9bd-6dbe-42ce-9e78-ce839cf6d4d3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_95a9cefd-2934-440f-9df1-83e4d2312110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a46eeb9c-4d40-42d2-ae0b-cfebf6283098" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_95a9cefd-2934-440f-9df1-83e4d2312110" xlink:to="loc_us-gaap_EquitySecuritiesMember_a46eeb9c-4d40-42d2-ae0b-cfebf6283098" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_c9b8159b-831b-490e-83d2-47f9ef3e2284" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_0f77481d-d080-469e-9947-d7f6f3d677ce" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_c9b8159b-831b-490e-83d2-47f9ef3e2284" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_c9b8159b-831b-490e-83d2-47f9ef3e2284_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_c9b8159b-831b-490e-83d2-47f9ef3e2284" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_c9b8159b-831b-490e-83d2-47f9ef3e2284_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_20e72f59-2eb0-4504-8a0b-76b0e09ec0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_c9b8159b-831b-490e-83d2-47f9ef3e2284" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_20e72f59-2eb0-4504-8a0b-76b0e09ec0b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_5e590b7c-90b2-490a-8cfd-8bdf3c15d1f0" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_20e72f59-2eb0-4504-8a0b-76b0e09ec0b0" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_5e590b7c-90b2-490a-8cfd-8bdf3c15d1f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_5518bff5-a8cf-4d24-b89e-66b16a115205" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_20e72f59-2eb0-4504-8a0b-76b0e09ec0b0" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_5518bff5-a8cf-4d24-b89e-66b16a115205" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended" id="ie4dbc20fb5b84f74b3833dc0aa0385e7_FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_e5b4bc54-62a3-4b89-b0a3-c1ac15daddf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_e5b4bc54-62a3-4b89-b0a3-c1ac15daddf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_10eca3ce-1a5e-4d68-a049-e73f0d597323" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_10eca3ce-1a5e-4d68-a049-e73f0d597323" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_398b9c12-3a86-4455-8f7c-0dbd6ab89703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_398b9c12-3a86-4455-8f7c-0dbd6ab89703" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_873bd3ba-16b9-4ac5-8779-dbda28a26a00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_873bd3ba-16b9-4ac5-8779-dbda28a26a00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7abb9f96-29cd-4400-b120-e636111edfc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7abb9f96-29cd-4400-b120-e636111edfc9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_71b177f9-1ad9-4e9d-a275-8cd444fa1e85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_71b177f9-1ad9-4e9d-a275-8cd444fa1e85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_93414a3e-c885-40c4-b561-dc554f06ddae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_93414a3e-c885-40c4-b561-dc554f06ddae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d10cb709-2dc8-4a48-b68d-110691b4c1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d10cb709-2dc8-4a48-b68d-110691b4c1bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_a54448cc-ca0b-45dc-b468-8ae5f500b6f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_a54448cc-ca0b-45dc-b468-8ae5f500b6f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_54317ae8-b195-4cc7-b0f5-32064656925b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeAssets_54317ae8-b195-4cc7-b0f5-32064656925b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bb2a1ebd-85ec-4005-8aa4-689063fdfdf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bb2a1ebd-85ec-4005-8aa4-689063fdfdf6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5f3a9458-8ba2-4f88-ae95-a350d61a38ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5f3a9458-8ba2-4f88-ae95-a350d61a38ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_69d72fac-615d-4070-a177-da9b55074f12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeLiabilities_69d72fac-615d-4070-a177-da9b55074f12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b2e266a0-608e-4217-acf5-8a0c675bfdd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b2e266a0-608e-4217-acf5-8a0c675bfdd6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_952b7751-0160-4f70-8576-4faff884971c" xlink:href="jnj-20210404.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_952b7751-0160-4f70-8576-4faff884971c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_09b144ea-84c0-4d3c-9aa6-da7ba80b2b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_09b144ea-84c0-4d3c-9aa6-da7ba80b2b2b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_5f26ad66-6203-4912-ab04-a83b080213a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_5f26ad66-6203-4912-ab04-a83b080213a6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a5b63cd1-0b18-4f64-adbd-21615c7ad45a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_91c57802-cbdc-4fc6-bd75-0fb82b232ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_91c57802-cbdc-4fc6-bd75-0fb82b232ba6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7d4dab66-446a-4f0b-a748-f4af34b597ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7d4dab66-446a-4f0b-a748-f4af34b597ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7d4dab66-446a-4f0b-a748-f4af34b597ed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7d4dab66-446a-4f0b-a748-f4af34b597ed" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7d4dab66-446a-4f0b-a748-f4af34b597ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f1f8a47b-56d2-465a-b1ac-f03bdca2acc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7d4dab66-446a-4f0b-a748-f4af34b597ed" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f1f8a47b-56d2-465a-b1ac-f03bdca2acc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4a38b196-14ed-4347-9848-de9ee9a44965" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f1f8a47b-56d2-465a-b1ac-f03bdca2acc8" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4a38b196-14ed-4347-9848-de9ee9a44965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_12ee8190-eade-4cdf-8a2c-11a72f9beabc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f1f8a47b-56d2-465a-b1ac-f03bdca2acc8" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_12ee8190-eade-4cdf-8a2c-11a72f9beabc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_16e2b8fd-89cb-4383-8a66-ac6f4c86540f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_16e2b8fd-89cb-4383-8a66-ac6f4c86540f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16e2b8fd-89cb-4383-8a66-ac6f4c86540f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_16e2b8fd-89cb-4383-8a66-ac6f4c86540f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16e2b8fd-89cb-4383-8a66-ac6f4c86540f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01418659-b369-47e4-9a51-13cc937cb37a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_16e2b8fd-89cb-4383-8a66-ac6f4c86540f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01418659-b369-47e4-9a51-13cc937cb37a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_1a372e7a-5dd0-460c-b01f-628fab60b316" xlink:href="jnj-20210404.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01418659-b369-47e4-9a51-13cc937cb37a" xlink:to="loc_jnj_AurisHealthMember_1a372e7a-5dd0-460c-b01f-628fab60b316" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_9d36a06e-6773-4e6c-be82-79339eb59315" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:to="loc_us-gaap_InvestmentTypeAxis_9d36a06e-6773-4e6c-be82-79339eb59315" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_9d36a06e-6773-4e6c-be82-79339eb59315_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_9d36a06e-6773-4e6c-be82-79339eb59315" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_9d36a06e-6773-4e6c-be82-79339eb59315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7f6189e1-9128-4afe-9fa2-09be6ff04d94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_9d36a06e-6773-4e6c-be82-79339eb59315" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7f6189e1-9128-4afe-9fa2-09be6ff04d94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_561a55af-af60-4611-a71a-ee91eb83073c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7f6189e1-9128-4afe-9fa2-09be6ff04d94" xlink:to="loc_us-gaap_EquitySecuritiesMember_561a55af-af60-4611-a71a-ee91eb83073c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_632435b7-4693-4c1b-abe0-5be26a0bc47b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_632435b7-4693-4c1b-abe0-5be26a0bc47b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_632435b7-4693-4c1b-abe0-5be26a0bc47b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_632435b7-4693-4c1b-abe0-5be26a0bc47b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_632435b7-4693-4c1b-abe0-5be26a0bc47b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8e0db5d3-83b8-441e-9c0b-c8d525d4d6c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_632435b7-4693-4c1b-abe0-5be26a0bc47b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8e0db5d3-83b8-441e-9c0b-c8d525d4d6c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_c2bb5555-c99d-415c-83ef-da92a003b2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8e0db5d3-83b8-441e-9c0b-c8d525d4d6c3" xlink:to="loc_us-gaap_InterestRateContractMember_c2bb5555-c99d-415c-83ef-da92a003b2ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1053f6d5-dac9-4b83-9474-cbb5d1d10bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8e0db5d3-83b8-441e-9c0b-c8d525d4d6c3" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1053f6d5-dac9-4b83-9474-cbb5d1d10bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_53cc5748-771c-4f14-9ca1-a8940a6635a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8e0db5d3-83b8-441e-9c0b-c8d525d4d6c3" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_53cc5748-771c-4f14-9ca1-a8940a6635a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e57572e-ab69-452c-a7b7-c54a3ceeaed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e57572e-ab69-452c-a7b7-c54a3ceeaed1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e57572e-ab69-452c-a7b7-c54a3ceeaed1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e57572e-ab69-452c-a7b7-c54a3ceeaed1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3e57572e-ab69-452c-a7b7-c54a3ceeaed1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baddf8c6-a9f9-4932-8141-e02a5bfd9550" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e57572e-ab69-452c-a7b7-c54a3ceeaed1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baddf8c6-a9f9-4932-8141-e02a5bfd9550" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_747f48c8-cd69-4dee-b7a7-31eee6b68652" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baddf8c6-a9f9-4932-8141-e02a5bfd9550" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_747f48c8-cd69-4dee-b7a7-31eee6b68652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9c796297-15c9-438a-97e7-bc069c9df41e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baddf8c6-a9f9-4932-8141-e02a5bfd9550" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9c796297-15c9-438a-97e7-bc069c9df41e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3a9b19f5-c6bf-4412-815b-18009c0fc8b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baddf8c6-a9f9-4932-8141-e02a5bfd9550" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3a9b19f5-c6bf-4412-815b-18009c0fc8b6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="ic03de6ee8f9240f4bdad2008fc3b053e_FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_46f08924-8283-4896-92ff-b5029236cd1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_fded5c86-4755-402a-bddc-eaf695338a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_46f08924-8283-4896-92ff-b5029236cd1e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_fded5c86-4755-402a-bddc-eaf695338a5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_7a3a2c41-5967-4110-8b17-d05a7ca75a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_fded5c86-4755-402a-bddc-eaf695338a5d" xlink:to="loc_us-gaap_HeldToMaturitySecurities_7a3a2c41-5967-4110-8b17-d05a7ca75a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_32d45f65-95ec-43fb-bcbd-f698977679ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_fded5c86-4755-402a-bddc-eaf695338a5d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_32d45f65-95ec-43fb-bcbd-f698977679ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_418ca3f3-7f64-4204-86b6-8cd5f4c7f9d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_fded5c86-4755-402a-bddc-eaf695338a5d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_418ca3f3-7f64-4204-86b6-8cd5f4c7f9d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_567bb031-f32a-49c6-84e6-a1f8ac2cc36c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_fded5c86-4755-402a-bddc-eaf695338a5d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_567bb031-f32a-49c6-84e6-a1f8ac2cc36c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_acc4d24c-33cb-4a45-8cf9-560bce69d5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_46f08924-8283-4896-92ff-b5029236cd1e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_acc4d24c-33cb-4a45-8cf9-560bce69d5f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_968204df-7fdf-47be-9665-8e3e6417e182" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_acc4d24c-33cb-4a45-8cf9-560bce69d5f7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_968204df-7fdf-47be-9665-8e3e6417e182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c0a36144-f92a-42dd-8e07-7dd124245e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_acc4d24c-33cb-4a45-8cf9-560bce69d5f7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c0a36144-f92a-42dd-8e07-7dd124245e6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3ab6cd07-e57e-4599-bd30-95bdd6417e32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_acc4d24c-33cb-4a45-8cf9-560bce69d5f7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3ab6cd07-e57e-4599-bd30-95bdd6417e32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95836941-1af4-4362-84fe-2e446da2847e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_acc4d24c-33cb-4a45-8cf9-560bce69d5f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95836941-1af4-4362-84fe-2e446da2847e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_46f08924-8283-4896-92ff-b5029236cd1e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0eb22c96-6328-493a-9341-4c27e50c655c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0eb22c96-6328-493a-9341-4c27e50c655c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_6f666598-d68b-422f-a199-fa899a044ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_6f666598-d68b-422f-a199-fa899a044ec7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4316dac8-28cb-4683-a846-c16081b18538" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4316dac8-28cb-4683-a846-c16081b18538" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_4e252c84-ce1c-4d24-9e7d-28f551da596f" xlink:href="jnj-20210404.xsd#jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:to="loc_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_4e252c84-ce1c-4d24-9e7d-28f551da596f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_cf90d213-bb9c-4876-8312-083f74a6f608" xlink:href="jnj-20210404.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_cf90d213-bb9c-4876-8312-083f74a6f608" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_900be597-9439-498e-91eb-a9abd92653d7" xlink:href="jnj-20210404.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_900be597-9439-498e-91eb-a9abd92653d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fac577a6-9a66-4e39-9372-65ca8c2fb641" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_46f08924-8283-4896-92ff-b5029236cd1e" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fac577a6-9a66-4e39-9372-65ca8c2fb641" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_c2110483-bfc6-42ff-8f94-957e286247ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fac577a6-9a66-4e39-9372-65ca8c2fb641" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_c2110483-bfc6-42ff-8f94-957e286247ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_c2110483-bfc6-42ff-8f94-957e286247ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_c2110483-bfc6-42ff-8f94-957e286247ac" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_c2110483-bfc6-42ff-8f94-957e286247ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_9d3edbda-f6bb-420d-89b1-c8c7ba77d0cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_c2110483-bfc6-42ff-8f94-957e286247ac" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_9d3edbda-f6bb-420d-89b1-c8c7ba77d0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_85ba256b-9013-48f4-b77c-87a6859234f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_9d3edbda-f6bb-420d-89b1-c8c7ba77d0cd" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_85ba256b-9013-48f4-b77c-87a6859234f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_8ee947d9-1bb3-466c-bcac-6ebb503857e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_9d3edbda-f6bb-420d-89b1-c8c7ba77d0cd" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_8ee947d9-1bb3-466c-bcac-6ebb503857e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4bc6b80d-7dd0-4be2-baac-7494727be339" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fac577a6-9a66-4e39-9372-65ca8c2fb641" xlink:to="loc_us-gaap_InvestmentTypeAxis_4bc6b80d-7dd0-4be2-baac-7494727be339" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4bc6b80d-7dd0-4be2-baac-7494727be339_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4bc6b80d-7dd0-4be2-baac-7494727be339" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4bc6b80d-7dd0-4be2-baac-7494727be339_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4bc6b80d-7dd0-4be2-baac-7494727be339" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_2b0af9d5-5c08-4e13-9c92-4697a2358b23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_CashMember_2b0af9d5-5c08-4e13-9c92-4697a2358b23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_afeba3a8-101a-4540-83d3-c775eb002e09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_afeba3a8-101a-4540-83d3-c775eb002e09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_ef1aeda9-37c4-4110-8520-1b863127ea58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_ef1aeda9-37c4-4110-8520-1b863127ea58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherReverseRepurchaseAgreementsMember_1eeea560-b2e7-41cb-8405-7c8697584205" xlink:href="jnj-20210404.xsd#jnj_OtherReverseRepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_jnj_OtherReverseRepurchaseAgreementsMember_1eeea560-b2e7-41cb-8405-7c8697584205" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9ac98049-7fe4-4744-804c-e52b9758cf03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9ac98049-7fe4-4744-804c-e52b9758cf03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_15f892fe-d9e5-438d-9206-853d23493103" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_15f892fe-d9e5-438d-9206-853d23493103" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_40ab87de-d0b1-4599-be4d-6ae3a295290f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_BankTimeDepositsMember_40ab87de-d0b1-4599-be4d-6ae3a295290f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_511c6288-260c-4750-afe9-baf9c4dc14d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_511c6288-260c-4750-afe9-baf9c4dc14d2" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended" id="i97460fa5881443428b37249d3179c53c_FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended" id="i92fe9c835b8d44b6aade6d965cdbc091_FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_abd8eaff-77d8-4659-ba01-8847fce4bd7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_5f925e6a-d395-4d2b-bfc8-f7c172b17ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_abd8eaff-77d8-4659-ba01-8847fce4bd7f" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_5f925e6a-d395-4d2b-bfc8-f7c172b17ef3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_835b0af4-793d-4325-9d8a-a43252cf138e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_5f925e6a-d395-4d2b-bfc8-f7c172b17ef3" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_835b0af4-793d-4325-9d8a-a43252cf138e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_47d4f69b-a31e-4827-bbd3-1ae526367e91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_835b0af4-793d-4325-9d8a-a43252cf138e" xlink:to="loc_us-gaap_ShortTermBorrowings_47d4f69b-a31e-4827-bbd3-1ae526367e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_7d8236f8-3e10-436d-acbf-59780b1dca0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_5f925e6a-d395-4d2b-bfc8-f7c172b17ef3" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_7d8236f8-3e10-436d-acbf-59780b1dca0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1f045301-80a5-434c-bf06-f1df107869ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_7d8236f8-3e10-436d-acbf-59780b1dca0d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1f045301-80a5-434c-bf06-f1df107869ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1eed42bc-4afc-4a06-a42b-9c8a887d15ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_5f925e6a-d395-4d2b-bfc8-f7c172b17ef3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1eed42bc-4afc-4a06-a42b-9c8a887d15ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3435fa3-7a6a-4f50-8ecd-0a462eacf208" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_abd8eaff-77d8-4659-ba01-8847fce4bd7f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3435fa3-7a6a-4f50-8ecd-0a462eacf208" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_af60550f-8e1c-469a-b821-5e99302d890b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3435fa3-7a6a-4f50-8ecd-0a462eacf208" xlink:to="loc_us-gaap_DebtInstrumentAxis_af60550f-8e1c-469a-b821-5e99302d890b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_af60550f-8e1c-469a-b821-5e99302d890b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_af60550f-8e1c-469a-b821-5e99302d890b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_af60550f-8e1c-469a-b821-5e99302d890b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_af60550f-8e1c-469a-b821-5e99302d890b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_6f2c33ec-ae9f-49e6-b8c6-2ed75fff0218" xlink:href="jnj-20210404.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_6f2c33ec-ae9f-49e6-b8c6-2ed75fff0218" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_3a6c9c65-ea20-4806-bd17-11dfbf087abd" xlink:href="jnj-20210404.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.375Notesdue2023Member_3a6c9c65-ea20-4806-bd17-11dfbf087abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member_556eb75a-9d0c-4053-8da2-762f01dcfb8b" xlink:href="jnj-20210404.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2.05Notesdue2023Member_556eb75a-9d0c-4053-8da2-762f01dcfb8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_10bfd54d-6733-4bb0-9c58-f49e04482c4f" xlink:href="jnj-20210404.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A0.650NotesDue2024Member_10bfd54d-6733-4bb0-9c58-f49e04482c4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_601b7345-0ae7-46d7-9ef9-1f4643cf152e" xlink:href="jnj-20210404.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A5.50NotesDue2024Member_601b7345-0ae7-46d7-9ef9-1f4643cf152e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_127eab07-c717-4392-a1ce-4ed8656741e7" xlink:href="jnj-20210404.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2.625Notesdue2025Member_127eab07-c717-4392-a1ce-4ed8656741e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member_1dfa48fd-6e98-4133-b97d-707904a9cd94" xlink:href="jnj-20210404.xsd#jnj_A0550NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A0550NotesDue2025Member_1dfa48fd-6e98-4133-b97d-707904a9cd94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_a3064d42-f180-4186-b922-71f3e952b303" xlink:href="jnj-20210404.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2.45Notesdue2026Member_a3064d42-f180-4186-b922-71f3e952b303" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_5f852914-ce53-4739-af58-d1ee0154affc" xlink:href="jnj-20210404.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2.95Notesdue2027Member_5f852914-ce53-4739-af58-d1ee0154affc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_c9cf2cb3-584e-4204-8da0-aae93e76815c" xlink:href="jnj-20210404.xsd#jnj_A095NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A095NotesDue2027Member_c9cf2cb3-584e-4204-8da0-aae93e76815c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_91c60111-21cc-48ee-93de-c5b0bba49ea1" xlink:href="jnj-20210404.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2.900Notesdue2028Member_91c60111-21cc-48ee-93de-c5b0bba49ea1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_cb160829-64c9-48d5-9f08-19973d99d830" xlink:href="jnj-20210404.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A1.150NotesDue2028Member_cb160829-64c9-48d5-9f08-19973d99d830" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_6c46dcb3-4c83-4b72-8095-427495211474" xlink:href="jnj-20210404.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A6.95Notesdue2029Member_6c46dcb3-4c83-4b72-8095-427495211474" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member_c2239297-5291-4e35-b14e-c0f316152962" xlink:href="jnj-20210404.xsd#jnj_A1300NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A1300NotesDue2030Member_c2239297-5291-4e35-b14e-c0f316152962" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_895b92f9-7f53-40df-9d28-885e873bd737" xlink:href="jnj-20210404.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_895b92f9-7f53-40df-9d28-885e873bd737" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_4f83f3ba-be07-4917-8d4c-7d9d781bcc02" xlink:href="jnj-20210404.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A4.375Notesdue2033Member_4f83f3ba-be07-4917-8d4c-7d9d781bcc02" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_cb36f0e5-8247-40fc-8fa7-0c6ec114cc1d" xlink:href="jnj-20210404.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A1.650NotesDue2035Member_cb36f0e5-8247-40fc-8fa7-0c6ec114cc1d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_4e0771ab-1a64-409c-8430-951583f1b3fa" xlink:href="jnj-20210404.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.55Notesdue2036Member_4e0771ab-1a64-409c-8430-951583f1b3fa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_5088723c-2e57-438e-b7a2-e2f9b4357a3f" xlink:href="jnj-20210404.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A5.95Notesdue2037Member_5088723c-2e57-438e-b7a2-e2f9b4357a3f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_2e6241a0-b1dc-4e4b-96f9-b1dbb1d0684c" xlink:href="jnj-20210404.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.625Notesdue2037Member_2e6241a0-b1dc-4e4b-96f9-b1dbb1d0684c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_2be723b3-bffd-4633-a8e7-b5c2a59211d6" xlink:href="jnj-20210404.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.400Notesdue2038Member_2be723b3-bffd-4633-a8e7-b5c2a59211d6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_6b4153da-e19c-42c6-b5bc-47f1a28eb781" xlink:href="jnj-20210404.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_6b4153da-e19c-42c6-b5bc-47f1a28eb781" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_eaa9ddfc-3f99-42f7-98ed-dd91326e75da" xlink:href="jnj-20210404.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_eaa9ddfc-3f99-42f7-98ed-dd91326e75da" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_98fc3aad-d80b-4cfa-99c7-589b48257fd9" xlink:href="jnj-20210404.xsd#jnj_A210NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A210NotesDue2040Member_98fc3aad-d80b-4cfa-99c7-589b48257fd9" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_e991de51-7c2e-49d5-93a2-1c36cb333338" xlink:href="jnj-20210404.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A4.85Notesdue2041Member_e991de51-7c2e-49d5-93a2-1c36cb333338" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_240a6b74-8cf7-42b9-af9b-b9731d82266d" xlink:href="jnj-20210404.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A4.50Notesdue2043Member_240a6b74-8cf7-42b9-af9b-b9731d82266d" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_7b4c4401-b112-4cd3-ae33-a50423435d9b" xlink:href="jnj-20210404.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.70Notesdue2046Member_7b4c4401-b112-4cd3-ae33-a50423435d9b" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_47529063-cbad-4e6e-a413-d473eac2cad3" xlink:href="jnj-20210404.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.75Notesdue2047Member_47529063-cbad-4e6e-a413-d473eac2cad3" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_dc4ff408-2d87-448f-bd3e-00bd8fe406d1" xlink:href="jnj-20210404.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.500Notesdue2048Member_dc4ff408-2d87-448f-bd3e-00bd8fe406d1" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_90886c8e-a4f8-4022-94d5-b9c341dd9db3" xlink:href="jnj-20210404.xsd#jnj_A2250NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2250NotesDue2050Member_90886c8e-a4f8-4022-94d5-b9c341dd9db3" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_67fe3a2e-fe4f-4710-8fb1-7c6633bd872b" xlink:href="jnj-20210404.xsd#jnj_A2450NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2450NotesDue2060Member_67fe3a2e-fe4f-4710-8fb1-7c6633bd872b" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember_dbe33f20-ee52-41c5-a577-3334f6e2ea93" xlink:href="jnj-20210404.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_NotesDuePeriodFifteenMember_dbe33f20-ee52-41c5-a577-3334f6e2ea93" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_082e7251-c77c-4fa3-97be-2674f0767e53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3435fa3-7a6a-4f50-8ecd-0a462eacf208" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_082e7251-c77c-4fa3-97be-2674f0767e53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_082e7251-c77c-4fa3-97be-2674f0767e53_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_082e7251-c77c-4fa3-97be-2674f0767e53" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_082e7251-c77c-4fa3-97be-2674f0767e53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_84bbf98b-4369-4586-8c81-d0f449a3bccc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_082e7251-c77c-4fa3-97be-2674f0767e53" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_84bbf98b-4369-4586-8c81-d0f449a3bccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_aab19486-045e-41db-a064-57ebc55fb101" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_84bbf98b-4369-4586-8c81-d0f449a3bccc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_aab19486-045e-41db-a064-57ebc55fb101" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0a0c87a-72a8-4d8c-b297-266918eff339" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_aab19486-045e-41db-a064-57ebc55fb101" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0a0c87a-72a8-4d8c-b297-266918eff339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8936c8f5-857a-41a4-8482-8277c18ec050" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_aab19486-045e-41db-a064-57ebc55fb101" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8936c8f5-857a-41a4-8482-8277c18ec050" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20210404.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended" id="i927951852a554328bce970af22fda276_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="extended" id="idacb0b8ecdfd47f18963bf7dfc6d270f_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b184d5a-db9f-48d4-9fab-c776b73fb693" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:href="jnj-20210404.xsd#jnj_IncomeTaxTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b184d5a-db9f-48d4-9fab-c776b73fb693" xlink:to="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00464d1c-ebaa-4fe3-a2cd-7f0e4bc01143" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00464d1c-ebaa-4fe3-a2cd-7f0e4bc01143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_03c1db49-1a35-46d1-add2-c65b10de52a5" xlink:href="jnj-20210404.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_03c1db49-1a35-46d1-add2-c65b10de52a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_d5b13688-656e-4544-a7aa-3811445240d2" xlink:href="jnj-20210404.xsd#jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_d5b13688-656e-4544-a7aa-3811445240d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_1f99cc61-2099-4482-b258-43e965b31793" xlink:href="jnj-20210404.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_1f99cc61-2099-4482-b258-43e965b31793" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent_0b7c46ab-765c-4a87-9fac-1c1bdc34e05b" xlink:href="jnj-20210404.xsd#jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent_0b7c46ab-765c-4a87-9fac-1c1bdc34e05b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_47243112-a53e-4ac5-af0e-abcd6e1c0c01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_47243112-a53e-4ac5-af0e-abcd6e1c0c01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_388cb02c-4bdd-4a24-9822-470366856600" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b184d5a-db9f-48d4-9fab-c776b73fb693" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_388cb02c-4bdd-4a24-9822-470366856600" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_251533c6-0d6a-4e33-b018-fc02c388e1e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_388cb02c-4bdd-4a24-9822-470366856600" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_251533c6-0d6a-4e33-b018-fc02c388e1e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_251533c6-0d6a-4e33-b018-fc02c388e1e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_251533c6-0d6a-4e33-b018-fc02c388e1e2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_251533c6-0d6a-4e33-b018-fc02c388e1e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_360e0695-efe3-49a1-bf32-6120bd3cc764" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_251533c6-0d6a-4e33-b018-fc02c388e1e2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_360e0695-efe3-49a1-bf32-6120bd3cc764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_5020723f-dc13-4013-abb3-14cd4433f7c4" xlink:href="jnj-20210404.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_360e0695-efe3-49a1-bf32-6120bd3cc764" xlink:to="loc_jnj_AurisHealthMember_5020723f-dc13-4013-abb3-14cd4433f7c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20210404.xsd#PensionsandOtherBenefitPlans"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended" id="i4a73913ac8c44e1583909656810671c9_PensionsandOtherBenefitPlans"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended" id="i08f5e698eb7a4af796c203ddcd3a7c3f_PensionsandOtherBenefitPlansTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="icff1a35fb737409bad4d9de7f9e00a7a_PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e6542c1-0411-42b5-9183-341286bf41db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e6542c1-0411-42b5-9183-341286bf41db" xlink:to="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_7b7cc591-3215-480a-947e-952fc31c0795" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_7b7cc591-3215-480a-947e-952fc31c0795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_c0f0b670-355e-45d5-a9c1-cd87e8329623" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_c0f0b670-355e-45d5-a9c1-cd87e8329623" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b9fafefa-2432-4a90-8e43-621cc2e81dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b9fafefa-2432-4a90-8e43-621cc2e81dc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_4aa3165d-7851-4ce7-a065-f59a0fdd42c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_4aa3165d-7851-4ce7-a065-f59a0fdd42c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ddac3852-92bb-4c44-82b1-9f11bf0b8a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ddac3852-92bb-4c44-82b1-9f11bf0b8a8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_314b3f27-03d7-4934-9087-c210d3b88272" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_314b3f27-03d7-4934-9087-c210d3b88272" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e89d98b6-5746-4f7d-9dfd-30fffab33911" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e89d98b6-5746-4f7d-9dfd-30fffab33911" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5cc51e5d-d0a5-4c31-8d37-1a74833acbbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e6542c1-0411-42b5-9183-341286bf41db" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5cc51e5d-d0a5-4c31-8d37-1a74833acbbe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8f89ea19-2340-4da6-9377-5abfe517053c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5cc51e5d-d0a5-4c31-8d37-1a74833acbbe" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8f89ea19-2340-4da6-9377-5abfe517053c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8f89ea19-2340-4da6-9377-5abfe517053c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8f89ea19-2340-4da6-9377-5abfe517053c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8f89ea19-2340-4da6-9377-5abfe517053c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_727e60d0-fa07-44ad-ae28-5c1159e7d860" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8f89ea19-2340-4da6-9377-5abfe517053c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_727e60d0-fa07-44ad-ae28-5c1159e7d860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_08d1a852-f403-456a-9907-34ffb7a5c6ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_727e60d0-fa07-44ad-ae28-5c1159e7d860" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_08d1a852-f403-456a-9907-34ffb7a5c6ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3b8f4f5d-343b-46f5-8908-56a235b7c327" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_727e60d0-fa07-44ad-ae28-5c1159e7d860" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3b8f4f5d-343b-46f5-8908-56a235b7c327" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended" id="i88270599e2074c3cb8c0e215321a2029_PensionsandOtherBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_23497297-a6ce-4780-9608-c28e59d0d022" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_f0937098-e87c-4669-80c9-b44a96d4913a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_23497297-a6ce-4780-9608-c28e59d0d022" xlink:to="loc_us-gaap_PensionContributions_f0937098-e87c-4669-80c9-b44a96d4913a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_24486f70-27a0-42f3-9091-681e0cf55a67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_23497297-a6ce-4780-9608-c28e59d0d022" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_24486f70-27a0-42f3-9091-681e0cf55a67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_6bc5bfdb-d281-4375-ab8e-b0ecc3ee7f56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_24486f70-27a0-42f3-9091-681e0cf55a67" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_6bc5bfdb-d281-4375-ab8e-b0ecc3ee7f56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6bc5bfdb-d281-4375-ab8e-b0ecc3ee7f56_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_6bc5bfdb-d281-4375-ab8e-b0ecc3ee7f56" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6bc5bfdb-d281-4375-ab8e-b0ecc3ee7f56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_403b6448-6fb1-4bb4-a5ff-5f3778e32e08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_6bc5bfdb-d281-4375-ab8e-b0ecc3ee7f56" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_403b6448-6fb1-4bb4-a5ff-5f3778e32e08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_37cf9a00-6295-4b60-929b-9161467b0f4c" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_403b6448-6fb1-4bb4-a5ff-5f3778e32e08" xlink:to="loc_country_US_37cf9a00-6295-4b60-929b-9161467b0f4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_c650ed55-9cf2-45b8-b303-e7b684115af2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_403b6448-6fb1-4bb4-a5ff-5f3778e32e08" xlink:to="loc_us-gaap_ForeignPlanMember_c650ed55-9cf2-45b8-b303-e7b684115af2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20210404.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended" id="ia63758ec50494abb849540b5501f13f0_AccumulatedOtherComprehensiveIncome"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended" id="i229bf875d3094c97b6c1eba70dcf680d_AccumulatedOtherComprehensiveIncomeTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="i449cfdf6296c4d8aa76ba69ea405b6ae_AccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_989a2778-7e67-4553-abb4-a588ef14b324" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_bcff6703-9354-4a3b-95ec-0bc18cf0c0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_989a2778-7e67-4553-abb4-a588ef14b324" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_bcff6703-9354-4a3b-95ec-0bc18cf0c0bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97300088-35c7-45fb-8b23-bb37683787df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_bcff6703-9354-4a3b-95ec-0bc18cf0c0bd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97300088-35c7-45fb-8b23-bb37683787df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3ead1387-37eb-4dd5-afab-eafb881380d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_bcff6703-9354-4a3b-95ec-0bc18cf0c0bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3ead1387-37eb-4dd5-afab-eafb881380d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0e3b21ef-3b3a-4a8d-b7e5-16c872f42aea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_be33cdcc-d211-4f4e-a621-d19b91babe6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_989a2778-7e67-4553-abb4-a588ef14b324" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_be33cdcc-d211-4f4e-a621-d19b91babe6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eff534f8-3d59-4ade-b1ae-f3859ea0a523" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_be33cdcc-d211-4f4e-a621-d19b91babe6f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eff534f8-3d59-4ade-b1ae-f3859ea0a523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eff534f8-3d59-4ade-b1ae-f3859ea0a523_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eff534f8-3d59-4ade-b1ae-f3859ea0a523" xlink:to="loc_us-gaap_EquityComponentDomain_eff534f8-3d59-4ade-b1ae-f3859ea0a523_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eff534f8-3d59-4ade-b1ae-f3859ea0a523" xlink:to="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a8ebcf36-1d11-4640-9e17-7457a5ed757d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a8ebcf36-1d11-4640-9e17-7457a5ed757d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_49300b1d-c710-4c5a-b73a-85f4039da4f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_49300b1d-c710-4c5a-b73a-85f4039da4f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_bd1d8050-ea4c-44c6-84f0-df7ce9b2e7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_bd1d8050-ea4c-44c6-84f0-df7ce9b2e7cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3bbaf10a-2d59-4039-8d4f-a31a42fec82b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3bbaf10a-2d59-4039-8d4f-a31a42fec82b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9cee8940-81a6-4bd7-a70c-7d961091934b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9cee8940-81a6-4bd7-a70c-7d961091934b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20210404.xsd#EarningsPerShare"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended" id="id43481fd719c4415b0174cc2b884c1e2_EarningsPerShare"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#EarningsPerShareTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended" id="idd165f507ac74b40b24e7c3f6114715d_EarningsPerShareTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#EarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended" id="i5f39aad45fc04219a14b97cfdff373c1_EarningsPerShareDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended" id="idb39a265bae04b48a91c85eda7ccf7b4_SegmentsofBusinessandGeographicAreas"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended" id="i17bb806c4e314614bb554b74c54f78fa_SegmentsofBusinessandGeographicAreasTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended" id="i88f67aaf89b744f09eeed8ef5dd85efa_SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bac759a7-a861-47c7-9de5-c070dd1e7068" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_bc3e98d3-c364-4e7e-955a-0a09c56df3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bac759a7-a861-47c7-9de5-c070dd1e7068" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_bc3e98d3-c364-4e7e-955a-0a09c56df3f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6650932a-08c9-4e6e-83e3-588c69c6ae48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_bc3e98d3-c364-4e7e-955a-0a09c56df3f4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6650932a-08c9-4e6e-83e3-588c69c6ae48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_b8027403-5661-43e4-bcf5-3448d8c327c2" xlink:href="jnj-20210404.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_bc3e98d3-c364-4e7e-955a-0a09c56df3f4" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_b8027403-5661-43e4-bcf5-3448d8c327c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bac759a7-a861-47c7-9de5-c070dd1e7068" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f8a41dfe-2533-45ac-874b-d177ccf336f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f8a41dfe-2533-45ac-874b-d177ccf336f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8a41dfe-2533-45ac-874b-d177ccf336f1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f8a41dfe-2533-45ac-874b-d177ccf336f1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8a41dfe-2533-45ac-874b-d177ccf336f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce643884-e68e-4875-9d12-8fceca3fb9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f8a41dfe-2533-45ac-874b-d177ccf336f1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce643884-e68e-4875-9d12-8fceca3fb9d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_08315b60-c120-4247-aa81-36a76de14b05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_08315b60-c120-4247-aa81-36a76de14b05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_08315b60-c120-4247-aa81-36a76de14b05_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_08315b60-c120-4247-aa81-36a76de14b05" xlink:to="loc_us-gaap_SegmentDomain_08315b60-c120-4247-aa81-36a76de14b05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5ee45377-aca6-42c9-8b71-f7a3a2dba0af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_08315b60-c120-4247-aa81-36a76de14b05" xlink:to="loc_us-gaap_SegmentDomain_5ee45377-aca6-42c9-8b71-f7a3a2dba0af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_8d849341-d17c-4754-bbed-b7ec58b1a0ab" xlink:href="jnj-20210404.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5ee45377-aca6-42c9-8b71-f7a3a2dba0af" xlink:to="loc_jnj_ConsumerMember_8d849341-d17c-4754-bbed-b7ec58b1a0ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_52344d53-45db-4943-9af3-73c07dc79264" xlink:href="jnj-20210404.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5ee45377-aca6-42c9-8b71-f7a3a2dba0af" xlink:to="loc_jnj_PharmaceuticalMember_52344d53-45db-4943-9af3-73c07dc79264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_1f1200a9-38a7-42ce-bdac-69724d640fce" xlink:href="jnj-20210404.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5ee45377-aca6-42c9-8b71-f7a3a2dba0af" xlink:to="loc_jnj_MedicalDevicesMember_1f1200a9-38a7-42ce-bdac-69724d640fce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_7a2aa77f-1f19-4075-8411-e057f04577ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:to="loc_us-gaap_SubsegmentsAxis_7a2aa77f-1f19-4075-8411-e057f04577ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_7a2aa77f-1f19-4075-8411-e057f04577ea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_7a2aa77f-1f19-4075-8411-e057f04577ea" xlink:to="loc_us-gaap_SubsegmentsDomain_7a2aa77f-1f19-4075-8411-e057f04577ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_7a2aa77f-1f19-4075-8411-e057f04577ea" xlink:to="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_7b6c35bc-6a98-4470-97b0-64fd9165a440" xlink:href="jnj-20210404.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_ImmunologyMember_7b6c35bc-6a98-4470-97b0-64fd9165a440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_176bf43a-8d5b-473a-a4a2-c9760b49a141" xlink:href="jnj-20210404.xsd#jnj_InfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_InfectiousDiseasesMember_176bf43a-8d5b-473a-a4a2-c9760b49a141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_fa7cba94-b669-472d-a542-08641aa09630" xlink:href="jnj-20210404.xsd#jnj_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_NeuroscienceMember_fa7cba94-b669-472d-a542-08641aa09630" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_1cf5c261-aa08-4853-87f1-c1889369af4d" xlink:href="jnj-20210404.xsd#jnj_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_OncologyMember_1cf5c261-aa08-4853-87f1-c1889369af4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_bf41f794-9716-4d07-9eb8-804e6cf24b2a" xlink:href="jnj-20210404.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_PulmonaryHypertensionMember_bf41f794-9716-4d07-9eb8-804e6cf24b2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_5243ccac-d56c-40b1-a94b-c7ea5ed09f80" xlink:href="jnj-20210404.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_5243ccac-d56c-40b1-a94b-c7ea5ed09f80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_938c1fc8-dc9e-4acd-93fe-33a279702810" xlink:href="jnj-20210404.xsd#jnj_InterventionalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_InterventionalSolutionsMember_938c1fc8-dc9e-4acd-93fe-33a279702810" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_5f191ab5-4587-4ec2-97ad-91775e2fa94a" xlink:href="jnj-20210404.xsd#jnj_OrthopaedicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_OrthopaedicsMember_5f191ab5-4587-4ec2-97ad-91775e2fa94a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_0e320797-9fc8-4906-b701-898378919458" xlink:href="jnj-20210404.xsd#jnj_SurgeryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_SurgeryMember_0e320797-9fc8-4906-b701-898378919458" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_dd1eaf2e-2cea-49db-90b9-f7a9067a3029" xlink:href="jnj-20210404.xsd#jnj_VisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_VisionMember_dd1eaf2e-2cea-49db-90b9-f7a9067a3029" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d611beb7-b199-49df-a141-8138fd2fa97b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:to="loc_srt_ProductOrServiceAxis_d611beb7-b199-49df-a141-8138fd2fa97b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d611beb7-b199-49df-a141-8138fd2fa97b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d611beb7-b199-49df-a141-8138fd2fa97b" xlink:to="loc_srt_ProductsAndServicesDomain_d611beb7-b199-49df-a141-8138fd2fa97b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d611beb7-b199-49df-a141-8138fd2fa97b" xlink:to="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_d5b2818b-101d-4ad7-a277-3305e307c66c" xlink:href="jnj-20210404.xsd#jnj_OTCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OTCMember_d5b2818b-101d-4ad7-a277-3305e307c66c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember_4eed34d1-0cf3-4f53-a057-d0c0d7c13bce" xlink:href="jnj-20210404.xsd#jnj_BeautyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_BeautyMember_4eed34d1-0cf3-4f53-a057-d0c0d7c13bce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_4618cf7a-106b-45c1-bc9e-dbdd2f3f7690" xlink:href="jnj-20210404.xsd#jnj_OralCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OralCareMember_4618cf7a-106b-45c1-bc9e-dbdd2f3f7690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_36baddbe-6b16-48a2-989b-c54ffe3495e1" xlink:href="jnj-20210404.xsd#jnj_BabyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_BabyCareMember_36baddbe-6b16-48a2-989b-c54ffe3495e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_5c34d3f6-8e51-4bc8-8dda-d0fc0f0e57c6" xlink:href="jnj-20210404.xsd#jnj_WomensHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_WomensHealthMember_5c34d3f6-8e51-4bc8-8dda-d0fc0f0e57c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_5ba34878-e3cb-408e-9b1f-92b81029cc7b" xlink:href="jnj-20210404.xsd#jnj_WoundCareandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_WoundCareandOtherMember_5ba34878-e3cb-408e-9b1f-92b81029cc7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_790fd98d-f6c7-486b-978c-e3738d891f2d" xlink:href="jnj-20210404.xsd#jnj_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_RemicadeMember_790fd98d-f6c7-486b-978c-e3738d891f2d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_e467b682-73bf-437d-98ec-5859888b76ac" xlink:href="jnj-20210404.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_SimponiSimponiAriaMember_e467b682-73bf-437d-98ec-5859888b76ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_70e3369e-2fb6-4e79-9144-89a232ae543a" xlink:href="jnj-20210404.xsd#jnj_StelaraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_StelaraMember_70e3369e-2fb6-4e79-9144-89a232ae543a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_b349eac9-9929-48d5-91a2-e728c370a894" xlink:href="jnj-20210404.xsd#jnj_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_TremfyaMember_b349eac9-9929-48d5-91a2-e728c370a894" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_058d2bda-e83d-4565-b1f4-799be5f1dbe2" xlink:href="jnj-20210404.xsd#jnj_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OtherImmunologyMember_058d2bda-e83d-4565-b1f4-799be5f1dbe2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_3f089c27-65cd-47a6-9533-7202d98fc06d" xlink:href="jnj-20210404.xsd#jnj_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_COVID19Member_3f089c27-65cd-47a6-9533-7202d98fc06d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_432fc764-342c-4c57-84b5-3b0848245453" xlink:href="jnj-20210404.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_EDURANTrilpivirineMember_432fc764-342c-4c57-84b5-3b0848245453" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_cbaa17bd-eb73-4844-b1e6-12ee62d0aa4e" xlink:href="jnj-20210404.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_cbaa17bd-eb73-4844-b1e6-12ee62d0aa4e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_9f9a2892-9d75-4b33-91b0-782d8fc7a327" xlink:href="jnj-20210404.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_9f9a2892-9d75-4b33-91b0-782d8fc7a327" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_b20cbdd9-3c0b-40bc-a00f-5c9f76232e1a" xlink:href="jnj-20210404.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_b20cbdd9-3c0b-40bc-a00f-5c9f76232e1a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_848aed5b-6d13-4cee-b902-07ae0c7072f0" xlink:href="jnj-20210404.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_848aed5b-6d13-4cee-b902-07ae0c7072f0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_f5c3a2f6-0f53-4238-91d3-6e0177c76b7e" xlink:href="jnj-20210404.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_RISPERDALCONSTAMember_f5c3a2f6-0f53-4238-91d3-6e0177c76b7e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_ed219d8d-ce46-49c9-bfef-911be22dfce7" xlink:href="jnj-20210404.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_ed219d8d-ce46-49c9-bfef-911be22dfce7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_955c657d-0f63-4fbb-8186-0ad9fd088f71" xlink:href="jnj-20210404.xsd#jnj_DARZALEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_DARZALEXMember_955c657d-0f63-4fbb-8186-0ad9fd088f71" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember_7820290c-0fab-4627-a194-97b91aacfb45" xlink:href="jnj-20210404.xsd#jnj_ERLEADAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_ERLEADAMember_7820290c-0fab-4627-a194-97b91aacfb45" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_09b7446a-b2b4-4328-a5e0-3a8810e05977" xlink:href="jnj-20210404.xsd#jnj_IMBRUVICAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_IMBRUVICAMember_09b7446a-b2b4-4328-a5e0-3a8810e05977" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_ca0d8fc9-8392-4a1e-b18d-2bcc968fc8f3" xlink:href="jnj-20210404.xsd#jnj_ZYTIGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_ZYTIGAMember_ca0d8fc9-8392-4a1e-b18d-2bcc968fc8f3" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_c1d45ca4-3c3f-440a-a6e4-17b3ac289196" xlink:href="jnj-20210404.xsd#jnj_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OtherOncologyMember_c1d45ca4-3c3f-440a-a6e4-17b3ac289196" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_c9856624-1a26-4b98-a7d8-2a7399bcf518" xlink:href="jnj-20210404.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OPSUMITMember_c9856624-1a26-4b98-a7d8-2a7399bcf518" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_ce2cb972-29e0-4ab9-99d6-7aa3f2a4c59a" xlink:href="jnj-20210404.xsd#jnj_UPTRAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_UPTRAVIMember_ce2cb972-29e0-4ab9-99d6-7aa3f2a4c59a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_f75a1466-58bb-47aa-a217-9f59a2491f44" xlink:href="jnj-20210404.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_XareltoMember_f75a1466-58bb-47aa-a217-9f59a2491f44" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_ac922321-7b21-43f4-a3b0-6ea28bcd36f8" xlink:href="jnj-20210404.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_ac922321-7b21-43f4-a3b0-6ea28bcd36f8" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PROCRITEPREXMember_a7f4599e-7720-4ad1-b16e-69cf84069a67" xlink:href="jnj-20210404.xsd#jnj_PROCRITEPREXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_PROCRITEPREXMember_a7f4599e-7720-4ad1-b16e-69cf84069a67" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_fdbff5a4-d5db-4ad1-a57f-50424ef3948d" xlink:href="jnj-20210404.xsd#jnj_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OtherMember_fdbff5a4-d5db-4ad1-a57f-50424ef3948d" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_9d96c9c1-ed08-41ba-88db-df788081a27a" xlink:href="jnj-20210404.xsd#jnj_HIPSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_HIPSMember_9d96c9c1-ed08-41ba-88db-df788081a27a" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_1a089be2-23c3-49f2-8697-820dde28bc2a" xlink:href="jnj-20210404.xsd#jnj_KNEESMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_KNEESMember_1a089be2-23c3-49f2-8697-820dde28bc2a" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_0e4313cf-0ae5-42c3-82d1-af61d65f8383" xlink:href="jnj-20210404.xsd#jnj_TRAUMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_TRAUMAMember_0e4313cf-0ae5-42c3-82d1-af61d65f8383" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_eb5d12ff-59dd-4f85-97d6-0dee01016d85" xlink:href="jnj-20210404.xsd#jnj_SPINEOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_SPINEOTHERMember_eb5d12ff-59dd-4f85-97d6-0dee01016d85" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_dfda6fad-37c9-4ee4-8740-99df9756da4e" xlink:href="jnj-20210404.xsd#jnj_ADVANCEDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_ADVANCEDMember_dfda6fad-37c9-4ee4-8740-99df9756da4e" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_699f1575-27cb-4ae6-9b79-699b3c053d8b" xlink:href="jnj-20210404.xsd#jnj_GENERALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_GENERALMember_699f1575-27cb-4ae6-9b79-699b3c053d8b" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_bf7fa241-4622-4ba1-b8d4-914735f5ad6a" xlink:href="jnj-20210404.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_bf7fa241-4622-4ba1-b8d4-914735f5ad6a" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_05f87a27-7265-40dd-b52b-c802475e60f2" xlink:href="jnj-20210404.xsd#jnj_SURGICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_SURGICALMember_05f87a27-7265-40dd-b52b-c802475e60f2" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_287b612c-e74a-4dea-b30a-bfafcce43974" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:to="loc_srt_StatementGeographicalAxis_287b612c-e74a-4dea-b30a-bfafcce43974" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_287b612c-e74a-4dea-b30a-bfafcce43974_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_287b612c-e74a-4dea-b30a-bfafcce43974" xlink:to="loc_srt_SegmentGeographicalDomain_287b612c-e74a-4dea-b30a-bfafcce43974_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_755f4c60-6441-4ad6-953f-74157748b30a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_287b612c-e74a-4dea-b30a-bfafcce43974" xlink:to="loc_srt_SegmentGeographicalDomain_755f4c60-6441-4ad6-953f-74157748b30a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3e0185d2-bcf6-439b-8aa9-9dddef4eddeb" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_755f4c60-6441-4ad6-953f-74157748b30a" xlink:to="loc_country_US_3e0185d2-bcf6-439b-8aa9-9dddef4eddeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_36013afd-d233-4160-a698-640b70617bd1" xlink:href="jnj-20210404.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_755f4c60-6441-4ad6-953f-74157748b30a" xlink:to="loc_jnj_UNITEDSTATESExportsMember_36013afd-d233-4160-a698-640b70617bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_c9f3176c-b87c-495b-a3fc-3b0fc348d613" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_755f4c60-6441-4ad6-953f-74157748b30a" xlink:to="loc_us-gaap_NonUsMember_c9f3176c-b87c-495b-a3fc-3b0fc348d613" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended" id="i233a5cfca3b248669113712dc0ce5dbc_SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6c717786-8e71-42e5-b0a6-e07826ecf841" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_OperatingIncomeLoss_6c717786-8e71-42e5-b0a6-e07826ecf841" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss_4ac88e29-4eb3-4630-85d6-699603de0add" xlink:href="jnj-20210404.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_jnj_PercentageChangeInOperatingIncomeLoss_4ac88e29-4eb3-4630-85d6-699603de0add" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f3677702-029e-49e4-9081-fb92aff96270" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f3677702-029e-49e4-9081-fb92aff96270" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_5a5d994a-9a97-46fc-a2db-d4c36abf775c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_AdjustmentForAmortization_5a5d994a-9a97-46fc-a2db-d4c36abf775c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_36a7bceb-86dc-4df5-b48d-424e59a8b55d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_36a7bceb-86dc-4df5-b48d-424e59a8b55d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnSecurities_2827c612-0a7a-4395-9d86-d64a39012546" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_UnrealizedGainLossOnSecurities_2827c612-0a7a-4395-9d86-d64a39012546" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_0b0e750c-3c34-40da-8bd1-7eb423a518a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_LitigationSettlementExpense_0b0e750c-3c34-40da-8bd1-7eb423a518a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers_a9a14309-8e37-40d6-afb7-f1b4daf934f6" xlink:href="jnj-20210404.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_jnj_AmountPrepaidAndDueToManufacturers_a9a14309-8e37-40d6-afb7-f1b4daf934f6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7860a57c-733d-4c7e-9e68-3cf413c192e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7860a57c-733d-4c7e-9e68-3cf413c192e0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a5475463-9875-408a-8990-f646aa7fe8a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_RestructuringCharges_a5475463-9875-408a-8990-f646aa7fe8a9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_350762cb-4cbe-4a85-b93b-736184818ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_350762cb-4cbe-4a85-b93b-736184818ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_350762cb-4cbe-4a85-b93b-736184818ed1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_350762cb-4cbe-4a85-b93b-736184818ed1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_350762cb-4cbe-4a85-b93b-736184818ed1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_603a2fd0-5fc9-4576-b388-296dfbff3659" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_350762cb-4cbe-4a85-b93b-736184818ed1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_603a2fd0-5fc9-4576-b388-296dfbff3659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_2eaff85e-77fe-4ac3-a842-097c767a3bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_603a2fd0-5fc9-4576-b388-296dfbff3659" xlink:to="loc_us-gaap_OtherIncomeMember_2eaff85e-77fe-4ac3-a842-097c767a3bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_569992ed-03c3-49bb-9e89-caf94ccf5163" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_569992ed-03c3-49bb-9e89-caf94ccf5163" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_569992ed-03c3-49bb-9e89-caf94ccf5163_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_569992ed-03c3-49bb-9e89-caf94ccf5163" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_569992ed-03c3-49bb-9e89-caf94ccf5163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0755e85-48d0-45fa-a462-629a433148b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_569992ed-03c3-49bb-9e89-caf94ccf5163" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0755e85-48d0-45fa-a462-629a433148b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_8421e46f-c08a-4639-9862-bd9ce40c3553" xlink:href="jnj-20210404.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0755e85-48d0-45fa-a462-629a433148b5" xlink:to="loc_jnj_AurisHealthMember_8421e46f-c08a-4639-9862-bd9ce40c3553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_72a77526-d0f0-4566-9ebd-2a485dc236b6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:to="loc_srt_ConsolidationItemsAxis_72a77526-d0f0-4566-9ebd-2a485dc236b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_72a77526-d0f0-4566-9ebd-2a485dc236b6_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_72a77526-d0f0-4566-9ebd-2a485dc236b6" xlink:to="loc_srt_ConsolidationItemsDomain_72a77526-d0f0-4566-9ebd-2a485dc236b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_44f42990-5cac-4acd-86a2-08557df9efd6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_72a77526-d0f0-4566-9ebd-2a485dc236b6" xlink:to="loc_srt_ConsolidationItemsDomain_44f42990-5cac-4acd-86a2-08557df9efd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_06f00567-ded8-46fc-8dbb-72894ab224ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_44f42990-5cac-4acd-86a2-08557df9efd6" xlink:to="loc_us-gaap_OperatingSegmentsMember_06f00567-ded8-46fc-8dbb-72894ab224ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_f375bd5d-bbb0-436b-9362-dd89309b791c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_44f42990-5cac-4acd-86a2-08557df9efd6" xlink:to="loc_us-gaap_CorporateNonSegmentMember_f375bd5d-bbb0-436b-9362-dd89309b791c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_35d1de4a-b551-4e8d-9356-482384d6f173" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_35d1de4a-b551-4e8d-9356-482384d6f173" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_35d1de4a-b551-4e8d-9356-482384d6f173_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_35d1de4a-b551-4e8d-9356-482384d6f173" xlink:to="loc_us-gaap_SegmentDomain_35d1de4a-b551-4e8d-9356-482384d6f173_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_25275ea7-dcff-4d0f-9382-048b9617496f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_35d1de4a-b551-4e8d-9356-482384d6f173" xlink:to="loc_us-gaap_SegmentDomain_25275ea7-dcff-4d0f-9382-048b9617496f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_69ac4a06-33a3-474f-af62-2b1e29d80ecf" xlink:href="jnj-20210404.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_25275ea7-dcff-4d0f-9382-048b9617496f" xlink:to="loc_jnj_ConsumerMember_69ac4a06-33a3-474f-af62-2b1e29d80ecf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_c46af234-5b54-4fd7-9352-1ddb203a1d32" xlink:href="jnj-20210404.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_25275ea7-dcff-4d0f-9382-048b9617496f" xlink:to="loc_jnj_PharmaceuticalMember_c46af234-5b54-4fd7-9352-1ddb203a1d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_1b341b25-5173-498c-bc7d-88de278ffcdc" xlink:href="jnj-20210404.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_25275ea7-dcff-4d0f-9382-048b9617496f" xlink:to="loc_jnj_MedicalDevicesMember_1b341b25-5173-498c-bc7d-88de278ffcdc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended" id="i2d5cfadfff4644e4b75896ea4ad1efc9_SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c74374e3-756a-4315-8fbc-488a832d4830" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_496f9de3-c4e2-4b74-8ca0-0d2630b6c56f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c74374e3-756a-4315-8fbc-488a832d4830" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_496f9de3-c4e2-4b74-8ca0-0d2630b6c56f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ad423ee8-5191-4965-882f-a2672f5df436" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_496f9de3-c4e2-4b74-8ca0-0d2630b6c56f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ad423ee8-5191-4965-882f-a2672f5df436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea_66d1ee61-0f7e-4821-acca-32f3a938023b" xlink:href="jnj-20210404.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_496f9de3-c4e2-4b74-8ca0-0d2630b6c56f" xlink:to="loc_jnj_PercentageChangeInSalesByGeographicArea_66d1ee61-0f7e-4821-acca-32f3a938023b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_32c4a039-f8cc-475a-83ea-6703eb0645fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c74374e3-756a-4315-8fbc-488a832d4830" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_32c4a039-f8cc-475a-83ea-6703eb0645fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_916b5e35-1ad3-4024-be01-ddf96f49889f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_32c4a039-f8cc-475a-83ea-6703eb0645fd" xlink:to="loc_srt_StatementGeographicalAxis_916b5e35-1ad3-4024-be01-ddf96f49889f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_916b5e35-1ad3-4024-be01-ddf96f49889f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_916b5e35-1ad3-4024-be01-ddf96f49889f" xlink:to="loc_srt_SegmentGeographicalDomain_916b5e35-1ad3-4024-be01-ddf96f49889f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_742d66dd-afc3-4072-b0d8-a6c636acf283" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_916b5e35-1ad3-4024-be01-ddf96f49889f" xlink:to="loc_srt_SegmentGeographicalDomain_742d66dd-afc3-4072-b0d8-a6c636acf283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d35441a0-64b1-472a-b5ea-10438e662cb1" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_742d66dd-afc3-4072-b0d8-a6c636acf283" xlink:to="loc_country_US_d35441a0-64b1-472a-b5ea-10438e662cb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_9fead61c-dd85-4c83-8283-98bfc40351a1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_742d66dd-afc3-4072-b0d8-a6c636acf283" xlink:to="loc_srt_EuropeMember_9fead61c-dd85-4c83-8283-98bfc40351a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_020ad19e-534d-4cb5-baa4-d68aa867dc67" xlink:href="jnj-20210404.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_742d66dd-afc3-4072-b0d8-a6c636acf283" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_020ad19e-534d-4cb5-baa4-d68aa867dc67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_1fb5b5ed-6b29-4648-9fb8-c8a809ae5e81" xlink:href="jnj-20210404.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_742d66dd-afc3-4072-b0d8-a6c636acf283" xlink:to="loc_jnj_AsiaPacificAfricaMember_1fb5b5ed-6b29-4648-9fb8-c8a809ae5e81" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20210404.xsd#AcquisitionsandDivestitures"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended" id="i16516c6979e7435abcb2bdbc5e3a37ad_AcquisitionsandDivestitures"/>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended" id="i94731ce0d1ab42d79c30ae7ba6bda23b_AcquisitionsandDivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_31cd409b-63ea-4882-a1a0-7bb92f818e17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_31cd409b-63ea-4882-a1a0-7bb92f818e17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1c18e86d-9ce9-4faf-9aae-5651f63d1b69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1c18e86d-9ce9-4faf-9aae-5651f63d1b69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_72dad612-f70a-429c-bb10-db7cae6bdd8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_72dad612-f70a-429c-bb10-db7cae6bdd8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_63e32cc2-ab4f-4c6e-8624-ac75ace530d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_Goodwill_63e32cc2-ab4f-4c6e-8624-ac75ace530d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_2066bfd3-9650-498f-a1db-83b0308fb908" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_2066bfd3-9650-498f-a1db-83b0308fb908" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_9d645d61-d6d0-4752-ba6f-fbd278cc5caf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_9d645d61-d6d0-4752-ba6f-fbd278cc5caf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4de7ca8c-f678-4bfd-8264-c26a65dfd937" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4de7ca8c-f678-4bfd-8264-c26a65dfd937" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e8a3b29-fd79-42bd-bdff-036a2e08d0ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e8a3b29-fd79-42bd-bdff-036a2e08d0ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fb696187-a7a0-4398-b5fc-207804ea534b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e8a3b29-fd79-42bd-bdff-036a2e08d0ea" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fb696187-a7a0-4398-b5fc-207804ea534b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fb696187-a7a0-4398-b5fc-207804ea534b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fb696187-a7a0-4398-b5fc-207804ea534b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fb696187-a7a0-4398-b5fc-207804ea534b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1c71c39-52a2-4d34-87a1-b2cb1297bb80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fb696187-a7a0-4398-b5fc-207804ea534b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1c71c39-52a2-4d34-87a1-b2cb1297bb80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_16c22209-b5d0-4170-8cdf-76413b598778" xlink:href="jnj-20210404.xsd#jnj_EvraAndDoxilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1c71c39-52a2-4d34-87a1-b2cb1297bb80" xlink:to="loc_jnj_EvraAndDoxilMember_16c22209-b5d0-4170-8cdf-76413b598778" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d0ef32f3-2c2d-4127-a291-06f4fdf3d19b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e8a3b29-fd79-42bd-bdff-036a2e08d0ea" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d0ef32f3-2c2d-4127-a291-06f4fdf3d19b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0ef32f3-2c2d-4127-a291-06f4fdf3d19b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d0ef32f3-2c2d-4127-a291-06f4fdf3d19b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0ef32f3-2c2d-4127-a291-06f4fdf3d19b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_568bcc85-0b66-4bce-81a9-8abbaa939b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d0ef32f3-2c2d-4127-a291-06f4fdf3d19b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_568bcc85-0b66-4bce-81a9-8abbaa939b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_58b18a6d-f37b-4802-b66f-d87a3b9c5907" xlink:href="jnj-20210404.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_568bcc85-0b66-4bce-81a9-8abbaa939b7c" xlink:to="loc_jnj_BermekimabMember_58b18a6d-f37b-4802-b66f-d87a3b9c5907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalInc.Member_d3c11a05-a733-42be-9918-39b2756a6857" xlink:href="jnj-20210404.xsd#jnj_VerbSurgicalInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_568bcc85-0b66-4bce-81a9-8abbaa939b7c" xlink:to="loc_jnj_VerbSurgicalInc.Member_d3c11a05-a733-42be-9918-39b2756a6857" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="extended" id="ica0e455fba28418280c8c58bb06ae2d9_BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20210404.xsd#LegalProceedings"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended" id="i685e6bca5a1c49598d9490db10a9974b_LegalProceedings"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#LegalProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended" id="i77ac0cd1fa4247fe93f40c33859ef2f6_LegalProceedingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_943639fb-a7a0-4dff-b93c-6a5f00358c79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:href="jnj-20210404.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_943639fb-a7a0-4dff-b93c-6a5f00358c79" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_e9e2d224-c832-4a29-aa89-7a110e45ae6d" xlink:href="jnj-20210404.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_e9e2d224-c832-4a29-aa89-7a110e45ae6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_65654e90-53cf-4099-81de-9847ccfeedbf" xlink:href="jnj-20210404.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:to="loc_jnj_Numberofpatientsinsettlement_65654e90-53cf-4099-81de-9847ccfeedbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_9df3250d-ecaa-463d-81bb-cd3bb06b75ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_9df3250d-ecaa-463d-81bb-cd3bb06b75ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_c91ccfde-56dc-4798-8c4b-fc000f02c6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_c91ccfde-56dc-4798-8c4b-fc000f02c6e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_681d08ec-cb2a-4961-9f58-bce774b53d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_681d08ec-cb2a-4961-9f58-bce774b53d7e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_bf3d5574-3352-4490-a18b-5a13237fc4b5" xlink:href="jnj-20210404.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_bf3d5574-3352-4490-a18b-5a13237fc4b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_943639fb-a7a0-4dff-b93c-6a5f00358c79" xlink:to="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_87f4a946-e87d-496c-a7a7-e73d17c3fad8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:to="loc_srt_LitigationCaseAxis_87f4a946-e87d-496c-a7a7-e73d17c3fad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_87f4a946-e87d-496c-a7a7-e73d17c3fad8_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_87f4a946-e87d-496c-a7a7-e73d17c3fad8" xlink:to="loc_srt_LitigationCaseTypeDomain_87f4a946-e87d-496c-a7a7-e73d17c3fad8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f5dad4b7-e8e3-43ab-9ed3-213e6b9d9949" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_87f4a946-e87d-496c-a7a7-e73d17c3fad8" xlink:to="loc_srt_LitigationCaseTypeDomain_f5dad4b7-e8e3-43ab-9ed3-213e6b9d9949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_d832a36f-917e-4240-acdd-fd2ccf2a2cae" xlink:href="jnj-20210404.xsd#jnj_DePuyASRU.S.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f5dad4b7-e8e3-43ab-9ed3-213e6b9d9949" xlink:to="loc_jnj_DePuyASRU.S.Member_d832a36f-917e-4240-acdd-fd2ccf2a2cae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_9b9072ec-14ad-4fdd-85e7-ddb11d0ebaf5" xlink:href="jnj-20210404.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f5dad4b7-e8e3-43ab-9ed3-213e6b9d9949" xlink:to="loc_jnj_RisperdalMember_9b9072ec-14ad-4fdd-85e7-ddb11d0ebaf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_fc6fe6e1-a4cb-443f-b9f6-ceeec61ba84d" xlink:href="jnj-20210404.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f5dad4b7-e8e3-43ab-9ed3-213e6b9d9949" xlink:to="loc_jnj_BabyPowderMember_fc6fe6e1-a4cb-443f-b9f6-ceeec61ba84d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_8e52e753-6cf9-45f9-ac35-5fc4dde62565" xlink:href="jnj-20210404.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f5dad4b7-e8e3-43ab-9ed3-213e6b9d9949" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_8e52e753-6cf9-45f9-ac35-5fc4dde62565" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_83e0b5bb-1849-47b5-8c0d-c4a96c3205d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:to="loc_us-gaap_LitigationStatusAxis_83e0b5bb-1849-47b5-8c0d-c4a96c3205d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_83e0b5bb-1849-47b5-8c0d-c4a96c3205d0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_83e0b5bb-1849-47b5-8c0d-c4a96c3205d0" xlink:to="loc_us-gaap_LitigationStatusDomain_83e0b5bb-1849-47b5-8c0d-c4a96c3205d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_949ab9a5-7756-4a4b-a317-861d76664155" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_83e0b5bb-1849-47b5-8c0d-c4a96c3205d0" xlink:to="loc_us-gaap_LitigationStatusDomain_949ab9a5-7756-4a4b-a317-861d76664155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_4943267e-6986-4050-aa7d-f1567fdacde8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_949ab9a5-7756-4a4b-a317-861d76664155" xlink:to="loc_us-gaap_SettledLitigationMember_4943267e-6986-4050-aa7d-f1567fdacde8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_16302a67-05e5-41fc-b6fd-d8d92dd0c9c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_949ab9a5-7756-4a4b-a317-861d76664155" xlink:to="loc_us-gaap_JudicialRulingMember_16302a67-05e5-41fc-b6fd-d8d92dd0c9c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_11d30ea4-90f4-49f1-aae9-d4d167e9bccd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_949ab9a5-7756-4a4b-a317-861d76664155" xlink:to="loc_us-gaap_PendingLitigationMember_11d30ea4-90f4-49f1-aae9-d4d167e9bccd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e5212845-46eb-48fb-831a-d471d5aabf56" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:to="loc_srt_ProductOrServiceAxis_e5212845-46eb-48fb-831a-d471d5aabf56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5212845-46eb-48fb-831a-d471d5aabf56_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e5212845-46eb-48fb-831a-d471d5aabf56" xlink:to="loc_srt_ProductsAndServicesDomain_e5212845-46eb-48fb-831a-d471d5aabf56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e5212845-46eb-48fb-831a-d471d5aabf56" xlink:to="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_f92446d9-23f5-4c18-90e8-cb080c7088f0" xlink:href="jnj-20210404.xsd#jnj_AsrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_AsrMember_f92446d9-23f5-4c18-90e8-cb080c7088f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_1c3de180-4841-454d-a29c-2129c8d59b3e" xlink:href="jnj-20210404.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_1c3de180-4841-454d-a29c-2129c8d59b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_3ddf0068-6d27-4c43-a18e-11ad173a97aa" xlink:href="jnj-20210404.xsd#jnj_PelvicMeshesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_PelvicMeshesMember_3ddf0068-6d27-4c43-a18e-11ad173a97aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_9cc45d3c-0bd0-467b-9d4d-a2992819959c" xlink:href="jnj-20210404.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_RisperdalMember_9cc45d3c-0bd0-467b-9d4d-a2992819959c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_279e3c89-fbaf-4614-97d2-ae81b972408a" xlink:href="jnj-20210404.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_XareltoMember_279e3c89-fbaf-4614-97d2-ae81b972408a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_452276ad-8406-43af-83d9-34de404ed540" xlink:href="jnj-20210404.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_TalcMember_452276ad-8406-43af-83d9-34de404ed540" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_42bdabe0-1849-4e6b-bb34-71a9151eb6bc" xlink:href="jnj-20210404.xsd#jnj_InvokanaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_InvokanaMember_42bdabe0-1849-4e6b-bb34-71a9151eb6bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_50f26ea3-8160-488e-afef-b4b5db2b70b5" xlink:href="jnj-20210404.xsd#jnj_PhysiomeshMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_PhysiomeshMember_50f26ea3-8160-488e-afef-b4b5db2b70b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_7b03cd74-9c9f-4c00-ad25-afec4f03f4ad" xlink:href="jnj-20210404.xsd#jnj_OpioidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_OpioidMember_7b03cd74-9c9f-4c00-ad25-afec4f03f4ad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_bc917c78-8a16-485a-ac63-e6288ca9f438" xlink:href="jnj-20210404.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_bc917c78-8a16-485a-ac63-e6288ca9f438" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_bc917c78-8a16-485a-ac63-e6288ca9f438_default" xlink:href="jnj-20210404.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_bc917c78-8a16-485a-ac63-e6288ca9f438" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_bc917c78-8a16-485a-ac63-e6288ca9f438_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_1fbca2be-6ea7-4ad8-bd6a-a803bb4e0686" xlink:href="jnj-20210404.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_bc917c78-8a16-485a-ac63-e6288ca9f438" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_1fbca2be-6ea7-4ad8-bd6a-a803bb4e0686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_847f7f64-6212-4f48-a238-b25fb06a92a1" xlink:href="jnj-20210404.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_1fbca2be-6ea7-4ad8-bd6a-a803bb4e0686" xlink:to="loc_jnj_RisperdalMember_847f7f64-6212-4f48-a238-b25fb06a92a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84d0ad96-f70a-41a2-824d-83ac393de14d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84d0ad96-f70a-41a2-824d-83ac393de14d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_84d0ad96-f70a-41a2-824d-83ac393de14d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84d0ad96-f70a-41a2-824d-83ac393de14d" xlink:to="loc_us-gaap_LossContingencyNatureDomain_84d0ad96-f70a-41a2-824d-83ac393de14d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b9cf850f-1a88-4fd8-a6f4-587a2f6f8947" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84d0ad96-f70a-41a2-824d-83ac393de14d" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b9cf850f-1a88-4fd8-a6f4-587a2f6f8947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_8e3b5a5b-3808-4728-8f6e-812e256727b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b9cf850f-1a88-4fd8-a6f4-587a2f6f8947" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_8e3b5a5b-3808-4728-8f6e-812e256727b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20210404.xsd#Restructuring"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended" id="ib512eafa4488476387bc20a5af2e5857_Restructuring"/>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#RestructuringTables"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended" id="i9c046ce1af2d4f13aa8a23a1f9160cb0_RestructuringTables"/>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="i95d8829ded054d95856d2464bd666061_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0ed36c38-933a-4727-8c2e-beb85e3015e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:to="loc_us-gaap_RestructuringCharges_0ed36c38-933a-4727-8c2e-beb85e3015e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_f6cf0310-4db0-4c46-ac4e-9940bcc62fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_f6cf0310-4db0-4c46-ac4e-9940bcc62fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_a2de3b28-9cee-4674-bb12-bb4dab782aa3" xlink:href="jnj-20210404.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_a2de3b28-9cee-4674-bb12-bb4dab782aa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_ca723c9d-9ef6-48f8-9b12-8f47b7565d54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_ca723c9d-9ef6-48f8-9b12-8f47b7565d54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_19b29391-5f1b-4427-8637-0718e419d059" xlink:href="jnj-20210404.xsd#jnj_RestructuringandRelatedCostDurationofRestructuringPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:to="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_19b29391-5f1b-4427-8637-0718e419d059" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6592f620-624f-4629-8856-6b2653cde291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6592f620-624f-4629-8856-6b2653cde291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6592f620-624f-4629-8856-6b2653cde291_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6592f620-624f-4629-8856-6b2653cde291" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6592f620-624f-4629-8856-6b2653cde291_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_071a4e68-2c27-4279-95dc-97c0008f53cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6592f620-624f-4629-8856-6b2653cde291" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_071a4e68-2c27-4279-95dc-97c0008f53cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_fc00de50-4c3f-4e58-b9e2-7e9487f11e10" xlink:href="jnj-20210404.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_071a4e68-2c27-4279-95dc-97c0008f53cd" xlink:to="loc_jnj_SupplyChainMember_fc00de50-4c3f-4e58-b9e2-7e9487f11e10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d266dbe2-a7bb-4220-b374-977d8eaf5373" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d266dbe2-a7bb-4220-b374-977d8eaf5373" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d266dbe2-a7bb-4220-b374-977d8eaf5373_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d266dbe2-a7bb-4220-b374-977d8eaf5373" xlink:to="loc_us-gaap_SegmentDomain_d266dbe2-a7bb-4220-b374-977d8eaf5373_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dbc342d6-733a-47f4-bc4e-b56f3262f89f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d266dbe2-a7bb-4220-b374-977d8eaf5373" xlink:to="loc_us-gaap_SegmentDomain_dbc342d6-733a-47f4-bc4e-b56f3262f89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_140b80e2-b80f-4801-8adb-4e9668f0cc25" xlink:href="jnj-20210404.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dbc342d6-733a-47f4-bc4e-b56f3262f89f" xlink:to="loc_jnj_MedicalDevicesMember_140b80e2-b80f-4801-8adb-4e9668f0cc25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_20964b70-f706-406b-8b4f-d4f4d7a22f70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:to="loc_us-gaap_RestructuringPlanAxis_20964b70-f706-406b-8b4f-d4f4d7a22f70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_20964b70-f706-406b-8b4f-d4f4d7a22f70_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_20964b70-f706-406b-8b4f-d4f4d7a22f70" xlink:to="loc_us-gaap_RestructuringPlanDomain_20964b70-f706-406b-8b4f-d4f4d7a22f70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3b910c40-70cd-4f8d-a5a9-eb3989dc9587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_20964b70-f706-406b-8b4f-d4f4d7a22f70" xlink:to="loc_us-gaap_RestructuringPlanDomain_3b910c40-70cd-4f8d-a5a9-eb3989dc9587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_dcf5c724-8410-4d43-a33e-8acbc2e22c41" xlink:href="jnj-20210404.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_3b910c40-70cd-4f8d-a5a9-eb3989dc9587" xlink:to="loc_jnj_SupplyChainMember_dcf5c724-8410-4d43-a33e-8acbc2e22c41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1b869f31-1266-4ce3-8df2-df2a24922520" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:to="loc_srt_RangeAxis_1b869f31-1266-4ce3-8df2-df2a24922520" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b869f31-1266-4ce3-8df2-df2a24922520_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1b869f31-1266-4ce3-8df2-df2a24922520" xlink:to="loc_srt_RangeMember_1b869f31-1266-4ce3-8df2-df2a24922520_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_10108700-adef-401e-9048-c858c825c43c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1b869f31-1266-4ce3-8df2-df2a24922520" xlink:to="loc_srt_RangeMember_10108700-adef-401e-9048-c858c825c43c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4bf99377-e673-4766-830a-7d78d7908711" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_10108700-adef-401e-9048-c858c825c43c" xlink:to="loc_srt_MinimumMember_4bf99377-e673-4766-830a-7d78d7908711" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b755ee75-8d4a-43f1-8f55-5dc404999051" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_10108700-adef-401e-9048-c858c825c43c" xlink:to="loc_srt_MaximumMember_b755ee75-8d4a-43f1-8f55-5dc404999051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ed7dd730-72c7-483b-8604-223372176b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ed7dd730-72c7-483b-8604-223372176b6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ed7dd730-72c7-483b-8604-223372176b6d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ed7dd730-72c7-483b-8604-223372176b6d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ed7dd730-72c7-483b-8604-223372176b6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e481cf25-c718-4838-8216-8b020dcd7a62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ed7dd730-72c7-483b-8604-223372176b6d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e481cf25-c718-4838-8216-8b020dcd7a62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_8a36f6b8-5324-4a1e-b9d0-b67f1c7473d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e481cf25-c718-4838-8216-8b020dcd7a62" xlink:to="loc_us-gaap_RestructuringChargesMember_8a36f6b8-5324-4a1e-b9d0-b67f1c7473d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d7744093-7b72-48b1-b7aa-24c1322f51b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e481cf25-c718-4838-8216-8b020dcd7a62" xlink:to="loc_us-gaap_CostOfSalesMember_d7744093-7b72-48b1-b7aa-24c1322f51b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_71f1bec7-dfa0-4553-85a6-03c74be66113" xlink:href="jnj-20210404.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e481cf25-c718-4838-8216-8b020dcd7a62" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_71f1bec7-dfa0-4553-85a6-03c74be66113" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended" id="i85ccd3b3e36f493e9036bbc72b4e43e3_RestructuringScheduleofRestructuringReserveDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c20bbb3a-9009-4314-bfcb-41528e52b54c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c20bbb3a-9009-4314-bfcb-41528e52b54c" xlink:to="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_10d94c04-bed7-4fe6-abe2-c15d1456149e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:to="loc_us-gaap_RestructuringReserve_10d94c04-bed7-4fe6-abe2-c15d1456149e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_7021b443-545f-4f1a-acfd-27cc5ade7afc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:to="loc_us-gaap_RestructuringCharges_7021b443-545f-4f1a-acfd-27cc5ade7afc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_6f221f2a-b84b-4ddd-bbb9-b99b6cc770df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:to="loc_us-gaap_PaymentsForRestructuring_6f221f2a-b84b-4ddd-bbb9-b99b6cc770df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_d3456e02-4f42-4d68-a325-47ee1d54f66a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_d3456e02-4f42-4d68-a325-47ee1d54f66a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c8b0d098-75ab-4fbd-9a1f-f1f9ac7ed001" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_39683605-b91c-4ad2-8593-a480f3c22c91" xlink:href="jnj-20210404.xsd#jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c20bbb3a-9009-4314-bfcb-41528e52b54c" xlink:to="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_39683605-b91c-4ad2-8593-a480f3c22c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bb6f1fe-4420-417e-80c9-ae99b3ba1f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c20bbb3a-9009-4314-bfcb-41528e52b54c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bb6f1fe-4420-417e-80c9-ae99b3ba1f5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_717b9206-99da-4e84-b43a-9e691d6dbb70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bb6f1fe-4420-417e-80c9-ae99b3ba1f5f" xlink:to="loc_us-gaap_RestructuringPlanAxis_717b9206-99da-4e84-b43a-9e691d6dbb70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_717b9206-99da-4e84-b43a-9e691d6dbb70_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_717b9206-99da-4e84-b43a-9e691d6dbb70" xlink:to="loc_us-gaap_RestructuringPlanDomain_717b9206-99da-4e84-b43a-9e691d6dbb70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b8a704b1-6d53-46ab-afe6-58fca6cee5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_717b9206-99da-4e84-b43a-9e691d6dbb70" xlink:to="loc_us-gaap_RestructuringPlanDomain_b8a704b1-6d53-46ab-afe6-58fca6cee5a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_44481e5d-9857-490a-a692-c039ef29cada" xlink:href="jnj-20210404.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_b8a704b1-6d53-46ab-afe6-58fca6cee5a1" xlink:to="loc_jnj_MedicalDevicesMember_44481e5d-9857-490a-a692-c039ef29cada" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_3a960ab2-6d61-41c9-9c00-dded03493299" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bb6f1fe-4420-417e-80c9-ae99b3ba1f5f" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_3a960ab2-6d61-41c9-9c00-dded03493299" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3a960ab2-6d61-41c9-9c00-dded03493299_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3a960ab2-6d61-41c9-9c00-dded03493299" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3a960ab2-6d61-41c9-9c00-dded03493299_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_fb1e34d8-5542-4ff6-8b48-8b8fc8e83abd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3a960ab2-6d61-41c9-9c00-dded03493299" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_fb1e34d8-5542-4ff6-8b48-8b8fc8e83abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_da18bff2-d11c-4d72-9b8e-424383131e35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_fb1e34d8-5542-4ff6-8b48-8b8fc8e83abd" xlink:to="loc_us-gaap_EmployeeSeveranceMember_da18bff2-d11c-4d72-9b8e-424383131e35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_238f80e1-249b-4ff5-a19e-50a01e6fb377" xlink:href="jnj-20210404.xsd#jnj_AssetWriteoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_fb1e34d8-5542-4ff6-8b48-8b8fc8e83abd" xlink:to="loc_jnj_AssetWriteoffMember_238f80e1-249b-4ff5-a19e-50a01e6fb377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_a9a91aeb-99a2-44ca-be02-bb947ee14860" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_fb1e34d8-5542-4ff6-8b48-8b8fc8e83abd" xlink:to="loc_us-gaap_OtherRestructuringMember_a9a91aeb-99a2-44ca-be02-bb947ee14860" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>jnj-20210404_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1a2ac66c-2667-4890-bd3c-b889272a48e4,g:4415be36-51dc-414c-a907-a89d836331d3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c59c9c2d-06fc-43f9-9b82-c0180ae8f047_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c5602648-b419-477d-a888-1925d23eadb0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8896c152-ce2e-4591-92bc-4cf863240c3b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8562c1e5-7c18-45f6-8b76-be11fe911022_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_42c3d180-8e0a-4868-823f-9fe4a7fef414_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_2d3cc985-662f-4b6e-9089-11e5c0723ce8_terseLabel_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_label_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_documentation_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:href="jnj-20210404.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:to="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyPowderMember_99c4f305-4070-4814-88e0-693d71fc5360_terseLabel_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder</link:label>
    <link:label id="lab_jnj_BabyPowderMember_label_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:label id="lab_jnj_BabyPowderMember_documentation_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember" xlink:href="jnj-20210404.xsd#jnj_BabyPowderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyPowderMember" xlink:to="lab_jnj_BabyPowderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_707d1792-b3ff-49b4-ac58-c5f5147d43be_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration reversal</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c36f7ef9-608a-4d1f-8cd7-1e6010da04d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_6407b089-c385-4895-af27-bd50ba8ca96b_terseLabel_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value (6)</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_label_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:href="jnj-20210404.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:to="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_fb70fe4b-bcc1-47aa-a565-f170cb5873d3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8fd218d4-76d1-4f8a-9241-750fcf25c1cd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_99606a8c-444f-450f-8a68-9c65aad1781e_terseLabel_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for activity</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_label_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Duration of Restructuring Plan</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_documentation_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Duration of Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:href="jnj-20210404.xsd#jnj_RestructuringandRelatedCostDurationofRestructuringPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:to="lab_jnj_RestructuringandRelatedCostDurationofRestructuringPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_fbeebe45-dd90-4b9b-a464-39099c5b5f9a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConsumerMember_9d526e88-1a28-4f07-92a6-340e57db9ea5_terseLabel_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Health</link:label>
    <link:label id="lab_jnj_ConsumerMember_label_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer [Member]</link:label>
    <link:label id="lab_jnj_ConsumerMember_documentation_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember" xlink:href="jnj-20210404.xsd#jnj_ConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConsumerMember" xlink:to="lab_jnj_ConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DARZALEXMember_8c663ff9-6bfb-4934-bae1-17597f3cd2ba_terseLabel_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX&#174;</link:label>
    <link:label id="lab_jnj_DARZALEXMember_label_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:label id="lab_jnj_DARZALEXMember_documentation_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember" xlink:href="jnj-20210404.xsd#jnj_DARZALEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DARZALEXMember" xlink:to="lab_jnj_DARZALEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_4317cfd8-a434-4474-b2d5-163479066e81_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities - Carrying Amount</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_0d46176c-8df3-4efa-9f48-eff402ed2e2e_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. sovereign securities(1)</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7ccaface-d555-4383-9219-2c399d8cb015_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ADVANCEDMember_62176721-8540-4892-a02b-dfddb5d331a5_terseLabel_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_label_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_documentation_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember" xlink:href="jnj-20210404.xsd#jnj_ADVANCEDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ADVANCEDMember" xlink:to="lab_jnj_ADVANCEDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0d4dbed7-68bb-47cc-b0b7-4dc51d539ff7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_c10cceac-17e7-4947-baf3-972c461035b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_306f2586-2d6d-4643-9eb3-55609f4cca20_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, related to acquisitions and divestitures</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_f04b0385-e4c8-429a-bf16-cc0229dab543_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_37a2372c-a670-47b3-96fa-5801d44bd5ca_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_6265da08-ab69-4ef8-b09b-1569b228fa59_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_3a6acd4e-3af5-4ef5-a7c3-697ad858befd_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change in Operating Income Loss</link:label>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_label_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change in Operating Income Loss</link:label>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in operating income loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss" xlink:href="jnj-20210404.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInOperatingIncomeLoss" xlink:to="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a8ae3b3d-9606-4942-99f2-e4ed20bd0f82_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Standards Recently Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f4532b86-ceeb-4bfc-bca0-019aa5763080_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bb0dcb08-fbc7-4777-8db1-f64c34135290_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5c0351da-fc98-4205-8625-275631d7595f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_b1b7cacb-1c7e-4dff-9ff3-aada243cbe87_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_fa311003-4b4e-4615-809a-fc655b8e4a4a_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_1a08a5b1-bba3-4584-9cf6-8c61d67af05b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_20bf9132-8e61-42b5-9b1f-e0944ff418a6_terseLabel_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_label_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_documentation_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member" xlink:href="jnj-20210404.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.75Notesdue2047Member" xlink:to="lab_jnj_A3.75Notesdue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_344e913e-a2b5-4822-9d1d-7788336bc25b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_42c0014a-1fba-49ce-a9b4-c6b312908aee_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_100bbd77-2097-4c18-bd53-d97522640bea_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding &#8212; diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_a19dcfa6-7de2-4a99-bbfe-48d761f28d80_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:to="lab_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_4883915d-e96b-488e-8458-c9f85119cbee_verboseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_aad5a302-ee23-44af-9b53-fc61150f0639_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_f656e42e-d78a-4ffa-8d8d-ac6cf7e9b8a1_terseLabel_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES / OTHER</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_label_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_documentation_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember" xlink:href="jnj-20210404.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONTACTLENSESOTHERMember" xlink:to="lab_jnj_CONTACTLENSESOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_89430ace-f872-4750-b6e4-c2b96049f3be_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for Sale Securities Maturities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_ca41fdfa-ddd5-442b-853b-4857118f4572_negatedTerseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Unrecognized Loss</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:href="jnj-20210404.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:to="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_cde60db4-3e26-432f-8388-b059538386f3_negatedTerseLabel_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: shares which could be repurchased under treasury stock method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_label_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Which Could Be Repurchased Under Treasury Stock Method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_documentation_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:href="jnj-20210404.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:to="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1b4ad599-6aab-4c07-968c-70c3ef2c1fa9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_HIPSMember_692f523e-3fab-411f-a5e0-7a3815bb8a67_terseLabel_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS</link:label>
    <link:label id="lab_jnj_HIPSMember_label_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:label id="lab_jnj_HIPSMember_documentation_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember" xlink:href="jnj-20210404.xsd#jnj_HIPSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_HIPSMember" xlink:to="lab_jnj_HIPSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_53d7bca7-0da5-43fd-a888-5aa8f2bd749c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dbbb63c3-97cd-45f9-9eac-560b98321830_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_40e2b0f1-9edd-4f01-abfe-cc2e1d48efb0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_f1c3918d-b535-44a7-a51a-12652dedf0e0_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9c361634-7b1c-4dcd-8f67-d89c4ec0906d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_cc4c4cde-38f1-42e2-a95a-38c8a37d33b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; Hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_228859f9-1fca-44b9-a614-e3fd7511d1ee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_4979a248-74f8-4c93-b76c-7ff0b090a2b7_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7fad1269-8bb8-4d5f-9d0b-5cb07590cf21_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Unrecognized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_8d6f7e93-59c2-4b60-b753-7ba1cea85918_verboseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due May 2035</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_54c764ca-70d2-441d-8f90-ee6f148949b3_terseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes due 2035 (1.5B Euro 1.1757)</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_label_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_documentation_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member" xlink:href="jnj-20210404.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.650NotesDue2035Member" xlink:to="lab_jnj_A1.650NotesDue2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_42a6a02b-f5b4-4652-9d01-e255f9fef79d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_c400f55d-c203-4b67-ba76-b7fd52cef4b6_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_653aea1f-2be9-4bf1-bc32-140c3f1b0ef4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) reclassified from AOCI into income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_d41cfbd4-86d1-44c7-b614-1c159c8d8347_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of basic net earnings per share to diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_e1accd10-a358-4812-9c80-201e821a2dbb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_8d7d7245-025a-499a-ae03-863d3b896a4f_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:href="jnj-20210404.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentRollForward_dec43a62-acc4-4480-81bb-7217b4a15843_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_label_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentRollForward" xlink:to="lab_jnj_EquityInvestmentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_cc0cd1de-2785-4ec2-9aee-370362ac0967_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_74454af5-c5e5-4b08-9bcd-bbb91b65d824_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_e2163b0b-b7e2-4ae5-b183-a414cce116aa_terseLabel_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_label_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_documentation_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember" xlink:href="jnj-20210404.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTHERNEUROSCIENCEMember" xlink:to="lab_jnj_OTHERNEUROSCIENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_a11b53a6-23a7-4834-872d-7db267505be9_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International retirement plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_e7d12a48-8a2a-42c5-a48b-c32a2db402ef_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_3dc83f87-c423-4d6d-bedf-194cd524c3e1_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6b05c924-988f-4fbc-bdc9-6cf53450a208_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_fb808153-335a-4424-93c3-b192e5624c0c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term taxes payable (Note 5)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b5b73bd6-ebc4-48fa-b469-ac17f842bc29_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_8cc83af8-dd9b-4099-acb6-6c349cb73a2f_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities at fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument Detail [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PhysiomeshMember_a0e5134d-d1c3-4235-92a4-273ef9080113_terseLabel_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_label_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_documentation_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember" xlink:href="jnj-20210404.xsd#jnj_PhysiomeshMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PhysiomeshMember" xlink:to="lab_jnj_PhysiomeshMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_08600cc9-2899-4547-8663-d71beae9fc0a_verboseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_7e686ebd-5c58-44e0-bc1e-97217fa95ec1_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_ebb28d7a-215c-455c-b383-f4b6f5624998_terseLabel_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_label_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_documentation_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement" xlink:href="jnj-20210404.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Numberofpatientsinsettlement" xlink:to="lab_jnj_Numberofpatientsinsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4a2b3e60-5a0f-43b2-889a-2d5a570982a9_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments of Business and Geographic Areas</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_078ec3f4-4c95-42a4-afc3-810c1bb0b1e7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_434e0a84-9cdc-42d6-8805-94e3f83da4e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_db4db20f-a894-48a4-bc59-92e162303794_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information, Revenue for Reportable Segment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_3c4ffe51-b87b-43f6-b6f8-a675738d69e2_terseLabel_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_label_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_documentation_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member" xlink:href="jnj-20210404.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.95Notesdue2029Member" xlink:to="lab_jnj_A6.95Notesdue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_170f4476-d34a-4d82-902c-418c727919d8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_55d7d73a-1bd4-4031-a6f6-0ac8f3de11ab_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_18ea1e60-061a-4fe5-b39c-e4cfcedbb952_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_fcfd4f3e-d566-4079-8f6b-3be91c659025_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_85153a5c-7cfe-440a-bf69-ebf963ed695b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ff0b0db-1c90-4783-b323-c19f130f3c9b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_81f1bcd8-8c38-4eac-9ba6-d5d72a04007f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7bc7f123-5a8d-439c-8b1a-9b68b4b9cc6f_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with definite lives:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvokanaMember_5c330bd5-9ba8-4ac0-b29d-8478a34cd58a_terseLabel_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana</link:label>
    <link:label id="lab_jnj_InvokanaMember_label_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:label id="lab_jnj_InvokanaMember_documentation_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember" xlink:href="jnj-20210404.xsd#jnj_InvokanaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvokanaMember" xlink:to="lab_jnj_InvokanaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_0b1aa131-d184-4862-9fd3-b574d9637494_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_4497aa43-d465-4db4-b062-fc063a203f65_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_e777ae91-e03d-4c48-b7ed-e319203d33d9_terseLabel_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S.</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_label_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_documentation_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember" xlink:href="jnj-20210404.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WesternHemisphereExcludingUSMember" xlink:to="lab_jnj_WesternHemisphereExcludingUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_b1bd9429-1578-43e5-9052-d2c54c2780e7_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_14000290-5f2e-4f6c-aa34-5fce6ce5c6f9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_eb7dd087-89d3-464a-afb6-918188c659d1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_e9d80b58-24db-488d-ac8d-043521782d9d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_918e8e3f-f1b2-4cdc-a0d3-7a48ce8d4f76_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_c44db604-2105-4c3e-ab81-65a804962d8e_terseLabel_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income percent to sales</link:label>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_label_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income Interest Percent To Sales</link:label>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_documentation_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income interest percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales" xlink:href="jnj-20210404.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvestmentIncomeInterestPercentToSales" xlink:to="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a8242550-ac44-49d6-9bd0-f59348f0d17a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_5603b3dd-75e2-4ac0-8fc8-8f67704f49cc_terseLabel_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net percent to sales</link:label>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_label_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Operating Income Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non operating income expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:href="jnj-20210404.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:to="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_899b6d44-24fc-45f1-8cbd-3ae065933c53_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_4d28cc42-437b-4c95-8fb0-a8625359877c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Amount</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_09f9e5bf-7f15-4733-ac40-e91e90b127db_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BeautyMember_7593e120-2dd4-4d2b-a7e2-556dd951ea87_terseLabel_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin Health/Beauty</link:label>
    <link:label id="lab_jnj_BeautyMember_label_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty [Member]</link:label>
    <link:label id="lab_jnj_BeautyMember_documentation_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember" xlink:href="jnj-20210404.xsd#jnj_BeautyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BeautyMember" xlink:to="lab_jnj_BeautyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent_d1ea217c-5c9a-47d7-aa7c-570e2d1fec8f_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net impact to tax rate due to change in contingent consideration liability</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Contingent Consideration Liability, Percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Contingent Consideration Liability, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent" xlink:href="jnj-20210404.xsd#jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_16f14039-9bdf-42be-a489-02bc646925a1_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Business Segments</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_f2ebbae3-b0fc-4832-8245-8f106d443c4a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_881b25c1-cec6-44a0-a5e9-cd96f02337e4_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_059189c7-f491-4020-8bb0-688f70737e3d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_bbdd538c-7a68-4106-ae7a-a2554102d361_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c96019a5-482d-45dc-9b75-6b026327cb5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_9a69c38f-1041-47ea-815c-fc8dfea16bb0_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: common stock held in treasury, at cost (487,141,000 and 487,331,000 shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_449c1701-0b17-4c58-b2ea-cf4030e24866_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_ba698847-a431-47c8-b765-481d2d48c0d1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_09ac0d5d-6a64-4fad-87c6-cc072b24be9d_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d15ef4ac-dafa-4fcb-b287-6e9c5d06a258_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_8cd0ee18-945f-4809-9519-0afd973cc162_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_COVID19Member_0ffd4163-b878-455c-bc11-76cde928b7fd_terseLabel_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_jnj_COVID19Member_label_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_jnj_COVID19Member_documentation_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member" xlink:href="jnj-20210404.xsd#jnj_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_COVID19Member" xlink:to="lab_jnj_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_93aad36e-99f1-4318-8384-4a43e2e8a752_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_557a0be2-3a08-4369-aef0-a1af3c977739_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by geographic area</link:label>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments, Geographical Areas [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:to="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2b3b5fcb-2383-4bb1-97c6-7a29e4f88e98_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_67ec1041-e8f7-4031-92c1-d1180af6b543_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b9e40392-afbf-4937-b469-5f8bfbff793d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Segment Operating Income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_5b5bb12f-6aa7-49ca-9db9-a22ecfef234e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_8f4b6dcd-febc-4a9b-96ad-1e0ae075398f_terseLabel_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member" xlink:href="jnj-20210404.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.375Notesdue2023Member" xlink:to="lab_jnj_A3.375Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_eea66c44-d5aa-419b-a8c4-202fa95b2a7b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_a7198e3c-d382-4695-85af-23f246b7a012_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Note 3)</link:label>
    <link:label id="lab_us-gaap_Goodwill_ab52155e-bbc6-49ae-a9e6-d4a806392ed8_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Beginning of Period</link:label>
    <link:label id="lab_us-gaap_Goodwill_d5cf4edb-f0cc-4b46-93cf-128ea2845c28_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill End of Period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DePuyASRU.S.Member_d558dc74-e0d9-4905-90ae-11816516137d_terseLabel_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S.</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_label_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_documentation_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member" xlink:href="jnj-20210404.xsd#jnj_DePuyASRU.S.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DePuyASRU.S.Member" xlink:to="lab_jnj_DePuyASRU.S.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A095NotesDue2027Member_035f87e7-4ed6-4f60-996d-2e1c9f536836_terseLabel_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_label_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_documentation_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member" xlink:href="jnj-20210404.xsd#jnj_A095NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A095NotesDue2027Member" xlink:to="lab_jnj_A095NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_f087af28-a1e3-4558-991d-ae24d106ec76_terseLabel_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA&#174; / PREZCOBIX&#174; / REZOLSTA&#174; / SYMTUZA&#174;</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_label_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_documentation_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:href="jnj-20210404.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:to="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_0e051192-944f-4294-91b4-027dbb5f4eaa_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_3a29f715-83de-4b66-b704-49022763b0a5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_911761ae-619f-4a2a-86fa-72d131f49558_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_da4532ed-8dee-4f94-b58c-5da1ad327b2a_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fc4d5bc4-a2e7-4b43-87a5-e0c569d27ab1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fd0bf659-1198-41fe-a5d4-111a324beab2_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73c30acd-4fab-4da6-a1ba-2b451348a150_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3575ea94-d3da-4fca-b268-6f10e160a364_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0fdec876-ff81-46e5-9c82-85fbb49a2ca0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f12a6fe8-51bc-4876-b12d-f39d1d44078e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_07100a9d-554c-453b-98af-0836d2f4c275_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e07e7bdd-cb05-4383-acd7-aa8beb5edf2e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c02aa1a5-23b4-404f-afe6-74c1f0a6fe8b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bccd77b1-576c-44b7-8a56-894c26bbb21d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SupplyChainMember_f3c71638-448f-4777-9957-e3df9b01aebe_terseLabel_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:label id="lab_jnj_SupplyChainMember_label_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain [Member]</link:label>
    <link:label id="lab_jnj_SupplyChainMember_documentation_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember" xlink:href="jnj-20210404.xsd#jnj_SupplyChainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SupplyChainMember" xlink:to="lab_jnj_SupplyChainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_58daac7e-350d-4b54-a1ed-0ffbfb9ff91f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_69e6de8f-e2fc-4895-82e1-d81dc5cf726b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_51f903fa-dfca-42b9-9508-93d2ecfd2c38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_d01c82b9-cd9a-4307-8be1-d952da90ba64_terseLabel_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member" xlink:href="jnj-20210404.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.375Notesdue2033Member" xlink:to="lab_jnj_A4.375Notesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_59d32767-a10d-400d-8a85-0fa29f90c0e9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_ec4aac76-a9f4-497a-b97e-b3912a74a9ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_78082e10-d672-475c-a4c9-76b7f1649df7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_41ad3018-030a-45c8-8029-5957d81e7f01_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_f5cbb715-734a-415b-b55c-830bd317b80c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_12a49b1f-c7c9-4d19-9ae3-c46defdabaea_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_af0b3c35-905b-41b0-ba0d-0250c9f4ac5d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities - Carrying Amount</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1aacb07d-aefe-417b-9c20-b7eea3b22d71_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ce8e04f1-a2c2-4428-b62a-6e741b3a7e40_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ce5304e0-7400-4788-9b85-9ac0a7eb7782_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d69af5ce-76f3-49ce-b89b-bc28bb3e75f1_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVG. SHARES OUTSTANDING</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_5b958541-5e4a-4694-a558-606f1e37691d_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1d70793b-fff0-4382-88ba-1771ec412ef7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted prices in active markets for identical assets and liabilities Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_be2d8a84-62d5-44f1-8bc0-49772db3b213_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_fcc239a1-fb1e-4e33-924c-9d549ad34213_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_fe366942-8892-414a-801c-a6437774a097_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1befdc9c-c5b9-4c8f-bc85-7499b9b5a849_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_67971f10-7acf-40d9-81c4-5b49897c265d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_3477d6be-b2c2-4f81-b7ec-e31d89299d1a_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1300NotesDue2030Member_a53554c0-a260-4f98-b4ee-5ade91e4c64b_terseLabel_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:label id="lab_jnj_A1300NotesDue2030Member_label_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.300% Notes due 2030 [Member]</link:label>
    <link:label id="lab_jnj_A1300NotesDue2030Member_documentation_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.300% Notes due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member" xlink:href="jnj-20210404.xsd#jnj_A1300NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1300NotesDue2030Member" xlink:to="lab_jnj_A1300NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_9df55d18-d922-4120-9ee7-3b954f68903f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate on non-current debt</link:label>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_fd6bbaaf-c13e-459c-b116-973883af3ca6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_4d9e1ee1-0f61-4359-b278-0bfde9fd0d10_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments and settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_819a6eaa-425d-4005-987d-ccb8edae9d31_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposal of assets/businesses, net (Note 10)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_70660d12-7399-4e54-83e0-b44cdec0bb3e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, trade, less allowances for doubtful accounts and credit losses $270 (2020, $293)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_db769bdf-b238-43e1-b4bb-05eb8a6f630b_terseLabel_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular / Metabolism / Other</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_label_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_documentation_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember" xlink:href="jnj-20210404.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CardiovascularMetabolismOtherMember" xlink:to="lab_jnj_CardiovascularMetabolismOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_aa015abd-48d5-43c6-ab1e-d2cf80c88a63_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1ab4173f-f670-4120-9965-93575f124bf8_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_26679cf9-c912-4a62-9da5-f50ac021c66a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_dabb5920-ebaa-434b-ba9e-41592467bb7a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goods in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ab63f193-1046-42c7-8b11-20a5eff9885d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_1b88f8e4-4e4b-4478-96b2-ed3c74bd8a54_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost amortization during period</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:href="jnj-20210404.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_b3c01328-f668-4871-a52b-c2b299c268b3_terseLabel_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals)</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_label_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals) [Abstract]</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_documentation_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding Textuals Abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract" xlink:href="jnj-20210404.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalProceedingTextualsAbstract" xlink:to="lab_jnj_LegalProceedingTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_5474123c-dae9-420a-b4f7-7dfef6734faf_terseLabel_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA&#174; / XEPLION&#174; / INVEGA TRINZA&#174; / TREVICTA&#174;</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_label_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_documentation_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:href="jnj-20210404.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:to="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a4627f3b-1556-4ba5-9377-734c0883bc8f_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_77f18bea-f7eb-4900-9504-223caaa99aa6_verboseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates, returns and promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_label_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_documentation_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:href="jnj-20210404.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:to="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_df94bf03-fa17-4309-9be0-d181fb580dab_terseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:href="jnj-20210404.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:to="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_554f19ea-9bb4-4fd6-b937-b15ba271d0ad_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyCareMember_94f64516-39eb-4f2c-a292-c9c7f04ed277_terseLabel_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care</link:label>
    <link:label id="lab_jnj_BabyCareMember_label_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:label id="lab_jnj_BabyCareMember_documentation_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember" xlink:href="jnj-20210404.xsd#jnj_BabyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyCareMember" xlink:to="lab_jnj_BabyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_dbc86eb5-1e2a-4e81-8451-d232c5e654cb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_c71e0681-d257-4a37-93a6-3f79ffd3c107_terseLabel_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_label_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System [Member]</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_documentation_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular cup system.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:href="jnj-20210404.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:to="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9c9a836b-7d20-49be-9937-6ed0cb20623f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_39d0b5e6-32b5-4d33-96e9-79b54793e4c7_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_3701725c-991c-4b72-b960-c2b6c69a4024_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_bcef34ba-77b1-4a0e-8943-1c28cbd32007_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_90c9c5b0-1883-4753-8433-ead5f3fb03ca_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7767bf62-34e7-40d6-9d1b-71953c83b5f2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1d39b6c5-9a6a-490b-89cb-047a81ff2fd4_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_08728d13-9061-4fe9-917b-deae2eee8cf9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_10423684-6907-4e8e-8070-91fa0958f075_terseLabel_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_label_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_documentation_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member" xlink:href="jnj-20210404.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Debenturesdue2040Member" xlink:to="lab_jnj_A4.50Debenturesdue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_b86ee848-2ba8-42db-9569-7a39f2768cad_terseLabel_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_label_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_documentation_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member" xlink:href="jnj-20210404.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55Notesdue2036Member" xlink:to="lab_jnj_A3.55Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d6d090d2-819b-48df-96e3-5c661d8748af_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_acf7e2e0-a325-476d-8b79-d77c07e98011_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par Value $1.00</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_0238596b-2176-4182-8d97-7e6ac4e6136b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued Amount</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e408c8f9-79c7-4799-8d32-b065abfa39ac_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TalcMember_7fb2745d-8fe6-4f18-82e4-32f88d3be151_terseLabel_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc</link:label>
    <link:label id="lab_jnj_TalcMember_label_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:label id="lab_jnj_TalcMember_documentation_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember" xlink:href="jnj-20210404.xsd#jnj_TalcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TalcMember" xlink:to="lab_jnj_TalcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0debd65a-6f66-42ea-bd85-f7ce21347a5d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_37d607cc-32ef-4b75-a76b-22d02dad508b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_37438bc6-fb3b-4ac3-88b2-452f662042e7_terseLabel_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects</link:label>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_label_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DamagesFromProductDefectsMember" xlink:to="lab_us-gaap_DamagesFromProductDefectsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_5ca91ddd-9f82-4b3d-852e-52367b008507_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_85b605e3-e629-41ce-a3c9-bd21314143f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnSecurities_d2bd4453-c354-40f1-963a-8fa6c8c0b4dc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnSecurities_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnSecurities" xlink:to="lab_us-gaap_UnrealizedGainLossOnSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_5e5b9a04-733d-4781-886f-fcfba3a0a812_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_2ea9e563-73bf-41cd-8957-6b6492bcf8e5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Income on Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6378d311-cb57-4ed4-a4db-e0535b2834fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_28cea5b2-8bcf-4af0-8a47-a3adccf7ae10_terseLabel_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_label_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member" xlink:href="jnj-20210404.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.85Debenturesdue2038Member" xlink:to="lab_jnj_A5.85Debenturesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_38a8b6c6-4437-46a6-b692-04ae0357f0c6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9f59549f-cda5-49cb-b782-42cc7febe792_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_4d3cac39-33d5-46fb-9b08-94134eee0b28_terseLabel_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIMPONI / SIMPONI ARIA&#174;</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_label_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_documentation_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember" xlink:href="jnj-20210404.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SimponiSimponiAriaMember" xlink:to="lab_jnj_SimponiSimponiAriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PelvicMeshesMember_107cecbd-03e1-4075-8b47-e2338df5c61f_terseLabel_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_label_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes [Member]</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_documentation_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic meshes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember" xlink:href="jnj-20210404.xsd#jnj_PelvicMeshesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PelvicMeshesMember" xlink:to="lab_jnj_PelvicMeshesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f34beaa-2e49-46b3-8cbd-fa22522bc796_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_9888c54c-a276-4cbc-8114-f4c04c9f4df6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3a78b2bd-7b82-4b33-bcf6-e32baa971ce4_totalLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_XareltoMember_84f98b79-6ce1-43e8-86db-d381f5fdcf3c_terseLabel_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XARELTO&#174;</link:label>
    <link:label id="lab_jnj_XareltoMember_label_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:label id="lab_jnj_XareltoMember_documentation_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember" xlink:href="jnj-20210404.xsd#jnj_XareltoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_XareltoMember" xlink:to="lab_jnj_XareltoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_f48dd203-3f85-4aad-8499-4fdb89a7b0ea_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherReverseRepurchaseAgreementsMember_f10f51ed-1ab3-461a-bf64-ab88eae539aa_terseLabel_en-US" xlink:label="lab_jnj_OtherReverseRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other reverse repurchase agreements</link:label>
    <link:label id="lab_jnj_OtherReverseRepurchaseAgreementsMember_label_en-US" xlink:label="lab_jnj_OtherReverseRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Reverse Repurchase Agreements [Member]</link:label>
    <link:label id="lab_jnj_OtherReverseRepurchaseAgreementsMember_documentation_en-US" xlink:label="lab_jnj_OtherReverseRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Reverse Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherReverseRepurchaseAgreementsMember" xlink:href="jnj-20210404.xsd#jnj_OtherReverseRepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherReverseRepurchaseAgreementsMember" xlink:to="lab_jnj_OtherReverseRepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_bade49f7-527d-4f27-91e7-df1cdcebaa24_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_628b77e0-3509-4d5f-b3f1-03fcc36a2c0c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_107f4a44-6a76-4fc8-b8e9-d0a363c659a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivative Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_302d68a0-dc64-4b93-a1a8-e267e2f2759a_terseLabel_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_label_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_documentation_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member" xlink:href="jnj-20210404.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.45Notesdue2026Member" xlink:to="lab_jnj_A2.45Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_cd400351-8712-474a-83dd-7e76f02e2d1b_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_1ff357cc-d337-4d6c-b3c5-27d09c38b2dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and notes payable</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_54934dce-620e-4631-a4de-ca67f2744d9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_8aaf200a-d190-4027-ab05-f43a5f2aee6c_terseLabel_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_label_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_documentation_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member" xlink:href="jnj-20210404.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Notesdue2043Member" xlink:to="lab_jnj_A4.50Notesdue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_c0c0fa82-1ff0-4fb0-8ea5-0415952891b8_terseLabel_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income (Note 5)</link:label>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_label_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense Benefit Percent To Sales</link:label>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_documentation_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense benefit percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:href="jnj-20210404.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:to="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_b88ec8df-9950-4e60-afb2-23ee013054c6_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_77bf4d97-b115-4ee7-b233-efd45ff45e45_terseLabel_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers percent to sales</link:label>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_label_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue Goods Net Percent To Sales</link:label>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_documentation_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue goods net percentage to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales" xlink:href="jnj-20210404.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesRevenueGoodsNetPercentToSales" xlink:to="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_59f8a97f-8873-465d-bc8b-35b4aa2de7be_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities(1)</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5943f379-e0c9-459f-aaaf-021b18efc949_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_cdb366a7-aff4-463e-9fda-c5f920f08354_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_d1202502-c8a0-4e70-b270-ec99799ee971_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_ec98096b-816f-4973-92d5-cc6e8a194370_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales/ Purchases/Other</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_label_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:to="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_28c64bb2-ed92-46ed-b9ce-3fd8376e7a96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1a30d02c-9579-4f9d-b101-baff95d6d468_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities not Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_929586e1-f643-459d-9857-a4fd4052fc03_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_374b8ed9-de2c-447f-941e-fa83b29fe46b_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b2345649-bb60-4921-abe8-04722f569869_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Weighted-Average Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_a41f9b7f-1910-4259-9db6-c126f3fa3b5a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ZYTIGAMember_2d280733-9743-4f23-a311-77d760d5ee1e_terseLabel_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA&#174; / abiraterone acetate</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_label_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_documentation_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember" xlink:href="jnj-20210404.xsd#jnj_ZYTIGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ZYTIGAMember" xlink:to="lab_jnj_ZYTIGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_4f69244e-6315-4366-819e-8579062fd23a_verboseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:href="jnj-20210404.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:to="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_97476c02-2c4f-4bd4-9d17-21e43c9059a5_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_b6d96f5d-b5d4-4dd3-b040-404ecb2f5629_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_9e76a3c9-b54a-4781-996b-ada93c7c8da3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_90c3a2d0-9f39-45c9-ba7c-6c049a240165_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_a7a2690d-613d-468d-a8f4-e40e61f8e46c_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_5d1ad1ff-1a60-427b-b69f-3f5c4e471287_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_036d15e6-505c-4df0-b28c-98f923a92290_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_9752f4d4-b6bd-4395-af5f-3e6451ac74c9_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Axis]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:href="jnj-20210404.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:to="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_3f2eec63-3b91-4164-8d63-abb7e27f796e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ca85e118-eea5-4b22-822a-0da9330477c3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Accumulated OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PharmaceuticalMember_a0863fa4-ece5-42ed-b04d-ae84d5c36954_terseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PHARMACEUTICAL</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_label_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_documentation_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember" xlink:href="jnj-20210404.xsd#jnj_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PharmaceuticalMember" xlink:to="lab_jnj_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_6d0cd46d-e00d-4999-834f-63d0f0709518_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_07a95746-3956-467d-bddd-72ccb1242731_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_401213c2-4110-442c-813b-a2d75e00b433_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8d0dcd8a-f36f-47d9-a4e0-17826cbbd7ef_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss) (Note 7)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VerbSurgicalInc.Member_b462ac5f-71e7-4aa4-82ae-009bf2ee032a_terseLabel_en-US" xlink:label="lab_jnj_VerbSurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc.</link:label>
    <link:label id="lab_jnj_VerbSurgicalInc.Member_label_en-US" xlink:label="lab_jnj_VerbSurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc. [Member]</link:label>
    <link:label id="lab_jnj_VerbSurgicalInc.Member_documentation_en-US" xlink:label="lab_jnj_VerbSurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalInc.Member" xlink:href="jnj-20210404.xsd#jnj_VerbSurgicalInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VerbSurgicalInc.Member" xlink:to="lab_jnj_VerbSurgicalInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_973dc48a-e6c6-419c-b2f6-eacde8d07d28_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d3c84b70-9f3a-41d6-92d7-8f7ab4f8108e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_5e4be6a0-70ae-42d7-85a8-8686cbbec7d8_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Geographic Area</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Geographic Area</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by geographic area.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea" xlink:href="jnj-20210404.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesByGeographicArea" xlink:to="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgeryMember_412b78da-c02a-4fb3-9f9e-593b42e1f358_terseLabel_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery</link:label>
    <link:label id="lab_jnj_SurgeryMember_label_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:label id="lab_jnj_SurgeryMember_documentation_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember" xlink:href="jnj-20210404.xsd#jnj_SurgeryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgeryMember" xlink:to="lab_jnj_SurgeryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_296d12e5-d240-4bd0-a71b-c6895e02f8af_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RemicadeMember_7a39ed31-130c-48e1-92cb-bba1fbd1f09a_terseLabel_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REMICADE&#174;</link:label>
    <link:label id="lab_jnj_RemicadeMember_label_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_jnj_RemicadeMember_documentation_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember" xlink:href="jnj-20210404.xsd#jnj_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RemicadeMember" xlink:to="lab_jnj_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9094a89b-21be-4b19-a87e-5e2c4a2c42b9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TremfyaMember_e7f313ed-b7dd-4b6a-a36f-2b4745f4d567_terseLabel_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TREMFYA&#174;</link:label>
    <link:label id="lab_jnj_TremfyaMember_label_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_jnj_TremfyaMember_documentation_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfaya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember" xlink:href="jnj-20210404.xsd#jnj_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TremfyaMember" xlink:to="lab_jnj_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3e5c571c-4cae-46bf-a63d-858ae3194c89_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NeuroscienceMember_1a7f267c-bf84-4562-98b1-0d0f812d28ea_terseLabel_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_label_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_documentation_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember" xlink:href="jnj-20210404.xsd#jnj_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NeuroscienceMember" xlink:to="lab_jnj_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_933aba8a-1658-4ae1-ba02-6ce61f6e0ac8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_392aad75-2c2a-4bde-a2be-013e1cda248c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Fair Value Reflected in Net Income</link:label>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueAdjustment" xlink:to="lab_us-gaap_EquityFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0cdd5a32-9afd-4a7c-b06e-b7995d715671_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d2529dca-c638-46c2-bf8a-ab6f2227be35_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_347fa02d-6813-4dbb-98ae-12d4046d4bbe_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_39e2fff5-b764-475a-a437-85c419693b88_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_b6d52ac5-47a4-4c0c-b2f2-97c0adfa3620_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_6133c4d9-331d-4489-853a-1caaff06c366_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_876d8a65-409d-40bd-aafa-b760658d728f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bdf2fded-9bdb-43ad-b48d-c69e446e3f8b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_86a04452-3e60-47f2-b5a6-e0191a882bfd_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities - Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_0434ba9e-bcb3-4788-9845-36d68f5f9ad9_verboseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VisionMember_3ebbfcff-208c-43d4-95b0-00ff50603bc7_terseLabel_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision</link:label>
    <link:label id="lab_jnj_VisionMember_label_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision [Member]</link:label>
    <link:label id="lab_jnj_VisionMember_documentation_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember" xlink:href="jnj-20210404.xsd#jnj_VisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VisionMember" xlink:to="lab_jnj_VisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a53d77cc-3e4a-4610-a7a2-cbf81d87a4c3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ae117324-842e-44b1-9864-e482fb40697e_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6002bf30-75da-494f-96a3-d1da8fa087a8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6ec68b69-826e-4643-8ec5-5258afee956c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_d9210ad3-50a9-471b-bda9-f559b938ac73_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2142722e-6d06-495c-ab19-d8e1bb976d0d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e7579748-db6b-4ed9-899c-b7852e7be1cf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_05641f89-b190-44b2-b4ae-2f8535155132_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_55065b33-128e-4010-abcf-3e178aced929_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_5dc310bf-e192-42ce-bcf2-c9e152d5814e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_69c9ca6e-967a-4287-bb62-c9f0fadfe764_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GENERALMember_0d6e1fe7-46e6-448e-870e-7c810c012467_terseLabel_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL</link:label>
    <link:label id="lab_jnj_GENERALMember_label_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:label id="lab_jnj_GENERALMember_documentation_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember" xlink:href="jnj-20210404.xsd#jnj_GENERALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GENERALMember" xlink:to="lab_jnj_GENERALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_b73f6da5-3fae-4909-994b-73bd31253227_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_1bba0efe-d770-4249-be49-2ed19250cead_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_88fca192-fe72-40a1-a8a7-28c2ae794977_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f68a593f-695e-4504-86fe-cfbe018cd6a1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_795eb301-f282-43d4-9617-051ae8e09835_terseLabel_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Notes due 2048</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_label_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_documentation_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member" xlink:href="jnj-20210404.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.500Notesdue2048Member" xlink:to="lab_jnj_A3.500Notesdue2048Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_976da998-b1f4-48b3-976b-c4ec399ebf02_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_e459adeb-910e-4013-be3d-8e70168f93d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0550NotesDue2025Member_0c23df50-aab9-42fe-aa48-3818d11610c3_terseLabel_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:label id="lab_jnj_A0550NotesDue2025Member_label_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.550 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A0550NotesDue2025Member_documentation_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.550 Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member" xlink:href="jnj-20210404.xsd#jnj_A0550NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0550NotesDue2025Member" xlink:to="lab_jnj_A0550NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_7d6568ef-42f1-4164-9370-d21b108f8fb0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_32b2bace-9b3e-4777-a58e-40a763d7e061_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_411075e7-cc45-4ca4-ac66-91be70966f2d_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:href="jnj-20210404.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:to="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_dd435912-bcad-4cbf-a788-1aba32022fe6_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3769f619-52e0-4394-9d5f-2cc19f1fea8a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cca15c24-2be9-42b2-9573-0d7d90758d5f_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_f69e9443-1a41-4d70-a25c-3a00d1671bed_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_a403ebb8-c636-4e21-b792-e6b70f925a05_terseLabel_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_label_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_documentation_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales" xlink:href="jnj-20210404.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Restructuringchargepercenttosales" xlink:to="lab_jnj_Restructuringchargepercenttosales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8a575d3e-1936-418e-8e3b-e047c9e5d83c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_dffc0eaf-fc21-4246-b6b1-a59ee7dc8ef1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED BY FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_6b5bb98e-535f-4fe4-8c36-dead20b4f658_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3dd29162-891e-483b-a165-642019432793_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_7200600f-d9b4-4d13-894a-60cd6d83b777_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets/businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SPINEOTHERMember_ac0b34ca-1c39-4f25-bf2b-1b2b24ff72ac_terseLabel_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE, SPORTS &amp; OTHER</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_label_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_documentation_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember" xlink:href="jnj-20210404.xsd#jnj_SPINEOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SPINEOTHERMember" xlink:to="lab_jnj_SPINEOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_71fe0f24-f0b3-4ca2-8376-a65276bece12_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3fcb0210-ee78-4e0e-84b8-69710d8192e9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_287843c5-e5f6-4f5e-aeb8-bcc608d1bf26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_43767d26-e2a0-4c5e-9f11-7024fb4d9ef8_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) amortization during period</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:href="jnj-20210404.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_3ad028d9-9fbb-4644-bc97-c41b420c5802_terseLabel_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold percent to sales</link:label>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_label_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods Sold Percent To Sales</link:label>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_documentation_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales" xlink:href="jnj-20210404.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CostOfGoodsSoldPercentToSales" xlink:to="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_e38562a3-7960-45ef-926c-833d58f19de3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_1447489c-80c3-4840-aea7-6b54fa5de6e8_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations (Note 6)</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5a311967-4eab-42b8-abc2-8d5d14d21446_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net (Note 3)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a8afe22e-9371-48a3-941b-12101d815869_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets - net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImmunologyMember_02f338d2-962c-4fb0-8311-71840b76257c_terseLabel_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_jnj_ImmunologyMember_label_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_jnj_ImmunologyMember_documentation_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember" xlink:href="jnj-20210404.xsd#jnj_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImmunologyMember" xlink:to="lab_jnj_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_435de0e0-56c1-4fbd-92ee-8c53280890b0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (primarily licenses and milestones)</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4aaa5f4c-92fb-4104-a3f3-1eeff987ccbc_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_12da02b0-051d-4b38-97e8-9ffb5d8acf4b_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_251f8ac0-0c42-41c1-9b61-bc6d271749fb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1b7f61a7-d0d7-471e-abe9-d768ecac7f84_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d54bee94-f8bb-4c37-9368-3ab4b280ff1f_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_7081c702-b8b5-478d-9bca-45bca5856ba9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_cb2f9477-8b71-4d3b-94c4-9d5bbb8bec20_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_baa980ee-8ef3-4e99-97cb-e7f9b70f3e33_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_da2977e1-74b3-495e-aab5-c4f750656696_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_b9265546-ec21-49c2-921a-c89e2a5586c3_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:href="jnj-20210404.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_153d8ae4-9117-4ee1-a434-3ef9e8ea0b68_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_52a09f3c-3c94-4696-b927-717367bb2832_terseLabel_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="jnj-20210404.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_26c7e27f-626e-4e0a-90d3-082f98c8edd7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_204a872e-7380-4f90-908e-6b34cafc6e04_verboseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_bc56fe0d-fd52-47d7-b98e-d798397f0c0c_terseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes due 2028 (750MM Euro 1.1757)</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_label_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_documentation_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member" xlink:href="jnj-20210404.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.150NotesDue2028Member" xlink:to="lab_jnj_A1.150NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_dec8dea4-1994-4321-a01d-b41f22645159_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_84eeba38-bdc4-4ddb-9eb1-affa1386b9d6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Unrecognized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3804d856-3558-48d0-8f4e-6280f6ef491a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_fa66bfc8-3adb-4d04-93e5-e2db525d1c46_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt shares</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_139df152-f8a1-4c59-99aa-d0e9426978cf_terseLabel_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT&#174; / rilpivirine</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_label_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_documentation_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember" xlink:href="jnj-20210404.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EDURANTrilpivirineMember" xlink:to="lab_jnj_EDURANTrilpivirineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_48e6e381-a691-4777-89e9-b7163b744cd7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_a9083c91-df9f-4e81-94c5-685e58dcac8a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_18a8ffa5-d7e6-4c85-bddb-444462e796c1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_d254a8cd-5d5a-4a70-8326-6562133b081d_verboseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due May 2024</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_8d0c61ab-47c6-4118-b12c-7758132c541b_terseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes due 2024 (750MM Euro 1.1757)</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member" xlink:href="jnj-20210404.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.650NotesDue2024Member" xlink:to="lab_jnj_A0.650NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_100b8ee7-5cb9-4f47-90d4-f0c1a6fa127a_terseLabel_en-US" xlink:label="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of cash outlays for severance expected to be paid out</link:label>
    <link:label id="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_label_en-US" xlink:label="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid</link:label>
    <link:label id="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_documentation_en-US" xlink:label="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:href="jnj-20210404.xsd#jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:to="lab_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_cb683374-4eac-43bb-853c-d0f5d77a1198_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of additional possible loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_label_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_documentation_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:href="jnj-20210404.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:to="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1e0364f3-6976-47f7-8a88-c8a58a3137b0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_7f0d4ce5-330f-4e6f-bd5e-fc15b76c9998_totalLabel_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income percent to sales</link:label>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_label_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments Percent To Sales</link:label>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_documentation_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales" xlink:href="jnj-20210404.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales" xlink:to="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_f5a6ce4d-8d48-4c0b-8ad0-798b01a73cb0_terseLabel_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount prepaid and due to manufacturers</link:label>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_label_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Prepaid and Due to Manufacturers</link:label>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_documentation_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Prepaid and Due to Manufacturers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers" xlink:href="jnj-20210404.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AmountPrepaidAndDueToManufacturers" xlink:to="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WomensHealthMember_e98a2e17-037c-4232-9758-412cc9b489bb_terseLabel_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health</link:label>
    <link:label id="lab_jnj_WomensHealthMember_label_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:label id="lab_jnj_WomensHealthMember_documentation_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember" xlink:href="jnj-20210404.xsd#jnj_WomensHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WomensHealthMember" xlink:to="lab_jnj_WomensHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bbedf7c6-619a-4999-b1e6-b2856e192075_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_e7d05116-7bf6-42e8-b9ec-d5fee03faab9_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_e9be2cc7-9d5d-4def-adf9-496cc6ed0a42_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IMBRUVICAMember_51da5b78-65bc-4fca-a43a-32373509d750_terseLabel_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA&#174;</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_label_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_documentation_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember" xlink:href="jnj-20210404.xsd#jnj_IMBRUVICAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IMBRUVICAMember" xlink:to="lab_jnj_IMBRUVICAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_7cfc09c1-f1f6-4602-96f1-9767c72d982d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6228a6d7-dd61-4f87-82ef-1c75788e2216_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Profit by Segment of Business</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_9954ed05-2d88-4ea7-8cc9-8e82e3f0caa5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2250NotesDue2050Member_aa138cc3-d3ee-4a0a-8ad4-2b7a36a704e3_terseLabel_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2050</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_label_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050 [Member]</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_documentation_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member" xlink:href="jnj-20210404.xsd#jnj_A2250NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2250NotesDue2050Member" xlink:to="lab_jnj_A2250NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_ddd045ae-3c4d-42d7-9ce3-22c72ff5ae16_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_4fef961f-930b-40ff-9b78-043224c03a3b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_16518d91-bafa-4e95-a088-bdfca56d9286_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3660f2f7-bbb6-4c8f-8806-c53afe9ba464_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_d1b33e13-64a9-4473-8456-87cd307d66d3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_79fbf4a0-4545-4e04-ba1e-7e27f405529d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_970b25e0-0b58-46fe-b94d-a726f6a5c620_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OralCareMember_889d77de-a226-4144-a026-9fd12281ddfe_terseLabel_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care</link:label>
    <link:label id="lab_jnj_OralCareMember_label_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:label id="lab_jnj_OralCareMember_documentation_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember" xlink:href="jnj-20210404.xsd#jnj_OralCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OralCareMember" xlink:to="lab_jnj_OralCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_c611ac27-718f-4a13-a65d-283f5b515b68_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_fe7b2290-ba84-421a-93cc-17f29af9a5ad_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f5629c5a-a502-4eec-a87d-bcd248b16651_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a2f930a6-ec22-4dcd-afb5-9d71d046f773_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OPSUMITMember_8b921681-596f-47d4-9b7d-439a1c523d3a_terseLabel_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT&#174;</link:label>
    <link:label id="lab_jnj_OPSUMITMember_label_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:label id="lab_jnj_OPSUMITMember_documentation_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember" xlink:href="jnj-20210404.xsd#jnj_OPSUMITMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OPSUMITMember" xlink:to="lab_jnj_OPSUMITMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1ab5c143-4b40-4f5d-b2ab-6a30b32ff146_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_7392b1a2-073a-4d83-bd7b-114be0baeb07_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities - Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_6401566a-6872-49e6-ae2e-5a228f63bc9a_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:href="jnj-20210404.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_98b105fb-1827-4cf0-af4b-a776ee10b412_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_2f967465-b0ac-407c-959f-4f41da07119b_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_a1994d52-ce26-4006-9186-62cfded91434_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_f39f62d7-06ec-4d72-853d-c843feb872db_negatedLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Unrecognized Loss</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_d1b36906-d261-4993-8475-8faf2090d1f5_verboseLabel_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due January 2022</link:label>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_label_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_documentation_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member" xlink:href="jnj-20210404.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.250NotesDue2022Member" xlink:to="lab_jnj_A0.250NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_dd999ba0-5795-4236-85aa-d0dd9e9b7cd8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_ce3bb98f-4c2a-4908-9bf8-95956b2defd7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_183cac68-fbb0-4ac3-8a6a-ed8f446f1e65_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_f8af8edd-1390-4e69-a329-ec1b3d8df7c5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_bb9b613c-c02b-435e-8a3f-4407a48b5824_terseLabel_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90%&#160;Notes due 2028</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_label_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_documentation_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member" xlink:href="jnj-20210404.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.900Notesdue2028Member" xlink:to="lab_jnj_A2.900Notesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_daa170a8-c619-49ac-9515-4b995214b545_terseLabel_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Exports</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_label_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_documentation_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember" xlink:href="jnj-20210404.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UNITEDSTATESExportsMember" xlink:to="lab_jnj_UNITEDSTATESExportsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_a18c86f2-2865-44ee-aef9-86491f35edb3_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_c7599dc1-745f-453c-9221-b29e20083b05_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_70c02bb0-cbc2-415d-bc7a-b22fbfdbbf44_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AssetWriteoffMember_765aa40e-9487-486f-af84-098ba5cfaf7c_terseLabel_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_label_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_documentation_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember" xlink:href="jnj-20210404.xsd#jnj_AssetWriteoffMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AssetWriteoffMember" xlink:to="lab_jnj_AssetWriteoffMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_6fc20255-d52f-4ae7-b669-d11f794283a0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges recorded to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_04d27e0d-fb23-4fee-ad3a-4812be45be75_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits(1)</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_efb68352-3f65-4558-b0ba-ba3feecc4b3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b808beb5-83e5-44ea-888d-5a5d110c3cce_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_a7ccc417-7049-428f-b9bb-7c92ab8276ec_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_d107a3d2-5f02-4c98-86c1-f9832ef71711_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of previously held equity investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_cb735097-6bfa-4f99-9d7d-ce218f0b7bf0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6c5f1b62-a311-4f8f-84c2-5fb4beef9087_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsrMember_05470491-d244-42a8-b39e-4280bbf090ee_terseLabel_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR</link:label>
    <link:label id="lab_jnj_AsrMember_label_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR [Member]</link:label>
    <link:label id="lab_jnj_AsrMember_documentation_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember" xlink:href="jnj-20210404.xsd#jnj_AsrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsrMember" xlink:to="lab_jnj_AsrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_27ce59ef-fb01-4c7a-b0af-d02dcb2a68b3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_41ba5a19-d09a-433b-af6e-91b7a1b1057c_terseLabel_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of the estimated fair value over the carrying value of debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_label_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Fair Value Over Carrying Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_documentation_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of fair value over carrying value of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:href="jnj-20210404.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:to="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GrossProfitPercentToSales_3f9a9594-1ff3-4dde-8fdd-64c09970a378_totalLabel_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit Percent To Sales</link:label>
    <link:label id="lab_jnj_GrossProfitPercentToSales_label_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit Percent To Sales</link:label>
    <link:label id="lab_jnj_GrossProfitPercentToSales_documentation_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales" xlink:href="jnj-20210404.xsd#jnj_GrossProfitPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GrossProfitPercentToSales" xlink:to="lab_jnj_GrossProfitPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_99fe07cc-e677-483a-a1a0-df71b50c355e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, marketing and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_942d4035-0d4e-46ce-87d1-06185f4510da_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation/Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_f06f688a-3a60-4058-92b2-509159cec304_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_6f67c70b-c899-4c50-93a4-4e422d502a57_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_7e442c83-46ee-4743-98b5-55ac1727d58c_terseLabel_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member" xlink:href="jnj-20210404.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.95Debenturesdue2033Member" xlink:to="lab_jnj_A4.95Debenturesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_KNEESMember_5ee0c959-dba9-4af4-b115-82bcae022eb5_terseLabel_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES</link:label>
    <link:label id="lab_jnj_KNEESMember_label_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:label id="lab_jnj_KNEESMember_documentation_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember" xlink:href="jnj-20210404.xsd#jnj_KNEESMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_KNEESMember" xlink:to="lab_jnj_KNEESMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_10806f03-2284-4a08-a904-70b122179eef_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_ee63d194-6afa-47f4-a704-ab1451ba8035_terseLabel_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling marketing and administrative expenses percent to sales</link:label>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_label_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling general and administrative expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:href="jnj-20210404.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:to="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_77cb1a46-dd50-4461-b87a-cf7ee1a3a9f3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JudicialRulingMember_5566fbd4-6f58-42d6-9485-76708a32663b_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember" xlink:to="lab_us-gaap_JudicialRulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_6b772086-d7bf-4a7a-a8e6-ce1d46dcbaec_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note 4)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_d5cb46b7-1011-45b6-be4a-a1f12b622e3f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_9059629d-973c-47a5-8369-bbe7b70e6245_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4028ddae-73df-47bc-a060-4f8c0ba25a59_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7ed9dd71-9992-4606-9da6-da438f23b6cb_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9e2547b0-18ac-4e61-86ea-8e02081345bc_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2c473627-d604-4e51-9c0f-5997d1f0922f_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_ac7ab88d-94a8-48ed-b1c2-4e9a8ae60400_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee related obligations</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6dbc5ce4-47c1-4782-8ec4-071d52b65728_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1610de5f-65ec-4c66-b29a-29ec4272f768_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_48680704-4be3-4cdf-a0e5-e3c059f5981e_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_7bfa93a9-2fe3-4c40-8a70-9529539308ef_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeTaxTextualsAbstract_c706586f-484f-4885-bdd6-21c81c08b158_verboseLabel_en-US" xlink:label="lab_jnj_IncomeTaxTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax (Textuals)</link:label>
    <link:label id="lab_jnj_IncomeTaxTextualsAbstract_label_en-US" xlink:label="lab_jnj_IncomeTaxTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax (Textuals) [Abstract]</link:label>
    <link:label id="lab_jnj_IncomeTaxTextualsAbstract_documentation_en-US" xlink:label="lab_jnj_IncomeTaxTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Textuals Abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxTextualsAbstract" xlink:href="jnj-20210404.xsd#jnj_IncomeTaxTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeTaxTextualsAbstract" xlink:to="lab_jnj_IncomeTaxTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_22964fba-87f3-4887-ab1b-28724747db9a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1704f781-13b1-466a-a81b-63ec4c3f78fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ce73a917-2a30-42d1-afee-2fa7b2400a8e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_83094662-61fe-4f8b-bc0b-7b0876a836d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Derivatives not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_93914582-d68c-4e51-a357-437c7030cd23_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency, number of claimants</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_label_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingency Number Of Claimant</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency number of claimant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:href="jnj-20210404.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:to="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8143504a-72ea-47b0-89ce-145fb80be539_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f3b99368-9ea2-4452-94c4-d3cf959ae7d9_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_03eb1320-efea-4c0e-b988-92bb2c958fa7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_14911a13-0d44-4a85-bb5d-fbcf8a45ca21_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_aec68aeb-18fa-445d-9a49-e7b41f55958d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Current Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_ed3e38c0-9272-41db-b465-8d5b8050a004_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b2a0f751-2ff6-4625-8ad4-08ddaf31b285_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_f04ad8da-a038-48d0-955e-323fa8da8351_terseLabel_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA&#174; / INVOKAMET&#174;</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_label_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_documentation_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember" xlink:href="jnj-20210404.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVOKANAINVOKAMETMember" xlink:to="lab_jnj_INVOKANAINVOKAMETMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_3326858c-fb29-4571-bad6-386454280913_terseLabel_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40%&#160;Notes due 2038</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_label_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member" xlink:href="jnj-20210404.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.400Notesdue2038Member" xlink:to="lab_jnj_A3.400Notesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_7213bcf8-340f-4211-b5ca-bdcf2150db66_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b58b46d6-fe15-4ab6-a6fe-16b436ec1b93_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f7df01a7-15ee-4124-8572-2ca9ec797024_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0c734dec-72b2-4181-8517-a5258cdd3419_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ca70eab8-e7e4-4899-94f7-f79f03384845_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_e76c432e-33af-4502-bc2f-54d603c73590_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_9042aaaf-93dd-49a2-bc88-c1b91bbcdf81_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_939129ab-8bfb-4463-b8e4-da3b74db83e9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_6e62d62d-a55d-4bc1-804f-5e3260f02a16_terseLabel_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023</link:label>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member" xlink:href="jnj-20210404.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.05Notesdue2023Member" xlink:to="lab_jnj_A2.05Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_da389945-ae84-47b3-91b2-50994e0280e2_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability related to TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:href="jnj-20210404.xsd#jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_67467ea2-85dd-4963-b6e2-b5bcc64b7f89_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AurisHealthMember_04039e64-c127-461b-973d-b80aedd3772b_terseLabel_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:label id="lab_jnj_AurisHealthMember_label_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health [Member]</link:label>
    <link:label id="lab_jnj_AurisHealthMember_documentation_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember" xlink:href="jnj-20210404.xsd#jnj_AurisHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AurisHealthMember" xlink:to="lab_jnj_AurisHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e832ed26-d5ba-49f6-a7ca-d279bb9bdcdf_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_666c5659-378b-41b8-8ad4-28f759a6cabc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_a049a783-ff85-46ed-b41a-e103377ea170_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Unrecognized Gain</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_738473e3-edb7-4ad9-95c7-a6562eff7f38_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_73945598-faab-433f-8ebe-f1c52a2a6d76_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_bc836fa7-2101-473d-96ee-9f90eeeb52c3_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, end of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_05ce4703-4c48-46b8-8d9a-f55555339b87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_d208b113-8be4-4665-bcb9-b42522e312e4_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_4965cd3d-a18a-446a-ac4c-0e6b991ac1ee_terseLabel_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_label_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due Period Fifteen Member</link:label>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_documentation_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes due period fifteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember" xlink:href="jnj-20210404.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NotesDuePeriodFifteenMember" xlink:to="lab_jnj_NotesDuePeriodFifteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_7a82cf29-d3c1-4270-aeca-c1f0188bf216_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_73aba349-56fd-48a0-8816-ed694ae0ad2b_terseLabel_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_label_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business [Table Text Block]</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_documentation_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:href="jnj-20210404.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:to="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_66887e94-3466-4b2b-97a5-7a8f300a9ec3_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit losses and accounts receivable allowances</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_1e9915c6-d224-4658-a5e5-b243ed9110ba_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6af5ed57-d79b-4136-bc1e-000a2fb18fd0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f1d5531c-b0ee-4218-bd6e-a0e2ccb329dd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_2ab39c83-c99b-4c08-9821-6a8ff95b1f6f_verboseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due November 2024</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_85edac9d-a433-4840-8305-068c41ef7243_terseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes due 2024 (500 MM GBP 1.3799)</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member" xlink:href="jnj-20210404.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.50NotesDue2024Member" xlink:to="lab_jnj_A5.50NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_0a46566e-f8e6-4b65-a640-102e41c33ba4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_8b96729c-d1b8-4f16-8726-a6f8a49e4be6_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit related to TRAF, percent</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset, Percent</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" xlink:href="jnj-20210404.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5670a2fc-a491-40f2-9b19-9c5aa03175ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RisperdalMember_3c345d3f-4df2-405e-b9e3-e1c9472ee1a8_terseLabel_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal</link:label>
    <link:label id="lab_jnj_RisperdalMember_label_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal [Member]</link:label>
    <link:label id="lab_jnj_RisperdalMember_documentation_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember" xlink:href="jnj-20210404.xsd#jnj_RisperdalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RisperdalMember" xlink:to="lab_jnj_RisperdalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionContributions_3b715e7d-acca-4167-84b8-9ec32b716fdb_terseLabel_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to pension plans</link:label>
    <link:label id="lab_us-gaap_PensionContributions_label_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionContributions" xlink:to="lab_us-gaap_PensionContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_0132ac4d-6c95-4b94-9f07-d63afb72a6f0_terseLabel_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_label_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_documentation_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member" xlink:href="jnj-20210404.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.70Notesdue2046Member" xlink:to="lab_jnj_A3.70Notesdue2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_9b0a1e3a-d2c8-483f-9a96-aa95227ad054_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_4dbd93d2-dd4c-42fd-991f-6d923ada4226_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_8fd256c8-b4fd-4b88-b704-cbf2d1a11851_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_c7ad70e0-29ee-47f9-bd2a-d6ce5393983d_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_54004697-0a65-4536-8a57-f5ac7f33d948_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_67233cce-23fa-4109-8c50-5d76e26e1b5b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired (Note 10)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MedicalDevicesMember_f7a8feb4-84bd-4f5c-baed-13951b6b9b2b_verboseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_13f8893c-6e5b-439c-afa2-0f2c29bee793_terseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEDICAL DEVICES</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_label_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_documentation_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember" xlink:href="jnj-20210404.xsd#jnj_MedicalDevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MedicalDevicesMember" xlink:to="lab_jnj_MedicalDevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ce18d64d-31e0-475d-ad76-4801725e3d3b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_5a680e38-083e-4428-837b-1b67fea0db10_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_8204092f-9536-4e5c-8d69-040b0d58c36c_terseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Unrecognized Gain</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Accumulated Gross Unrealized Gain</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Accumulated Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" xlink:href="jnj-20210404.xsd#jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" xlink:to="lab_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_488ad4b3-6ffe-429b-9718-33f2be02030a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_49d1a71b-e426-4e67-a500-a9584cb2f574_verboseLabel_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of foreign exchange contracts into earnings, period</link:label>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_label_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Reclassification of Cash Flow Hedge Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:to="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherOncologyMember_37f5bb63-3f8c-446d-9f0e-4477c93115c8_terseLabel_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER ONCOLOGY(1)</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_label_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_documentation_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember" xlink:href="jnj-20210404.xsd#jnj_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherOncologyMember" xlink:to="lab_jnj_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_530a3be1-5eff-4db6-9742-e1dcc11317e8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4dcf2dfa-e21d-4c6f-b884-fc12dff131a3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_de2cd18e-5260-4aae-b789-76384d221c2a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income on derivatives, after tax</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a02d644e-cb76-49be-a8a5-057a4f47ab88_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_551a6231-cf99-4893-8c50-de8447a74576_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f3683677-b6b9-4f3f-9e0a-2e151388416e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_a890b2d5-b1d9-4a32-8bba-74724b5650a9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_86b02ec1-4414-4ef2-91f0-bddecbc33f6b_terseLabel_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_label_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member" xlink:href="jnj-20210404.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.73Debenturesdue2023Member" xlink:to="lab_jnj_A6.73Debenturesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_1189328e-bd82-4c9c-8084-1dd44158e257_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_b1bb95b3-9f5b-4359-ac37-2414e70a8edf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_51d69c8f-0517-4e55-92fa-421ba4aba2dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1238e149-37d4-4ea7-ab04-27a8581d6520_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_972a3fed-0ef7-496b-ba94-5872f1bfac42_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ERLEADAMember_2a89a2b9-5b58-481a-85e8-32f0bb190a0f_terseLabel_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:label id="lab_jnj_ERLEADAMember_label_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA [Member]</link:label>
    <link:label id="lab_jnj_ERLEADAMember_documentation_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember" xlink:href="jnj-20210404.xsd#jnj_ERLEADAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ERLEADAMember" xlink:to="lab_jnj_ERLEADAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_32697239-fc80-45a3-ad6c-a90e0cc35139_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with indefinite lives:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_08074733-5a2b-462e-9fbe-6b56ac1088e5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_76cd04e8-e77c-40ef-a3d2-a25ccf335cce_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_2c377f6a-64e5-4b7c-966a-376bee891225_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_df1d2cde-5e0f-4500-9a70-1c1cb205d322_terseLabel_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_label_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_documentation_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember" xlink:href="jnj-20210404.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PatentsAndTrademarksMember" xlink:to="lab_jnj_PatentsAndTrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_71ef2b05-6453-4477-81f0-adc51d9dd605_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring (Note 12)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_cd840fc3-b5c8-498c-8004-f68725c814df_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_a58d1b57-3652-4e48-b7aa-6c3353aafc56_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_a63410d6-f10a-4c61-9e90-7d403460a02b_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee1ac500-483c-4f10-a6d4-32f3b6b99dbb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED BY INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_5eae8944-5b25-44c2-8471-fbf40d9bf844_terseLabel_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member" xlink:href="jnj-20210404.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.625Notesdue2037Member" xlink:to="lab_jnj_A3.625Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3d64da0d-8fd1-4dd6-a84f-2658b7bd6239_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherImmunologyMember_18616577-485e-47b9-9de4-602839c8f00c_terseLabel_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER IMMUNOLOGY</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_label_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_documentation_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember" xlink:href="jnj-20210404.xsd#jnj_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherImmunologyMember" xlink:to="lab_jnj_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2f38da3a-848d-4b71-a6a5-0d2502156c1c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition cost</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BermekimabMember_55416529-c786-40a2-b29a-774247ab424d_terseLabel_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab</link:label>
    <link:label id="lab_jnj_BermekimabMember_label_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:label id="lab_jnj_BermekimabMember_documentation_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember" xlink:href="jnj-20210404.xsd#jnj_BermekimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BermekimabMember" xlink:to="lab_jnj_BermekimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_a5c91c5d-349b-410e-ac96-bd5d9c7f7f3c_terseLabel_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA&#174;</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_label_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_documentation_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember" xlink:href="jnj-20210404.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RISPERDALCONSTAMember" xlink:to="lab_jnj_RISPERDALCONSTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_47affe3f-77c0-43a4-9df5-1f8198847449_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_09f63d0d-fbfc-4f80-a604-e01aa1135f93_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_cc920215-2f03-48b4-a298-1ddff4bdcdb0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ae2b038e-8f80-4b93-a9a5-6e20aa110532_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_7fc13ff4-6b13-47c5-9de8-593fdd02d673_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EvraAndDoxilMember_689562e6-c395-4fdc-a32c-b4a9e8d85bfb_terseLabel_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_label_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil [Member]</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_documentation_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember" xlink:href="jnj-20210404.xsd#jnj_EvraAndDoxilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EvraAndDoxilMember" xlink:to="lab_jnj_EvraAndDoxilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f027aa2e-f3d8-4040-a745-fa34cd7c6cd1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2937a3fd-6545-4152-901e-3dc0a1b7d4ce_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_77057137-c71f-4eac-a6fc-1ad9ca374a51_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_33076fcd-8f9c-4304-a042-cc95da1604f8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_511c93f4-9785-478a-8274-3640399561e4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_b3947e95-eb3f-4243-9564-2bfad0a9b8d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_58f81ceb-24c0-48d7-ae4a-1dc7947d3953_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterventionalSolutionsMember_746e120c-988a-406d-a9e0-280d85e6baad_verboseLabel_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_label_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_documentation_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember" xlink:href="jnj-20210404.xsd#jnj_InterventionalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterventionalSolutionsMember" xlink:to="lab_jnj_InterventionalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_195517bd-69e3-4ac9-832a-786d02624386_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (Note 2)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_1febde81-68c8-4937-b794-9ed528e603e0_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_71935b87-e66d-4c93-bd69-24196229e6c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f02b6787-652b-46f1-bcd7-006a34a70726_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost/(credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestExpensePercentToSales_7780bb16-8873-4b53-9d29-dfbe276d562b_terseLabel_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized percent to sales</link:label>
    <link:label id="lab_jnj_InterestExpensePercentToSales_label_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_InterestExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales" xlink:href="jnj-20210404.xsd#jnj_InterestExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestExpensePercentToSales" xlink:to="lab_jnj_InterestExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_3c0f2b98-bd0e-41fb-9f96-0066701bb201_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_858b4687-e12e-4a5d-b32a-1de8c132cc4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_4e65384c-0e88-4aa7-a944-af957451325d_verboseLabel_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_label_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_documentation_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:href="jnj-20210404.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:to="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_70c79075-5d78-4780-b1c8-a6e8086460eb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_bc16b4cf-8b7a-477d-920e-14904fb5e98f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8ef6ecc6-eef1-40aa-800e-aad6bf7503e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4779cde4-2b2a-4e2c-89e5-cb456543538c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_e67ae1a4-2a7a-4df3-a2d3-dc888a595108_terseLabel_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_label_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_documentation_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member" xlink:href="jnj-20210404.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.95Notesdue2027Member" xlink:to="lab_jnj_A2.95Notesdue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_640ace40-3ca8-46ac-8b20-a705985f5ecb_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0b1510c6-fd54-4322-ae00-64c8e3528cbc_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_505f0590-c62d-4da3-bba8-aa2466a0cfb4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_8c872bbf-d5fe-40b2-835d-8909c71ce0b4_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OpioidMember_21e3173d-09f9-450e-88e9-280603005a2a_terseLabel_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:label id="lab_jnj_OpioidMember_label_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">opioid [Member]</link:label>
    <link:label id="lab_jnj_OpioidMember_documentation_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember" xlink:href="jnj-20210404.xsd#jnj_OpioidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OpioidMember" xlink:to="lab_jnj_OpioidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_42d69c3e-20b5-43d5-917a-fa29b0587816_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2450NotesDue2060Member_d9a0bd42-f9af-4dcf-a981-02cb9c51109b_terseLabel_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2060</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_label_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060 [Member]</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_documentation_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member" xlink:href="jnj-20210404.xsd#jnj_A2450NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2450NotesDue2060Member" xlink:to="lab_jnj_A2450NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_39e8a567-e7de-4b73-9075-e5ff2acad5a5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_c3c8df71-ae5d-49fd-89de-d2c403bc2a36_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_12c239ce-490e-4081-b9d2-918e82b08355_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_83341a3c-e13d-4433-86f4-0fcea04ff900_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide effective income tax rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_4b083d89-6649-4726-b82a-8aff48a4a365_terseLabel_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_label_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_documentation_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member" xlink:href="jnj-20210404.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.85Notesdue2041Member" xlink:to="lab_jnj_A4.85Notesdue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_d308ace9-2f3e-4c18-ac63-467654bad348_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_e431d646-73fa-4e81-9a0d-a0055af8bda2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1b160695-caac-46e4-8424-ffedb9e25406_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherMember_246059bc-4766-4193-9564-b46bc222bc40_terseLabel_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_OtherMember_label_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_jnj_OtherMember_documentation_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember" xlink:href="jnj-20210404.xsd#jnj_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherMember" xlink:to="lab_jnj_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_7d73d606-9f6e-443f-891f-1237df7e6efe_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f9eadb87-31d5-4459-a7b0-87223763e105_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock &#8212; par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_f431b163-0dc3-465d-918e-dd2e5dc9427a_verboseLabel_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income)/Interest expense, net</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember" xlink:href="jnj-20210404.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestIncomeExpenseNetMember" xlink:to="lab_jnj_InterestIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_2aa2afd5-6c46-43ba-8b2c-aa3ed8d8c5b4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_45fae32a-3920-45e6-b4a4-81efbb73ae9e_verboseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TRAUMAMember_ab862726-dd7d-4114-b1fb-21d03f2ab16d_terseLabel_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA</link:label>
    <link:label id="lab_jnj_TRAUMAMember_label_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:label id="lab_jnj_TRAUMAMember_documentation_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember" xlink:href="jnj-20210404.xsd#jnj_TRAUMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TRAUMAMember" xlink:to="lab_jnj_TRAUMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_aa5b5473-e9fa-4306-843a-48b3dbc7a336_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_953294d8-2c96-4104-a378-05c00670fdc4_terseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_972a5b29-bef1-4a44-aec4-258ddf4822ef_verboseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember" xlink:href="jnj-20210404.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherIncomeExpenseNetMember" xlink:to="lab_jnj_OtherIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a7f8f8d4-96e0-4814-b43a-6729f22456f6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_80202e97-1b49-4b24-99de-fe17b0460ee3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_104a3447-8a9c-47e5-9eba-c8ce20d5dd29_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2b0e59dd-ecac-4c3e-9fff-bb416d1b0911_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_75080a12-8c5e-43b5-a812-e7d271597e0f_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_234488c9-2a3a-4835-ad1c-6f8d03ca29c3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OncologyMember_4500b2c0-4519-4456-ad8f-e7b161f85498_terseLabel_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_jnj_OncologyMember_label_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_jnj_OncologyMember_documentation_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember" xlink:href="jnj-20210404.xsd#jnj_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OncologyMember" xlink:to="lab_jnj_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_99f33505-fbe8-4433-a3e4-bf6ed1bd2079_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential shares exercisable under stock option plans</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_00bde606-fd11-4703-aa3e-20ff92841d4b_terseLabel_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_e85ca92a-0baf-49a5-8bf5-2599771e2b07_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring estimated cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTCMember_3d50fa9e-3ada-4e37-871c-40ca5096e1c3_terseLabel_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_jnj_OTCMember_label_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_documentation_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember" xlink:href="jnj-20210404.xsd#jnj_OTCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTCMember" xlink:to="lab_jnj_OTCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_2b906c48-19eb-4c0b-bcde-bd262f3d14cc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7f0d8d44-79ac-4c36-830e-27c52c854db1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4184cf70-7cf4-4678-8cce-909bfb4ad131_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding &#8212; basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_04f56b72-12cd-44a6-bd7b-f46f3dad18fc_terseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_label_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense Excluding Acquired In Process Cost Percent To Sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_documentation_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense excluding acquired in process cost percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:href="jnj-20210404.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:to="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_1837e56f-638c-48c8-87be-999cff2a844f_periodStartLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning of period</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_8f816edf-43b8-4c09-a4b7-7e83ab3b9bab_periodEndLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, end of period</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c2ef3639-7bf9-4b9b-86c3-11ae4d568237_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_3a369623-fbb5-4278-812a-73899f94e809_terseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Estimated Fair Value</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:href="jnj-20210404.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:to="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_f64edaed-2e7e-4a7d-b75e-0a74a45ca389_terseLabel_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member" xlink:href="jnj-20210404.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.95Notesdue2037Member" xlink:to="lab_jnj_A5.95Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_e97992e5-fcfe-466f-810b-4be29ec2e3ae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_177d47e9-9325-4617-ac7a-b1ae073c1b76_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_acc7423c-462a-4d73-a68b-2831648fe1e0_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2577be0c-4eaa-48b1-8dfb-abdad234a6c2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_aaa77668-f10e-413a-9f5a-b69e5d8bf8c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other current and non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_881bf6d9-e69c-4d45-bbf4-73f97a022164_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_0c518e81-966c-4394-82d8-c0b94a6cead6_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d8dd57fb-f279-4ec2-b628-107edff54c46_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_4ff573cf-774b-46a1-8529-73864c44a9ef_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit related to TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:href="jnj-20210404.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PROCRITEPREXMember_6bcdd2df-2a19-495c-aa41-6e70b6b9b885_terseLabel_en-US" xlink:label="lab_jnj_PROCRITEPREXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROCRIT&#174; / EPREX&#174;</link:label>
    <link:label id="lab_jnj_PROCRITEPREXMember_label_en-US" xlink:label="lab_jnj_PROCRITEPREXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROCRIT/EPREX [Member]</link:label>
    <link:label id="lab_jnj_PROCRITEPREXMember_documentation_en-US" xlink:label="lab_jnj_PROCRITEPREXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROCRIT/EPREX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PROCRITEPREXMember" xlink:href="jnj-20210404.xsd#jnj_PROCRITEPREXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PROCRITEPREXMember" xlink:to="lab_jnj_PROCRITEPREXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f3e1a218-78cd-47f0-868f-149c2f873e59_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_0fd0cc8f-de07-4507-b84f-c1b55a6852f4_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum length of time for hedge exposure</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a9745c8-90ac-486c-b802-fa6390195d2f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A210NotesDue2040Member_360173e7-3201-4757-af6e-002efadbb298_terseLabel_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_label_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_documentation_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member" xlink:href="jnj-20210404.xsd#jnj_A210NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A210NotesDue2040Member" xlink:to="lab_jnj_A210NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_937c0f1f-eb8d-4ccd-92e5-1c4f3b902fa2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_ec564e6a-ea15-4b38-b3ec-4d8a9ea966d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_8d9ad9a5-72a2-45de-a620-aed2319841a7_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Domain]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:href="jnj-20210404.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:to="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_f4a4ff20-f6cf-4704-9284-65a9c92ee9c4_terseLabel_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA&#174; / methylphenidate</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_label_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_documentation_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember" xlink:href="jnj-20210404.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONCERTAMethylphenidateMember" xlink:to="lab_jnj_CONCERTAMethylphenidateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_5ba77800-a2e3-44e9-9c23-8fb200c5f2a3_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StelaraMember_f824ceaf-41a6-448a-adf2-a8d9a285e67f_terseLabel_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STELARA&#174;</link:label>
    <link:label id="lab_jnj_StelaraMember_label_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:label id="lab_jnj_StelaraMember_documentation_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember" xlink:href="jnj-20210404.xsd#jnj_StelaraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StelaraMember" xlink:to="lab_jnj_StelaraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7d12f3d9-f882-43f2-8748-01075df3297f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SURGICALMember_761c284e-1854-4a1b-8d96-e640bb524e13_terseLabel_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL</link:label>
    <link:label id="lab_jnj_SURGICALMember_label_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:label id="lab_jnj_SURGICALMember_documentation_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember" xlink:href="jnj-20210404.xsd#jnj_SURGICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SURGICALMember" xlink:to="lab_jnj_SURGICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_aa9c29b0-4da5-42d7-86b9-94dc54830788_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_04d099ee-2d24-4ec1-88df-4120a3cc4095_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of property and intangibles</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OrthopaedicsMember_a575b39e-91ec-45c7-99df-1847bcb04010_terseLabel_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_label_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_documentation_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember" xlink:href="jnj-20210404.xsd#jnj_OrthopaedicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OrthopaedicsMember" xlink:to="lab_jnj_OrthopaedicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_f851c416-f806-4910-84f7-6c73ae07691f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_a6b60c20-eaed-4132-8cba-c46041631663_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_b7303b52-f50b-41a3-840c-0a44b73052b8_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_dc5c6536-860e-4cb9-97c0-e41a9b4ffd28_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit plans:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InfectiousDiseasesMember_cfba0597-290e-4445-b8ca-fa1fa822a1f0_terseLabel_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember" xlink:href="jnj-20210404.xsd#jnj_InfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InfectiousDiseasesMember" xlink:to="lab_jnj_InfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_3ec3808c-171a-42f9-9677-5fed47f50667_terseLabel_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_label_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_documentation_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember" xlink:href="jnj-20210404.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PulmonaryHypertensionMember" xlink:to="lab_jnj_PulmonaryHypertensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e22c0e0-cf8b-421b-8e92-bf174d139da7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_9641fb25-3544-42bf-aff9-0a4fb70d283c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0b086181-6925-452f-9737-fd4a6b8f779a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_11ce73db-db63-4901-8007-b8d67a28a968_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_8f172cbe-45c1-4c33-865b-f5e39b2c627a_totalLabel_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings percent to sales</link:label>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_label_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Parent Percent to Sales</link:label>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_documentation_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Parent Percent to Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales" xlink:href="jnj-20210404.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales" xlink:to="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_95f7b86b-861b-47c7-b999-503841749878_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff3f77ba-0236-4d85-8914-f5c3189a4914_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_0a0ebab2-50db-4a30-aabe-7843eec6f6a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Equity Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ff08e9ea-ba0c-4a73-bff7-917a4e790b8a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_8640fd1b-f58c-4411-9530-8a7ad0a7f521_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeMember_56cb80ca-b724-41fc-bb27-6b26673ab55f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:label id="lab_us-gaap_OtherIncomeMember_label_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeMember" xlink:to="lab_us-gaap_OtherIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_3fb49a02-c27a-4ff2-b597-dc87cc36309f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_cb42bf4d-1520-4948-a8e9-6d451d99e1fd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_87079a8c-2167-4b46-9c48-cfd97e416a21_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a0d7fbaf-349e-4843-8bd5-a701313cdd82_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_a406cfef-6f80-4190-a6cd-7a18383d5d37_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent Change (as a percent)</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:href="jnj-20210404.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:to="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_2f83df56-ae48-49fd-ab51-7e92f86f0424_terseLabel_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625% Notes due 2025</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_label_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_documentation_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member" xlink:href="jnj-20210404.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.625Notesdue2025Member" xlink:to="lab_jnj_A2.625Notesdue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_32f6db88-1648-4ce8-984f-16d80dd2d907_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_4cb1eafb-84d4-472a-a95f-4af6091f9b7d_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Gov't securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_6dd49226-3f05-4553-a3e1-87285c9864f2_terseLabel_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_label_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_documentation_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember" xlink:href="jnj-20210404.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsiaPacificAfricaMember" xlink:to="lab_jnj_AsiaPacificAfricaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UPTRAVIMember_341df63f-8a65-4596-8d85-b5b7ada11856_terseLabel_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI&#174;</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_label_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_documentation_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember" xlink:href="jnj-20210404.xsd#jnj_UPTRAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UPTRAVIMember" xlink:to="lab_jnj_UPTRAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7496ea67-b63d-4699-aac5-665761403cdc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f721b220-f79a-4a64-a916-4e2ceb8195a3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WoundCareandOtherMember_f9b13e9b-ec11-4cdb-9ad6-cfeeb2a4f130_terseLabel_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care/Other</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_label_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_documentation_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember" xlink:href="jnj-20210404.xsd#jnj_WoundCareandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WoundCareandOtherMember" xlink:to="lab_jnj_WoundCareandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_16398ae8-0562-4b8d-8b5d-702067688ab9_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_label_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Loaned or Sold under Agreements to Repurchase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:to="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_152eed3a-b2c2-4796-8024-34993bc9551e_terseLabel_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER INFECTIOUS DISEASES</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember" xlink:href="jnj-20210404.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherInfectiousDiseasesMember" xlink:to="lab_jnj_OtherInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_64e4478c-917b-4225-83ba-d5344719cb6b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_043abe6a-915b-416e-b453-90e0b901b515_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_9633e8c2-e7e2-4335-892c-5d80074ffbc5_terseLabel_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost savings expected</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_label_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_documentation_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:href="jnj-20210404.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:to="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_524cc088-963c-464c-9498-166047e782c7_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_7a9d66a1-5063-46a6-a13d-cb50031c8b16_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_fb929c21-6995-4f6b-aa16-11ea161ce1ca_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_daba340a-16c5-454c-a87a-7e0788973d15_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_02ff9cc7-a29e-4ffe-b4c2-38ea3a668339_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_b1e775c3-f017-4beb-8aa1-cc4702eb9348_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_e442a851-8340-4c74-991c-28971579590a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>jnj-20210404_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:1a2ac66c-2667-4890-bd3c-b889272a48e4,g:4415be36-51dc-414c-a907-a89d836331d3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20210404.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_396464ca-bd9a-4d46-826c-6a687987d47e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_baee2fbc-d2a7-4962-9722-ddb313cd5f85" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_396464ca-bd9a-4d46-826c-6a687987d47e" xlink:to="loc_dei_EntitiesTable_baee2fbc-d2a7-4962-9722-ddb313cd5f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_375d938f-a9e8-483e-86b5-3ca3185a765a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_baee2fbc-d2a7-4962-9722-ddb313cd5f85" xlink:to="loc_us-gaap_StatementClassOfStockAxis_375d938f-a9e8-483e-86b5-3ca3185a765a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_375d938f-a9e8-483e-86b5-3ca3185a765a" xlink:to="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f9e8497f-646e-45e9-867b-52ec13c8ced2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:to="loc_us-gaap_CommonStockMember_f9e8497f-646e-45e9-867b-52ec13c8ced2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member_fd0c36e2-1a82-4f17-acb9-36af50c4ba7c" xlink:href="jnj-20210404.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:to="loc_jnj_A0.250NotesDue2022Member_fd0c36e2-1a82-4f17-acb9-36af50c4ba7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_1fc64329-ed71-4c92-bb78-f7f83304325c" xlink:href="jnj-20210404.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:to="loc_jnj_A0.650NotesDue2024Member_1fc64329-ed71-4c92-bb78-f7f83304325c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_86fe2876-363f-4975-9488-0d8f37e05a99" xlink:href="jnj-20210404.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:to="loc_jnj_A5.50NotesDue2024Member_86fe2876-363f-4975-9488-0d8f37e05a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_61bc4ca6-cc6c-4491-8155-e01a255d2831" xlink:href="jnj-20210404.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:to="loc_jnj_A1.150NotesDue2028Member_61bc4ca6-cc6c-4491-8155-e01a255d2831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_7218af75-7c41-4c45-a066-d362c052b869" xlink:href="jnj-20210404.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3553f926-f461-4c2e-9c97-f458debc09d0" xlink:to="loc_jnj_A1.650NotesDue2035Member_7218af75-7c41-4c45-a066-d362c052b869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_baee2fbc-d2a7-4962-9722-ddb313cd5f85" xlink:to="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ff4d4451-173f-4af9-bd08-ddb15b8187fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_DocumentType_ff4d4451-173f-4af9-bd08-ddb15b8187fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_3fb5b4ef-0b42-4854-97cd-b4f16df25745" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_DocumentQuarterlyReport_3fb5b4ef-0b42-4854-97cd-b4f16df25745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_70648b3d-cfe5-44f9-9c32-7da6958e38fd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_DocumentPeriodEndDate_70648b3d-cfe5-44f9-9c32-7da6958e38fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_806762a1-7177-42a7-ac6b-591513d0d0d7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_DocumentTransitionReport_806762a1-7177-42a7-ac6b-591513d0d0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_43a33eb9-c895-4431-b19c-0dc2189512bf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityFileNumber_43a33eb9-c895-4431-b19c-0dc2189512bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c28ba9c0-ba04-4a1a-95be-6cda1327150b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityRegistrantName_c28ba9c0-ba04-4a1a-95be-6cda1327150b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_815c53e5-cc11-41ae-a99f-ddd75c6ed193" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_815c53e5-cc11-41ae-a99f-ddd75c6ed193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a113127d-f91c-4e82-854c-035bb0f2e576" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityTaxIdentificationNumber_a113127d-f91c-4e82-854c-035bb0f2e576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c8ca8674-f2a5-4747-b927-934d96f35e89" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityAddressAddressLine1_c8ca8674-f2a5-4747-b927-934d96f35e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_228cbba3-f94a-41ca-8074-5c129beb6b4f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityAddressCityOrTown_228cbba3-f94a-41ca-8074-5c129beb6b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_be3b8652-0ac0-44d8-98e1-975b9e8cd474" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityAddressStateOrProvince_be3b8652-0ac0-44d8-98e1-975b9e8cd474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_79d15c4a-3ebe-4bf5-a223-73ed5370dde8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityAddressPostalZipCode_79d15c4a-3ebe-4bf5-a223-73ed5370dde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0a6b5bdc-c9dc-42e5-8bfa-35f6fcd5e244" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_CityAreaCode_0a6b5bdc-c9dc-42e5-8bfa-35f6fcd5e244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a1eadc1f-4e6a-4215-9565-5a3191d5779e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_LocalPhoneNumber_a1eadc1f-4e6a-4215-9565-5a3191d5779e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7945e949-0bf2-4557-939a-58705c4ae5c3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityCurrentReportingStatus_7945e949-0bf2-4557-939a-58705c4ae5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_80d23260-7ca5-4c43-8b22-0acc15788ba5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityInteractiveDataCurrent_80d23260-7ca5-4c43-8b22-0acc15788ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_42f9c72c-a161-403f-86ff-7f4bbe62fa38" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityFilerCategory_42f9c72c-a161-403f-86ff-7f4bbe62fa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ca0aecd7-40ec-4c57-8d29-23591d6728d5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntitySmallBusiness_ca0aecd7-40ec-4c57-8d29-23591d6728d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8b61313b-4743-4c97-9823-86255dc7ac31" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityEmergingGrowthCompany_8b61313b-4743-4c97-9823-86255dc7ac31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8d9cbc1a-b209-4167-8554-a3b80300627d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityShellCompany_8d9cbc1a-b209-4167-8554-a3b80300627d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6b7bb619-4ea1-46be-8a12-b96a0d1fc7f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_Security12bTitle_6b7bb619-4ea1-46be-8a12-b96a0d1fc7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d21ef0f3-1a1d-489c-b543-ed591955c1cc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_TradingSymbol_d21ef0f3-1a1d-489c-b543-ed591955c1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c80127a7-c9c3-4fdb-a07b-24918fe75ee7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_SecurityExchangeName_c80127a7-c9c3-4fdb-a07b-24918fe75ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0b05f2ad-791e-48f6-bbb5-0dfa9420f5d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0b05f2ad-791e-48f6-bbb5-0dfa9420f5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d4630cb1-35fe-4f7a-a62f-99cec164b8dc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_EntityCentralIndexKey_d4630cb1-35fe-4f7a-a62f-99cec164b8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7e238b9a-d8c5-4f98-9b69-7388a2c72a7c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_CurrentFiscalYearEndDate_7e238b9a-d8c5-4f98-9b69-7388a2c72a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0934e737-744e-42d7-8d52-e9f5bae5870b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_DocumentFiscalYearFocus_0934e737-744e-42d7-8d52-e9f5bae5870b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8175de5b-9803-49d6-ae9e-eddfa80a494a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8175de5b-9803-49d6-ae9e-eddfa80a494a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2a30e3d9-1e7f-45a0-a197-2a227069340a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d1951789-415d-407e-a560-8856a755dc5f" xlink:to="loc_dei_AmendmentFlag_2a30e3d9-1e7f-45a0-a197-2a227069340a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f5121d28-15b1-4301-9df0-8356466e5561" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d6249c9b-d5c7-40dd-8bb8-f86e2d77c17d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f5121d28-15b1-4301-9df0-8356466e5561" xlink:to="loc_us-gaap_AssetsAbstract_d6249c9b-d5c7-40dd-8bb8-f86e2d77c17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_50a6c260-f801-4bbf-a0bb-d5aa5c304324" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6249c9b-d5c7-40dd-8bb8-f86e2d77c17d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_50a6c260-f801-4bbf-a0bb-d5aa5c304324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fec31d0-1d47-4949-bbb0-06cdb129e4e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50a6c260-f801-4bbf-a0bb-d5aa5c304324" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fec31d0-1d47-4949-bbb0-06cdb129e4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_020eef38-ae3e-40a6-b54a-23bde5162458" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50a6c260-f801-4bbf-a0bb-d5aa5c304324" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_020eef38-ae3e-40a6-b54a-23bde5162458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_807399ee-a1bb-4aa7-bc9a-79ddec7ca03f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50a6c260-f801-4bbf-a0bb-d5aa5c304324" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_807399ee-a1bb-4aa7-bc9a-79ddec7ca03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_72de3d7a-46c2-4e7a-9d26-4b99b6f91124" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50a6c260-f801-4bbf-a0bb-d5aa5c304324" xlink:to="loc_us-gaap_InventoryNet_72de3d7a-46c2-4e7a-9d26-4b99b6f91124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7c0e8eb2-e77d-4366-8ac9-5f6b24b6c73e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50a6c260-f801-4bbf-a0bb-d5aa5c304324" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7c0e8eb2-e77d-4366-8ac9-5f6b24b6c73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d6ad26c3-2137-473d-a815-0549de9a05d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50a6c260-f801-4bbf-a0bb-d5aa5c304324" xlink:to="loc_us-gaap_AssetsCurrent_d6ad26c3-2137-473d-a815-0549de9a05d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_12751f05-380d-4c59-97e0-7cc6c8ee929b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6249c9b-d5c7-40dd-8bb8-f86e2d77c17d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_12751f05-380d-4c59-97e0-7cc6c8ee929b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_98e7196a-0b54-4408-817b-80b09d1708ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6249c9b-d5c7-40dd-8bb8-f86e2d77c17d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_98e7196a-0b54-4408-817b-80b09d1708ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_32d14f1c-8d91-43b0-abc7-505a2e520a12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6249c9b-d5c7-40dd-8bb8-f86e2d77c17d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_32d14f1c-8d91-43b0-abc7-505a2e520a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b83d07d1-179a-42a6-b34c-d70bdf625a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6249c9b-d5c7-40dd-8bb8-f86e2d77c17d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b83d07d1-179a-42a6-b34c-d70bdf625a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d5f7e534-99e8-46b9-b2a0-ac835a778951" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6249c9b-d5c7-40dd-8bb8-f86e2d77c17d" xlink:to="loc_us-gaap_Goodwill_d5f7e534-99e8-46b9-b2a0-ac835a778951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8b6c0939-584e-4dd7-b2ad-f09d6b59e96b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6249c9b-d5c7-40dd-8bb8-f86e2d77c17d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8b6c0939-584e-4dd7-b2ad-f09d6b59e96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2f16755f-b6ca-4fec-84c4-c1418fe26af9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6249c9b-d5c7-40dd-8bb8-f86e2d77c17d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2f16755f-b6ca-4fec-84c4-c1418fe26af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5ba21bd3-4f8b-4390-8d7c-f11ba8fa47e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6249c9b-d5c7-40dd-8bb8-f86e2d77c17d" xlink:to="loc_us-gaap_Assets_5ba21bd3-4f8b-4390-8d7c-f11ba8fa47e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e27da9bc-2110-49e8-9614-a0b0608585f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f5121d28-15b1-4301-9df0-8356466e5561" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e27da9bc-2110-49e8-9614-a0b0608585f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_854f27c0-b3da-420c-9f43-519b52b64bee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e27da9bc-2110-49e8-9614-a0b0608585f6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_854f27c0-b3da-420c-9f43-519b52b64bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_4a9e7ce8-7f07-4629-883f-dba7ae9c1cac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_854f27c0-b3da-420c-9f43-519b52b64bee" xlink:to="loc_us-gaap_ShortTermBorrowings_4a9e7ce8-7f07-4629-883f-dba7ae9c1cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eb172f68-74e7-4778-bcd5-dd7f5073ef09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_854f27c0-b3da-420c-9f43-519b52b64bee" xlink:to="loc_us-gaap_AccountsPayableCurrent_eb172f68-74e7-4778-bcd5-dd7f5073ef09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7c656fc1-b193-492e-a1d7-d6a8e56a3287" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_854f27c0-b3da-420c-9f43-519b52b64bee" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7c656fc1-b193-492e-a1d7-d6a8e56a3287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_52dc9029-f33f-403a-83df-2f48c29a99de" xlink:href="jnj-20210404.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_854f27c0-b3da-420c-9f43-519b52b64bee" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_52dc9029-f33f-403a-83df-2f48c29a99de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2127f58b-fe1e-4216-af7f-e100e8fcebc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_854f27c0-b3da-420c-9f43-519b52b64bee" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2127f58b-fe1e-4216-af7f-e100e8fcebc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_14e7bb70-9ab1-451b-b8df-7526379fb979" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_854f27c0-b3da-420c-9f43-519b52b64bee" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_14e7bb70-9ab1-451b-b8df-7526379fb979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_348d5ec5-8163-456c-9007-074d950093df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_854f27c0-b3da-420c-9f43-519b52b64bee" xlink:to="loc_us-gaap_LiabilitiesCurrent_348d5ec5-8163-456c-9007-074d950093df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d85c80fc-d3b3-4730-8f81-1bfe6a807167" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e27da9bc-2110-49e8-9614-a0b0608585f6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d85c80fc-d3b3-4730-8f81-1bfe6a807167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4b64e623-63b2-4eab-8377-7e730dc34848" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e27da9bc-2110-49e8-9614-a0b0608585f6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4b64e623-63b2-4eab-8377-7e730dc34848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_1e3beed5-64cf-4170-a87c-52b9f0d75e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e27da9bc-2110-49e8-9614-a0b0608585f6" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_1e3beed5-64cf-4170-a87c-52b9f0d75e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_7608f270-6ace-4261-8225-5f277bf70ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e27da9bc-2110-49e8-9614-a0b0608585f6" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_7608f270-6ace-4261-8225-5f277bf70ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e5516265-833a-434c-9d8c-848aa86c02b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e27da9bc-2110-49e8-9614-a0b0608585f6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e5516265-833a-434c-9d8c-848aa86c02b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_aabf576c-7c7b-4585-867a-aaa72116778d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e27da9bc-2110-49e8-9614-a0b0608585f6" xlink:to="loc_us-gaap_Liabilities_aabf576c-7c7b-4585-867a-aaa72116778d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_71b73577-2b15-4442-a4d0-82184f0f8282" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e27da9bc-2110-49e8-9614-a0b0608585f6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_71b73577-2b15-4442-a4d0-82184f0f8282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_638d3db7-c3e1-4645-a813-ebdb60b2306c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e27da9bc-2110-49e8-9614-a0b0608585f6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_638d3db7-c3e1-4645-a813-ebdb60b2306c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3f37a0a9-a02b-4608-a9da-0cc6dbb40df1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_638d3db7-c3e1-4645-a813-ebdb60b2306c" xlink:to="loc_us-gaap_CommonStockValue_3f37a0a9-a02b-4608-a9da-0cc6dbb40df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c7ae44e8-1d67-4f29-946b-5a74818eb360" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_638d3db7-c3e1-4645-a813-ebdb60b2306c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c7ae44e8-1d67-4f29-946b-5a74818eb360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1eaf474b-d61a-4087-930f-db5abe357e7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_638d3db7-c3e1-4645-a813-ebdb60b2306c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1eaf474b-d61a-4087-930f-db5abe357e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a2a754f6-f4d8-4512-80c4-d908bb1b4a27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_638d3db7-c3e1-4645-a813-ebdb60b2306c" xlink:to="loc_us-gaap_TreasuryStockValue_a2a754f6-f4d8-4512-80c4-d908bb1b4a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aebdc7bf-cea0-4e43-907e-091210f187c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_638d3db7-c3e1-4645-a813-ebdb60b2306c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aebdc7bf-cea0-4e43-907e-091210f187c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d823bce4-57e6-477b-811d-c90b33922c87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e27da9bc-2110-49e8-9614-a0b0608585f6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d823bce4-57e6-477b-811d-c90b33922c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2d2f03bb-d835-4468-8376-0c7975ad953a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9b0ed5cf-b91e-4a2d-a10b-7597c14cfd66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d2f03bb-d835-4468-8376-0c7975ad953a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9b0ed5cf-b91e-4a2d-a10b-7597c14cfd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ed2e9004-d464-4942-aaad-d663bc91e9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9b0ed5cf-b91e-4a2d-a10b-7597c14cfd66" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ed2e9004-d464-4942-aaad-d663bc91e9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_73d1fcac-d5be-47e0-a768-ec5edbc15daf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d2f03bb-d835-4468-8376-0c7975ad953a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_73d1fcac-d5be-47e0-a768-ec5edbc15daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fc26828e-014d-472f-99c8-57d669670662" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_73d1fcac-d5be-47e0-a768-ec5edbc15daf" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fc26828e-014d-472f-99c8-57d669670662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20c85c44-7d46-43db-813e-5cfdec8f73b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_73d1fcac-d5be-47e0-a768-ec5edbc15daf" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_20c85c44-7d46-43db-813e-5cfdec8f73b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c54805ea-5525-4b06-8c2e-20c42371a9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_73d1fcac-d5be-47e0-a768-ec5edbc15daf" xlink:to="loc_us-gaap_CommonStockSharesIssued_c54805ea-5525-4b06-8c2e-20c42371a9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_81168264-50bc-4416-b501-fc323440a861" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_73d1fcac-d5be-47e0-a768-ec5edbc15daf" xlink:to="loc_us-gaap_TreasuryStockShares_81168264-50bc-4416-b501-fc323440a861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f8e5437a-f50b-4ee0-beb3-6fac78c9608a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f8e5437a-f50b-4ee0-beb3-6fac78c9608a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales_70673819-0955-46ce-9ad8-2370972210c3" xlink:href="jnj-20210404.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_jnj_SalesRevenueGoodsNetPercentToSales_70673819-0955-46ce-9ad8-2370972210c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8db1a1df-a22b-41bd-8af7-b1c61545c60c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8db1a1df-a22b-41bd-8af7-b1c61545c60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales_f585911c-9723-4814-a5dc-d4d5644e472a" xlink:href="jnj-20210404.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_jnj_CostOfGoodsSoldPercentToSales_f585911c-9723-4814-a5dc-d4d5644e472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_02c74efe-d6a1-42d1-be0b-7eb62d652f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_GrossProfit_02c74efe-d6a1-42d1-be0b-7eb62d652f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_21c60a2f-70ce-43d0-a10e-d642a7aeb490" xlink:href="jnj-20210404.xsd#jnj_GrossProfitPercentToSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_jnj_GrossProfitPercentToSales_21c60a2f-70ce-43d0-a10e-d642a7aeb490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9f6c5170-2c20-45ee-a564-54dc40089531" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9f6c5170-2c20-45ee-a564-54dc40089531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_70eaf816-bd9c-460f-a946-2d9b1b295e22" xlink:href="jnj-20210404.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_70eaf816-bd9c-460f-a946-2d9b1b295e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_089e19c4-ae72-4fde-b22a-fc21749c43e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_089e19c4-ae72-4fde-b22a-fc21749c43e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_b0517aa5-3e9e-4419-b67e-2e628566af33" xlink:href="jnj-20210404.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_b0517aa5-3e9e-4419-b67e-2e628566af33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cf58ed5d-1a99-469d-bf35-96eb71bcda4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cf58ed5d-1a99-469d-bf35-96eb71bcda4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales_5ebcd035-18f7-4c3a-82fa-af53ae899e31" xlink:href="jnj-20210404.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_jnj_InvestmentIncomeInterestPercentToSales_5ebcd035-18f7-4c3a-82fa-af53ae899e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c3de02f4-2593-4086-b865-0508e68d6b85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_InterestExpense_c3de02f4-2593-4086-b865-0508e68d6b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales_836e5d7b-d440-4f41-98da-e55a912ca313" xlink:href="jnj-20210404.xsd#jnj_InterestExpensePercentToSales"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_jnj_InterestExpensePercentToSales_836e5d7b-d440-4f41-98da-e55a912ca313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_836ff5ad-7b12-4b4b-914a-aa117dcddc85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_836ff5ad-7b12-4b4b-914a-aa117dcddc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_17e6f503-5a03-492a-9940-9abf393a7628" xlink:href="jnj-20210404.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_17e6f503-5a03-492a-9940-9abf393a7628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_727b9b51-081a-4dc4-9e17-b155248be15a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_RestructuringCharges_727b9b51-081a-4dc4-9e17-b155248be15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales_2101ea4b-46b3-45a4-87a2-53c68780d0a1" xlink:href="jnj-20210404.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_jnj_Restructuringchargepercenttosales_2101ea4b-46b3-45a4-87a2-53c68780d0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fec2d657-7a42-40d1-8a67-c3e44a27c093" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fec2d657-7a42-40d1-8a67-c3e44a27c093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_08f7172b-3e32-4063-bc1b-160c294d730b" xlink:href="jnj-20210404.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales_08f7172b-3e32-4063-bc1b-160c294d730b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_00793493-a37b-4f45-bf34-eec650524390" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_00793493-a37b-4f45-bf34-eec650524390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_523cf68b-2a46-4820-941e-0f4973a70649" xlink:href="jnj-20210404.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_523cf68b-2a46-4820-941e-0f4973a70649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5e15a993-60b9-4be6-8ad0-3df6cd4e7ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_NetIncomeLoss_5e15a993-60b9-4be6-8ad0-3df6cd4e7ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales_af913571-ff6a-4580-accb-a8f01f54818b" xlink:href="jnj-20210404.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_jnj_NetIncomeAttributableToParentPercentToSales_af913571-ff6a-4580-accb-a8f01f54818b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f34a3d9c-71d0-4c84-8f3f-806768f8cdfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_f34a3d9c-71d0-4c84-8f3f-806768f8cdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4c7260cf-51ed-4f5e-bfd8-1d422d4aca7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f34a3d9c-71d0-4c84-8f3f-806768f8cdfa" xlink:to="loc_us-gaap_EarningsPerShareBasic_4c7260cf-51ed-4f5e-bfd8-1d422d4aca7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_063e218b-bb34-48ee-a001-e07f5b373f87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f34a3d9c-71d0-4c84-8f3f-806768f8cdfa" xlink:to="loc_us-gaap_EarningsPerShareDiluted_063e218b-bb34-48ee-a001-e07f5b373f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e8f93da2-d549-4f58-b7f9-86877a4bf36a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_da1d6fd0-70fa-4325-bd87-6dd6dfe65d3d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e8f93da2-d549-4f58-b7f9-86877a4bf36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6472f7a-a7ed-4039-bb3d-1fd5347a6188" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e8f93da2-d549-4f58-b7f9-86877a4bf36a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6472f7a-a7ed-4039-bb3d-1fd5347a6188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8998057c-9068-4bdd-8ef3-875728b71160" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e8f93da2-d549-4f58-b7f9-86877a4bf36a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8998057c-9068-4bdd-8ef3-875728b71160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cbcddf43-d405-4b52-9bf6-4acf5d1b4aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_335cccc2-7073-4232-aab1-bc0f6af2b61b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cbcddf43-d405-4b52-9bf6-4acf5d1b4aa6" xlink:to="loc_us-gaap_NetIncomeLoss_335cccc2-7073-4232-aab1-bc0f6af2b61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9a2084-3bd5-4c5a-b504-2e38ee2b9655" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cbcddf43-d405-4b52-9bf6-4acf5d1b4aa6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9a2084-3bd5-4c5a-b504-2e38ee2b9655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2971fbc7-0e4e-4fad-aaf4-7e2edf34b7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9a2084-3bd5-4c5a-b504-2e38ee2b9655" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_2971fbc7-0e4e-4fad-aaf4-7e2edf34b7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_bd6c3b22-8c5b-4266-ad78-69fd0b81b335" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9a2084-3bd5-4c5a-b504-2e38ee2b9655" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_bd6c3b22-8c5b-4266-ad78-69fd0b81b335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7f9f5c15-7b26-4874-9224-a57ece7b8b19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_bd6c3b22-8c5b-4266-ad78-69fd0b81b335" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7f9f5c15-7b26-4874-9224-a57ece7b8b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_de13894c-66de-4fc4-b8ef-24af24c5718e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_bd6c3b22-8c5b-4266-ad78-69fd0b81b335" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_de13894c-66de-4fc4-b8ef-24af24c5718e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_627f29e7-766a-462d-8932-31ed76bf45af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_bd6c3b22-8c5b-4266-ad78-69fd0b81b335" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_627f29e7-766a-462d-8932-31ed76bf45af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_dd431598-6bd5-4d65-949e-ec8869abaf36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9a2084-3bd5-4c5a-b504-2e38ee2b9655" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_dd431598-6bd5-4d65-949e-ec8869abaf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_e208e7aa-0098-46b2-80b2-b85e908b3d2c" xlink:href="jnj-20210404.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_dd431598-6bd5-4d65-949e-ec8869abaf36" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_e208e7aa-0098-46b2-80b2-b85e908b3d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_0625fadf-107e-4e74-9e0d-26b87623997a" xlink:href="jnj-20210404.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_dd431598-6bd5-4d65-949e-ec8869abaf36" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_0625fadf-107e-4e74-9e0d-26b87623997a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_257ab479-d0e3-4d68-807b-ea742fac4d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_dd431598-6bd5-4d65-949e-ec8869abaf36" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_257ab479-d0e3-4d68-807b-ea742fac4d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_6a46cf4e-77a3-4dce-8e57-d4c660b7711d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7c9a2084-3bd5-4c5a-b504-2e38ee2b9655" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_6a46cf4e-77a3-4dce-8e57-d4c660b7711d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_6e8d5191-fa99-43fa-9f9a-5f07205b16b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_6a46cf4e-77a3-4dce-8e57-d4c660b7711d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_6e8d5191-fa99-43fa-9f9a-5f07205b16b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_e9392a1c-e507-4dac-bab9-310ea4c2fee7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_6a46cf4e-77a3-4dce-8e57-d4c660b7711d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_e9392a1c-e507-4dac-bab9-310ea4c2fee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_470cb5b7-6f96-4f0a-b151-dbd1a2b44e8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_6a46cf4e-77a3-4dce-8e57-d4c660b7711d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_470cb5b7-6f96-4f0a-b151-dbd1a2b44e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d2b6175f-759f-4277-8240-20df891fa8a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cbcddf43-d405-4b52-9bf6-4acf5d1b4aa6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d2b6175f-759f-4277-8240-20df891fa8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d6cc61fe-fd2e-4b92-85da-b29573854686" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cbcddf43-d405-4b52-9bf6-4acf5d1b4aa6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d6cc61fe-fd2e-4b92-85da-b29573854686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d86d7f4c-22e0-4f8d-af6a-58e461f0b171" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_4671cf5e-d67a-4015-956b-d35482de9ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d86d7f4c-22e0-4f8d-af6a-58e461f0b171" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_4671cf5e-d67a-4015-956b-d35482de9ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_fdb3fc08-54e9-400a-9bce-700d61ab7476" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d86d7f4c-22e0-4f8d-af6a-58e461f0b171" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_fdb3fc08-54e9-400a-9bce-700d61ab7476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_9993a15c-232d-46e6-bf2d-772beed298f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d86d7f4c-22e0-4f8d-af6a-58e461f0b171" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_9993a15c-232d-46e6-bf2d-772beed298f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_5d5d2328-43e3-420b-a9bc-d80b5e067356" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d86d7f4c-22e0-4f8d-af6a-58e461f0b171" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_5d5d2328-43e3-420b-a9bc-d80b5e067356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1ff46a9e-d551-4f98-bb84-7acca33209d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bfea3c11-4be7-458e-b824-802e1ed4c741" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1ff46a9e-d551-4f98-bb84-7acca33209d9" xlink:to="loc_us-gaap_StatementTable_bfea3c11-4be7-458e-b824-802e1ed4c741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cdfaca74-f589-4161-9e1a-c213cd44b9a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bfea3c11-4be7-458e-b824-802e1ed4c741" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cdfaca74-f589-4161-9e1a-c213cd44b9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_718bd21b-9a2b-43a2-b279-21fd40e58d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cdfaca74-f589-4161-9e1a-c213cd44b9a8" xlink:to="loc_us-gaap_EquityComponentDomain_718bd21b-9a2b-43a2-b279-21fd40e58d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ce6461c5-6536-438a-9618-a558b033136d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_718bd21b-9a2b-43a2-b279-21fd40e58d9b" xlink:to="loc_us-gaap_RetainedEarningsMember_ce6461c5-6536-438a-9618-a558b033136d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_65b79a2c-64bc-4185-b896-698bd7ff0306" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_718bd21b-9a2b-43a2-b279-21fd40e58d9b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_65b79a2c-64bc-4185-b896-698bd7ff0306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9ffeaf04-aea7-48a7-904b-c3a1df582808" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_718bd21b-9a2b-43a2-b279-21fd40e58d9b" xlink:to="loc_us-gaap_CommonStockMember_9ffeaf04-aea7-48a7-904b-c3a1df582808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_0a9125e4-3a9e-4203-912d-acf67e4ff653" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_718bd21b-9a2b-43a2-b279-21fd40e58d9b" xlink:to="loc_us-gaap_TreasuryStockMember_0a9125e4-3a9e-4203-912d-acf67e4ff653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bfea3c11-4be7-458e-b824-802e1ed4c741" xlink:to="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3fc10a0a-11fd-4b28-8222-fe761bfa2155" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3fc10a0a-11fd-4b28-8222-fe761bfa2155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_199f17e0-2796-4964-9b02-45f9409d2305" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_NetIncomeLoss_199f17e0-2796-4964-9b02-45f9409d2305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_145d52b6-2288-419b-b786-253cea0147f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_DividendsCommonStockCash_145d52b6-2288-419b-b786-253cea0147f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_e4e7ca42-6bfd-4796-a1e1-29ea0e916bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_e4e7ca42-6bfd-4796-a1e1-29ea0e916bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_72142805-30f4-485b-9cd4-b15dd7e22e74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_72142805-30f4-485b-9cd4-b15dd7e22e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e42470d-3d86-457d-a5a1-cca69bd0522e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e42470d-3d86-457d-a5a1-cca69bd0522e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9c0c34a5-f048-4067-88ff-81d2c727562b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_445605d6-e129-48d9-9093-f92d23b02aa9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9c0c34a5-f048-4067-88ff-81d2c727562b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_efb630fc-0e43-46cd-b479-2693fa3984f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1f2862f8-77ec-4d6d-a4fc-7040844c2e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_efb630fc-0e43-46cd-b479-2693fa3984f2" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1f2862f8-77ec-4d6d-a4fc-7040844c2e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20210404.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7eacea0a-b8f0-4538-a528-da3fc79de91f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1d52a716-ec8d-42b7-8bf7-d0267b75b8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eacea0a-b8f0-4538-a528-da3fc79de91f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1d52a716-ec8d-42b7-8bf7-d0267b75b8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a0f4f809-49a9-497e-a3b8-e28b0e94f976" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1d52a716-ec8d-42b7-8bf7-d0267b75b8c6" xlink:to="loc_us-gaap_NetIncomeLoss_a0f4f809-49a9-497e-a3b8-e28b0e94f976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b059b320-61f5-4518-8712-40c3dd87d8f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1d52a716-ec8d-42b7-8bf7-d0267b75b8c6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b059b320-61f5-4518-8712-40c3dd87d8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_027f351b-099b-4b8f-804d-2527a47ac05f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b059b320-61f5-4518-8712-40c3dd87d8f7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_027f351b-099b-4b8f-804d-2527a47ac05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_58c822fd-d1a7-4ab9-9742-98e1e499d68c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b059b320-61f5-4518-8712-40c3dd87d8f7" xlink:to="loc_us-gaap_ShareBasedCompensation_58c822fd-d1a7-4ab9-9742-98e1e499d68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_11221d38-30b0-4564-a205-51eacbe71c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b059b320-61f5-4518-8712-40c3dd87d8f7" xlink:to="loc_us-gaap_AssetImpairmentCharges_11221d38-30b0-4564-a205-51eacbe71c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e0e20060-0132-4bfa-ad0e-f6e8ade68693" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b059b320-61f5-4518-8712-40c3dd87d8f7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e0e20060-0132-4bfa-ad0e-f6e8ade68693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_97d92ff0-4a85-4f96-b59d-9753337607da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b059b320-61f5-4518-8712-40c3dd87d8f7" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_97d92ff0-4a85-4f96-b59d-9753337607da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_365214d9-91d1-463c-8605-7be1b8c531be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b059b320-61f5-4518-8712-40c3dd87d8f7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_365214d9-91d1-463c-8605-7be1b8c531be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_b0aaf1e0-6c00-4d5d-8a12-d90248b2281a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b059b320-61f5-4518-8712-40c3dd87d8f7" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_b0aaf1e0-6c00-4d5d-8a12-d90248b2281a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a91a4147-eb4b-4d21-a026-ce4d731c1874" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1d52a716-ec8d-42b7-8bf7-d0267b75b8c6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a91a4147-eb4b-4d21-a026-ce4d731c1874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fd17387f-bbc8-44ea-ab96-49d6d2b1296e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a91a4147-eb4b-4d21-a026-ce4d731c1874" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fd17387f-bbc8-44ea-ab96-49d6d2b1296e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_eaf53b6b-5057-4678-bcb5-b972beba373f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a91a4147-eb4b-4d21-a026-ce4d731c1874" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_eaf53b6b-5057-4678-bcb5-b972beba373f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0f3db584-2e53-49f5-9c11-33e1ee4f8824" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a91a4147-eb4b-4d21-a026-ce4d731c1874" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0f3db584-2e53-49f5-9c11-33e1ee4f8824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a18f9c72-2e29-43a3-b114-ad11b3eb6a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a91a4147-eb4b-4d21-a026-ce4d731c1874" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a18f9c72-2e29-43a3-b114-ad11b3eb6a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f0d8a912-b8da-4a06-bd94-2323c554053b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a91a4147-eb4b-4d21-a026-ce4d731c1874" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f0d8a912-b8da-4a06-bd94-2323c554053b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4e3dd61-364a-4f5d-b624-0dce4fb08d2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a91a4147-eb4b-4d21-a026-ce4d731c1874" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4e3dd61-364a-4f5d-b624-0dce4fb08d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1701313-4302-49ca-8ef1-21a4a47b26d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eacea0a-b8f0-4538-a528-da3fc79de91f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1701313-4302-49ca-8ef1-21a4a47b26d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16d8c9e9-4b6e-4fec-a8d1-dcb6e68b2df2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1701313-4302-49ca-8ef1-21a4a47b26d7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16d8c9e9-4b6e-4fec-a8d1-dcb6e68b2df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_0f4d9f40-4d10-4109-b2fe-5df1738cc94b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1701313-4302-49ca-8ef1-21a4a47b26d7" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_0f4d9f40-4d10-4109-b2fe-5df1738cc94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_92e2adfe-6008-429b-bc76-2c34f9cc939b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1701313-4302-49ca-8ef1-21a4a47b26d7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_92e2adfe-6008-429b-bc76-2c34f9cc939b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_daff0ad4-fc76-491d-998a-b621cc518548" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1701313-4302-49ca-8ef1-21a4a47b26d7" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_daff0ad4-fc76-491d-998a-b621cc518548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_76ab955b-0727-462a-a406-4d62964d9af5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1701313-4302-49ca-8ef1-21a4a47b26d7" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_76ab955b-0727-462a-a406-4d62964d9af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_3801dae2-37d2-49eb-957a-762d2b4b03dd" xlink:href="jnj-20210404.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1701313-4302-49ca-8ef1-21a4a47b26d7" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_3801dae2-37d2-49eb-957a-762d2b4b03dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c9217545-9ac4-4623-b7b9-d1ea8c84dd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1701313-4302-49ca-8ef1-21a4a47b26d7" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c9217545-9ac4-4623-b7b9-d1ea8c84dd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54965f29-df2a-41b2-8973-fe7cac3e7510" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1701313-4302-49ca-8ef1-21a4a47b26d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54965f29-df2a-41b2-8973-fe7cac3e7510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b8cac2-225c-4eaf-8093-0be2c0215946" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eacea0a-b8f0-4538-a528-da3fc79de91f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b8cac2-225c-4eaf-8093-0be2c0215946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_8fb3c2c7-0947-449e-a4cf-94de66ff8706" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b8cac2-225c-4eaf-8093-0be2c0215946" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_8fb3c2c7-0947-449e-a4cf-94de66ff8706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_eff61c5d-2574-452f-9994-6634580e70c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b8cac2-225c-4eaf-8093-0be2c0215946" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_eff61c5d-2574-452f-9994-6634580e70c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_b7eff14f-f768-41dc-aeda-ad79745f119d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b8cac2-225c-4eaf-8093-0be2c0215946" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_b7eff14f-f768-41dc-aeda-ad79745f119d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_e76d4cf1-e814-4317-b85c-24f858191489" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b8cac2-225c-4eaf-8093-0be2c0215946" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_e76d4cf1-e814-4317-b85c-24f858191489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_af617a4e-661b-4049-adfd-896e8a4404bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b8cac2-225c-4eaf-8093-0be2c0215946" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_af617a4e-661b-4049-adfd-896e8a4404bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f631a9fe-601a-4729-8daa-0837ae26333c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b8cac2-225c-4eaf-8093-0be2c0215946" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f631a9fe-601a-4729-8daa-0837ae26333c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_f7fd8a3c-6797-489d-a75a-2d837fd21f59" xlink:href="jnj-20210404.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b8cac2-225c-4eaf-8093-0be2c0215946" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_f7fd8a3c-6797-489d-a75a-2d837fd21f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_c3faac9b-95e0-42f8-9c8e-bf47d88bef9e" xlink:href="jnj-20210404.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b8cac2-225c-4eaf-8093-0be2c0215946" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_c3faac9b-95e0-42f8-9c8e-bf47d88bef9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1bd93ed2-7e78-4b13-ba6a-ef83eb004fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b8cac2-225c-4eaf-8093-0be2c0215946" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1bd93ed2-7e78-4b13-ba6a-ef83eb004fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fce16c0-f6ed-48cc-bdf0-51c670b0bbd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5b8cac2-225c-4eaf-8093-0be2c0215946" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fce16c0-f6ed-48cc-bdf0-51c670b0bbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_996ae365-b84a-41b0-9495-cffbbe27f22e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eacea0a-b8f0-4538-a528-da3fc79de91f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_996ae365-b84a-41b0-9495-cffbbe27f22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e2548c99-396f-4b61-90db-c6196c2306cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eacea0a-b8f0-4538-a528-da3fc79de91f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e2548c99-396f-4b61-90db-c6196c2306cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2fcaeb11-6af8-4bef-951b-c4a6ea668631" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eacea0a-b8f0-4538-a528-da3fc79de91f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2fcaeb11-6af8-4bef-951b-c4a6ea668631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6440705f-49f1-42da-9f7c-33b484d599df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eacea0a-b8f0-4538-a528-da3fc79de91f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6440705f-49f1-42da-9f7c-33b484d599df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_293986d3-16ae-4d21-898e-86ecbbd67359" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7eacea0a-b8f0-4538-a528-da3fc79de91f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_293986d3-16ae-4d21-898e-86ecbbd67359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_8fc51ccb-0faa-4114-9015-d3d3e26924cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_293986d3-16ae-4d21-898e-86ecbbd67359" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_8fc51ccb-0faa-4114-9015-d3d3e26924cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_7a40a7fd-69fb-459e-9dab-bd30d05916f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_293986d3-16ae-4d21-898e-86ecbbd67359" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_7a40a7fd-69fb-459e-9dab-bd30d05916f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_2a44ff5b-a6ca-408d-96f6-9997a75f803b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_293986d3-16ae-4d21-898e-86ecbbd67359" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_2a44ff5b-a6ca-408d-96f6-9997a75f803b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20210404.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3fb6702d-9882-4864-a589-b23a54e6640f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_15f1868e-1295-4211-9dce-f15d54b99be2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3fb6702d-9882-4864-a589-b23a54e6640f" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_15f1868e-1295-4211-9dce-f15d54b99be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20210404.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_557c0cbc-4ba9-4d77-903f-21fb469fd8b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_250c682e-76bc-412d-8f30-07fab8ce6888" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_557c0cbc-4ba9-4d77-903f-21fb469fd8b3" xlink:to="loc_us-gaap_UseOfEstimates_250c682e-76bc-412d-8f30-07fab8ce6888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d4cd422a-1ff1-41ea-9bbf-33ce70c661b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_557c0cbc-4ba9-4d77-903f-21fb469fd8b3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d4cd422a-1ff1-41ea-9bbf-33ce70c661b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5cb95bf1-42e2-451c-8121-cb27d8337f0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_557c0cbc-4ba9-4d77-903f-21fb469fd8b3" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5cb95bf1-42e2-451c-8121-cb27d8337f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e052da45-2499-4c1a-a9fc-ebfd40ebbfea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_557c0cbc-4ba9-4d77-903f-21fb469fd8b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e052da45-2499-4c1a-a9fc-ebfd40ebbfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20210404.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4de29e4d-207e-48a4-96e8-7f96b25011e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_3367ade9-8789-4317-97d1-4bdcc8927a50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4de29e4d-207e-48a4-96e8-7f96b25011e7" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_3367ade9-8789-4317-97d1-4bdcc8927a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_80406859-71ee-4f74-91c8-977a817efd19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_01e33829-9b9f-4828-8df6-7211c80c01e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_80406859-71ee-4f74-91c8-977a817efd19" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_01e33829-9b9f-4828-8df6-7211c80c01e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6582d7aa-043f-49ae-bdad-13284ff296f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_afda394e-988b-4adf-8756-de2b4388609a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6582d7aa-043f-49ae-bdad-13284ff296f9" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_afda394e-988b-4adf-8756-de2b4388609a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_75f565ee-cb36-4e24-a263-2baee9b72f71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6582d7aa-043f-49ae-bdad-13284ff296f9" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_75f565ee-cb36-4e24-a263-2baee9b72f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_25fef1bc-a774-4830-bc39-711ce338cf5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6582d7aa-043f-49ae-bdad-13284ff296f9" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_25fef1bc-a774-4830-bc39-711ce338cf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_99e4e7cb-6957-4141-91bf-6a6ae6694849" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6582d7aa-043f-49ae-bdad-13284ff296f9" xlink:to="loc_us-gaap_InventoryNet_99e4e7cb-6957-4141-91bf-6a6ae6694849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9fd125b6-84f7-4710-ae5f-78dff167b5a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_bff2e2dd-466c-4757-a736-9c28e0d4acac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9fd125b6-84f7-4710-ae5f-78dff167b5a0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_bff2e2dd-466c-4757-a736-9c28e0d4acac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d221cbe6-8c56-43d3-bc14-8e39802ffc4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_8b9cd8c2-dcbd-4332-8157-516006e6f6af" xlink:href="jnj-20210404.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d221cbe6-8c56-43d3-bc14-8e39802ffc4a" xlink:to="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_8b9cd8c2-dcbd-4332-8157-516006e6f6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_e11d0cdc-31db-45e5-a3e8-659ef8e96ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d221cbe6-8c56-43d3-bc14-8e39802ffc4a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_e11d0cdc-31db-45e5-a3e8-659ef8e96ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_33b0cbdb-abc2-4cbd-97f3-94ec6b703875" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d221cbe6-8c56-43d3-bc14-8e39802ffc4a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_33b0cbdb-abc2-4cbd-97f3-94ec6b703875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9e8f5818-c98e-4608-b428-25f613ec410f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_103ccd1d-115c-49f0-b7a1-c67ce374a8eb" xlink:href="jnj-20210404.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9e8f5818-c98e-4608-b428-25f613ec410f" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_103ccd1d-115c-49f0-b7a1-c67ce374a8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fb2bb52-7a45-4beb-9dc2-0cd8b2782a46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_103ccd1d-115c-49f0-b7a1-c67ce374a8eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fb2bb52-7a45-4beb-9dc2-0cd8b2782a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a5256c4-64a4-4c82-a03b-df4ecb90ed6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fb2bb52-7a45-4beb-9dc2-0cd8b2782a46" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a5256c4-64a4-4c82-a03b-df4ecb90ed6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_a00fdf62-69c3-4350-a199-b3f1ea0648a5" xlink:href="jnj-20210404.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a5256c4-64a4-4c82-a03b-df4ecb90ed6f" xlink:to="loc_jnj_PatentsAndTrademarksMember_a00fdf62-69c3-4350-a199-b3f1ea0648a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_3e63ab6e-d4e1-451c-b555-973fa84709d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a5256c4-64a4-4c82-a03b-df4ecb90ed6f" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_3e63ab6e-d4e1-451c-b555-973fa84709d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5f19a0a4-ed8a-4057-9862-692de92ef5d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_103ccd1d-115c-49f0-b7a1-c67ce374a8eb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5f19a0a4-ed8a-4057-9862-692de92ef5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96931810-6be4-498b-ae23-176a14e3e55d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5f19a0a4-ed8a-4057-9862-692de92ef5d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96931810-6be4-498b-ae23-176a14e3e55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_cadd8caf-0261-47d9-a6e0-3c4838e8080d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96931810-6be4-498b-ae23-176a14e3e55d" xlink:to="loc_us-gaap_TrademarksMember_cadd8caf-0261-47d9-a6e0-3c4838e8080d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_1d2d1765-01a4-40d4-95cd-b03b53a8630e" xlink:href="jnj-20210404.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96931810-6be4-498b-ae23-176a14e3e55d" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_1d2d1765-01a4-40d4-95cd-b03b53a8630e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_d4103580-c5e6-46a7-afe3-9910e4c9b91e" xlink:href="jnj-20210404.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_103ccd1d-115c-49f0-b7a1-c67ce374a8eb" xlink:to="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_d4103580-c5e6-46a7-afe3-9910e4c9b91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_019859c5-1433-4bbf-9c04-0de90f8718ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_d4103580-c5e6-46a7-afe3-9910e4c9b91e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_019859c5-1433-4bbf-9c04-0de90f8718ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ea44ccb6-19e1-4d4b-9ae9-a0f30d6bcf1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_019859c5-1433-4bbf-9c04-0de90f8718ee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ea44ccb6-19e1-4d4b-9ae9-a0f30d6bcf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ec35fab9-ca76-4291-9438-0b714648b058" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ea44ccb6-19e1-4d4b-9ae9-a0f30d6bcf1f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ec35fab9-ca76-4291-9438-0b714648b058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_15c68125-6a56-4406-9afd-7d46452fe878" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ea44ccb6-19e1-4d4b-9ae9-a0f30d6bcf1f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_15c68125-6a56-4406-9afd-7d46452fe878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d5a0262d-bee1-4dfa-a05c-e9475bab471b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ea44ccb6-19e1-4d4b-9ae9-a0f30d6bcf1f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d5a0262d-bee1-4dfa-a05c-e9475bab471b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ccffe8ca-3d9b-47c9-be7a-e61f619a918e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_019859c5-1433-4bbf-9c04-0de90f8718ee" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ccffe8ca-3d9b-47c9-be7a-e61f619a918e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb47d9c9-1a57-476e-a323-7d5f969c965d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ccffe8ca-3d9b-47c9-be7a-e61f619a918e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb47d9c9-1a57-476e-a323-7d5f969c965d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3b7c64ac-c7fb-488c-ad9e-555d82f7ff07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ccffe8ca-3d9b-47c9-be7a-e61f619a918e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3b7c64ac-c7fb-488c-ad9e-555d82f7ff07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d9d4c901-eb03-467f-a7db-55e01a444fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5f15a458-1ce5-4742-bad6-70d034b17841" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d9d4c901-eb03-467f-a7db-55e01a444fc5" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5f15a458-1ce5-4742-bad6-70d034b17841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b209e4bc-0879-4f0e-acab-b0614664c1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5f15a458-1ce5-4742-bad6-70d034b17841" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b209e4bc-0879-4f0e-acab-b0614664c1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_90dc8320-8d8b-4520-ad98-4c9538975bab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b209e4bc-0879-4f0e-acab-b0614664c1f2" xlink:to="loc_us-gaap_SegmentDomain_90dc8320-8d8b-4520-ad98-4c9538975bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_caa6566b-728e-46ff-a8ca-4bb741fe9a4a" xlink:href="jnj-20210404.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_90dc8320-8d8b-4520-ad98-4c9538975bab" xlink:to="loc_jnj_ConsumerMember_caa6566b-728e-46ff-a8ca-4bb741fe9a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_4ccea77e-0c64-4a60-9e8b-0d5f432a113b" xlink:href="jnj-20210404.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_90dc8320-8d8b-4520-ad98-4c9538975bab" xlink:to="loc_jnj_PharmaceuticalMember_4ccea77e-0c64-4a60-9e8b-0d5f432a113b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_49c42f1b-8d71-4d4e-bc39-781602f6e5ba" xlink:href="jnj-20210404.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_90dc8320-8d8b-4520-ad98-4c9538975bab" xlink:to="loc_jnj_MedicalDevicesMember_49c42f1b-8d71-4d4e-bc39-781602f6e5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_219402ed-4eef-42dc-9ff3-7d1e61913eed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5f15a458-1ce5-4742-bad6-70d034b17841" xlink:to="loc_us-gaap_GoodwillLineItems_219402ed-4eef-42dc-9ff3-7d1e61913eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_19202ebe-e090-4a3f-a3d5-14a74c42b997" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_219402ed-4eef-42dc-9ff3-7d1e61913eed" xlink:to="loc_us-gaap_GoodwillRollForward_19202ebe-e090-4a3f-a3d5-14a74c42b997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8141fdb2-595d-46f5-a34c-5685c0afb0c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_19202ebe-e090-4a3f-a3d5-14a74c42b997" xlink:to="loc_us-gaap_Goodwill_8141fdb2-595d-46f5-a34c-5685c0afb0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_6edfc0e3-d211-4aa5-ac11-c375287efecc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_19202ebe-e090-4a3f-a3d5-14a74c42b997" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_6edfc0e3-d211-4aa5-ac11-c375287efecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_0f6bc09d-c7f1-44e6-a9d1-f555d55f0370" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_19202ebe-e090-4a3f-a3d5-14a74c42b997" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_0f6bc09d-c7f1-44e6-a9d1-f555d55f0370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fd3bd095-2e9b-451c-85ef-d69b647edaba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_19202ebe-e090-4a3f-a3d5-14a74c42b997" xlink:to="loc_us-gaap_Goodwill_fd3bd095-2e9b-451c-85ef-d69b647edaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_66a0acc7-1575-4965-990e-01c38a7de555" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02b7f9df-897d-488c-b570-57b4f993cd40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_66a0acc7-1575-4965-990e-01c38a7de555" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02b7f9df-897d-488c-b570-57b4f993cd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_470775d8-e57f-4aea-9fe2-2fde7c79186a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02b7f9df-897d-488c-b570-57b4f993cd40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_470775d8-e57f-4aea-9fe2-2fde7c79186a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7229547-b2e9-4dd4-8995-d391495aa477" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_470775d8-e57f-4aea-9fe2-2fde7c79186a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7229547-b2e9-4dd4-8995-d391495aa477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_7945435f-2244-4d41-a18d-80a7ffdc4e97" xlink:href="jnj-20210404.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7229547-b2e9-4dd4-8995-d391495aa477" xlink:to="loc_jnj_PatentsAndTrademarksMember_7945435f-2244-4d41-a18d-80a7ffdc4e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_2ffdeaee-ab94-4948-b9ab-2ff54ce01188" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7229547-b2e9-4dd4-8995-d391495aa477" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_2ffdeaee-ab94-4948-b9ab-2ff54ce01188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c05b71a7-d964-4919-aa14-2263a1c2ba80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_02b7f9df-897d-488c-b570-57b4f993cd40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c05b71a7-d964-4919-aa14-2263a1c2ba80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_be7780ab-c1e1-4240-b5ae-4ffc8b8609c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c05b71a7-d964-4919-aa14-2263a1c2ba80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_be7780ab-c1e1-4240-b5ae-4ffc8b8609c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_351afcce-ec81-49f3-9551-c0de5e37c3d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c05b71a7-d964-4919-aa14-2263a1c2ba80" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_351afcce-ec81-49f3-9551-c0de5e37c3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97b103bf-821f-4528-834b-9717289007c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_11921267-9996-4854-b268-b6c637a627b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97b103bf-821f-4528-834b-9717289007c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_11921267-9996-4854-b268-b6c637a627b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_833ea096-271a-4ce9-8e5a-98ec66ca3be8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97b103bf-821f-4528-834b-9717289007c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_833ea096-271a-4ce9-8e5a-98ec66ca3be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fb93cc07-8b02-4f3d-b5e9-e9bcd92b37eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97b103bf-821f-4528-834b-9717289007c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fb93cc07-8b02-4f3d-b5e9-e9bcd92b37eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d3fdb36a-0038-4eab-9a4b-f7882ce01bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97b103bf-821f-4528-834b-9717289007c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d3fdb36a-0038-4eab-9a4b-f7882ce01bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_dc9946da-111d-4db3-8f51-67ea05f5386a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97b103bf-821f-4528-834b-9717289007c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_dc9946da-111d-4db3-8f51-67ea05f5386a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1493b61f-77d3-4da5-ba6b-4a7d49c409c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_754deec2-6556-4d4b-8347-0326789f73fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1493b61f-77d3-4da5-ba6b-4a7d49c409c4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_754deec2-6556-4d4b-8347-0326789f73fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fffafc43-7eef-463f-a12b-3e98727aab1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c2b96962-9777-4662-9a15-8a6e3aec51d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fffafc43-7eef-463f-a12b-3e98727aab1c" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c2b96962-9777-4662-9a15-8a6e3aec51d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f39fb83c-3dce-44f9-a9c3-a73473a3e2d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fffafc43-7eef-463f-a12b-3e98727aab1c" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f39fb83c-3dce-44f9-a9c3-a73473a3e2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7a5af224-59c2-469c-85ef-088236682ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fffafc43-7eef-463f-a12b-3e98727aab1c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7a5af224-59c2-469c-85ef-088236682ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_aac357e0-a9b0-4446-9400-12fc75c745ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fffafc43-7eef-463f-a12b-3e98727aab1c" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_aac357e0-a9b0-4446-9400-12fc75c745ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_6bedf884-5a41-4069-b531-05921bf7cfcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fffafc43-7eef-463f-a12b-3e98727aab1c" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_6bedf884-5a41-4069-b531-05921bf7cfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_8cdd0f21-5f1e-478f-b2e6-9d288761b141" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fffafc43-7eef-463f-a12b-3e98727aab1c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_8cdd0f21-5f1e-478f-b2e6-9d288761b141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0c5c40ab-c5ad-4c6d-b262-7c46450b01f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fffafc43-7eef-463f-a12b-3e98727aab1c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0c5c40ab-c5ad-4c6d-b262-7c46450b01f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d33ffbe6-177f-4717-8163-1207b4aa5007" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d33ffbe6-177f-4717-8163-1207b4aa5007" xlink:to="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_9ccb600e-107a-4f6c-a49c-d72cd2e8d7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_9ccb600e-107a-4f6c-a49c-d72cd2e8d7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_916bc0ab-b1db-4a61-b538-6cfbaf9790c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_9ccb600e-107a-4f6c-a49c-d72cd2e8d7ca" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_916bc0ab-b1db-4a61-b538-6cfbaf9790c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_34018127-432c-44f2-a7e9-aef74fbcba1f" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_916bc0ab-b1db-4a61-b538-6cfbaf9790c8" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_34018127-432c-44f2-a7e9-aef74fbcba1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_63be8fc7-59f2-4952-9b1f-4e43a92a2d81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_63be8fc7-59f2-4952-9b1f-4e43a92a2d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bcb4554-cbb6-45c9-9d9b-c7e9b3b013da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_63be8fc7-59f2-4952-9b1f-4e43a92a2d81" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bcb4554-cbb6-45c9-9d9b-c7e9b3b013da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_4e0902a3-7ab4-45bd-8f8e-2a8df4f926d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bcb4554-cbb6-45c9-9d9b-c7e9b3b013da" xlink:to="loc_us-gaap_EquitySecuritiesMember_4e0902a3-7ab4-45bd-8f8e-2a8df4f926d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a1f485b7-e551-49c6-94b4-4d5f6c4d8fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a1f485b7-e551-49c6-94b4-4d5f6c4d8fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c6f735d4-f5f9-419f-9463-9dd217a5f30f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a1f485b7-e551-49c6-94b4-4d5f6c4d8fbe" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c6f735d4-f5f9-419f-9463-9dd217a5f30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d458ce2f-82b7-4df9-859e-01bbbb2614f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c6f735d4-f5f9-419f-9463-9dd217a5f30f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d458ce2f-82b7-4df9-859e-01bbbb2614f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_4a4079ac-e8b9-4551-840e-1696008cf50a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c6f735d4-f5f9-419f-9463-9dd217a5f30f" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_4a4079ac-e8b9-4551-840e-1696008cf50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_255ba6f8-27ac-410f-b7cc-cfc9d5d0c96d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_255ba6f8-27ac-410f-b7cc-cfc9d5d0c96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_71fdd901-dabe-4f05-8e8c-56654c42dce1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_255ba6f8-27ac-410f-b7cc-cfc9d5d0c96d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_71fdd901-dabe-4f05-8e8c-56654c42dce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c8ad3d85-9302-467e-80b6-cf3ab47c20ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_71fdd901-dabe-4f05-8e8c-56654c42dce1" xlink:to="loc_us-gaap_CommercialPaperMember_c8ad3d85-9302-467e-80b6-cf3ab47c20ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0d83ef32-cb07-4f08-9492-ebb89111c1bd" xlink:to="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_9331ebe9-fe48-470a-8229-27a21cfcfef6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_9331ebe9-fe48-470a-8229-27a21cfcfef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_71a806b0-a0e4-403d-8ee9-c4312f36e22d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_DerivativeNotionalAmount_71a806b0-a0e4-403d-8ee9-c4312f36e22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_d2a87ca7-98b1-4aa6-9c6f-65e973e8e7af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_d2a87ca7-98b1-4aa6-9c6f-65e973e8e7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_4e6fd776-25b4-4950-9dea-e811b029062f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_4e6fd776-25b4-4950-9dea-e811b029062f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_79f544f6-4f4f-4e1e-957a-abe7e2a31e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_79f544f6-4f4f-4e1e-957a-abe7e2a31e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_46242c6e-afe7-4c97-be2b-f60bf1cea675" xlink:href="jnj-20210404.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_46242c6e-afe7-4c97-be2b-f60bf1cea675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_06e8ffeb-e60e-47c2-a151-1b803f906505" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_06e8ffeb-e60e-47c2-a151-1b803f906505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_807fd7aa-7039-4051-8e5d-bd2cba501929" xlink:href="jnj-20210404.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_807fd7aa-7039-4051-8e5d-bd2cba501929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_e0d1fd01-776a-4d8c-9dd1-798ef398d0de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_ShortTermBorrowings_e0d1fd01-776a-4d8c-9dd1-798ef398d0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_425e78b8-6ec3-4014-90c9-7e7ea90328ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_425e78b8-6ec3-4014-90c9-7e7ea90328ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_1d97f0df-3cc4-4078-a4c0-ba2eff4d4a92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7f476871-0fd9-4e1c-ae5e-ccc3073946ca" xlink:to="loc_us-gaap_DebtInstrumentTerm_1d97f0df-3cc4-4078-a4c0-ba2eff4d4a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3f8699c4-14e8-4344-92d8-d597ee19b3ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_61cc2c49-b3ab-4746-a780-e673f988f9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3f8699c4-14e8-4344-92d8-d597ee19b3ce" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_61cc2c49-b3ab-4746-a780-e673f988f9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_de346e05-4dab-4143-b97c-c3e6d8511c1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_61cc2c49-b3ab-4746-a780-e673f988f9cd" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_de346e05-4dab-4143-b97c-c3e6d8511c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_814eb8a1-21fe-42e0-a393-7f7072e65506" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_de346e05-4dab-4143-b97c-c3e6d8511c1e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_814eb8a1-21fe-42e0-a393-7f7072e65506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_19bca4a7-23bc-46fb-86a1-637f4228e5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_814eb8a1-21fe-42e0-a393-7f7072e65506" xlink:to="loc_us-gaap_FairValueHedgingMember_19bca4a7-23bc-46fb-86a1-637f4228e5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_c2bf07dd-33e5-4f18-87a7-e6e425234983" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_814eb8a1-21fe-42e0-a393-7f7072e65506" xlink:to="loc_us-gaap_CashFlowHedgingMember_c2bf07dd-33e5-4f18-87a7-e6e425234983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_47ac3fa5-4d5c-46db-83aa-f1591cc41c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_61cc2c49-b3ab-4746-a780-e673f988f9cd" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_47ac3fa5-4d5c-46db-83aa-f1591cc41c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4a966886-55c3-408e-9da9-65175e75d992" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_47ac3fa5-4d5c-46db-83aa-f1591cc41c9f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4a966886-55c3-408e-9da9-65175e75d992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_4c947897-78a2-4b5e-80de-9f923657388b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4a966886-55c3-408e-9da9-65175e75d992" xlink:to="loc_us-gaap_InterestRateContractMember_4c947897-78a2-4b5e-80de-9f923657388b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_6fa11ae8-d633-4785-934b-08e572c6723c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4a966886-55c3-408e-9da9-65175e75d992" xlink:to="loc_us-gaap_ForeignExchangeContractMember_6fa11ae8-d633-4785-934b-08e572c6723c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_c02009da-7d7f-4231-a4d8-42f57826bb2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4a966886-55c3-408e-9da9-65175e75d992" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_c02009da-7d7f-4231-a4d8-42f57826bb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_aeb48961-1dde-476c-b1e6-bc1abb241f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_61cc2c49-b3ab-4746-a780-e673f988f9cd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_aeb48961-1dde-476c-b1e6-bc1abb241f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_aeb48961-1dde-476c-b1e6-bc1abb241f7e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_23c23bb6-ddab-4b17-9c35-35e13d5a5d75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:to="loc_us-gaap_SalesMember_23c23bb6-ddab-4b17-9c35-35e13d5a5d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_7b95c37b-36d6-49d6-b947-0f31573524ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:to="loc_us-gaap_CostOfSalesMember_7b95c37b-36d6-49d6-b947-0f31573524ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_92645ec9-4abd-4265-b1a4-77bf9cd2ba34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_92645ec9-4abd-4265-b1a4-77bf9cd2ba34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_12eeb092-99fb-4f11-bf4a-1a04b6f9d45e" xlink:href="jnj-20210404.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_12eeb092-99fb-4f11-bf4a-1a04b6f9d45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_cdb5d93a-c83a-4c57-a432-bd4db4049741" xlink:href="jnj-20210404.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_796187d6-27c3-46fd-ab12-2c24315688af" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_cdb5d93a-c83a-4c57-a432-bd4db4049741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_33537c0d-67b7-4b53-a15a-6d32d745faf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_61cc2c49-b3ab-4746-a780-e673f988f9cd" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_33537c0d-67b7-4b53-a15a-6d32d745faf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_3f3743e4-b2b2-4e00-a5c3-54d1d8d54178" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_33537c0d-67b7-4b53-a15a-6d32d745faf8" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_3f3743e4-b2b2-4e00-a5c3-54d1d8d54178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_f4b3ee9b-d761-4570-9a66-f8eac03c487b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_33537c0d-67b7-4b53-a15a-6d32d745faf8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_f4b3ee9b-d761-4570-9a66-f8eac03c487b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_dbc92215-4f79-4dd3-8b6f-f70010c439c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_33537c0d-67b7-4b53-a15a-6d32d745faf8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_dbc92215-4f79-4dd3-8b6f-f70010c439c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f6e7622e-04f5-45d4-a56e-a27463c52c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99e462ae-fb38-45d2-a0a1-73129207fcfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f6e7622e-04f5-45d4-a56e-a27463c52c1c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99e462ae-fb38-45d2-a0a1-73129207fcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_07d310a5-fb80-4704-b16f-31b5c4191588" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99e462ae-fb38-45d2-a0a1-73129207fcfe" xlink:to="loc_us-gaap_HedgingDesignationAxis_07d310a5-fb80-4704-b16f-31b5c4191588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e13ba3ae-2783-4c78-98f0-095729f1f85c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_07d310a5-fb80-4704-b16f-31b5c4191588" xlink:to="loc_us-gaap_HedgingDesignationDomain_e13ba3ae-2783-4c78-98f0-095729f1f85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_646d89ea-32d8-43eb-b8b0-4564ab9e7eba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e13ba3ae-2783-4c78-98f0-095729f1f85c" xlink:to="loc_us-gaap_NondesignatedMember_646d89ea-32d8-43eb-b8b0-4564ab9e7eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f3d46499-d32b-422c-826d-e2843949e710" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99e462ae-fb38-45d2-a0a1-73129207fcfe" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f3d46499-d32b-422c-826d-e2843949e710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_65d6c88f-0484-4dcc-ac77-7929531c0aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f3d46499-d32b-422c-826d-e2843949e710" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_65d6c88f-0484-4dcc-ac77-7929531c0aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d5d4366c-f19c-4fb2-860e-3fb45b118dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_65d6c88f-0484-4dcc-ac77-7929531c0aa4" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d5d4366c-f19c-4fb2-860e-3fb45b118dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_71f7a009-9c3a-4350-b328-9e8c1bb34a43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99e462ae-fb38-45d2-a0a1-73129207fcfe" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_71f7a009-9c3a-4350-b328-9e8c1bb34a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a4ff8a73-f54a-4fa0-b69c-23d38bf7eb67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_71f7a009-9c3a-4350-b328-9e8c1bb34a43" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a4ff8a73-f54a-4fa0-b69c-23d38bf7eb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_da81ac33-59b8-4095-8607-7f2607cf1b7e" xlink:href="jnj-20210404.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a4ff8a73-f54a-4fa0-b69c-23d38bf7eb67" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_da81ac33-59b8-4095-8607-7f2607cf1b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5a0b0a65-0f89-411f-aad4-720ba58b89e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_99e462ae-fb38-45d2-a0a1-73129207fcfe" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5a0b0a65-0f89-411f-aad4-720ba58b89e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_1dd4bbcc-b5a7-414f-8db1-f30225333a79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5a0b0a65-0f89-411f-aad4-720ba58b89e4" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_1dd4bbcc-b5a7-414f-8db1-f30225333a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3b5a3c4a-bf93-4a8a-aa3e-901ee722cf66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_db3e3616-f8af-469d-b791-63e661db760b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3b5a3c4a-bf93-4a8a-aa3e-901ee722cf66" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_db3e3616-f8af-469d-b791-63e661db760b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_77521711-e091-4c81-a8a9-0e947b258765" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_db3e3616-f8af-469d-b791-63e661db760b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_77521711-e091-4c81-a8a9-0e947b258765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d6a9f918-564d-4972-bdca-e3023cb1b2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_77521711-e091-4c81-a8a9-0e947b258765" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d6a9f918-564d-4972-bdca-e3023cb1b2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_48f3be11-3d02-4462-a86b-5e0360c2799f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d6a9f918-564d-4972-bdca-e3023cb1b2c3" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_48f3be11-3d02-4462-a86b-5e0360c2799f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b26c6c75-d2e3-446b-8926-fc66c73e6cc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_db3e3616-f8af-469d-b791-63e661db760b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b26c6c75-d2e3-446b-8926-fc66c73e6cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_48e7e881-4fb9-45db-852f-ad367b8878a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b26c6c75-d2e3-446b-8926-fc66c73e6cc8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_48e7e881-4fb9-45db-852f-ad367b8878a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_12c68a54-99bf-47bb-93f2-89acc63dcbfb" xlink:href="jnj-20210404.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_48e7e881-4fb9-45db-852f-ad367b8878a4" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_12c68a54-99bf-47bb-93f2-89acc63dcbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b9db5e8c-c73d-41bf-b2b3-270cf609cc7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_db3e3616-f8af-469d-b791-63e661db760b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b9db5e8c-c73d-41bf-b2b3-270cf609cc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_5486b5eb-13aa-4370-8361-5484ef18b737" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b9db5e8c-c73d-41bf-b2b3-270cf609cc7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_5486b5eb-13aa-4370-8361-5484ef18b737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_81ea48a6-1524-4e65-9ae2-c221199c11dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b9db5e8c-c73d-41bf-b2b3-270cf609cc7f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_81ea48a6-1524-4e65-9ae2-c221199c11dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ab2923e6-3057-44bf-a268-0f9637c330dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_0f77481d-d080-469e-9947-d7f6f3d677ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ab2923e6-3057-44bf-a268-0f9637c330dd" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_0f77481d-d080-469e-9947-d7f6f3d677ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4e2cd9bd-6dbe-42ce-9e78-ce839cf6d4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_0f77481d-d080-469e-9947-d7f6f3d677ce" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4e2cd9bd-6dbe-42ce-9e78-ce839cf6d4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_95a9cefd-2934-440f-9df1-83e4d2312110" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4e2cd9bd-6dbe-42ce-9e78-ce839cf6d4d3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_95a9cefd-2934-440f-9df1-83e4d2312110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a46eeb9c-4d40-42d2-ae0b-cfebf6283098" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_95a9cefd-2934-440f-9df1-83e4d2312110" xlink:to="loc_us-gaap_EquitySecuritiesMember_a46eeb9c-4d40-42d2-ae0b-cfebf6283098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_c9b8159b-831b-490e-83d2-47f9ef3e2284" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_0f77481d-d080-469e-9947-d7f6f3d677ce" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_c9b8159b-831b-490e-83d2-47f9ef3e2284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_20e72f59-2eb0-4504-8a0b-76b0e09ec0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_c9b8159b-831b-490e-83d2-47f9ef3e2284" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_20e72f59-2eb0-4504-8a0b-76b0e09ec0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_5e590b7c-90b2-490a-8cfd-8bdf3c15d1f0" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_20e72f59-2eb0-4504-8a0b-76b0e09ec0b0" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_5e590b7c-90b2-490a-8cfd-8bdf3c15d1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_5518bff5-a8cf-4d24-b89e-66b16a115205" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_20e72f59-2eb0-4504-8a0b-76b0e09ec0b0" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_5518bff5-a8cf-4d24-b89e-66b16a115205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_61a5bb5e-a6bf-4620-8fd6-a4c735302f28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_0f77481d-d080-469e-9947-d7f6f3d677ce" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_61a5bb5e-a6bf-4620-8fd6-a4c735302f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_61a5bb5e-a6bf-4620-8fd6-a4c735302f28" xlink:to="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_42aaea83-2232-459a-a17e-4b69a75373de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_42aaea83-2232-459a-a17e-4b69a75373de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_a625eb2c-e32c-4964-b808-c01662f17a74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_a625eb2c-e32c-4964-b808-c01662f17a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_025569ba-e2f3-47e5-a168-47e7fe2a6d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:to="loc_us-gaap_EquityFairValueAdjustment_025569ba-e2f3-47e5-a168-47e7fe2a6d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_5194c16f-355b-4cbc-9d07-0e7adef7294e" xlink:href="jnj-20210404.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_5194c16f-355b-4cbc-9d07-0e7adef7294e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_c90202cc-e2a0-4ca3-9e56-46a982bd4703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_c90202cc-e2a0-4ca3-9e56-46a982bd4703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_25cf9d98-7e60-4474-9476-35a4b063acd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_25cf9d98-7e60-4474-9476-35a4b063acd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e39be03f-170c-4299-a032-dabf8f92f109" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_092b892f-0b46-403a-b0e2-11e03858405b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e39be03f-170c-4299-a032-dabf8f92f109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9ecc144e-efec-482c-aee3-ada717de038c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9ecc144e-efec-482c-aee3-ada717de038c" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7d4dab66-446a-4f0b-a748-f4af34b597ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7d4dab66-446a-4f0b-a748-f4af34b597ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f1f8a47b-56d2-465a-b1ac-f03bdca2acc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7d4dab66-446a-4f0b-a748-f4af34b597ed" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f1f8a47b-56d2-465a-b1ac-f03bdca2acc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4a38b196-14ed-4347-9848-de9ee9a44965" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f1f8a47b-56d2-465a-b1ac-f03bdca2acc8" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4a38b196-14ed-4347-9848-de9ee9a44965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_12ee8190-eade-4cdf-8a2c-11a72f9beabc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f1f8a47b-56d2-465a-b1ac-f03bdca2acc8" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_12ee8190-eade-4cdf-8a2c-11a72f9beabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_16e2b8fd-89cb-4383-8a66-ac6f4c86540f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_16e2b8fd-89cb-4383-8a66-ac6f4c86540f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01418659-b369-47e4-9a51-13cc937cb37a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_16e2b8fd-89cb-4383-8a66-ac6f4c86540f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01418659-b369-47e4-9a51-13cc937cb37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_1a372e7a-5dd0-460c-b01f-628fab60b316" xlink:href="jnj-20210404.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01418659-b369-47e4-9a51-13cc937cb37a" xlink:to="loc_jnj_AurisHealthMember_1a372e7a-5dd0-460c-b01f-628fab60b316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_9d36a06e-6773-4e6c-be82-79339eb59315" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:to="loc_us-gaap_InvestmentTypeAxis_9d36a06e-6773-4e6c-be82-79339eb59315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7f6189e1-9128-4afe-9fa2-09be6ff04d94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_9d36a06e-6773-4e6c-be82-79339eb59315" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7f6189e1-9128-4afe-9fa2-09be6ff04d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_561a55af-af60-4611-a71a-ee91eb83073c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7f6189e1-9128-4afe-9fa2-09be6ff04d94" xlink:to="loc_us-gaap_EquitySecuritiesMember_561a55af-af60-4611-a71a-ee91eb83073c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_632435b7-4693-4c1b-abe0-5be26a0bc47b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_632435b7-4693-4c1b-abe0-5be26a0bc47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8e0db5d3-83b8-441e-9c0b-c8d525d4d6c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_632435b7-4693-4c1b-abe0-5be26a0bc47b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8e0db5d3-83b8-441e-9c0b-c8d525d4d6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_c2bb5555-c99d-415c-83ef-da92a003b2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8e0db5d3-83b8-441e-9c0b-c8d525d4d6c3" xlink:to="loc_us-gaap_InterestRateContractMember_c2bb5555-c99d-415c-83ef-da92a003b2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1053f6d5-dac9-4b83-9474-cbb5d1d10bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8e0db5d3-83b8-441e-9c0b-c8d525d4d6c3" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1053f6d5-dac9-4b83-9474-cbb5d1d10bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_53cc5748-771c-4f14-9ca1-a8940a6635a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8e0db5d3-83b8-441e-9c0b-c8d525d4d6c3" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_53cc5748-771c-4f14-9ca1-a8940a6635a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e57572e-ab69-452c-a7b7-c54a3ceeaed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e57572e-ab69-452c-a7b7-c54a3ceeaed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baddf8c6-a9f9-4932-8141-e02a5bfd9550" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e57572e-ab69-452c-a7b7-c54a3ceeaed1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baddf8c6-a9f9-4932-8141-e02a5bfd9550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_747f48c8-cd69-4dee-b7a7-31eee6b68652" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baddf8c6-a9f9-4932-8141-e02a5bfd9550" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_747f48c8-cd69-4dee-b7a7-31eee6b68652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9c796297-15c9-438a-97e7-bc069c9df41e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baddf8c6-a9f9-4932-8141-e02a5bfd9550" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9c796297-15c9-438a-97e7-bc069c9df41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3a9b19f5-c6bf-4412-815b-18009c0fc8b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_baddf8c6-a9f9-4932-8141-e02a5bfd9550" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3a9b19f5-c6bf-4412-815b-18009c0fc8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b22f499c-9173-4667-8b26-3a9f825a2595" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_e5b4bc54-62a3-4b89-b0a3-c1ac15daddf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_e5b4bc54-62a3-4b89-b0a3-c1ac15daddf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_10eca3ce-1a5e-4d68-a049-e73f0d597323" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_10eca3ce-1a5e-4d68-a049-e73f0d597323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_398b9c12-3a86-4455-8f7c-0dbd6ab89703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_398b9c12-3a86-4455-8f7c-0dbd6ab89703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_873bd3ba-16b9-4ac5-8779-dbda28a26a00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_873bd3ba-16b9-4ac5-8779-dbda28a26a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7abb9f96-29cd-4400-b120-e636111edfc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7abb9f96-29cd-4400-b120-e636111edfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_71b177f9-1ad9-4e9d-a275-8cd444fa1e85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_71b177f9-1ad9-4e9d-a275-8cd444fa1e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_93414a3e-c885-40c4-b561-dc554f06ddae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_ba7734eb-b077-4921-92b2-4f78260b8ddb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_93414a3e-c885-40c4-b561-dc554f06ddae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d10cb709-2dc8-4a48-b68d-110691b4c1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_d10cb709-2dc8-4a48-b68d-110691b4c1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_a54448cc-ca0b-45dc-b468-8ae5f500b6f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_a54448cc-ca0b-45dc-b468-8ae5f500b6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_54317ae8-b195-4cc7-b0f5-32064656925b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeAssets_54317ae8-b195-4cc7-b0f5-32064656925b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bb2a1ebd-85ec-4005-8aa4-689063fdfdf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bb2a1ebd-85ec-4005-8aa4-689063fdfdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5f3a9458-8ba2-4f88-ae95-a350d61a38ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5f3a9458-8ba2-4f88-ae95-a350d61a38ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_69d72fac-615d-4070-a177-da9b55074f12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_DerivativeLiabilities_69d72fac-615d-4070-a177-da9b55074f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b2e266a0-608e-4217-acf5-8a0c675bfdd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b2e266a0-608e-4217-acf5-8a0c675bfdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_952b7751-0160-4f70-8576-4faff884971c" xlink:href="jnj-20210404.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_952b7751-0160-4f70-8576-4faff884971c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_09b144ea-84c0-4d3c-9aa6-da7ba80b2b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_09b144ea-84c0-4d3c-9aa6-da7ba80b2b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_5f26ad66-6203-4912-ab04-a83b080213a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_5f26ad66-6203-4912-ab04-a83b080213a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a5b63cd1-0b18-4f64-adbd-21615c7ad45a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a5b63cd1-0b18-4f64-adbd-21615c7ad45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_91c57802-cbdc-4fc6-bd75-0fb82b232ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46bfeb43-a998-4ad1-99cf-3e718b731164" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_91c57802-cbdc-4fc6-bd75-0fb82b232ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_30e0911c-3df1-4434-b79c-336bce6bcfe0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fac577a6-9a66-4e39-9372-65ca8c2fb641" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_30e0911c-3df1-4434-b79c-336bce6bcfe0" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fac577a6-9a66-4e39-9372-65ca8c2fb641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_c2110483-bfc6-42ff-8f94-957e286247ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fac577a6-9a66-4e39-9372-65ca8c2fb641" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_c2110483-bfc6-42ff-8f94-957e286247ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_9d3edbda-f6bb-420d-89b1-c8c7ba77d0cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_c2110483-bfc6-42ff-8f94-957e286247ac" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_9d3edbda-f6bb-420d-89b1-c8c7ba77d0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_85ba256b-9013-48f4-b77c-87a6859234f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_9d3edbda-f6bb-420d-89b1-c8c7ba77d0cd" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_85ba256b-9013-48f4-b77c-87a6859234f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_8ee947d9-1bb3-466c-bcac-6ebb503857e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_9d3edbda-f6bb-420d-89b1-c8c7ba77d0cd" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_8ee947d9-1bb3-466c-bcac-6ebb503857e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4bc6b80d-7dd0-4be2-baac-7494727be339" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fac577a6-9a66-4e39-9372-65ca8c2fb641" xlink:to="loc_us-gaap_InvestmentTypeAxis_4bc6b80d-7dd0-4be2-baac-7494727be339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4bc6b80d-7dd0-4be2-baac-7494727be339" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_2b0af9d5-5c08-4e13-9c92-4697a2358b23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_CashMember_2b0af9d5-5c08-4e13-9c92-4697a2358b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_afeba3a8-101a-4540-83d3-c775eb002e09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_afeba3a8-101a-4540-83d3-c775eb002e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_ef1aeda9-37c4-4110-8520-1b863127ea58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_ef1aeda9-37c4-4110-8520-1b863127ea58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherReverseRepurchaseAgreementsMember_1eeea560-b2e7-41cb-8405-7c8697584205" xlink:href="jnj-20210404.xsd#jnj_OtherReverseRepurchaseAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_jnj_OtherReverseRepurchaseAgreementsMember_1eeea560-b2e7-41cb-8405-7c8697584205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9ac98049-7fe4-4744-804c-e52b9758cf03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9ac98049-7fe4-4744-804c-e52b9758cf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_15f892fe-d9e5-438d-9206-853d23493103" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_15f892fe-d9e5-438d-9206-853d23493103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_40ab87de-d0b1-4599-be4d-6ae3a295290f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_BankTimeDepositsMember_40ab87de-d0b1-4599-be4d-6ae3a295290f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_511c6288-260c-4750-afe9-baf9c4dc14d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_14012367-281f-4040-85e6-dc387eba61e8" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_511c6288-260c-4750-afe9-baf9c4dc14d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_46f08924-8283-4896-92ff-b5029236cd1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_fac577a6-9a66-4e39-9372-65ca8c2fb641" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_46f08924-8283-4896-92ff-b5029236cd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_fded5c86-4755-402a-bddc-eaf695338a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_46f08924-8283-4896-92ff-b5029236cd1e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_fded5c86-4755-402a-bddc-eaf695338a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_7a3a2c41-5967-4110-8b17-d05a7ca75a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_fded5c86-4755-402a-bddc-eaf695338a5d" xlink:to="loc_us-gaap_HeldToMaturitySecurities_7a3a2c41-5967-4110-8b17-d05a7ca75a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_32d45f65-95ec-43fb-bcbd-f698977679ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_fded5c86-4755-402a-bddc-eaf695338a5d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_32d45f65-95ec-43fb-bcbd-f698977679ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_418ca3f3-7f64-4204-86b6-8cd5f4c7f9d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_fded5c86-4755-402a-bddc-eaf695338a5d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_418ca3f3-7f64-4204-86b6-8cd5f4c7f9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_567bb031-f32a-49c6-84e6-a1f8ac2cc36c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_fded5c86-4755-402a-bddc-eaf695338a5d" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_567bb031-f32a-49c6-84e6-a1f8ac2cc36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_acc4d24c-33cb-4a45-8cf9-560bce69d5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_46f08924-8283-4896-92ff-b5029236cd1e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_acc4d24c-33cb-4a45-8cf9-560bce69d5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_968204df-7fdf-47be-9665-8e3e6417e182" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_acc4d24c-33cb-4a45-8cf9-560bce69d5f7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_968204df-7fdf-47be-9665-8e3e6417e182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c0a36144-f92a-42dd-8e07-7dd124245e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_acc4d24c-33cb-4a45-8cf9-560bce69d5f7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c0a36144-f92a-42dd-8e07-7dd124245e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3ab6cd07-e57e-4599-bd30-95bdd6417e32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_acc4d24c-33cb-4a45-8cf9-560bce69d5f7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3ab6cd07-e57e-4599-bd30-95bdd6417e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95836941-1af4-4362-84fe-2e446da2847e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_acc4d24c-33cb-4a45-8cf9-560bce69d5f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95836941-1af4-4362-84fe-2e446da2847e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_46f08924-8283-4896-92ff-b5029236cd1e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0eb22c96-6328-493a-9341-4c27e50c655c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0eb22c96-6328-493a-9341-4c27e50c655c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_6f666598-d68b-422f-a199-fa899a044ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_6f666598-d68b-422f-a199-fa899a044ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4316dac8-28cb-4683-a846-c16081b18538" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4316dac8-28cb-4683-a846-c16081b18538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_4e252c84-ce1c-4d24-9e7d-28f551da596f" xlink:href="jnj-20210404.xsd#jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:to="loc_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain_4e252c84-ce1c-4d24-9e7d-28f551da596f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_cf90d213-bb9c-4876-8312-083f74a6f608" xlink:href="jnj-20210404.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_cf90d213-bb9c-4876-8312-083f74a6f608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_900be597-9439-498e-91eb-a9abd92653d7" xlink:href="jnj-20210404.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_4931c06e-74f1-43a1-9c5c-0b60ea2a0db1" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_900be597-9439-498e-91eb-a9abd92653d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_44ab75e4-9183-4421-8d33-4273bda36b50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_e44c3833-1194-4da8-b510-460ec74b5a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_44ab75e4-9183-4421-8d33-4273bda36b50" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_e44c3833-1194-4da8-b510-460ec74b5a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_dcbc65ea-5c36-495a-bb8c-b3b9d3bed207" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_e44c3833-1194-4da8-b510-460ec74b5a7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_dcbc65ea-5c36-495a-bb8c-b3b9d3bed207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c5d5ac69-ff3b-4416-8e7f-ca4ae494fe77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_e44c3833-1194-4da8-b510-460ec74b5a7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c5d5ac69-ff3b-4416-8e7f-ca4ae494fe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_7a9eaa18-ea36-4d8d-8b94-338a3857b278" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_e44c3833-1194-4da8-b510-460ec74b5a7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_7a9eaa18-ea36-4d8d-8b94-338a3857b278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_dff317f2-8c45-49bf-add2-636087bd0d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_e44c3833-1194-4da8-b510-460ec74b5a7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_dff317f2-8c45-49bf-add2-636087bd0d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5ac0483a-b1e5-4192-b5fc-f2f0d9e6f709" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_44ab75e4-9183-4421-8d33-4273bda36b50" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5ac0483a-b1e5-4192-b5fc-f2f0d9e6f709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f78aad7b-c0b8-49b4-9493-6663a650f474" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5ac0483a-b1e5-4192-b5fc-f2f0d9e6f709" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f78aad7b-c0b8-49b4-9493-6663a650f474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f02eb116-dca2-41a6-a4ae-0cb82c69fa4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5ac0483a-b1e5-4192-b5fc-f2f0d9e6f709" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f02eb116-dca2-41a6-a4ae-0cb82c69fa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_d64668f4-3695-4360-8a47-d4bd62571153" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5ac0483a-b1e5-4192-b5fc-f2f0d9e6f709" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_d64668f4-3695-4360-8a47-d4bd62571153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_efd1a77a-d2b4-4235-ae08-ebd6f15be906" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5ac0483a-b1e5-4192-b5fc-f2f0d9e6f709" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_efd1a77a-d2b4-4235-ae08-ebd6f15be906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8e23992b-1413-44b7-9499-1fd9dec02955" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3435fa3-7a6a-4f50-8ecd-0a462eacf208" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8e23992b-1413-44b7-9499-1fd9dec02955" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3435fa3-7a6a-4f50-8ecd-0a462eacf208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_af60550f-8e1c-469a-b821-5e99302d890b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3435fa3-7a6a-4f50-8ecd-0a462eacf208" xlink:to="loc_us-gaap_DebtInstrumentAxis_af60550f-8e1c-469a-b821-5e99302d890b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_af60550f-8e1c-469a-b821-5e99302d890b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_6f2c33ec-ae9f-49e6-b8c6-2ed75fff0218" xlink:href="jnj-20210404.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_6f2c33ec-ae9f-49e6-b8c6-2ed75fff0218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_3a6c9c65-ea20-4806-bd17-11dfbf087abd" xlink:href="jnj-20210404.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.375Notesdue2023Member_3a6c9c65-ea20-4806-bd17-11dfbf087abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member_556eb75a-9d0c-4053-8da2-762f01dcfb8b" xlink:href="jnj-20210404.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2.05Notesdue2023Member_556eb75a-9d0c-4053-8da2-762f01dcfb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_10bfd54d-6733-4bb0-9c58-f49e04482c4f" xlink:href="jnj-20210404.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A0.650NotesDue2024Member_10bfd54d-6733-4bb0-9c58-f49e04482c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_601b7345-0ae7-46d7-9ef9-1f4643cf152e" xlink:href="jnj-20210404.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A5.50NotesDue2024Member_601b7345-0ae7-46d7-9ef9-1f4643cf152e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_127eab07-c717-4392-a1ce-4ed8656741e7" xlink:href="jnj-20210404.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2.625Notesdue2025Member_127eab07-c717-4392-a1ce-4ed8656741e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member_1dfa48fd-6e98-4133-b97d-707904a9cd94" xlink:href="jnj-20210404.xsd#jnj_A0550NotesDue2025Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A0550NotesDue2025Member_1dfa48fd-6e98-4133-b97d-707904a9cd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_a3064d42-f180-4186-b922-71f3e952b303" xlink:href="jnj-20210404.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2.45Notesdue2026Member_a3064d42-f180-4186-b922-71f3e952b303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_5f852914-ce53-4739-af58-d1ee0154affc" xlink:href="jnj-20210404.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2.95Notesdue2027Member_5f852914-ce53-4739-af58-d1ee0154affc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_c9cf2cb3-584e-4204-8da0-aae93e76815c" xlink:href="jnj-20210404.xsd#jnj_A095NotesDue2027Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A095NotesDue2027Member_c9cf2cb3-584e-4204-8da0-aae93e76815c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_91c60111-21cc-48ee-93de-c5b0bba49ea1" xlink:href="jnj-20210404.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2.900Notesdue2028Member_91c60111-21cc-48ee-93de-c5b0bba49ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_cb160829-64c9-48d5-9f08-19973d99d830" xlink:href="jnj-20210404.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A1.150NotesDue2028Member_cb160829-64c9-48d5-9f08-19973d99d830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_6c46dcb3-4c83-4b72-8095-427495211474" xlink:href="jnj-20210404.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A6.95Notesdue2029Member_6c46dcb3-4c83-4b72-8095-427495211474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member_c2239297-5291-4e35-b14e-c0f316152962" xlink:href="jnj-20210404.xsd#jnj_A1300NotesDue2030Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A1300NotesDue2030Member_c2239297-5291-4e35-b14e-c0f316152962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_895b92f9-7f53-40df-9d28-885e873bd737" xlink:href="jnj-20210404.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_895b92f9-7f53-40df-9d28-885e873bd737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_4f83f3ba-be07-4917-8d4c-7d9d781bcc02" xlink:href="jnj-20210404.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A4.375Notesdue2033Member_4f83f3ba-be07-4917-8d4c-7d9d781bcc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_cb36f0e5-8247-40fc-8fa7-0c6ec114cc1d" xlink:href="jnj-20210404.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A1.650NotesDue2035Member_cb36f0e5-8247-40fc-8fa7-0c6ec114cc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_4e0771ab-1a64-409c-8430-951583f1b3fa" xlink:href="jnj-20210404.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.55Notesdue2036Member_4e0771ab-1a64-409c-8430-951583f1b3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_5088723c-2e57-438e-b7a2-e2f9b4357a3f" xlink:href="jnj-20210404.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A5.95Notesdue2037Member_5088723c-2e57-438e-b7a2-e2f9b4357a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_2e6241a0-b1dc-4e4b-96f9-b1dbb1d0684c" xlink:href="jnj-20210404.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.625Notesdue2037Member_2e6241a0-b1dc-4e4b-96f9-b1dbb1d0684c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_2be723b3-bffd-4633-a8e7-b5c2a59211d6" xlink:href="jnj-20210404.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.400Notesdue2038Member_2be723b3-bffd-4633-a8e7-b5c2a59211d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_6b4153da-e19c-42c6-b5bc-47f1a28eb781" xlink:href="jnj-20210404.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_6b4153da-e19c-42c6-b5bc-47f1a28eb781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_eaa9ddfc-3f99-42f7-98ed-dd91326e75da" xlink:href="jnj-20210404.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_eaa9ddfc-3f99-42f7-98ed-dd91326e75da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_98fc3aad-d80b-4cfa-99c7-589b48257fd9" xlink:href="jnj-20210404.xsd#jnj_A210NotesDue2040Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A210NotesDue2040Member_98fc3aad-d80b-4cfa-99c7-589b48257fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_e991de51-7c2e-49d5-93a2-1c36cb333338" xlink:href="jnj-20210404.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A4.85Notesdue2041Member_e991de51-7c2e-49d5-93a2-1c36cb333338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_240a6b74-8cf7-42b9-af9b-b9731d82266d" xlink:href="jnj-20210404.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A4.50Notesdue2043Member_240a6b74-8cf7-42b9-af9b-b9731d82266d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_7b4c4401-b112-4cd3-ae33-a50423435d9b" xlink:href="jnj-20210404.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.70Notesdue2046Member_7b4c4401-b112-4cd3-ae33-a50423435d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_47529063-cbad-4e6e-a413-d473eac2cad3" xlink:href="jnj-20210404.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.75Notesdue2047Member_47529063-cbad-4e6e-a413-d473eac2cad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_dc4ff408-2d87-448f-bd3e-00bd8fe406d1" xlink:href="jnj-20210404.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A3.500Notesdue2048Member_dc4ff408-2d87-448f-bd3e-00bd8fe406d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_90886c8e-a4f8-4022-94d5-b9c341dd9db3" xlink:href="jnj-20210404.xsd#jnj_A2250NotesDue2050Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2250NotesDue2050Member_90886c8e-a4f8-4022-94d5-b9c341dd9db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_67fe3a2e-fe4f-4710-8fb1-7c6633bd872b" xlink:href="jnj-20210404.xsd#jnj_A2450NotesDue2060Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_A2450NotesDue2060Member_67fe3a2e-fe4f-4710-8fb1-7c6633bd872b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember_dbe33f20-ee52-41c5-a577-3334f6e2ea93" xlink:href="jnj-20210404.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e5d61ba0-6392-4f65-8743-838584d413f4" xlink:to="loc_jnj_NotesDuePeriodFifteenMember_dbe33f20-ee52-41c5-a577-3334f6e2ea93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_082e7251-c77c-4fa3-97be-2674f0767e53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3435fa3-7a6a-4f50-8ecd-0a462eacf208" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_082e7251-c77c-4fa3-97be-2674f0767e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_84bbf98b-4369-4586-8c81-d0f449a3bccc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_082e7251-c77c-4fa3-97be-2674f0767e53" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_84bbf98b-4369-4586-8c81-d0f449a3bccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_aab19486-045e-41db-a064-57ebc55fb101" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_84bbf98b-4369-4586-8c81-d0f449a3bccc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_aab19486-045e-41db-a064-57ebc55fb101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0a0c87a-72a8-4d8c-b297-266918eff339" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_aab19486-045e-41db-a064-57ebc55fb101" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0a0c87a-72a8-4d8c-b297-266918eff339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8936c8f5-857a-41a4-8482-8277c18ec050" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_aab19486-045e-41db-a064-57ebc55fb101" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8936c8f5-857a-41a4-8482-8277c18ec050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_abd8eaff-77d8-4659-ba01-8847fce4bd7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3435fa3-7a6a-4f50-8ecd-0a462eacf208" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_abd8eaff-77d8-4659-ba01-8847fce4bd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_5f925e6a-d395-4d2b-bfc8-f7c172b17ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_abd8eaff-77d8-4659-ba01-8847fce4bd7f" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_5f925e6a-d395-4d2b-bfc8-f7c172b17ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_835b0af4-793d-4325-9d8a-a43252cf138e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_5f925e6a-d395-4d2b-bfc8-f7c172b17ef3" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_835b0af4-793d-4325-9d8a-a43252cf138e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_47d4f69b-a31e-4827-bbd3-1ae526367e91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_835b0af4-793d-4325-9d8a-a43252cf138e" xlink:to="loc_us-gaap_ShortTermBorrowings_47d4f69b-a31e-4827-bbd3-1ae526367e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_7d8236f8-3e10-436d-acbf-59780b1dca0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_5f925e6a-d395-4d2b-bfc8-f7c172b17ef3" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_7d8236f8-3e10-436d-acbf-59780b1dca0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1f045301-80a5-434c-bf06-f1df107869ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_7d8236f8-3e10-436d-acbf-59780b1dca0d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1f045301-80a5-434c-bf06-f1df107869ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1eed42bc-4afc-4a06-a42b-9c8a887d15ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_5f925e6a-d395-4d2b-bfc8-f7c172b17ef3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1eed42bc-4afc-4a06-a42b-9c8a887d15ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20210404.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_19a681d3-1ab3-416b-82bc-4513d0661545" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a57667ab-ce7c-4fda-97e7-bec1b8197c11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19a681d3-1ab3-416b-82bc-4513d0661545" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a57667ab-ce7c-4fda-97e7-bec1b8197c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_76afc43a-493e-4a75-96cf-58f7db63388b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_388cb02c-4bdd-4a24-9822-470366856600" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76afc43a-493e-4a75-96cf-58f7db63388b" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_388cb02c-4bdd-4a24-9822-470366856600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_251533c6-0d6a-4e33-b018-fc02c388e1e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_388cb02c-4bdd-4a24-9822-470366856600" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_251533c6-0d6a-4e33-b018-fc02c388e1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_360e0695-efe3-49a1-bf32-6120bd3cc764" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_251533c6-0d6a-4e33-b018-fc02c388e1e2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_360e0695-efe3-49a1-bf32-6120bd3cc764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_5020723f-dc13-4013-abb3-14cd4433f7c4" xlink:href="jnj-20210404.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_360e0695-efe3-49a1-bf32-6120bd3cc764" xlink:to="loc_jnj_AurisHealthMember_5020723f-dc13-4013-abb3-14cd4433f7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b184d5a-db9f-48d4-9fab-c776b73fb693" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_388cb02c-4bdd-4a24-9822-470366856600" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b184d5a-db9f-48d4-9fab-c776b73fb693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:href="jnj-20210404.xsd#jnj_IncomeTaxTextualsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b184d5a-db9f-48d4-9fab-c776b73fb693" xlink:to="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00464d1c-ebaa-4fe3-a2cd-7f0e4bc01143" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_00464d1c-ebaa-4fe3-a2cd-7f0e4bc01143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_03c1db49-1a35-46d1-add2-c65b10de52a5" xlink:href="jnj-20210404.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_03c1db49-1a35-46d1-add2-c65b10de52a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_d5b13688-656e-4544-a7aa-3811445240d2" xlink:href="jnj-20210404.xsd#jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_d5b13688-656e-4544-a7aa-3811445240d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_1f99cc61-2099-4482-b258-43e965b31793" xlink:href="jnj-20210404.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent_1f99cc61-2099-4482-b258-43e965b31793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent_0b7c46ab-765c-4a87-9fac-1c1bdc34e05b" xlink:href="jnj-20210404.xsd#jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent_0b7c46ab-765c-4a87-9fac-1c1bdc34e05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_47243112-a53e-4ac5-af0e-abcd6e1c0c01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_IncomeTaxTextualsAbstract_5e1dd9fc-85fd-4ae4-8565-af1038b0b3c6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_47243112-a53e-4ac5-af0e-abcd6e1c0c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20210404.xsd#PensionsandOtherBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2a93236f-7e33-4b5b-a8c6-8f8888066dad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_91e5822c-4779-4810-a044-3e4fdfd4bef9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2a93236f-7e33-4b5b-a8c6-8f8888066dad" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_91e5822c-4779-4810-a044-3e4fdfd4bef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9e98d5d4-5806-4a3c-8b7a-2d3ef78480a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_f8881ed2-7a80-47d7-a7e0-2d36fa12db38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9e98d5d4-5806-4a3c-8b7a-2d3ef78480a8" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_f8881ed2-7a80-47d7-a7e0-2d36fa12db38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6131e548-b5de-4681-9c17-f960412c84ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5cc51e5d-d0a5-4c31-8d37-1a74833acbbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6131e548-b5de-4681-9c17-f960412c84ab" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5cc51e5d-d0a5-4c31-8d37-1a74833acbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8f89ea19-2340-4da6-9377-5abfe517053c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5cc51e5d-d0a5-4c31-8d37-1a74833acbbe" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8f89ea19-2340-4da6-9377-5abfe517053c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_727e60d0-fa07-44ad-ae28-5c1159e7d860" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8f89ea19-2340-4da6-9377-5abfe517053c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_727e60d0-fa07-44ad-ae28-5c1159e7d860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_08d1a852-f403-456a-9907-34ffb7a5c6ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_727e60d0-fa07-44ad-ae28-5c1159e7d860" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_08d1a852-f403-456a-9907-34ffb7a5c6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3b8f4f5d-343b-46f5-8908-56a235b7c327" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_727e60d0-fa07-44ad-ae28-5c1159e7d860" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3b8f4f5d-343b-46f5-8908-56a235b7c327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e6542c1-0411-42b5-9183-341286bf41db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5cc51e5d-d0a5-4c31-8d37-1a74833acbbe" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e6542c1-0411-42b5-9183-341286bf41db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0e6542c1-0411-42b5-9183-341286bf41db" xlink:to="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_7b7cc591-3215-480a-947e-952fc31c0795" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_7b7cc591-3215-480a-947e-952fc31c0795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_c0f0b670-355e-45d5-a9c1-cd87e8329623" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_c0f0b670-355e-45d5-a9c1-cd87e8329623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b9fafefa-2432-4a90-8e43-621cc2e81dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b9fafefa-2432-4a90-8e43-621cc2e81dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_4aa3165d-7851-4ce7-a065-f59a0fdd42c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_4aa3165d-7851-4ce7-a065-f59a0fdd42c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ddac3852-92bb-4c44-82b1-9f11bf0b8a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ddac3852-92bb-4c44-82b1-9f11bf0b8a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_314b3f27-03d7-4934-9087-c210d3b88272" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_314b3f27-03d7-4934-9087-c210d3b88272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e89d98b6-5746-4f7d-9dfd-30fffab33911" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_d586621d-641f-4ad3-a56e-c0fc91ffaf69" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e89d98b6-5746-4f7d-9dfd-30fffab33911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c1457df6-6231-4c30-a8c6-57b1d3d2652c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_24486f70-27a0-42f3-9091-681e0cf55a67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c1457df6-6231-4c30-a8c6-57b1d3d2652c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_24486f70-27a0-42f3-9091-681e0cf55a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_6bc5bfdb-d281-4375-ab8e-b0ecc3ee7f56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_24486f70-27a0-42f3-9091-681e0cf55a67" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_6bc5bfdb-d281-4375-ab8e-b0ecc3ee7f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_403b6448-6fb1-4bb4-a5ff-5f3778e32e08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_6bc5bfdb-d281-4375-ab8e-b0ecc3ee7f56" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_403b6448-6fb1-4bb4-a5ff-5f3778e32e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_37cf9a00-6295-4b60-929b-9161467b0f4c" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_403b6448-6fb1-4bb4-a5ff-5f3778e32e08" xlink:to="loc_country_US_37cf9a00-6295-4b60-929b-9161467b0f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_c650ed55-9cf2-45b8-b303-e7b684115af2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_403b6448-6fb1-4bb4-a5ff-5f3778e32e08" xlink:to="loc_us-gaap_ForeignPlanMember_c650ed55-9cf2-45b8-b303-e7b684115af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_23497297-a6ce-4780-9608-c28e59d0d022" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_24486f70-27a0-42f3-9091-681e0cf55a67" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_23497297-a6ce-4780-9608-c28e59d0d022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_f0937098-e87c-4669-80c9-b44a96d4913a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_23497297-a6ce-4780-9608-c28e59d0d022" xlink:to="loc_us-gaap_PensionContributions_f0937098-e87c-4669-80c9-b44a96d4913a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20210404.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f3501f14-ece2-4996-bbe8-c3a4f0958ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_346d1b19-076d-4ffe-aed1-36e6dc5f4808" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f3501f14-ece2-4996-bbe8-c3a4f0958ac0" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_346d1b19-076d-4ffe-aed1-36e6dc5f4808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ff61ef22-c195-4569-840c-398d582449f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_25701685-6fbb-4a97-94b4-7cdc0aec0ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ff61ef22-c195-4569-840c-398d582449f2" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_25701685-6fbb-4a97-94b4-7cdc0aec0ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e5661aab-8f16-4d27-8815-b5b14c4424b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_be33cdcc-d211-4f4e-a621-d19b91babe6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e5661aab-8f16-4d27-8815-b5b14c4424b1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_be33cdcc-d211-4f4e-a621-d19b91babe6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eff534f8-3d59-4ade-b1ae-f3859ea0a523" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_be33cdcc-d211-4f4e-a621-d19b91babe6f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eff534f8-3d59-4ade-b1ae-f3859ea0a523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eff534f8-3d59-4ade-b1ae-f3859ea0a523" xlink:to="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a8ebcf36-1d11-4640-9e17-7457a5ed757d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a8ebcf36-1d11-4640-9e17-7457a5ed757d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_49300b1d-c710-4c5a-b73a-85f4039da4f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_49300b1d-c710-4c5a-b73a-85f4039da4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_bd1d8050-ea4c-44c6-84f0-df7ce9b2e7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_bd1d8050-ea4c-44c6-84f0-df7ce9b2e7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3bbaf10a-2d59-4039-8d4f-a31a42fec82b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3bbaf10a-2d59-4039-8d4f-a31a42fec82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9cee8940-81a6-4bd7-a70c-7d961091934b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87edc801-cb22-491f-9663-05a0684c7681" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9cee8940-81a6-4bd7-a70c-7d961091934b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_989a2778-7e67-4553-abb4-a588ef14b324" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_be33cdcc-d211-4f4e-a621-d19b91babe6f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_989a2778-7e67-4553-abb4-a588ef14b324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_bcff6703-9354-4a3b-95ec-0bc18cf0c0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_989a2778-7e67-4553-abb4-a588ef14b324" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_bcff6703-9354-4a3b-95ec-0bc18cf0c0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97300088-35c7-45fb-8b23-bb37683787df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_bcff6703-9354-4a3b-95ec-0bc18cf0c0bd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97300088-35c7-45fb-8b23-bb37683787df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3ead1387-37eb-4dd5-afab-eafb881380d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_bcff6703-9354-4a3b-95ec-0bc18cf0c0bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3ead1387-37eb-4dd5-afab-eafb881380d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0e3b21ef-3b3a-4a8d-b7e5-16c872f42aea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_bcff6703-9354-4a3b-95ec-0bc18cf0c0bd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0e3b21ef-3b3a-4a8d-b7e5-16c872f42aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20210404.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_36d3e7e3-9d54-4ede-81d9-f4e35a937695" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3f3cb9b2-52e5-4319-9eff-e72fddae1838" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_36d3e7e3-9d54-4ede-81d9-f4e35a937695" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3f3cb9b2-52e5-4319-9eff-e72fddae1838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_09bd89bc-c708-4123-be65-02d1e43364d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a4bdd84e-2405-448b-a6b0-ad0d893b2da7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_09bd89bc-c708-4123-be65-02d1e43364d6" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a4bdd84e-2405-448b-a6b0-ad0d893b2da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a4a79113-cb23-4c68-bb39-2b85182dac95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_922aeff4-59f2-4be9-b814-41525b57c9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a4a79113-cb23-4c68-bb39-2b85182dac95" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_922aeff4-59f2-4be9-b814-41525b57c9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_009bc8fd-ca4c-4551-a00f-3096f8a1671b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_922aeff4-59f2-4be9-b814-41525b57c9ff" xlink:to="loc_us-gaap_EarningsPerShareBasic_009bc8fd-ca4c-4551-a00f-3096f8a1671b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5a1cc32-31c1-40f1-a1fa-0bf6b681a108" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_922aeff4-59f2-4be9-b814-41525b57c9ff" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5a1cc32-31c1-40f1-a1fa-0bf6b681a108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f1e12c6d-5392-42dd-8f33-92d29dd000d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_922aeff4-59f2-4be9-b814-41525b57c9ff" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f1e12c6d-5392-42dd-8f33-92d29dd000d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_9779302b-b320-470b-b558-4882d7a5de31" xlink:href="jnj-20210404.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_922aeff4-59f2-4be9-b814-41525b57c9ff" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_9779302b-b320-470b-b558-4882d7a5de31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_d41866d6-7f61-4a0d-9a01-a820abf58281" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_922aeff4-59f2-4be9-b814-41525b57c9ff" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_d41866d6-7f61-4a0d-9a01-a820abf58281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_573aa516-1fdd-4d23-8d04-78ea127c03dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_922aeff4-59f2-4be9-b814-41525b57c9ff" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_573aa516-1fdd-4d23-8d04-78ea127c03dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_11f00643-28e1-424a-aeef-172bf5d7b925" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_922aeff4-59f2-4be9-b814-41525b57c9ff" xlink:to="loc_us-gaap_EarningsPerShareDiluted_11f00643-28e1-424a-aeef-172bf5d7b925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e7a27a93-18f6-4118-8b2e-765706574fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_922aeff4-59f2-4be9-b814-41525b57c9ff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e7a27a93-18f6-4118-8b2e-765706574fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_841f50b4-15f8-4b64-bbf7-d3c027b04858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_537e274b-f3b1-4a3b-bd1a-14f123dc32d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_841f50b4-15f8-4b64-bbf7-d3c027b04858" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_537e274b-f3b1-4a3b-bd1a-14f123dc32d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9ba69482-622b-4d20-983e-13e8d00618d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_d42c86b1-5160-452f-b30e-cf5ac733ffb2" xlink:href="jnj-20210404.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9ba69482-622b-4d20-983e-13e8d00618d3" xlink:to="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_d42c86b1-5160-452f-b30e-cf5ac733ffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9c5a7860-7f99-4b46-8d35-88490eb7882f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9ba69482-622b-4d20-983e-13e8d00618d3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9c5a7860-7f99-4b46-8d35-88490eb7882f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_7ebd56e1-b724-496d-8f39-5b70c1259290" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9ba69482-622b-4d20-983e-13e8d00618d3" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_7ebd56e1-b724-496d-8f39-5b70c1259290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1d59811d-7164-4cc7-908c-29e529ee7aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1d59811d-7164-4cc7-908c-29e529ee7aa0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f8a41dfe-2533-45ac-874b-d177ccf336f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f8a41dfe-2533-45ac-874b-d177ccf336f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce643884-e68e-4875-9d12-8fceca3fb9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f8a41dfe-2533-45ac-874b-d177ccf336f1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce643884-e68e-4875-9d12-8fceca3fb9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_08315b60-c120-4247-aa81-36a76de14b05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_08315b60-c120-4247-aa81-36a76de14b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5ee45377-aca6-42c9-8b71-f7a3a2dba0af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_08315b60-c120-4247-aa81-36a76de14b05" xlink:to="loc_us-gaap_SegmentDomain_5ee45377-aca6-42c9-8b71-f7a3a2dba0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_8d849341-d17c-4754-bbed-b7ec58b1a0ab" xlink:href="jnj-20210404.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5ee45377-aca6-42c9-8b71-f7a3a2dba0af" xlink:to="loc_jnj_ConsumerMember_8d849341-d17c-4754-bbed-b7ec58b1a0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_52344d53-45db-4943-9af3-73c07dc79264" xlink:href="jnj-20210404.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5ee45377-aca6-42c9-8b71-f7a3a2dba0af" xlink:to="loc_jnj_PharmaceuticalMember_52344d53-45db-4943-9af3-73c07dc79264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_1f1200a9-38a7-42ce-bdac-69724d640fce" xlink:href="jnj-20210404.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5ee45377-aca6-42c9-8b71-f7a3a2dba0af" xlink:to="loc_jnj_MedicalDevicesMember_1f1200a9-38a7-42ce-bdac-69724d640fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_7a2aa77f-1f19-4075-8411-e057f04577ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:to="loc_us-gaap_SubsegmentsAxis_7a2aa77f-1f19-4075-8411-e057f04577ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_7a2aa77f-1f19-4075-8411-e057f04577ea" xlink:to="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_7b6c35bc-6a98-4470-97b0-64fd9165a440" xlink:href="jnj-20210404.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_ImmunologyMember_7b6c35bc-6a98-4470-97b0-64fd9165a440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_176bf43a-8d5b-473a-a4a2-c9760b49a141" xlink:href="jnj-20210404.xsd#jnj_InfectiousDiseasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_InfectiousDiseasesMember_176bf43a-8d5b-473a-a4a2-c9760b49a141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_fa7cba94-b669-472d-a542-08641aa09630" xlink:href="jnj-20210404.xsd#jnj_NeuroscienceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_NeuroscienceMember_fa7cba94-b669-472d-a542-08641aa09630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_1cf5c261-aa08-4853-87f1-c1889369af4d" xlink:href="jnj-20210404.xsd#jnj_OncologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_OncologyMember_1cf5c261-aa08-4853-87f1-c1889369af4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_bf41f794-9716-4d07-9eb8-804e6cf24b2a" xlink:href="jnj-20210404.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_PulmonaryHypertensionMember_bf41f794-9716-4d07-9eb8-804e6cf24b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_5243ccac-d56c-40b1-a94b-c7ea5ed09f80" xlink:href="jnj-20210404.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_5243ccac-d56c-40b1-a94b-c7ea5ed09f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_938c1fc8-dc9e-4acd-93fe-33a279702810" xlink:href="jnj-20210404.xsd#jnj_InterventionalSolutionsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_InterventionalSolutionsMember_938c1fc8-dc9e-4acd-93fe-33a279702810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_5f191ab5-4587-4ec2-97ad-91775e2fa94a" xlink:href="jnj-20210404.xsd#jnj_OrthopaedicsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_OrthopaedicsMember_5f191ab5-4587-4ec2-97ad-91775e2fa94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_0e320797-9fc8-4906-b701-898378919458" xlink:href="jnj-20210404.xsd#jnj_SurgeryMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_SurgeryMember_0e320797-9fc8-4906-b701-898378919458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_dd1eaf2e-2cea-49db-90b9-f7a9067a3029" xlink:href="jnj-20210404.xsd#jnj_VisionMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_146bf868-fde5-4cd3-af3b-18cf5ce061ce" xlink:to="loc_jnj_VisionMember_dd1eaf2e-2cea-49db-90b9-f7a9067a3029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d611beb7-b199-49df-a141-8138fd2fa97b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:to="loc_srt_ProductOrServiceAxis_d611beb7-b199-49df-a141-8138fd2fa97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d611beb7-b199-49df-a141-8138fd2fa97b" xlink:to="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_d5b2818b-101d-4ad7-a277-3305e307c66c" xlink:href="jnj-20210404.xsd#jnj_OTCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OTCMember_d5b2818b-101d-4ad7-a277-3305e307c66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember_4eed34d1-0cf3-4f53-a057-d0c0d7c13bce" xlink:href="jnj-20210404.xsd#jnj_BeautyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_BeautyMember_4eed34d1-0cf3-4f53-a057-d0c0d7c13bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_4618cf7a-106b-45c1-bc9e-dbdd2f3f7690" xlink:href="jnj-20210404.xsd#jnj_OralCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OralCareMember_4618cf7a-106b-45c1-bc9e-dbdd2f3f7690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_36baddbe-6b16-48a2-989b-c54ffe3495e1" xlink:href="jnj-20210404.xsd#jnj_BabyCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_BabyCareMember_36baddbe-6b16-48a2-989b-c54ffe3495e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_5c34d3f6-8e51-4bc8-8dda-d0fc0f0e57c6" xlink:href="jnj-20210404.xsd#jnj_WomensHealthMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_WomensHealthMember_5c34d3f6-8e51-4bc8-8dda-d0fc0f0e57c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_5ba34878-e3cb-408e-9b1f-92b81029cc7b" xlink:href="jnj-20210404.xsd#jnj_WoundCareandOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_WoundCareandOtherMember_5ba34878-e3cb-408e-9b1f-92b81029cc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_790fd98d-f6c7-486b-978c-e3738d891f2d" xlink:href="jnj-20210404.xsd#jnj_RemicadeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_RemicadeMember_790fd98d-f6c7-486b-978c-e3738d891f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_e467b682-73bf-437d-98ec-5859888b76ac" xlink:href="jnj-20210404.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_SimponiSimponiAriaMember_e467b682-73bf-437d-98ec-5859888b76ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_70e3369e-2fb6-4e79-9144-89a232ae543a" xlink:href="jnj-20210404.xsd#jnj_StelaraMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_StelaraMember_70e3369e-2fb6-4e79-9144-89a232ae543a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_b349eac9-9929-48d5-91a2-e728c370a894" xlink:href="jnj-20210404.xsd#jnj_TremfyaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_TremfyaMember_b349eac9-9929-48d5-91a2-e728c370a894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_058d2bda-e83d-4565-b1f4-799be5f1dbe2" xlink:href="jnj-20210404.xsd#jnj_OtherImmunologyMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OtherImmunologyMember_058d2bda-e83d-4565-b1f4-799be5f1dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_3f089c27-65cd-47a6-9533-7202d98fc06d" xlink:href="jnj-20210404.xsd#jnj_COVID19Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_COVID19Member_3f089c27-65cd-47a6-9533-7202d98fc06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_432fc764-342c-4c57-84b5-3b0848245453" xlink:href="jnj-20210404.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_EDURANTrilpivirineMember_432fc764-342c-4c57-84b5-3b0848245453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_cbaa17bd-eb73-4844-b1e6-12ee62d0aa4e" xlink:href="jnj-20210404.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_cbaa17bd-eb73-4844-b1e6-12ee62d0aa4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_9f9a2892-9d75-4b33-91b0-782d8fc7a327" xlink:href="jnj-20210404.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_9f9a2892-9d75-4b33-91b0-782d8fc7a327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_b20cbdd9-3c0b-40bc-a00f-5c9f76232e1a" xlink:href="jnj-20210404.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_b20cbdd9-3c0b-40bc-a00f-5c9f76232e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_848aed5b-6d13-4cee-b902-07ae0c7072f0" xlink:href="jnj-20210404.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_848aed5b-6d13-4cee-b902-07ae0c7072f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_f5c3a2f6-0f53-4238-91d3-6e0177c76b7e" xlink:href="jnj-20210404.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_RISPERDALCONSTAMember_f5c3a2f6-0f53-4238-91d3-6e0177c76b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_ed219d8d-ce46-49c9-bfef-911be22dfce7" xlink:href="jnj-20210404.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_ed219d8d-ce46-49c9-bfef-911be22dfce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_955c657d-0f63-4fbb-8186-0ad9fd088f71" xlink:href="jnj-20210404.xsd#jnj_DARZALEXMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_DARZALEXMember_955c657d-0f63-4fbb-8186-0ad9fd088f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember_7820290c-0fab-4627-a194-97b91aacfb45" xlink:href="jnj-20210404.xsd#jnj_ERLEADAMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_ERLEADAMember_7820290c-0fab-4627-a194-97b91aacfb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_09b7446a-b2b4-4328-a5e0-3a8810e05977" xlink:href="jnj-20210404.xsd#jnj_IMBRUVICAMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_IMBRUVICAMember_09b7446a-b2b4-4328-a5e0-3a8810e05977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_ca0d8fc9-8392-4a1e-b18d-2bcc968fc8f3" xlink:href="jnj-20210404.xsd#jnj_ZYTIGAMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_ZYTIGAMember_ca0d8fc9-8392-4a1e-b18d-2bcc968fc8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_c1d45ca4-3c3f-440a-a6e4-17b3ac289196" xlink:href="jnj-20210404.xsd#jnj_OtherOncologyMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OtherOncologyMember_c1d45ca4-3c3f-440a-a6e4-17b3ac289196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_c9856624-1a26-4b98-a7d8-2a7399bcf518" xlink:href="jnj-20210404.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OPSUMITMember_c9856624-1a26-4b98-a7d8-2a7399bcf518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_ce2cb972-29e0-4ab9-99d6-7aa3f2a4c59a" xlink:href="jnj-20210404.xsd#jnj_UPTRAVIMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_UPTRAVIMember_ce2cb972-29e0-4ab9-99d6-7aa3f2a4c59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_f75a1466-58bb-47aa-a217-9f59a2491f44" xlink:href="jnj-20210404.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_XareltoMember_f75a1466-58bb-47aa-a217-9f59a2491f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_ac922321-7b21-43f4-a3b0-6ea28bcd36f8" xlink:href="jnj-20210404.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_ac922321-7b21-43f4-a3b0-6ea28bcd36f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PROCRITEPREXMember_a7f4599e-7720-4ad1-b16e-69cf84069a67" xlink:href="jnj-20210404.xsd#jnj_PROCRITEPREXMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_PROCRITEPREXMember_a7f4599e-7720-4ad1-b16e-69cf84069a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_fdbff5a4-d5db-4ad1-a57f-50424ef3948d" xlink:href="jnj-20210404.xsd#jnj_OtherMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_OtherMember_fdbff5a4-d5db-4ad1-a57f-50424ef3948d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_9d96c9c1-ed08-41ba-88db-df788081a27a" xlink:href="jnj-20210404.xsd#jnj_HIPSMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_HIPSMember_9d96c9c1-ed08-41ba-88db-df788081a27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_1a089be2-23c3-49f2-8697-820dde28bc2a" xlink:href="jnj-20210404.xsd#jnj_KNEESMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_KNEESMember_1a089be2-23c3-49f2-8697-820dde28bc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_0e4313cf-0ae5-42c3-82d1-af61d65f8383" xlink:href="jnj-20210404.xsd#jnj_TRAUMAMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_TRAUMAMember_0e4313cf-0ae5-42c3-82d1-af61d65f8383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_eb5d12ff-59dd-4f85-97d6-0dee01016d85" xlink:href="jnj-20210404.xsd#jnj_SPINEOTHERMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_SPINEOTHERMember_eb5d12ff-59dd-4f85-97d6-0dee01016d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_dfda6fad-37c9-4ee4-8740-99df9756da4e" xlink:href="jnj-20210404.xsd#jnj_ADVANCEDMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_ADVANCEDMember_dfda6fad-37c9-4ee4-8740-99df9756da4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_699f1575-27cb-4ae6-9b79-699b3c053d8b" xlink:href="jnj-20210404.xsd#jnj_GENERALMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_GENERALMember_699f1575-27cb-4ae6-9b79-699b3c053d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_bf7fa241-4622-4ba1-b8d4-914735f5ad6a" xlink:href="jnj-20210404.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_bf7fa241-4622-4ba1-b8d4-914735f5ad6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_05f87a27-7265-40dd-b52b-c802475e60f2" xlink:href="jnj-20210404.xsd#jnj_SURGICALMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1a6fb94-2f93-4820-8a2e-21c3053f307e" xlink:to="loc_jnj_SURGICALMember_05f87a27-7265-40dd-b52b-c802475e60f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_287b612c-e74a-4dea-b30a-bfafcce43974" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:to="loc_srt_StatementGeographicalAxis_287b612c-e74a-4dea-b30a-bfafcce43974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_755f4c60-6441-4ad6-953f-74157748b30a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_287b612c-e74a-4dea-b30a-bfafcce43974" xlink:to="loc_srt_SegmentGeographicalDomain_755f4c60-6441-4ad6-953f-74157748b30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3e0185d2-bcf6-439b-8aa9-9dddef4eddeb" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_755f4c60-6441-4ad6-953f-74157748b30a" xlink:to="loc_country_US_3e0185d2-bcf6-439b-8aa9-9dddef4eddeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_36013afd-d233-4160-a698-640b70617bd1" xlink:href="jnj-20210404.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_755f4c60-6441-4ad6-953f-74157748b30a" xlink:to="loc_jnj_UNITEDSTATESExportsMember_36013afd-d233-4160-a698-640b70617bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_c9f3176c-b87c-495b-a3fc-3b0fc348d613" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_755f4c60-6441-4ad6-953f-74157748b30a" xlink:to="loc_us-gaap_NonUsMember_c9f3176c-b87c-495b-a3fc-3b0fc348d613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bac759a7-a861-47c7-9de5-c070dd1e7068" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_aa72efe7-acb9-4e4a-bdcc-502bbaedb7a1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_bac759a7-a861-47c7-9de5-c070dd1e7068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_bc3e98d3-c364-4e7e-955a-0a09c56df3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bac759a7-a861-47c7-9de5-c070dd1e7068" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_bc3e98d3-c364-4e7e-955a-0a09c56df3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6650932a-08c9-4e6e-83e3-588c69c6ae48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_bc3e98d3-c364-4e7e-955a-0a09c56df3f4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6650932a-08c9-4e6e-83e3-588c69c6ae48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_b8027403-5661-43e4-bcf5-3448d8c327c2" xlink:href="jnj-20210404.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_bc3e98d3-c364-4e7e-955a-0a09c56df3f4" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_b8027403-5661-43e4-bcf5-3448d8c327c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b2c3a581-d0af-480c-b9da-b04e9ef64c76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b2c3a581-d0af-480c-b9da-b04e9ef64c76" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_350762cb-4cbe-4a85-b93b-736184818ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_350762cb-4cbe-4a85-b93b-736184818ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_603a2fd0-5fc9-4576-b388-296dfbff3659" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_350762cb-4cbe-4a85-b93b-736184818ed1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_603a2fd0-5fc9-4576-b388-296dfbff3659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_2eaff85e-77fe-4ac3-a842-097c767a3bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_603a2fd0-5fc9-4576-b388-296dfbff3659" xlink:to="loc_us-gaap_OtherIncomeMember_2eaff85e-77fe-4ac3-a842-097c767a3bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_569992ed-03c3-49bb-9e89-caf94ccf5163" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_569992ed-03c3-49bb-9e89-caf94ccf5163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0755e85-48d0-45fa-a462-629a433148b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_569992ed-03c3-49bb-9e89-caf94ccf5163" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0755e85-48d0-45fa-a462-629a433148b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_8421e46f-c08a-4639-9862-bd9ce40c3553" xlink:href="jnj-20210404.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0755e85-48d0-45fa-a462-629a433148b5" xlink:to="loc_jnj_AurisHealthMember_8421e46f-c08a-4639-9862-bd9ce40c3553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_72a77526-d0f0-4566-9ebd-2a485dc236b6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:to="loc_srt_ConsolidationItemsAxis_72a77526-d0f0-4566-9ebd-2a485dc236b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_44f42990-5cac-4acd-86a2-08557df9efd6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_72a77526-d0f0-4566-9ebd-2a485dc236b6" xlink:to="loc_srt_ConsolidationItemsDomain_44f42990-5cac-4acd-86a2-08557df9efd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_06f00567-ded8-46fc-8dbb-72894ab224ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_44f42990-5cac-4acd-86a2-08557df9efd6" xlink:to="loc_us-gaap_OperatingSegmentsMember_06f00567-ded8-46fc-8dbb-72894ab224ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_f375bd5d-bbb0-436b-9362-dd89309b791c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_44f42990-5cac-4acd-86a2-08557df9efd6" xlink:to="loc_us-gaap_CorporateNonSegmentMember_f375bd5d-bbb0-436b-9362-dd89309b791c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_35d1de4a-b551-4e8d-9356-482384d6f173" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_35d1de4a-b551-4e8d-9356-482384d6f173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_25275ea7-dcff-4d0f-9382-048b9617496f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_35d1de4a-b551-4e8d-9356-482384d6f173" xlink:to="loc_us-gaap_SegmentDomain_25275ea7-dcff-4d0f-9382-048b9617496f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_69ac4a06-33a3-474f-af62-2b1e29d80ecf" xlink:href="jnj-20210404.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_25275ea7-dcff-4d0f-9382-048b9617496f" xlink:to="loc_jnj_ConsumerMember_69ac4a06-33a3-474f-af62-2b1e29d80ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_c46af234-5b54-4fd7-9352-1ddb203a1d32" xlink:href="jnj-20210404.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_25275ea7-dcff-4d0f-9382-048b9617496f" xlink:to="loc_jnj_PharmaceuticalMember_c46af234-5b54-4fd7-9352-1ddb203a1d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_1b341b25-5173-498c-bc7d-88de278ffcdc" xlink:href="jnj-20210404.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_25275ea7-dcff-4d0f-9382-048b9617496f" xlink:to="loc_jnj_MedicalDevicesMember_1b341b25-5173-498c-bc7d-88de278ffcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c3c86ee4-8ec9-4173-93b5-646685486878" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6c717786-8e71-42e5-b0a6-e07826ecf841" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_OperatingIncomeLoss_6c717786-8e71-42e5-b0a6-e07826ecf841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss_4ac88e29-4eb3-4630-85d6-699603de0add" xlink:href="jnj-20210404.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_jnj_PercentageChangeInOperatingIncomeLoss_4ac88e29-4eb3-4630-85d6-699603de0add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f3677702-029e-49e4-9081-fb92aff96270" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f3677702-029e-49e4-9081-fb92aff96270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_5a5d994a-9a97-46fc-a2db-d4c36abf775c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_AdjustmentForAmortization_5a5d994a-9a97-46fc-a2db-d4c36abf775c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_36a7bceb-86dc-4df5-b48d-424e59a8b55d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_36a7bceb-86dc-4df5-b48d-424e59a8b55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnSecurities_2827c612-0a7a-4395-9d86-d64a39012546" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_UnrealizedGainLossOnSecurities_2827c612-0a7a-4395-9d86-d64a39012546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_0b0e750c-3c34-40da-8bd1-7eb423a518a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_LitigationSettlementExpense_0b0e750c-3c34-40da-8bd1-7eb423a518a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers_a9a14309-8e37-40d6-afb7-f1b4daf934f6" xlink:href="jnj-20210404.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_jnj_AmountPrepaidAndDueToManufacturers_a9a14309-8e37-40d6-afb7-f1b4daf934f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7860a57c-733d-4c7e-9e68-3cf413c192e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7860a57c-733d-4c7e-9e68-3cf413c192e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a5475463-9875-408a-8990-f646aa7fe8a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f87839d7-92a3-4672-898d-5780351ff1be" xlink:to="loc_us-gaap_RestructuringCharges_a5475463-9875-408a-8990-f646aa7fe8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_194e64ff-0221-4068-bdd7-4935f25f3c20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_32c4a039-f8cc-475a-83ea-6703eb0645fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_194e64ff-0221-4068-bdd7-4935f25f3c20" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_32c4a039-f8cc-475a-83ea-6703eb0645fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_916b5e35-1ad3-4024-be01-ddf96f49889f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_32c4a039-f8cc-475a-83ea-6703eb0645fd" xlink:to="loc_srt_StatementGeographicalAxis_916b5e35-1ad3-4024-be01-ddf96f49889f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_742d66dd-afc3-4072-b0d8-a6c636acf283" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_916b5e35-1ad3-4024-be01-ddf96f49889f" xlink:to="loc_srt_SegmentGeographicalDomain_742d66dd-afc3-4072-b0d8-a6c636acf283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d35441a0-64b1-472a-b5ea-10438e662cb1" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_742d66dd-afc3-4072-b0d8-a6c636acf283" xlink:to="loc_country_US_d35441a0-64b1-472a-b5ea-10438e662cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_9fead61c-dd85-4c83-8283-98bfc40351a1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_742d66dd-afc3-4072-b0d8-a6c636acf283" xlink:to="loc_srt_EuropeMember_9fead61c-dd85-4c83-8283-98bfc40351a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_020ad19e-534d-4cb5-baa4-d68aa867dc67" xlink:href="jnj-20210404.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_742d66dd-afc3-4072-b0d8-a6c636acf283" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_020ad19e-534d-4cb5-baa4-d68aa867dc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_1fb5b5ed-6b29-4648-9fb8-c8a809ae5e81" xlink:href="jnj-20210404.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_742d66dd-afc3-4072-b0d8-a6c636acf283" xlink:to="loc_jnj_AsiaPacificAfricaMember_1fb5b5ed-6b29-4648-9fb8-c8a809ae5e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c74374e3-756a-4315-8fbc-488a832d4830" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_32c4a039-f8cc-475a-83ea-6703eb0645fd" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c74374e3-756a-4315-8fbc-488a832d4830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_496f9de3-c4e2-4b74-8ca0-0d2630b6c56f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c74374e3-756a-4315-8fbc-488a832d4830" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_496f9de3-c4e2-4b74-8ca0-0d2630b6c56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ad423ee8-5191-4965-882f-a2672f5df436" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_496f9de3-c4e2-4b74-8ca0-0d2630b6c56f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ad423ee8-5191-4965-882f-a2672f5df436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea_66d1ee61-0f7e-4821-acca-32f3a938023b" xlink:href="jnj-20210404.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_496f9de3-c4e2-4b74-8ca0-0d2630b6c56f" xlink:to="loc_jnj_PercentageChangeInSalesByGeographicArea_66d1ee61-0f7e-4821-acca-32f3a938023b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20210404.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_885828ce-56a7-4913-902e-dac95f6802a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_46b40742-0ac6-46f7-bec2-8f81f1d7b9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_885828ce-56a7-4913-902e-dac95f6802a8" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_46b40742-0ac6-46f7-bec2-8f81f1d7b9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_0ce2c374-cb7e-47a0-8364-7372d013e1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e8a3b29-fd79-42bd-bdff-036a2e08d0ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0ce2c374-cb7e-47a0-8364-7372d013e1b5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e8a3b29-fd79-42bd-bdff-036a2e08d0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fb696187-a7a0-4398-b5fc-207804ea534b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e8a3b29-fd79-42bd-bdff-036a2e08d0ea" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fb696187-a7a0-4398-b5fc-207804ea534b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1c71c39-52a2-4d34-87a1-b2cb1297bb80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fb696187-a7a0-4398-b5fc-207804ea534b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1c71c39-52a2-4d34-87a1-b2cb1297bb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_16c22209-b5d0-4170-8cdf-76413b598778" xlink:href="jnj-20210404.xsd#jnj_EvraAndDoxilMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1c71c39-52a2-4d34-87a1-b2cb1297bb80" xlink:to="loc_jnj_EvraAndDoxilMember_16c22209-b5d0-4170-8cdf-76413b598778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d0ef32f3-2c2d-4127-a291-06f4fdf3d19b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e8a3b29-fd79-42bd-bdff-036a2e08d0ea" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d0ef32f3-2c2d-4127-a291-06f4fdf3d19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_568bcc85-0b66-4bce-81a9-8abbaa939b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d0ef32f3-2c2d-4127-a291-06f4fdf3d19b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_568bcc85-0b66-4bce-81a9-8abbaa939b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_58b18a6d-f37b-4802-b66f-d87a3b9c5907" xlink:href="jnj-20210404.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_568bcc85-0b66-4bce-81a9-8abbaa939b7c" xlink:to="loc_jnj_BermekimabMember_58b18a6d-f37b-4802-b66f-d87a3b9c5907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalInc.Member_d3c11a05-a733-42be-9918-39b2756a6857" xlink:href="jnj-20210404.xsd#jnj_VerbSurgicalInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_568bcc85-0b66-4bce-81a9-8abbaa939b7c" xlink:to="loc_jnj_VerbSurgicalInc.Member_d3c11a05-a733-42be-9918-39b2756a6857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e8a3b29-fd79-42bd-bdff-036a2e08d0ea" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_31cd409b-63ea-4882-a1a0-7bb92f818e17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_31cd409b-63ea-4882-a1a0-7bb92f818e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1c18e86d-9ce9-4faf-9aae-5651f63d1b69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1c18e86d-9ce9-4faf-9aae-5651f63d1b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_72dad612-f70a-429c-bb10-db7cae6bdd8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_72dad612-f70a-429c-bb10-db7cae6bdd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_63e32cc2-ab4f-4c6e-8624-ac75ace530d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_Goodwill_63e32cc2-ab4f-4c6e-8624-ac75ace530d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_2066bfd3-9650-498f-a1db-83b0308fb908" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_2066bfd3-9650-498f-a1db-83b0308fb908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_9d645d61-d6d0-4752-ba6f-fbd278cc5caf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_9d645d61-d6d0-4752-ba6f-fbd278cc5caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4de7ca8c-f678-4bfd-8264-c26a65dfd937" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dfd1d69-1963-495e-a243-ea62de5f4567" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_4de7ca8c-f678-4bfd-8264-c26a65dfd937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20210404.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37600d4b-ead9-4e4a-9dcc-86a5e8055d21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_7b62c0d0-51c3-44f0-a76a-a00ec41eb955" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37600d4b-ead9-4e4a-9dcc-86a5e8055d21" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_7b62c0d0-51c3-44f0-a76a-a00ec41eb955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#LegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6de70d25-14ba-4928-8648-bdaadfdc3365" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6de70d25-14ba-4928-8648-bdaadfdc3365" xlink:to="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_87f4a946-e87d-496c-a7a7-e73d17c3fad8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:to="loc_srt_LitigationCaseAxis_87f4a946-e87d-496c-a7a7-e73d17c3fad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f5dad4b7-e8e3-43ab-9ed3-213e6b9d9949" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_87f4a946-e87d-496c-a7a7-e73d17c3fad8" xlink:to="loc_srt_LitigationCaseTypeDomain_f5dad4b7-e8e3-43ab-9ed3-213e6b9d9949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_d832a36f-917e-4240-acdd-fd2ccf2a2cae" xlink:href="jnj-20210404.xsd#jnj_DePuyASRU.S.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f5dad4b7-e8e3-43ab-9ed3-213e6b9d9949" xlink:to="loc_jnj_DePuyASRU.S.Member_d832a36f-917e-4240-acdd-fd2ccf2a2cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_9b9072ec-14ad-4fdd-85e7-ddb11d0ebaf5" xlink:href="jnj-20210404.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f5dad4b7-e8e3-43ab-9ed3-213e6b9d9949" xlink:to="loc_jnj_RisperdalMember_9b9072ec-14ad-4fdd-85e7-ddb11d0ebaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_fc6fe6e1-a4cb-443f-b9f6-ceeec61ba84d" xlink:href="jnj-20210404.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f5dad4b7-e8e3-43ab-9ed3-213e6b9d9949" xlink:to="loc_jnj_BabyPowderMember_fc6fe6e1-a4cb-443f-b9f6-ceeec61ba84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_8e52e753-6cf9-45f9-ac35-5fc4dde62565" xlink:href="jnj-20210404.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f5dad4b7-e8e3-43ab-9ed3-213e6b9d9949" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_8e52e753-6cf9-45f9-ac35-5fc4dde62565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_83e0b5bb-1849-47b5-8c0d-c4a96c3205d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:to="loc_us-gaap_LitigationStatusAxis_83e0b5bb-1849-47b5-8c0d-c4a96c3205d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_949ab9a5-7756-4a4b-a317-861d76664155" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_83e0b5bb-1849-47b5-8c0d-c4a96c3205d0" xlink:to="loc_us-gaap_LitigationStatusDomain_949ab9a5-7756-4a4b-a317-861d76664155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_4943267e-6986-4050-aa7d-f1567fdacde8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_949ab9a5-7756-4a4b-a317-861d76664155" xlink:to="loc_us-gaap_SettledLitigationMember_4943267e-6986-4050-aa7d-f1567fdacde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_16302a67-05e5-41fc-b6fd-d8d92dd0c9c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_949ab9a5-7756-4a4b-a317-861d76664155" xlink:to="loc_us-gaap_JudicialRulingMember_16302a67-05e5-41fc-b6fd-d8d92dd0c9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_11d30ea4-90f4-49f1-aae9-d4d167e9bccd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_949ab9a5-7756-4a4b-a317-861d76664155" xlink:to="loc_us-gaap_PendingLitigationMember_11d30ea4-90f4-49f1-aae9-d4d167e9bccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e5212845-46eb-48fb-831a-d471d5aabf56" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:to="loc_srt_ProductOrServiceAxis_e5212845-46eb-48fb-831a-d471d5aabf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e5212845-46eb-48fb-831a-d471d5aabf56" xlink:to="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_f92446d9-23f5-4c18-90e8-cb080c7088f0" xlink:href="jnj-20210404.xsd#jnj_AsrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_AsrMember_f92446d9-23f5-4c18-90e8-cb080c7088f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_1c3de180-4841-454d-a29c-2129c8d59b3e" xlink:href="jnj-20210404.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_1c3de180-4841-454d-a29c-2129c8d59b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_3ddf0068-6d27-4c43-a18e-11ad173a97aa" xlink:href="jnj-20210404.xsd#jnj_PelvicMeshesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_PelvicMeshesMember_3ddf0068-6d27-4c43-a18e-11ad173a97aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_9cc45d3c-0bd0-467b-9d4d-a2992819959c" xlink:href="jnj-20210404.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_RisperdalMember_9cc45d3c-0bd0-467b-9d4d-a2992819959c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_279e3c89-fbaf-4614-97d2-ae81b972408a" xlink:href="jnj-20210404.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_XareltoMember_279e3c89-fbaf-4614-97d2-ae81b972408a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_452276ad-8406-43af-83d9-34de404ed540" xlink:href="jnj-20210404.xsd#jnj_TalcMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_TalcMember_452276ad-8406-43af-83d9-34de404ed540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_42bdabe0-1849-4e6b-bb34-71a9151eb6bc" xlink:href="jnj-20210404.xsd#jnj_InvokanaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_InvokanaMember_42bdabe0-1849-4e6b-bb34-71a9151eb6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_50f26ea3-8160-488e-afef-b4b5db2b70b5" xlink:href="jnj-20210404.xsd#jnj_PhysiomeshMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_PhysiomeshMember_50f26ea3-8160-488e-afef-b4b5db2b70b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_7b03cd74-9c9f-4c00-ad25-afec4f03f4ad" xlink:href="jnj-20210404.xsd#jnj_OpioidMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e071d31-576d-45fd-92ac-b5083722df36" xlink:to="loc_jnj_OpioidMember_7b03cd74-9c9f-4c00-ad25-afec4f03f4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_bc917c78-8a16-485a-ac63-e6288ca9f438" xlink:href="jnj-20210404.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_bc917c78-8a16-485a-ac63-e6288ca9f438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_1fbca2be-6ea7-4ad8-bd6a-a803bb4e0686" xlink:href="jnj-20210404.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_bc917c78-8a16-485a-ac63-e6288ca9f438" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_1fbca2be-6ea7-4ad8-bd6a-a803bb4e0686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_847f7f64-6212-4f48-a238-b25fb06a92a1" xlink:href="jnj-20210404.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_1fbca2be-6ea7-4ad8-bd6a-a803bb4e0686" xlink:to="loc_jnj_RisperdalMember_847f7f64-6212-4f48-a238-b25fb06a92a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84d0ad96-f70a-41a2-824d-83ac393de14d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84d0ad96-f70a-41a2-824d-83ac393de14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b9cf850f-1a88-4fd8-a6f4-587a2f6f8947" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84d0ad96-f70a-41a2-824d-83ac393de14d" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b9cf850f-1a88-4fd8-a6f4-587a2f6f8947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_8e3b5a5b-3808-4728-8f6e-812e256727b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b9cf850f-1a88-4fd8-a6f4-587a2f6f8947" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_8e3b5a5b-3808-4728-8f6e-812e256727b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_943639fb-a7a0-4dff-b93c-6a5f00358c79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e11feb7c-fcb8-4671-b8c4-54a20a6bca72" xlink:to="loc_us-gaap_LossContingenciesLineItems_943639fb-a7a0-4dff-b93c-6a5f00358c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:href="jnj-20210404.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_943639fb-a7a0-4dff-b93c-6a5f00358c79" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_e9e2d224-c832-4a29-aa89-7a110e45ae6d" xlink:href="jnj-20210404.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_e9e2d224-c832-4a29-aa89-7a110e45ae6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_65654e90-53cf-4099-81de-9847ccfeedbf" xlink:href="jnj-20210404.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:to="loc_jnj_Numberofpatientsinsettlement_65654e90-53cf-4099-81de-9847ccfeedbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_9df3250d-ecaa-463d-81bb-cd3bb06b75ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_9df3250d-ecaa-463d-81bb-cd3bb06b75ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_c91ccfde-56dc-4798-8c4b-fc000f02c6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_c91ccfde-56dc-4798-8c4b-fc000f02c6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_681d08ec-cb2a-4961-9f58-bce774b53d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_681d08ec-cb2a-4961-9f58-bce774b53d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_bf3d5574-3352-4490-a18b-5a13237fc4b5" xlink:href="jnj-20210404.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_b095783f-a832-46c6-86f2-e6bfc1ef0aab" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_bf3d5574-3352-4490-a18b-5a13237fc4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20210404.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_19716362-0015-49ea-aec3-77c3fd83b9ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_14943eab-c77c-4c36-b0e4-33730ec73f19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_19716362-0015-49ea-aec3-77c3fd83b9ea" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_14943eab-c77c-4c36-b0e4-33730ec73f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20210404.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_50fea576-9992-4424-9110-e6bcb14237f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f3425ee9-3bd7-4164-82d7-aabb9500cde5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_50fea576-9992-4424-9110-e6bcb14237f1" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f3425ee9-3bd7-4164-82d7-aabb9500cde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_990d3f3a-dee3-48d6-ba02-e972aba70b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_990d3f3a-dee3-48d6-ba02-e972aba70b3b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6592f620-624f-4629-8856-6b2653cde291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6592f620-624f-4629-8856-6b2653cde291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_071a4e68-2c27-4279-95dc-97c0008f53cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6592f620-624f-4629-8856-6b2653cde291" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_071a4e68-2c27-4279-95dc-97c0008f53cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_fc00de50-4c3f-4e58-b9e2-7e9487f11e10" xlink:href="jnj-20210404.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_071a4e68-2c27-4279-95dc-97c0008f53cd" xlink:to="loc_jnj_SupplyChainMember_fc00de50-4c3f-4e58-b9e2-7e9487f11e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d266dbe2-a7bb-4220-b374-977d8eaf5373" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d266dbe2-a7bb-4220-b374-977d8eaf5373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dbc342d6-733a-47f4-bc4e-b56f3262f89f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d266dbe2-a7bb-4220-b374-977d8eaf5373" xlink:to="loc_us-gaap_SegmentDomain_dbc342d6-733a-47f4-bc4e-b56f3262f89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_140b80e2-b80f-4801-8adb-4e9668f0cc25" xlink:href="jnj-20210404.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dbc342d6-733a-47f4-bc4e-b56f3262f89f" xlink:to="loc_jnj_MedicalDevicesMember_140b80e2-b80f-4801-8adb-4e9668f0cc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_20964b70-f706-406b-8b4f-d4f4d7a22f70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:to="loc_us-gaap_RestructuringPlanAxis_20964b70-f706-406b-8b4f-d4f4d7a22f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3b910c40-70cd-4f8d-a5a9-eb3989dc9587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_20964b70-f706-406b-8b4f-d4f4d7a22f70" xlink:to="loc_us-gaap_RestructuringPlanDomain_3b910c40-70cd-4f8d-a5a9-eb3989dc9587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_dcf5c724-8410-4d43-a33e-8acbc2e22c41" xlink:href="jnj-20210404.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_3b910c40-70cd-4f8d-a5a9-eb3989dc9587" xlink:to="loc_jnj_SupplyChainMember_dcf5c724-8410-4d43-a33e-8acbc2e22c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1b869f31-1266-4ce3-8df2-df2a24922520" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:to="loc_srt_RangeAxis_1b869f31-1266-4ce3-8df2-df2a24922520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_10108700-adef-401e-9048-c858c825c43c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1b869f31-1266-4ce3-8df2-df2a24922520" xlink:to="loc_srt_RangeMember_10108700-adef-401e-9048-c858c825c43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4bf99377-e673-4766-830a-7d78d7908711" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_10108700-adef-401e-9048-c858c825c43c" xlink:to="loc_srt_MinimumMember_4bf99377-e673-4766-830a-7d78d7908711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b755ee75-8d4a-43f1-8f55-5dc404999051" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_10108700-adef-401e-9048-c858c825c43c" xlink:to="loc_srt_MaximumMember_b755ee75-8d4a-43f1-8f55-5dc404999051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ed7dd730-72c7-483b-8604-223372176b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ed7dd730-72c7-483b-8604-223372176b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e481cf25-c718-4838-8216-8b020dcd7a62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ed7dd730-72c7-483b-8604-223372176b6d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e481cf25-c718-4838-8216-8b020dcd7a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_8a36f6b8-5324-4a1e-b9d0-b67f1c7473d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e481cf25-c718-4838-8216-8b020dcd7a62" xlink:to="loc_us-gaap_RestructuringChargesMember_8a36f6b8-5324-4a1e-b9d0-b67f1c7473d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d7744093-7b72-48b1-b7aa-24c1322f51b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e481cf25-c718-4838-8216-8b020dcd7a62" xlink:to="loc_us-gaap_CostOfSalesMember_d7744093-7b72-48b1-b7aa-24c1322f51b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_71f1bec7-dfa0-4553-85a6-03c74be66113" xlink:href="jnj-20210404.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e481cf25-c718-4838-8216-8b020dcd7a62" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_71f1bec7-dfa0-4553-85a6-03c74be66113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cc102e56-b4e0-48cd-8220-a6202db52caa" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0ed36c38-933a-4727-8c2e-beb85e3015e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:to="loc_us-gaap_RestructuringCharges_0ed36c38-933a-4727-8c2e-beb85e3015e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_f6cf0310-4db0-4c46-ac4e-9940bcc62fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_f6cf0310-4db0-4c46-ac4e-9940bcc62fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_a2de3b28-9cee-4674-bb12-bb4dab782aa3" xlink:href="jnj-20210404.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_a2de3b28-9cee-4674-bb12-bb4dab782aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_ca723c9d-9ef6-48f8-9b12-8f47b7565d54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_ca723c9d-9ef6-48f8-9b12-8f47b7565d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_19b29391-5f1b-4427-8637-0718e419d059" xlink:href="jnj-20210404.xsd#jnj_RestructuringandRelatedCostDurationofRestructuringPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3958b068-5674-40b7-9279-5c99654b7295" xlink:to="loc_jnj_RestructuringandRelatedCostDurationofRestructuringPlan_19b29391-5f1b-4427-8637-0718e419d059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20210404.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f09ed283-dc5d-4072-87a4-a4575b11198e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bb6f1fe-4420-417e-80c9-ae99b3ba1f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f09ed283-dc5d-4072-87a4-a4575b11198e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bb6f1fe-4420-417e-80c9-ae99b3ba1f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_717b9206-99da-4e84-b43a-9e691d6dbb70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bb6f1fe-4420-417e-80c9-ae99b3ba1f5f" xlink:to="loc_us-gaap_RestructuringPlanAxis_717b9206-99da-4e84-b43a-9e691d6dbb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b8a704b1-6d53-46ab-afe6-58fca6cee5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_717b9206-99da-4e84-b43a-9e691d6dbb70" xlink:to="loc_us-gaap_RestructuringPlanDomain_b8a704b1-6d53-46ab-afe6-58fca6cee5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_44481e5d-9857-490a-a692-c039ef29cada" xlink:href="jnj-20210404.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_b8a704b1-6d53-46ab-afe6-58fca6cee5a1" xlink:to="loc_jnj_MedicalDevicesMember_44481e5d-9857-490a-a692-c039ef29cada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_3a960ab2-6d61-41c9-9c00-dded03493299" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bb6f1fe-4420-417e-80c9-ae99b3ba1f5f" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_3a960ab2-6d61-41c9-9c00-dded03493299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_fb1e34d8-5542-4ff6-8b48-8b8fc8e83abd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3a960ab2-6d61-41c9-9c00-dded03493299" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_fb1e34d8-5542-4ff6-8b48-8b8fc8e83abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_da18bff2-d11c-4d72-9b8e-424383131e35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_fb1e34d8-5542-4ff6-8b48-8b8fc8e83abd" xlink:to="loc_us-gaap_EmployeeSeveranceMember_da18bff2-d11c-4d72-9b8e-424383131e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_238f80e1-249b-4ff5-a19e-50a01e6fb377" xlink:href="jnj-20210404.xsd#jnj_AssetWriteoffMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_fb1e34d8-5542-4ff6-8b48-8b8fc8e83abd" xlink:to="loc_jnj_AssetWriteoffMember_238f80e1-249b-4ff5-a19e-50a01e6fb377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_a9a91aeb-99a2-44ca-be02-bb947ee14860" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_fb1e34d8-5542-4ff6-8b48-8b8fc8e83abd" xlink:to="loc_us-gaap_OtherRestructuringMember_a9a91aeb-99a2-44ca-be02-bb947ee14860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c20bbb3a-9009-4314-bfcb-41528e52b54c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2bb6f1fe-4420-417e-80c9-ae99b3ba1f5f" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_c20bbb3a-9009-4314-bfcb-41528e52b54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c20bbb3a-9009-4314-bfcb-41528e52b54c" xlink:to="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_10d94c04-bed7-4fe6-abe2-c15d1456149e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:to="loc_us-gaap_RestructuringReserve_10d94c04-bed7-4fe6-abe2-c15d1456149e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_7021b443-545f-4f1a-acfd-27cc5ade7afc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:to="loc_us-gaap_RestructuringCharges_7021b443-545f-4f1a-acfd-27cc5ade7afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_6f221f2a-b84b-4ddd-bbb9-b99b6cc770df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:to="loc_us-gaap_PaymentsForRestructuring_6f221f2a-b84b-4ddd-bbb9-b99b6cc770df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_d3456e02-4f42-4d68-a325-47ee1d54f66a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_d3456e02-4f42-4d68-a325-47ee1d54f66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c8b0d098-75ab-4fbd-9a1f-f1f9ac7ed001" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d3052ffc-4f3a-4ee1-9cf0-c37236607e6f" xlink:to="loc_us-gaap_RestructuringReserve_c8b0d098-75ab-4fbd-9a1f-f1f9ac7ed001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_39683605-b91c-4ad2-8593-a480f3c22c91" xlink:href="jnj-20210404.xsd#jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c20bbb3a-9009-4314-bfcb-41528e52b54c" xlink:to="loc_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid_39683605-b91c-4ad2-8593-a480f3c22c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>jnj-20210404_g1.jpg
<TEXT>
begin 644 jnj-20210404_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI"[AG&17J%?)?[8__!'G_@GW^V3XD\;?&C]M#P%)XJU+5M#6SL]>U?6IX?\
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MJ<YW*H!])? W]LG]DO\ :;UW5_"_[.O[2O@?QSJ6@*K:YI_A3Q/:W\VGAF9
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M5M&UG3X;[2-5TZX6:WO+:9!)%-%(I*NCHRLK D$$$5^9O_!;']M7]CWXN_\
M!&;P%^UE\<OV3;WXJ?"/XBWVB:DF@KXUET+5=(NKF!YK:5)(89 SQGSH9 '4
M#<0/,5CCU;Q3_P %3/V;OV'?^"<_[,WBWX;_  .N%U#XS>%O"ND? WX,Z?K*
MK(SWMC9FWLY+R16V06ZW$$<ER4=LNAV,SXH ^[*Y[XH?%GX8_!/PA<?$#XO>
M/=)\-:': F[U?6[Y+:V@ 5G)>1R%4!49B20 %)KY._9 _P""M/B'XU_\%&OB
M9_P2W_:#_9SC\$?$GX>:''K<&I^'O$LFL:-K&GNEH_F1S2V=K+$VV]@P&C*M
M\XW J%;Z?_:/M+>__9X\>V-W$)(IO!>J1RH>C*;24$?E0!Y;:?\ !6K_ ()=
MW]A-JME_P4,^#,MI;,JW-U'\1].,4)/3>_G87/N17L7PL^,/PD^.?A&+X@?!
M/XI>'/&.@SNR0:WX6UNWU"TD88RJS0.Z$C(R >XK\#O^#0']IO\ 90_9^_9C
M_:"M_P!J+X[^ O"-A?:_IDCVGC7Q%9V:WMLMI<+*%BN'!G7YMI50V2P7!)Q7
M7?\ !IU\.?C _P"WC^TE\>_@WX-US0OV9/$C:BG@];VREMK&^NCK DTS[.K@
M"1H+#[2CE,^7YR*V-P% '[S45\)?$+_@L_JGB#XE?M">#/V-?V<['XD:9^R[
MH#W_ ,5]>UCQJVCQS7D:W$DVEZ8B65S]IN$2SNPSR&%!+#Y>2'#UB?M,?\'%
M?[)WP4_81^$O[9OPV\$:SXWU#XY7#V?PW\!I=QV-S/>02K#>17<Y$B6ZVT[+
M#(ZK+EW3:&5MX /T(KSC3?VOOV7]8_:2O_V/=+^._AF?XH:7I2ZEJ'@:+5$.
MHV]LRHX=HLY!V21OM^\$=7QM(-?(7C[_ (+._'OX*?\ !0_P9_P3(^+/[#FC
MW'Q#\<Z%;:UH-_X7^+<;Z;<6,GV@2D/?6%JWFQ-:78\O&9/(&TY<(/)_@1\9
MOV,]6_X.;?'WPFU/]@TZ!\?;#PH_]I_%*S^(<]]I]S;'2K.:*:.Q:")(YY;*
M:WB=P,KM<98EF8 _5RBO@0_\%L/$GQJ^-OQ]^&/["?[,^E?$;1_V:]&>Y^(G
MB?Q!X^?18]0O4^TEM/TM(K"Z\]_]#NU$TK0QL\! .QED.Q'_ ,%QO@WX^_X)
M+:Q_P5C_ &>_AI<^*-#\,#;XJ\%:KK2Z;?Z;/'-%%<6QD2&=&E3SH9%'"R12
M*VY20M 'W'17Y'?$;_@Z%^(/@7]B?X9_\%$1_P $Q?$'_"IO''BR;P]J>N7O
MQ'LXYK:\CGO$*V<"V[/=IY=E,?-D%NGFHT.>!(?U;\!>-= ^)/@;1?B+X4N6
MFTO7])MM2TV9TVF2WGB66-B#T)5@<4 :U%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?AW_ ,'#_P"P!\>O@?\ \%(OA)_P6]_9]^&>K>,O#_@W7= O/BAH
MGA^S-Q>V9TJ[21;ORU^9H);5!"S 8B,(9B X*_H!^UE_P62_86^''["&O?M.
M?#']I/PAXKN-8\*S?\(!X?T/6H;G4M;U6>$K:64=FC&<2F9T61&0-$ Y<+L;
M'V)7YD_ME_\ ! 3QI?\ _!0?3/\ @JM_P3.^/^C?"_XLP:@;W7M \4:(]WH&
MMSO$89I'$!$D'GQ,ZS*%?S"YD4Q29=@#@O\ @U(_X)4_%K]@']G3QG^U%^U+
MX=F\,>*_BC'9_8?#FK)Y-SHNBV@ED62Z5L&&69YF=HFYC2&+=M9G1?F9OC_\
M#%_X/4Q\3S\8?#/_  C)L?[.'B,:Y ;#[7_PA'V?R?M&[RP_G_N<;L^9\GWN
M*_<S]GE_VIG\).?VK[?X?Q:Z"@C7X>37TEH1@[V)O%5QDXPN#@9RQKT"@!L,
MT-S"EQ;RK)'(H9'1LA@>001U%?D'_P '#O\ P7&_9A^ _BZS_P"";.K:YXHU
M&RUU5/QVN/AX\!U&RT5TW?V)#)++&D,]XI"S29+0VTAPK/,I3]?J* /R^_X)
MZ_M\? G_ (+B?LJ?&O\ 8@_9*_9QO?A=\*?#7P=_X0VW;75A22&YU6UO+6VC
MMXK:1T2&"&W=V)+.S2)]W:=_YT_#;3=1^#O_  ;,?M$_\$V/B/9/IGQW'[0N
MGZ#9_"N3#:WJ%X^J:!<Q?9K1<RW$<D5M<-')&K)((F*DCFOZ5ZSYO"7A2Y\1
M1>+[CPSI\FK6\)A@U1[*,W,<9SE%D(W!>3P#CDT ?EG\0OVRO"?_  ;=?\$-
M_A%\$?B!-:W/QCF\(&T\-^$59)RFL7,CW=]<R*'7?:VDUT^XAE$K".,,OF;U
M\K_X(D?\%M_V0_&_Q;\$?\$]_P!C+]G+X@7/C?XD^*K[7?B=\4/B2]D)]:NQ
M;3WVIZM<FUG=GGE$#1Q1Y6.+?&!N";7_ &PHH _#?_@]F^)/P\OOV9_A'\,;
M'QUI$_B2U^(=Q>76@0ZC$UY!;C3W7S7A#;T3,B#<0 =P]:_7_P#8]^(_P_\
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MOAS]H+X9WW@W3-)^'FBZ-XP_X1O6O"<L"EKM;DJ]JNIQS3.\B227+& ,42,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC[IQUW_!;;XS?"*?_@Y/_8L\2V_Q0\/R:;I$/AN75M1BUB%H+*.;7+B2)Y9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]MOF34445PG<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;5M8U">[N[F0R7%U<RM))*Y.2S,Q)8D]S4%%%?=))*R/@6VW=A1113$%%%%
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M3MJX/Y;Q^3LOY3]5X=\7,[RZ2IYDO;T^^BFOGM+YJ[_F/Z?J*_,3]A+_ (.
M-(\3WEI\-?VV]-MM*N9-L5MXZTFV*VTC=!]K@7/DY[RQY3)Y1%!:OTPT+7M#
M\4:-:^(O#6LVNHZ?>P+-97UC<++#/&PRKHZ$JRD<@@D&OP;/>',WX<Q/L<=3
MY;[26L9>C_3==4C]^R'B7)^)<-[; U.:V\7I*/JOUU3Z-ENBBBO#/>"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJMK.LZ1X=TBZ\0>(-4
MM[&QL;=Y[V]NYECB@B12SR.[$!5 !))X %-)R=D)M15V6'=(D,DCA5499F.
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M#[]IR[_;-\'_  B\3V7Q2O[F>>_\:K\7/%#WERTR;)1(6U(K(C+A=C J %
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M;X:N-)UG3)C'=6=RN#[.IZ.C#!5U)# @@D&OHO\ X)Q_\$K_ (K_ +=VM_\
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M52A5E3FK2BVFNS6C/[CI5:=>E&I!WC))I]T]4%%%%9F@4444 %%%% !1110
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M^\46MWKOCWXU>,+'2-+T72IXPVDV=S<BV74KK<?EB\YMBJ!ND*2[?]6U?45
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MP_V3MR#W!!KGZ_LFG4A5IJ<'=-73[IG\65*<Z51PFK-.S79K<****L@****
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MDGR1;WRSRM\D,22ROA(V(_++_@W4_P""./[8?_!-WX(_&[X[_&+]G&U\-_M
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M*_-C]-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN\?1OF_K7LY/.U2<.ZO]W_#GSW$%-NG"?9M??_PQF4445[Y\P%%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ)^LM?\ MT_:_!SA^6(S"IFU5>[33C#_ !M:M>D=/^WC2HHHK^>3^C0HHHH
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MK)K[K*LN6!I<TOC>_EY?Y]W\CX+-LR>.K<L?@6WGY_Y=E\PHHHKU3R0HHHH
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MX)@^(+J^^(GPJ\*G1-4\'64:R75WIZ3W4_F6\#@K>!UO+B*:V/SNGE^6&88
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^-?^"G_QO_9[_:%^.W[)GB/X1Z=\#O%4OBT6GCB_TV75[_5/)5;>SMET^YN
MEFLZQW$LLS12.;2%%AP[/']O44 ?G_\ "'3O^"N/[0?_  4)_:(_9M_;H^%6
MB)^R3X@\)ZKHW@^[L'M89;JUN2EO"L,\$GVII9;22X,_F@".1?D*?*'^0_\
M@K;_ ,&J'[.FF?LEM=?\$I?V5=6U'XK?\)+9!;>\^([*G]FXD^T'.J7:09!\
MOON]!UK]O** /G;_ ()0_L::#^P7^P!\-/V==-\&3>']4L?#%G>^,-*GU7[:
M8=>N((Y=2 E$CH1]J,N!&QC ^X=N*^B:** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /SY_X*P?\G$Z+_P!B5;?^E=Y7S#7T]_P5@_Y.)T7_ +$JV_\
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MZ/XF_8,LI;G1[RYAE34KJ+5M-,+21JV99HXT<IG+)Y6X8,8*\Y\0KV#XF?\
M!/S]HO1/'J6UI^V'X8^.>L2>%F1XXO%$>N?VPLGAEM+8XN#:O8/9P0&/,3VX
MF4DKYM 'Z]W>J:98,%OM1@A)9% EF5>78J@Y/5B"!ZD8%%_J>FZ7&DNIZA!;
M++*L4;3RA [L<*HR>6)Z#J:_)KXB?L]?L,?%?]KS]O'PC^VGH?@YKFT\#^$-
M5MH[V=(WL+U_#DYN-3T^(D%;H3E=L\:^;NE"Y_?%7YW1?%OA;2]3\'_LY_\
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M%Z^$S_96BSQ6@M[&*&P>X=Y+>#'F%9)V:6269B55UB2MJ_P:_:ZTCXP#XP^
M_C]X5NDNOA]I&A:]X5\0>$KC[)>ZC:7%],^I02PW8:S,GVS:8MDP*Q*"<A6'
MM]% 'S-^S_\ L,?%+]EWX=ZII7P5^-V@Z9XF\=?'2;XB?%+4CX)W6&I)=S1?
M;].L;0W.;(/;P0Q),TDK*R/(P9I#CZ9HHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>jnj-20210404_g2.jpg
<TEXT>
begin 644 jnj-20210404_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5-%%RT]SIMLXRD]VD*N;2)AR))MBD D' )KUROYUOV+/^"R?C_\ X(:?M_\
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MAT6..R@TFU>6*U'D7$MU<K'$\C1F.--A7:[NWET ?T645^?\7_!>/PM\0?\
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M\2?\(]KFF:W-=+(VI)>+Y1O8#"BQ?97NHHT;]X$9AD\1^R__ ,$%/@S\+_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K!\;?%#X=_#>?2+/QWXST[2KCQ!JL>F:#:WERJ
MS:E>/DK!!']Z:3 9BJ D*C,<*K$;KND:&21@JJ,LQ. !7Y<_\$+_ -HO5/\
M@J1^V%^T;_P4K\;SF_TOP_XCC\ ?!+3IVS#X?T*,&XN'B7D)->9LI9I!\Q*;
M,[%50 ?H!\/_ -K[]E_XK?'+Q5^S/\-_COX9UOQ_X(A67Q7X2T[5$DO=-0LJ
MEI(P<X5G17QG8SJK;2P!]'K\G_\ @ES\9_V.?&G_  7._:<\"_#?]@=? 7QQ
MTO1=5E\<>.5^(\^IZ?J[1ZG91SK;P/;QBV6YFD@N'D$>[,?* DBM3X4_\'&_
MQ;_: \5?'CX4? K_ ()F:QX@\8? BVU"?7H(_B9:Q:9+'93W$-RYNIK5'7F
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSNJ1QH@+.S$@!0"23@5^FE17-E9WAB:\M(I3#*)(3)&&\MP" RYZ'!/(YY-
M'\__ /P50\<>'?VNO^"!O[%'[!_[,VJ6WC3XNZS<^#=,'@'0[I)M3LI]+\.W
M%AJ N8%)>V$%TZ12&4($^8L0%;%/_@Y1T/PE^S?K7_!./]G+7OB-I5WJ7PHL
MC8>))%O4W6\%O_PC5NMW*IPT<<GV.=E9@ 1&^/NG'[_V'@SP?I6O77BK2_"F
MFVVJ7RXO=2M[&-+BX''#R ;GZ#J3T%:5 'X.?\%MOC-\(I_^#D_]BSQ+;_%#
MP_)IND0^&Y=6U&+6(6@LHYM<N)(GED#;8U:-T<%B 4=6^Z0:D^,/Q:^%\O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 45XM^T;_P4)_9$_996>S^
M+'QCTY-6A!_XI[2F^V:@6[*T,63%GL9"B^]?"WQU_P"#BOQ%=//IG[-OP&MK
M./)$.L>,KLS2,/7[+;LJH1[S.,]N.?J\EX(XGSY*>%P[Y']J7NQ^3E:__;MS
MY+.^.>%N'VX8O$KG7V8^]+YJ-[?]O6/U2KG?'7Q>^$_POB$_Q+^*'AWPZA7<
M'UW6X+0$>N977BOP0^+O_!33]NGXURS#Q=^T=X@M;68D'3_#]P-,@"_W"MJ$
M+C_?+$]R:\.O[^_U6\DU'4[V:YN)F+33SR%W=O4L>2?K7Z5E_@CBYI/'8N,?
M*$7+\6X_DS\QS'QSP<&XX#!REYSDH_A%2_\ 2D?OWXU_X*O_ /!//P%(8=9_
M:>T2Y<9P-%MKG403Z;K6*1?QSBO/-?\ ^"[W_!/_ $<D:=XC\4:KCH;#PS(N
M?^_[1U^(-%?58?P8X7II>UJU9/\ Q12_"%_Q/E,1XV<55'^ZI4HK_#)O[W.W
MX'[13_\ !P5^P[%(4C\*?$24#^--!M,'_OJ[!_2K6E_\%^_V$[]@+O3_ !U8
MY/)NO#T)QS_TSN'^M?BG176_!_@]JUJG_@?_  #C7C)QDG>]-_\ ;G_!/W;\
M*_\ !:W_ ()U>)I%@N?C3=Z3(V J:KX9OE!/NT<3J/Q(KUCP#^W-^QS\3YTL
M_ _[37@J\N),>79MX@@AG?Z12LKG\J_G,HKS,5X*</U$_J^(J0?GRR7_ *3%
M_B>IA?'#B&F_]HP]*:\N:+_]*DOP/ZAH)X;F%;BVF62-U#(Z,"&!Z$$=13J_
MFD^&GQ[^-WP:NTOOA/\ %SQ)X<=&W :-K,UNK'ON5&"L#W!!![U]3_!?_@O!
M^VY\-6ALO']UH/CJQ0@2#6M-%O<[!V6:V\L9_P!IT<^N:^-S/P6SS#IRP5>%
M5=G>$O\ VZ/WR1]IE?C=D.):CC:$Z3[JTX_/X9?=%G[:45\0?L^?\%YOV0/B
MKY&E?%FSU;X>ZG)@.=2B-Y8;CV6XA7<!_M21(H]:^S/!WC;P;\0_#UOXN\ ^
M*]-UO2KM=UKJ6DWL=Q!*/57C)4_@:_,LVR#.LCJ<F/H2I^;6C])*\7\FS]1R
MCB'),^I\^ Q$:G=)ZKUB[27S2-.BBBO'/9"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **Y_P"*'Q4^'?P6\#W_ ,2?BIXOLM#T/38M]YJ%_+M1/10.KN3P
MJ*"S$@ $G%?DW^WM_P %R?B+\7C>_#']DTWOA/PTVZ*Y\3.?+U34%Z'RL'_1
M(SZ@F4C!W)DI7U/#/!^=<58CDPD+03]Z;TC'Y]7Y*[]%J?*<4<99)PGA^?&3
MO-KW81UE+Y=%YNR]7H???[8__!3O]E[]C2VGT;Q;XG_M[Q6B?N?".@R++=*V
M.//;.RV7I]\[L'*HU?EI^U=_P64_:\_:6^T^'_#WB$> O#4V5_L?PO.R3RQG
MM-=\2OP2"$\M&'5#7R=<W-S>W,EY>7#RS2N7EEE<LSL3DL2>22><TROZ0X:\
M-.'>'XQJ5(>VK+[4UHG_ '8ZI>KN_,_FGB?Q/XDXBE*G3G["B_L0>K7]Z6C?
MFE:/D*[O(YDD<LS'+,QR2?6DHHK]#/S@**** "BBB@ HHHH **** "BBB@ K
MT_\ 94^,W[1?PI^)]A;_ +/'Q2U?PY?ZA=*+C[%,6MW106>2> AHYD1 SD,K
M8"G%>85[_P#LB?#[[#I%Y\2M3M<2WN;32BZ](E/[Z49'=@J!E/\ !*IZURXV
MG1KX:5*K%2C+2S2:?JGH^YUX&K7H8F-6E)QE'6\6TUZ-:KL?J9^S]_P5&\.Z
MS+%X9^/>DG3)B=D6OV2%X7[ S1J,H?5D!4D_=05]9:#K^A>*=(@U_P -:Q:Z
MA8W2;[>\LYUDCD7U5E)!K\9J[CX*?M%_%KX ZT-5^'7BB6"!Y UWI<Y,EK=>
MSQDXSCC<N&'8BOQ?B7PFP&-3KY3+V4_Y'=P?H]7'\5Y(_;.&/%[,,$U0S>/M
M8?SJRFO5:*7X/S9^ME%>-_LP_MI?#3]H^R324E71_$T<>;G0[J49EP.7@8X\
MU>IQPRXY&,$^R5^!YCEF/RG%RPV,IN$UT?YKHUV:T9_066YG@,XP<<5@ZBG"
M6S7Y/JFNJ>J"BBBN$[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML*[PFK^:?5/S3T84445YIZ84444 %%%% !1110 4444 %%%% !1110 4444
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MOVD_C#+XY\>W%[+XXFUO5-%N+76S=WBWMP)81I:B/?<*'W1&-EY"E02#F_\
M!1[_ (-^?V2?^"IGQMM_CA^U'\</C USIVF)8:'H&@>);"WTS28!@N+>&2PD
M96D?+N[.S,<#.U$50"__ ,$:?V<_V1_V _A!!^RC\./VAO#/Q!^*OB:UN_&W
MQ0\1:)J45U)JEYYL$5Q<.8BP@MT>XCBA1RI<+(X4MYQ'U?\ "CX^? KX\>&;
MOQK\#OC3X2\9Z-I]Y)9W^K>%/$=KJ-K;7$8!DADEMY'1)%!!9200",CFOE3_
M ()V_P#!!#]AS_@F?:_$2S^!NJ>.=:3XG>'H]$\1GQAKEO.R62B8-' UM;0&
M/?YQW$EC\B8VX.<K]G/_ (-]OV2OV6/V,OB7^Q'\&_C9\6])\/\ Q8U-;CQ?
MX@M?$EDFKRVJIY?V".467E10-'N1]L7F.LCJS[3M !Y!J?B;]DO_ (*(?\%"
M='_X*0_M'?'OP+I'P0_9LMKZ'X,Z;K7BBTCD\1:PL@>^\2R1M)NCLHWMH5M5
M(W3FU2X&(R@D_4+0]9L?$6B6?B#3#(;:^M8[BW,T+1OL=0R[D8!E.",@@$="
M*_*/1_\ @S3_ ."3^D:O:ZLWQ!^-%T+6Y28VMWXLTUHIMK!MC@::"5.,$ @X
M)Y%?JUK^LV?AK0+WQ#?G;;Z?9R7$QSC"(A8_H#3C%RDDMV*4E%-O9'\\7[?W
MQ'?XL?MJ_$[QOYQDBF\8WEM:N3]ZWMW^S0G_ +]Q)7D%6=:U:\U[6+O7-0?=
M<7MS)/.WJ[L68_F35:O[QP.%C@L%2P\=H1C%?))?H?P'C\5+'8ZKB9;SE*3_
M .WFW^H4445U'(%%%% !1110 4444 ?6O_!&[]D2P_:D_:NM];\86 G\+^!(
MH]8U:&1,I=7 ?%K;-VPT@,A!X9('4_>K]TZ^,O\ @A9\#+'X6_L1V?Q"FL@F
MJ>/=5N-2NI&7#_9XI&M[=/\ =VQO(/\ KN?6OLVOY%\3,]J9UQ35@G^[HOV<
M5YKXG\Y7U[)=C^P_"_(*>2<*49M?O*Z523\I?"OE&VG=ON%%%%?GI^BA1110
M 4444 %%%% !1110!X]^W!\"(OCK\"]0L["U#ZUHBMJ.BL!\S.BG?"/^NB94
M#INV$]*_+ROVDK\H_P!KGX:P?";]HKQ1X/L+7R;,:A]JL(P,*L$ZB557V7?M
M_P" U^]>#F=SG"OE51Z1]^'DKVDOO<7\V?S_ .-&1PA.AFU-:R_=S\W:\']R
MDODD>;T445^Y'X.%%%% !1110 4444 %?5WP?_X*"?#?]BK]COP-XV^-NI06
M'A&[^,B>#=<U^]G*0Z%#>VL]S#=R'!"Q"Z\F-V8JJ)*[D_)@_*-?;'_!)^]T
MSQ#X-\>?#W7+*"[M/M-I/)9W42R1S)*DJ.&5@0P_=*"#ZBOSCQ5POUC@^I.W
M\.4)?CR_^W'Z5X38KZOQE3A?^)&<?PYO_;3\??\ @L9^Q-\#O'/[77B#]HK_
M ()J^,=-M_CC?_M,>'](^'7A/X:7ULT>JVTWA32-3DU:"*U_U7D7[RRRW8Q%
MFX<RMD*:^A_VGOA+XH_8I_X.W?A5^VW\;4^Q?#SXQ6<>GV/BZ4>7I]OJQ\,2
M:)]B>5L*DAFBMW"L1E+E2"<,!^Q'P@_96_9R^ /BGQ-XT^"OP8\/^&-3\8:A
M'>^(;G1[!8?M,R6T-LN%'RQ+Y=O%E(PJ%PTA4N[LW6>,/!/@SXA^'Y_"?C_P
MCIFN:5= ?:=,UBPCN;>7!R-T<BE6P>>17\M']7'XH_\ !,#P9J7@/_@NM^WA
M_P %)_#^BWMW\'/!>C>)+74-7\/P&>/6=2^U6E_<V]I@A;J9/L-TSA2=KR1@
MX\Q375?MD?M42_\ !R%_P08^+WC#]DGX&^*M(\1^!/&=K,GA+442YFU5K$P7
M4JVSP@B9S:3NPB4;_-C"8.]&;]B?#?A?PSX-T*V\+^$/#MCI6F6<?EVFG:;:
M)!! G7:D: *HY/ %1>$O!?@[P#HZ^'? OA/3-%T]97E6QTFPCMH0[L6=@D8"
M[F8DDXR2230!_.)^W'KGAS]M#_@VU_8L_9_^ %K#XF^*H^*=GX7LO!>F2++J
MR3VEAJ]K=QM #OC7?]CD9F "I+$Y(4@U_1'\!_!&N?#+X'>#/AOXFU07VI>'
MO"FG:;J%ZK%A<3P6T<4D@+<G<R$Y//-6M&^$7PG\.>,[WXC^'OAAX=L/$.I
MC4=>LM%@BO;H'J))U0.__ B:Z&@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K@_VI]6_L#]F+XCZ[OV_8O >L3[LXQLLIFSV]*[RO+OVX?\ DROXO_\
M9+O$'_IMGKNRR*GF5"+ZSC_Z4CAS23AEE>2Z0E_Z2S^<BBBBO[N/X%"BBB@
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M_P#MK[+E\S^@O!KBZG34LBQ4K7;E2;\]90_]N7=\WDC[2HHHK^?S^A@HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'PE_P7\^!?_"POV2],^,.G6>^]\!:\DD\@7)6QN]L$H_[_  M3
M]%-?C)7],/QJ^%7AWXY?"/Q)\'O%:_\ $O\ $FC7&GW#A<M$)$*B1?\ :0D,
M/=17\V_Q$\!^(_A=X^UKX;>+[/[/JN@:K<:?J,/99H9&C?'J,J<'N,&OZ6\&
M<Y6*R6KETW[U&5U_AGK^$D[^J/YA\:\E>%SNEF4%[M:-G_CAIKZQ<;>C,:BB
MBOV8_%0HHHH **** "BBB@ K;^'/Q&\;_"/QSIGQ)^&_B6YTC7-'NEN-.U&T
M?#Q../HRD$JRD%64E2""16)145*<*L'":NFK-/5-/=,NG4G2J*<&U).Z:T::
MV:?<_=/_ ()R_P#!57X6_MFZ%9^ ?&UW:^'OB3!;@7FC2-L@U0J/FFLV8_-D
M#<82=Z<XW*I>OK6OY?M,U/4M%U&#6-'U">TN[699;6ZMI3')#(IRKJRD%6!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5^.__!?7]E27X;?'G3OVFO#=@1H_CN(6^KF-,+!JD$87
M)QP/-A56 ZEHI2>M?L17D_[;?[,.B_M?_LU^(_@AJ4D4%W?6PGT.^E7(M-0B
M^>"0]PNX;&QR4=QWKZ_@;B%\-<1TL5)_NW[L_P##+=_]NNTOE8^.X[X<7$_#
M=7"Q7[R/OP_QQV7_ &\KQ^=S^<^BM#Q;X4\1>!/%.I>"?%^DS6&JZ1?2V>I6
M-PN'@GC<HZ,/4,"/PK/K^RXRC.*E%W3/XJE&4).,E9K=!1115$A1110 4444
M %%%% !1110  D'(.".AK[V_X(K_ !8^/6J_%OQ!IMU\7_$L_AO2/#/[O1;G
M69Y;2.XDGB$;K$[%%(1)1D 'GVKX)K]%_P#@B%X0^R?#_P =^/F0_P"GZS::
M>C$=/L\32$#_ ,"5S]!7R/'#H+ANM[2*=[)72>KDN_E<^PX$5=\34?9R<4KM
MV;6BBWT\['Z#)\5O'\:;%\0-C_:MXB?S*U%=?$GQS=KLE\1S@?\ 3(*A_-0*
MPZ*_GA8/")W5./W(_HUXW&-6=27WO_,FO+^_U&7S]0O9IW_OS2%C^9J&BBNA
M)15D<[;D[L****8@HHHH ^?_ -H_]E&/5_/\>_"W3U2[YDO]'B7"S]R\0[/Z
MIT;M@\-\T21O%(T4J%64D,K#!!]#7Z+UXW^T7^R[8?$6.;QEX&@BMM> +SV^
M0L=_]>RR>C=#T;KN'Z/POQ@Z'+A,?+W=HS?3REY>?3KIM^:\5<&*OS8S+X^]
MO*"Z^<?/NNO37?Y+HJ;4-/OM)OI=,U.SEM[B"0I-!,A5XV!P00>0:AK]434E
M='Y,TXNSW"BBBF(*N>'M!U;Q5KUEX9T&S:XO=1NX[:S@7K)*[!57\215.OJ[
M_@E[\ ;CQ1X\N/CIK]A_Q+=!#V^DF1>)KUUPS#U$<;'_ ($ZD<J:\7B'.:&0
M9/6QU3[*T7>3TBOF_P +OH>WPYDE?B'.J.!I?;>K[16LG\E^-EU/LSX)?"S2
M?@M\*]%^&FC[633+-4GF5<>?.?FEE_X$Y8^P(':NJHHK^,\1B*V+Q$ZU5WE)
MMM]VW=O[S^U\-AZ.$P\*%%6A!))=DE9+[@HHHK$V"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBOM3O\DG^K1^C^&F']IF]6L_LPM\Y-?HF>A4445^+G[:%%%% !1110 4444
M%%%% 'F?Q_\ V<="^+]BVL:5Y5CK\,>(;PKA+@#I'+CJ.P;J/<<5\@^)/#>N
M^$-;N/#OB73);.]M7V3P2CD'L0>A!'((R""""0:_0JN'^-GP+\+_ !FT7R;]
M1:ZI;H18:FB9:/OL8?Q(3V[9R,<Y^XX8XMJ98UAL4W*ET?6/^<?+IT[/X7BG
MA"GFB>*PB4:W5;*?^4O/KU[KX?HK9\>> ?%'PV\1S>&/%FG&WN8N48<I,F>)
M$;^)3CK[$'!! R(HI)I%AAC9W=@J(HR6)Z #O7[!3JTJU-5*<DXO5-;-'XS5
MI5:-5TZD6I)V:>Z9T/PE^&'B7XR?$32_AQX4@W7>IW(C\PKE8(QR\K?[*J"Q
M^F!R17ZQ_##X<^&OA)X!TOX=^$K;RK'2[411D@;I&ZO(V.K,Q9B?5C7B_P"P
M/^R4?@-X0;QYXVL@/%>N6RB6)QSIUL2&$'^^2 S^X"_PDGZ&K^9/$OBV.?YD
ML)A97H4GNMI3V<O-+:/S:T9_4?ACP?+A_+'C,5&U>LMGO&&ZCY-[R^2>J"BB
MBOS(_40HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/FM5U6ESX%HIT\$UM,]M<PM')&Q62-U(96!P00>AIM?KNY^.[!1110 4444
M?6?_  1M\(C7OVJ[SQ%-!E-#\*74\<A'W99)(80/J4DD_ &OU)KX(_X(?>$6
MCTWX@^/)H@1+/86%L^.A19I)!_X_%^5?>]?@?'>(]OQ)4C_(HQ_"_P";9_0/
M .']APU3EUFY2_&WY)!1117QY]F%%%% !1110 4444 %%%<I\?\ XU?#[]F/
MX#^*?VD_C'J[:9X0\'::;S6]2\DOL!98XXD ^_+)(\<:(.6>11WS43J0I0<I
MNR1=.G.K-1@KM]CK8HI)I%AAC9W8@*JC))] *]'\ _!_RFCUGQ;&"PPT5CU
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MU5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:1_X)O\ ['G[5$TVK?$_X0V<6M3 [O$6AL;*^+'^)WCP)C_UU5Q[5\*_'O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@ HHJ"WU72[N^N-,M=2MY;FTV?:[>.96>'>,KO4'*Y'(SU%
M$]%%-EEB@B:::141%+.[' 4#J2>PH =14=G>6>HV<6H:?=1SV\\:R03PR!DD
M1AE65AP00001UJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ,[QC_ ,BCJO\ V#9__1;5X)7O_B2TN-0\.ZA86D>^6>RE
MCB3(&YBA &3P.37D?_"I?B#_ -"__P"3<7_Q=?3Y!B*%&C-5)I:]6D?+<08?
M$5JT'3@Y:/9-_D<Y7O?@[_D4=*_[!L'_ *+6O)_^%2_$'_H7_P#R;B_^+KUS
MPW:7&G^';"PNX]DL%E%'*F0=K! ",C@\BC/\10K48*G-/7HTQ</X?$4:TW4@
MXZ=4UU\R[1117S!]4%%%% 'PK\3/$DO[77_!:MOV)?BQ +[X6_"SX'0^,[CP
M9=#=9>(]>OM1^S0S7T1^2[M[:!&\N"0,@GD\P@LB%?8?B[\+OV3/V%+KQ)_P
M44?PU;^$-+\!?"[7(O$^E^%M/CM[;4;5I;*\,WV:/;&]VIT\1(X =Q.$9B%0
M*?M(_L.>(?'?[3GA;]N7]FWXJ6G@;XK^&?#<_AF_NM7T)M2TGQ/H$LPN#IM_
M;I/!*!'.OG0SQ2JT;LQ995.RM;XD_LI^,_VK/@?XQ^"G[8GC[3K[2/&GA&]T
M"\T7P+I\UA;6L=S'M>YWW$LSSW"$!HG(1$YS$Q.Z@#DU_;P^*G@;XR_"KX4?
M';X%:+HL?QPTF]/P_P!3TCQ?+=Q6NLV]C]N_LG42UG'Y1D@$C)<Q>:I>)T\O
MA&D\R^"/_!73XS?$KP;\"OC5XU_9,T70/ ?QH^*%]X ^UVOQ#>]U/3-62YU.
M&WF6V^P1QSV;'3&5Y&FCE#2DB':@:3T[X>?L+?%J^UWX/:_^TQ\;-!\8W?P(
ML;L>"K[3?"<ME)J>I26#:='J>H*]W*"Z6LDV88MBM-,9 RA41>#\"_\ !);X
MC>"?V:?@5^SS'^U'HERWP3^-[_$--9/PWF4:P6N]2N?L)A_M0_9^=3E7SM\G
M$:'9UR =S\"?^"A6K?M(_&77OAA\)/"?@Z^F\*>.=?\ #7C#P]>>-9+;Q!X<
M.GF\CMK^\L3:$BTO9K:'RY49@D=W"P\XEUCYKP=_P54\3>*/V?OV>/CW<_LY
MV-K#\<OB[_P@>HZ8GCAY'\/3FXU*%;J-_L"B^3_B6N2K"W(\Q1DX-;Q_X)VZ
M_P",?VJ? '[4OQ=\;^%KWQ+\-?%FLZCHWC#P[X3DT_7=5TF\@O8+?0K^X-S(
MLUK;QW:9;!\UK2(A(=T@;SCPU_P26_:$\._#_P"%_P &(/VM_#7_  B?P:^/
M!\?^!HG^&\KWEQ:FXU.X^PZA)_:*K-(IU$Q)+"L "H6=)&8!0"7X@?\ !67]
MH/P+\*/BW\=)/V.M!N/#GP0^,S^#/',<7Q+<WEU9*=-7[;IR'3PD\H_M 2-#
M.]NH6,*LCLS%.UU[_@I?XJ^!/Q3^*W@+]K[X&6'A>R^'_P (!\3-(U#PGXJ;
M6'U'1Q<7%J]I,DEK;"&_$L"@1QM+$WGJ!*=NYL?Q_P#\$L/B=XY_9M_:$_9]
M/[4&A6K?'?XIR>,1K'_"MYG_ +#5_P"SP;3R?[4'VD[=.B EWQ<NY*'@#IOV
M@O\ @FFW[4?QP\;?$#XR?%NPN/"WC[]G^;X7ZWX7TOPK);W,:2W4ET=1AO'O
M9%1UDE)6(P,!M7+M@Y ,?5/^"C7[1/A+Q!XOTGQ7^Q%K+6.B?"?4/&FD>)8H
M];L]':YLOFN-$O+R^T>$6]RT>9(9421)0K@K&5RWI?["'[2/[0?[5?PLTWXV
M?%K]GS1? _AOQ5X-\/\ B#P3-IWC0ZI<WT=_9?:+B.YB^S1"U,+&,)AY/,24
M$[&5D'!?#G]B[]NR]^ GB;X%_M/?M[Z/XV2Z\#7_ (7\,ZO8_#5["5A<VYM_
M[2U95U!O[0N4B)"QQM;Q;F=W$CE&C]O_ &3?@IK7[-G[,7P^_9XU_P 9VOB*
MX\">#=-\/#7+/1VL$O8[*VCMDE\AIYS&S)&I(\QADG&!Q0!\4_"/4/AY\%O^
M"YO[3?B#3/V>=7UR\D^'7@.XM;CP=X5CNI+&:>/5%N9205,33B.(,PYD\KYL
M[:Y#]@#XU?!C]F/Q[^W;^U1J/P;GT>#0OC3IUGIFAC0([74@UUIVG16^G(B
MF+SKVX3"#*[IMY!)-?8_P?\ V-/'_P ,?V^/BO\ MHZE\:])U/3_ (H>'=!T
MA_",/@V2WFTR/2DN1"XO3?.)2YNY2X,"]% Q@Y\LN?\ @D1?>,?#'[3W@CXI
M?M%QWFF?M'^)[?Q"DOAOPC)IM[X5U&UBMEM)H9GOIQ<>5)9VTPRD>70\@$
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MYEO%4JV+PM2G#V<E><)15[QTNTE<^F****_FX_I<**** /A'_@OQX.^'>O\
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M(=1D)@>0NTBJWG(@\H@'M?\ P3V_Y,%^!_\ V1_PS_Z:K:O7ZXC]F?X2:I\
MOV=O OP*UGQ7;Z[<>#/".GZ&VLVNF-9)>BTMT@640--,8BRQ@E?,?DGFNWH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>jnj-20210404_g3.jpg
<TEXT>
begin 644 jnj-20210404_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYT4?ZF\-_P#/C_R:?_R0?ZZ\3?\ /_\ \EA_\B?1G_#?W_5)O_*]_P#:*/\
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MR$;DW([J0",ACFOL#P__ ,@&Q_Z\XO\ T 5I3Q-2685,.TK1C&2?7WG-:_\
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M*%>A!)-3DXOR]R4M/_ 3'"X6GB,/7FVTZ<5)=G[\8Z_^!'VI1117:<(4444
M%%%% !7Z,5^<]?HQ7YCXC_\ ,+_V_P#^V'ZEX:_\Q7_</_V\****_,3]2"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K\YZ_1BOSGK].\./^8K_MS_V\
M_+?$K_F%_P"XG_M@4445^G'Y:%%%% !1110!\A_M(?M)_LS?M#^"=1^!WQ6U
M3PY;7/A_XS:?HOC#PAXEOHD,EC%JRJMTT<VTM;S6X27S "BEF7<2A-0?\$?O
M %_\.?"/Q2T#P%JNI7?P>7XDW1^#DNI3/('T[://>U=\F2S,V1%("1)M=P27
M+'ZB\??"?X;_ !2CL8_B#X.LM5&F:C!?6)NH\F&>&021L",$@.H)4_*W0@CB
MNA "@*H  ' %>3#+JCQ\<35DFXJR:5FT[Z/7;K;JTGIL>O/,J2R^6%I1:4G=
MINZ35M5IOI:_1-K7<^?-' ^-/_!1G5=:<"72/@IX)CTNUW=!KNLE+BX88ZM%
M86]JO/07K>M>@_%+]J/X,?!KXM>!/@C\0/$<]IXB^(]W<VWA2UCT^:5+B2!4
M:0,Z*5C_ -8@!8C);T!([RUT[3[&6>:RL887N9?-N7BB"F5]H7<Q'WCA0,GG
M  [4EQING7=W!?W5A!+/:LQM9I(@SPEAM8J2,KD'!QU'%=<*%6E"7))<TI7;
M:OI?:UU]E**=^E[=#DGB*56<>>+Y8QLDG;6V][/>3<FK=;7ZGQ]_P7K\5^&-
M(_X)B?$/PUJOB*QMM1U9]'32[">[1)KQDUFQD<1(3N?:BLQV@X"DFOJ[X=>*
M/#7C/P/I?B3PAXAL=5T^YLHVM[[3KM)X91M RKH2I_ UM44H864<?/$\VDHQ
MC:VW*Y.][]>;MT">*C/+X8;EUC*4KWWYE%6M;IRKKU"BBBNPXPHHHH ****
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M%%%%?,'U(4444 %%%% !1110 4444 %?.?[?W_,I?]O_ /[;U]&5\Y_M_?\
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M^/7PK^!7P<U'X^_$SQ(]EX5TJRBN[S4H+">Y812.B1LL4*/(^YI$& IQNR<
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M:M^"R^,/%7A"XTW5-.N/L6H7:P%;2_D"Y,L#'_QY/X&.,D$5[?6=X2\)>&?
M?AFR\&^#=$M]-TO3;=8+&QM8]L<48Z #]23R223DFM&@ HHHH **** "BBB@
M K]&*_.>OT8K\Q\1_P#F%_[?_P#;#]2\-?\ F*_[A_\ MX4445^8GZD%%%%
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M]?3\&_\ )24/^WO_ $B1\MQK_P DS7_[=_\ 2XGSG1117[J?@@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7Z,5^<]?HQ7YCXC_P#,+_V__P"V
M'ZEX:_\ ,5_W#_\ ;PHHHK\Q/U(**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OSGK]&*_.>OT[PX_P"8K_MS_P!O/RWQ*_YA?^XG_M@4445^G'Y:%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!]&?L _P#,V_\ ;A_[<5]&
M5\Y_L _\S;_VX?\ MQ7T97X5QE_R4E?_ +=_](B?O?!7_),T/^WO_2Y!1117
MS!]2%%%% !1110 4444 %%%% !7SG^W]_P RE_V__P#MO7T97SG^W]_S*7_;
M_P#^V]?3\&_\E)0_[>_](D?+<:_\DS7_ .W?_2XGSG1117[J?@@4444 %?.G
M[4,W_!1O5+;7O%G[,&O^ ?#.F^'()7TO1_%.D2WUYXD>)"SEY4E6.SB8@I&H
M#NV [M&&VI]%UY1^V7\(/CW\<_@;K/PT_9^^.%EX$U35+":WEU2ZT'[8TR.N
MTPJYD'V<."RM($=U#94 CGCQU.53#2Y>:Z6T79OT=U^?KV.W 5(4\5'FY;-K
M62NDNNEG^7I;</V&OVB]7_:T_9-\$?M$:_X3&AWWB;23->Z:A8QQRI+)"[1[
MOF\MVC+IDD['7)/4^1?M>_MZ>/?AE^U/\)OV?_@UHUK<:9KGQ,T[0/B!XANH
MA)';O<1^:NFP<\S^25FD;_EDLD Y,IV\5\!_V_\ XD^%?^":DWCOQW\,8=+\
M;^#/%DWP[N;/PWX=EGL;*]MI5MQ>?9+568001'>T40PS0E$V!UV^#?M0?MB?
MLGZ;K?[-/A_X9MX[N+;P7\9;?7/$VI:[X#U."\U.1P[W-XWF0*;FYFF=Y&6,
M%B6.U0  /GL7G$8Y;22K6E:#;>C=VD].E]6^RTZW7T6#R:4LSJMT;PYII)7D
ME9-K7K;1+N]>EG^L5?.'_!4W]ISX]_L?_LC>(OC[\#O#WAFZET3[(MY<^()Y
MG: 7%W%:JT5O&H65@\Z-EI5 P<JW2O>_ _C#1_B%X*T?Q]X=%R-/US2[?4+$
M7EH\$WDS1K(F^*0!XVVL,HP#*<@@$5\M?\%VO^45/Q3_ .X'_P"GS3Z]O-JL
MX917JTI6:A)IKRBVCP\HI0GG%"E5C=.<4T_.23/;/VH_VAXOV9?V4_%?[1VH
M:/\ VC)X:\--?Q6 ?8MS<%0L4989VJTC("0#@$G!Q7EOPE_:;^-7AK]I[X??
ML_\ QMUW2]<C^)WPND\26-[IND_9&TS5+?8]S:J [;[5HI08RY,BM&0SOO&W
MV_XA_"7P5\>/@9J?P:^(VGM=:'XF\/-I^IPQR;'\J2+:61OX77AE;LP![5X;
MK?P/B_9K\3>'?C[XS\93_$+QWHGA*'P!\)="%@MB+F:4[MTN'D+W$BQ!KBY7
M9'';P2N(E ;..,6-C7C5C*T%RWU\_>NNMXV4=]>QK@G@I8>5*<;S?-;3NO=L
M^EI7<KM:=SUOQ;\3?%.N_''2?@E\+IH%;3$BU?Q_JLD(D73[!MXM[)0>/M-T
MZ,1U\N"&5SAGA+>CU\P>'_B'XN^"GQGT_P#8P^%6FZ5XH^)VN^$;WXA_$3Q7
MXAN)+:UN',\=H"%B5FS+-M@B3.VVM[=!B0(%/J_[(W[2OA?]KS]G?PU^T)X2
MTF?3K;7[:3S],NI \EE<PS/!/ S  -LEB=0V!N4!L#.*Z,+BZ=2K*G*7OZNW
M16M=+H[77-YO[L,7A*E.C&I&/N*ROU=[V;ZJ_*^6_1?-^D4445Z!YP4444 %
M?HQ7YSU^C%?F/B/_ ,PO_;__ +8?J7AK_P Q7_</_P!O"BBBOS$_4@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *_.>OT8K\YZ_3O#C_ )BO^W/_ &\_
M+?$K_F%_[B?^V!1117Z<?EH4444 <U\6?!/B'XC>#9O!>@>/=0\-+?RK'J.K
M:,P2^CM>LB6TIR()7P$\W!9%9BF'"LOR9\,/V:?'/[+W_!2_PWX7_9S^)WC/
M4_AYK?@;4-0^*'AWQ/XFN=4M]-E#%+"X22Y9F2:>?<%&2Y6WN"#MR!]L$!@5
M.>1V-?"7[1'[*>G?LT_\%!_@I^T=^S!KFN6&O?$;QV^@_$70IM>NKV/6]-^R
M2SS74BW$CMB".%B>=JL8F 5AEO%S:DHNE74+N,XW:=I)<R6BV=[VDM+KSL>W
ME%5R57#N=E*$[)J\6^5O5[JUKQ>MG;I<];_X*UR>.='_ &"?B)XW^'WQ8\2>
M%-1T+0'NH;CPW>);O.1)&-CR;#*J[=R_NW0_.<D\8]<_9JNKJ^_9R\ 7M[<R
M333>"=*>::5RS.QLXB6)/))/))KRO_@K;_RC;^,'_8H2?^C(Z]1_9?\ ^3:?
MAW_V(ND?^D<5:PTSN?\ U[C_ .E2,IV>1PT_Y>2_])B/_:(^'/C?XO?"75/A
MAX#^(MWX1N=="6EYXETR1EO;"T9QY[6I'W9VC#1HY(\LR>9\Q0(WQ'^UA_P3
MVE^#6@>#?#OPT_;O_:3O/%GCGQ[I?AW1(]5^+<TL*))(9KVYDCBB1F6*R@N9
M/E( 8)]#^A>GZEIVKVBW^E7\%U S,%FMY0Z$J2K $$C@@@^A!%> B)/C7_P4
MA,[ RZ3\#_ ^U,\!=?UOD_5HM/MQ]!?^_.>:8+#8J,>97E)J*=WHMVUK:ZCS
M._DC3*L;B<+*7*[1@G)JRU>R3TO9RY5;S9Y=\9+O5?BW^VE\8?@_\1]?U6Q\
M-> O@-;ZAX-MK?5I[80W-SYYFU=61P6N(FA6-)B28]C;2I=]W>_LP_M6^.[C
M_@G+\,OC?\2-+FUOQUXI\/6=EI&E;O+G\0:M(&2WYQA!*L?VB23&V.(2RD;$
M->O_ !=_9^^!WQ:D/B'XK>$+:Y>WTBXL+J_-[-:-)ITF&GM)Y(70S6K;0SPR
M%HCC)4UXS?>,Y-*^$GC/]OJV\'1'0O 7P^U23X,^%OLWE0QZ9;VC2'4#&N/+
M-YY,:QX ,=FD>-AFF6LG0KX/$SJ<^ZD_E=.[7]Q>['>]ULC:->AC,-"FH?"X
M^E[-63_OOWI;6L]W8]Q^!_PVU?X8^!$TKQ7XHDUSQ!J%U+J/B767W!;N_F(:
M4Q(Q/E0KA8XHQ]R*.->2"3U]?$OP6_:*^.7@GXB_LJ#QE\4-0\60?M#^"-0O
M?%]K?QPF*RU!-+M]3AN+)8D7R8U\UX#&#L,85R-X+-]M5Z& Q-'$4FJ::Y;*
MSWUBI+O?22OYW/.S#"UL-63J-/FN[K;23B^UM8NWE8****[C@"BBB@#Z,_8!
M_P"9M_[</_;BOHROG/\ 8!_YFW_MP_\ ;BOHROPKC+_DI*__ &[_ .D1/WO@
MK_DF:'_;W_I<@HHHKY@^I"BBB@ HHHH **** "BBB@ KYS_;^_YE+_M__P#;
M>OHROG/]O[_F4O\ M_\ _;>OI^#?^2DH?]O?^D2/EN-?^29K_P#;O_I<3YSH
MHHK]U/P0**** "O$;?X;?M[:?\2?$L]M^U#X(N_".KW\L^@V^J_#B1]0T*%B
M=MO&\%Y#'.$!P))@Q) 8@C*GVZBL:M"-:UVU;LVOOLU?YFU&O*C>R3OW2?W7
M3M\CC_@5\$_!W[/OPXM?AOX+:YFACN;B\O\ 4;^0/=:E?7$S3W-W.R@!I997
M=VP HSM4*H51QO[4G[)O_#2OCKX4>-/^$_\ [%_X5A\0+?Q/]F_LK[3_ &GY
M2E?L^[S4\G.?OX?']TU[%14SPN'J4%1<?=5M-MFFMO0J&+Q%/$.O&7ON^N^Z
M:>_J>;?%KX:?'CQ=\9/A[XT^&OQ[_P"$9\+>';R[D\:^%_[%CN/^$BBDC00Q
M^:QS#L(?D?\ /3/517.?M_?LG>)_VW/V;]:_9LTKXJ6/A+3O$+VIU349_#3Z
MC-MM[N&Z01 74"IEX%!+;L@G&.M>V44JN#H5Z=2G4NXU/B5WM:UEKHK=K=7N
MRJ6,KT*M.I3LI4_A=EO>]WIJ[][]%T,OP5IGB71O"UEI7B_6['4=0M[=8[B]
MT[37M(92!C*Q/-,R?0R-7+:3\)]:U+X[:A\:/B!J5K=C3K+^S? NF6^YH],M
M9%1KJY?<!FZGD 0D9"0P1JIR\N[O:*U=*$E%/9?IM?O_ )Z[F,:LXN3773[]
M[=NVG338\,^+?[-'Q"7]J>P_;'^ ^J:'_P )0OP^NO!VKZ1XFEFBL[JS>Y6[
MM[A9(4D9989U)*%")4<IOB(#5T/[%W[,6D?L=_LU>&?V?-*\0RZPVB0S27^K
MS0B-KV[GGDN)Y=@)V*997VKD[5"C)QD^I45C#!8>GB'6BO>=_P ;7^_E5_3S
M=]ZF-Q%7#JA)^ZK?^2WM?TYG;U]+%%%%=1R!1110 5^C%?G/7Z,5^8^(_P#S
M"_\ ;_\ [8?J7AK_ ,Q7_</_ -O"BBBOS$_4@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *_.>OT8K\YZ_3O#C_F*_[<_P#;S\M\2O\ F%_[B?\ M@44
M45^G'Y:%%%% ' _M&_LT_"C]JGP##\.?B]I^H36%KJD.I6,VE:Q<6-Q:W<08
M1S1RP.K!@'?@DCG.,@$'PL_9L^&?PFU6/Q-I;:YK6N1V!L8_$/B_Q+>:Q?QV
MQ*LT4<UW+(849D1F6/:'**6!(!KOJ*Q>&P[K>U<%S=[:Z;&ZQ.(5'V2F^7M?
M37?[SC?CK\ ?A;^TI\/[OX6?&31K[4O#^H)LO]-M->O;!+E-RMLD-I-$SKE0
M=K$CVY-:?P]^&7A#X6^!++X:>#K>^CT;3K-;6RMM0UBZO7B@5 BQB6YDDD*A
M0  6XQ6_15>QH^U=3E7-:U[:V[7WL1[:M[)4N9\J=[7TOWMM<\__ &:/V8_@
M[^R+\+(/@U\"_#T^F:!;WL]W';7%_+<OYLS[G)>5F;T &>@'?).S\.OA#X)^
M%NI>)]9\)V4RW?C#Q')K>O7-S<-*\]V\,4.06^ZBQ01(J#A0O'4UT]%*%"A3
MC&,(I*.R2VZ:=M"IXBO5E*4Y-N6[;WZZ]]3G?BI\,O#WQA\$77P[\77%V-(U
M%XAJMK:3B/[=;K(KO:RG!)AE"F.11@O&[+D!C6QJ6B:/K&BW'AO5=+M[C3[J
MU>VN;*:(-%+"RE6C93P5*D@CI@XJU15\D.9RMJ]/E_3,^>?*HWT6OS_I(\=^
M$O[#WP7^#_C#P[XQTBYUS5)/!.B7&C^ ++7=2%Q!X8L)ROFP6@V!SN5$C\R9
MI91&BQAP@VU[%1144:%'#QY:<4EY?=^22]$D76KUL1+FJ2;?G]_YMOU;>X44
M45J9!1110!]&?L _\S;_ -N'_MQ7T97SG^P#_P S;_VX?^W%?1E?A7&7_)25
M_P#MW_TB)^]\%?\ ),T/^WO_ $N04445\P?4A1110 4444 %%%% !1110 5\
MY_M_?\RE_P!O_P#[;U]&5\Y_M_?\RE_V_P#_ +;U]/P;_P E)0_[>_\ 2)'R
MW&O_ "3-?_MW_P!+B?.=%%%?NI^"!1110 4444 %%%% !1110 4444 %%%%
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M.>OT[PX_YBO^W/\ V\_+?$K_ )A?^XG_ +8%%%%?IQ^6A1110 4444 %%%%
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M:_\ ,5_W#_\ ;PHHHK\Q/U(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M\YZ_1BOSGK].\./^8K_MS_V\_+?$K_F%_P"XG_M@4445^G'Y:%%%% !1110
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M4 %%%% !1110 4444 %%%% !1110 4444 ?1G[ /_,V_]N'_ +<5]&5\Y_L
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MW%?1E?.?[ /_ #-O_;A_[<5]&5^%<9?\E)7_ .W?_2(G[WP5_P DS0_[>_\
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M=\*_^$];?_$4 >6?\/2/^"?/_1UGA7_P(D_^(H_X>D?\$^?^CK/"O_@1)_\
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M6>%?_ B3_P"(KU/_ (49\$O^B.^%?_">MO\ XBC_ (49\$O^B.^%?_">MO\
MXB@#RS_AZ1_P3Y_Z.L\*_P#@1)_\11_P](_X)\_]'6>%?_ B3_XBO4_^%&?!
M+_HCOA7_ ,)ZV_\ B*/^%&?!+_HCOA7_ ,)ZV_\ B* /+/\ AZ1_P3Y_Z.L\
M*_\ @1)_\11_P](_X)\_]'6>%?\ P(D_^(KU/_A1GP2_Z([X5_\ ">MO_B*/
M^%&?!+_HCOA7_P )ZV_^(H \L_X>D?\ !/G_ *.L\*_^!$G_ ,11_P /2/\
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M_P#%5^DO_"C/@E_T1WPK_P"$];?_ !%'_"C/@E_T1WPK_P"$];?_ !%?6?\
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MI+_PHSX)?]$=\*_^$];?_$4?\*,^"7_1'?"O_A/6W_Q%'_$0<Z_Y]T_NE_\
M)A_Q#K)/^?E3[X__ "!^;7_#2O[/7_1;?"O_ (/8/_BJ/^&E?V>O^BV^%?\
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M&/#G@OXB_MN^$_"&A6FEZ7IW[8_B>#3].L+=88+:)5A"QQHH"HBC@*
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M#HGA_2;:PLK==MO:6<"Q11+G.%10 HR>PJS110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>jnj-20210404_g4.jpg
<TEXT>
begin 644 jnj-20210404_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]4CV\DXHP&?5I4L/&2<5=\R2ZVZ29OT445\Z?1A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?)/[<'_ "6.#_L!P?\
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M_P#_ ,EA_P#(GT9_PW]_U2;_ ,KW_P!HH_X;^_ZI-_Y7O_M%?.=%'^IO#?\
MSX_\FG_\D'^NO$W_ #__ /)8?_(GT9_PW]_U2;_RO?\ VBC_ (;^_P"J3?\
ME>_^T5\YT4?ZF\-_\^/_ ":?_P D'^NO$W_/_P#\EA_\B?1G_#?W_5)O_*]_
M]HH_X;^_ZI-_Y7O_ +17SG11_J;PW_SX_P#)I_\ R0?ZZ\3?\_\ _P EA_\
M(GT9_P -_?\ 5)O_ "O?_:*/^&_O^J3?^5[_ .T5\YT4?ZF\-_\ /C_R:?\
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M<?![PE<>/?BOX\TCPUHEJ\:7.KZYJ$=K;1,[!$#22$*"S$ #/)-9/PB_:,^
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M@_[ <'_HR6O':_H'AO\ Y$.'_P */YXXF_Y'^)_Q,****]L\(**** "BBB@
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MGA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?=WP-_Y(YX8_[
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M,*_^!?FCJJ***_)3]?"BBB@ HHHH **** "BBB@#E?CE_P D<\3_ /8#N?\
MT6:^$:^[OCE_R1SQ/_V [G_T6:^$:_6O#S_D7UO\2_)'Y#XC_P#(PH?X7^84
M445^A'YR%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[%^P_P#\
MECG_ .P'/_Z,BKQVO8OV'_\ DL<__8#G_P#1D5>)Q+_R(<1_A9[G#/\ R/\
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M[^'7[0%KI^BMJ^H,?#&HV_R00[CA+.9F[] LIQN)P<9%?*W_  49O/VEKO\
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M8X/^P'!_Z,EKQVO8OVX/^2QP?]@.#_T9+7CM?T#PW_R(</\ X4?SQQ-_R/\
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MLOS;=H# DC!QY!^V-IOP-_;L\=_!$_LV^+] \6^+?#'Q0TGQ"_B?PK?17?\
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M]/KYH\?_ /!(#_@GM\4O'&J_$GX@_!+4]5UW6[QKK5=2NOB%KQDN)3W.+X
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MCGB?_L!W/_HLU\(U^M>'G_(OK?XE^2/R'Q'_ .1A0_PO\PHHHK]"/SD****
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7L7[#__ "6.?_L!S_\
MHR*O':]B_8?_ .2QS_\ 8#G_ /1D5>)Q+_R(<1_A9[G#/_(_PW^-'UM1117\
M_']$!1110 4444 %%%% !1110 4444 %%%% !1110!\D_MP?\EC@_P"P'!_Z
M,EKQVO8OVX/^2QP?]@.#_P!&2UX[7] \-_\ (AP_^%'\\<3?\C_$_P")A111
M7MGA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?=WP-_Y(YX8_
M[ =M_P"BQ7PC7W=\#?\ DCGAC_L!VW_HL5^>^(G^X4?\3_(_1?#C_D85_P#
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M* "ON[X&_P#)'/#'_8#MO_18KX1K[N^!O_)'/#'_ & [;_T6*_/?$3_<*/\
MB?Y'Z+X<?\C"O_@7YHZJBBBOR4_7PHHHH **** "BBB@ HHHH Y7XY?\D<\3
M_P#8#N?_ $6:^$:^[OCE_P D<\3_ /8#N?\ T6:^$:_6O#S_ )%];_$OR1^0
M^(__ ",*'^%_F%%%%?H1^<A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>Q?L/_ /)8Y_\ L!S_ /HR*O':]B_8?_Y+'/\ ]@.?_P!&15XG$O\
MR(<1_A9[G#/_ "/\-_C1];4445_/Q_1 4444 %%%% !1110 4444 <3\;?VD
M/@9^SAI=CK?QR^)>F^&;34KAH+&?4G95FD5=Q5< \@<UYS_P](_X)\_]'6>%
M?_ B3_XBO:O$G@SP?XR@BMO%_A33=5CA<M#'J5C'.L;$8)4.#@X[BLC_ (49
M\$O^B.^%?_">MO\ XB@#RS_AZ1_P3Y_Z.L\*_P#@1)_\11_P](_X)\_]'6>%
M?_ B3_XBO4_^%&?!+_HCOA7_ ,)ZV_\ B*/^%&?!+_HCOA7_ ,)ZV_\ B* /
M+/\ AZ1_P3Y_Z.L\*_\ @1)_\11_P](_X)\_]'6>%?\ P(D_^(KU/_A1GP2_
MZ([X5_\ ">MO_B*/^%&?!+_HCOA7_P )ZV_^(H ^(_VJ/VT_V3?B1\2H?$'@
MO]H/PK>VBZ5%"TW]JI'AP\A(Q(5/1ASC'->;?\-*_L]?]%M\*_\ @]@_^*K]
M)?\ A1GP2_Z([X5_\)ZV_P#B*/\ A1GP2_Z([X5_\)ZV_P#B*^PP7&V:X#"0
MP].$'&"LKJ5_G[R/C,=P-E.88R>)J3FI3=W9QM\KQ?YGYM?\-*_L]?\ 1;?"
MO_@]@_\ BJ/^&E?V>O\ HMOA7_P>P?\ Q5?I+_PHSX)?]$=\*_\ A/6W_P 1
M1_PHSX)?]$=\*_\ A/6W_P 177_Q$'.O^?=/[I?_ "9R?\0ZR3_GY4^^/_R!
M^;7_  TK^SU_T6WPK_X/8/\ XJC_ (:5_9Z_Z+;X5_\ ![!_\57Z2_\ "C/@
ME_T1WPK_ .$];?\ Q%'_  HSX)?]$=\*_P#A/6W_ ,11_P 1!SK_ )]T_NE_
M\F'_ !#K)/\ GY4^^/\ \@?FU_PTK^SU_P!%M\*_^#V#_P"*H_X:5_9Z_P"B
MV^%?_![!_P#%5^DO_"C/@E_T1WPK_P"$];?_ !%'_"C/@E_T1WPK_P"$];?_
M !%'_$0<Z_Y]T_NE_P#)A_Q#K)/^?E3[X_\ R!^;7_#2O[/7_1;?"O\ X/8/
M_BJ/^&E?V>O^BV^%?_![!_\ %5^DO_"C/@E_T1WPK_X3UM_\11_PHSX)?]$=
M\*_^$];?_$4?\1!SK_GW3^Z7_P F'_$.LD_Y^5/OC_\ ('YM?\-*_L]?]%M\
M*_\ @]@_^*H_X:5_9Z_Z+;X5_P#![!_\57Z2_P#"C/@E_P!$=\*_^$];?_$4
M?\*,^"7_ $1WPK_X3UM_\11_Q$'.O^?=/[I?_)A_Q#K)/^?E3[X__('YM?\
M#2O[/7_1;?"O_@]@_P#BJ/\ AI7]GK_HMOA7_P 'L'_Q5?I+_P *,^"7_1'?
M"O\ X3UM_P#$4?\ "C/@E_T1WPK_ .$];?\ Q%'_ !$'.O\ GW3^Z7_R8?\
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M?]%M\*_^#V#_ .*KZR^%7_!2W]@WPW\-="\/ZU^U'X5AN[+2H(;F'[6S;'5
M",JI!Y[@D5[G_P *,^"7_1'?"O\ X3UM_P#$4?\ "C/@E_T1WPK_ .$];?\
MQ%>-G/$N/SRC&G7C%*+NN5->75L]O).%\!D-:57#RDW)6?,T^M^D4>6?\/2/
M^"?/_1UGA7_P(D_^(H_X>D?\$^?^CK/"O_@1)_\ $5ZG_P *,^"7_1'?"O\
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M4\-M#]K9=[LA &64 <]R0*^3?^&E?V>O^BV^%?\ P>P?_%5^DO\ PHSX)?\
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MSX)?]$=\*_\ A/6W_P 11_PHSX)?]$=\*_\ A/6W_P 11_Q$'.O^?=/[I?\
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M^'_%9\*ZP=*\1/X>U2.[33[X1I(UM(\1*B55=2R9RN<'!R*Z^@ HKPKXT_\
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M-_#/Q:LM8TC2[*<QK!IFO--=ZEI$1&##:RF!XRB;<+>3%=I.:ZK]BK2/"O\
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M-OO&6H:!%<^/O#FGZ5JA)%S9Z7JSWUNI]4F>&%G'UC4^U:E% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>jnj-20210404_g5.jpg
<TEXT>
begin 644 jnj-20210404_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!_KKPS_S_P#_ "6?_P B?1E%?.?_  W]_P!4F_\ *]_]HH_X;^_ZI-_Y7O\
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MS^6"=GXZ?M0?L\_LRZ99ZO\ '[XQ:!X3AU&5H]/&L7ZQO=,N-WEI]YPN5W$
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M44 %%%% !1110 5\M_MX_P#(_P"B_P#8'/\ Z->OJ2OEO]O'_D?]%_[ Y_\
M1KU]=P/_ ,E!#TE^1\?QU_R3M3UC^9X71117[<?A84444 %?.'_!5;X0_&KX
MR?LA7^C_  %T:/6==T7Q!IFNMX9F;Y-=M[*Y6=[(J>'W;%;8?OF,*.2*^CZ\
M\_:+_:.\%_LR:-X=\8_$F5;3P_JWBF#1]6UN:0K#I"S03M'<S':0L7G1Q1,S
M%503;BV%P>3'PHU<'4A5ERQ:LWVOI?\ K3OH=F7U*U+&TYT8\TDTTN]M;?\
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M#>3XY_LVZK^S]X TKP]\1X_C#8FUO?#VGQVDG_"/VL,D^HM,(E4/!&B0C#9
M,P0<2D'[?KX)^$W_  5@_P"">+>*[OXT^,_V@(O$GQ+\06J:=I7AW0/#6J3'
M3K9I 8='L6EM8U=GE*&69RGG2X9MD<<21_>D+R/"CRQ;&*@LA.=I],CK595/
M UJM:MAYQ?,TVHM.UE97MU=F_2RZ$9M#'4:5&CB(27*FDY)J]W=VOT5TO6[Z
MCJ***]D\4**** "OT ^'G_(@:'_V![;_ -%+7Y_U^@'P\_Y$#0_^P/;?^BEK
M\X\1?]VP_K+\D?I?AO\ [SB/2/YLV****_*C]9"BBB@ HHHH **** "BBB@
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M_E>_^T4?\-_?]4F_\KW_ -HH_P!3>)/^?'_DT/\ Y(/]=>&?^?\ _P"2S_\
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M7_8''_HU*^?XJ_Y)[$>B_-'T7"?_ "46']7^3/J2BBBOP,_H(**** "BBB@
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M]^./PXT?XM_"GQ1;ZSX>UZS6ZTO4K;.V:,D@Y# ,K!@59& 964J0""*^0/\
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M=?\ ).U/6/YGA=%%%?MQ^%A1110 4444 %%%% !1110 4444 %%%% !1110
M5^@'P\_Y$#0_^P/;?^BEK\_Z_0#X>?\ (@:'_P!@>V_]%+7YQXB_[MA_67Y(
M_2_#?_><1Z1_-FQ1117Y4?K(4444 %%%% !1110 5C_$/_D0-<_[ ]S_ .BF
MK8K'^(?_ "(&N?\ 8'N?_135OA?]YAZK\S#%?[M/T?Y'Y_T445_2I_,04444
M %%%% '.M\)OALWQ'B^+O_"&V(\20:?+8QZNL6)1!(Z.ZG'!):-?F(W  @$
MD'HJ**F,8QO96N5*<I6YG>P5!#ING6][/J=O801W-RJ"XN$B >4+D*&8#+8R
M<9Z9-3T51-V5+O0-"U#4;?6+_1;2>[M,_9;J:V5I(<]=C$97\*MT44K)#;;"
MBBBF(**** "O=/V#O^1_UK_L#C_T:E>%U[I^P=_R/^M?]@<?^C4KY_BK_DGL
M1Z+\T?1<)_\ )18?U?Y,^I****_ S^@@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OEO\ ;Q_Y'_1?^P.?_1KU]25\M_MX_P#(_P"B_P#8'/\
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M !#_ .1 US_L#W/_ **:M\+_ +S#U7YF&*_W:?H_R/S_ ****_I4_F(****
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MNRUVZ\467A^QAU.^B2.]U&*T19[A$^XKR ;G"Y. 20,\56T_P%X-TKQCJ/Q
MT[P[;0ZUJUO#!J6I(G[VXCB!$:L>X7)Q6O10!S^D?"WP)H7Q#U?XK:7H7E:_
MKUK;VVJZ@;J5O.B@!$2A&8HF 3]U1GOFC1_AQHNB?$/6/B5:ZCJ3WVMVMO!=
M6T]\SVT2P@A3%$>(V.?F(ZXKH** .?T?P'/I'Q"UGQZ_C?7+M-7MK>%-#N[T
M-86'E*07@BVC8SYRY).2.U?=_P %OAYX^T3Q/=_$36/C'J&I^'];\-:1#H_@
MR?3XDM]$EAMPLTL4R_/(9B0S!N%(XZU\85^@'P\_Y$#0_P#L#VW_ **6OSKQ
M#G*&%H)=7);>C^6VZ]#](\.81GBJ[?11>[_O+Y[[/3J8OA?PM\9=.^,OBGQ3
MXI^*=GJ/@S4;.Q3PKX5BT-(9M(FC0BYD>Y!W3B5L,%8#9R!2^%K3X\Q?&/Q5
M=^,M6\,2> I;2Q'@RTT^WG&J0SB,_;#=NW[ID+[3&$Y SNKL:*_+75;O=+5)
M;+I;7UTU>[UON?JZHI6LWHV]WUOIKTUT6RTML<=X5U+XZ7'QC\5Z;XQ\->'[
M?P+;VMB?!NIV-[(^H7DS1DW:W,;#9&J. $*YW Y/2D\*>,/B_JOQC\6>#_%/
MP<CTKP?I-M8/X5\8CQ##.VNRRQLUS&;11YEMY#@+N<_O-V5& :[*BAU(N_NK
M5)==+6UWW=M;W6KTVL*G)6]Y[M]-;WTVV5]+6>BUWOQOA/XE>,?$/QB\6_#;
M5?@_J^DZ/X=M["32O%]W-&;376N(B\B6ZJ=RF%AL?=CDC&0:7PE\8H_%GQA\
M7?!\?#+QAIK>$8+"4^)=6T3R=(U@7432;;"YWG[2T6W9*-J['('-=C10YTW?
MW>B6[WTN_GKIMKIL"A45O>ZM[+;6R^6FN^FNYQWA'XY^"?&WQ@\7_!#1H-47
M6_!$.GRZT]UI<L5JRWD32P^3,PV3?*I#!2=I&#BG^$_CM\)_'/Q8\6_ [PKX
MOCN_%7@6.PD\5Z0MM,K:>M[$9K4EV0(^^-2PV,V,<X/%==4<=I:Q7$EW%;1K
M+,%$LJH S@=,GJ<9./3-#E1=_=>RMKUTNWIL]=-+76KMJ*-96O);N^G36R6N
MC6EWK>ST5],/0?BK\-_%'CW7_A;X=\;:;>^(_"R6K^(]$M[I6N=.6YC,EN94
M'*"1 64GJ ?2JOC+QCX1UC0O%WA#2?%6FW6K:/HLAU?2[>^C>XL1+ [1&:-2
M6BWJ"R[@-P&1FMC3?!WA'1O$.I^+M'\+:;::MK0@&LZI;6,<=Q?B%2D/G2*
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M_P B!H?_ &![;_T4M?G'B+_NV']9?DC]+\-_]YQ'I'\V;%%%%?E1^LA1110
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M^/E7-ZVU_$\S&?5UBZGU?^'S/E_PWT_ ****Z#F"OT ^'G_(@:'_ -@>V_\
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MI'\V;%%%%?E1^LA1110 4444 %%%% !6/\0_^1 US_L#W/\ Z*:MBL?XA_\
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MU;X7_>8>J_,PQ7^[3]'^1^?]%%%?TJ?S$%%%% !1110 4444 %%%% !1110
M4444 %%%% !7NG[!W_(_ZU_V!Q_Z-2O"Z]T_8._Y'_6O^P./_1J5\_Q5_P D
M]B/1?FCZ+A/_ )*+#^K_ "9]24445^!G]!!1110 4444 %%%% !1110 4444
M %%%% !17A6K?\%-/V"=#U2YT35_VHO#%O=V=P\%U!)/)NCD1BK*?DZ@@C\*
M@_X>D?\ !/G_ *.L\*_^!$G_ ,10![Y17@?_  ](_P""?/\ T=9X5_\  B3_
M .(H_P"'I'_!/G_HZSPK_P"!$G_Q% 'OE?+?[>/_ "/^B_\ 8'/_ *->NH_X
M>D?\$^?^CK/"O_@1)_\ $5X)^UI^V_\ LB_$WQ?IFJ>!_P!H?PK?06^FF*:3
M^U$BVOYC'&)-I/!'2OJ.#L1A\+GD*E::C&TM6TEMW9\KQGA\1BLAG3HP<I7C
MHDV]^R.>HKB?^&E?V>O^BV^%?_![!_\ %4?\-*_L]?\ 1;?"O_@]@_\ BJ_8
M?[;R7_H)I_\ @<?\S\9_L/._^@6I_P" 2_R.VHKB?^&E?V>O^BV^%?\ P>P?
M_%4?\-*_L]?]%M\*_P#@]@_^*H_MO)?^@FG_ .!Q_P P_L/._P#H%J?^ 2_R
M.VHKB?\ AI7]GK_HMOA7_P 'L'_Q5'_#2O[/7_1;?"O_ (/8/_BJ/[;R7_H)
MI_\ @<?\P_L/._\ H%J?^ 2_R.VHKB?^&E?V>O\ HMOA7_P>P?\ Q5'_  TK
M^SU_T6WPK_X/8/\ XJC^V\E_Z":?_@<?\P_L/._^@6I_X!+_ ".VHKB?^&E?
MV>O^BV^%?_![!_\ %4?\-*_L]?\ 1;?"O_@]@_\ BJ/[;R7_ *":?_@<?\P_
ML/._^@6I_P" 2_R.VHKB?^&E?V>O^BV^%?\ P>P?_%4?\-*_L]?]%M\*_P#@
M]@_^*H_MO)?^@FG_ .!Q_P P_L/._P#H%J?^ 2_R.VHKB?\ AI7]GK_HMOA7
M_P 'L'_Q5'_#2O[/7_1;?"O_ (/8/_BJ/[;R7_H)I_\ @<?\P_L/._\ H%J?
M^ 2_R.VHKB?^&E?V>O\ HMOA7_P>P?\ Q5'_  TK^SU_T6WPK_X/8/\ XJC^
MV\E_Z":?_@<?\P_L/._^@6I_X!+_ ".VK] /AY_R(&A_]@>V_P#12U^9/_#2
MO[/7_1;?"O\ X/8/_BJ^P/!O_!3G]@32O"&E:7?_ +4_A6.>VTV"*>/[2YVN
ML:@C(7!Y!Z5\!QYC\#C*%!8>K&=G*_+).VBWLS]"X P&/P6(KO$4I034;<T6
MKZO:Z1]'45X'_P /2/\ @GS_ -'6>%?_  (D_P#B*/\ AZ1_P3Y_Z.L\*_\
M@1)_\17YJ?IQ[Y17@?\ P](_X)\_]'6>%?\ P(D_^(H_X>D?\$^?^CK/"O\
MX$2?_$4 >^45X'_P](_X)\_]'6>%?_ B3_XBC_AZ1_P3Y_Z.L\*_^!$G_P 1
M0![Y17@?_#TC_@GS_P!'6>%?_ B3_P"(H_X>D?\ !/G_ *.L\*_^!$G_ ,10
M![Y6/\0_^1 US_L#W/\ Z*:O&_\ AZ1_P3Y_Z.L\*_\ @1)_\16;XR_X*<_L
M":KX0U72[#]J?PK)/<Z;/%!']I<;G:-@!DK@<D=:VPS4<1!O:Z_,QQ*<L/-+
M>S_(^=:*XG_AI7]GK_HMOA7_ ,'L'_Q5'_#2O[/7_1;?"O\ X/8/_BJ_H/\
MMO)?^@FG_P"!Q_S/YU_L/._^@6I_X!+_ ".VHKB?^&E?V>O^BV^%?_![!_\
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M@_\ BJ/[;R7_ *":?_@<?\P_L/._^@6I_P" 2_R.VHKB?^&E?V>O^BV^%?\
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M%&?!+_HCOA7_ ,)ZV_\ B*ZFB@#EO^%&?!+_ *([X5_\)ZV_^(H_X49\$O\
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M *([X5_\)ZV_^(KJ:* .6_X49\$O^B.^%?\ PGK;_P"(H_X49\$O^B.^%?\
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MO4/CY;^&;-+.SO+.X=[72!<1Q 1FXENE>09&]TT[=R(LBU_P24^(&J_M2?\
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M'Q%X?\(Z'=^)_%>NV>F:986[3WVHZA=)#!;1*,M))(Y"HH')8D 5C_"3XO\
MPN^/7P]T_P"+/P7\>Z7XG\,:MYITO7M%NUGM;Q8Y7A=HI%^5U$D;KN4D';D$
MCFN;_:]^'?@'XG_LS>.?"_Q(\$Z3K^FGPIJ,OV'6=/CN8A(+24!PL@(# $X8
M<C)P:^:/^#;W_E"5\ _^Q?U#_P!.U[0!]OT444 %%%% !1110 4444 %%%%
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M3(8$<$&O;X]1T^;3UU:*^A:U:$3+<K*#&8R-P<-TVXYSTQ7R-^U!_P $\?\
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M66.9%):)B.0& )'(XK[SHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOP[HEY>:AHN@V5I<:C-YVH3VMJD;W,F,;Y&4 NWN<FKM 'P]^RW^U5_P3/\
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>jnj-20210404_g6.jpg
<TEXT>
begin 644 jnj-20210404_g6.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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MS 'W_4&GZIIFK1//I6HP7*13R02/;S*X26-BCH2#PRL"I'4$$'D5^=/[>O\
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M1U6)E#(%(!H ^??V$?B[_P $^OV_/^"8GP2_:K^.7A[X<>(+7X:^%]-:\O\
MQ?8V=P?!^O6=O#!<@-,";63SHE9/NF1?(< Y2OS4_: O==\(_P#![#X0U?XR
M3/#I%]J6E1^$9+IML3P3>%C;6XBW=CJ!E7 ZR[P.M?IC^RO_ ,&Z_P#P2=_8
M\^-<'Q]^$?[.]Q/K^GWJW>A#Q)XCO-2M=)G4DI+!!/(R&1"<I)()'0_,K*>:
M]/\ V\_^"3O[$/\ P4AO/#WB+]IOX8W-QXB\)N#X;\7>']8GTW5;!0_F>6MQ
M RED#_.JN&",2R;6)) /R,_X+VW%G-_P=/\ [&4=K/$[Q2_#A+E8V!*/_P )
MK?L V.AVLIP><$'H13_^#W*1;'XB_LLZG=ADMXU\4EYBIVC;-HQ;ZX!!Q[UY
MA_P5R^$7[-W[)/\ P<B_LB>"_A%=166CZ%>_#Z\\7ZIJGB";4;V2]'BZ[>:Y
MU&\NI))I9_LX@)>5R5B6)1A%11^ZW[?'_!-W]C[_ (*<?"O3_A=^UG\./[>L
M-*O3?:#J5AJ$EK>:=,R[6>">(@A77 9#N1L*2I*J0 ?C;_P=Y>)O#NH?\%$_
MV5/#EAKMG-J%C;FXO;**Y5I8(IM5M1%(Z@Y57\J3:3PWEMCH:[W_ (/@O^2
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M=>*-1M]/AT_2O&TM]/>7"QQV\<7BRS,CNS$!54 DL3@#DFOUU_9#_P""-_\
MP3K_ &#?BK??&S]D[X'ZIX2\2ZI:O;:K?Q_$;Q!>)?Q.V\K<0W=_+%/\WS R
M(Q#?,,'FJGB3_@BC_P $T?%G[7-W^V_K'[-=K_PG^I7)NM8N;;6KZ&PU.X)#
M--=6,<PMKAG90SAXRDC#>ZLQ+4 ?E3_P5WDC_P"(M[]F!]XP?^$)P<^NK7F*
M/C3X0\9^#/\ @]G\&^(/B@EQ'I?B1[.^\)7$Q*I-:?\ ")2VB>7GC:+V">,@
M=65CU)K]6?C/_P $6_\ @G%^T'^TU;_MD?%WX):YJWQ-LM0M;W3?%J_%#Q);
M3V$UM()+<VRP:@D=LL;@,B1*JJ>0!DUW'[5W_!._]E7]L\^$]5^-O@>]D\1>
M ;Y+SP-XUT37;K3]<T&X4JPDM[Z"19N61&*NS*S*&(+ $ 'XS_M>>&O''Q#_
M .#S[X>Z9\+#/+>Z)<>';S6GME/^C6,&C_:+OS".%5K8LO)P?-5>2P!K_M1?
M\KK'@7_L(:%_ZC5?LU^R_P#\$Y?V5_V2_B7XI^.OPY\(ZCJGQ%\;[1XN^(WC
M#7+C5M;U-%"!8FN;AF,40$<0\J(1QXBC^7Y%QQOC'_@BW_P3B\??M7)^W'XM
M^">NW?Q7BU:#4H/&O_"T?$D=S#<0JJ1>6J:@(XT1%5!$JB,(-NW;Q0!^2_B;
M_E>=C_["%I_ZKF.NV_X+=_\ !&OXB?M$?M6?$3_@I9_P2?\ B]?0_&#X:ZU:
M1_$_P/IM^]EJ=OJ4.E6ES%?:9,C*1*]E-;,83@2GS#&[.3$?TQO/^"+7_!.&
M_P#VM6_;LNO@GKK?%QM7&IGQR/BEXD6[%P(O)& -1\L1B$"$1!?+$0\O;L^6
MM;XH_P#!*K]E?XF?&;QK^T39:A\0?"'CKXB);P^-/$O@+XEZKI$NK6T%E!91
M6TL4$XA:-8;= O[O>K%V5E9V) /%?^#;W_@H-\8/^"CW_!.O_A</Q\T*TC\7
M>'_&MYX<UK7K&P2V3Q%)#;6DZZ@T: *)62Y6.0J I>%B H.U? O^#T7PMXBU
MS_@EMX.UW289)+/1?C7IMQJH3.(XWTS5(4D;M@22HF3WE'K7Z=_LS?LQ? C]
MCKX+:-^SU^S9\.++PKX0T")DT[2;$NV"S%GDDDD9I)I'8EFD=F9B<DFL7]N3
M]D'X9_MZ_LG^-_V2?BXKIHOC/1VM6O(8PTMA<JRRVUW&#P7AGCBE4'@E,'@F
M@#*_X)IZAI^K?\$Y?@!JFDHJVMQ\%/"LENJ$85&TBU*@8]!BOQ-_X,S?^2J?
MM7_]B_I'_H_4Z_3K_@D39_$?X4?LKVG_  2J_;/L]0T7XB?##2[G1-.U#3-1
MNK&'Q;X9CD*V>JZ1>P-'(5C@DA@D$;K/;O&ID6/S(\]O^S3_ ,$2?^":O['5
MQXGNOV8_@9KG@R3QGHCZ3XF?2/BGXE!OK1L_*V[46VN-S;95Q(FYMK+DT ?D
M5_P9E:=XNUSX.?MFZ%X$N7BUJZ\-^&(=%=)-I2[>W\1+$P/\)W[.?85S?_!J
M+X.\#?M >"_CK^P9\1/VH?B#\/-9U*1+JX\$^';[3;4:_82V\MG?JR7EE/*9
M(0L:.$9"JSJ<<,1^VO[$O_!(_P#X)_\ _!.?Q/K/B[]C'X)W_@J\\0VT4&N)
M#X\UR]M[Y(BYB\VWO+V6%V3S)-CE-R^8^TC<<^8?M&?\&Z__  2@_:?_ &@[
MG]ISX@_L_P![8>*M2U!K[7IO"WBF]TN#5;EB2\TT5O*H61R27>+RV=B68EB2
M0#Y+_P""GW[&/[)O[!W_  ;4_M(?LY_L9^-]>\0>&-,\=Z1)J5SKNIK>M;ZI
M_P )%H*75O'-'#'&Z1F-5<(&"3"9&8.CHOOG_!J_K.D6W_!$SX-Z+<:K;1WE
MU>^*'M;1YU$LRIKU[O*J3E@N],D#C<,]17VGJ/[)'[-.J_LT2?L<7OP6T$_"
M^70/[%?P6EGLLOL6/]6%4@J<_.) 0X?Y]V_YJX#]AK_@EI^Q!_P3DM=1@_9+
M^$,N@R:F'2>ZU#Q!?:E+%"[J[PPM>32>1&S)&S+'M$C1HS[BBD '&?\ !>+P
M3\1/B'_P1^^/_A;X66MS/K$G@*:X%O9@F66U@FBGNT4#EBUM',-HY;..]?F1
M_P $O]:T"P_X,_OCY,;F)2FG^,[:[(.,7$L42QJ<]R)(L?45^]LD:2HT4J!E
M8$,K#((]#7QWK?\ P0E_X)WZII/BCP'I/@GQ9H'@'QOKR:UXS^%GAGQ_J>G^
M&=9OE='$LEC#,J1C=%%F.$QQGRH_E^1< 'Y]?\$&/!GC_P +?\&M7[2&L>,[
M6YBL/$.E_$74?"IGSMDT\>'8K5FCS_#]KMKL<<;@U=Y_P90?\HW/B7_V7"[_
M /3/I5?J'\0_V/\ ]G;XF_LW/^R'KWP_>P^&TFB?V,_A/PMK-YHEN=-\EH39
M;M.F@?[.T3,C1;MC*<,#7(?L3?\ !,G]BO\ X)TV&K:/^QM\+-3\':?KD_GZ
MII7_  G.M:A9SS;57SOL]]>31++M1%\Q5#[5 SCB@#WJBBB@ HHHH **** "
MOD#_ (+\?\H;/VA/^R?S?^CHJ^OZ^0/^"_'_ "AL_:$_[)_-_P"CHJ /XPJ*
M** /W^_X--O^4IG[7?\ V\?^GR>OW^K\ ?\ @TV_Y2F?M=_]O'_I\GK]_J "
MBBB@ HHHH **** "BBB@ HHHH **** .&U/]F+]FO6]2N-9UG]GKP-=WEW.\
MUW=W7A.SDEFE=BS.[-&2S$DDDG))S79:9IFFZ)IMOHVC:?!:6=I D-I:6L2Q
MQ0Q(H5415 "J    , #%3T4 %%%?._\ P5B^*OQE^ O_  3N^+'Q]^ 'Q$E\
M,^+/ OA"[U[2;]=.M;N.5K9#(T$L5U#*C1NH(.T*V<88<Y /HBBO@/\ X-O?
MV\OVEO\ @HK_ ,$][WX__M6>,+37/$\/Q%U+28[VRTBWLD%K#;VCQIY<"*F0
MTK_-C)S["OOR@ HHHH **** "BBB@ HHHH **^$_^"Z _P""S[?#CX=C_@CG
M]G_M7_A*9?\ A._+.E_:_L^R/[+C^T_W/V??YOG;?G_U7\'F5]K> _\ A,O^
M$&T;_A8WV'_A(?[)MO[>_LS=]F^V^4OG^5NY\OS-VW/.,9H UJ*** "BBO(/
MV^=>^)G@O]C;XE?$KX/?%"^\(^)/"/@C5M>TC5;+3;.[#3V=E-.D,T5W#*CP
MLZ+O"A'P/E=>: /7Z*_*O_@W7_X* _MR?\%9/V*OBUXC_:!_:#&G^+]&\9PZ
M9X7\5Z%X4TV)M-3[+#.-UN8?)G4N2'5UW,CLJNC;77ZC_P"";7_!1Z[_ &K?
M%_Q(_9.^/N@:=X:^._P3UQM*^(.@Z8SBQU2#<1;ZSIPD)D^R7";'V.2\)D56
M)#(S@'UC1110 4444 %%%% !1110 4444 %?('_!?C_E#9^T)_V3^;_T=%7U
M_7R!_P %^/\ E#9^T)_V3^;_ -'14 ?QA4444 ?O]_P:;?\ *4S]KO\ [>/_
M $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\ 4 %%%% !1110 4444 %%%% !
M1110!\7?\%__ -N[XA?\$\?^"8GC?XY?!ZZ^R^,M1N+3P]X6U(QA_P"S[J\D
MVM= $$%XH5F=,@CS%3((R#^?6A?\$8/C'^VI_P $L/V5OVO?^"?GQ4T;PM^T
M7"4\3^,?BUK^M7=OK&O-?;I+@W.I11S7%P]O.L:I'*&41K(JD9VO^G/_  6#
M_P"">\/_  4Z_8%\9?LHV6OV^D:[?BWU'PEJUX&,-KJEK()8?-V@D1R /"[
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MWX$2_#>\O=?^'!TGPK?ZY;W^H06/_"5S;'O6MBT$4[2><?*BDE54\O+[RZ(
M>B?\'DFI:M\+_P!I_P#9^\6?#76[_P /ZCXDTO5$\07>B7\MJVHBWN;%8#-Y
M; 2%%E=0S9(4[<X  /\ @Z\U'5OAC_P4Z_9TUSX<:YJ&@7/BBPMF\1R:-?RV
MPU-H=4BBB>=8V E=8R(]S ML55SA5 ^BO^#K3_@EE^UW^W;HGP?^.?['WPV;
MQGJ?PYN-4MM?\-6EU&EW);W36DD,\*2.HE5'MG5U4E_WJ$*0K$>'_P#!8O\
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M_P!B;X6R_"_X+Z3='^T=6N-8\3^(=8N?M.J>(]6N&WW.HW]P0#/<2MR6P%4
M*BJBJH]3HH **** "BBB@ HHHH **** "BBB@ KY _X+\?\ *&S]H3_LG\W_
M *.BKZ_KY _X+\?\H;/VA/\ LG\W_HZ*@#^,*BBB@#]_O^#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OD#_@OQ_P H;/VA/^R?S?\
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MIHWB<PR*5WB2-DPZ*'C+@'N5%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^CHJ^OZ^0/^"_'_ "AL_:$_[)_-_P"CHJ /XPJ*** /W^_X--O^4IG[7?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^0/^"_'_ "AL_:$_
M[)_-_P"CHJ^OZ^0/^"_'_*&S]H3_ +)_-_Z.BH _C"HHHH _?[_@TV_Y2F?M
M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK]_J "O)/VT_BM^RW^SI\
M$[C]J']K+0M*N="^'-Y#J^E7E]H*:A=V>I,WV:V:P1E9UO)'G$$9CVL3-C<
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MA^Q-^W?XV^.:3^&/"2^)K_QCX^G\2'2F6XU[R(XKN;YEWAI2T.,+L1LGS#@
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M5_.MYTO_ #U;_OJCSI?^>K?]]4?\06Q7_0:O_ '_ /)!_P 1NPO_ $!2_P#
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MC_B-.%_Z G_X&O\ Y$/^((XK_H-C_P" /_Y(_":BOW9_X</?\$_/^A8\3?\
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M_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7R!_P7X_Y0V?M"?]D_F_\ 1T5?7]?('_!?
MC_E#9^T)_P!D_F_]'14 ?QA4444 ?O\ ?\&FW_*4S]KO_MX_]/D]?O\ 5^ /
M_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444 %%%% !1110 4444
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M?\I3/VN_^WC_ -/D]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1110
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M<)"QS);X =<;HUF9V 5'K]?:* /S/_X+ ^(_@]_P5*^&/[/7[-O[''Q9\/\
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M$^-;CSM<\5?#S3+O7K@)M$U^(%CN9 !T#3)(P'8-B@#W:BBB@ KY _X+\?\
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M\8ZY?Z;;6VAW\,#V[Q:M/*78RC!!!Q@5^@G_ !&\_LL_]&/?$#_PHK'_  H
M_;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\
M0?\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^
M(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\
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MPH _;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H
M_;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\
M0?\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^
M(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\
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4KLZ-O=4&XCY>@]: /PMHHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>jnj-20210404_g7.jpg
<TEXT>
begin 644 jnj-20210404_g7.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
MB$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-
MO^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@
MJ9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?
M])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZOCO_@L+_P2[_X*
M!_\ !'OX;>#OB1\2/^"BFN>,8/&.N3Z;;6VAZ_JL#V[Q0B4NQEFP00<8%?UA
M5^(/_![S_P FL_ __LH&H_\ I"* //\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\
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MBO88H3]HA:,K-$T2A=\;(\BOD?L#^W!_P58\ ?\ !.7P%\!_AB? T'BKQ_\
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M[T]+6=+>X$RW=O%L>.:1(V0G>&.,<''T!7\W?_!.#XU>)?@#_P '.O[6^O\
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M\$A4[9%*R(Z2+PRN,A6#HH!]$T444 %%%% !1110 4444 %?B#_P>\_\FL_
M_P#[*!J/_I"*_;ZOQ!_X/>?^36?@?_V4#4?_ $A% 'G_ /P:;?\ *4S]KO\
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M^":_B*[\<_LP_!:2W\2W=O);-XF\0:O/J-[!;N07A@:9BMNK8&[RE4O@!RP
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M_:%_90_X)O\ Q _:M_9E^,-SX4\4^ K2UO+6/^Q;"^M-066_M;=X[B.[@D;
M25RIB:,AB"V\#;0!]=T5^=7_  25_;0_;\_;\_X(@:S^TA:>*]$UCX[ZC9^)
M[3P=?WFEVUG9MJ,#2QV(>)%6$ .$&6&TG[_&:]._X(A+_P %65_9&O\ _A[H
M8O\ A/\ _A+KHZ#YIL/MO]D^5#L^T_V?^XW>=Y^S'S[-N[^&@#['HHHH ***
M* "BBB@ HHHH **_/C_@Y#_;)_:P_P""?G[#&G_M2_LD?&1O#>MV?C6QTF_T
M^[T"PO[2]MKF.<EF6Y@=TE5XX]K(ZKM+@JQ*E?HG_@EA\>?B7^U#_P $Z_@[
M^T+\9-8AU#Q3XO\  MGJ6NWL%G';I-<R*2S".,!$!]% % 'OU%%% !17PO\
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M?2JKF-+G=BXCA:&0;C;UM?\ !>'1O$.B_P#!RK^SW\*/A)\1=?\  =MX_O/
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M_P""[W[8WQ)_:$_X+-?LY_\ !(BQ\37]A\)M8\3>&+OXF:3IU[);?\)0M_J
MWVEPR$,]LMH@Q'G:7G=F!,<96[_P4?\ V OVZ?\ @NM_P4B^#T'Q#_8O\3_!
MWX-?"VS$7C;6?'VKZ9)+?/)=)-?062V-S.+A9(X8H8I%.WEG?8,(?8/^"S7_
M  2;^/OCS_@HO\"O^"N?[('@-O&>M_#3Q#HO_"P_A]9WUO;7VJZ;87_VE;BR
M:Y>.)Y_)>:%D9U)"PE Q#"@#YW_;'^-X_P"",'_!QW\&_A+^Q]I$7A#X2_&/
MPUX;C\??"WP]"+70I9;_ %:^TIKR"QCQ#!/&+>"</$J%G5P21+)N\S_X*@?M
MI:?^R%_P<#^--9_X*N_LJ3_%3X,:QX:L]-^'%IJ4!E3P_I;Q6SG5-'CD(B-P
MMPEPLK*T<P=GVRIM"M]8?%+_ ()G?M#?\%5/^"YWP_\ ^"A?Q:^!^O\ PU^#
M/P>T'18]*MO'+6T.K^);_3[NYU"*..S@FE:" 75R-[S%=R1$*&+_ "^I_M\_
M"?XL_M+7/QW_ &:OVW/^":?B_P",/PKGUE+SX"^.O UWI$VJ:5<2Z-9>9$D<
MUU#<6>R^\_9<@-&P,D<R^6H\P 7PS\(OC?XD_P""$GB#P'_P1B_:FA\7ZOXH
MU75]3^&GCO4/$$L>H#3+_79;VXM9+RZ.^+48H9Y[8RS;'61"6,<GS+^2?_!6
MG5_A7^S[^Q%^SG\0O@E-H>E_M.?#[Q!_9'Q<^+?PBGN)89-5CM"_V>YUZ(F+
M4-2'E12S*LTK1.9<[$D0-]N_#/\ X(X_\%0/V;_^#;/QA^Q;\(M4$/QD\<^,
MW\1Z_P"$=.\00QRPZ7/]EAN-'AO/,6$2-#:K))B0(_F3Q!F#Y;P3]IK_ ()"
M?\%I_C]_P1:^#/[+,O[%7@CP_=_"'Q3++!X1T/Q7;/KNLQ7"7._4IP91:0D-
M*H>-9I9I6E,A$00HP!]/?\'*WQ%\0_%__@W4^&_Q:\6S+)JOBB^\%:OJ<B(%
M#7%SITDTA 4  %W;@ "ON'_@A;_RA^_9V_[)?IW_ * :^-O^"I?[$_\ P4B_
M:[_X(6_!_P#8G\!?L5SR_$O2AX=37M&L?B!HK6VDV^F6+VY,US=7-LKS2,$(
MC@$R*&(\T[<G[>_X(Z_"[XW_  (_X)N_"GX!_M%?!_4/!7B[P/X8AT75M*OM
M5T^]65H<@3Q2V%S/&T; @C<RN#D%1P2 ?$W_  =V?\%&OCC^QC^RAX#^ O[/
MWC*_\,ZQ\8=4U.+5O$6DSM#=PZ5I\=L9[>&5"&A:62]MP74AO+21>CFOG3_@
MMSX#T?\ X(L? G]D?]K+_@GOI=M\./'EB5TSQ;J&@1^2OC)%L;:X?^V%0@:D
M6D67<\VYB)V^883;]U_\''W_  2#\=_\%7?V4M!'P'GLO^%F?#;5;C4/"MCJ
M5RL$.JVUS&B7=CYKD+#(_DV[H[D)N@"L5#ET^</^"E_[$G[=O_!;KP;^S/\
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M %%%% !1110 5^(/_![S_P FL_ __LH&H_\ I"*_;ZOQ!_X/>?\ DUGX'_\
M90-1_P#2$4 >?_\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\ MX_]
M/D]?O]0 4444 %%%% !1110 4444 %%%% !1110 445!'J>FRZE+H\6H0-=P
M01S3VJR@R1QR%U1V7.0K&.0 G@F-@/NG !/1110 45\T^/O^"O'[ ?PK\/\
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M K\0?^#WG_DUGX'_ /90-1_](17[?5^(/_![S_R:S\#_ /LH&H_^D(H \_\
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M#OB$2L+6>Z:U<O9BV,IE22.3$49D,B[-IW,47\__ /@LY_RMG?LN?]A#X?\
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MN]UOQ'87-OK-B-+N$D)AL;&)'MTMIF8395 [P#>6>-6_&_\ ;$_X)[?M/?\
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MZ+088K&YNHK[2[IAO2QN%M98&@(4+(P^6-UD5OU;_9#_ ."R'_!/+]NGX_\
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M2V@GOOBOKL%E#-.JO<2B&"4H@)R["-'<@9.U&/0$T ?JO1110 4444 %%%%
M!7X@_P#![S_R:S\#_P#LH&H_^D(K]OJ_$'_@]Y_Y-9^!_P#V4#4?_2$4 >?_
M /!IM_RE,_:[_P"WC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %%%%
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M4 <_K?PH^&?B+X6W7P0UGP'I,W@^]T%]$N?#/V%%L7TYX3 UIY*@*(O*.S8
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M"[1-6U#QCX]O(KGQMX[\6Z]<:KK6M/$NR)9KJX9F$<:X5(DVQJ!PN>:]HHH
M^&_CW_P;F?\ !)G]HK]H2Z_:9\;?L]WNG^)=3U!K[7!X7\57VEVNIW+DF266
M*WE4([DDNT/EER69B69B?=/C7_P3B_8W^/WP0\$_LW^/O@]'!X)^'.M6NK>"
MM"\-ZK=Z.ND7EM:W%K;S026,L4L;1)=2LI5P0^U_O*#7N%% '@W[/O\ P3A_
M9J_9W^-^J?M-:1#XH\5?$C5=%31I/'7Q"\77FN:G;:6C;UL8);IV\B'=\Q"
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M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_$'_@]
MY_Y-9^!__90-1_\ 2$5^WU?B#_P>\_\ )K/P/_[*!J/_ *0B@#S_ /X--O\
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M8W^]TH \&M_V@?\ @NA::C<ZO:?\$IO@O%=W@07=S'\?-LDX0$('8:=EMH)
MSTR<5Z?^PY\2_P#@H#\1OC-\19/VXOV3_"_PRM[/PWX<7PE/X7\3)K46K,T^
MKF[#W@AB?,6+;]PPQ'YV\?ZXY\X_X=R_\%2/^D\_Q _\,IX6_P#D>N__ &&/
MV=?VD/@!\>_B7'^TA_P4 OOCC?:KX3\,'38=7\,V.DW>@Q1W.M[BT%BJQ-'.
MTGRR$;R;>13PBT ?4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKE]H/P;^)5AXJ.FM(E_J'AT/>6$$L;A'A:]B5K?SE8X,7F>8"K97Y6Q\ _\
M!7_]J;Q#\:?V^/A1_P $?_"</C&3PIXAT&7QI\=HO &GW,^J:OH,;RQVVAHU
MO@V\-W/$8[F1WB4131AI%5F#?4O[#7[>O[)_Q[\6>(_V0OA!X%UOX;>,/A/9
MV\&K_"/Q;X831K[2=/*HMO-!!&SPR6A5HPKPNR@/'G DC+ 'TE1110 4444
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M[6 @=-!^+W[5OBO5/",Q'R7NGQ7D@%U&?XD:66:/.>L#?B ?I-1110 4444
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MQ@8KUFOC3_@O""?^"?NI #D^)]-_]#:M*48SJQC)V3:,ZLI0I2E%7:3/*O\
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M<>_]"S_RG5_S/U^_XB0?@5_T;SXF_P#!M;_X4?\ $2#\"O\ HWGQ-_X-K?\
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MXB5Q[_T+/_*=7_,_7[_B)!^!7_1O/B;_ ,&UO_A2I_P<?? R1@B?L\>)B3T
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M_P#"D/@M_P!$A\+_ /@@MO\ XBC_ (4A\%O^B0^%_P#P06W_ ,17444 <O\
M\*0^"W_1(?"__@@MO_B*/^%(?!;_ *)#X7_\$%M_\17444 -@@@M8$MK:%(X
MXT"QQHH"JH&  !T %.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OQ!_X/>?^36?@?\ ]E U'_TA%?M]7X@_\'O/_)K/P/\
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MT+_P3,T3_@I-K>JP:=X='@2;6_%\,!W'3+JSC<7]JJDY9DGBEC0=7&PC[XH
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M_"[W*>#M._:4A^%_QSM+<,T:>'=0\'^%[F"\9%[174T\Q/\ %*MLO?G]3O\
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MM]IVGZG$L&I6,-PB2K(B3Q!PKJ<JP!Z$$ @]B*FH _+/]G?X^_!S3/\ @O\
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MC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %%%% !1110 4444 %%%%
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M\\6^,_$=AI&E:? T]_J>J7B6]O;1+U>220A44=R2 *_-/_@NI^P5\"=5\!?
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M?Q8B^&7A5IQDZ9HFBFX0009_U232L+B11C=)\QY% 'Z&>$?%_A/Q_P"%]/\
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M:W]_'%+?W#3P*(H48AI7RR\*"1G)XK[8HH ^=/\ @DC\2? 'Q+_X)F_ 74?
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MX4 ?M]17X@_\1O/[+/\ T8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4
M?M]17X@_\1O/[+/_ $8]\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^
M(/\ Q&\_LL_]&/?$#_PHK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\
M$;S^RS_T8]\0/_"BL?\ "C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_
M -&/?$#_ ,**Q_PH_P"(WG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&
M/?$#_P **Q_PH_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\
M**Q_PH_XC>?V6?\ HQ[X@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_
M  H_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\
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8NM2N;G7-3MYTN$EMQ$$41#(((SDT ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>jnj-20210404_g8.jpg
<TEXT>
begin 644 jnj-20210404_g8.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
MB$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-
MO^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@
MJ9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J\K_ &W?^#=W
M_@I;^Q'^R?XZ_:P\4_\ !4R\US3_  +H;:E=Z3I^KZS'-=(KJNQ&>;:#\W4^
ME?TI5\@?\%^/^4-G[0G_ &3^;_T=%0!_(#_PUA^U-_T<K\0/_"ROO_CM%<!1
M0!^_W_!IM_RE,_:[_P"WC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %
M%%% !1110 4444 %%%% !1110 4444 >"?M:_P#!3K]B']A+4K/3?VN/C)<>
M!AJ4C1Z9?:MX2U9K.]=421DANHK5X)F574LJ.2N<$ @@<5:_\%Q_^"5LVDZ3
MXDU#]K;3]*T?72!H^O\ B'PWJNF:;>9SC9>7=K' PX/._'!]#7P?_P 'M,43
M?L%_":<Q*77XO!5<KR =+O<@'T.!^0KZK_X)+?L]?"G]J[_@W[^$7[._QN\+
M6^L>&/%GPH_L_5+.XC#$*\DP$L9(.R6-L.CCYD=%8$$ T ?<?@[QGX/^(GA:
MQ\<?#_Q7INNZ+JELMQIFL:/?1W5K=PM]V2*6,LDBGLRD@UXA\/?^"I'["_Q3
M_;4\0_\ !/?P+\=;6^^*_AB"635?#BZ=<H@>%5:>&.Y:,02RQ*P+QHY9</QF
M-POX=_\ !I_^V-\9_P!F?_@HGXS_ ."6'C'Q1/J?A773K:Z3I5S,WE:?K^F%
MWDFA!SY*3007 D 'S-'">JG/V%^PE^TO^P'X\_X.#?B7\.] _P""<;^#/VB8
M(M<M_$WQ"C\?RZAIDUQ;*JW$MO;F-$C:Y4+NF$22$%BRAGD# '[!T5^;OP>_
MX."K[XA_\%3(O^"3?CO]BG4/!?CU-?NM.O\ 5-9\=PO8K'!:O>&> K:[YQ+;
M)YD"X3S/,C!,>XE?J:^_:U^,MQ^W)J_[&?@_]G'3]2M](^'T'BRZ\;S>.##:
M6T-S-<VUG:7$*V3R17$UQ:7& N]?)B>3<67RB 0_LU_\%2_V%?VN_P!H[QS^
MR=^SY\=K7Q!X[^'9F_X271X].N85589UMIY()98UCN4CG98V:)F 9EY(92?>
M=8U2VT/2+K6[V*Y>&SMGGF2SLY;B9E12Q"11*TDK8'"(K,QP "2!7Y&_\$.O
MVE/^"=OQ>_X*P?'_ ,'_ +//_!.Z[^%'Q;@TS5[GX@>*9O&KZI;7#P:S;P7E
MM:PD!+>.6ZD68^6JJWE+P % ]WD_X+FZ]\;?V^/&'[!?_!/+]C2Y^,VH_#6U
MN)/B%XKO?B!;>'].LI()D@E@M6EMYQ=R"5_) 8PJTB/@^6IE !]!_LX?\%3?
MV"OVM_CAK/[-7[/W[0%OKOCSP[:75SKOA:70=1LKNP2VGCM[@2K=V\6QXYI4
MC9"=X8XQP<?0-?SQ?\&^WBZ+X@?\'.W[3_CR/P?JWAXZWIOCF_ET+7[407VG
MR3>);"1[>XC5F"3(S,K@,P# X)'-?JYX\_X*M2>*OVZM<_X)T_L1?!&P^*7Q
M%\%^&)=<^(%[KGC0Z!H>@(OE+'9M>1V=Y)->.\T*^4D.U/,^:0%)1& ?8-%?
M&G[+?_!8WX??MC_L'_$#]K[X)?".\/B?X5QW\?C[X6:]K:6MYIUW91&:XMUN
M4BD20-$CM#)L"R,NQC$0^SYD^#G_  =#Z]^TQ^RM\2_VD_V:?^"7WC[Q4?A3
M;MJ/C&TE\965EI^FZ5' T\MW+?21'+JJ2$6\$,\I6)W8(H!8 _6:N>^*GQ1\
M'_!CP%J/Q,\?S:A%HVD0&?49],T.[U&6&(<M(8;2*64HHRS,$(506) !-?//
M_!+#_@JY\%_^"H?[&4_[8'AKP]/X+M]#U.\TWQIHVM:@DJZ+=6T,=Q+_ *2%
M198?(FBD$I5.&(*J5(KYS^$G_!>+QS^WKX?^+WBS]C?_ ()[^)O&GP8^'L5Q
MIVM_$?\ X3*VM-3O<V\C226&C2P;KK9%B;RC<1RF-T 3S'$1 /L?]C?_ (*,
M?L6?\%!+;Q#>?L=_'C3_ !O'X5DM4\0/8Z?=P?8VN!*80WVB&/=N$$N-N<;#
MG'&?;*_ /_@R1\2:'X-^&7[4WB_Q1J4=EIFE-X8O-1O)B=D$$4.LO)(V.RJI
M)^E?:?@#_@O[\2?C5^R%\0?^"A'P$_8";Q=\'O NHZC:RS6'Q3@7Q.8[1%<W
MEUI'V$I:6VUP[8NI9DBS*(749(!^E-0:IJFF:'IEQK6M:C!9V=G \]W=W4RQ
MQ01(I9G=F("J "22<  DU."",@U^'/\ P=O_ /!2K]K7X*V_AK]@_P"'OPUN
M/#'@?XAJ+C5?&QUBV:X\500/ TVG6\44C26ENKS1I*TP1YB"BCR0QF /W&HK
MY3^)_P#P4ZN/V1OV+_%G[8__  45_9NU3X-P>'-4%EIGA,>+--UZ^UYY(XS
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M_!1GXDV_QG_:/^"4[>,88(H)O$_AO6[C3;N\ACP$2X\E@DY50%5W4R*H"A@
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M44 ?O]_P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U
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MP7X_Y0V?M"?]D_F_]'14 ?QA4444 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^
M/_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5\@?\%^/^4-G[0G_ &3^;_T=%7U_7R!_P7X_
MY0V?M"?]D_F_]'14 ?QA4444 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!I
MM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110
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M\/MXH:2^;4$T@7/\ M_L!G\G$'F-&R#<\K-!^VC>_P#!1OXR?'#Q+\$_"_\
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MKZTN4+"2V=C?*$WOY<B3 L22!\S^(/VXO^"L.N?M-^$OVA?^' OC9/\ A&/
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MY!_UTXM_Z#JO_@;.R_X:'^.O_18/$W_@^N/_ (NC_AH?XZ_]%@\3?^#ZX_\
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M57Q)11_Q"[@S_GP__ Y_YA_Q%;C7_G_'_P  A_D?;?\ P_W_ &^?^@WX9_\
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M]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ KP+_ (*%_&S]K#X%?#?PCXF_8S^
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M"5=U_P NY=_0_HD_X)@_\F _"O\ [%:/_P!&/7O%>#_\$P?^3 ?A7_V*T?\
MZ,>O>*_C _MH*^0/^"_'_*&S]H3_ +)_-_Z.BKZ_KY _X+\?\H;/VA/^R?S?
M^CHJ /XPJ*** /W^_P"#3;_E*9^UW_V\?^GR>OW^K\ ?^#3;_E*9^UW_ -O'
M_I\GK]_J "BBB@ HHHH **** "L[Q'X.\(^,(([;Q=X6TW58X7+0QZC8QSJC
M$8) <'!QZ5HT4 <O_P *0^"W_1(?"_\ X(+;_P"(H_X4A\%O^B0^%_\ P06W
M_P 17444 <O_ ,*0^"W_ $2'PO\ ^""V_P#B*/\ A2'P6_Z)#X7_ /!!;?\
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M?"__ ((+;_XBNHHH Y?_ (4A\%O^B0^%_P#P06W_ ,11_P *0^"W_1(?"_\
MX(+;_P"(KJ** (-+TK2]$T^+2=%TVWL[6!-L%M:PK''&OHJJ  /I4]%% !7R
M!_P7X_Y0V?M"?]D_F_\ 1T5?7]?('_!?C_E#9^T)_P!D_F_]'14 ?QA4444
M?O\ ?\&FW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R
M!_P7X_Y0V?M"?]D_F_\ 1T5?7]?('_!?C_E#9^T)_P!D_F_]'14 ?QA4444
M?O\ ?\&FW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4
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M_%+3=>\+^-?BKXA\2Z?H6ESLR>#8;J6/R-"=7 :*6"V2!I$*@>9,[*71ED<
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M6^(GCS3[[4;G6/"/A#PWX-\+:(D9OO$&MWUG;PV>G6JR,B>9(V3EF541'=B
MIH ^I:*^4/&O_!2CQA^S3^T-\./@=^W+^SQ8^ M,^+NJ?V/X$\=^&?&YUW2O
M[9(!CTO4#+96<EG<2Y C*K-$[9'F *Q7%\2_\%9?%MO^W=XV_P""??@/]A;Q
MWKOC3POX$B\1Z1G7--@AUI);F.&-_-$TD-G:89W:>XE20>7Y:V[R.B, ?9-<
M;\>OVAO@?^RY\-+[XQ?M#?%'1O"'AG3A_I6L:W>+#$&P2$7/,CD*Q"("QVG
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MR*]GK+\2>"/!?C+[/_PF'A#2]5^R2>9:_P!I:?'/Y+_WDWJ=IX'(]* /AO\
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M_:$3XV>$OA#XLTO2_AQ\;O*4R^(H[BR:XNK&:9&9;B>R)MXY7WNXEFD1G;:
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MMV-.L8X/.D_OOL W-[GFM*@#\J_^";/Q#\ _%+]O+_@I1X2^'GC[1=:O]?\
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M?AGP5I6GZSXAOOB4NO:G96$<4^H^1H-MY1G=0&E*>=)@L21O..M 'Z54444
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M>)/B-HMIJFG?M7^%==O=+FU*);F'3;:UU$3W;1EMRPH98@SD!09%YYK]5:*
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MZ7]KT2TCM?M&YAY)F=66,/C>1@9K]-Z* $CDCFC66*161E!5E.00>A!I:**
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M-?&>OV>E:/H]A->ZKJFHW*PV]G;1(9)9I9'(5$1%9F8D  $DX%?ECJ7_  <
M_P#!&_\ :)^.EOXV^/\ ^V-IVF>"OAUXA:?P#X-F\*:S<'5]5@9D37[WR;)X
MRL9R;*WW'9G[3*/.\A+7]7:* /S'_P""I>H6W[<W[)'[._\ P5>_9>\(:_K>
MB?!+XV:5\0H+"31I$OM9\)V]]Y=[=P6I'FX>."*[1642&W4L45SM&C_P4V7P
M%_P54_:#_93_ &7/V9?'^D>-M T+XL6/Q4^(^N>&-12]LM'T+3H)/L_VB6$L
MD4EZUQ)# K?,Q#L!M1R/TGJEHOASP]X;BF@\.Z#96"7%PT]PEE:I$)96^](P
M4#<Q[L>30!^=G_!0K_@MU_P3BT'XXZO^P!\3OVR;+P5IFGHT'Q<\0:79ZC=7
M10EDE\/V4EA;R^3<O@I=7!96MHV,<1^T.7M>KU'XO_L8_P#!:[_@GC\;/V,_
M^">GB!+_ ,+:=\/D\-Z-KMOX<N-+T:RU-K=WL;"!+B*)RL!@MFD"QA$CFB"L
M26"_>M% 'Y0ZU^U?I_BC_@W@A_8_TB/?\?+[X31?!>3X/QS*/$(\1K:KHT\#
MV8/F(HB#W;2$"(6_[TMY9!K]!?V$/V;O^&/OV+_A=^R]+?Q7=QX%\#:;I&H7
MD&?+N;N*W1;B5,@$*\WF, ><,*],3PYX>CUU_%,>@V2ZG);B"345M4$[1 Y$
M9DQN*@\[<XJ[0 4444 %?('_  7X_P"4-G[0G_9/YO\ T=%7U_7R!_P7X_Y0
MV?M"?]D_F_\ 1T5 '\85%%% '[_?\&FW_*4S]KO_ +>/_3Y/7[_5_)[_ ,$N
M_P#@L+\-O^"/?_!0/]HKXD?$CX.ZYXQ@\8ZY?Z;;6VAW\,#V[Q:M/*78RC!!
M!Q@5^@G_ !&\_LL_]&/?$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X45C_A
M1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\ A1_Q
M&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/
M_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_]&/?
M$#_PHK'_  H _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ _P#"
MBL?\* /V^HK\0?\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?
M\* /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBO
MQ!_XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZBOQ!_
MXC>?V6?^C'OB!_X45C_A1_Q&\_LL_P#1CWQ _P#"BL?\* /V^HK\0?\ B-Y_
M99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\* /V^HK\0?^(WG]EG_H
MQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\
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LE?LG^%OV2/&FAZAXZ\-OIMIJVH:Y:20VKLZ-O=4&XCY>@]: /PMHHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>jnj-20210404_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jnj="http://www.jnj.com/20210404"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jnj-20210404.xsd" xlink:type="simple"/>
    <context id="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie0aa473acf8a4d8fab6230244556c8da_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic746560139dc41349deb2325633b7ea4_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2783afe2aa264bce937ed802ab36bb6f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i143b4f489f304a75aa99c0136cd5ebff_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i11b2ac8bef704242b9043de1cdfb6053_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i224f75bae26342ffb97488937c270d87_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ifde8fdc6f153456891b3a67798d76d3f_I20210423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-04-23</instant>
        </period>
    </context>
    <context id="ic8bf9ed56e84446385347cf261ab52e6_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i554ccf5c7c5d4082a647db172a33ff5e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i45b058f1e15f44aea2e4af4460a4bbeb_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4622c24078884c9b85a313f0376a062f_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="id5bf68e42813419189d9d5ff49143138_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie77099172951473bbab56c32e4583bd4_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ibb70055ec76a478fb6bd6838dbc2aeaa_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i90694bac6fa841438f930b207399b28a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2c6da1c0265643db83e0afcdaa488d07_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3029d43aa1d647acbb02dc5cdfe3bd78_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i5337f7aeb8794921aa62a3f210452e64_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia9d7acadaebe4196a88b514c7f9d15cb_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i57b90fcac8194c0c83439d028eb794fa_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i81a1c011ad384c69babb9ebc86eb4a3a_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ia6b4922887c94a5e974f74b0748d2716_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ibb9aaa3bb3c148dea235f3a41f284cfa_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ic07ec8e0b215404d950899c6b10f4fbc_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ie740235dd54d4a0ea8cbd91b22b8ba76_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i2f57ab699b4e44729a17b2ccc22e7648_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i74d8ed8a180c4d6fb9225796febd9cbc_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ie2f9f433686145c29000c017762e5f79_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i4d880e598230476c96c6eb9db808e92c_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i3e28a2034ae84b938a05edbccc78058c_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i5f5d1f228aa9422383b1640228e75524_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i08ed9aabae5243eab0507179e5521406_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i938fd3f47216423db6add422786e33d8_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i38454aa367154112bb15da46777db708_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0082d9cc376345feb045a0d2dc22b630_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i57d42da3fc7e4a9c8e74db6c49bd6a30_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="icfe502bb02104e159d70555125632c61_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i377d715a6bfa41408e72610b259d73ff_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ibc8848a62dcb4452a2fc843002a09302_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i40f64fb8b6794e99af54c94ba64590f2_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i388de1b5762e4c0fb0d8bbd78e4af41a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ide5b19ddfb3441d99114a1bb6fd6c98c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6244cbbe09374700aeac1db74a330aae_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9cb654a681744cccadb2bf5b36aa0112_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id0bb046f4ee745b8a6a3a214d7610a6d_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i765e60a738e846889a642c75a5734d75_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3e47fb2653614b9fb11a7cb9230babba_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="id62f882886ab4b96929fde2ec8b4ad23_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="icd17c512c40140ec8ea55845257d1f58_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i30217af13d8d4037a36480117a2ddbe0_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9b0bf4ce3bd940f0b30c1308159ff8a6_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie72107b2f41048608d40b52f7842ac46_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i19e2c42c0f614e9b9a6645e5624ab2fb_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i6d3517c75cc34f07baec1683d55a7bd2_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8c6b3c3cbf0f47ce9e5cbd3982f08fa7_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie01d964788264049a7b9adb01bd01ac5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i13a02c0a42a74896bf7be48d3b1027e1_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i874f30e6f0c8448b864fdca3e1298a1f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie68b3ac552404011acaedf92944e753a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5a9a259f20724c67beb3b788b0f25057_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i342418f455914456a29f58d87b451c6d_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i2b1bec5d96714b3eba498d07a965ad79_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i72b8cfc3f21b47e1a9083977bf9e2a88_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9fca4d1476a349df850a392206294580_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9619cfd7a6d6418e84ba17ca620027fe_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="idbc060006e064bbca9524dae843e6335_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie7a18315fb614992b5e5d355a07e9360_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0906ba73795343c2a2e180261f092582_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i26027c48bade4ff7acf52354b330290d_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1341509a716f4cf7adb94b1d81181765_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia3cc70b838c74057a0eddbcc40f06c72_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i878350a72ee146ab880ae401386a353d_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i822c73144e3a487798d589465af318e5_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i4b9dc30fa88d4596b1e3378aeddbe13f_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if38820cb50084fd0a8928b4fff09c1b2_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="iad3b2a712b0e498c9cafbdd3bdc0628b_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i140d1f4f250d42e78b3172103a09a2c9_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4dd389ffc711425dad2694706f9e91f0_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idf315858f46544fda7be3aa113c4fe5e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0216e83e61184ac5a91bab7c9e89040e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i204355d7d9a948e5a652a98e8a346114_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i22bf2da4717d42ec8e7363aaabf9331c_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="iadca5d6789ff4116b0dce69a9dfc7267_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="id2257a4164c24da4808f08e7779edb63_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="iaf3c269c11bd42aea7263d884b1eb127_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9b228055f3cd41bb8574ba5091b477ab_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="icea3523edfc54b9795f412328fb8cc54_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8d3a64af1b114e0faba3662a1c101141_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i40ee10e36a6846f9a154a6a47b79529a_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i14fe7f8132004082bcb935f2f27f8655_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i35bdc996add34d468a13b2fe99d899e7_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i87420fbb466e4d8f880a94561a21e400_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i946eb5aeb32245f6be05dc48e566fa0b_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i232b3bcc9db9455c814fc452f8315a6d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i6bc1a06bc0d240b8852a2c4d4a71d78a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic7bd67d98bc44c14b76b19b4583f853b_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia18cccc27ae74f93a145a0bb576d9145_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="idac7648f2ee14ded909ba25b98704f30_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie3db46d4c79c4830b0ea1b74ee41714e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic55cbe2969894f10bd11012937cb3cdd_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="iddd05909aea443d3b6e90c5026e77987_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i750ed2565a694c9c819af99b440bccb0_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3281569ca4124bab9a05c92d04b015b3_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="iee80bb4dedc94292864c36970f859808_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic246ecfdb3484602b3397443c4ae0302_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i1cca5da5737441298ed9e781c444cab4_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i8c58449914d342049beb19957b06dcd4_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i6112627e2fe7456bbf10241a8ee92b8e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i62b449f24e1840a188eeaea7b64de5c5_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i087920326dbc4003933caee61ef1d032_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i9081f2f0d3934ae7b2f8a1376e4c854c_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="if1d3968138264974924b828c7a733b2e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i4b53ffb9394c4a118127e114b531b8f2_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8fef9ce1b1c94e7baad55d8c2f003ca8_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="if9108e0198f1454fbc22f7c1d46a4ac8_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ie06eb83c93424fc38c8f74e769309ab0_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2ee15e9e3be0451c9104456ede3ce154_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic6c3f15ce4ab427d911866506af070e3_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib7915bfce2cf46dca29a5703af986b2e_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="icfdfbb11f0c04c20a79df23a07ba5ecc_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0bde608450a04e129af5ff3ed4538b5d_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ib0e402b3caab4da7802a67171676c4f0_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic2aae0ebe6c54209a9f723970cc996ab_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">jnj:OtherReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i21d02a87aab8433eb31b762adf895c58_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i53522da16d414a2cbe5ee063bc15169e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i9c13e647c3264f6d9f7597704bbc8077_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="id34dd034a8ce44d78c8d013272369235_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i55ad5b35a58e4a549a452417ff62e50f_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia551774380104d5a9cb2e81ed84e5fbc_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ie6527580553d4feaa0905f4262bf370f_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="if362b20960c24710b7e9131a1f050ad8_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i31f92bb8177d4d7b8cd1179e1735f8d6_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i080bcda1e8fc49b9b3b8f7f21d977c2e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="id4db85c50deb4321b0098f8ccf20b46a_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i1cc61c2b232f40b88208ae48fe534d86_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="iffab5554feae486aaf2e6e43a90b37e5_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i9bcc1b72d9204d9fb6b0776f239845df_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i9d1395460274475eb8aec4f946ce6846_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i66c7696b31ef458dbdebd3465124db85_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i232ebe15fffe4208ae8fe01bb810d201_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i6ecca6252ec6440ab50478e4522c9cb9_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia4b9cda0ccb141c2b49c9bbf460578e8_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i01bc079fc7af4d169035bc9957d09c9d_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i17306623a4594a4599e905c0006aa969_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ieb973d605fa44eeba1302fbb97d677fa_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i7218d516a3fa4b1a991bda3b84a3972b_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="if02515bdf715434b91522300dc22073a_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i50dd314f98bc4ea585b34a6ef22d88bd_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i85a39dbd593546cb8669a44bf5ba1f36_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ib067ee5fb75e4a41a8dd5a32a4fc5baf_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ida015c71d6964ba4b2e11a562c29b0eb_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i5af5af1c6e1541e99b3ea8ce7066da11_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0514f7f1d16f40e0b128088ad9ec2a66_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0c97765733f04d0ab64e6cc604f9feaf_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="id9fca91959a44bc99f389c8604972d5a_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i5ab9b12aba8443be862462c8b208e6ff_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i2e9d564117274a81b671fc45094fcb9d_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i885f427d1f254de2a0594cd4499d4276_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ib87c8983a8b144e0a0b7a8d79fd69370_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i641f9be9a5ad45c5b83f607f6d1f3eda_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i79896030d67642908f3083ddc47a69c0_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i65d0ffe736bd4dcfbd632eed9b5f65e0_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i20ee57fedc3544d9bd6c9bd722f91f29_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i7487f3b4696241b19abfcd01b9537fbf_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i7a6737fe6b814f04816f11baa77695f0_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i88bd89b0cd024d28be4458c01e872c39_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="idd0df51e9f6e40ed9d88e684d9499266_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i68d584c5a1bd4ff0b1a6d41603dd3b08_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i65e137191bb04b98bfcb88e12baff57b_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3a9d444d344a4100a0391cef4739483c_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i5388981f8dd34003b44bcdbb65f1e543_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0d20b300aee54da4b4d3efd6dc870a65_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i7d5f6e95714e4bae9c1e910ae22b802f_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i89ecc979877e4f0e8a892f8c76441de8_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ieb5caa2a14204d6898789b7e13ec13e5_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ie8f2e21bf85c4d6aa21abd973b571c71_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i05cd1ceca68a4be7b9e6e339e53f6023_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ib5d469fc5b8845779a850f71b49f8b62_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i481f371accbb49f5a40e7d7669b9063d_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i9a96ed3119e94dd8ad5b849b0dfa13af_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="icb0b9ad2fc354d65944c2a61b639e19f_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="if558e7c662c6460dbcfc287f05df9a6d_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ib8522b9e894d4fdcbef8ee00218f96cd_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i16824b55647942daa85e7513f921c7ed_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i4df43fc8b5ab4339afaf013e8ee480e5_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i36ff32f415f941d28b01c0eae65ebd16_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i298a5e31ae074ef2b1abcdecc4c9bd6e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i85c5519ac2c74223abd4ff4bb596aa99_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i001e8a223ba8491f983e78ad8fa58d53_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i41eefdb455ed41d6bb26fb8467d496d7_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ib24e4cc519e54204a76fb775b089fea4_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i08bc89cac5b142cba9c10b6895ceadba_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i66627c055dbf4a0eb408404ce5322e9e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i4ec5bd94c75b4263b7251abd5a82e702_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3b60cd521d53474e8b55300042817025_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i7388370141f140dd8d9ec8e9d39c42fb_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i1155094efd13425786f2ecdb88995104_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i21042b2cd4f347c5865cf57c2a26b8a2_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0b2aff0da8e54f4589d4056567f1b3f6_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i57fe94aa53c54ce5bf1df72bd198dfae_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i4a5b5475dca04fa0909cd83bb83e1b41_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic90df002b0584aeeb48770c1c328a738_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ieee3f15e281e4b1c872375fbc9f0e83e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0c851c9ae9be4c899817cd64ae156b3f_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i520739d470874963ac1889aae3a2cb7a_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ie8b7274f1d224358bbaae38c9f942bb2_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i5ec18e7fe67d455d845353e1a9594d67_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i953edb0e44f84203a69075078f4a87a2_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i630bac5b3b4c4c1ebdb26307f5299f07_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3d26316cfec049b1a3d5289265e218b2_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3157c394710c4db09c9733fc27554cec_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="id7da76c95df1476cbe7abf79df1c0a8e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i552a9d1be5df4fa5b99522a4cbd14464_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i084e71373b7e4ff08ea007b9768f21b0_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0d6e2c751f95477baa381dda34964d6d_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i2340f88dd3fd42c6881635ed13a8ad1e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0a22670a5e304df9807dd47199a4122b_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ifb901ca38ff742d2b392935788bce117_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="idd2f5ee051df4ee7affc9c9a72a15930_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i34901dc3115b4d80b6bc2c5a322da841_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i8a5e79fdc705408d96c62523a56dd2c9_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i3ea6a649ed4a4d8b953110b3f73c6be4_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i7d3f229defa146f0a98220762a4f2b93_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i830d1be156484a03851fff96315b9dea_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i8b6b59bed6954d418eb4c5847b9548be_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i423d7e8b4b254413810c2f5c4fda19b5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i70e622c310144cc8949249a07bf071cc_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i154642870660410a90785a135a0fb8f5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ib4d8262305ed4a808270a6d930b2b201_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic5c0764f40c2472b8a0a5b59873f1ca3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1d76493e48f94dcba8cc74f15393b857_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8a475b649b7b482bafe66f589d72289e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia40af87a50514bc5a829dc0dd0888e9e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i28d96c7a5b464914b6d3373fefe93b84_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i816f31f509494a34bc7e2cedd91d16d2_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic10284d081934582868002bbf2ed2c0c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia1354338217d411997a1333f76f744ea_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9e23c8ee5426493fa9a9020a4460a66e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1971251aab8f40e581900d63eac2f931_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i10269159ffc3444fbcf1d8e9aa219a53_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ie7c535299fe9457290a897be433005f5_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i7b83b2a50512439ea7c32eba157340bc_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i2ae622fe28cc41748a80fa1570cfe35c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4f1ff6fb4d12459fb76b519f3aa064d0_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="idffd022b600f4ab19da11eb4a92bbea7_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iaba9b1b928784fbca8eb92f74ca624c0_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i92d7961dbf5348efbc49acaf2aed16bd_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i723bca619dee4d77adbb0ace89cf793c_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i25dc22f2e2bd45de940fef17d3860c93_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id1a0e1bfa74b499eaf41e73bfbea7789_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i50e3695fe3ad4d6397fe1681cee71dbb_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i166260d97d024b4da59529851700b260_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i1b585d84ee0b4c8e899f4c0c52424cb1_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7d9e5272e1d64d9291f65425f7a17561_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="iddfeadcc4c9f4c14b150e5ed0df1edc8_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i906fd8e56b88496dad9f6b80d29a44da_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i3854ce9adfd64c2682550767fe397150_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib661f1c760ad44e9b55754282fa57e3c_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8faa580354e043dfaf23f1f42fb88960_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i32385508ea6d4658b01bac013205426a_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i92ebcd0a77d74afaa4aef8e33703f1b2_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic4a5cd00fdb24916a240b612026b1e93_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i67c2a0954d344c4bb590b8e16e9b3919_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib9058a80fcd945bd954291432adf44b8_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8bae718df24b4f13951655bc41d7bf96_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i983c24aea97b44299332fe0f8a655f72_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i44787243fb164e10b42245b3160597dd_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i95a750086de9495a8afc776a19ad7a9a_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i42bf8dca10bb48398b2f3f163ed419bf_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9fa60389107541e38de00816279454bf_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i331b3b92b0b34bafa98699f766892580_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i964cf45dd1db45268ef9917e50464450_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i60d3b975b16e4b83a8d7a02ed320e405_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idf40698a4cb8405c9ebbbf461d299a30_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if9d7ab27284c405ca2762880403e8d9e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic71b279765044852900c44013574acce_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ied69986251ca49af95c8ab2e38acfc45_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i26bfd85decb944d8a5ff899f4f8b8a85_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i01ebdcc3eb7548edaa2a797dcee28eb1_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5b4f194c8d2948e682ea7750ae9e4ae0_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i289737a850a54d0cbb70e8bba2e95d4a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0432cb1fa6fe47fbbcfad08028e0cc71_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ifc8d5d21439a44449fe0a777201e9ce6_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="iff567a96444d40aaaaee5e54bec7304e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib06bac64a0724d9ea69537ebd326bdd3_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i4d625febf4bb4703b403d98d5ce8c57b_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia82ae2d3a5a249beac2043ef02e2f433_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i6171f8ab5dda4d0c9faa7382c2f231b3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5d1f27f9c7334c3f9ad28edfbf7dcaa1_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i69ea8e5d1357498b955cea3a65e70a42_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i61d81d5483f04c2ea8808ff914905c50_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ibd8ce529fd4e489ca217b53ba112079a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9f8e51a1f6cb449ea7ff42d6f4948b73_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i136d588a998d4a2da83c088f3e0ce2d7_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1ef18e066a7d417b8a7dedcd9680329b_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="icaf4afeb424b42099ca0595af209f4c9_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i29009a53b5dc403aa2843d2d81dd1cdc_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i6114f587788a46509aa693a877fbec65_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9d2ad3a676074fd39646dd2b42a1a394_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if3ec26a4598846aa90c13dbf69fee0e6_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib369d313870f4e40bcae5f48dbba9156_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i49f387a41d284ee49ce4f7ab58e64040_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i146ce49a479f4a72b766a6152145d2db_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i03d35b2d6abf46dabb281f94354a317e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie48b966b3ecb41279941f7e8cedc781e_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ia5832713827f49e68a1d9256b8db22f8_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3cbb2403d3fa48e6a6c860006059dbbb_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i36c510944ae54934a1107ef6d1ded6a8_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iefd6ad0e6e1643d381813d989c2cec70_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i32aca65dc81d4c26ac1e08379d1ef4bb_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i148fd285f2164e8b84b5f919df795949_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i06e61e62b4724e93ae93816c2f3192f8_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i80770d9508b2437f8389e28b2b941a02_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8fbc72131dcb4cfb8a2b4aefd58180c0_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i529ed72788a0459399f52e3044b3e2ec_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ia66fb5605b064618a2816914b2ab7bfa_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iac8d1c045b4547659ceadd21ec5dcc69_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i093cfc8901c7491da04dfd1a8c00c997_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idac706fc6d814cd3b02325aac9a6a583_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i2e51d8457af2428d92fb1a6f3d416b27_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib7477ed6ae844839a6a17c6320a1490a_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i2bee09b00e4e4176b4a2035aa5f68b99_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4f88fa52f8b64198a27db57dc8f3446d_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i433a9d857de442baa6ab86474c907a9e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="icaf7597b20ee4154a38d35f8a5783413_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="id1e6b6d91108495abc61b13e632ed5e5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iafed813fd0b0453992e024335f1146fd_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i80ed82867cff4a2a90aaf86dabd6f75a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i36f05bd8bedc483e9e416de970f7e815_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9f4e287198db4e008b203874b5cc8f67_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5cedc93843e0405aa3fa264e1182e575_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ic8276bebcd3646be90506d64f62c9552_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iab0a5e29a43049de90706107caedb36e_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i361f978e79cb45ce9e204e867cf6632d_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0ad6a0b3794e4083b20fb16dbb34c231_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ifad881d92a614ae4a72edef7e338e323_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i20adde6886944d06ab57d875198dab9d_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i59f953f7b8304173993dce91c2663860_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id1c4623cb45a4be88936c830cca8137d_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i60a0def5e08a4ad8961fabcaa36ce515_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie1cdd7d8723049d19609b00fa9d90353_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i831167bcd06748238ad090de986cb792_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia20e73715a764fab811e562e85895b43_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8fa7ccc867e0451d8c3472534acc0afe_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8be1c5255c4b4a188392c9c769c5191a_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9a0dc7a2446b402d88958e72d228822f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0bf0bee74b66411f86595a8d281104e2_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i0b10e6ae68dd44b5aa1f27dc3875bf97_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i988753d50e764ca9a7c00a80520f3048_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i6a9e5fed8d614670826d46986af440a1_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ife89528554c54fccbdf65c21b5a431c8_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if8754c3942af4f6d99cc04b08b970f18_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i176baa8660424665898357a803f03887_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i6d57014634294477bf7002a25123153e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2265d889108547338b832b208684da7d_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i7c291b0634924a55bacc7238c574ac85_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i22b68654dad44b8cba983ed66dcf3568_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i902b036bad4646c3acfbaa6a61042bcd_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i64d06d5b850a4229a8ead53a9c9ba9e8_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9c130fa5cebe472c9176470dc88dbbb5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3c030aed94064ab6a76b0da185985ac9_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9e4e92c9d6c74bb2895cb6659afe4aec_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i08530f48301640e2a981713098e61fde_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i5b34fffac82440368445497712324317_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib4bdee0e174a46a0b8c038d4489acc40_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i686fb29be97940259a0115fdd23a57e4_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i63eeae9617e4445594405644c82b4ae2_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i58449ca63dee493eb4a627122847148a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ibba918ab4a4549e78a7dbbe69cf89f5e_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ibcab1dd336244969a3214dd17843013a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ieee11dbbba0341acad84e21d44b66cb0_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ifcb7c0f2ea9d4046a2c03e628109123a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1561310f3be0405d937bd6b471583f21_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ifab1d64419004688bb06b6ce8e08f292_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="if345aeec465f40d3988084e400c97b4e_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i2a80582d773f48a88dd91b183eca0b21_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1b3b072e6a9b4111a82aad6be86d93c6_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i22f5c3eb00ca4f86a05c633b971c6262_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6c42bc98065a4fcba4fa265b813a01b1_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8f35f4e601b0404393243d21e82cb121_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="if7c978b217504b4e97c5a3da905e7be6_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i215e664def914a8f8dae6cdfc6d30664_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iad1e1a3f79d44f43a2ae8c994d019ed7_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ie6cfc8b3edfc4a0ea32dd87a1d6bfe83_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i864c9546ca1845cea37de582336593f0_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i92f4c2b4bc544bb9938f19f240de842b_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i91610b7c00884714803dc8fef0f20607_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ib2ac86b2ad464bea9af64abe75679432_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iec972b10c7b0493883f2bd7563ffbd99_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8cfbea1e8ef24573bc5a395f4dc46921_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic0afc2d9300442c481f53a34f4d5eadf_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i3cee6a4e627d4c4281ce1b29360ea956_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id3511302b1ae41809e6440adaa75a4b8_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i69417898b97a46fbb70d8ba92644a167_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iac5940573a824aea9b11c62a69e8e3fe_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8a54ac8edede45ddbaab8f1db84179d2_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia2ad067eaffd4f1391d0486fc4161840_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if080c4dd59e944648097620649b8fb6f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2b2d16f32fba47f09eaaea5712a0b4fa_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ie9de68fe20a54bb3938d8f34bc55a8a9_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iaa43d68970b74de495b2ce1d7600846a_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="idebe2f3e24dc4867b6dc012fde3f09fd_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib6f3f4cd739b446e89e809b5ac4d5df4_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i2a98910058dc499f9afafc26d4f8d7a2_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8c52fe15105d49e18829d0a70625bdad_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9cf69631e6a64a778cb06aa103ea457a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i25d01b70ce6a4d158b8e85edb95cab4a_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ic10b7e28bcf94b0f8cf1550242af73c0_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1ccc8d4aa3944fc9a6f5d46048c4e46b_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i0a43fa091bd04904af477b8da882ccc9_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i63ca74a38d344c029cb03ec16c2adf4e_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ie1056e17dd9d4f2cac9bf0fbd592a173_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0278ad7c322f4c488129c6b911f43d45_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8d4763b134be49d4b30da01bf1ba44e0_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia8b19e46a75b4847a0c6f53f552cfbc8_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ie48200892c424f87b7edda0ba0409c96_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i96c5442217af4f099da88cd8d2d16584_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i769a39b459364823ac7bbeb1e988ee9a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id3d972234fcd4ba498f466945a9c4cc4_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i3f07da4bc71140e69f2cd469df1ff0a4_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic1c7abf55c7f4cd1825fbdb35e87d736_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i871b3677375a4491991a21ca121e6485_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic19c69b6d1454567bbf90da51c867584_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i712cec174e7a4562b67a334df7885636_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib6cb98336e1146a28b4c4b2c51be0b43_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i0c23981dbe7c474d94010c344d4e9738_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3eaafeabe91c4ea48c2ad1d1f12dba58_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i24a8dc58bc5a4da4ad5d964b5437e8b6_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8f8096a899854fcf930ca0cea72e522b_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="idf849323318a42d78e841021176dc0db_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3881e94557524789a9ff7fc5efb2d29a_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="id087d3cf08544d0e8465c05939e54c06_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9f4ecbbe64184af588dc9aa7b93d8f9c_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i90325c74593949fc87a8cc588c4f9fee_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i794c9a7bb0c54961a3e9869aa082ba42_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i123f5966e05a44d085563e3eeb9a895f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ide5f1afa7b3f4d9c86ef358c4ed464c0_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i12bbf63564d04cae9ff269c9f4bbb527_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="icfc39cb498d44439a78cc49f5f336acd_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i4b9a89680513428485a34f3f48c896f6_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7783e4e0f34f45f8b3873d934bac73a8_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9ca9de72471f4144afc322742d3ee277_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i87786ad4f32e48449a1996e1153a6164_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i1fe0a5b0064547b1a5b98fe08aa407bf_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i782d96754043498593d177ed7e9d7435_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8ad2d868e8f94f1ea0241239aa8abf8a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia564284c6bec4f09a465f098bbfaf35b_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i2237e862843c453cba68d7ee3d286ba2_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i06dac5d761d243b8861130b807832ca5_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i1d2cab6e4a2f4243aff50d87fb678757_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i56e25388aba946e39f461155f1e66bb3_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if1ed7f86f44840468b3a6ca64ad69b92_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2ac1b72498c54651b9f3390eaf7bc4a4_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i78be76eb6d4c4d7297a4bf4093369453_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic869379c2ad541c399cbf3c1fb6a954e_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="id9c30797b0cf4d2cb47f26f7a4501b8c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ibedf86a241dc4b5bbb19ba292a60a3fa_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8b64f045460a4ca8858056eef80e48c5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1cf5f96085f349f4b87d2aa43da1a71b_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i4c259fa6ac434248908eaf1d9085cbae_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iab22b59ea5b8436eb6d4e323ffdb8113_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ie92f35e3cc8049518e4c913312f61c94_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i75a7e770b127440794059c8ec0d770e5_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if67e32a6ba574c4bb1df1943ab8a91c6_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib935f1d5a67d445e8d777642f2400a7a_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PROCRITEPREXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i3db4b7b2b9104e8aa81ffe56c63244b3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9c6a9d00e90848c58e88acd8954635ae_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i9387bd1d4a9542529ff61ba379041ef5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iedc20ebf5bd042ad896ae4efdc519047_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if65d5eedb28a4d1fac8ffba1883d31d7_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i36ee165c65f3448d9fd58f57b88afb73_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i0a203809cc6644f48256490ae13f0ab3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i438067415c5c4f5985d9ae849a5e2a71_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="id10068aaaa974a5aa7d0db7ddb857b8a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3b613e89c6de4696b5f46fb3913eb864_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ibdca448a11c64bc48442f40fa88d4ce3_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i6eda2d70fc65473fa36d660afce9a681_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7f0decb1dd364c8da7e609d042602990_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i7d9df6ec7e15475b80a0ddd952dd424b_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id3f8f49e166a42308c773c330db2cdac_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i0c9c51f138064f7693ff21bd0cbc01dd_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i80a728efc7c4431185d2257b26f2c766_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i046c37ec387d418792e0b7796ecad6b5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic3aa1d5138aa4eef99d2d397be8bb5a9_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i04925e843e58499d8cb79ab41d517312_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i311fa4ee096d498cb9fc15d6e2eac138_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i5de8902fb1d64e47b0f656f4518cc948_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id1b6bee78af44dfb8c09e1d37795edec_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i2eed8f3fd6bb4026b042b674919fe034_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6edb3ee83adb4242bda5469bdac2cd58_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i51f6c8b86b7546149befa4e5f3fca4d5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idebb01df50a34ff1b884a2077e7460a5_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8154d1203f304af6adf50d35bf4f7880_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8740a5ae1646469f9c8fd93ba62467bc_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i06f962900d174483a2d8ef350b1d7647_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4a878e7d9cdf44f8a0e5b960ec217e8b_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="id864ff961e674fb1b62f80b8c6932ea9_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib2c551cbda52435687542e1e45b23fd4_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i67be5d04e3c440f888ad9161a9e5eda7_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9037030323674d438622ead7d2365cee_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i03bec226c4414b32b21f05d00c95bd73_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1806bc88b23744e38bf7a4a18ee82827_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ic4fc05c968db431dafa927a4b29febff_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib713a362c12a4e0f8c0fdb3f559dd81d_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i0230b4c2f04f45c08018028261942d70_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5da6efb5d0a745239d6361465c0a8cf7_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i59adb5a67adb476b8ee2fd372e3f1de0_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5d6ab8313ed7411fb9fcccd2fb2fc054_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i70464af74e1244fe971e0ce8df9c1139_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i87c7441a2ff64814bc9edd9ebb11379a_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i2f75cbd2f3e44e86b3159f06713cea79_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i46794c3f5f7641c28479e5843b966ae4_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ifbbac775d46c4b0caf203e09c5683d11_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i73332a11822c4dfab9561d066cb74b28_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i381d0ba83d1f41bdb53476e56a42a36e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="icae9f5809e1e453ca62e9f4b2040f4f4_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="iee3f3e37530b4bc5bc81e9b8b73ec767_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i373fb25b6ac74376b24f1838469cdc56_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i1d757ba0d9b54fa8a6d3b798835d364a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib89e19ebfa6741fab1ef7e4ccb9bce83_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i829ccedf81764d70b896a39ffc2b8d95_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia475a9342c1549239a4b78261b9b833c_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ia646bd76b4f54d908a6d0888a0bab427_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="icc399b9993724391a7b071eb85f26048_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="icc92d2e4cf8a4de7b8c3172a78c2d8ff_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iab081c7294c94dacb3f3da911787176a_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="id694df27cb364c85abe72911f2a4f74b_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iaee0751bab8e4f7b823728d29fc3a815_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i309da13ba23248d2bbd4befdd7ec001c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i52d6c8b409ec42199210aa34c876fc99_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="icf3ceb4f65cc4b228df4f27cfee4babf_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia0ae566a0efc441eb0fb6ea1cc2e1608_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="idae5fbf3821e4b25b63bbfb4f1173093_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0fa44b2106d7456086d7300b833a26cc_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i173c358b9082487dacc6b62f9414e27e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="if4d24994a8ef4424b6c1f77a1a7134a4_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i44aeed20d86c44c5b5a4ebeafec47aed_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i51883c3c4f5f4d9989d8ea8605f231dd_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i5d094f0fc9b241f89a961261247144f3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia3abe5bb0d9c4e3298e7a1b39eb3e953_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ie1952414febe4c02a498725387577ba4_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i12f37539b91d45b7b48a375afd131b53_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="id8585c10f5564b039e486807c6255230_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3e06d38a4dbb4397aa56a49e80a320af_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i317a97ccb069420ab772ab1f52d977ba_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ied6815bd7b754e4a902dee41b3bff0ac_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ib2ac2702e3294ccc936243e7e77b3337_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8d9f04a32215495f8fb5d9251c0b8172_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i0effaa8d4d19429294ebb6baadb91fe8_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5dba1ed2af8443a0a29e304aa9362c9e_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i27ba1a98c3ed46fea5a3c71020abc7e5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1eeba07dc96844578537afa4da1d4909_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i88511d277635488580602c5f2d2efbe9_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ibc1d3ef8e82b4cab9d2f209a70930bad_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia49cb056ac9642fab13eb3c45dd7beb7_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i61df9a2348d5485696295a61a5f0b0ba_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7dc14d98635140cf98a64f0c2425a440_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8774a60d6f6649268ae5cf40efca6063_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6f824bef77534b77acea435e4bcf50ed_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="id645f8a91fb54b40adfd453cef0dbd05_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia347c7ffc8b448789de799026384d1b8_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i46b22e45743641e680c31d8beb794e56_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idfce5280afb34c08b7d2df0de5af45e1_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="if4237eb3d9454518b7d9808794278432_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia6730cd63c2644e6b98a2fca79af18d2_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i7090787364da465d986409e41cdb9e8e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic00b4438aac54f08b9632ab4416202d2_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i67972ac0db9340ad9d3acaa558c457e3_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i4aeec3665cb149868af31f13c90e99f3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7cff44da9a7a458490003f90a4b032fa_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i5e19dfed28af47909fc2e122d61ba3e1_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic3d17e0cdb3e4dc9a51f76c0b873f000_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="ia707285795354a909320047e9adde65b_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0d72ee63d68e465c9fb647ef821fca86_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i6f4c6a54630d423ab63d36db8db32449_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5d9f14bc65a147d0b6ffd1245515b56e_D20191230-20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="i8daceaf8ad2943238f7e0666635677be_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="i0ebc13e73dd24d8bbb4f49c2c087c1ff_I20200329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VerbSurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="ic5b57e148881429fbffa7b15c1969483_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i32c65ab8cb634ad9bd5a0e2f7d30a359_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="icd5cde0149284609a90fe89bccf88fe6_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i08582f9cef4d4567a55ffdc339dd9b58_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i4720b5ba970c4ae58eeca3720feaa0b3_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ibaeacf387226456196518be5d4285e6c_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="if6fb78dabc7c431c8db3fa456cae770d_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i41413d437f794ec3a9f045f6a27f2722_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ifd2cd7a8594949e083f88b8b79935b39_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i9b1fe073177c4b3ab83e3d3452139524_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i13f02d9a0d3b4b66a1c40f110cbc1e1e_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i6d9b48d0973f493eb3ab6b9a6476c385_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i709811f027d74897b86c8f1d12b504ed_D20200601-20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="i62bf76445bd948c38790ffcd119476a4_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5db493405e0444d89bf7eaab26517bde_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i6e04dd168b1041b3919b1a56f47b4ecf_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2f0753d19d5149c091394208cbea890d_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i851c9cc374994813ad167606b1ea44ed_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="id807403c46b245c9bd8b6055a4d42cef_D20200120-20200120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-20</startDate>
            <endDate>2020-01-20</endDate>
        </period>
    </context>
    <context id="ic02f715544ff4105bfd2a3c2d151ac0c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3b908089cc6a4f068612a9b2d5d34ca1_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i96add54e896749258f1ad0c9536687a7_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8a22a8f09eac408299c442ea44cab0af_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1552e8f8c0724beea6478ac55c3106db_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i95abcc6431244e8a90f59ff7792cfc79_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i2e03a943b1aa425496029ce0733bd863_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i0290e1c992b748a9908d71498dc82a4e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3aabc22a7d5a4aa597cd7da431d465a3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8f3ba126d47a4b5a846574f6d9d31fa6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib0b5e6d446af4a1ca2c03a629dbf4eae_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i009c62493dd242ae928d25a27ed97197_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i36ee9965a40148bda5e997a88d5d4930_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i52afe008fb4f4c819028d3daabd32602_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i50377f6db9174c48a6ce24be02ba8d60_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idca084b4733440fcbbf545f29821a06d_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0856470384d143029d8218bb9189e71f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic1cbff6b8f7d426ab49cc6dad88e6c0f_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i378ddce2634145fcb6a28fcfb5b8592e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ia10eefa077224d8094f6feb17315c535_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i9d58eb1fecdb4c148121d9d91c2a78c6_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="claimant">
        <measure>jnj:claimant</measure>
    </unit>
    <unit id="patient">
        <measure>jnj:patient</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83L2ZyYWc6MjIwZjM1MDAyNDRlNDBjOThjNDEzYTIyNTA5MWIzN2YvdGFibGU6NzkyMDY4MGViM2ZhNDMyMDkwZTc2ODYzZWZkMTBjODEvdGFibGVyYW5nZTo3OTIwNjgwZWIzZmE0MzIwOTBlNzY4NjNlZmQxMGM4MV80LTEtMS0xLTA_4b902f60-716e-4910-a918-92b6db47126a">0000200406</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83L2ZyYWc6MjIwZjM1MDAyNDRlNDBjOThjNDEzYTIyNTA5MWIzN2YvdGFibGU6NzkyMDY4MGViM2ZhNDMyMDkwZTc2ODYzZWZkMTBjODEvdGFibGVyYW5nZTo3OTIwNjgwZWIzZmE0MzIwOTBlNzY4NjNlZmQxMGM4MV81LTEtMS0xLTA_108187ad-57a2-43d9-9e30-ea4afb331f66">--01-02</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83L2ZyYWc6MjIwZjM1MDAyNDRlNDBjOThjNDEzYTIyNTA5MWIzN2YvdGFibGU6NzkyMDY4MGViM2ZhNDMyMDkwZTc2ODYzZWZkMTBjODEvdGFibGVyYW5nZTo3OTIwNjgwZWIzZmE0MzIwOTBlNzY4NjNlZmQxMGM4MV85LTEtMS0xLTA_8874e416-d5d7-4e80-a4ec-f426e59921b6">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83L2ZyYWc6MjIwZjM1MDAyNDRlNDBjOThjNDEzYTIyNTA5MWIzN2YvdGFibGU6NzkyMDY4MGViM2ZhNDMyMDkwZTc2ODYzZWZkMTBjODEvdGFibGVyYW5nZTo3OTIwNjgwZWIzZmE0MzIwOTBlNzY4NjNlZmQxMGM4MV8xMC0xLTEtMS0w_7b92d37e-ecd9-4b9b-bee4-74032abf94f9">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83L2ZyYWc6MjIwZjM1MDAyNDRlNDBjOThjNDEzYTIyNTA5MWIzN2YvdGFibGU6NzkyMDY4MGViM2ZhNDMyMDkwZTc2ODYzZWZkMTBjODEvdGFibGVyYW5nZTo3OTIwNjgwZWIzZmE0MzIwOTBlNzY4NjNlZmQxMGM4MV8xMS0xLTEtMS0w_515b572f-0a58-4cd8-a709-5be06ec17e32">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDY2_380bdbdf-6110-46b4-9de3-152364cadc13">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6NDU3MzAyYWFlYTFlNGJkNmI0NWU1ZGU0MDUyMzFjNGUvdGFibGVyYW5nZTo0NTczMDJhYWVhMWU0YmQ2YjQ1ZTVkZTQwNTIzMWM0ZV8xLTAtMS0xLTA_74ec096b-2878-44bd-9e59-6360e720eac7">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8xMjI_6190eb87-ce2f-4611-abaa-ee4ea1842f55">2021-04-04</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6OWQ3Njc4OTRjMzQ4NGIxZGJkYWU4MDIwOTNjYWYyOWIvdGFibGVyYW5nZTo5ZDc2Nzg5NGMzNDg0YjFkYmRhZTgwMjA5M2NhZjI5Yl8xLTAtMS0xLTA_aa5313a5-809d-4374-89ea-af8e991536e1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDY3_5eaf7f5c-5c4c-4648-a129-02dffe2629f2">1-3215</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDcy_9ef1b45c-4c23-42b2-b109-c77153b8b92d">Johnson &amp; Johnson</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MDcxMjQzZmQ2M2I2NGEyYjhmMWFjYzBjOGEyYWJmODIvdGFibGVyYW5nZTowNzEyNDNmZDYzYjY0YTJiOGYxYWNjMGM4YTJhYmY4Ml8wLTAtMS0xLTA_9b6599ad-7861-4e1f-8fb4-138975df9df4">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MDcxMjQzZmQ2M2I2NGEyYjhmMWFjYzBjOGEyYWJmODIvdGFibGVyYW5nZTowNzEyNDNmZDYzYjY0YTJiOGYxYWNjMGM4YTJhYmY4Ml8wLTItMS0xLTA_984958d1-67eb-4f33-876c-75e2d91401e3">22-1024240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDcz_1852a8bc-b74b-4034-bba8-064a30007846">One Johnson &amp; Johnson Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDY4_bfc42653-6e7b-4e14-8a50-17f3331a578d">New Brunswick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDY5_86f58ff8-2160-48b9-ac73-f323d5ff80da">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDYy_8ee14754-bfe3-4a8d-a3be-1c7bddfbf7d6">08933</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDYz_dda649d0-4db1-4d3a-9342-cc8552070302">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDY0_688efaa1-5cc1-475a-a976-fd5436b4e606">524-0400</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDY1_acafa34e-81ef-4abc-afaf-d3b6eae42952">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDcw_11afba81-9d4b-42ca-ace9-cc496872247e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6OTAzNmZlMzVjYmQ1NGY0NmE4Y2M3M2MxMWQ1NDcxZWMvdGFibGVyYW5nZTo5MDM2ZmUzNWNiZDU0ZjQ2YThjYzczYzExZDU0NzFlY18wLTEtMS0xLTA_9cb2d50b-5b54-437d-ad00-d36164e00291">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6OTAzNmZlMzVjYmQ1NGY0NmE4Y2M3M2MxMWQ1NDcxZWMvdGFibGVyYW5nZTo5MDM2ZmUzNWNiZDU0ZjQ2YThjYzczYzExZDU0NzFlY18xLTQtMS0xLTA_d37983b8-0aea-450a-b01c-4409a238ec78">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6OTAzNmZlMzVjYmQ1NGY0NmE4Y2M3M2MxMWQ1NDcxZWMvdGFibGVyYW5nZTo5MDM2ZmUzNWNiZDU0ZjQ2YThjYzczYzExZDU0NzFlY18yLTItMS0xLTA_62e07e17-79ef-4395-b0a7-e732cd57a2df">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDcx_b8bb9d7f-a4f4-4ee1-be8d-afa187b7fa3f">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="ie0aa473acf8a4d8fab6230244556c8da_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8xLTAtMS0xLTA_33543ead-4582-433a-831e-0be89d9bb73b">Common Stock, Par Value $1.00</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie0aa473acf8a4d8fab6230244556c8da_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8xLTEtMS0xLTA_a280448c-34f4-432a-987e-a4f8ad5f7c3f">JNJ</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie0aa473acf8a4d8fab6230244556c8da_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8xLTItMS0xLTA_f09e4dc0-1692-4185-bc71-ab83330176a1">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ic746560139dc41349deb2325633b7ea4_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8yLTAtMS0xLTA_61352186-6f7a-4a1a-88d5-9eb1aae8b98b">0.250% Notes Due January 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic746560139dc41349deb2325633b7ea4_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8yLTEtMS0xLTA_8d45afcc-1390-4a95-8f71-c8a1c6b9db19">JNJ22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic746560139dc41349deb2325633b7ea4_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8yLTItMS0xLTA_ace9fe1e-c77c-4058-938d-e188e1c4aa9e">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i2783afe2aa264bce937ed802ab36bb6f_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8zLTAtMS0xLTA_8dba46a4-7f3d-4f32-8c1e-ab12ecc0a90e">0.650% Notes Due May 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2783afe2aa264bce937ed802ab36bb6f_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8zLTEtMS0xLTA_392efad8-a0fc-4ec2-b3b2-0a769e2d293c">JNJ24C</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2783afe2aa264bce937ed802ab36bb6f_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl8zLTItMS0xLTA_7eabcecc-d52e-4b5d-bd8b-bdb34c2a65c3">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i143b4f489f304a75aa99c0136cd5ebff_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl80LTAtMS0xLTA_ffdb027b-a238-4557-91d3-4fc0793a291a">5.50% Notes Due November 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i143b4f489f304a75aa99c0136cd5ebff_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl80LTEtMS0xLTA_33a3f6af-82db-422d-bc1a-7bf84a24e187">JNJ24BP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i143b4f489f304a75aa99c0136cd5ebff_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl80LTItMS0xLTA_fac92212-edd9-43d9-b305-e5a0ff46652f">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i11b2ac8bef704242b9043de1cdfb6053_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl81LTAtMS0xLTA_15ee8d1c-7ddb-40fe-8cd9-3b6efca9c395">1.150% Notes Due November 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i11b2ac8bef704242b9043de1cdfb6053_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl81LTEtMS0xLTA_7faa71d6-0e3b-4b86-87dc-212e19634166">JNJ28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i11b2ac8bef704242b9043de1cdfb6053_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl81LTItMS0xLTA_735c1bbf-c86b-409d-a9d8-13c244d891cb">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i224f75bae26342ffb97488937c270d87_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl82LTAtMS0xLTA_23a4a3c8-7d69-4582-a552-3e99caca8318">1.650% Notes Due May 2035</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i224f75bae26342ffb97488937c270d87_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl82LTEtMS0xLTA_1e988b86-de5a-4219-b9ab-af6c6084003c">JNJ35</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i224f75bae26342ffb97488937c270d87_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGFibGU6MTk2MjUzZGMxYWJkNGYzNmIwNTg3YTA1ZmE2Mjc0ZmYvdGFibGVyYW5nZToxOTYyNTNkYzFhYmQ0ZjM2YjA1ODdhMDVmYTYyNzRmZl82LTItMS0xLTA_b34759eb-c837-4d80-bab7-fd2e8d088d1e">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ifde8fdc6f153456891b3a67798d76d3f_I20210423"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8xL2ZyYWc6ZThlYTgwMTY4ODJkNGM0NTlhZjcwODg1NDcwNzJjYWQvdGV4dHJlZ2lvbjplOGVhODAxNjg4MmQ0YzQ1OWFmNzA4ODU0NzA3MmNhZF8yMDAx_5186a535-3b8f-4295-9281-a494dadcf715"
      unitRef="shares">2633396003</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMy0yLTEtMS0w_ea04587e-bd63-46e4-bede-da1bacd96200"
      unitRef="usd">12671000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMy00LTEtMS0w_336a3158-5e08-4840-8b4f-1e7e6e81ec76"
      unitRef="usd">13985000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNC0yLTEtMS0w_1e4e83ab-140a-4759-8fa0-862474fba010"
      unitRef="usd">11948000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNC00LTEtMS0w_829e900b-6232-46a0-b806-cd5143f2bf90"
      unitRef="usd">11200000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNS0wLTEtMS0wL3RleHRyZWdpb246YTk2ZmUwNDMyMmQzNGYwZDk0MTE4NWZhNzQ3NDQ0MDJfODg_7ae82640-fbad-42d8-9430-3d12c644f034"
      unitRef="usd">270000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNS0wLTEtMS0wL3RleHRyZWdpb246YTk2ZmUwNDMyMmQzNGYwZDk0MTE4NWZhNzQ3NDQ0MDJfOTg_9fcb06a7-d47b-4e95-b3b8-6678e10daf18"
      unitRef="usd">293000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNS0yLTEtMS0w_a5d1eedf-5d0e-4b75-a6a8-fc932b618c1f"
      unitRef="usd">14938000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNS00LTEtMS0w_49c35633-e6c1-475f-a730-8f347780e4ad"
      unitRef="usd">13576000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNi0yLTEtMS0w_c23ea3a2-7e2b-4add-b893-1724671a7007"
      unitRef="usd">9952000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNi00LTEtMS0w_29d969fe-f9b5-47dd-aba7-7d76e1673b3d"
      unitRef="usd">9344000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNy0yLTEtMS0w_607021da-3797-4839-ad8d-f2083a2f3a8a"
      unitRef="usd">3024000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNy00LTEtMS0w_ea4d4f5e-863e-422e-b656-cd17bf38d565"
      unitRef="usd">3132000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfOS0yLTEtMS0w_58694b0d-22d7-4102-ba45-a8af0235ceb0"
      unitRef="usd">52533000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfOS00LTEtMS0w_cba32ba1-10e6-4cdc-8509-1013c38cdcad"
      unitRef="usd">51237000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTAtMi0xLTEtMA_794b1671-2e06-4650-8a41-ca9b88ab388b"
      unitRef="usd">46430000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTAtNC0xLTEtMA_636da5bd-e4e0-4b4f-b134-59db45ef400e"
      unitRef="usd">46804000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTEtMi0xLTEtMA_0351379a-da93-4c25-b61c-b5f8b609ae25"
      unitRef="usd">28063000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTEtNC0xLTEtMA_e0e4c0c8-6058-4dee-a234-2a1cffb71711"
      unitRef="usd">28038000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTItMi0xLTEtMA_c7f0c2b8-a662-4ffd-a213-4f5ec7e9227f"
      unitRef="usd">18367000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTItNC0xLTEtMA_d1bb90a1-f2c1-4381-a59d-12364cdeb49d"
      unitRef="usd">18766000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTMtMi0xLTEtMA_daea7e21-ae5f-45d2-8ec3-41b0081f615e"
      unitRef="usd">51110000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTMtNC0xLTEtMA_425539fa-0fe3-40c5-9132-b52611586896"
      unitRef="usd">53402000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTQtMi0xLTEtMA_d86e8e04-e3a9-42e6-9cce-bc77d199a354"
      unitRef="usd">35688000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTQtNC0xLTEtMA_f1d23e80-7247-4f59-9945-0668104946e5"
      unitRef="usd">36393000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTUtMi0xLTEtMA_6e13c0a1-a806-4bac-90f9-d2c67d17abbf"
      unitRef="usd">8321000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTUtNC0xLTEtMA_362a25d0-a1c1-4c45-833e-aa8415279689"
      unitRef="usd">8534000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTYtMi0xLTEtMA_e2045ade-8de0-42e5-8623-bc53abf526d0"
      unitRef="usd">6538000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTYtNC0xLTEtMA_5f926787-3856-44bf-8510-8cedb4b3be79"
      unitRef="usd">6562000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTctMi0xLTEtMA_e83ed07a-0e96-4119-a5fd-d8eddb802d22"
      unitRef="usd">172557000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMTctNC0xLTEtMA_6c35b75b-b232-4408-9355-efa92733c2cd"
      unitRef="usd">174894000000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjAtMi0xLTEtMA_8a48e019-4e53-4b82-b49d-61c5e815e403"
      unitRef="usd">3350000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjAtNC0xLTEtMA_74106587-7c47-4b0b-b1e0-209e9e13e0b9"
      unitRef="usd">2631000000</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjEtMi0xLTEtMA_7f7160a2-dce0-4bd2-99cd-833bfbc38abb"
      unitRef="usd">8503000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjEtNC0xLTEtMA_db67bcf7-f045-477b-9264-bf42baf3ebcd"
      unitRef="usd">9505000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjItMi0xLTEtMA_249c0b30-951e-4ed8-b088-abfd37f7600d"
      unitRef="usd">13223000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjItNC0xLTEtMA_bb9081f4-f860-490c-8b6d-e0379415990b"
      unitRef="usd">13968000000</us-gaap:AccruedLiabilitiesCurrent>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjMtMi0xLTEtMA_d6e46dfb-b47e-47a7-bb15-ed7aa0a42e24"
      unitRef="usd">11919000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjMtNC0xLTEtMA_01ff0c08-8e26-43cb-a252-5b962bbbf1e7"
      unitRef="usd">11513000000</jnj:AccruedRebatesReturnsAndPromotions>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjQtMi0xLTEtMA_18964d22-3cf9-4594-ab4e-de0a9cf0958c"
      unitRef="usd">2060000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjQtNC0xLTEtMA_17672ee2-83a1-4437-8935-651439e8e081"
      unitRef="usd">3484000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjUtMi0xLTEtMA_9f5678a3-bca9-41e4-8ad8-9a43b7f22503"
      unitRef="usd">1877000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjUtNC0xLTEtMA_a9b64bbf-2db0-4bf9-8be0-d4b4ab7e1253"
      unitRef="usd">1392000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjYtMi0xLTEtMA_4ac95e2b-6329-4a18-8763-a565c419675c"
      unitRef="usd">40932000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjYtNC0xLTEtMA_05dd8e3b-cbb4-4f50-93b0-6d946516ff2d"
      unitRef="usd">42493000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjctMi0xLTEtMA_22e26871-1b12-41f0-bed1-ca2d755ad6bc"
      unitRef="usd">30263000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjctNC0xLTEtMA_ceeafa0b-9dc0-48d4-a9a8-3c8f2414687e"
      unitRef="usd">32635000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjgtMi0xLTEtMA_cf54771d-88de-4caa-8a55-02aaae2d1588"
      unitRef="usd">6507000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjgtNC0xLTEtMA_270d791a-f9b7-4ce5-8dd2-d4095cc001ed"
      unitRef="usd">7214000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjktMi0xLTEtMA_97c833b7-8e66-4c3e-8e4d-b64fa7190e7e"
      unitRef="usd">10512000000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMjktNC0xLTEtMA_ffec4349-80fa-402d-8501-3705ef82895c"
      unitRef="usd">10771000000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzAtMi0xLTEtMA_2748a117-6605-402b-b683-595c7729930b"
      unitRef="usd">6568000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzAtNC0xLTEtMA_42b62ad8-d3b3-44e1-93cc-93f0744c2e7d"
      unitRef="usd">6559000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzEtMi0xLTEtMA_4f8d73fb-0d15-47e0-bbdd-52506543e329"
      unitRef="usd">11941000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzEtNC0xLTEtMA_baa51517-ebbb-444c-a325-72b8254bf88a"
      unitRef="usd">11944000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzItMi0xLTEtMA_e72dce38-6f55-49ad-8652-751fb85567ae"
      unitRef="usd">106723000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzItNC0xLTEtMA_3af66a18-cc5d-411e-9371-98ca0622ad70"
      unitRef="usd">111616000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzMtMi0xLTEtMA_328524da-db51-4234-9787-54e372ad0d92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzMtNC0xLTEtMA_7379be89-5ef2-4919-b3f5-7f38eb3e1db1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmRkNzgyYWEzODY0MDRjZmU5NDJjYTY1NDUwNmIyODAyXzI5_0ca6ae09-e13d-40f9-b9f2-55fb006d6bf5"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmRkNzgyYWEzODY0MDRjZmU5NDJjYTY1NDUwNmIyODAyXzI5_bc2dc826-1e43-4730-94d2-32e853d97db2"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmRkNzgyYWEzODY0MDRjZmU5NDJjYTY1NDUwNmIyODAyXzU0_c834f35d-eeb2-4647-9e55-4aaebf079641"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmRkNzgyYWEzODY0MDRjZmU5NDJjYTY1NDUwNmIyODAyXzU0_f7b540eb-d02d-431b-ad86-2ebca88486f0"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmRkNzgyYWEzODY0MDRjZmU5NDJjYTY1NDUwNmIyODAyXzcy_0580e30a-ab04-4b41-89bf-f227c0b7efa0"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOmRkNzgyYWEzODY0MDRjZmU5NDJjYTY1NDUwNmIyODAyXzcy_a446190b-29ca-41d3-988b-92287ab4c07a"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtMi0xLTEtMA_2e157177-aba6-4d8e-9e54-986f349c9558"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzUtNC0xLTEtMA_4ddfa7dd-d3e1-4180-938a-cf52d0a527cf"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzYtMi0xLTEtMA_c651fb06-6e84-4722-9483-d28f56148b7e"
      unitRef="usd">-15328000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzYtNC0xLTEtMA_6a443f6c-0189-4a66-b672-f3b6a94cba3e"
      unitRef="usd">-15242000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzctMi0xLTEtMA_09b7a172-f14d-4df1-b43c-6c080c8fce89"
      unitRef="usd">116508000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzctNC0xLTEtMA_ef0894c9-5097-4572-b727-02369a5b7ac3"
      unitRef="usd">113890000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjI2NWI0ODllN2VkYjQ5YTc5OTdmZjliYTI0MmEzZjYxXzUw_c07bdcc4-17f9-4912-8d16-b9381b06d511"
      unitRef="shares">487141000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjI2NWI0ODllN2VkYjQ5YTc5OTdmZjliYTI0MmEzZjYxXzU3_872a6eb4-af20-42d8-bc00-c670a7ab42a7"
      unitRef="shares">487331000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzgtMi0xLTEtMA_0ddca983-962f-4c73-9d16-09c0a5c51c5b"
      unitRef="usd">38466000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzgtNC0xLTEtMA_00da024f-edf2-41f0-89b7-60264326aa06"
      unitRef="usd">38490000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzktMi0xLTEtMA_9ce76a0e-2a87-40bc-b8b6-1c423cbba6c6"
      unitRef="usd">65834000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfMzktNC0xLTEtMA_fa5baab5-afd1-41ed-aca1-1f4acdb50814"
      unitRef="usd">63278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNDAtMi0xLTEtMA_83664fe0-9eeb-4b02-a017-61f10f7c7ba8"
      unitRef="usd">172557000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yMi9mcmFnOmQyZWYwOTI0NjAzYjRmOWNiMTI2ZDk1NTU0ZjU5OTg0L3RhYmxlOjZiODAyNjNiMTBhNzQ1MjNhYzdlNDhlMjVmYmQ2YTc2L3RhYmxlcmFuZ2U6NmI4MDI2M2IxMGE3NDUyM2FjN2U0OGUyNWZiZDZhNzZfNDAtNC0xLTEtMA_1aa17da0-36b7-4c70-9ebf-e7171ab1c15e"
      unitRef="usd">174894000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMi0yLTEtMS0w_693445e8-5fad-4081-8e52-9525cb735422"
      unitRef="usd">22321000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMi00LTEtMS0w_3de7e9e5-0b2f-451c-abe4-ea0e305ec0b6"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMi02LTEtMS0w_3f6de200-8518-42cc-85cd-a423aeffc68f"
      unitRef="usd">20691000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMi04LTEtMS0w_0cbe3fc5-e24d-4086-ae08-d4c664b6d70a"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMy0yLTEtMS0w_37b28962-4cf3-4aeb-ac0a-652e4386c685"
      unitRef="usd">7063000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMy00LTEtMS0w_fd2cc3b9-da17-46d9-8ce0-c6e473c06cd1"
      unitRef="number">0.317</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMy02LTEtMS0w_cd579375-342e-4463-bcc2-f32dc24fefe9"
      unitRef="usd">7062000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMy04LTEtMS0w_0bf4a40b-2518-4691-b00f-6490464ed4bf"
      unitRef="number">0.341</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:GrossProfit
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNC0yLTEtMS0w_36180ef9-52b2-43c0-960d-3c73dfe42017"
      unitRef="usd">15258000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNC00LTEtMS0w_4b84f74d-3d16-4c0a-b7e0-d0317e5caeb2"
      unitRef="number">0.683</jnj:GrossProfitPercentToSales>
    <us-gaap:GrossProfit
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNC02LTEtMS0w_7d9cb2b4-d1af-4713-9f1a-d8b2dcd2de19"
      unitRef="usd">13629000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNC04LTEtMS0w_da9273f1-d3f1-41c0-8bf1-684c34433a9c"
      unitRef="number">0.659</jnj:GrossProfitPercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNS0yLTEtMS0w_eb144445-c6ba-49ac-8e10-b7850856785e"
      unitRef="usd">5432000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNS00LTEtMS0w_faf2cca0-9501-408b-b90e-c271df75cc3d"
      unitRef="number">0.243</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNS02LTEtMS0w_84ea302b-a9a2-402b-bcea-9d8a0ffcf099"
      unitRef="usd">5203000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNS04LTEtMS0w_5198d0e7-52e2-408b-86ce-b21040207e01"
      unitRef="number">0.251</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNi0yLTEtMS0w_48f99fe5-64dd-4ac8-9bc2-f15b4952b3ea"
      unitRef="usd">3178000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNi00LTEtMS0w_5d67763b-5c56-4326-9b31-62a88d63ca0e"
      unitRef="number">0.142</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNi02LTEtMS0w_c5142440-af0c-43f1-8602-6dd73a82de5a"
      unitRef="usd">2580000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfNi04LTEtMS0w_a0922dd6-edf9-4327-b8f8-49b8154a74b2"
      unitRef="number">0.125</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOC0yLTEtMS0w_cef3aa6e-966a-4d3b-a49a-8a129a7d0517"
      unitRef="usd">15000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOC00LTEtMS0w_ff51be7b-a958-4801-aa2a-6060029eec6d"
      unitRef="number">-0.001</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOC02LTEtMS0w_e43026a3-b9b2-4926-9550-d9e41351a261"
      unitRef="usd">67000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOC04LTEtMS0w_2a0df218-f06c-400f-8247-05b0f30baba5"
      unitRef="number">-0.003</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InterestExpense
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOS0yLTEtMS0w_219eb7ff-2023-43de-8f27-cf09a9460f56"
      unitRef="usd">63000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOS00LTEtMS0w_26cf0c2e-2c6d-42b2-82a3-fa321050a166"
      unitRef="number">0.003</jnj:InterestExpensePercentToSales>
    <us-gaap:InterestExpense
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOS02LTEtMS0w_3b0db69f-f049-457a-b74c-a31a670d8d3b"
      unitRef="usd">25000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfOS04LTEtMS0w_272b8240-bb08-41a5-ad2a-8bb78dfb1bd9"
      unitRef="number">0.001</jnj:InterestExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTAtMi0xLTEtMA_fcddb69c-5acc-4293-ab67-46caed4996da"
      unitRef="usd">882000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTAtNC0xLTEtMA_17e96aa0-98b1-4a95-81b9-28caec2b314f"
      unitRef="number">-0.039</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTAtNi0xLTEtMA_cbffe618-b0f6-4265-95a6-e203cec17a9b"
      unitRef="usd">679000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTAtOC0xLTEtMA_98ecc5c8-e108-4919-b49e-23c6e8269fd5"
      unitRef="number">-0.033</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:RestructuringCharges
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTEtMi0xLTEtMA_2a5c2a16-285b-4953-b72a-ded6d1b59bcc"
      unitRef="usd">53000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTEtNC0xLTEtMA_c19b613c-87ea-403b-bcb0-f60e5f22c1a2"
      unitRef="number">0.002</jnj:Restructuringchargepercenttosales>
    <us-gaap:RestructuringCharges
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTEtNi0xLTEtMA_c0044e62-eb06-4ac8-828b-77e7f19044ee"
      unitRef="usd">58000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTEtOC0xLTEtMA_e3f7f33d-307d-4eaa-bd37-78b64b080c98"
      unitRef="number">0.003</jnj:Restructuringchargepercenttosales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTItMi0xLTEtMA_3f24c895-214a-42c7-9f3e-1d34a2574709"
      unitRef="usd">7429000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTItNC0xLTEtMA_e4ca10b9-b491-47cc-ad7b-f815609b61a6"
      unitRef="number">0.333</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTItNi0xLTEtMA_6b0e8a0b-ac6f-4453-a39d-d360d425466f"
      unitRef="usd">6509000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTItOC0xLTEtMA_f29dbfe9-ddee-4b33-8396-aaa7c35db61a"
      unitRef="number">0.315</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTMtMi0xLTEtMA_f0f46f37-e5f4-4eda-8dea-d99ad15e1b19"
      unitRef="usd">1232000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTMtNC0xLTEtMA_f22a34da-7c58-4b37-b66e-a269ec40d0ab"
      unitRef="number">0.055</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTMtNi0xLTEtMA_872ab4e6-71c8-49fd-9ab7-73b420ff6228"
      unitRef="usd">713000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTMtOC0xLTEtMA_626fe3ca-cd88-4c3d-80e7-02526570961d"
      unitRef="number">0.035</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTQtMi0xLTEtMA_73cb9704-9606-48b1-9abe-ea41152a085c"
      unitRef="usd">6197000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTQtNC0xLTEtMA_d7452376-ad0e-442e-a05a-ef28497b508b"
      unitRef="number">0.278</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTQtNi0xLTEtMA_c925264e-2eb9-4c56-ab93-3b4a51c69965"
      unitRef="usd">5796000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTQtOC0xLTEtMA_dec551e5-19c2-43fe-b2f5-619dcda58e57"
      unitRef="number">0.280</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:EarningsPerShareBasic
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTctMi0xLTEtMA_4daa789b-5f57-4f12-a810-d65ebd199bd1"
      unitRef="usdPerShare">2.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTctNi0xLTEtMA_05c7cd87-af6a-4ce0-9330-23a4ed0502ad"
      unitRef="usdPerShare">2.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTgtMi0xLTEtMA_d4eb09af-6ead-4a7f-9688-001ae6085f22"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMTgtNi0xLTEtMA_0f8c0543-ffde-4a34-809e-8b2fbbb7e1b9"
      unitRef="usdPerShare">2.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMjEtMi0xLTEtMA_12a060e4-6274-48ed-ab9b-5d050bac36ad"
      unitRef="shares">2631600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMjEtNi0xLTEtMA_d18e89a9-682b-4972-a002-d8e404f1e428"
      unitRef="shares">2633700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMjItMi0xLTEtMA_46cfaa17-4e51-49e4-9250-f28b5a3d5a0f"
      unitRef="shares">2672700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8yOC9mcmFnOmMxY2FlNzk1MmIwZDQwYjJhOTJiMmEzMTA5NTAxZWY4L3RhYmxlOjQ5NjU2NjJmZWY4NjQ0OTI4ZWM5NWI1MTVmZDMwZmI3L3RhYmxlcmFuZ2U6NDk2NTY2MmZlZjg2NDQ5MjhlYzk1YjUxNWZkMzBmYjdfMjItNi0xLTEtMA_11b26d3c-3c13-4ad8-bf29-f5bf6960897a"
      unitRef="shares">2671000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMy0xLTEtMS0w_9bce3874-c2ed-4921-a4fd-3131459a84ca"
      unitRef="usd">6197000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMy0zLTEtMS0w_de2ccbd1-b556-433d-b553-ef2f3589674e"
      unitRef="usd">5796000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfNi0xLTEtMS0w_9dd2eece-278a-458d-85cc-9be768b292dd"
      unitRef="usd">276000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfNi0zLTEtMS0w_72112c89-6949-45f2-854d-e2a445e4f0d2"
      unitRef="usd">-1519000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfOS0xLTEtMS0w_db6636f8-b4f6-49c7-884a-be49aa26d5d1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfOS0zLTEtMS0w_32d6a916-2fc3-4609-8a25-5bd983b812a2"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTAtMS0xLTEtMA_00643a45-d25b-4dec-8878-c84e03ec6e72"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTAtMy0xLTEtMA_3a467431-322e-4255-959b-3cc8f9e658cd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTItMS0xLTEtMA_c1c3f887-9d94-4138-a428-2be89d1c29b7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTItMy0xLTEtMA_cf81322b-7b77-4e63-8a03-237735384680"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTUtMS0xLTEtMA_f19d0260-8511-4b92-b7a3-867465effd51"
      unitRef="usd">41000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTUtMy0xLTEtMA_af17ff20-6c2d-42a3-82d3-4b38749bc316"
      unitRef="usd">6000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTYtMS0xLTEtMA_5abd5e74-de03-4bcb-9d57-ecb4f0155633"
      unitRef="usd">-274000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTYtMy0xLTEtMA_3f1514d0-23a6-45ee-a6bb-0ffb001c89d4"
      unitRef="usd">-201000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTgtMS0xLTEtMA_b4c2cc52-c681-4b91-881a-cfe97a52e13b"
      unitRef="usd">-233000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMTgtMy0xLTEtMA_3769d2fd-978e-4c03-bc59-1a82f1d2e1c1"
      unitRef="usd">-195000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjEtMS0xLTEtMA_b1a79861-fd7a-47e3-82ca-5aef2b05a61c"
      unitRef="usd">-522000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjEtMy0xLTEtMA_6838842d-00d1-42be-9e38-dd33aaa9a637"
      unitRef="usd">832000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjItMS0xLTEtMA_59b619ad-e438-4e7d-b590-549370080574"
      unitRef="usd">73000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjItMy0xLTEtMA_9a20e7fc-5bc1-427b-8d68-ccbebe1e61e2"
      unitRef="usd">-138000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjMtMS0xLTEtMA_d75d2299-b572-4078-ac46-55e2de3d330b"
      unitRef="usd">-595000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjMtMy0xLTEtMA_c9589383-f4f8-40cf-b396-e05169e2f972"
      unitRef="usd">970000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjUtMS0xLTEtMA_951bfad8-3de5-4167-9b2b-835dcd1f58fc"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjUtMy0xLTEtMA_65f65337-f87b-451b-bc90-83f0205f6740"
      unitRef="usd">-352000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjctMS0xLTEtMA_f06f2b0a-8f5a-4fd6-9b01-10025773d940"
      unitRef="usd">6111000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjFlYTJkZDEwODRhNTQxOTNiNmVjOTdkZDlmNTEyMDFlL3RhYmxlcmFuZ2U6MWVhMmRkMTA4NGE1NDE5M2I2ZWM5N2RkOWY1MTIwMWVfMjctMy0xLTEtMA_9026541a-3fcb-43e9-85aa-3222e8d5a254"
      unitRef="usd">5444000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMTU5_326d438a-c338-420f-929b-30e589c1807b"
      unitRef="usd">-319000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMTc1_69aaab6b-2848-4185-8c0b-ec5656e19dab"
      unitRef="usd">46000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMjE5OTAyMzI1NTkwOQ_22754afe-3da8-458a-ad40-855978903121"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMjEy_23805f73-df91-4bac-a9ec-35ad9e12431b"
      unitRef="usd">-66000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMjI4_93289742-c4a5-43a5-ae53-213f9ddfe5ec"
      unitRef="usd">-56000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMjYz_fe97683b-c906-4b06-b403-03cc3580ce39"
      unitRef="usd">-157000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV8zNC9mcmFnOjEyODVmM2M5ZjczNzRhZjQ5ZGQ3NDVmNDc3YTU2MjIyL3RhYmxlOjY2MzMxOWQxMzM4YjQ2MjU5YjVhM2NkOTBkNTY4MzllL3RhYmxlcmFuZ2U6NjYzMzE5ZDEzMzhiNDYyNTliNWEzY2Q5MGQ1NjgzOWVfMC0wLTEtMS0wL3RleHRyZWdpb246NGNmZjA2MGI0NDk1NDNiNzkxMWRkOTA2YzJhZjk0OWVfMjc5_52efb6ff-ad3b-40c6-84d2-e983118c25b4"
      unitRef="usd">256000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMS0xLTEtMS0w_35fb2b56-5422-4053-835c-b09dcce381cd"
      unitRef="usd">63278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i554ccf5c7c5d4082a647db172a33ff5e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMS0zLTEtMS0w_24981763-49f5-4f70-b0a3-3aed28d4f2fe"
      unitRef="usd">113890000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i45b058f1e15f44aea2e4af4460a4bbeb_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMS01LTEtMS0w_95a2dcc5-8913-4f04-8e9f-c0f15ee66063"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4622c24078884c9b85a313f0376a062f_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMS03LTEtMS0w_2016793f-73f5-496c-a19d-36a495086b4b"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5bf68e42813419189d9d5ff49143138_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMS05LTEtMS0w_1b4b22ae-0c39-4fdf-8a81-251706094f9e"
      unitRef="usd">-38490000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMi0xLTEtMS0w_8535544e-8122-40f6-abc3-5a2f28636070"
      unitRef="usd">6197000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie77099172951473bbab56c32e4583bd4_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMi0zLTEtMS0w_23cb91b4-1825-42ed-a343-630dc84386c0"
      unitRef="usd">6197000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMy0wLTEtMS0wL3RleHRyZWdpb246ZThmYmZiMGM2NDZiNDQ2MGExMjQzZTg5NDY4YWE4NzhfMjY_ead893e5-296b-4a01-91c7-a9e1935331c7"
      unitRef="usdPerShare">1.01</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMy0xLTEtMS0w_4c6f12bb-c6ef-41a1-9bfa-da69b18fe94e"
      unitRef="usd">2659000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie77099172951473bbab56c32e4583bd4_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfMy0zLTEtMS0w_9b2d7010-3351-4027-9eeb-636b779688ae"
      unitRef="usd">2659000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNC0xLTEtMS0w_cd67cc8e-bdf9-40b8-bb6f-5f2204849d29"
      unitRef="usd">542000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ie77099172951473bbab56c32e4583bd4_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNC0zLTEtMS0w_87c9dd0f-31ee-4412-816c-75a2bb3c3de5"
      unitRef="usd">-920000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ibb70055ec76a478fb6bd6838dbc2aeaa_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNC05LTEtMS0w_01bd3da7-c04d-4fd1-9840-0b44159cd697"
      unitRef="usd">1462000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNS0xLTEtMS0w_6d904187-919e-4efe-a7a7-176145fc33d3"
      unitRef="usd">1438000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibb70055ec76a478fb6bd6838dbc2aeaa_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNS05LTEtMS0w_4b65325c-5bd0-4afa-86a0-0f23d02d2514"
      unitRef="usd">1438000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNy0xLTEtMS0w_c79f442d-518b-4123-93a3-d5d32620f9a0"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i90694bac6fa841438f930b207399b28a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfNy01LTEtMS0w_41678c89-8cca-432f-b7c5-ab6633398953"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfOC0xLTEtMS0w_b44db08c-2fee-4745-a164-ead11939f448"
      unitRef="usd">65834000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c6da1c0265643db83e0afcdaa488d07_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfOC0zLTEtMS0w_68338751-2622-48ef-9ed5-e191bf96cbae"
      unitRef="usd">116508000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3029d43aa1d647acbb02dc5cdfe3bd78_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfOC01LTEtMS0w_3bce0a9a-c8ba-4b64-a743-a7c7dbb2105c"
      unitRef="usd">-15328000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5337f7aeb8794921aa62a3f210452e64_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfOC03LTEtMS0w_0a2903f7-e071-4c9d-97d5-dd087a8aef04"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9d7acadaebe4196a88b514c7f9d15cb_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOmFlNDVjOGY3MDE4MDRiODFhMmZiNTcyYzJkNjNiZjk0L3RhYmxlcmFuZ2U6YWU0NWM4ZjcwMTgwNGI4MWEyZmI1NzJjMmQ2M2JmOTRfOC05LTEtMS0w_f6f979a9-3614-4e1c-b768-4d9986d5b0f7"
      unitRef="usd">-38466000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57b90fcac8194c0c83439d028eb794fa_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMS0xLTEtMS0w_403baab9-5493-4ea2-b962-2d522154720f"
      unitRef="usd">59471000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81a1c011ad384c69babb9ebc86eb4a3a_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMS0zLTEtMS0w_ebdb8c4e-6fd8-43c1-a531-2027d16fd9f2"
      unitRef="usd">110659000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6b4922887c94a5e974f74b0748d2716_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMS01LTEtMS0w_959cdf4d-c1ce-4d80-b859-8a67d733d07f"
      unitRef="usd">-15891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibb9aaa3bb3c148dea235f3a41f284cfa_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMS03LTEtMS0w_1c657a40-8b01-4dfd-9895-e42e62a5d8b1"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic07ec8e0b215404d950899c6b10f4fbc_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMS05LTEtMS0w_3239ff59-48ff-46eb-a330-07886a3c9d2e"
      unitRef="usd">-38417000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMy0xLTEtMS0w_95a7a5c1-467d-4a7f-ab43-eba7ddf16d22"
      unitRef="usd">5796000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie740235dd54d4a0ea8cbd91b22b8ba76_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfMy0zLTEtMS0w_85f1167f-d902-44b7-a9e4-253c55d2bb95"
      unitRef="usd">5796000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNC0wLTEtMS0wL3RleHRyZWdpb246OGI5ZDYwZGM3YjFlNDdjYzk0Zjc2OTNjODgxZDhmZGJfMjY_4b05a36d-ea7d-401e-831a-2933c1605642"
      unitRef="usdPerShare">0.95</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNC0xLTEtMS0w_cfaa4a64-e634-499b-99aa-85e11bf1aa5e"
      unitRef="usd">2505000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie740235dd54d4a0ea8cbd91b22b8ba76_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNC0zLTEtMS0w_6dc9644b-90b6-4849-ba02-d83fee86813d"
      unitRef="usd">2505000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNS0xLTEtMS0w_17cf6645-0c04-486d-8cdf-ea1260e245a7"
      unitRef="usd">595000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ie740235dd54d4a0ea8cbd91b22b8ba76_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNS0zLTEtMS0w_4e150652-4c38-40d8-beae-3f1ad4435247"
      unitRef="usd">-1049000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i2f57ab699b4e44729a17b2ccc22e7648_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNS05LTEtMS0w_b9362970-de11-4a29-8cdf-00c690572edb"
      unitRef="usd">1644000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNi0xLTEtMS0w_4ae8a18a-6b64-4a8e-a20d-fc15a34ebc81"
      unitRef="usd">1711000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2f57ab699b4e44729a17b2ccc22e7648_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfNi05LTEtMS0w_7225c99d-0c93-472e-8c91-b98d60964404"
      unitRef="usd">1711000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOC0xLTEtMS0w_50d20366-29b4-4815-95de-a13e58eb476e"
      unitRef="usd">-352000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i74d8ed8a180c4d6fb9225796febd9cbc_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOC01LTEtMS0w_3e96f5a2-6cad-4b0a-9e44-d20aa60e8867"
      unitRef="usd">-352000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2f9f433686145c29000c017762e5f79_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOS0xLTEtMS0w_2e7f96b8-f9df-48d5-a924-d1a2e07ff811"
      unitRef="usd">61294000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d880e598230476c96c6eb9db808e92c_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOS0zLTEtMS0w_0669d414-cae6-498b-81d1-7829190a8fe5"
      unitRef="usd">112901000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e28a2034ae84b938a05edbccc78058c_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOS01LTEtMS0w_c99b5979-568c-4da4-9ceb-dd7e7aadad0d"
      unitRef="usd">-16243000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f5d1f228aa9422383b1640228e75524_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOS03LTEtMS0w_69710fe6-5231-467f-9993-9768d7dc3244"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08ed9aabae5243eab0507179e5521406_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80MC9mcmFnOmRiMTNhMjYwNmUxNzQ0NGZhMWUyNzA2YjQ3Nzk3MGQ5L3RhYmxlOjUyYmY1YWQ0ZWE3ZTQ0OTE5NmMzZWI4ZDc1ZjhiZGI5L3RhYmxlcmFuZ2U6NTJiZjVhZDRlYTdlNDQ5MTk2YzNlYjhkNzVmOGJkYjlfOS05LTEtMS0w_06aee904-78f3-419b-bda3-bb05e83b7c0e"
      unitRef="usd">-38484000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMy0yLTEtMS0w_f432f2c9-f397-4c07-8a36-f429596a6974"
      unitRef="usd">6197000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMy00LTEtMS0w_c7d5b1ed-cb12-473b-9c97-3553208519d9"
      unitRef="usd">5796000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNS0yLTEtMS0w_bf262e89-f0c4-497e-ba46-ecd2113dd2f4"
      unitRef="usd">1894000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNS00LTEtMS0w_43606439-96c8-4036-a94b-f8eaa78d6d59"
      unitRef="usd">1747000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNi0yLTEtMS0w_b60cf351-e80e-4d40-91f8-a62a72633c90"
      unitRef="usd">307000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNi00LTEtMS0w_642169f3-c827-42b4-93a5-4cbea8a606bd"
      unitRef="usd">263000000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfOS0yLTEtMS0w_b0170fe1-f10d-42ed-9668-56975d025f2b"
      unitRef="usd">14000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfOS00LTEtMS0w_d0ff1bc3-4e96-451a-a4e8-8879b5f9ada3"
      unitRef="usd">11000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTAtMi0xLTEtMA_6bfd3c74-efbf-40cc-a740-ea136567bcc8"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTAtNC0xLTEtMA_71686bd4-75a7-4345-8ce4-32603ddbe68e"
      unitRef="usd">-983000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTEtMi0xLTEtMA_0fdd416e-aff2-481f-9293-13932b4baa13"
      unitRef="usd">580000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTEtNC0xLTEtMA_825c2df9-7de9-4bb1-b426-cb6df6479a62"
      unitRef="usd">0</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTMtMi0xLTEtMA_947ae293-4a04-4ddb-b09b-f9f34e387ed5"
      unitRef="usd">-730000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTMtNC0xLTEtMA_8fa13225-c351-4ebe-95f8-e6ba0f643443"
      unitRef="usd">54000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTQtMi0xLTEtMA_d2025d03-1560-4b92-819d-51c12473bf0e"
      unitRef="usd">-13000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTQtNC0xLTEtMA_97c58c0e-3a08-416b-a73b-334043fb8a1d"
      unitRef="usd">22000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTYtMi0xLTEtMA_e5f63a45-bdaf-479b-9754-6583736875ca"
      unitRef="usd">1604000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTYtNC0xLTEtMA_602216fc-e7fa-40a6-83b0-9f60a725f545"
      unitRef="usd">812000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTctMi0xLTEtMA_ca161d4d-78a7-4db6-a4bc-d65a3ba61f75"
      unitRef="usd">695000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTctNC0xLTEtMA_8648032f-97d0-4282-a562-a75819cbd9b1"
      unitRef="usd">159000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTgtMi0xLTEtMA_2d9e36f5-622d-4331-b598-7ff2a133ea31"
      unitRef="usd">-2336000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTgtNC0xLTEtMA_a397ea54-9266-43bf-9b28-aa8d5c6ccf87"
      unitRef="usd">-2523000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTktMi0xLTEtMA_f9979034-16b0-4c5c-9988-50036b5cd999"
      unitRef="usd">-2522000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMTktNC0xLTEtMA_517851c8-2d6a-4db7-a3cc-566604466e2e"
      unitRef="usd">-271000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjAtMi0xLTEtMA_1e11e725-2caf-4b86-8879-aa48d4010432"
      unitRef="usd">-902000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjAtNC0xLTEtMA_28489545-63d9-43f4-bde8-9e067d57782e"
      unitRef="usd">-329000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjItMi0xLTEtMA_3375905a-b1bb-47a7-a291-e9062f86c7f0"
      unitRef="usd">4074000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjItNC0xLTEtMA_781829e7-d745-4a35-b92b-d0ffc8a3994d"
      unitRef="usd">3358000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjUtMi0xLTEtMA_b9895d5e-8dfd-4a11-959a-c0d274eb7727"
      unitRef="usd">677000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjUtNC0xLTEtMA_bc54747e-98c3-496d-bd97-997c720c008f"
      unitRef="usd">625000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjYtMi0xLTEtMA_2d4f12b8-ea8f-4cc3-88b1-edb40fd4a5c5"
      unitRef="usd">603000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjYtNC0xLTEtMA_a7a5b59c-402e-410a-87bd-3ed508aeaa2d"
      unitRef="usd">17000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjctMi0xLTEtMA_c81b2b33-39d9-41c4-bb0a-75685813caa7"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjctNC0xLTEtMA_6b297692-23cd-4546-a660-e1e9110973ec"
      unitRef="usd">939000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjgtMi0xLTEtMA_82452388-01ef-487a-b99c-d4370bf8cddb"
      unitRef="usd">5994000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjgtNC0xLTEtMA_af1a8299-7528-45c8-8036-2f0df482f882"
      unitRef="usd">2064000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjktMi0xLTEtMA_62da906c-62cc-4eb8-8dde-b917af52d7fc"
      unitRef="usd">5233000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMjktNC0xLTEtMA_50e25502-1028-4e14-9529-d1882d3e0aa3"
      unitRef="usd">1544000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzAtMi0xLTEtMA_6a6db6ec-c42d-4615-b339-f053d3098a23"
      unitRef="usd">751000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzAtNC0xLTEtMA_920809c0-63a2-4e86-8854-f2bdb4f84c1d"
      unitRef="usd">1743000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzEtMi0xLTEtMA_dfd97aaf-ff5c-422f-9921-41a7d1a78670"
      unitRef="usd">101000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzEtNC0xLTEtMA_0aa4f718-4d28-47b5-ba77-f1a0c68d1654"
      unitRef="usd">257000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzMtMi0xLTEtMA_84184de7-61eb-4c1e-97ff-ea099543ac8e"
      unitRef="usd">-185000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzMtNC0xLTEtMA_b958e0a5-b00a-4deb-b4cb-324723645d38"
      unitRef="usd">-581000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzYtMi0xLTEtMA_fca1e0b8-e081-4b29-b793-d5a30ebf7e4a"
      unitRef="usd">2659000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzYtNC0xLTEtMA_91d0ab8f-c37b-4eae-8be8-b7cbd2c4b779"
      unitRef="usd">2505000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzctMi0xLTEtMA_81ef23cd-4ad7-4344-8082-fee7574d3293"
      unitRef="usd">1438000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzctNC0xLTEtMA_d8e3d41b-0b73-4592-9c9c-ef3eeb866ee0"
      unitRef="usd">1711000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzgtMi0xLTEtMA_5007839d-d7ec-4ef8-bab9-8dc86ff073d3"
      unitRef="usd">23000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzgtNC0xLTEtMA_94ddf51a-bc87-47de-81f4-7162cc6d03d8"
      unitRef="usd">10000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzktMi0xLTEtMA_46eec95d-232c-46e9-972a-3c84807736b0"
      unitRef="usd">475000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfMzktNC0xLTEtMA_6ba672bd-78e2-4721-b6b5-348dab268641"
      unitRef="usd">18000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDAtMi0xLTEtMA_98c694df-a02c-4671-9455-bf94049fe089"
      unitRef="usd">1000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDAtNC0xLTEtMA_7dff3b0e-b2c5-4c4d-824a-3cdb36411fb6"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDEtMi0xLTEtMA_44d49a14-0de3-4c58-8ff5-6f930f1b2af8"
      unitRef="usd">1001000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDEtNC0xLTEtMA_768ca66a-5d3d-4000-a7e7-e86d1628090e"
      unitRef="usd">11000000</us-gaap:RepaymentsOfLongTermDebt>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDItMi0xLTEtMA_f9b7d0c4-9956-4d17-ae4c-9aa844a39793"
      unitRef="usd">236000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDItNC0xLTEtMA_24290ff3-1444-48af-9105-1b234ce33fdb"
      unitRef="usd">332000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDMtMi0xLTEtMjg0NA_4e3facf3-7060-4091-8fc3-6580be18aab2"
      unitRef="usd">212000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDMtNC0xLTEtMjg0NA_fab56371-101b-4950-a408-cb6b2c61262a"
      unitRef="usd">0</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDMtMi0xLTEtMA_5f0c33d1-3377-4ca0-8097-5d68756a4681"
      unitRef="usd">-24000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDMtNC0xLTEtMA_40894ebb-bc4f-4fe2-af76-b7ae8b9ee92d"
      unitRef="usd">-412000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDUtMi0xLTEtMA_28a1fcb4-4ae6-4c35-b5c2-e9471d8d5385"
      unitRef="usd">-5125000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDUtNC0xLTEtMA_7c65c8d3-ef88-4e0a-abc1-c82f35d07479"
      unitRef="usd">-4315000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDctMi0xLTEtMA_6e1266db-07d5-45a2-97d5-780e6002d100"
      unitRef="usd">-78000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDctNC0xLTEtMA_71256e5b-8083-41ce-b889-8ca87872da4c"
      unitRef="usd">-237000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDgtMi0xLTEtMA_f8307e20-37fd-4323-9121-dda911261776"
      unitRef="usd">-1314000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDgtNC0xLTEtMA_07b7d412-bef6-428e-a4a7-d22df7d4a42e"
      unitRef="usd">-1775000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDktMi0xLTEtMA_8dcfb7d2-5754-43e6-a3bf-557aa22abf29"
      unitRef="usd">13985000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i57b90fcac8194c0c83439d028eb794fa_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNDktNC0xLTEtMA_5b6fd381-0d7a-437c-adf2-ffd82da8181c"
      unitRef="usd">17305000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTAtMi0xLTEtMA_4431e89d-ca3b-4ea2-9174-bf094e435d1f"
      unitRef="usd">12671000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie2f9f433686145c29000c017762e5f79_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTAtNC0xLTEtMA_8f4af21c-ce78-4087-be55-298b52db2cbf"
      unitRef="usd">15530000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTctMi0xLTEtMA_902335d5-e7b5-4d0c-ad7c-8322b499054c"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTctNC0xLTEtMA_62cdf1b4-f427-4501-80cd-71dffd9e6ba7"
      unitRef="usd">1136000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTgtMi0xLTEtMA_fbaebbc1-d09c-4d99-b835-e636894e622d"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTgtNC0xLTEtMA_f261fe5b-2bcc-4f08-b5af-d752e361ae84"
      unitRef="usd">197000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTktMi0xLTEtMA_19b5e58e-d9fe-43fb-ae79-c5d04a63a31d"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV80Ni9mcmFnOmM5ZTFiMTAyZTQ4ZjQwN2RhZTM0NzhhMGZkNWEzNzZhL3RhYmxlOjQ4ZjQ0NDUwZmMwYTQ0MTE4M2U2MjM4Mjc2NTA5MTk5L3RhYmxlcmFuZ2U6NDhmNDQ0NTBmYzBhNDQxMTgzZTYyMzgyNzY1MDkxOTlfNTktNC0xLTEtMA_e66c96aa-d589-42dd-8345-fe97f2c6c91a"
      unitRef="usd">939000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81Mi9mcmFnOmFmZDMwM2QzNDhjMjRmZGFhMDE5OWUxNzM0YWNiNmFjL3RleHRyZWdpb246YWZkMzAzZDM0OGMyNGZkYWEwMTk5ZTE3MzRhY2I2YWNfMjc3NQ_f8f71753-f6ce-4995-800d-d1b42de1245b">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp;amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April 4, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#x2019;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the quarter ended April 4, 2021, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in the fiscal first quarter of 2021 that impacted the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the fiscal first quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81Mi9mcmFnOmFmZDMwM2QzNDhjMjRmZGFhMDE5OWUxNzM0YWNiNmFjL3RleHRyZWdpb246YWZkMzAzZDM0OGMyNGZkYWEwMTk5ZTE3MzRhY2I2YWNfMjc3Nw_1b24cab2-600f-4d9d-9364-75a044a482c7">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April 4, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#x2019;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the quarter ended April 4, 2021, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81Mi9mcmFnOmFmZDMwM2QzNDhjMjRmZGFhMDE5OWUxNzM0YWNiNmFjL3RleHRyZWdpb246YWZkMzAzZDM0OGMyNGZkYWEwMTk5ZTE3MzRhY2I2YWNfMjc3OA_2162a6c7-8f9d-411f-ac34-3550b724f46f">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in the fiscal first quarter of 2021 that impacted the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the fiscal first quarter of 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81Mi9mcmFnOmFmZDMwM2QzNDhjMjRmZGFhMDE5OWUxNzM0YWNiNmFjL3RleHRyZWdpb246YWZkMzAzZDM0OGMyNGZkYWEwMTk5ZTE3MzRhY2I2YWNfMjc3OQ_7c84d726-a219-437b-83db-98d9b68a5efa">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RleHRyZWdpb246NzljNDJjMzBkY2RiNDY3Y2IyYjRmNjdiOTk2MzE5MmFfMTY5_c79418e2-dd8a-46da-8918-69b17bcc1f68">INVENTORIES &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RleHRyZWdpb246NzljNDJjMzBkY2RiNDY3Y2IyYjRmNjdiOTk2MzE5MmFfMTU0_1ff89537-7479-436f-9e7f-7ea1af08da5b">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfMS0yLTEtMS0w_8c48bfdd-8656-49d7-b3a3-0641f1ac4c85"
      unitRef="usd">1557000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfMS00LTEtMS0w_62072658-a68e-4a67-b57a-32d15213af79"
      unitRef="usd">1410000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfMi0yLTEtMS0w_0b610c55-2f10-476f-8b4d-1c43c403569d"
      unitRef="usd">2034000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfMi00LTEtMS0w_2fe90940-2b94-4b2c-8e33-d4c171c60692"
      unitRef="usd">2040000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfMy0yLTEtMS0w_886dc1cd-4692-4afb-9a0e-12505d0b0b94"
      unitRef="usd">6361000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfMy00LTEtMS0w_0123a106-6bc2-4339-a0bf-8528502ce0a4"
      unitRef="usd">5894000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfNC0yLTEtMS0w_5c47ce52-3607-4bfb-b450-137a5edfe34e"
      unitRef="usd">9952000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81NS9mcmFnOjc5YzQyYzMwZGNkYjQ2N2NiMmI0ZjY3Yjk5NjMxOTJhL3RhYmxlOjRmNzMwMzU0YTc1NzRiMjM4NzMzZDE3YTBmMjhhY2QyL3RhYmxlcmFuZ2U6NGY3MzAzNTRhNzU3NGIyMzg3MzNkMTdhMGYyOGFjZDJfNC00LTEtMS0w_997c59fe-52cb-4b56-a471-75cba1adea6c"
      unitRef="usd">9344000000</us-gaap:InventoryNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTY3Nw_6df017a2-5a5a-46bc-a9dd-7bbdfc4028ee">INTANGIBLE ASSETS AND GOODWILL&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2020. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of April&#160;4, 2021 was allocated by segment of business as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions and divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.2 billion and $1.1&#160;billion for the fiscal first quarters ended April&#160;4, 2021 and March&#160;29, 2020, respectively. Intangible asset write-downs are included in Other (income) expense, net. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,300&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTY5Mg_3eeb7493-af4e-48a6-ba8f-8b01a6838a3a">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;</jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i938fd3f47216423db6add422786e33d8_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMi0yLTEtMS0w_ffa375b4-9651-4187-95b4-d85ae715f082"
      unitRef="usd">39505000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i38454aa367154112bb15da46777db708_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMi00LTEtMS0w_8e7c7362-7830-4232-88a5-1c892845907d"
      unitRef="usd">39990000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i938fd3f47216423db6add422786e33d8_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMy0yLTEtMS0w_7093b024-d933-4f7c-a360-a5cf1bac623a"
      unitRef="usd">18006000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i38454aa367154112bb15da46777db708_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMy00LTEtMS0w_2562d416-f6c9-4b17-8b19-d693cba24a7b"
      unitRef="usd">17618000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i938fd3f47216423db6add422786e33d8_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNC0yLTEtMS0w_a331f7d9-b96e-4146-ab61-fea2aada30a1"
      unitRef="usd">21499000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i38454aa367154112bb15da46777db708_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNC00LTEtMS0w_a14c92ab-9a9f-4d3f-a7f1-219725b7e8f4"
      unitRef="usd">22372000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0082d9cc376345feb045a0d2dc22b630_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNS0yLTEtMS0w_26a7c575-5178-45e0-ac70-0bb77831f9b8"
      unitRef="usd">22793000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i57d42da3fc7e4a9c8e74db6c49bd6a30_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNS00LTEtMS0w_0c7dfe36-efdb-43bd-81c0-b52387b81692"
      unitRef="usd">22898000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0082d9cc376345feb045a0d2dc22b630_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNi0yLTEtMS0w_ea7bfc49-8fa1-4cd4-b14e-e1547626053b"
      unitRef="usd">11031000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i57d42da3fc7e4a9c8e74db6c49bd6a30_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNi00LTEtMS0w_d7ece31e-2058-4f47-b662-0a4c4dee3272"
      unitRef="usd">10912000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0082d9cc376345feb045a0d2dc22b630_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNy0yLTEtMS0w_7b557916-561f-4350-8567-cee10967a986"
      unitRef="usd">11762000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i57d42da3fc7e4a9c8e74db6c49bd6a30_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfNy00LTEtMS0w_1e4b34df-8497-4fc9-866c-15d0c14587c4"
      unitRef="usd">11986000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="icfe502bb02104e159d70555125632c61_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfOS0yLTEtMS0w_1dce76ab-6f98-4923-8ff6-afffb5af8c81"
      unitRef="usd">7061000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i377d715a6bfa41408e72610b259d73ff_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfOS00LTEtMS0w_df6bab6e-4c66-47f7-b7ac-8f512de52562"
      unitRef="usd">7195000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ibc8848a62dcb4452a2fc843002a09302_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMTAtMi0xLTEtMA_911dab9b-8d92-49bc-8a56-55f03b1492be"
      unitRef="usd">10788000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i40f64fb8b6794e99af54c94ba64590f2_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMTAtNC0xLTEtMA_3d1b8e6e-2b51-4812-8460-bba815efe828"
      unitRef="usd">11849000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMTEtMi0xLTEtMA_cfc7d1b1-b685-4af3-9f2c-cd6df9416a29"
      unitRef="usd">17849000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMTEtNC0xLTEtMA_1169ff8c-f44d-42ae-9a33-90adfe53cf29"
      unitRef="usd">19044000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMTItMi0xLTEtMA_b4268bfe-9187-413f-b498-621d869d648c"
      unitRef="usd">51110000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjkyMzEyMmU0MjNiNTQxZGE5NzRlOTg3YTczOGNkN2Q4L3RhYmxlcmFuZ2U6OTIzMTIyZTQyM2I1NDFkYTk3NGU5ODdhNzM4Y2Q3ZDhfMTItNC0xLTEtMA_6529e7ab-86c4-4b91-8ea8-895ce4e3f429"
      unitRef="usd">53402000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTY3OA_fb3814eb-085a-479f-b9c7-08eee4b57af0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of April&#160;4, 2021 was allocated by segment of business as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions and divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i388de1b5762e4c0fb0d8bbd78e4af41a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMS0yLTEtMS0w_f5f4e0ec-d0d5-4305-9a84-8ed25d27a38b"
      unitRef="usd">10336000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ide5b19ddfb3441d99114a1bb6fd6c98c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMS00LTEtMS0w_105787c3-92e0-4f00-a105-3945f37cd8f9"
      unitRef="usd">11009000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6244cbbe09374700aeac1db74a330aae_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMS02LTEtMS0w_2675cb9c-dc3c-4547-9106-2e40cdc284e2"
      unitRef="usd">15048000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMS04LTEtMS0w_1ef23048-50b0-461f-8b43-6efcbe4ee04b"
      unitRef="usd">36393000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i9cb654a681744cccadb2bf5b36aa0112_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMi0yLTEtMS0w_0fd9f022-57ee-4594-8d8e-b72bc70e4bed"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="id0bb046f4ee745b8a6a3a214d7610a6d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMi00LTEtMS0w_0cd06d0b-99b9-4391-a605-67a703f324cd"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i765e60a738e846889a642c75a5734d75_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMi02LTEtMS0w_ab7cf6ed-821d-4632-8c0d-4a4db706f0fc"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfMi04LTEtMS0w_d7c595a9-7eaa-4f32-b6b7-2ae35b8a26f7"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i9cb654a681744cccadb2bf5b36aa0112_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNC0yLTEtMS0w_5f2da9a6-4a53-48b4-ac5a-f51165acbc1f"
      unitRef="usd">-310000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="id0bb046f4ee745b8a6a3a214d7610a6d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNC00LTEtMS0w_37ede2be-4677-44d6-8408-d3714a138690"
      unitRef="usd">-262000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i765e60a738e846889a642c75a5734d75_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNC02LTEtMS0w_bfc0a89d-3587-4c7f-b008-1207b2a4098b"
      unitRef="usd">-133000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNC04LTEtMS0w_79ca4d34-cda6-4052-a591-e7a1db6f25a7"
      unitRef="usd">-705000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i3e47fb2653614b9fb11a7cb9230babba_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNS0yLTEtMS0w_8a620bdf-98c6-49dd-9441-8f80ff4de56f"
      unitRef="usd">10026000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id62f882886ab4b96929fde2ec8b4ad23_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNS00LTEtMS0w_3fbd1081-6b67-4256-aaf6-f38526609159"
      unitRef="usd">10747000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icd17c512c40140ec8ea55845257d1f58_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNS02LTEtMS0w_274d1d0e-c445-4857-bcec-9e09068b396b"
      unitRef="usd">14915000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjZlOTZkZDU5Njk0YTQ4OTg5MDRlZjM1NTg4ODA3MmQzL3RhYmxlcmFuZ2U6NmU5NmRkNTk2OTRhNDg5ODkwNGVmMzU1ODg4MDcyZDNfNS04LTEtMS0w_c2123615-b1b5-4d6c-902d-0cadf373fff0"
      unitRef="usd">35688000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i30217af13d8d4037a36480117a2ddbe0_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfOTUy_342b9e45-da01-4406-a1c0-5a5be0c6196b">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9b0bf4ce3bd940f0b30c1308159ff8a6_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTA2MQ_648b1415-2132-45ee-9064-fc4cec135b8f">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTE2Nw_0e6702bc-eeda-4582-b8f1-12249e75cc24"
      unitRef="usd">1200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTE3NA_5e5db372-f7ab-4fa5-8d59-49584193c357"
      unitRef="usd">1100000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RleHRyZWdpb246NDA1Y2Q0ZjAzNmQ4NGQ4ZWIxMGFmYzlkOTg2YjNjNGFfMTY4MQ_14208d82-2b7a-44ee-9459-956af8ce1f13">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,300&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjE4MWZhZTJiOTVhNTQwOTlhMmIwZTU0MDAxODRlNzkxL3RhYmxlcmFuZ2U6MTgxZmFlMmI5NWE1NDA5OWEyYjBlNTQwMDE4NGU3OTFfMi0wLTEtMS0w_a7bb5c6a-079a-472e-aed2-9d6e9bba0622"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjE4MWZhZTJiOTVhNTQwOTlhMmIwZTU0MDAxODRlNzkxL3RhYmxlcmFuZ2U6MTgxZmFlMmI5NWE1NDA5OWEyYjBlNTQwMDE4NGU3OTFfMi0yLTEtMS0w_681122ad-e75a-4ceb-b208-306ed376393a"
      unitRef="usd">4400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjE4MWZhZTJiOTVhNTQwOTlhMmIwZTU0MDAxODRlNzkxL3RhYmxlcmFuZ2U6MTgxZmFlMmI5NWE1NDA5OWEyYjBlNTQwMDE4NGU3OTFfMi00LTEtMS0w_62cf4862-ff34-4582-a367-dba69ae72a60"
      unitRef="usd">4300000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjE4MWZhZTJiOTVhNTQwOTlhMmIwZTU0MDAxODRlNzkxL3RhYmxlcmFuZ2U6MTgxZmFlMmI5NWE1NDA5OWEyYjBlNTQwMDE4NGU3OTFfMi02LTEtMS0w_703876a6-86a6-4759-9344-75cd06d2e73e"
      unitRef="usd">4100000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV81OC9mcmFnOjQwNWNkNGYwMzZkODRkOGViMTBhZmM5ZDk4NmIzYzRhL3RhYmxlOjE4MWZhZTJiOTVhNTQwOTlhMmIwZTU0MDAxODRlNzkxL3RhYmxlcmFuZ2U6MTgxZmFlMmI5NWE1NDA5OWEyYjBlNTQwMDE4NGU3OTFfMi04LTEtMS0w_530b93d8-f5a7-47e8-94f9-df3bff063c62"
      unitRef="usd">3300000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwMDU_b92663fe-031f-4da0-a156-2c4d33a9f32e">FAIR VALUE MEASUREMENTSThe Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges.  Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of April&#160;4, 2021, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $102 million net, primarily related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April&#160;4, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $41.2&#160;billion and $31.2&#160;billion, respectively. As of January&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $37.8 billion and $30.6 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April&#160;4, 2021, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $57&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net investment hedge&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2021 and 2020, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.532%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal first quarters ended in 2021 and 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated&lt;br/&gt;OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="33" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity investments without readily determinable market values, $55 million of the decrease in the fair value reflected in net income were the result of impairments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#x2019;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following three levels of inputs are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2014; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2014; Significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2014; Significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of April&#160;4, 2021 and January&#160;3, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,481 million, which are classified as Level 1 and contingent consideration of $633 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classified as non-current other assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Includes $589 million and $594 million, classified as non-current other liabilities as of April&#160;4, 2021 and January&#160;3, 2021, respectively.  Includes $11 million and $39 million classified as current liabilities as of April&#160;4, 2021 and January&#160;3, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a contingent consideration reversal of $983 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense, net. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash, cash equivalents and current marketable securities as of April&#160;4, 2021 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. sovereign securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other sovereign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fiscal year ended January&#160;3, 2021 the carrying amount was approximately the same as the estimated fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale securities as of April&#160;4, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments not measured at Fair Value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;4, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73% Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 (750MM Euro 1.1757)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Notes due 2024 (500 MM GBP 1.3799)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028 (750MM Euro 1.1757)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035 (1.5B Euro 1.1757)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average effective interest rate on non-current debt is 2.98%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the estimated fair value over the carrying value of debt was $5.4 billion at January 4, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The current debt balance as of April 4, 2021 includes $0.3&#160;billion of commercial paper which has a weighted average interest rate of 0.12% and a weighted average maturity of two months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="ie72107b2f41048608d40b52f7842ac46_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTY0Mw_557aaed6-21f0-41f5-9785-4a4e7a892251"
      unitRef="usd">102000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie72107b2f41048608d40b52f7842ac46_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMjI0MA_3b9238f6-196d-48dd-8eba-71504b8b7a12"
      unitRef="usd">41200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i19e2c42c0f614e9b9a6645e5624ab2fb_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMjI0Nw_67ebdcba-81e4-4186-8264-e522c6621440"
      unitRef="usd">31200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6d3517c75cc34f07baec1683d55a7bd2_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMjQwMg_d394032a-d2eb-4887-95ae-6c0a3b3b7d8f"
      unitRef="usd">37800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8c6b3c3cbf0f47ce9e5cbd3982f08fa7_I20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMjQwOQ_52c8f306-ccb8-4caa-99cd-5693c4986957"
      unitRef="usd">30600000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfNDU0MA_cc88f8da-d74e-4bff-ab6b-aaa6fec3a70d"
      unitRef="usd">-57000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfNDc5OA_930788ce-7edf-4500-ad0b-fab0660c5355">next 12 months</us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfNDk1OQ_f8a72e3a-a7f6-462c-9dac-0c65bcb6569f">P18M</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwNjI_1336a9a0-e05a-44a1-ae2c-f951f899b350">The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2021 and 2020, net of tax:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal first quarters ended in 2021 and 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated&lt;br/&gt;OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ie01d964788264049a7b9adb01bd01ac5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtMS0xLTEtMA_54cc2b87-95a1-4b60-a4d9-6589aa303b19"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i13a02c0a42a74896bf7be48d3b1027e1_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtMi0xLTEtMA_45c0ebd0-8c36-47e0-8391-36fd5bbc43b6"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i874f30e6f0c8448b864fdca3e1298a1f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtMy0xLTEtMA_716823bc-3cff-4333-9391-7f57b8af5ef7"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ie68b3ac552404011acaedf92944e753a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtNC0xLTEtMA_f8cef261-da30-44e4-85a8-18dae22814d0"
      unitRef="usd">40000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5a9a259f20724c67beb3b788b0f25057_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtNS0xLTEtMA_8b779a8f-a367-4c39-9e5e-c68e669574fb"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i342418f455914456a29f58d87b451c6d_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtNi0xLTEtMA_f2a52962-2c01-498a-8e72-868f16bbdc9f"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i2b1bec5d96714b3eba498d07a965ad79_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtNy0xLTEtMA_709cb0dc-58ff-4b96-ab76-8b43374dbdf8"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i72b8cfc3f21b47e1a9083977bf9e2a88_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtOC0xLTEtMA_cc2f4aa7-86bc-4e19-802a-11d8ada4a379"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i9fca4d1476a349df850a392206294580_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtOS0xLTEtMA_31141bca-702e-4603-96e9-cc817706d3b6"
      unitRef="usd">40000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i9619cfd7a6d6418e84ba17ca620027fe_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTMtMTAtMS0xLTA_889ab2a3-7473-44ab-89a9-66e5cd19de05"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ie01d964788264049a7b9adb01bd01ac5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtMS0xLTEtMA_a7d2cdac-b2ea-4da2-94a5-599ca29fdd8e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i13a02c0a42a74896bf7be48d3b1027e1_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtMi0xLTEtMA_110018ad-8cbe-4ce5-bb86-9cfc45f7f484"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i874f30e6f0c8448b864fdca3e1298a1f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtMy0xLTEtMA_f5964462-1156-41c8-972e-4783f0e175b2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ie68b3ac552404011acaedf92944e753a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtNC0xLTEtMA_1d886092-1002-4c45-909d-9201f5c880b1"
      unitRef="usd">40000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5a9a259f20724c67beb3b788b0f25057_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtNS0xLTEtMA_b9d1d1f0-f52b-4019-83d2-8af52627925a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i342418f455914456a29f58d87b451c6d_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtNi0xLTEtMA_274470e3-7274-4ae7-ad29-87a008df893a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i2b1bec5d96714b3eba498d07a965ad79_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtNy0xLTEtMA_10bde833-0f87-44ca-9b15-2b99c9599c5a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i72b8cfc3f21b47e1a9083977bf9e2a88_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtOC0xLTEtMA_a5b3937d-9226-4711-8a23-90940982fc89"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9fca4d1476a349df850a392206294580_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtOS0xLTEtMA_cda92364-7492-453a-85cd-5369d671fc48"
      unitRef="usd">40000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9619cfd7a6d6418e84ba17ca620027fe_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTQtMTAtMS0xLTA_2437c9d9-af8a-4a0d-8e20-250e613666bd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="idbc060006e064bbca9524dae843e6335_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtMS0xLTEtMA_85a72590-b24e-459f-976e-e27559e957f5"
      unitRef="usd">17000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ie7a18315fb614992b5e5d355a07e9360_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtMi0xLTEtMA_4fc4fbf9-c8d2-42be-be1f-751868218a12"
      unitRef="usd">34000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i0906ba73795343c2a2e180261f092582_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtMy0xLTEtMA_002b0504-9e0f-475d-8e13-44b691f5e4a4"
      unitRef="usd">-113000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i26027c48bade4ff7acf52354b330290d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtNC0xLTEtMA_71965bdd-e6dd-4c5e-b99a-99759019b49a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i1341509a716f4cf7adb94b1d81181765_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtNS0xLTEtMA_8ced4e44-f782-4c1a-a11e-4ac6a16e9c52"
      unitRef="usd">3000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ia3cc70b838c74057a0eddbcc40f06c72_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtNi0xLTEtMA_bd8ddd1e-0118-4001-b7eb-2d9c7999babb"
      unitRef="usd">9000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i878350a72ee146ab880ae401386a353d_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtNy0xLTEtMA_0a75e830-54fe-43fb-ba20-1e617c657f43"
      unitRef="usd">-173000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i822c73144e3a487798d589465af318e5_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtOC0xLTEtMA_029e6fe9-a255-419b-a75e-37f4b2276801"
      unitRef="usd">-110000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i4b9dc30fa88d4596b1e3378aeddbe13f_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtOS0xLTEtMA_43f24a08-9610-42d3-83b9-3ec551de7100"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="if38820cb50084fd0a8928b4fff09c1b2_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMTgtMTAtMS0xLTA_bacce9a5-0ea4-4d4d-8f18-01ac5a6cb57e"
      unitRef="usd">-2000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="idbc060006e064bbca9524dae843e6335_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItMS0xLTEtMA_6a9d7a29-765b-4f3e-8e2d-494551ae833a"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ie7a18315fb614992b5e5d355a07e9360_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItMi0xLTEtMA_2c13e3bc-92f0-4e18-8573-166b35683e42"
      unitRef="usd">-193000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i0906ba73795343c2a2e180261f092582_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItMy0xLTEtMA_a3b9ca3c-81a7-45ad-932a-ebabf802d333"
      unitRef="usd">-76000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i26027c48bade4ff7acf52354b330290d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItNC0xLTEtMA_15bcf6f1-1d7e-48d9-9399-64990999806e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1341509a716f4cf7adb94b1d81181765_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItNS0xLTEtMA_8fa10cd3-1fbe-4c08-a36a-6b3a8828a9db"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ia3cc70b838c74057a0eddbcc40f06c72_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItNi0xLTEtMA_a70a4779-e647-470e-bb15-16278f1cc02f"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i878350a72ee146ab880ae401386a353d_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItNy0xLTEtMA_2e7becf4-56e8-4727-9314-50ef4e203d6d"
      unitRef="usd">302000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i822c73144e3a487798d589465af318e5_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItOC0xLTEtMA_e9a5a336-de2f-422f-8a90-1aea08157745"
      unitRef="usd">-110000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4b9dc30fa88d4596b1e3378aeddbe13f_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItOS0xLTEtMA_2897bdba-a740-43c4-b342-e79abbbd72a1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if38820cb50084fd0a8928b4fff09c1b2_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjItMTAtMS0xLTA_eed336aa-cedb-42f3-b88f-30f9243ddb15"
      unitRef="usd">-36000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iad3b2a712b0e498c9cafbdd3bdc0628b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtMS0xLTEtMA_7e494537-6ef2-447e-acb9-e93e7c7f7071"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i140d1f4f250d42e78b3172103a09a2c9_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtMi0xLTEtMA_e30bcf32-95e8-4c65-9d7c-44e03747462a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i4dd389ffc711425dad2694706f9e91f0_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtMy0xLTEtMA_98cf980b-e61b-4ae5-b621-d27ef460f7c5"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="idf315858f46544fda7be3aa113c4fe5e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtNC0xLTEtMA_9ba0a6cd-2358-4c1c-99a4-d110b2f70e8d"
      unitRef="usd">92000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i0216e83e61184ac5a91bab7c9e89040e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtNS0xLTEtMA_53a7ea57-cf45-4ae2-889a-916594c2ad93"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i204355d7d9a948e5a652a98e8a346114_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtNi0xLTEtMA_2e73e88c-ee5c-42cd-b874-d1db6c285133"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i22bf2da4717d42ec8e7363aaabf9331c_D20191230-20200329"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtNy0xLTEtMA_05956402-96c0-4a5b-bca4-d125bca5b642"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iadca5d6789ff4116b0dce69a9dfc7267_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtOC0xLTEtMA_06e2ba67-0dcd-437d-8b71-a54020f27727"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="id2257a4164c24da4808f08e7779edb63_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtOS0xLTEtMA_4a446925-4a8a-45d9-b1a1-db3b07adb8da"
      unitRef="usd">98000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iaf3c269c11bd42aea7263d884b1eb127_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjUtMTAtMS0xLTA_5aee254b-6764-484d-86ee-188b82fe82d2"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iad3b2a712b0e498c9cafbdd3bdc0628b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctMS0xLTEtMA_998c0d52-1fa6-4f05-a808-75765e774521"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i140d1f4f250d42e78b3172103a09a2c9_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctMi0xLTEtMA_5131542d-2a2c-48c5-9a94-580aa8bdd6d3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4dd389ffc711425dad2694706f9e91f0_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctMy0xLTEtMA_845de5ed-ca6e-4fbe-a09b-fd7673638bcc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="idf315858f46544fda7be3aa113c4fe5e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctNC0xLTEtMA_4a9ace5c-0690-4848-84b0-d8966fe48a97"
      unitRef="usd">-307000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i0216e83e61184ac5a91bab7c9e89040e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctNS0xLTEtMA_28ca5345-524a-48b2-b6b4-1b4eda34cd18"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i204355d7d9a948e5a652a98e8a346114_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctNi0xLTEtMA_3aa5a1d5-b254-486a-8b7d-7f82494a4023"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i22bf2da4717d42ec8e7363aaabf9331c_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctNy0xLTEtMA_ad62edd5-6e56-45f0-a844-c13c691c8b31"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iadca5d6789ff4116b0dce69a9dfc7267_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctOC0xLTEtMA_0bcd7a0f-dda3-4f6c-9b28-4a96f5e9775d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id2257a4164c24da4808f08e7779edb63_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctOS0xLTEtMA_b21eb616-1da4-4977-a1a2-ba1525ca8f72"
      unitRef="usd">625000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iaf3c269c11bd42aea7263d884b1eb127_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmU0NWI5MzMyZjgzMTQyNzI5YWEzODY1MWMyZmUwYjMxL3RhYmxlcmFuZ2U6ZTQ1YjkzMzJmODMxNDI3MjlhYTM4NjUxYzJmZTBiMzFfMjctMTAtMS0xLTA_812d466d-12c7-433f-bebc-74cb8632e8cd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwMjg_c4e933cb-99f3-41cd-9548-6cde4a3f8145">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.532%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i9b228055f3cd41bb8574ba5091b477ab_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRjNzAwNDM1YjcxMjQwNmVhYmIwOTJiNzUzY2UyODE3L3RhYmxlcmFuZ2U6NGM3MDA0MzViNzEyNDA2ZWFiYjA5MmI3NTNjZTI4MTdfNC00LTEtMS0w_d6cf8ec7-75de-42a9-b66a-228daae1081b"
      unitRef="usd">-16000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="icea3523edfc54b9795f412328fb8cc54_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRjNzAwNDM1YjcxMjQwNmVhYmIwOTJiNzUzY2UyODE3L3RhYmxlcmFuZ2U6NGM3MDA0MzViNzEyNDA2ZWFiYjA5MmI3NTNjZTI4MTdfNC02LTEtMS0w_61efab88-8f74-4d85-9c7e-6383cb17ba2f"
      unitRef="usd">89000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfMy0yLTEtMS0w_5ebac5d3-9cf1-449a-b277-a04b068a4ea2"
      unitRef="usd">209000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfMy00LTEtMS0w_325fe074-4a31-4a63-b66c-9ec302c56fae"
      unitRef="usd">46000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i8d3a64af1b114e0faba3662a1c101141_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfMy04LTEtMS0w_aa6dedf3-362e-49d1-99b0-7f6267d2d402"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i40ee10e36a6846f9a154a6a47b79529a_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfMy0xMC0xLTEtMA_6e5a7768-5292-4224-8916-37dda8967262"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i14fe7f8132004082bcb935f2f27f8655_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfNC0yLTEtMS0w_12625a20-fa56-4c84-ab90-7c0416dfc1b3"
      unitRef="usd">361000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i35bdc996add34d468a13b2fe99d899e7_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfNC00LTEtMS0w_740c5d80-854b-429d-a5d8-8c228d49190e"
      unitRef="usd">827000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i87420fbb466e4d8f880a94561a21e400_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfNC04LTEtMS0w_5ade0b11-93c9-4c3a-8eba-4e185e2ffcd6"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i946eb5aeb32245f6be05dc48e566fa0b_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjQ3NWJlM2FhZThiYzQ4NDE4NDc5ZWQzNmUzZjE0NWJjL3RhYmxlcmFuZ2U6NDc1YmUzYWFlOGJjNDg0MTg0NzllZDM2ZTNmMTQ1YmNfNC0xMC0xLTEtMA_522f389e-ee31-48ef-b55e-ac6dc8b88775"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwMTY_404d638d-c71f-4fb0-801c-e8b476ac4490">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i232b3bcc9db9455c814fc452f8315a6d_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfMi0yLTEtMS0w_da3f2d7c-1b7e-44d9-88ea-9e47275149b8"
      unitRef="usd">1481000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i6bc1a06bc0d240b8852a2c4d4a71d78a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfMi00LTEtMS0w_131e8248-62fd-4a3f-a46a-c53cb610e355"
      unitRef="usd">-36000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i6bc1a06bc0d240b8852a2c4d4a71d78a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfMi02LTEtMS0w_9702c491-ca3c-4b05-8910-c12afcef2a89"
      unitRef="usd">7000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ic7bd67d98bc44c14b76b19b4583f853b_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfMi04LTEtMS0w_3e07f81c-5db7-4825-92d7-35f66d549cfc"
      unitRef="usd">1452000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic7bd67d98bc44c14b76b19b4583f853b_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfMi0xMC0xLTEtMA_fffaadf0-8a65-4001-8041-17463de5f436"
      unitRef="usd">1452000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ia18cccc27ae74f93a145a0bb576d9145_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfNC0yLTEtMS0w_4be66762-d261-4845-9813-2e757530f54b"
      unitRef="usd">738000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment
      contextRef="idac7648f2ee14ded909ba25b98704f30_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfNC00LTEtMS0w_90b80eaa-2577-4ab0-a1d4-dbb7da6bebaf"
      unitRef="usd">-55000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="idac7648f2ee14ded909ba25b98704f30_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfNC02LTEtMS0w_f70ccd22-5a6e-4248-92c4-7f36fdd0155e"
      unitRef="usd">81000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ie3db46d4c79c4830b0ea1b74ee41714e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfNC04LTEtMS0w_bb264466-f9ac-41a7-b55c-6abbf5b97d6c"
      unitRef="usd">764000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie3db46d4c79c4830b0ea1b74ee41714e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjU1ZGVlZTAyMjE2MzRhZTI5NDhmMzA2MmEyN2VkYWEzL3RhYmxlcmFuZ2U6NTVkZWVlMDIyMTYzNGFlMjk0OGYzMDYyYTI3ZWRhYTNfNC0xMC0xLTEtMA_558a3d71-6897-439f-9a0c-cb9899730b34"
      unitRef="usd">764000000</us-gaap:OtherAssetsNoncurrent>
    <jnj:EquityFairValueAdjustmentImpairmentLoss
      contextRef="idac7648f2ee14ded909ba25b98704f30_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfNjQ4NA_689e17ca-555e-4b07-bd65-c88bbbbb25c9"
      unitRef="usd">-55000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwNTM_d874a7e5-bdbf-4e65-8515-d3af6db4f447">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of April&#160;4, 2021 and January&#160;3, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,481 million, which are classified as Level 1 and contingent consideration of $633 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classified as non-current other assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Includes $589 million and $594 million, classified as non-current other liabilities as of April&#160;4, 2021 and January&#160;3, 2021, respectively.  Includes $11 million and $39 million classified as current liabilities as of April&#160;4, 2021 and January&#160;3, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. &lt;/span&gt;&lt;/div&gt;The Company recorded a contingent consideration reversal of $983 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense, net.</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ic55cbe2969894f10bd11012937cb3cdd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNC0yLTEtMS0w_51d11691-f095-457c-8aac-3aa153700d04"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="iddd05909aea443d3b6e90c5026e77987_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNC00LTEtMS0w_9d8b16aa-5974-4909-b949-2934fdb8195a"
      unitRef="usd">561000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i750ed2565a694c9c819af99b440bccb0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNC02LTEtMS0w_32ec99e6-1b98-477e-a1e5-cf6d95138d35"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ie72107b2f41048608d40b52f7842ac46_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNC04LTEtMS0w_0c22250c-f22b-4ee2-8669-e6a7256b6c77"
      unitRef="usd">561000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i3281569ca4124bab9a05c92d04b015b3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNC0xMC0xLTEtMA_80de9269-77f9-4378-9c33-867d1a028896"
      unitRef="usd">849000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="iee80bb4dedc94292864c36970f859808_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNS0yLTEtMS0w_51a95925-1d92-42e9-9ceb-c7942ed6bc58"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ic246ecfdb3484602b3397443c4ae0302_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNS00LTEtMS0w_bc3aed2a-4983-4365-be45-4055d7fa66c6"
      unitRef="usd">522000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i1cca5da5737441298ed9e781c444cab4_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNS02LTEtMS0w_94f969b7-6fc9-400c-a5bc-b8d4b4abe275"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i8c58449914d342049beb19957b06dcd4_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNS04LTEtMS0w_0203435e-58ab-46d2-a2ca-3c050233c414"
      unitRef="usd">522000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i6112627e2fe7456bbf10241a8ee92b8e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNS0xMC0xLTEtMA_30ea51a4-a6a0-4cf3-bad6-9f28b973cc93"
      unitRef="usd">240000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i62b449f24e1840a188eeaea7b64de5c5_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNy0yLTEtMS0w_d95e7617-0db2-4af4-8905-719ef8ee76d3"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i087920326dbc4003933caee61ef1d032_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNy00LTEtMS0w_4524ad2e-7a4f-436e-9661-0e0bc5845586"
      unitRef="usd">1083000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i9081f2f0d3934ae7b2f8a1376e4c854c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNy02LTEtMS0w_b881775b-347b-4389-bdf5-aeb7d052bbc7"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNy04LTEtMS0w_0b95cd1c-953b-4bef-9dfe-b438931dd296"
      unitRef="usd">1083000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="if1d3968138264974924b828c7a733b2e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfNy0xMC0xLTEtMA_386a8e9d-4fe4-42a2-a763-1e107f94ecb2"
      unitRef="usd">1089000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ic55cbe2969894f10bd11012937cb3cdd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfOS0yLTEtMS0w_f33875ec-8f74-43e9-a1d5-12b75366394c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="iddd05909aea443d3b6e90c5026e77987_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfOS00LTEtMS0w_a9681353-e1e5-4e63-9cc5-9cbc95f9016c"
      unitRef="usd">565000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i750ed2565a694c9c819af99b440bccb0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfOS02LTEtMS0w_277d5e22-6c0d-4920-a434-2919ebd0515f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ie72107b2f41048608d40b52f7842ac46_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfOS04LTEtMS0w_c9263a66-9e4b-4ef7-bd83-8299edc944b8"
      unitRef="usd">565000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i3281569ca4124bab9a05c92d04b015b3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfOS0xMC0xLTEtMA_adb78f11-a9a3-4aac-801c-11c3e5f5ae7f"
      unitRef="usd">702000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="iee80bb4dedc94292864c36970f859808_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTAtMi0xLTEtMA_dc0d73c5-f016-49ad-b0e7-83044275be2f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ic246ecfdb3484602b3397443c4ae0302_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTAtNC0xLTEtMA_1429cd9c-9b9a-4472-8679-b41d51b2daf9"
      unitRef="usd">540000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i1cca5da5737441298ed9e781c444cab4_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTAtNi0xLTEtMA_8cec1566-e142-4291-996c-dff0ee5f47dd"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i8c58449914d342049beb19957b06dcd4_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTAtOC0xLTEtMA_860cca82-3b68-4be0-a254-631f4d3196a3"
      unitRef="usd">540000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i6112627e2fe7456bbf10241a8ee92b8e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTAtMTAtMS0xLTA_80b62337-ac43-4282-a89e-a5fdd469dbc1"
      unitRef="usd">1569000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i62b449f24e1840a188eeaea7b64de5c5_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTItMi0xLTEtMA_5d36fb7b-0821-40c6-a0dd-45d906f78e3f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i087920326dbc4003933caee61ef1d032_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTItNC0xLTEtMA_1b876ec7-68ec-4809-ab21-e55ffdfbfae9"
      unitRef="usd">1105000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i9081f2f0d3934ae7b2f8a1376e4c854c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTItNi0xLTEtMA_a7dfe8cc-2a7a-4b8a-8864-637d6501b979"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTItOC0xLTEtMA_4aad8ff7-af33-4a2e-bd63-e6c6898e4806"
      unitRef="usd">1105000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="if1d3968138264974924b828c7a733b2e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTItMTAtMS0xLTA_23c32018-3a61-4463-a174-c5ca37b914d2"
      unitRef="usd">2271000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ic55cbe2969894f10bd11012937cb3cdd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTUtMi0xLTEtMA_cfbf59ae-c18d-416e-8184-f1e0ac8c3a98"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="iddd05909aea443d3b6e90c5026e77987_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTUtNC0xLTEtMA_b96f38a6-6895-4840-bd28-69a2ef40d8ef"
      unitRef="usd">51000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i750ed2565a694c9c819af99b440bccb0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTUtNi0xLTEtMA_29219705-7d9b-4e02-a3ce-35c0f4b302de"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ie72107b2f41048608d40b52f7842ac46_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTUtOC0xLTEtMA_e13c84d5-4846-4beb-a8f2-cd66b3d45de3"
      unitRef="usd">51000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i3281569ca4124bab9a05c92d04b015b3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTUtMTAtMS0xLTA_f553b083-2263-476c-a49b-b033a592ab12"
      unitRef="usd">49000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ic55cbe2969894f10bd11012937cb3cdd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTctMi0xLTEtMA_c9f7fff4-3e6b-4020-915f-33bed5a5ff57"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="iddd05909aea443d3b6e90c5026e77987_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTctNC0xLTEtMA_54728e7b-520b-48b1-bc58-ad44efffae0b"
      unitRef="usd">43000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i750ed2565a694c9c819af99b440bccb0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTctNi0xLTEtMA_297f5073-b9ca-4535-a6d1-5826cfd4a4f7"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ie72107b2f41048608d40b52f7842ac46_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTctOC0xLTEtMA_0c8f6e6e-da0f-47c4-bdcc-5350681801e7"
      unitRef="usd">43000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i3281569ca4124bab9a05c92d04b015b3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTctMTAtMS0xLTA_529fa54d-0f65-477b-9941-77b3228cd727"
      unitRef="usd">38000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i62b449f24e1840a188eeaea7b64de5c5_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTktMi0xLTEtMA_909c5866-e728-43d6-9689-2c322dacb004"
      unitRef="usd">1452000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i087920326dbc4003933caee61ef1d032_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTktNC0xLTEtMA_4f722440-56ff-4344-805b-b42d95ea2cab"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9081f2f0d3934ae7b2f8a1376e4c854c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTktNi0xLTEtMA_83078432-01a1-421b-85f5-80e8f47c579e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTktOC0xLTEtMA_c03cda27-83ba-4492-80e5-eb2c2a7c1338"
      unitRef="usd">1452000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMTktMTAtMS0xLTA_7922ff22-60f8-4d99-a2cb-a7b37306a597"
      unitRef="usd">1481000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62b449f24e1840a188eeaea7b64de5c5_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjAtMi0xLTEtMA_896348aa-e62d-43b8-a2b7-27fcf34d635f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i087920326dbc4003933caee61ef1d032_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjAtNC0xLTEtMA_acaf40e0-ee4f-45a5-b532-57e07342c723"
      unitRef="usd">14493000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9081f2f0d3934ae7b2f8a1376e4c854c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjAtNi0xLTEtMA_c2cdde8f-00f4-4f1c-beff-3a5f9535c8be"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjAtOC0xLTEtMA_b5f23008-9c8d-4c37-891f-f815dc3a0a5e"
      unitRef="usd">14493000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjAtMTAtMS0xLTA_3795a3f8-451e-48aa-8b1d-1a5f86c98f9d"
      unitRef="usd">14042000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i62b449f24e1840a188eeaea7b64de5c5_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjItMi0xLTEtMA_c4eff1eb-ddf9-4f34-b1d5-4806d755421c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i087920326dbc4003933caee61ef1d032_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjItNC0xLTEtMA_e26dfa9f-516b-49b6-aedf-26035bccc32d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9081f2f0d3934ae7b2f8a1376e4c854c_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjItNi0xLTEtMA_a20ab512-a7a4-4a46-9f2c-e593c3bc237e"
      unitRef="usd">600000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjItOC0xLTEtMA_9ff31e47-0c60-439b-b8ed-91523c867404"
      unitRef="usd">600000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmQ0ZDk0YmIwNjUyZTQ4YWU4YzRkODNmMWQ5OTFiOGVkL3RhYmxlcmFuZ2U6ZDRkOTRiYjA2NTJlNDhhZThjNGQ4M2YxZDk5MWI4ZWRfMjItMTAtMS0xLTA_65c8737b-7e66-4c02-83ac-53d29052198e"
      unitRef="usd">633000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfMi0yLTEtMS0w_fce27494-7991-41dc-886a-c3a5d546a6b4"
      unitRef="usd">1134000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfMi00LTEtMS0w_9572a46a-81e2-4438-9ec7-6a4607c79428"
      unitRef="usd">1138000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfMy0yLTEtMS0w_5c41c60e-2267-4a09-8bcd-fde465fab492"
      unitRef="usd">1028000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfMy00LTEtMS0w_7f47f689-42a8-4cf1-9195-7a6906657265"
      unitRef="usd">1107000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfNC0yLTEtMS0w_afff9db5-e259-427a-903f-c778e41e021f"
      unitRef="usd">106000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfNC00LTEtMS0w_485ec7d7-8549-4fa0-8037-cac2dad8c88e"
      unitRef="usd">31000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfNi0yLTEtMS0w_4aeba229-9be2-4437-879b-494cd3c85579"
      unitRef="usd">1148000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfNi00LTEtMS0w_1ebfa0ef-a05b-4923-b8a1-3d8d7ea9d84e"
      unitRef="usd">2309000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfNy0yLTEtMS0w_5feca86a-1f27-4859-b248-f1f2ae6146a5"
      unitRef="usd">1130000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfNy00LTEtMS0w_ac9ac62c-0ae9-4389-a35e-92ce1f4fb996"
      unitRef="usd">2172000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfOC0yLTEtMS0w_9190a406-e942-4a8f-b5e3-2f7ce677a4ee"
      unitRef="usd">18000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjhhYTIzMDQ3ZGFkMjQwZDI5NDIxNGFlZmU2OTQ5YTIyL3RhYmxlcmFuZ2U6OGFhMjMwNDdkYWQyNDBkMjk0MjE0YWVmZTY5NDlhMjJfOC00LTEtMS0w_593e1c5a-c1d3-4cb3-94e2-0e19d7619903"
      unitRef="usd">137000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iabd737cfbcd54bdbbcb2e9240b76d431_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfMy0yLTEtMS0w_fb112e04-5add-49cf-b70f-c75956f57d18"
      unitRef="usd">633000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i57b90fcac8194c0c83439d028eb794fa_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfMy00LTEtMS0w_dddb08fd-52d7-40d4-8e09-58eb75bc4e94"
      unitRef="usd">1715000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNC0yLTEtMS0w_8911c985-fde3-4510-842b-d6c8e726168e"
      unitRef="usd">15000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNC00LTEtMS0w_5c643d5a-983c-46a8-b51e-04bd6f2f2977"
      unitRef="usd">-977000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNS0yLTEtMS0w_c7010fcd-c5ea-473d-84fa-b941d8ae0641"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNS00LTEtMS0w_38c1205c-cb7f-4940-92d0-d18efd1d2ce5"
      unitRef="usd">106000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNi0yLTEtMS0w_52517cfb-dd05-44cb-8e11-809fdb8f9742"
      unitRef="usd">48000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNi00LTEtMS0w_727d6ea5-bc0b-4725-8009-32771fafdabf"
      unitRef="usd">60000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNy0yLTEtMS0w_7f0ee57a-9113-4612-bc6d-5293285e127a"
      unitRef="usd">600000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie2f9f433686145c29000c017762e5f79_I20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlYzMzNDJkODBmZTRmYmU5ZTViODc4ZGRkYTBjODIwL3RhYmxlcmFuZ2U6NGVjMzM0MmQ4MGZlNGZiZTllNWI4NzhkZGRhMGM4MjBfNy00LTEtMS0w_77896037-ee71-48df-b2ab-edb34bf9c98d"
      unitRef="usd">784000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4b53ffb9394c4a118127e114b531b8f2_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfODg1OA_d4304775-786a-44cd-9c38-646259256e06"
      unitRef="usd">1481000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8fef9ce1b1c94e7baad55d8c2f003ca8_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfODkyNg_c7fa5f3b-7f00-48f5-996a-f6c5e14b38a2"
      unitRef="usd">633000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if9108e0198f1454fbc22f7c1d46a4ac8_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfOTIzMg_4ff583cb-a855-434d-b11b-be9eadac9aec"
      unitRef="usd">589000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie06eb83c93424fc38c8f74e769309ab0_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfOTI0Nw_1d9664ab-2d8d-480a-b5f1-6c9363926e4c"
      unitRef="usd">594000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2ee15e9e3be0451c9104456ede3ce154_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfOTQwMQ_927376cb-7179-450f-9afb-6122bf1331cb"
      unitRef="usd">11000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic6c3f15ce4ab427d911866506af070e3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfOTQxNg_7aa08f04-c57c-4452-9f8b-f3fd2c3fd8a1"
      unitRef="usd">39000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ib7915bfce2cf46dca29a5703af986b2e_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfOTY2OQ_73cdb12d-f29d-46fa-820c-ea2435c8cf6a"
      unitRef="usd">-983000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwNTY_db0125ef-ece1-43b2-8f93-3c260893d10b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash, cash equivalents and current marketable securities as of April&#160;4, 2021 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. sovereign securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other sovereign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="icfdfbb11f0c04c20a79df23a07ba5ecc_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMS0xLTEtMS0w_afee55ae-7e5f-4c05-9707-9f430cd4f3e7"
      unitRef="usd">2247000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="icfdfbb11f0c04c20a79df23a07ba5ecc_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMS0zLTEtMS0w_9fa09481-5be9-42a9-b957-a5a8f1bacd4d"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="icfdfbb11f0c04c20a79df23a07ba5ecc_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMS01LTEtMS0w_78223eb1-8f38-4e93-91c9-3db961b21234"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="icfdfbb11f0c04c20a79df23a07ba5ecc_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMS03LTEtMS0w_d5ad262a-cb6b-4007-b8d7-0b701ba11390"
      unitRef="usd">2247000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icfdfbb11f0c04c20a79df23a07ba5ecc_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMS05LTEtMS0w_7e604f23-74f3-4d4f-b7fd-963332536371"
      unitRef="usd">2247000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i0bde608450a04e129af5ff3ed4538b5d_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMy0xLTEtMS0w_329ff2ca-df99-4cd4-b738-d96a97ea8535"
      unitRef="usd">400000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i0bde608450a04e129af5ff3ed4538b5d_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMy0zLTEtMS0w_53756f1f-116d-46dc-a1f2-add8cc70c127"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i0bde608450a04e129af5ff3ed4538b5d_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMy01LTEtMS0w_c0e5dad7-3fb9-42eb-985d-b845ef51a589"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i0bde608450a04e129af5ff3ed4538b5d_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMy03LTEtMS0w_c7241049-f67c-408a-87b0-37064f76e439"
      unitRef="usd">400000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0bde608450a04e129af5ff3ed4538b5d_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMy05LTEtMS0w_886839ca-fd84-4b8c-9083-2fd1b037958e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i0bde608450a04e129af5ff3ed4538b5d_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMy0xMS0xLTEtMA_1886fcb5-eae6-4afd-ade8-2b18d1004c72"
      unitRef="usd">400000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ib0e402b3caab4da7802a67171676c4f0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNC0xLTEtMS0w_88746f53-254c-4b2c-8f9e-765ef3d10e98"
      unitRef="usd">1199000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ib0e402b3caab4da7802a67171676c4f0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNC0zLTEtMS0w_e7f62a14-0e80-41e5-8b10-ec8736a9b6eb"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ib0e402b3caab4da7802a67171676c4f0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNC01LTEtMS0w_a24c071b-1b62-49d7-8396-949c14dc3ab6"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ib0e402b3caab4da7802a67171676c4f0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNC03LTEtMS0w_f52175db-0220-46d9-8e8b-711bbb75ff2f"
      unitRef="usd">1199000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib0e402b3caab4da7802a67171676c4f0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNC05LTEtMS0w_081636ee-bf76-4d73-bf54-dc5322231740"
      unitRef="usd">1199000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib0e402b3caab4da7802a67171676c4f0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNC0xMS0xLTEtMA_91330a3c-6f39-4298-b2d2-6ccf24cfe33f"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ic2aae0ebe6c54209a9f723970cc996ab_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNS0xLTEtMS0w_c79cdde4-a6a3-49de-b297-2ea2de77f7dd"
      unitRef="usd">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ic2aae0ebe6c54209a9f723970cc996ab_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNS0zLTEtMS0w_34d8ff91-26c1-4a7f-ac10-2b0267397583"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ic2aae0ebe6c54209a9f723970cc996ab_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNS01LTEtMS0w_fa0ddbf1-ec36-4efc-b92c-158bfe5852a2"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ic2aae0ebe6c54209a9f723970cc996ab_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNS03LTEtMS0w_a634630a-6cb5-4bd5-be87-7d7a8eeda567"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic2aae0ebe6c54209a9f723970cc996ab_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNS05LTEtMS0w_6b767675-9ed8-45cb-b4c7-df38eb285ef2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i21d02a87aab8433eb31b762adf895c58_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNi0xLTEtMS0w_695980ef-a952-45ac-b59d-25ba251a2ab4"
      unitRef="usd">3239000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i21d02a87aab8433eb31b762adf895c58_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNi0zLTEtMS0w_c664ed98-d187-49d9-b3d2-e35c38b8cecf"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i21d02a87aab8433eb31b762adf895c58_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNi01LTEtMS0w_7694df9e-d818-46c0-8a9f-0c6db97ee097"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i21d02a87aab8433eb31b762adf895c58_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNi03LTEtMS0w_56fa1aa6-b198-4ac4-ae5c-fea4785efe5c"
      unitRef="usd">3239000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i21d02a87aab8433eb31b762adf895c58_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNi05LTEtMS0w_8d8737c5-7162-4553-9b2f-eb1e2e106e3f"
      unitRef="usd">1890000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i21d02a87aab8433eb31b762adf895c58_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNi0xMS0xLTEtMA_79ce4a37-9f95-4b83-b69a-eed5bf9a89e4"
      unitRef="usd">1349000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i53522da16d414a2cbe5ee063bc15169e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNy0xLTEtMS0w_07c2a595-c43f-4228-88d7-f43ad057ac2c"
      unitRef="usd">2094000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i53522da16d414a2cbe5ee063bc15169e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNy0zLTEtMS0w_b09891ef-d9fe-4c28-9e2b-0cc626113799"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i53522da16d414a2cbe5ee063bc15169e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNy01LTEtMS0w_1a21bff0-ba43-43dd-a10d-215f2bd603c2"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i53522da16d414a2cbe5ee063bc15169e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNy03LTEtMS0w_07a60311-4628-40be-8185-e1e97086d0c8"
      unitRef="usd">2094000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i53522da16d414a2cbe5ee063bc15169e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfNy05LTEtMS0w_281f2699-963e-415c-b822-005c9b56adb7"
      unitRef="usd">2094000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i9c13e647c3264f6d9f7597704bbc8077_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOC0xLTEtMS0w_37d0e769-a18c-4b68-8cde-5c44964bc988"
      unitRef="usd">947000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i9c13e647c3264f6d9f7597704bbc8077_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOC0zLTEtMS0w_abc5eb17-067c-4912-8f51-68af46fe9ca3"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i9c13e647c3264f6d9f7597704bbc8077_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOC01LTEtMS0w_395e80fd-a01c-4cb5-a11b-9d412cb1bb02"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i9c13e647c3264f6d9f7597704bbc8077_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOC03LTEtMS0w_ccb15e9d-964f-4f9f-ab3a-4e1fe33f6746"
      unitRef="usd">947000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c13e647c3264f6d9f7597704bbc8077_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOC05LTEtMS0w_7b3f6462-5abf-47b0-ac0d-1284f2f6e4df"
      unitRef="usd">947000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOS0xLTEtMS0w_09767cb7-0348-4a4e-8ade-a44c58997779"
      unitRef="usd">10126000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOS0zLTEtMS0w_c55d50b9-9047-4209-9b4c-ee67af86bd29"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOS01LTEtMS0w_6c1d7071-d686-4b71-92ea-06ff889e1af8"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOS03LTEtMS0w_df171a7f-a531-4e02-b843-6df6be7c34a6"
      unitRef="usd">10126000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOS05LTEtMS0w_31626505-311f-4efc-a560-2f240239ba5e"
      unitRef="usd">8377000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib7d8cbd8cda1424a9ca9dece8ce2b2a3_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfOS0xMS0xLTEtMA_bd041861-c0f5-4371-bc1d-143291089580"
      unitRef="usd">1749000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTItMS0xLTEtMA_5ff05e1f-a2ac-464b-965b-44b09739ffea"
      unitRef="usd">14228000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTItMy0xLTEtMA_49195c19-166a-42bb-8704-0edcee5e9653"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTItNS0xLTEtMA_f5e6e0fb-745b-4796-805d-e44f1a013b8f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTItNy0xLTEtMA_b03bb212-59b2-47da-b85d-f7b408ea42ef"
      unitRef="usd">14229000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTItOS0xLTEtMA_87699035-aa74-481f-908e-049468ed98d3"
      unitRef="usd">4268000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="idfe6c6b7eb7946a2ba5e39af0d0bb062_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTItMTEtMS0xLTA_6d9e42dd-f704-412f-a0f6-2e73877b1d5a"
      unitRef="usd">9961000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id34dd034a8ce44d78c8d013272369235_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtMS0xLTEtMA_3d3d7013-7a1d-413b-8ff3-3dea5db91cee"
      unitRef="usd">8000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id34dd034a8ce44d78c8d013272369235_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtMy0xLTEtMA_b8ae70f2-e5cc-4c0a-8249-0d245eda5601"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id34dd034a8ce44d78c8d013272369235_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtNS0xLTEtMA_9e175d92-aafa-44c7-bbde-538ef8899377"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id34dd034a8ce44d78c8d013272369235_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtNy0xLTEtMA_db48f2f1-9593-4f4e-86b0-f9aea0fd141f"
      unitRef="usd">8000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id34dd034a8ce44d78c8d013272369235_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtOS0xLTEtMA_12763ac6-d3b5-4ba9-8135-ef6fdd422748"
      unitRef="usd">1000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id34dd034a8ce44d78c8d013272369235_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtMTEtMS0xLTA_03e1e097-8210-4609-8fb6-3cd14f7b771b"
      unitRef="usd">7000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id34dd034a8ce44d78c8d013272369235_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTMtMTEtMS0xLTA_f3342731-7ef2-4aa3-a68c-fbb891477940"
      unitRef="usd">7000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTQtMS0xLTEtMA_f00762ae-8fcf-41a4-b57e-3509028ce775"
      unitRef="usd">256000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTQtMy0xLTEtMA_0affdfa5-e76d-4def-b7e2-db02ac7aa7eb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTQtNS0xLTEtMA_eb35b467-1110-4960-8f25-2cb7e74fe5dc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTQtNy0xLTEtMA_8e75b115-df1a-4ac3-b02a-965d2ce8acb0"
      unitRef="usd">256000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTQtOS0xLTEtMA_0fdd4fef-c1a3-4f4e-a5d7-fb1daa23d96c"
      unitRef="usd">25000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ibdb68422c38a4463a845f9a0e34c7d1a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTQtMTEtMS0xLTA_63a2bd60-b071-4c3b-9842-61ee57056082"
      unitRef="usd">231000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i55ad5b35a58e4a549a452417ff62e50f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTUtMS0xLTEtMA_fb4d8fb1-704a-42d9-8c30-ae9e727dae39"
      unitRef="usd">14492000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i55ad5b35a58e4a549a452417ff62e50f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTUtMy0xLTEtMA_c9764e61-e615-4547-a04f-9f25418d3591"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i55ad5b35a58e4a549a452417ff62e50f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTUtNS0xLTEtMA_d667a7a3-d93a-4270-8679-4304b103713b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i55ad5b35a58e4a549a452417ff62e50f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTUtNy0xLTEtMA_42613c0e-cff9-4bac-abd9-c0a5f322ba1b"
      unitRef="usd">14493000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i55ad5b35a58e4a549a452417ff62e50f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTUtOS0xLTEtMA_bae475a9-fbef-44f2-8db9-dd7bd40d59f4"
      unitRef="usd">4294000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i55ad5b35a58e4a549a452417ff62e50f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTUtMTEtMS0xLTA_e6a6c966-f696-4881-bae6-835a192517e1"
      unitRef="usd">10199000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTYtMS0xLTEtMA_0b8df3ef-36ea-425b-8570-d2f93a82780a"
      unitRef="usd">24618000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <jnj:CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTYtMy0xLTEtMA_60e731c9-e697-43e6-a48a-b0f13f1bcf6e"
      unitRef="usd">1000000</jnj:CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain>
    <jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTYtNS0xLTEtMA_22a232b5-cdb5-4829-8486-390211359f8d"
      unitRef="usd">0</jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss>
    <jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTYtNy0xLTEtMA_42a079b9-8e01-4606-a4db-11a978af6a21"
      unitRef="usd">24619000000</jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTYtOS0xLTEtMA_add481dd-71fe-4a66-88bc-e34e32e1144d"
      unitRef="usd">12671000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjRlOTMwMTlkMGNhNDRmNTBiMjY2MGM2ZTJiOGQ4OWZlL3RhYmxlcmFuZ2U6NGU5MzAxOWQwY2E0NGY1MGIyNjYwYzZlMmI4ZDg5ZmVfMTYtMTEtMS0xLTA_5db65d5f-5eba-4d81-a98a-5a611a9b5a98"
      unitRef="usd">11948000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwMTk_413df230-255c-4149-a5eb-1634cfa5f8cc">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwNzA_b1424772-6bf0-4bf4-8a09-bb85f690f52c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale securities as of April&#160;4, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfMS0yLTEtMS0w_154c2ec9-01bd-4b8d-abdf-1f31a5367d24"
      unitRef="usd">14486000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfMS00LTEtMS0w_09a3188e-72d0-44d7-97b2-8b8e61fba3b2"
      unitRef="usd">14487000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfMi0yLTEtMS0w_a34a3787-7152-4313-831a-80e59c61b4cd"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfMi00LTEtMS0w_aa85ce27-e14d-42a5-9be5-53fc6d84d744"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfMy0yLTEtMS0w_4bf92425-44ad-48e0-9be7-551fd1f6d9a8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfMy00LTEtMS0w_e3774998-4a8e-446b-8ece-62345fbd6bea"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfNC0yLTEtMS0w_61d47383-8ad3-4de4-a8e8-96c7a1a143ce"
      unitRef="usd">14492000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOmNhOGUxN2RlMjI5NDRiNmZhZmEwZjI1YzBlOTExMDBiL3RhYmxlcmFuZ2U6Y2E4ZTE3ZGUyMjk0NGI2ZmFmYTBmMjVjMGU5MTEwMGJfNC00LTEtMS0w_ef0db8fc-2fcd-412a-8154-cbac0883b21b"
      unitRef="usd">14493000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTIwMTE_3efa5c98-2907-41d1-821b-1f4679c0a675">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments not measured at Fair Value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;4, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73% Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 (750MM Euro 1.1757)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Notes due 2024 (500 MM GBP 1.3799)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028 (750MM Euro 1.1757)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035 (1.5B Euro 1.1757)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="ia551774380104d5a9cb2e81ed84e5fbc_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNC0yLTEtMS0w_256989e6-dd3a-491f-8de3-e0dec3d89054"
      unitRef="usd">3350000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="ie6527580553d4feaa0905f4262bf370f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNC00LTEtMS0w_3562b329-a56a-40ad-962c-38c27523f6d7"
      unitRef="usd">3380000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if362b20960c24710b7e9131a1f050ad8_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOmUwZmU0N2Y2M2IwZTRmNjFhOWNkYWVmYzU3ZWVhM2Y2XzQ_d976cb9d-4822-4900-bcf6-35332ba89b04"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i31f92bb8177d4d7b8cd1179e1735f8d6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTEtMi0xLTEtMA_e506c04b-7338-499b-9d6c-79880b669ad4"
      unitRef="usd">250000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i080bcda1e8fc49b9b3b8f7f21d977c2e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTEtNC0xLTEtMA_5713b8c0-eab2-4ec9-b8bb-0cb240b9f87f"
      unitRef="usd">292000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id4db85c50deb4321b0098f8ccf20b46a_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTItMC0xLTEtMC90ZXh0cmVnaW9uOmM2MTdhMTc0NmViYjQ4ZGZiNDQyMjc3MTk5Mjk4YTZiXzQ_c5eca0a1-4d12-45da-ba40-21508a35ab6a"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1cc61c2b232f40b88208ae48fe534d86_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTItMi0xLTEtMA_7c9df107-c7a7-4015-adde-aae655391972"
      unitRef="usd">802000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iffab5554feae486aaf2e6e43a90b37e5_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTItNC0xLTEtMA_216a95d5-9ad3-4c3f-ac8d-0ef16542fdc7"
      unitRef="usd">868000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9bcc1b72d9204d9fb6b0776f239845df_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOmYyYzkxYjMxMzA3MjRjZjNiYzJmMTU2NmVmM2VlMDU5XzQ_7ab135a9-a56a-47e4-a65a-85d17a34c47f"
      unitRef="number">0.0205</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9d1395460274475eb8aec4f946ce6846_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTMtMi0xLTEtMA_a90a730e-607b-41e2-8505-8e6d2f6908bf"
      unitRef="usd">499000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i66c7696b31ef458dbdebd3465124db85_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTMtNC0xLTEtMA_9e51fae6-fb38-49e5-8a38-451bf0e50f2e"
      unitRef="usd">515000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i232ebe15fffe4208ae8fe01bb810d201_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOmJkNTgwNGNiNmY3YzRiYTg4ZTA5M2ZhMDZkODg2NTNkXzQ_fef2c663-44ed-4dc3-adc4-6afb6d92c3ef"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6ecca6252ec6440ab50478e4522c9cb9_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTQtMi0xLTEtMA_9da87d8d-144c-46af-ad9c-dc7670c7347f"
      unitRef="usd">880000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia4b9cda0ccb141c2b49c9bbf460578e8_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTQtNC0xLTEtMA_f8eb896e-6e00-4235-b478-3f4f89249631"
      unitRef="usd">904000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i01bc079fc7af4d169035bc9957d09c9d_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTUtMC0xLTEtMC90ZXh0cmVnaW9uOjJmNDFmMWViNjAwYjRmNzM4M2U3YzY0YWQ5ZGQ3Y2I1XzQ_197f7f2d-d31c-44ec-afe8-234ba5598797"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i17306623a4594a4599e905c0006aa969_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTUtMi0xLTEtMA_a02680c2-c47c-4c92-8ee2-187c21431db2"
      unitRef="usd">687000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ieb973d605fa44eeba1302fbb97d677fa_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTUtNC0xLTEtMA_614be717-2412-4d4e-8881-86ca5327f0b1"
      unitRef="usd">808000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7218d516a3fa4b1a991bda3b84a3972b_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTYtMC0xLTEtMC90ZXh0cmVnaW9uOjk3OTFlYzUzMTY0OTQ3Y2NhZTA1Yjc5NWZhMjRjMGYzXzQ_081d53f3-351a-4cea-a16e-b5225564b1cd"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if02515bdf715434b91522300dc22073a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTYtMi0xLTEtMA_55dbb6c8-4a29-4824-8c97-6f160837d4d3"
      unitRef="usd">749000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i50dd314f98bc4ea585b34a6ef22d88bd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTYtNC0xLTEtMA_69661ebd-b2ba-49a8-926c-b127a5c28cf8"
      unitRef="usd">797000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85a39dbd593546cb8669a44bf5ba1f36_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTgtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YWZhNDk1N2UzMDQ3ZGZiMTIwNDZhMjQ1NjliODE2XzQ_aaebb5fc-09b2-48a0-9015-a75c3bacb635"
      unitRef="number">0.0055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib067ee5fb75e4a41a8dd5a32a4fc5baf_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTgtMi0xLTEtMA_38df0697-a459-4b9f-a0e2-45cbcc853bba"
      unitRef="usd">996000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ida015c71d6964ba4b2e11a562c29b0eb_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTgtNC0xLTEtMA_8d2ccae3-d919-40c8-94e8-d2fd0de0424b"
      unitRef="usd">982000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5af5af1c6e1541e99b3ea8ce7066da11_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTktMC0xLTEtMC90ZXh0cmVnaW9uOjQ5MjgzODNjNTk0NjQxNzI5ZTY1ODAwNGQ3NzI4YTc1XzQ_b7999144-1d78-4157-9e51-c5a03fa78e55"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0514f7f1d16f40e0b128088ad9ec2a66_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTktMi0xLTEtMA_2de91aaf-750d-48cc-befe-8ff347b27256"
      unitRef="usd">1994000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0c97765733f04d0ab64e6cc604f9feaf_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMTktNC0xLTEtMA_2ead5f22-29bf-4a17-87fe-d0204d869ce8"
      unitRef="usd">2115000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id9fca91959a44bc99f389c8604972d5a_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0ODcwZDA4MjdkNjQyNzU5ZTVmNTRiMjZiMmU3ZDQ4XzQ_6ccc0691-395d-418f-8d20-8282f6d27369"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5ab9b12aba8443be862462c8b208e6ff_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjAtMi0xLTEtMA_45220b42-3488-4aaa-80c0-b19cc9df467b"
      unitRef="usd">997000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2e9d564117274a81b671fc45094fcb9d_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjAtNC0xLTEtMA_396a815a-bd43-437d-9875-4f92e1365286"
      unitRef="usd">1084000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i885f427d1f254de2a0594cd4499d4276_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjItMC0xLTEtMC90ZXh0cmVnaW9uOmJhNGQ1MmYyYjI3YjRiNjQ5ODQyOTgxNDRjM2I0NDFlXzQ_5f8336f2-05e3-4165-a7cb-c9476c408400"
      unitRef="number">0.0095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib87c8983a8b144e0a0b7a8d79fd69370_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjItMi0xLTEtMA_ca6dcbea-fc47-4b38-91f2-13baf924e001"
      unitRef="usd">1494000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i641f9be9a5ad45c5b83f607f6d1f3eda_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjItNC0xLTEtMA_3af012f1-4465-44dd-886f-6e19009be2b4"
      unitRef="usd">1445000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i79896030d67642908f3083ddc47a69c0_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOmQwOTRlMTJhYWExOTRkN2Q4YzE4MmMzMmEwZjMxNGUyXzQ_2a3053c6-d1cd-4fa4-b358-7843d4669c9e"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i65d0ffe736bd4dcfbd632eed9b5f65e0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjMtMi0xLTEtMA_642d1520-9212-44d8-b374-8479c1b7dd33"
      unitRef="usd">1495000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i20ee57fedc3544d9bd6c9bd722f91f29_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjMtNC0xLTEtMA_fb5da0fa-770a-4032-a787-3a540f15a2e2"
      unitRef="usd">1616000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7487f3b4696241b19abfcd01b9537fbf_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjQtMC0xLTEtMC90ZXh0cmVnaW9uOjhmNWIyZGNhMmFlZTRjYTRhMmE3NjI4YTQwNTMxOTZkXzQ_ea751742-eb8b-498b-9673-d952a4e4de1c"
      unitRef="number">0.01150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7a6737fe6b814f04816f11baa77695f0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjQtMi0xLTEtMA_6894b3a7-9d3c-41be-a963-1748ba9118a9"
      unitRef="usd">876000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i88bd89b0cd024d28be4458c01e872c39_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjQtNC0xLTEtMA_fa4cea81-dd73-475d-9df4-7d975a8c426c"
      unitRef="usd">955000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idd0df51e9f6e40ed9d88e684d9499266_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmUxOWFhODMyZjk4NDQ4ZWFiYTBlYWExYWE5YTYzNWRlXzQ_3240fa43-b72e-4728-a299-2a2bd52cdaa4"
      unitRef="number">0.0695</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i68d584c5a1bd4ff0b1a6d41603dd3b08_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjUtMi0xLTEtMA_e38a9ebd-865e-4310-a82d-25f7ebc45228"
      unitRef="usd">297000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i65e137191bb04b98bfcb88e12baff57b_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjUtNC0xLTEtMA_fe5dc06e-82ea-45db-baaa-439327c1cd9b"
      unitRef="usd">416000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3a9d444d344a4100a0391cef4739483c_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjM1MzYzZmM4YjA0ZTQzYjA5NTFkN2JlNDlhYWRiZTM0XzQ_a9175747-2789-4e47-9e0d-009158306b54"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5388981f8dd34003b44bcdbb65f1e543_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjctMi0xLTEtMA_3e5e8924-ff4d-4ba4-8138-35506d44122e"
      unitRef="usd">1743000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0d20b300aee54da4b4d3efd6dc870a65_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjctNC0xLTEtMA_d1d68f8b-5ed2-40ce-ad7e-b7046ce46bc9"
      unitRef="usd">1642000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7d5f6e95714e4bae9c1e910ae22b802f_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmM2MTcxOGYzYWQzNjQ2NDZhMGU5ZDkzYjQ4MWNiZDAwXzQ_064d5b23-d848-4fd5-9ec3-e48e6a91b687"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i89ecc979877e4f0e8a892f8c76441de8_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjgtMi0xLTEtMA_b2210f1b-b833-4f91-8978-3365fd4b4227"
      unitRef="usd">498000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ieb5caa2a14204d6898789b7e13ec13e5_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjgtNC0xLTEtMA_a302d277-3de6-47a3-b128-e26f7d1238d0"
      unitRef="usd">639000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie8f2e21bf85c4d6aa21abd973b571c71_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBlYTIyMzRiNWMxMzRhYTY5NjkzZWQ3ZjBjYTU5MjA3XzQ_3be28e57-ca52-44a3-9311-dfa75441d346"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i05cd1ceca68a4be7b9e6e339e53f6023_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjktMi0xLTEtMA_489501a7-cba4-4f6f-a735-ec69a582b4f7"
      unitRef="usd">855000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib5d469fc5b8845779a850f71b49f8b62_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMjktNC0xLTEtMA_2a94c776-6f3b-444e-b374-18e88541ea55"
      unitRef="usd">1046000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i481f371accbb49f5a40e7d7669b9063d_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmRhMjA0YmFjOGNjNDRiN2U4OTA3ODQzYTRjMTFjYzFlXzQ_eadffe87-2043-4142-a4af-c2afa277dbb0"
      unitRef="number">0.01650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9a96ed3119e94dd8ad5b849b0dfa13af_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzAtMi0xLTEtMA_a4ba431c-88e1-4ff6-bf30-7705d552f69f"
      unitRef="usd">1749000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icb0b9ad2fc354d65944c2a61b639e19f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzAtNC0xLTEtMA_1cfed088-ef26-4975-9a7d-7f46a4a2c664"
      unitRef="usd">2035000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if558e7c662c6460dbcfc287f05df9a6d_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEzM2QxZGM2Y2M3MTRhMjc4ODNjMjE0OTc3YjM5Y2ZkXzQ_83e819f9-8f21-4965-99cf-96b2e34e06f1"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib8522b9e894d4fdcbef8ee00218f96cd_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzEtMi0xLTEtMA_34e6871f-4f9d-4f4d-a901-c2ae32a2dfa5"
      unitRef="usd">990000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i16824b55647942daa85e7513f921c7ed_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzEtNC0xLTEtMA_f76dddb1-e17b-4d36-aa64-7f3557d74b21"
      unitRef="usd">1117000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4df43fc8b5ab4339afaf013e8ee480e5_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmEwYjA2ZGE4Y2IzMDQ1NTQ4ZTA2NWVkMTE3ZjA2NzU2XzQ_1d8e3106-a50d-48c9-b85c-8fea7487ad29"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i36ff32f415f941d28b01c0eae65ebd16_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzItMi0xLTEtMA_0e9a4c51-ea5e-47ab-9c37-f4d6e1722fd2"
      unitRef="usd">992000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i298a5e31ae074ef2b1abcdecc4c9bd6e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzItNC0xLTEtMA_b462efd2-f83e-48c0-a4aa-67dfe5f48999"
      unitRef="usd">1422000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85c5519ac2c74223abd4ff4bb596aa99_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjg5ODFmZTgzNzhhOTRjM2M4MmE2Yjg0ZTk4YWIyOTUzXzQ_f59ffb5d-4948-4981-b3a8-f7d7eb2d7c55"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i001e8a223ba8491f983e78ad8fa58d53_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzMtMi0xLTEtMA_9d663b95-373c-4823-a162-105d54106c79"
      unitRef="usd">1488000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i41eefdb455ed41d6bb26fb8467d496d7_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzMtNC0xLTEtMA_da95143e-0d1e-45d4-a48b-2065d087cd2e"
      unitRef="usd">1694000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib24e4cc519e54204a76fb775b089fea4_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ3NmFkNTBhM2U4MDQ2MTQ4OTBjYTljM2FlY2UxNjA4XzQ_194a3d97-9c7b-4062-b219-4d7260619878"
      unitRef="number">0.0340</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i08bc89cac5b142cba9c10b6895ceadba_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzQtMi0xLTEtMA_85a7563c-45d5-484a-83f0-4fb800e71012"
      unitRef="usd">991000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i66627c055dbf4a0eb408404ce5322e9e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzQtNC0xLTEtMA_37aed6b5-4d6c-4b26-95a8-767ef9af2fad"
      unitRef="usd">1097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4ec5bd94c75b4263b7251abd5a82e702_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjI1NDY1MTRlMTVjYjRlM2ZhMGQ1YmQ3OTFkYTdhOGU1XzQ_09722fee-109d-4d59-acf6-47a92e0213d9"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3b60cd521d53474e8b55300042817025_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzUtMi0xLTEtMA_f6a64138-3418-4710-a1f0-81075f948908"
      unitRef="usd">696000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7388370141f140dd8d9ec8e9d39c42fb_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzUtNC0xLTEtMA_e1b43cfb-64b1-4d02-bda5-62d79be0d591"
      unitRef="usd">992000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1155094efd13425786f2ecdb88995104_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjM1MDhhNWMxZTY2MzQ2ZTZiZGM3ZTBmMTI2NDAxY2Q4XzQ_8d5daf91-36c1-4283-b491-d9c42ca799ae"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i21042b2cd4f347c5865cf57c2a26b8a2_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzYtMi0xLTEtMA_5c3c3c4f-e629-4e69-8454-d7da0f67af3e"
      unitRef="usd">539000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0b2aff0da8e54f4589d4056567f1b3f6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzYtNC0xLTEtMA_593150eb-df7e-4768-a498-94221673c7be"
      unitRef="usd">676000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i57fe94aa53c54ce5bf1df72bd198dfae_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjA2MjkyOWIyZWRjODQwZWY4ZmZlYjQzZmY2NDEwNDE2XzQ_0efe28c1-29ec-465b-80ff-e916db04f4d6"
      unitRef="number">0.0210</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4a5b5475dca04fa0909cd83bb83e1b41_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzgtMi0xLTEtMA_ada3754b-a260-4179-88c5-86c581e5392b"
      unitRef="usd">986000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic90df002b0584aeeb48770c1c328a738_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzgtNC0xLTEtMA_24150865-eb78-478c-a6ab-55cfbcada028"
      unitRef="usd">907000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieee3f15e281e4b1c872375fbc9f0e83e_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjNlZTJhNTUwZmQ0MTQ4Y2U5NTNlN2I3N2E5NzM3Y2I5XzQ_4d454889-82ac-4185-bdef-79e828466861"
      unitRef="number">0.0485</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0c851c9ae9be4c899817cd64ae156b3f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzktMi0xLTEtMA_2736334d-a0f4-4713-ab62-d8ab92e331c1"
      unitRef="usd">297000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i520739d470874963ac1889aae3a2cb7a_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfMzktNC0xLTEtMA_e55566ea-5a37-4110-8c1b-376098b69069"
      unitRef="usd">385000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie8b7274f1d224358bbaae38c9f942bb2_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDAtMC0xLTEtMC90ZXh0cmVnaW9uOmIyYjY5NmY3YTNkZjQyNzRhZTcxNzU2NGVhNzVhMzBhXzQ_5f3f8073-7af6-491f-8d67-7509645d7d10"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5ec18e7fe67d455d845353e1a9594d67_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDAtMi0xLTEtMA_804f9c57-d0d2-43fd-b4a0-2a04b9dd7aaa"
      unitRef="usd">496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i953edb0e44f84203a69075078f4a87a2_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDAtNC0xLTEtMA_2e7415c7-be7e-4314-8b90-78a6e8b282d0"
      unitRef="usd">628000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i630bac5b3b4c4c1ebdb26307f5299f07_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDEtMC0xLTEtMC90ZXh0cmVnaW9uOjRlYWFlYTMwNmU5NDQwOWQ5YzcyM2E5MGNmY2U0NTgyXzQ_0defde2d-98e8-4878-888f-c226e9886e54"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3d26316cfec049b1a3d5289265e218b2_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDEtMi0xLTEtMA_4e75d4fe-b918-4b08-8e09-7ab9e12f69bb"
      unitRef="usd">1974000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3157c394710c4db09c9733fc27554cec_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDEtNC0xLTEtMA_b2000dea-bdcb-4150-8c52-3f7fd2079031"
      unitRef="usd">2257000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id7da76c95df1476cbe7abf79df1c0a8e_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmE4ZmY4YTFhN2MzMDRhYWU5ZmY4OTA3ZDNjNzQ1NjRmXzQ_b15ff602-5eb0-47bc-8081-6796d7559f32"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i552a9d1be5df4fa5b99522a4cbd14464_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDItMi0xLTEtMA_5856caff-6a04-4450-90c8-07081b0166d1"
      unitRef="usd">992000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i084e71373b7e4ff08ea007b9768f21b0_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDItNC0xLTEtMA_f4528e4e-a754-49c7-92b8-85fbebba0bee"
      unitRef="usd">1146000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d6e2c751f95477baa381dda34964d6d_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjFjZWVmOWYxODU1NDQyNjVhMzRmNDA5N2I5OWE1NjVmXzQ_801810a8-f27b-46c0-adb9-7d4729b03050"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2340f88dd3fd42c6881635ed13a8ad1e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDMtMi0xLTEtMA_ad8ea7f7-3452-468f-b3db-a1aa5b9ff93f"
      unitRef="usd">742000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0a22670a5e304df9807dd47199a4122b_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDMtNC0xLTEtMA_70e08a85-2212-4ba5-9a80-0dbbf081614a"
      unitRef="usd">827000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifb901ca38ff742d2b392935788bce117_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDQtMC0xLTEtMC90ZXh0cmVnaW9uOmQyNzFkMzBmMTA3YTQ0NjRiZWJiM2U0MzI5NDI0YzQzXzQ_b5b1a1e0-9dee-4d82-bcd0-ca2240154002"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idd2f5ee051df4ee7affc9c9a72a15930_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDQtMi0xLTEtMA_0acc9be2-1a67-4b31-8e19-e7a3b0214493"
      unitRef="usd">984000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i34901dc3115b4d80b6bc2c5a322da841_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDQtNC0xLTEtMA_fe25f69c-c1cb-414c-a00f-b100e4d1cc5f"
      unitRef="usd">883000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8a5e79fdc705408d96c62523a56dd2c9_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDUtMC0xLTEtMC90ZXh0cmVnaW9uOmVhODA1MWRiZmJhYTQ4NzA4ZTc3YWRmYjM2NDBjYTFjXzQ_449cec2a-6488-4948-bad5-188879a0aafb"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3ea6a649ed4a4d8b953110b3f73c6be4_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDUtMi0xLTEtMA_982f628f-bd98-4a94-af66-cbcc6118159b"
      unitRef="usd">1228000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7d3f229defa146f0a98220762a4f2b93_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDUtNC0xLTEtMA_be7e6aa6-3a7a-49d6-b9c3-d6c557ddad36"
      unitRef="usd">1104000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i830d1be156484a03851fff96315b9dea_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDYtMi0xLTEtMA_1e17ddab-9024-44e9-9625-e1c9dfc1cc97"
      unitRef="usd">7000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8b6b59bed6954d418eb4c5847b9548be_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDYtNC0xLTEtMA_d8eb3b2e-4004-46b1-9e0b-30093121c65c"
      unitRef="usd">6000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia551774380104d5a9cb2e81ed84e5fbc_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDctMi0xLTEtMA_82bc48d4-5812-48e8-bf39-2368a70be388"
      unitRef="usd">30263000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie6527580553d4feaa0905f4262bf370f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RhYmxlOjYxN2UxYTQzNzc4ODRmODY5YjRmNTU5YzU4NzZkNjhiL3RhYmxlcmFuZ2U6NjE3ZTFhNDM3Nzg4NGY4NjliNGY1NTljNTg3NmQ2OGJfNDctNC0xLTEtMA_4eb6a328-2555-4165-887a-9cc5f772b46d"
      unitRef="usd">33300000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTEzODY_bebdd250-2cc6-4439-b3b4-56db4af028d6"
      unitRef="number">0.0298</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <jnj:ExcessOfFairValueOverCarryingValueOfDebt
      contextRef="i423d7e8b4b254413810c2f5c4fda19b5_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTE0NjY_416cc8d7-dd96-4e09-a439-70b7b6e8de6b"
      unitRef="usd">5400000000</jnj:ExcessOfFairValueOverCarryingValueOfDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="i70e622c310144cc8949249a07bf071cc_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTE1NTE_1b41ed78-e3cb-44e7-80ee-300e182b3880"
      unitRef="usd">300000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i70e622c310144cc8949249a07bf071cc_I20210404"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfMTE2MjA_7b102070-9a41-443d-abbf-4a02f0359605"
      unitRef="number">0.0012</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentTerm
      contextRef="i154642870660410a90785a135a0fb8f5_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV82NC9mcmFnOmRhMWY1MjhlNjUxZjQ5ZjlhMTQ5NGUxYTYyNWUxYWI2L3RleHRyZWdpb246ZGExZjUyOGU2NTFmNDlmOWExNDk0ZTFhNjI1ZTFhYjZfNjA0NzMxMzk2NzQ4NA_3926ee6c-80ee-4aec-8a30-5f8eebb49b0e">P2M</us-gaap:DebtInstrumentTerm>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfNTE0Nw_54547cd9-e82c-4ca9-bab5-c7b79f3fcb72">INCOME TAXES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The worldwide effective income tax rates for the fiscal first quarters of 2021 and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2020 were 16.6% an&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;d 11.0%, respectively. In 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF), which became effective on January 1, 2020. More information on the provisions of TRAF can be found in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. During the fiscal first quarter of 2020, the final canton where the Company maintains significant operations enacted TRAF legislation and, accordingly, the Company recorded an estimated deferred tax benefit of approximately $0.3 billion for the remeasurement of existing deferred tax liabilities offset by a related $0.2 billion increase in U.S. GILTI deferred taxes (1.3% net benefit to the effective tax rate).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In the first fiscal quarter of 2020, the Company reversed a contingent consideration liability related to the 2019 Auris Health acquisition that benefited the effective tax rate by 1.9% (for additional details see Note 18 to the Consolidated Financial Statements in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January 3, 2021). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Additionally, the Company had more income in higher tax jurisdictions relative to lower tax jurisdictions, as compared to the same period in the prior fiscal year. The Company also had additional tax benefits received from stock-based compensation that were either exercised or vested during each of the fiscal first quarters. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April&#160;4, 2021, the Company had approximately $3.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfMTE1_f4bdc827-bd69-4141-b3e2-63722db25df0"
      unitRef="number">0.166</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfMTIy_27e01967-a57c-48bb-ba6f-59fc488bf12e"
      unitRef="number">0.110</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfNjk4_368986b4-5072-4a1f-96e9-21e3a5e90aaf"
      unitRef="usd">300000000</jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset>
    <jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfNzgw_4719de9b-c893-4247-b2e7-8c6e77df3b79"
      unitRef="usd">200000000</jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit>
    <jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfMjc0ODc3OTA3NDgyNA_cfb1aef0-0f69-4600-8b89-2cee18c44600"
      unitRef="number">0.013</jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent>
    <jnj:EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent
      contextRef="ib7915bfce2cf46dca29a5703af986b2e_D20191230-20200329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfMjc0ODc3OTA3NTM5MA_5d42e6b1-295d-48f9-ab1b-dd062b111a91"
      unitRef="number">0.019</jnj:EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic8bf9ed56e84446385347cf261ab52e6_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83My9mcmFnOjkwZjExNjU4OThhOTQyMjc4ODQwYmEzY2YxNzk3N2M5L3RleHRyZWdpb246OTBmMTE2NTg5OGE5NDIyNzg4NDBiYTNjZjE3OTc3YzlfMzY0NQ_2628e2ba-5fe4-4599-a7e1-29f1522dfaf7"
      unitRef="usd">3300000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RleHRyZWdpb246NTZjODlkYjVkNWQ1NGI4ZTlkZmJhYjhlNDVmZGUyY2RfOTQz_5af0fa03-46df-4f60-8803-48663d31900a">PENSIONS AND OTHER BENEFIT PLANS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of Net Periodic Benefit Cost&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.187%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company Contributions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Three Months Ended April&#160;4, 2021, the Company contributed $24 million and $10 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RleHRyZWdpb246NTZjODlkYjVkNWQ1NGI4ZTlkZmJhYjhlNDVmZGUyY2RfOTM2_4deb34b5-067f-4042-844b-a7479b9f1a98">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.187%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMy0yLTEtMS0w_132ee049-7081-499b-9198-731e988c1d0c"
      unitRef="usd">353000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMy00LTEtMS0w_1f03b99a-be05-47b2-bd6b-a9c129c881fb"
      unitRef="usd">326000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMy02LTEtMS0w_6459926a-0053-4e3a-bfc0-eb61ef2e5b8e"
      unitRef="usd">77000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMy04LTEtMS0w_87fc4b78-ff0c-45bb-a068-c33bcaeeeee4"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNC0yLTEtMS0w_b83ee590-346f-4261-95af-b4a62b9aa835"
      unitRef="usd">193000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNC00LTEtMS0w_5d822e21-e03e-4490-8948-74768553cb30"
      unitRef="usd">240000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNC02LTEtMS0w_67696a6b-c86a-47ae-8b23-73797490b123"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNC04LTEtMS0w_22f3fa71-5b36-4e9e-89dc-5bb2142afd2c"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNS0yLTEtMS0w_e7b73706-0223-488c-9340-7f1c5985db37"
      unitRef="usd">680000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNS00LTEtMS0w_10d48b65-9cbe-4ccd-a0ac-74df2d9d6c25"
      unitRef="usd">614000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNS02LTEtMS0w_5e880b2f-305b-462c-aa52-08c2c340ac00"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNS04LTEtMS0w_58471107-48aa-4171-a52b-43e90205564a"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNi0yLTEtMS0w_9a954959-9ad2-4768-9acb-49e707752afb"
      unitRef="usd">-45000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNi00LTEtMS0w_469bc91b-0fc8-4acf-82c3-f4bcebb1baae"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNi02LTEtMS0w_fcd3b6dc-7b93-48ac-826f-4c11b2ed524e"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfNi04LTEtMS0w_74d83080-53ad-4a63-b981-78be0b0f793b"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOC0yLTEtMS0w_6ce0e9db-ff6d-4529-b811-a03f71800e6f"
      unitRef="usd">-314000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOC00LTEtMS0w_fb61d6a0-efe2-48c3-bf5e-3d7d32ab3d92"
      unitRef="usd">-223000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOC02LTEtMS0w_3cb7261a-2ea3-40be-80e6-6d6cd775850d"
      unitRef="usd">-38000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOC04LTEtMS0w_8a061323-435b-417a-af30-e5b8d5022d68"
      unitRef="usd">-36000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOS0yLTEtMS0w_cd32a7ae-5dad-40af-82fe-3c5a74e13d95"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOS00LTEtMS0w_51d4c4b2-de50-454c-9c9a-d41832d19d28"
      unitRef="usd">-19000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOS02LTEtMS0w_d4250ea2-a33d-41c2-9054-5942345f98d6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfOS04LTEtMS0w_c1ea82a4-9640-45c7-b2fe-c7ba7890ae1a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMTAtMi0xLTEtMA_db0c8578-3a9e-4006-837d-a165fff8a117"
      unitRef="usd">136000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i6603f8e085a741d1b09f794f075a0f36_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMTAtNC0xLTEtMA_452625f5-5aac-4998-80f4-4607231d5ee4"
      unitRef="usd">194000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4ab2a5cdb3f74f64815805468109a4dd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMTAtNi0xLTEtMA_84a4807f-36ac-4da9-ba58-cd34485faa82"
      unitRef="usd">125000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i5e1eb4d7af3e4399958d6edbba256e97_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RhYmxlOjU3MTQ5YzVkZDNkZjRhZjA4MjRkNmIwNTY0NGNlMDEyL3RhYmxlcmFuZ2U6NTcxNDljNWRkM2RmNGFmMDgyNGQ2YjA1NjQ0Y2UwMTJfMTAtOC0xLTEtMA_bbbc8832-b5bc-4b43-a554-90b0ea059834"
      unitRef="usd">131000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:PensionContributions
      contextRef="ib4d8262305ed4a808270a6d930b2b201_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RleHRyZWdpb246NTZjODlkYjVkNWQ1NGI4ZTlkZmJhYjhlNDVmZGUyY2RfNjcx_06a52131-4040-4838-a9d8-2e0cd31f7254"
      unitRef="usd">24000000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="ic5c0764f40c2472b8a0a5b59873f1ca3_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83Ni9mcmFnOjU2Yzg5ZGI1ZDVkNTRiOGU5ZGZiYWI4ZTQ1ZmRlMmNkL3RleHRyZWdpb246NTZjODlkYjVkNWQ1NGI4ZTlkZmJhYjhlNDVmZGUyY2RfNjc4_c1cd8ec4-66db-489e-8524-e3bf5175c872"
      unitRef="usd">10000000</us-gaap:PensionContributions>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RleHRyZWdpb246ODE0Yjg3MGIzYzIxNDI0Y2I0NzY5N2JkMWU2ZjE5YzRfOTMw_05f6e2d7-8e7a-47d0-80bb-db92348738eb">ACCUMULATED OTHER COMPREHENSIVE INCOME&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Accumulated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Comprehensive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details on reclassifications out of Accumulated Other Comprehensive Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Derivatives &amp;amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RleHRyZWdpb246ODE0Yjg3MGIzYzIxNDI0Y2I0NzY5N2JkMWU2ZjE5YzRfOTIz_4be41d42-72c4-47c9-acfa-bba9146d6c80">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Accumulated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Comprehensive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d76493e48f94dcba8cc74f15393b857_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNC0yLTEtMS0w_03187aff-6a5f-46d4-a6f5-a9667480dd5a"
      unitRef="usd">-8938000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a475b649b7b482bafe66f589d72289e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNC00LTEtMS0w_8d6fff22-87c9-43fd-829c-9583bc03c3ac"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia40af87a50514bc5a829dc0dd0888e9e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNC02LTEtMS0w_7d9cb251-7000-41ed-bde9-f223bf30bc5a"
      unitRef="usd">-6957000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28d96c7a5b464914b6d3373fefe93b84_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNC04LTEtMS0w_504c074c-2700-4ad0-b5fa-e50dd7a3b853"
      unitRef="usd">652000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i45b058f1e15f44aea2e4af4460a4bbeb_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNC0xMC0xLTEtMA_e23ca465-e397-4aa1-bf97-144d6afcd074"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i816f31f509494a34bc7e2cedd91d16d2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNS0yLTEtMS0w_abad06c2-7e2d-4ac8-a3a2-e112a03c5b63"
      unitRef="usd">276000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic10284d081934582868002bbf2ed2c0c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNS00LTEtMS0w_20c82f95-46a0-4ad7-a2af-a015071abb75"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia1354338217d411997a1333f76f744ea_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNS02LTEtMS0w_cbdcac5a-6ff8-44c8-bb5b-e53996f11e04"
      unitRef="usd">233000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9e23c8ee5426493fa9a9020a4460a66e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNS04LTEtMS0w_e0a85925-8042-4fcf-a974-a9140a808e16"
      unitRef="usd">-595000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i90694bac6fa841438f930b207399b28a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNS0xMC0xLTEtMA_ba7f3659-6087-4650-80f5-9f56ad516c4b"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1971251aab8f40e581900d63eac2f931_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNy0yLTEtMS0w_22ca9afb-6a73-4eed-91a5-77911db0d6f7"
      unitRef="usd">-8662000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10269159ffc3444fbcf1d8e9aa219a53_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNy00LTEtMS0w_3ccd9628-29e9-4f07-a231-b97e8084a8ba"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7c535299fe9457290a897be433005f5_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNy02LTEtMS0w_9ac65755-e3af-4b47-8496-f245be99b8dd"
      unitRef="usd">-6724000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b83b2a50512439ea7c32eba157340bc_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNy04LTEtMS0w_0d7b0b65-2c41-49d1-a231-a74029f2bb7c"
      unitRef="usd">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3029d43aa1d647acbb02dc5cdfe3bd78_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV83OS9mcmFnOjgxNGI4NzBiM2MyMTQyNGNiNDc2OTdiZDFlNmYxOWM0L3RhYmxlOmU2OGQ5MWYyMjY1MzRhZTA4ZDA0Y2EzZjkyOWEzMzJhL3RhYmxlcmFuZ2U6ZTY4ZDkxZjIyNjUzNGFlMDhkMDRjYTNmOTI5YTMzMmFfNy0xMC0xLTEtMA_7528ad39-b53b-471c-92fb-0621910c210d"
      unitRef="usd">-15328000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RleHRyZWdpb246MGZhNzA5OGE0NGMxNGU0OWEzZDdjZjhlODg5NDFmNjRfMTU4Mw_9fc350ee-43c0-449f-a3e1-1fd3f98b8000">EARNINGS PER SHARE&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.344%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares which could be repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,672.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The diluted net earnings per share calculation for the fiscal first quarter ended April&#160;4, 2021 excluded 9 million shares related to stock options, as the exercise price of these options was greater than their average market value. In the fiscal first quarter ended April&#160;4, 2021, the Company did not have convertible debt.&lt;/span&gt;&lt;/div&gt;The diluted net earnings per share calculation for the fiscal first quarter ended March&#160;29, 2020 excluded 10&#160;million shares related to stock options, as the exercise price of these options was greater than their average market value. The diluted net earnings per share calculation for the fiscal first quarter ended March&#160;29, 2020 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RleHRyZWdpb246MGZhNzA5OGE0NGMxNGU0OWEzZDdjZjhlODg5NDFmNjRfMTU4OA_80d62745-8def-4a83-b082-97c356267c98">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.344%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares which could be repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,672.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfMi0yLTEtMS0w_94b74e6a-f559-4866-bd62-48a9f0e73304"
      unitRef="usdPerShare">2.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfMi00LTEtMS0w_3c8be7cd-0db8-4894-add6-96636627d4e3"
      unitRef="usdPerShare">2.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfMy0yLTEtMS0w_acb0e7df-a695-44f6-bc2c-ecb19bbb8d79"
      unitRef="shares">2631600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfMy00LTEtMS0w_70e28837-a6dd-4616-a090-17266a3dd145"
      unitRef="shares">2633700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNC0yLTEtMS0w_1e884a63-1e84-4d4f-ab25-db80b3627806"
      unitRef="shares">128400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNC00LTEtMS0w_290543f4-0a17-446b-b3d0-0edb019dea55"
      unitRef="shares">126000000.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNS0yLTEtMS0w_2804459d-911f-4c8c-972c-0f36b5c0ed4c"
      unitRef="shares">87300000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNS00LTEtMS0w_2ba36315-643c-413b-9554-7ae122299dff"
      unitRef="shares">89400000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNi0yLTEtMS0w_03cb9a36-7bc1-4182-8d06-658093371773"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNi00LTEtMS0w_8813c43d-c0d3-4885-8511-298d2bd78a07"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNy0yLTEtMS0w_b8f2ffbb-fe36-4cc0-9bc3-aa3b95fea5fa"
      unitRef="shares">2672700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfNy00LTEtMS0w_e1a4307d-f203-4fff-bfc9-ee7614f556ff"
      unitRef="shares">2671000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfOC0yLTEtMS0w_3fde75df-7c22-496b-98a0-5b0f17a39073"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RhYmxlOjQ5MzhlNmRjZDhmMDQxZjE4OWNlMzU2Y2UxMjNiYjcxL3RhYmxlcmFuZ2U6NDkzOGU2ZGNkOGYwNDFmMTg5Y2UzNTZjZTEyM2JiNzFfOC00LTEtMS0w_fa867ac8-fed2-469d-8b14-b6c938327b31"
      unitRef="usdPerShare">2.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RleHRyZWdpb246MGZhNzA5OGE0NGMxNGU0OWEzZDdjZjhlODg5NDFmNjRfMjgx_ed96c58f-3037-44cc-b378-05b3f21b0e0d"
      unitRef="shares">9000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84Mi9mcmFnOjBmYTcwOThhNDRjMTRlNDlhM2Q3Y2Y4ZTg4OTQxZjY0L3RleHRyZWdpb246MGZhNzA5OGE0NGMxNGU0OWEzZDdjZjhlODg5NDFmNjRfNTg2_1b77898c-3a25-4555-907c-324d875ea157"
      unitRef="shares">10000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzg4OA_b6c0672b-fce8-4aa3-b3b0-4a46c47869b3">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY SEGMENT OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:168pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 vaccine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / PREZCOBIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; /  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;                         &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;                     REZOLSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / SYMTUZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / XEPLION&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVEGA   TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / TREVICTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; / &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;PROCRIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inclusive of VELCADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt"&gt;Includes amortization expense of  $0.1 billion in both the fiscal first quarter of 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes divestiture gains of $0.6&#160;billion in the fiscal first quarter of 2021 related to two brands outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes an unrealized loss on securities of $0.3&#160;billion in the fiscal first quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes litigation expense of $0.1&#160;billion in the fiscal first quarter of 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes amortization expense of $0.9&#160;billion and  $0.8 billion in the fiscal first quarter of 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In fiscal 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.0&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a contingent consideration reversal of $1.0&#160;billion in the fiscal first quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a restructuring related charge of $0.1 billion in both the fiscal first quarter of 2021 and 2020, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes amortization expense of $0.3&#160;billion and $0.2&#160;billion in the fiscal first quarter of 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Amounts not allocated to segments include interest income/expense and general corporate income/expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY GEOGRAPHIC AREA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere, excluding U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <jnj:SalesBySegmentOfBusinessTableTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzg4OQ_b5cdd07c-ba0f-4c3a-a910-98adb2561a25">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY SEGMENT OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:168pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 vaccine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / PREZCOBIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; /  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;                         &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;                     REZOLSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / SYMTUZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / XEPLION&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVEGA   TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / TREVICTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; / &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;PROCRIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDICAL DEVICES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inclusive of VELCADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;</jnj:SalesBySegmentOfBusinessTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ae622fe28cc41748a80fa1570cfe35c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNS0yLTEtMS0w_b0781b55-0010-423d-947b-afcd29cd6781"
      unitRef="usd">599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f1ff6fb4d12459fb76b519f3aa064d0_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNS00LTEtMS0w_48015686-73fe-4fd3-aba7-fe63daecc14e"
      unitRef="usd">689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2ae622fe28cc41748a80fa1570cfe35c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNS02LTEtMS0w_8d86b9de-3249-4905-a281-365bf8b0cbf8"
      unitRef="number">-0.130</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idffd022b600f4ab19da11eb4a92bbea7_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNi0yLTEtMS0w_b4389ef4-4423-44ee-b966-893f95c3d197"
      unitRef="usd">575000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaba9b1b928784fbca8eb92f74ca624c0_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNi00LTEtMS0w_984cc227-3d81-4816-81c6-021a2aeaed50"
      unitRef="usd">659000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idffd022b600f4ab19da11eb4a92bbea7_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNi02LTEtMS0w_72216938-3298-4aac-b7f2-31c74d779ede"
      unitRef="number">-0.128</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92d7961dbf5348efbc49acaf2aed16bd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNy0yLTEtMS0w_7dc05737-4702-4049-99eb-e289ebfdd40e"
      unitRef="usd">1175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i723bca619dee4d77adbb0ace89cf793c_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNy00LTEtMS0w_6d4a66e5-fb1a-4e65-9828-00ee03e060a5"
      unitRef="usd">1348000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i92d7961dbf5348efbc49acaf2aed16bd_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNy02LTEtMS0w_2d902666-7e04-4622-93c5-b9e3273d5b73"
      unitRef="number">-0.129</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25dc22f2e2bd45de940fef17d3860c93_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOS0yLTEtMS0w_cae1f0eb-6b6d-40fc-a421-359bbea0db15"
      unitRef="usd">634000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1a0e1bfa74b499eaf41e73bfbea7789_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOS00LTEtMS0w_4ce25c43-3cbf-4da6-a304-0f7d1e7c6d6e"
      unitRef="usd">659000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i25dc22f2e2bd45de940fef17d3860c93_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOS02LTEtMS0w_d7bddac8-8e4e-4b8a-b065-ad7fc0b3b644"
      unitRef="number">-0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50e3695fe3ad4d6397fe1681cee71dbb_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAtMi0xLTEtMA_dd36f792-cf40-4dd4-843b-691d155dfacc"
      unitRef="usd">529000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i166260d97d024b4da59529851700b260_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAtNC0xLTEtMA_c5222b86-f91f-4e37-b712-e02eb2fa2ed1"
      unitRef="usd">458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i50e3695fe3ad4d6397fe1681cee71dbb_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAtNi0xLTEtMA_bca39e46-acdc-482a-9720-24e4c09db821"
      unitRef="number">0.157</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b585d84ee0b4c8e899f4c0c52424cb1_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEtMi0xLTEtMA_6a902f89-1fbe-497a-8af4-5506a8735ea0"
      unitRef="usd">1163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d9e5272e1d64d9291f65425f7a17561_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEtNC0xLTEtMA_e9ec91be-a4c0-4315-8008-dfbf31d61178"
      unitRef="usd">1117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1b585d84ee0b4c8e899f4c0c52424cb1_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEtNi0xLTEtMA_7e3e3224-036c-4ee4-8a60-6c41a4c159c1"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddfeadcc4c9f4c14b150e5ed0df1edc8_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMtMi0xLTEtMA_ad45e8fa-67f9-4c2c-aa9a-a3f775932139"
      unitRef="usd">163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i906fd8e56b88496dad9f6b80d29a44da_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMtNC0xLTEtMA_bcf82a47-22c0-4254-a72a-b6f795f25d14"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iddfeadcc4c9f4c14b150e5ed0df1edc8_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMtNi0xLTEtMA_2911029c-413a-4030-91b6-e51ea2a3d736"
      unitRef="number">-0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3854ce9adfd64c2682550767fe397150_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQtMi0xLTEtMA_fd50486b-7857-4b74-bf70-9f18d933d44c"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib661f1c760ad44e9b55754282fa57e3c_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQtNC0xLTEtMA_3cc5dc0b-24d3-4e33-8cc0-a6a81e4d0066"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3854ce9adfd64c2682550767fe397150_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQtNi0xLTEtMA_54723cce-d3c4-46ec-be66-15ee425fc1fc"
      unitRef="number">0.160</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8faa580354e043dfaf23f1f42fb88960_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUtMi0xLTEtMA_0c571cef-7b3f-43eb-98be-21b47692da2e"
      unitRef="usd">417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32385508ea6d4658b01bac013205426a_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUtNC0xLTEtMA_479abbe7-3f16-4b2c-b3f5-9d85e3194204"
      unitRef="usd">395000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8faa580354e043dfaf23f1f42fb88960_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUtNi0xLTEtMA_6fc43e7b-b8f9-4de0-a4a3-aecbb66806cd"
      unitRef="number">0.057</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92ebcd0a77d74afaa4aef8e33703f1b2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTctMi0xLTEtMA_8a9c55e3-c478-4ab2-ac69-2be11d6eaf39"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4a5cd00fdb24916a240b612026b1e93_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTctNC0xLTEtMA_d53e54ff-13d4-41e2-9771-64cf35e01bf8"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i92ebcd0a77d74afaa4aef8e33703f1b2_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTctNi0xLTEtMA_0f2f802d-c2af-4a06-a839-871428e3e819"
      unitRef="number">0.042</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67c2a0954d344c4bb590b8e16e9b3919_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgtMi0xLTEtMA_1d45b148-25b5-442c-a58b-b429940c24ff"
      unitRef="usd">293000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9058a80fcd945bd954291432adf44b8_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgtNC0xLTEtMA_f661432f-e6b7-4401-b165-3cd9f9f68c32"
      unitRef="usd">269000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i67c2a0954d344c4bb590b8e16e9b3919_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgtNi0xLTEtMA_98282c5d-2acb-435e-97f2-4efc7b0065d4"
      unitRef="number">0.089</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bae718df24b4f13951655bc41d7bf96_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTktMi0xLTEtMA_8256c0da-42ff-49e0-a61c-b73c56262afd"
      unitRef="usd">389000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i983c24aea97b44299332fe0f8a655f72_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTktNC0xLTEtMA_b4dbfdfb-8d08-4aac-8164-1e1fe70129d8"
      unitRef="usd">361000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8bae718df24b4f13951655bc41d7bf96_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTktNi0xLTEtMA_f40fd784-0c37-4e14-8a0e-42c83070067e"
      unitRef="number">0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44787243fb164e10b42245b3160597dd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEtMi0xLTEtMA_8087ac15-5802-4d89-814e-4462039f8f3a"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95a750086de9495a8afc776a19ad7a9a_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEtNC0xLTEtMA_b18a1594-54fb-402a-8c4c-30a6800f1166"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i44787243fb164e10b42245b3160597dd_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEtNi0xLTEtMA_7e6d20d0-da20-428e-976e-bf769683b4a2"
      unitRef="number">-0.258</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42bf8dca10bb48398b2f3f163ed419bf_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjItMi0xLTEtMA_cb14d10d-861e-4f8d-b76b-372f5e22b601"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fa60389107541e38de00816279454bf_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjItNC0xLTEtMA_844ceed6-3911-4ffa-b238-8f9f27d8345e"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i42bf8dca10bb48398b2f3f163ed419bf_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjItNi0xLTEtMA_df274c71-19e0-40a4-a0dd-6d47b73a29c7"
      unitRef="number">-0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i331b3b92b0b34bafa98699f766892580_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMtMi0xLTEtMA_7e7a9579-7dc6-4f31-8b92-aa8ee8942aaf"
      unitRef="usd">222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i964cf45dd1db45268ef9917e50464450_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMtNC0xLTEtMA_0106baf4-ea08-4de8-b006-d4a30c9738a8"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i331b3b92b0b34bafa98699f766892580_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMtNi0xLTEtMA_02ac473e-2f28-4286-b4d5-2df46116bed4"
      unitRef="number">-0.043</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60d3b975b16e4b83a8d7a02ed320e405_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjUtMi0xLTEtMA_dd063895-9f3a-4d45-893d-477b6b828ddd"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf40698a4cb8405c9ebbbf461d299a30_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjUtNC0xLTEtMA_5d74c11c-3080-45c7-86d1-e748ca88aca1"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i60d3b975b16e4b83a8d7a02ed320e405_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjUtNi0xLTEtMA_5dfa4892-78a0-4fc5-ada6-c582088efc8f"
      unitRef="number">-0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9d7ab27284c405ca2762880403e8d9e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjYtMi0xLTEtMA_907b338a-5547-42bc-a869-91163d61e3ca"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic71b279765044852900c44013574acce_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjYtNC0xLTEtMA_ced3ece5-2b9d-4e22-8156-f5f7a733eed2"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if9d7ab27284c405ca2762880403e8d9e_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjYtNi0xLTEtMA_e59434c5-da31-460a-b9cf-2b0fcd4385a4"
      unitRef="number">0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied69986251ca49af95c8ab2e38acfc45_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjctMi0xLTEtMA_6c95cc7d-719f-419d-8348-b65a4a26f9fb"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26bfd85decb944d8a5ff899f4f8b8a85_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjctNC0xLTEtMA_79cb4bcf-b593-4a4a-9a1d-a18fa02756ea"
      unitRef="usd">171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ied69986251ca49af95c8ab2e38acfc45_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjctNi0xLTEtMA_5fd08b95-f563-49d3-854c-a294150fa0fd"
      unitRef="number">0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01ebdcc3eb7548edaa2a797dcee28eb1_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjktMi0xLTEtMA_83087310-8cda-4348-8504-3f4c1d954365"
      unitRef="usd">1611000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b4f194c8d2948e682ea7750ae9e4ae0_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjktNC0xLTEtMA_4654f94b-55bd-46c9-953e-8ca476828aee"
      unitRef="usd">1740000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i01ebdcc3eb7548edaa2a797dcee28eb1_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjktNi0xLTEtMA_4efb1a33-64af-4180-b94b-6acf36da84f0"
      unitRef="number">-0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i289737a850a54d0cbb70e8bba2e95d4a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzAtMi0xLTEtMA_8a3e9348-ef4c-47a3-aac8-711da988ef69"
      unitRef="usd">1932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0432cb1fa6fe47fbbcfad08028e0cc71_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzAtNC0xLTEtMA_273cf440-3771-4076-a9ec-7285353ff569"
      unitRef="usd">1885000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i289737a850a54d0cbb70e8bba2e95d4a_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzAtNi0xLTEtMA_e2648d7a-51e3-418a-a3d6-37dd416884bb"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cb654a681744cccadb2bf5b36aa0112_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzEtMi0xLTEtMA_f30f067e-0093-4b0b-b93a-d22f3719b1ab"
      unitRef="usd">3543000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc8d5d21439a44449fe0a777201e9ce6_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzEtNC0xLTEtMA_bae8d5cb-ee1e-46b7-af75-fa23abadcde6"
      unitRef="usd">3625000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9cb654a681744cccadb2bf5b36aa0112_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzEtNi0xLTEtMA_42277e78-b178-4427-8f70-bb6776142b60"
      unitRef="number">-0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff567a96444d40aaaaee5e54bec7304e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzYtMi0xLTEtMA_41888209-3f09-4cb4-8cde-03e563b29d6a"
      unitRef="usd">2413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib06bac64a0724d9ea69537ebd326bdd3_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzYtNC0xLTEtMA_b387fd16-d5f4-4bcb-a2db-bd0d9747bbdc"
      unitRef="usd">2410000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iff567a96444d40aaaaee5e54bec7304e_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzYtNi0xLTEtMA_31196ecf-b105-4985-933e-fb2bfcab66db"
      unitRef="number">0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d625febf4bb4703b403d98d5ce8c57b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzctMi0xLTEtMA_334ec2db-6764-4951-86d3-dae0d701c986"
      unitRef="usd">1501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia82ae2d3a5a249beac2043ef02e2f433_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzctNC0xLTEtMA_67ce7824-995c-42be-8753-107cdaf28c12"
      unitRef="usd">1228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4d625febf4bb4703b403d98d5ce8c57b_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzctNi0xLTEtMA_a0aae114-9d50-42b8-9650-a0424655d816"
      unitRef="number">0.223</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6171f8ab5dda4d0c9faa7382c2f231b3_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzgtMi0xLTEtMA_47702dcf-3ae1-4d91-90ab-a889ca439178"
      unitRef="usd">3914000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d1f27f9c7334c3f9ad28edfbf7dcaa1_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzgtNC0xLTEtMA_8ab34dee-1f5c-447b-9da2-1fa4d1dd665a"
      unitRef="usd">3638000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6171f8ab5dda4d0c9faa7382c2f231b3_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMzgtNi0xLTEtMA_87dec6f6-6056-40de-bb57-45d531bfac9a"
      unitRef="number">0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69ea8e5d1357498b955cea3a65e70a42_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDAtMi0xLTEtMA_f36caee6-6c84-4564-ae48-428925b751ce"
      unitRef="usd">489000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61d81d5483f04c2ea8808ff914905c50_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDAtNC0xLTEtMA_6751486d-efd0-44de-a70e-aa358e892063"
      unitRef="usd">625000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i69ea8e5d1357498b955cea3a65e70a42_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDAtNi0xLTEtMA_856ac835-0a72-4925-aef5-0b21b77c54e2"
      unitRef="number">-0.217</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd8ce529fd4e489ca217b53ba112079a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDEtMi0xLTEtMA_648e71e4-edd3-4f42-8fb9-2617c1af2c7a"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f8e51a1f6cb449ea7ff42d6f4948b73_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDEtNC0xLTEtMA_ad11f361-a2e6-4004-8c6f-46b816563049"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibd8ce529fd4e489ca217b53ba112079a_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDEtNi0xLTEtMA_f3fdbee3-54a0-4cb7-88b2-cbac3e3c4760"
      unitRef="number">-0.484</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i136d588a998d4a2da83c088f3e0ce2d7_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDItMi0xLTEtMA_a9dc2bca-220f-4898-824f-40f2bdd1bf3e"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ef18e066a7d417b8a7dedcd9680329b_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDItNC0xLTEtMA_c7640747-8f51-4cc4-9525-587b776bbdcc"
      unitRef="usd">256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i136d588a998d4a2da83c088f3e0ce2d7_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDItNi0xLTEtMA_0c051d17-d62d-4713-9db7-4e1bbae47170"
      unitRef="number">-0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icaf4afeb424b42099ca0595af209f4c9_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDMtMi0xLTEtMA_0918fb7b-21ec-455e-894d-827e3488d6dd"
      unitRef="usd">777000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29009a53b5dc403aa2843d2d81dd1cdc_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDMtNC0xLTEtMA_6b8cf5f4-33c4-44a5-b569-18ea9219d871"
      unitRef="usd">990000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icaf4afeb424b42099ca0595af209f4c9_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDMtNi0xLTEtMA_3854af7f-841b-4dd0-8098-5ba4c0d3b5e6"
      unitRef="number">-0.215</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6114f587788a46509aa693a877fbec65_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDUtMi0xLTEtMA_893c5d6f-0b09-4332-b3d8-3119e2cb4658"
      unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d2ad3a676074fd39646dd2b42a1a394_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDUtNC0xLTEtMA_b3d5647a-e5f4-4cdb-9aab-e929ba7d2d03"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6114f587788a46509aa693a877fbec65_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDUtNi0xLTEtMA_1c3912e7-3fdd-4398-92d8-dda50c04937e"
      unitRef="number">-0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3ec26a4598846aa90c13dbf69fee0e6_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDYtMi0xLTEtMA_0ac2ff59-3580-4b54-a27c-7804fdf6bd0e"
      unitRef="usd">307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib369d313870f4e40bcae5f48dbba9156_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDYtNC0xLTEtMA_39a634e9-5a11-4ee6-9c30-54ed4b1d9c72"
      unitRef="usd">258000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if3ec26a4598846aa90c13dbf69fee0e6_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDYtNi0xLTEtMA_dc6337a7-4844-4942-aefa-3050ddcbbeda"
      unitRef="number">0.189</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49f387a41d284ee49ce4f7ab58e64040_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDctMi0xLTEtMA_05ccaabf-ea59-4ee6-a032-a8febcf1b7fe"
      unitRef="usd">562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i146ce49a479f4a72b766a6152145d2db_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDctNC0xLTEtMA_a79b70a1-627c-4eff-985a-8542029ffc7e"
      unitRef="usd">529000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i49f387a41d284ee49ce4f7ab58e64040_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDctNi0xLTEtMA_7e3f2fab-94a9-4a3d-bb40-9b173c3cbaac"
      unitRef="number">0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03d35b2d6abf46dabb281f94354a317e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDktMi0xLTEtMA_268be6d3-8517-481f-ba60-335c8f6ffcbe"
      unitRef="usd">1331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie48b966b3ecb41279941f7e8cedc781e_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDktNC0xLTEtMA_4df0950d-a0b3-4198-911b-8c6d3ada4e00"
      unitRef="usd">1217000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i03d35b2d6abf46dabb281f94354a317e_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNDktNi0xLTEtMA_bdf9cb73-66cd-4271-bd61-09b1e6fe7333"
      unitRef="number">0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5832713827f49e68a1d9256b8db22f8_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTAtMi0xLTEtMA_78d8a4df-08e9-44f7-860c-f19feac31afb"
      unitRef="usd">817000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3cbb2403d3fa48e6a6c860006059dbbb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTAtNC0xLTEtMA_3bd7e37b-5a2f-41f7-99b4-966d62bb016c"
      unitRef="usd">603000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia5832713827f49e68a1d9256b8db22f8_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTAtNi0xLTEtMA_1467ca18-2639-4c7f-92ae-ae52a7ef379b"
      unitRef="number">0.356</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36c510944ae54934a1107ef6d1ded6a8_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTEtMi0xLTEtMA_32d6eec8-20f8-4da7-aadf-52c4aaa05269"
      unitRef="usd">2148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefd6ad0e6e1643d381813d989c2cec70_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTEtNC0xLTEtMA_d8c93038-b1e8-4c7a-91f9-605a915dedde"
      unitRef="usd">1819000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i36c510944ae54934a1107ef6d1ded6a8_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTEtNi0xLTEtMA_8990c636-4d83-4d85-90e1-1507c81a251c"
      unitRef="number">0.181</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32aca65dc81d4c26ac1e08379d1ef4bb_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTMtMi0xLTEtMA_40f901f7-11b2-4026-bc36-f04ead270f9b"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i148fd285f2164e8b84b5f919df795949_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTMtNC0xLTEtMA_53fc8710-5254-49fc-aa18-c88367bba01e"
      unitRef="usd">187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i32aca65dc81d4c26ac1e08379d1ef4bb_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTMtNi0xLTEtMA_f9f676f0-ded1-411c-b981-be925eea2b3d"
      unitRef="number">0.463</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06e61e62b4724e93ae93816c2f3192f8_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTQtMi0xLTEtMA_60d9aa04-4f5d-45b6-898c-08d8dc0c1789"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80770d9508b2437f8389e28b2b941a02_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTQtNC0xLTEtMA_b6dda175-5031-4ec0-9aad-c21cfb64bc02"
      unitRef="usd">109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i06e61e62b4724e93ae93816c2f3192f8_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTQtNi0xLTEtMA_59876762-48bb-4233-bca4-a5f845244088"
      unitRef="number">0.320</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fbc72131dcb4cfb8a2b4aefd58180c0_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTUtMi0xLTEtMA_697c9ae2-e494-4fad-8048-0c11136b00f0"
      unitRef="usd">418000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i529ed72788a0459399f52e3044b3e2ec_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTUtNC0xLTEtMA_3186e47b-810e-46cd-a14d-95dd4724c589"
      unitRef="usd">296000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8fbc72131dcb4cfb8a2b4aefd58180c0_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTUtNi0xLTEtMA_2c2ccf4c-420b-47b2-8b73-ef0c595210ff"
      unitRef="number">0.410</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia66fb5605b064618a2816914b2ab7bfa_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTctMi0xLTEtMA_a2af9239-87ca-4dbc-b8c8-c7ef13865e69"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac8d1c045b4547659ceadd21ec5dcc69_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTctNC0xLTEtMA_1ea1d88f-3264-4da9-9376-5a9a4a32c7ac"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i093cfc8901c7491da04dfd1a8c00c997_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTgtMi0xLTEtMA_ef4625a9-f159-4e10-a0ec-dde17c7b0121"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idac706fc6d814cd3b02325aac9a6a583_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTgtNC0xLTEtMA_9572da52-4a53-4b35-85b2-2c9f7c6b0c05"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i093cfc8901c7491da04dfd1a8c00c997_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTgtNi0xLTEtMA_3df0904b-234d-48d3-ba7e-ba382c0b4079"
      unitRef="number">-0.384</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e51d8457af2428d92fb1a6f3d416b27_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTktMi0xLTEtMA_291cdecc-3beb-4f06-9fa3-e2eceebbf832"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7477ed6ae844839a6a17c6320a1490a_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNTktNC0xLTEtMA_e51c8694-e5d3-46c1-b1e5-0591bb287b2d"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bee09b00e4e4176b4a2035aa5f68b99_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjItMi0xLTEtMA_e3d3d768-dfa4-4e14-b5fb-4fdd4194225f"
      unitRef="usd">512000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f88fa52f8b64198a27db57dc8f3446d_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjItNC0xLTEtMA_c967e88b-afd0-43c5-9763-a0a8b1466bfc"
      unitRef="usd">436000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2bee09b00e4e4176b4a2035aa5f68b99_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjItNi0xLTEtMA_3280aa8d-ee69-4edb-8388-df25752d39fa"
      unitRef="number">0.174</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i433a9d857de442baa6ab86474c907a9e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjMtMi0xLTEtMA_3530d519-395d-4267-8031-d2418a492b93"
      unitRef="usd">494000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icaf7597b20ee4154a38d35f8a5783413_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjMtNC0xLTEtMA_29f192b8-1bac-4ebb-99e6-c604dff9b5c9"
      unitRef="usd">483000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i433a9d857de442baa6ab86474c907a9e_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjMtNi0xLTEtMA_6e095442-02b0-44e1-b436-4f1fe245c7bf"
      unitRef="number">0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1e6b6d91108495abc61b13e632ed5e5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjQtMi0xLTEtMA_045f5b76-929d-4b0d-8a7b-b9ce90d3f5d7"
      unitRef="usd">1007000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafed813fd0b0453992e024335f1146fd_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjQtNC0xLTEtMA_60c44534-e0d6-4417-8529-4f631f9ced62"
      unitRef="usd">920000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id1e6b6d91108495abc61b13e632ed5e5_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjQtNi0xLTEtMA_f599c635-6792-4e48-b3a9-0a43c5d3b8f0"
      unitRef="number">0.095</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80ed82867cff4a2a90aaf86dabd6f75a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjYtMi0xLTEtMTA1Nw_d456ea68-2de4-4586-932c-a1e687c3dbf4"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36f05bd8bedc483e9e416de970f7e815_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjYtNC0xLTEtMTA2Ng_1f77c3b6-0adf-42a9-bf25-f5a08fa9e63f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f4e287198db4e008b203874b5cc8f67_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjctMi0xLTEtMTA1Nw_03c9eb0f-b724-4871-bce7-d46898352ee6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cedc93843e0405aa3fa264e1182e575_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjctNC0xLTEtMTA2Ng_c1a029d0-4ea8-479d-ac31-eb2799423fbb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8276bebcd3646be90506d64f62c9552_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjgtMi0xLTEtMTA1Nw_8b738e42-3cd2-4842-9b98-8bd0a2fe63a7"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab0a5e29a43049de90706107caedb36e_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjgtNC0xLTEtMTA2Ng_f2fcd354-f9fd-4156-b1b2-dbd4022eccf0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i361f978e79cb45ce9e204e867cf6632d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjYtMi0xLTEtMA_1635f7a7-07fb-43d3-af3e-f365bbc151be"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ad6a0b3794e4083b20fb16dbb34c231_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjYtNC0xLTEtMA_736657d3-b962-444f-9554-56b3b5d4892e"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i361f978e79cb45ce9e204e867cf6632d_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjYtNi0xLTEtMA_d3690dbf-a8da-4ad7-ab84-2f9ee105ff64"
      unitRef="number">-0.123</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifad881d92a614ae4a72edef7e338e323_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjctMi0xLTEtMA_b297a739-3042-4367-8ee4-f38978ca1064"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20adde6886944d06ab57d875198dab9d_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjctNC0xLTEtMA_9e23e0b5-1ec7-4634-87eb-a54be0fe13fc"
      unitRef="usd">212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifad881d92a614ae4a72edef7e338e323_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjctNi0xLTEtMA_8c70ad6d-f5dc-4ce9-b8b5-7d24b77f7dd2"
      unitRef="number">0.098</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59f953f7b8304173993dce91c2663860_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjgtMi0xLTEtMA_b4280720-22b7-4d8b-aed4-4d05819612d9"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1c4623cb45a4be88936c830cca8137d_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjgtNC0xLTEtMA_a8041759-6798-4665-a4db-c1cda2fa6393"
      unitRef="usd">224000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i59f953f7b8304173993dce91c2663860_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNjgtNi0xLTEtMA_a1406d1a-da45-42c6-b0b0-95ef959d9676"
      unitRef="number">0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60a0def5e08a4ad8961fabcaa36ce515_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzAtMi0xLTEtMA_423b5f5d-d555-4be3-bf2e-aef41867de1f"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1cdd7d8723049d19609b00fa9d90353_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzAtNC0xLTEtMA_6232ed21-c2e7-4b9b-bb78-938d1a590e90"
      unitRef="usd">396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i60a0def5e08a4ad8961fabcaa36ce515_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzAtNi0xLTEtMA_ac329665-60de-4e35-881b-7fc7942bdf1c"
      unitRef="number">-0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i831167bcd06748238ad090de986cb792_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzEtMi0xLTEtMA_41f22702-62b1-4460-bf0f-6ebbb367539f"
      unitRef="usd">166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia20e73715a764fab811e562e85895b43_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzEtNC0xLTEtMA_942e6b86-e314-4418-a7a8-ea0fb89a4983"
      unitRef="usd">184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i831167bcd06748238ad090de986cb792_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzEtNi0xLTEtMA_8dcb3fe6-b02e-4374-86ed-19a2a156a2d4"
      unitRef="number">-0.099</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fa7ccc867e0451d8c3472534acc0afe_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzItMi0xLTEtMA_1ea6c284-39ed-419f-9a3a-49fae226a094"
      unitRef="usd">546000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8be1c5255c4b4a188392c9c769c5191a_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzItNC0xLTEtMA_78e3cdc8-be6e-47b2-94e5-f86e47fb89a2"
      unitRef="usd">579000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8fa7ccc867e0451d8c3472534acc0afe_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzItNi0xLTEtMA_ae032613-721f-4a0a-a544-d9f416df6651"
      unitRef="number">-0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a0dc7a2446b402d88958e72d228822f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzQtMi0xLTEtMA_a2459cd7-ff53-495a-a637-b0a792dfecea"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bf0bee74b66411f86595a8d281104e2_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzQtNC0xLTEtMA_edd62b24-e6a6-4966-8766-53246c1ca91f"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9a0dc7a2446b402d88958e72d228822f_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzQtNi0xLTEtMA_d13bb66e-00a7-4ea0-8e9b-2f116d9ed01c"
      unitRef="number">-0.270</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b10e6ae68dd44b5aa1f27dc3875bf97_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzUtMi0xLTEtMA_d6894fa4-6901-4e65-a911-b3ca3116e36a"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i988753d50e764ca9a7c00a80520f3048_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzUtNC0xLTEtMA_1e3fd704-4541-4a5e-8802-ba10dcd2d06c"
      unitRef="usd">87000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0b10e6ae68dd44b5aa1f27dc3875bf97_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzUtNi0xLTEtMA_cb34ab30-d11a-4335-bd54-c4b4f743ffed"
      unitRef="number">0.097</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a9e5fed8d614670826d46986af440a1_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzYtMi0xLTEtMA_4eec6861-7e56-44e9-b5d2-d14afde95169"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife89528554c54fccbdf65c21b5a431c8_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzYtNC0xLTEtMA_77d13760-f209-4ce8-a8b5-b7de5c7a0328"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6a9e5fed8d614670826d46986af440a1_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzYtNi0xLTEtMA_332008fa-106f-4467-9226-1e0232c53ee4"
      unitRef="number">0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8754c3942af4f6d99cc04b08b970f18_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzktMi0xLTEtMA_1a3ee597-5b50-4d38-b1ba-9e044cd28548"
      unitRef="usd">771000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i176baa8660424665898357a803f03887_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzktNC0xLTEtMA_218bf60b-4aac-40e1-ac7e-53c2b9558e73"
      unitRef="usd">748000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if8754c3942af4f6d99cc04b08b970f18_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfNzktNi0xLTEtMA_91db36b2-b762-4577-b80e-762625277c5e"
      unitRef="number">0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d57014634294477bf7002a25123153e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODAtMi0xLTEtMA_91385859-2d81-419e-a543-3b5ae2305fa4"
      unitRef="usd">949000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2265d889108547338b832b208684da7d_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODAtNC0xLTEtMA_8b65384e-ecc2-4ed7-a233-7eb1c2a701b4"
      unitRef="usd">910000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6d57014634294477bf7002a25123153e_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODAtNi0xLTEtMA_6f4290fa-6730-4b07-b4b9-49d58ff54700"
      unitRef="number">0.043</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c291b0634924a55bacc7238c574ac85_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODEtMi0xLTEtMA_32c721b5-888d-4778-aed6-043275fdcb5d"
      unitRef="usd">1721000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22b68654dad44b8cba983ed66dcf3568_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODEtNC0xLTEtMA_469cc0eb-f578-4e41-8b82-a4f6a22176e3"
      unitRef="usd">1658000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7c291b0634924a55bacc7238c574ac85_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODEtNi0xLTEtMA_5cc637f7-d43b-440e-9816-d9bdb125782e"
      unitRef="number">0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i902b036bad4646c3acfbaa6a61042bcd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODMtMi0xLTEtMA_1fd4f930-111f-46b2-8f93-e9244e63e7f8"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64d06d5b850a4229a8ead53a9c9ba9e8_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODMtNC0xLTEtMA_c436ed6b-3eb5-4e98-940c-a0f05e0d9bf7"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i902b036bad4646c3acfbaa6a61042bcd_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODMtNi0xLTEtMA_2fe25a36-1059-4960-a443-f900b5c3486d"
      unitRef="number">-0.096</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c130fa5cebe472c9176470dc88dbbb5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODQtMi0xLTEtMA_27123bc4-19f3-4012-8046-77a66e1748ef"
      unitRef="usd">123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c030aed94064ab6a76b0da185985ac9_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODQtNC0xLTEtMA_3d27cbec-9fca-4ff2-9fb8-96a1fed77d6c"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9c130fa5cebe472c9176470dc88dbbb5_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODQtNi0xLTEtMA_dad1c41d-0081-4c24-adaf-3731f333fe05"
      unitRef="number">0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e4e92c9d6c74bb2895cb6659afe4aec_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODUtMi0xLTEtMA_fa168de8-3288-465b-bd71-d057a1d111db"
      unitRef="usd">171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08530f48301640e2a981713098e61fde_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODUtNC0xLTEtMA_917ba1c0-f4d9-46cd-b80e-f553e645672a"
      unitRef="usd">171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9e4e92c9d6c74bb2895cb6659afe4aec_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODUtNi0xLTEtMA_a11abd5f-3c8b-436d-8c86-325de67e0e8b"
      unitRef="number">0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b34fffac82440368445497712324317_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODctMi0xLTEtMA_d45ac75d-196a-4d53-afea-e36af113dcbe"
      unitRef="usd">589000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4bdee0e174a46a0b8c038d4489acc40_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODctNC0xLTEtMA_a4d641a8-6519-468f-bd0b-d94c4d251b23"
      unitRef="usd">544000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5b34fffac82440368445497712324317_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODctNi0xLTEtMA_d8806be7-e01e-41b9-996e-d9e9b031d17e"
      unitRef="number">0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i686fb29be97940259a0115fdd23a57e4_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODgtMi0xLTEtMA_a2277b48-91c2-401c-93d2-7e2ffe2e0188"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63eeae9617e4445594405644c82b4ae2_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODgtNC0xLTEtMA_0d934b85-617b-4485-b2cd-94c6db890b05"
      unitRef="usd">339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i686fb29be97940259a0115fdd23a57e4_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODgtNi0xLTEtMA_450a762d-0a04-4ada-86b0-0d85501ed4bd"
      unitRef="number">0.110</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58449ca63dee493eb4a627122847148a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODktMi0xLTEtMA_50b90a9a-273f-42fe-943d-40ec2a01683e"
      unitRef="usd">965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibba918ab4a4549e78a7dbbe69cf89f5e_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODktNC0xLTEtMA_96d4562d-5eae-4796-881a-a2fc43723cd6"
      unitRef="usd">883000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i58449ca63dee493eb4a627122847148a_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfODktNi0xLTEtMA_f4ac1f5b-d45d-424e-87ef-370922e02e4d"
      unitRef="number">0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcab1dd336244969a3214dd17843013a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTEtMi0xLTEtMA_9de003f8-67bc-49a8-a5cc-bacf716b06f8"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieee11dbbba0341acad84e21d44b66cb0_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTEtNC0xLTEtMA_1271b018-0a1c-4615-8ff9-add50a404a18"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibcab1dd336244969a3214dd17843013a_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTEtNi0xLTEtMA_8045f4fe-e6b7-43ff-a1c6-f7dabbbf3ab0"
      unitRef="number">-0.118</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcb7c0f2ea9d4046a2c03e628109123a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTItMi0xLTEtMA_529b7cfd-f87a-4cd9-afe6-fb1ad2dc622c"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1561310f3be0405d937bd6b471583f21_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTItNC0xLTEtMA_b1d8503e-d6ce-49ba-a9e0-4ae0d1b02d1c"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifcb7c0f2ea9d4046a2c03e628109123a_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTItNi0xLTEtMA_e3fb350d-136f-4b0d-bb78-04ab48e9ecd6"
      unitRef="number">-0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifab1d64419004688bb06b6ce8e08f292_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTMtMi0xLTEtMA_41a3e873-f7f3-4882-a84e-b8cbc2d6eadf"
      unitRef="usd">157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if345aeec465f40d3988084e400c97b4e_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTMtNC0xLTEtMA_0ce21107-7e06-4512-a099-28d48e6a26d8"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifab1d64419004688bb06b6ce8e08f292_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTMtNi0xLTEtMA_4879675e-c406-4e10-909f-8309ef87b2f3"
      unitRef="number">-0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a80582d773f48a88dd91b183eca0b21_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTUtMi0xLTEtMA_24d60329-bcf9-4747-bdb6-9a05c5edb64a"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b3b072e6a9b4111a82aad6be86d93c6_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTUtNC0xLTEtMA_8764f140-b80c-4e0f-b689-3fba27810ee9"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2a80582d773f48a88dd91b183eca0b21_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTUtNi0xLTEtMA_66a0441d-bf47-4e26-a09f-0aac741827d5"
      unitRef="number">-0.098</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22f5c3eb00ca4f86a05c633b971c6262_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTYtMi0xLTEtMA_48acdfeb-d9a0-4520-9b28-fbbe332dc319"
      unitRef="usd">361000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c42bc98065a4fcba4fa265b813a01b1_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTYtNC0xLTEtMA_7a819b8d-2853-4a11-9a4b-605e9ffefed3"
      unitRef="usd">360000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i22f5c3eb00ca4f86a05c633b971c6262_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTYtNi0xLTEtMA_480acf29-24e7-4944-af50-219295e3ebf9"
      unitRef="number">0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f35f4e601b0404393243d21e82cb121_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTctMi0xLTEtMA_3f8ff370-0f21-4b3d-bf6b-347e4629a4f7"
      unitRef="usd">428000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7c978b217504b4e97c5a3da905e7be6_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTctNC0xLTEtMA_b5077965-ccf7-4c2e-8eb1-e5b5d4002127"
      unitRef="usd">435000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8f35f4e601b0404393243d21e82cb121_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfOTctNi0xLTEtMA_9c08c10e-e7f3-4658-ba69-fadd0c65963a"
      unitRef="number">-0.015</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i215e664def914a8f8dae6cdfc6d30664_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAwLTItMS0xLTA_a32395a4-ed34-41ea-b7e9-0110e115bfd3"
      unitRef="usd">1377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad1e1a3f79d44f43a2ae8c994d019ed7_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAwLTQtMS0xLTA_ad101c5d-c841-437b-9d0a-b2871e338ebf"
      unitRef="usd">1175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i215e664def914a8f8dae6cdfc6d30664_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAwLTYtMS0xLTA_231d8714-1705-4c6c-a0c6-e28dad9bcbda"
      unitRef="number">0.172</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6cfc8b3edfc4a0ea32dd87a1d6bfe83_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAxLTItMS0xLTA_31484a45-7f24-437e-b50e-8a5c355c7330"
      unitRef="usd">2193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i864c9546ca1845cea37de582336593f0_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAxLTQtMS0xLTA_1033518d-85e5-4fae-a72c-d578655d7897"
      unitRef="usd">1839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie6cfc8b3edfc4a0ea32dd87a1d6bfe83_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAxLTYtMS0xLTA_c0cbc25c-6c52-48a7-bc66-9a0297c2a377"
      unitRef="number">0.193</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92f4c2b4bc544bb9938f19f240de842b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAyLTItMS0xLTA_025d774d-3b7c-4e60-a342-947f48bba056"
      unitRef="usd">3570000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91610b7c00884714803dc8fef0f20607_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAyLTQtMS0xLTA_666d5e16-1cdf-46b1-bace-3644d8f565ae"
      unitRef="usd">3013000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i92f4c2b4bc544bb9938f19f240de842b_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTAyLTYtMS0xLTA_8ba72ac3-1eb4-44f6-8dc8-0e1897df1a60"
      unitRef="number">0.185</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2ac86b2ad464bea9af64abe75679432_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA0LTItMS0xLTA_980b55a0-cc0b-415d-a134-0faefcb98695"
      unitRef="usd">691000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec972b10c7b0493883f2bd7563ffbd99_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA0LTQtMS0xLTA_ae17bcc3-c224-44f1-8179-ed9ef3f15da8"
      unitRef="usd">463000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib2ac86b2ad464bea9af64abe75679432_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA0LTYtMS0xLTA_bebb1900-526c-473a-9c3c-5fe25ff369a7"
      unitRef="number">0.492</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cfbea1e8ef24573bc5a395f4dc46921_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA1LTItMS0xLTA_a97b40ef-c5c4-44f7-9e4b-9c8250b757bf"
      unitRef="usd">674000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0afc2d9300442c481f53a34f4d5eadf_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA1LTQtMS0xLTA_0f8c15f4-7f48-494b-b6e7-3fb57ccc54a3"
      unitRef="usd">474000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8cfbea1e8ef24573bc5a395f4dc46921_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA1LTYtMS0xLTA_aa2a589d-90b3-453c-a1c8-75328c4737ad"
      unitRef="number">0.422</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3cee6a4e627d4c4281ce1b29360ea956_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA2LTItMS0xLTA_2715b48f-2f19-4436-b402-d1c627138e3f"
      unitRef="usd">1365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3511302b1ae41809e6440adaa75a4b8_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA2LTQtMS0xLTA_d4fccbab-c222-4653-beb9-8f96cd233b89"
      unitRef="usd">937000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3cee6a4e627d4c4281ce1b29360ea956_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA2LTYtMS0xLTA_3bab23d8-79e9-47ad-8922-b1ae693805b5"
      unitRef="number">0.456</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69417898b97a46fbb70d8ba92644a167_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA4LTItMS0xLTA_003e4770-97b7-43ba-abe6-c63fe52aa14e"
      unitRef="usd">171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac5940573a824aea9b11c62a69e8e3fe_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA4LTQtMS0xLTA_28735311-36f8-4474-bb9f-01bf71a90749"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i69417898b97a46fbb70d8ba92644a167_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA4LTYtMS0xLTA_c8c67431-7936-42b1-8340-73b7bedef973"
      unitRef="number">0.440</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a54ac8edede45ddbaab8f1db84179d2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA5LTItMS0xLTA_9d6d0443-792f-46e0-a5a8-953485529f56"
      unitRef="usd">90000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2ad067eaffd4f1391d0486fc4161840_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTA5LTQtMS0xLTA_6e33dffe-beb6-47cd-a92e-3e4a92e319ac"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if080c4dd59e944648097620649b8fb6f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEwLTItMS0xLTA_4f5cac6d-a44f-4a2d-8846-47d7c9081011"
      unitRef="usd">261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b2d16f32fba47f09eaaea5712a0b4fa_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEwLTQtMS0xLTA_c6bd27a5-418f-4cf6-a861-f906b59d87df"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if080c4dd59e944648097620649b8fb6f_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEwLTYtMS0xLTA_8c513572-2037-4338-a24a-b0ee52c0188a"
      unitRef="number">0.828</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9de68fe20a54bb3938d8f34bc55a8a9_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEyLTItMS0xLTA_eef5883c-ca32-4b9a-96fc-b704c6b7f9d5"
      unitRef="usd">444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa43d68970b74de495b2ce1d7600846a_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEyLTQtMS0xLTA_0b4e51bd-ab4a-4551-88af-1237e5078362"
      unitRef="usd">432000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie9de68fe20a54bb3938d8f34bc55a8a9_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEyLTYtMS0xLTA_dd434a79-d4f3-42a8-9b78-70d1b6608198"
      unitRef="number">0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idebe2f3e24dc4867b6dc012fde3f09fd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEzLTItMS0xLTA_db1d6146-7c16-446a-b504-ef8f1ae01b38"
      unitRef="usd">680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6f3f4cd739b446e89e809b5ac4d5df4_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEzLTQtMS0xLTA_6ead61e8-c2c1-4bde-965a-f75a0805436c"
      unitRef="usd">599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idebe2f3e24dc4867b6dc012fde3f09fd_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTEzLTYtMS0xLTA_f2695673-025f-44f2-9ee3-187de61d0d56"
      unitRef="number">0.135</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a98910058dc499f9afafc26d4f8d7a2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTE0LTItMS0xLTA_e0339646-0e6c-42d5-8f9d-ce10102a2fc8"
      unitRef="usd">1125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c52fe15105d49e18829d0a70625bdad_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTE0LTQtMS0xLTA_85d919a6-37a3-498d-aad5-9f15092d1487"
      unitRef="usd">1031000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2a98910058dc499f9afafc26d4f8d7a2_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTE0LTYtMS0xLTA_5e65babf-6f92-45ee-9adc-7bad3d912de9"
      unitRef="number">0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cf69631e6a64a778cb06aa103ea457a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIwLTItMS0xLTA_ea6eccb3-94a0-41b0-8fb0-c7f7e214c10c"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25d01b70ce6a4d158b8e85edb95cab4a_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIwLTQtMS0xLTA_6065269a-b98c-4faf-bec6-be895bba17fc"
      unitRef="usd">139000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9cf69631e6a64a778cb06aa103ea457a_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIwLTYtMS0xLTA_45d1a347-75f9-41c4-adce-58ec8469c2ac"
      unitRef="number">-0.642</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic10b7e28bcf94b0f8cf1550242af73c0_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIxLTItMS0xLTA_50bca223-6408-4c25-826c-b68d5cf7d7f4"
      unitRef="usd">588000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ccc8d4aa3944fc9a6f5d46048c4e46b_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIxLTQtMS0xLTA_88b29303-17e1-4b13-a84f-29deda5d4218"
      unitRef="usd">552000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic10b7e28bcf94b0f8cf1550242af73c0_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIxLTYtMS0xLTA_27b6a69b-cd85-4171-a201-07922355042e"
      unitRef="number">0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a43fa091bd04904af477b8da882ccc9_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIyLTItMS0xLTA_357f2e3d-6309-4760-a231-aa464dad624d"
      unitRef="usd">638000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63ca74a38d344c029cb03ec16c2adf4e_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIyLTQtMS0xLTA_2ad109e9-e6f5-42fb-98a1-32b879a01baf"
      unitRef="usd">690000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0a43fa091bd04904af477b8da882ccc9_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTIyLTYtMS0xLTA_55640c6d-d411-419b-9095-672d57f2502b"
      unitRef="number">-0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1056e17dd9d4f2cac9bf0fbd592a173_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI1LTItMS0xLTA_14ab167c-f2df-4eac-9d2d-d0f38042346f"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0278ad7c322f4c488129c6b911f43d45_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI1LTQtMS0xLTA_a75b566f-44d8-4dae-becf-30a83170d4be"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie1056e17dd9d4f2cac9bf0fbd592a173_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI1LTYtMS0xLTA_3074e3a1-8f5f-4d87-aa04-665ba67529df"
      unitRef="number">-0.051</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d4763b134be49d4b30da01bf1ba44e0_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI2LTItMS0xLTA_ddf2b520-fce1-4471-a2e8-e3f9c7add957"
      unitRef="usd">161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8b19e46a75b4847a0c6f53f552cfbc8_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI2LTQtMS0xLTA_145ef33f-8bf8-41d1-bf7b-f144d11bec82"
      unitRef="usd">190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8d4763b134be49d4b30da01bf1ba44e0_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI2LTYtMS0xLTA_4d7a4b2d-38ee-451e-86fa-cad21a6cd225"
      unitRef="number">-0.153</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie48200892c424f87b7edda0ba0409c96_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI3LTItMS0xLTA_52958510-d4ea-467c-9f91-de7f61a09c71"
      unitRef="usd">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96c5442217af4f099da88cd8d2d16584_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI3LTQtMS0xLTA_2dc8283c-ef79-47cb-9a77-106a895d20da"
      unitRef="usd">212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie48200892c424f87b7edda0ba0409c96_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTI3LTYtMS0xLTA_90423ce3-dc8d-4645-975f-f2c47a6f79ad"
      unitRef="number">-0.142</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i769a39b459364823ac7bbeb1e988ee9a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMwLTItMS0xLTA_a577d09f-f2db-4be2-ae0b-c1cf250a231c"
      unitRef="usd">573000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3d972234fcd4ba498f466945a9c4cc4_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMwLTQtMS0xLTA_d74854ff-e1cb-4361-88e7-b9defce844e9"
      unitRef="usd">486000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i769a39b459364823ac7bbeb1e988ee9a_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMwLTYtMS0xLTA_ede943e5-cb6c-407a-9eeb-61f0e0ccc359"
      unitRef="number">0.180</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f07da4bc71140e69f2cd469df1ff0a4_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMxLTItMS0xLTA_102fc816-a877-4849-ac1a-09675e51a3ca"
      unitRef="usd">288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1c7abf55c7f4cd1825fbdb35e87d736_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMxLTQtMS0xLTA_657baa9a-c721-416b-ab2c-2253ddcff4dc"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3f07da4bc71140e69f2cd469df1ff0a4_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMxLTYtMS0xLTA_0ac7f684-1cac-4078-9c07-664fac775722"
      unitRef="number">0.108</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i871b3677375a4491991a21ca121e6485_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMyLTItMS0xLTA_c06c9223-8cd8-43ef-be83-8a1cd9141d04"
      unitRef="usd">861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic19c69b6d1454567bbf90da51c867584_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMyLTQtMS0xLTA_f06be2f6-68b9-44b9-a136-7ec84ddb22f3"
      unitRef="usd">745000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i871b3677375a4491991a21ca121e6485_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTMyLTYtMS0xLTA_0b7eddf9-fac0-483c-b099-f0cd0749e29a"
      unitRef="number">0.155</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i712cec174e7a4562b67a334df7885636_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM0LTItMS0xLTA_fffcfc86-074f-410e-bb64-820d949a5a53"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6cb98336e1146a28b4c4b2c51be0b43_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM0LTQtMS0xLTA_376466fc-988c-4c36-b175-4b20d9adb20f"
      unitRef="usd">229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i712cec174e7a4562b67a334df7885636_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM0LTYtMS0xLTA_4c7c1fc8-76c9-473a-bd6d-60d1f470c068"
      unitRef="number">0.185</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c23981dbe7c474d94010c344d4e9738_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM1LTItMS0xLTA_cd30908d-5441-4dc5-ab57-4ebebc948dd2"
      unitRef="usd">179000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3eaafeabe91c4ea48c2ad1d1f12dba58_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM1LTQtMS0xLTA_9987de33-2992-44cc-ac7d-939e9f016b25"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0c23981dbe7c474d94010c344d4e9738_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM1LTYtMS0xLTA_a9f376e5-0d4a-4599-8d20-647217e4e5e0"
      unitRef="number">0.115</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24a8dc58bc5a4da4ad5d964b5437e8b6_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM2LTItMS0xLTA_90e1a9d0-55ad-4d75-94cf-24bac1a339aa"
      unitRef="usd">450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f8096a899854fcf930ca0cea72e522b_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM2LTQtMS0xLTA_3d5a6960-851c-4e4e-9762-ecb7fa751962"
      unitRef="usd">389000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i24a8dc58bc5a4da4ad5d964b5437e8b6_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM2LTYtMS0xLTA_6b793c78-2568-4111-a6a0-c1c47f981584"
      unitRef="number">0.156</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf849323318a42d78e841021176dc0db_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM4LTItMS0xLTA_451d23fe-3c72-4c89-837a-6156dac9cefe"
      unitRef="usd">259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3881e94557524789a9ff7fc5efb2d29a_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM4LTQtMS0xLTA_59db86e4-b31a-4e35-9044-a87d3c4d2ca3"
      unitRef="usd">212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idf849323318a42d78e841021176dc0db_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM4LTYtMS0xLTA_74d43521-e298-4dcd-be21-92345f5a2423"
      unitRef="number">0.219</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id087d3cf08544d0e8465c05939e54c06_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM5LTItMS0xLTA_3e53be67-9001-4a03-b7a7-d1b5c1a3e764"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f4ecbbe64184af588dc9aa7b93d8f9c_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM5LTQtMS0xLTA_f8f317b6-1f60-4b3a-9c86-d4a8e67236e6"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id087d3cf08544d0e8465c05939e54c06_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTM5LTYtMS0xLTA_0d45b7d3-aec0-4f97-9ab4-43c34ded6aed"
      unitRef="number">0.230</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90325c74593949fc87a8cc588c4f9fee_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQwLTItMS0xLTA_07d8953e-cb3c-479c-88c9-c358d1625262"
      unitRef="usd">305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i794c9a7bb0c54961a3e9869aa082ba42_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQwLTQtMS0xLTA_9eebc747-a986-453a-8339-9fa8b35f43d0"
      unitRef="usd">250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i90325c74593949fc87a8cc588c4f9fee_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQwLTYtMS0xLTA_a733ee6c-83d6-4525-91ce-ea54ffca0d67"
      unitRef="number">0.220</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i123f5966e05a44d085563e3eeb9a895f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQyLTItMS0xLTA_846b2d31-77af-4dd9-a624-131808db5dc7"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide5f1afa7b3f4d9c86ef358c4ed464c0_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQyLTQtMS0xLTA_3ba563c3-cda5-49b1-90c0-7df12abfa63c"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i123f5966e05a44d085563e3eeb9a895f_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQyLTYtMS0xLTA_46872867-258e-4125-bb6e-00e7eab9cb6c"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12bbf63564d04cae9ff269c9f4bbb527_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQzLTItMS0xLTA_5a33ef76-99c1-459b-9b8c-fac2097261a2"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfc39cb498d44439a78cc49f5f336acd_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQzLTQtMS0xLTA_14261f4d-bd48-4801-acd7-d68b40090e9f"
      unitRef="usd">62000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i12bbf63564d04cae9ff269c9f4bbb527_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQzLTYtMS0xLTA_ed21b6cb-440d-4b09-931b-4bd9a8ea1a21"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b9a89680513428485a34f3f48c896f6_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ0LTItMS0xLTA_01bc2b27-b2d1-4867-9aa8-720f9b102a34"
      unitRef="usd">105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7783e4e0f34f45f8b3873d934bac73a8_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ0LTQtMS0xLTA_76ff412c-e409-4220-a6a4-b9e5ff96d287"
      unitRef="usd">106000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4b9a89680513428485a34f3f48c896f6_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ0LTYtMS0xLTA_81de60c8-75b2-4f20-8148-8117b6f0cf0a"
      unitRef="number">-0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ca9de72471f4144afc322742d3ee277_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ3LTItMS0xLTA_32106b4d-cce7-4b9a-b21c-74e90f051cbc"
      unitRef="usd">799000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87786ad4f32e48449a1996e1153a6164_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ3LTQtMS0xLTA_47112f9c-6110-438c-9688-37b54708eeed"
      unitRef="usd">806000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9ca9de72471f4144afc322742d3ee277_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ3LTYtMS0xLTA_2f95ee30-7bcc-4cac-8268-6070f6fca85f"
      unitRef="number">-0.009</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fe0a5b0064547b1a5b98fe08aa407bf_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ4LTItMS0xLTA_f285e3dc-1673-41f7-aec8-5eeb57523da1"
      unitRef="usd">328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i782d96754043498593d177ed7e9d7435_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ4LTQtMS0xLTA_3e8dba79-5f9d-4ff6-a675-a30071904e6d"
      unitRef="usd">354000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1fe0a5b0064547b1a5b98fe08aa407bf_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ4LTYtMS0xLTA_1b87c1be-a7be-411d-aab1-de51e1c76040"
      unitRef="number">-0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ad2d868e8f94f1ea0241239aa8abf8a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ5LTItMS0xLTA_02afb35b-8af5-4e3a-995e-222381344549"
      unitRef="usd">1127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia564284c6bec4f09a465f098bbfaf35b_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ5LTQtMS0xLTA_2738c0b3-0299-4f74-a77d-82aa71c605cf"
      unitRef="usd">1160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8ad2d868e8f94f1ea0241239aa8abf8a_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTQ5LTYtMS0xLTA_19a8ed99-255a-4807-ba7d-731badbcd07f"
      unitRef="number">-0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2237e862843c453cba68d7ee3d286ba2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUxLTItMS0xLTA_7e692dd7-4ebb-4635-8bde-b438d2eeb231"
      unitRef="usd">589000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06dac5d761d243b8861130b807832ca5_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUxLTQtMS0xLTA_ad472025-ddcb-4634-8664-1ad6561dda86"
      unitRef="usd">527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2237e862843c453cba68d7ee3d286ba2_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUxLTYtMS0xLTA_bb66fb17-551e-4ae2-a729-aa7414508f68"
      unitRef="number">0.117</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d2cab6e4a2f4243aff50d87fb678757_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUyLTItMS0xLTA_b2ccd9bf-6b8e-417f-a0f6-8eb82bd6a585"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56e25388aba946e39f461155f1e66bb3_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUyLTQtMS0xLTA_d2ec2727-3226-47f5-8259-9ebf44c0de08"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1d2cab6e4a2f4243aff50d87fb678757_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUyLTYtMS0xLTA_ddfa079f-0d9c-455c-a4ff-be65dbefe3ab"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1ed7f86f44840468b3a6ca64ad69b92_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUzLTItMS0xLTA_cd68b7f8-bab8-47ce-976a-551e4c7ecc84"
      unitRef="usd">589000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ac1b72498c54651b9f3390eaf7bc4a4_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUzLTQtMS0xLTA_5c49ac34-bb1d-4bf4-bc20-59dfa135d089"
      unitRef="usd">527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if1ed7f86f44840468b3a6ca64ad69b92_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTUzLTYtMS0xLTA_eef06c60-bfb3-4fad-807c-ab98bea8b1da"
      unitRef="number">0.117</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78be76eb6d4c4d7297a4bf4093369453_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU1LTItMS0xLTA_55ab1949-554a-4066-9d2b-11be04c80be6"
      unitRef="usd">87000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic869379c2ad541c399cbf3c1fb6a954e_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU1LTQtMS0xLTA_58ab7844-c126-4b49-8973-597c5bfdae2e"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i78be76eb6d4c4d7297a4bf4093369453_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU1LTYtMS0xLTA_cc275771-f225-4b9c-a138-039d3670deb0"
      unitRef="number">-0.261</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9c30797b0cf4d2cb47f26f7a4501b8c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU2LTItMS0xLTA_375b2a65-3d26-431f-989e-bc5cb568aa0a"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibedf86a241dc4b5bbb19ba292a60a3fa_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU2LTQtMS0xLTA_a2e2d1ff-28fc-47c8-a61e-a1a12b6aa185"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id9c30797b0cf4d2cb47f26f7a4501b8c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU2LTYtMS0xLTA_f6050fee-29a6-459d-8f8f-2d2bbc16eaaa"
      unitRef="number">0.092</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b64f045460a4ca8858056eef80e48c5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU3LTItMS0xLTA_54d7026c-c937-4cb7-9bd0-6fce1f9416f6"
      unitRef="usd">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cf5f96085f349f4b87d2aa43da1a71b_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU3LTQtMS0xLTA_82194154-c5d2-47de-b597-506ed50b3a8b"
      unitRef="usd">175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8b64f045460a4ca8858056eef80e48c5_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU3LTYtMS0xLTA_d1bb54e6-192a-4d82-95d9-8f7f9fd5afa3"
      unitRef="number">-0.144</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c259fa6ac434248908eaf1d9085cbae_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU5LTItMS0xLTA_41a51054-e6dc-4f87-9718-41477a3cb6f0"
      unitRef="usd">62000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab22b59ea5b8436eb6d4e323ffdb8113_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU5LTQtMS0xLTA_136e64fc-7b42-46c5-bb83-119c1b3714a3"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4c259fa6ac434248908eaf1d9085cbae_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTU5LTYtMS0xLTA_f1cbcf73-a0a8-40ae-a2e9-8ddc4e818213"
      unitRef="number">-0.183</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie92f35e3cc8049518e4c913312f61c94_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYwLTItMS0xLTA_b1921521-c9f3-4894-81ff-1e3935c41737"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75a7e770b127440794059c8ec0d770e5_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYwLTQtMS0xLTA_8200a8ea-c204-416b-9d19-b3dcf4551c64"
      unitRef="usd">79000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie92f35e3cc8049518e4c913312f61c94_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYwLTYtMS0xLTA_002fa4f8-58ee-47b1-af9a-207d9dd40e8f"
      unitRef="number">-0.181</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if67e32a6ba574c4bb1df1943ab8a91c6_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYxLTItMS0xLTA_61eb9e35-8c5b-4c2d-b017-c3df3ff394ab"
      unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib935f1d5a67d445e8d777642f2400a7a_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYxLTQtMS0xLTA_5582d8ef-6c7e-4866-a64c-7ff217df553b"
      unitRef="usd">155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if67e32a6ba574c4bb1df1943ab8a91c6_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYxLTYtMS0xLTA_f458be3f-ebc3-4496-a914-250d1992a067"
      unitRef="number">-0.182</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3db4b7b2b9104e8aa81ffe56c63244b3_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYzLTItMS0xLTA_ee87855e-4b4a-48fd-9342-8e3fa3e503a8"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c6a9d00e90848c58e88acd8954635ae_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYzLTQtMS0xLTA_76c98275-52a9-45bc-a440-cca2b34380e5"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3db4b7b2b9104e8aa81ffe56c63244b3_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTYzLTYtMS0xLTA_acc509b4-21a8-4c56-bcab-56659e327627"
      unitRef="number">-0.288</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9387bd1d4a9542529ff61ba379041ef5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY0LTItMS0xLTA_da8aab68-a980-4a77-ba01-f70a5e2df78a"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedc20ebf5bd042ad896ae4efdc519047_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY0LTQtMS0xLTA_528901dc-9b31-44a1-a86e-19f0eb08daf9"
      unitRef="usd">217000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9387bd1d4a9542529ff61ba379041ef5_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY0LTYtMS0xLTA_dee2f907-a68b-41d8-bd73-2458aa808233"
      unitRef="number">-0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if65d5eedb28a4d1fac8ffba1883d31d7_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY1LTItMS0xLTA_e51ddbf5-544e-44d4-a455-534d16268c1b"
      unitRef="usd">261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36ee165c65f3448d9fd58f57b88afb73_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY1LTQtMS0xLTA_812f3bbb-6638-4bef-bec3-287c6f9cdcaf"
      unitRef="usd">302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if65d5eedb28a4d1fac8ffba1883d31d7_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY1LTYtMS0xLTA_b3065dfa-b799-4ae4-bccf-12e08b9dd94f"
      unitRef="number">-0.136</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a203809cc6644f48256490ae13f0ab3_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY4LTItMS0xLTA_8762b08f-3dd8-42c2-acb8-6f4d7b85ee8a"
      unitRef="usd">6446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i438067415c5c4f5985d9ae849a5e2a71_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY4LTQtMS0xLTA_be25a44b-9ec7-43bc-9ba5-4dea13a00ae3"
      unitRef="usd">6061000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0a203809cc6644f48256490ae13f0ab3_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY4LTYtMS0xLTA_e38833ef-6bd7-4ccd-843f-e38354f42ec7"
      unitRef="number">0.064</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id10068aaaa974a5aa7d0db7ddb857b8a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY5LTItMS0xLTA_e3adb20b-4dd8-4b66-a43d-293266ec686e"
      unitRef="usd">5753000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b613e89c6de4696b5f46fb3913eb864_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY5LTQtMS0xLTA_4cd7b44f-c897-422e-a055-ff576ed2d6a6"
      unitRef="usd">5073000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id10068aaaa974a5aa7d0db7ddb857b8a_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTY5LTYtMS0xLTA_e66e2e65-ad53-4813-b438-26484e04c536"
      unitRef="number">0.134</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0bb046f4ee745b8a6a3a214d7610a6d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTcwLTItMS0xLTA_a77961b2-dee7-4f39-a18b-fc9adbd1032c"
      unitRef="usd">12199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdca448a11c64bc48442f40fa88d4ce3_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTcwLTQtMS0xLTA_a575ddb4-d3cf-4caa-9138-7bb393f5d15f"
      unitRef="usd">11134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id0bb046f4ee745b8a6a3a214d7610a6d_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTcwLTYtMS0xLTA_3e42b386-ae7c-425f-9efc-0db89d4f286c"
      unitRef="number">0.096</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6eda2d70fc65473fa36d660afce9a681_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgyLTItMS0xLTA_e9330b7d-5675-46b2-b3f4-ee828b7b954f"
      unitRef="usd">434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f0decb1dd364c8da7e609d042602990_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgyLTQtMS0xLTA_f798be00-0013-49af-8395-faa05c560b1f"
      unitRef="usd">365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6eda2d70fc65473fa36d660afce9a681_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgyLTYtMS0xLTA_06ad5484-c519-4016-877d-47268e3262d2"
      unitRef="number">0.190</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d9df6ec7e15475b80a0ddd952dd424b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgzLTItMS0xLTA_31c7338b-7c43-44e1-9fe5-b42167a2ee06"
      unitRef="usd">514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3f8f49e166a42308c773c330db2cdac_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgzLTQtMS0xLTA_4ecc70e7-cd18-412f-b967-aabf1673b729"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7d9df6ec7e15475b80a0ddd952dd424b_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTgzLTYtMS0xLTA_8eb9488a-4b34-466e-beb4-56a2c5d079ae"
      unitRef="number">0.420</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c9c51f138064f7693ff21bd0cbc01dd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg0LTItMS0xLTA_909521ad-94bb-4837-bbe2-9411f5386ad2"
      unitRef="usd">949000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80a728efc7c4431185d2257b26f2c766_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg0LTQtMS0xLTA_c1ae7466-2905-4995-89d1-4dfee65f3c61"
      unitRef="usd">727000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0c9c51f138064f7693ff21bd0cbc01dd_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg0LTYtMS0xLTA_be95ad35-1f41-4ae4-a420-9005520a331a"
      unitRef="number">0.304</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i046c37ec387d418792e0b7796ecad6b5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg2LTItMS0xLTA_5de76eb5-138b-4500-b83d-d9c6cdbeb904"
      unitRef="usd">1249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3aa1d5138aa4eef99d2d397be8bb5a9_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg2LTQtMS0xLTA_b60983da-0a24-4d3e-b14d-c4d84c49e649"
      unitRef="usd">1250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i046c37ec387d418792e0b7796ecad6b5_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg2LTYtMS0xLTA_b45c11e0-4591-4e4a-903b-7585dcccc4a9"
      unitRef="number">-0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04925e843e58499d8cb79ab41d517312_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg3LTItMS0xLTA_5565d148-32e1-4770-ab3f-32b4a8b70f89"
      unitRef="usd">864000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i311fa4ee096d498cb9fc15d6e2eac138_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg3LTQtMS0xLTA_11f68887-4c2d-4d70-879d-b6ceeb15e3ad"
      unitRef="usd">788000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i04925e843e58499d8cb79ab41d517312_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg3LTYtMS0xLTA_035af759-0522-4f5d-bf5d-40e392a8ff13"
      unitRef="number">0.097</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5de8902fb1d64e47b0f656f4518cc948_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg4LTItMS0xLTA_0a4a51dd-6580-4045-aa31-d407696bf01b"
      unitRef="usd">2113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1b6bee78af44dfb8c09e1d37795edec_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg4LTQtMS0xLTA_97db0fd5-fa47-4f91-9539-c6e3e7602019"
      unitRef="usd">2038000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5de8902fb1d64e47b0f656f4518cc948_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTg4LTYtMS0xLTA_9062e80c-6c7b-4b2b-8c06-45131e2de16a"
      unitRef="number">0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2eed8f3fd6bb4026b042b674919fe034_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkwLTItMS0xLTA_7f664b03-5966-4b94-9d4b-998ba5f42c51"
      unitRef="usd">210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6edb3ee83adb4242bda5469bdac2cd58_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkwLTQtMS0xLTA_7ff4aede-80f6-4aef-80a2-5a800ddab8b7"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2eed8f3fd6bb4026b042b674919fe034_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkwLTYtMS0xLTA_435ec634-72fb-40cc-85be-6e3904b441b6"
      unitRef="number">0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51f6c8b86b7546149befa4e5f3fca4d5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkxLTItMS0xLTA_787bb719-d360-4a96-8a34-b3f9f1b35c66"
      unitRef="usd">146000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idebb01df50a34ff1b884a2077e7460a5_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkxLTQtMS0xLTA_c7aeb1a0-0848-437d-a5b8-72073d7512b0"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i51f6c8b86b7546149befa4e5f3fca4d5_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkxLTYtMS0xLTA_49892dbd-9d47-45fd-b63a-8e18c97ebaaf"
      unitRef="number">0.112</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8154d1203f304af6adf50d35bf4f7880_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkyLTItMS0xLTA_e4f5db1e-f48c-45d4-b370-0d652537d48a"
      unitRef="usd">357000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8740a5ae1646469f9c8fd93ba62467bc_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkyLTQtMS0xLTA_ee3bdba9-4136-4ff8-a881-e6040032a06e"
      unitRef="usd">337000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8154d1203f304af6adf50d35bf4f7880_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTkyLTYtMS0xLTA_6c543bfc-0680-4027-a996-c9848ec5d90c"
      unitRef="number">0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06f962900d174483a2d8ef350b1d7647_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk0LTItMS0xLTA_d803b7d2-2375-4d6e-8496-d153f0ee42ab"
      unitRef="usd">185000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a878e7d9cdf44f8a0e5b960ec217e8b_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk0LTQtMS0xLTA_fd91a30d-32b4-4c84-b326-1dc5dd4aad7c"
      unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i06f962900d174483a2d8ef350b1d7647_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk0LTYtMS0xLTA_c6d01440-f043-4ced-9211-3f076f2f0591"
      unitRef="number">-0.135</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id864ff961e674fb1b62f80b8c6932ea9_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk1LTItMS0xLTA_87b53229-438e-4ca9-a974-1d091a5d149d"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2c551cbda52435687542e1e45b23fd4_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk1LTQtMS0xLTA_f80fffb2-415b-4a92-8ead-93a395368da1"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id864ff961e674fb1b62f80b8c6932ea9_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk1LTYtMS0xLTA_77f8447a-a6ab-47da-89f3-216723d02f55"
      unitRef="number">0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67be5d04e3c440f888ad9161a9e5eda7_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk2LTItMS0xLTA_388091b4-79da-4e7c-824a-098caf920502"
      unitRef="usd">317000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9037030323674d438622ead7d2365cee_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk2LTQtMS0xLTA_0fc8e26e-58db-4ce4-ba75-afcdf7e1f85c"
      unitRef="usd">343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i67be5d04e3c440f888ad9161a9e5eda7_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk2LTYtMS0xLTA_a0eff06c-b84e-41d9-aaf0-bf635a63399d"
      unitRef="number">-0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03bec226c4414b32b21f05d00c95bd73_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk4LTItMS0xLTA_32c359a4-2514-4c32-9fee-ec8d311f1eb3"
      unitRef="usd">450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1806bc88b23744e38bf7a4a18ee82827_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk4LTQtMS0xLTA_b0b1d51d-6150-40b5-b39b-761685679621"
      unitRef="usd">407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i03bec226c4414b32b21f05d00c95bd73_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk4LTYtMS0xLTA_865fbc34-ed1a-4a74-ab05-2f03124de1f8"
      unitRef="number">0.107</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4fc05c968db431dafa927a4b29febff_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk5LTItMS0xLTA_caf3f231-d284-46d3-a764-0719e3300ae6"
      unitRef="usd">282000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib713a362c12a4e0f8c0fdb3f559dd81d_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk5LTQtMS0xLTA_6082de30-20d8-42f3-b012-61fe5ffe9158"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic4fc05c968db431dafa927a4b29febff_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMTk5LTYtMS0xLTA_85da5081-2186-4955-baed-6a2d8ad36682"
      unitRef="number">0.144</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0230b4c2f04f45c08018028261942d70_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAwLTItMS0xLTA_736d8963-8b04-440c-9129-eb4db8ae26f7"
      unitRef="usd">733000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5da6efb5d0a745239d6361465c0a8cf7_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAwLTQtMS0xLTA_37ccd2ca-be82-4e5e-bc17-ef8ecd55763e"
      unitRef="usd">654000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0230b4c2f04f45c08018028261942d70_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAwLTYtMS0xLTA_e693e8f9-d970-4d06-aa55-5511834fa5dc"
      unitRef="number">0.121</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59adb5a67adb476b8ee2fd372e3f1de0_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAyLTItMS0xLTA_5c873a33-c7b0-45d3-86af-44b794435f53"
      unitRef="usd">403000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d6ab8313ed7411fb9fcccd2fb2fc054_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAyLTQtMS0xLTA_37b5236d-d6d7-4dcd-b644-1db027b9a776"
      unitRef="usd">423000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i59adb5a67adb476b8ee2fd372e3f1de0_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAyLTYtMS0xLTA_16c686a3-9545-410f-8b60-fb999135500f"
      unitRef="number">-0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70464af74e1244fe971e0ce8df9c1139_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAzLTItMS0xLTA_583b351e-d62d-49ca-837f-a0473c811276"
      unitRef="usd">303000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87c7441a2ff64814bc9edd9ebb11379a_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAzLTQtMS0xLTA_9ecade36-b3d2-42fa-9f36-d3dd5c205f1e"
      unitRef="usd">280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i70464af74e1244fe971e0ce8df9c1139_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjAzLTYtMS0xLTA_b5a05d55-db84-48ff-9f46-bef16396963b"
      unitRef="number">0.084</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f75cbd2f3e44e86b3159f06713cea79_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA0LTItMS0xLTA_9e8bd62c-cb5b-499a-9544-f4b936f0e01b"
      unitRef="usd">706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46794c3f5f7641c28479e5843b966ae4_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA0LTQtMS0xLTA_ed169ca3-cf9c-4ffe-bc4c-4f73f209dd8b"
      unitRef="usd">703000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2f75cbd2f3e44e86b3159f06713cea79_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA0LTYtMS0xLTA_26d4b00d-9b56-4ede-8630-54155a07ddd7"
      unitRef="number">0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbbac775d46c4b0caf203e09c5683d11_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA2LTItMS0xLTA_e1a205de-3e1e-4002-afac-ae12766e0a82"
      unitRef="usd">898000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73332a11822c4dfab9561d066cb74b28_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA2LTQtMS0xLTA_18305704-c5c6-486f-afcc-47fb7e542bfb"
      unitRef="usd">844000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifbbac775d46c4b0caf203e09c5683d11_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA2LTYtMS0xLTA_f47474e9-9e7a-4a40-9d20-fbc4e565027f"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i381d0ba83d1f41bdb53476e56a42a36e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA3LTItMS0xLTA_3730f87d-641d-47c9-b96a-fed31a711e62"
      unitRef="usd">1474000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icae9f5809e1e453ca62e9f4b2040f4f4_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA3LTQtMS0xLTA_3c3d42f4-6dc0-48cb-a0b6-40775a853dd9"
      unitRef="usd">1257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i381d0ba83d1f41bdb53476e56a42a36e_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA3LTYtMS0xLTA_091def7a-0116-4c1e-97c4-c8fdc65755ac"
      unitRef="number">0.173</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee3f3e37530b4bc5bc81e9b8b73ec767_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA4LTItMS0xLTA_1a6965ba-4261-419c-aba9-66a6a926cec6"
      unitRef="usd">2372000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i373fb25b6ac74376b24f1838469cdc56_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA4LTQtMS0xLTA_018b5cd5-539b-49d4-904e-9c6f3656de19"
      unitRef="usd">2100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iee3f3e37530b4bc5bc81e9b8b73ec767_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjA4LTYtMS0xLTA_51f87948-caf0-45ae-875e-5983a1e59a78"
      unitRef="number">0.129</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d757ba0d9b54fa8a6d3b798835d364a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEwLTItMS0xLTA_b302708c-fd72-4c30-9c1c-9c8726e50a50"
      unitRef="usd">405000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib89e19ebfa6741fab1ef7e4ccb9bce83_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEwLTQtMS0xLTA_47780b76-1c77-4865-ab3c-490159899eaf"
      unitRef="usd">381000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1d757ba0d9b54fa8a6d3b798835d364a_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEwLTYtMS0xLTA_bf4a77b5-d7e4-4cd9-9b87-eea51bbc6666"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i829ccedf81764d70b896a39ffc2b8d95_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjExLTItMS0xLTA_c0263eac-368a-4cfb-a1e9-d02bf3805c70"
      unitRef="usd">713000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia475a9342c1549239a4b78261b9b833c_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjExLTQtMS0xLTA_dad4870e-5b43-47c0-b7ef-8b89d8e79df5"
      unitRef="usd">567000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i829ccedf81764d70b896a39ffc2b8d95_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjExLTYtMS0xLTA_6967383f-0a67-4084-9a8a-b4050f8ecfd7"
      unitRef="number">0.257</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia646bd76b4f54d908a6d0888a0bab427_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEyLTItMS0xLTA_5eb5bf82-df1c-444a-a9ac-9374006cd11f"
      unitRef="usd">1118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc399b9993724391a7b071eb85f26048_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEyLTQtMS0xLTA_92352db5-e00f-4f24-ab70-3043903b968c"
      unitRef="usd">948000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia646bd76b4f54d908a6d0888a0bab427_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjEyLTYtMS0xLTA_59455bb7-dd22-42aa-b5f2-b4d715329054"
      unitRef="number">0.180</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc92d2e4cf8a4de7b8c3172a78c2d8ff_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE0LTItMS0xLTA_b1163303-6aaa-4d57-b289-bbf8bf24c11f"
      unitRef="usd">493000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab081c7294c94dacb3f3da911787176a_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE0LTQtMS0xLTA_fa57e02c-51d6-4524-80c3-3bf1bfe6ea2f"
      unitRef="usd">463000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icc92d2e4cf8a4de7b8c3172a78c2d8ff_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE0LTYtMS0xLTA_57bc830c-79b9-42bc-9dbf-19a03c3a02bd"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id694df27cb364c85abe72911f2a4f74b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE1LTItMS0xLTA_3578baff-6bd3-4f74-b890-f9c569f808b6"
      unitRef="usd">761000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaee0751bab8e4f7b823728d29fc3a815_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE1LTQtMS0xLTA_bcc00bd0-196a-4a9b-b1a5-173fd2d96082"
      unitRef="usd">690000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id694df27cb364c85abe72911f2a4f74b_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE1LTYtMS0xLTA_b0dddba9-994b-46f3-8278-75b41aaff87f"
      unitRef="number">0.103</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i309da13ba23248d2bbd4befdd7ec001c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE2LTItMS0xLTA_95beb09a-73d5-460c-b0fa-980af7202188"
      unitRef="usd">1254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52d6c8b409ec42199210aa34c876fc99_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE2LTQtMS0xLTA_d8d1d95b-406c-4ae9-baef-e610395d63cf"
      unitRef="usd">1153000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i309da13ba23248d2bbd4befdd7ec001c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE2LTYtMS0xLTA_faec0509-a1d4-4dae-9875-c72322d69c9d"
      unitRef="number">0.088</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf3ceb4f65cc4b228df4f27cfee4babf_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE4LTItMS0xLTA_76f8d282-e7ef-42a3-a8bc-41b775a2a88d"
      unitRef="usd">472000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0ae566a0efc441eb0fb6ea1cc2e1608_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE4LTQtMS0xLTA_1747e17b-2002-49cc-8257-938b7a29cd21"
      unitRef="usd">439000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icf3ceb4f65cc4b228df4f27cfee4babf_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE4LTYtMS0xLTA_c9507164-e0bb-405c-8138-f15179693181"
      unitRef="number">0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idae5fbf3821e4b25b63bbfb4f1173093_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE5LTItMS0xLTA_8b83e1ca-9923-4225-a5c4-ad51e6fbbc03"
      unitRef="usd">673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fa44b2106d7456086d7300b833a26cc_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE5LTQtMS0xLTA_cfd0a1e0-44b4-4d26-9acd-b6673fbff7c4"
      unitRef="usd">628000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idae5fbf3821e4b25b63bbfb4f1173093_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjE5LTYtMS0xLTA_aa9e3496-b6f9-47a7-a075-31515a12b820"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i173c358b9082487dacc6b62f9414e27e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIwLTItMS0xLTA_6ba85d82-6ee5-497e-9e67-f3a30ed7682b"
      unitRef="usd">1145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4d24994a8ef4424b6c1f77a1a7134a4_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIwLTQtMS0xLTA_77273cb1-cfed-48b3-83fb-c9d239e2c51e"
      unitRef="usd">1067000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i173c358b9082487dacc6b62f9414e27e_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIwLTYtMS0xLTA_5830497d-1731-49d7-a31e-c345ba0f5489"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44aeed20d86c44c5b5a4ebeafec47aed_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIyLTItMS0xLTA_ab972fc8-29f6-4fda-a83d-a1660074bad7"
      unitRef="usd">371000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51883c3c4f5f4d9989d8ea8605f231dd_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIyLTQtMS0xLTA_02932d1c-e82a-4e38-9377-410cec15c4d6"
      unitRef="usd">346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i44aeed20d86c44c5b5a4ebeafec47aed_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIyLTYtMS0xLTA_a410b469-064c-44a9-933b-131c4184419b"
      unitRef="number">0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d094f0fc9b241f89a961261247144f3_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIzLTItMS0xLTA_2229e458-8d6d-4a33-bf5e-f2f5d01e5b1b"
      unitRef="usd">486000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3abe5bb0d9c4e3298e7a1b39eb3e953_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIzLTQtMS0xLTA_99edcb92-c5ee-4841-bdc2-04ade4d00358"
      unitRef="usd">467000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5d094f0fc9b241f89a961261247144f3_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjIzLTYtMS0xLTA_475df133-d7e5-498f-b012-3d4e83b5dddd"
      unitRef="number">0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1952414febe4c02a498725387577ba4_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI0LTItMS0xLTA_c03309fd-7bbd-4f7d-ae54-3568f331ffe2"
      unitRef="usd">857000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12f37539b91d45b7b48a375afd131b53_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI0LTQtMS0xLTA_666b8429-4c21-4b39-a1ae-eb072393b2f2"
      unitRef="usd">814000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie1952414febe4c02a498725387577ba4_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI0LTYtMS0xLTA_77ffc643-859c-4240-b0e6-99b00c875fb0"
      unitRef="number">0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8585c10f5564b039e486807c6255230_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI3LTItMS0xLTA_95c778bc-930d-4ee5-8d5a-16848770eb07"
      unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e06d38a4dbb4397aa56a49e80a320af_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI3LTQtMS0xLTA_b2f5403d-2ae0-4c0a-b759-6a206c492855"
      unitRef="usd">93000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id8585c10f5564b039e486807c6255230_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI3LTYtMS0xLTA_3094c735-58a4-4ba3-b395-ef740ff59735"
      unitRef="number">0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i317a97ccb069420ab772ab1f52d977ba_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI4LTItMS0xLTA_a5ac1368-b529-40eb-a74a-3aa7f55b342f"
      unitRef="usd">187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied6815bd7b754e4a902dee41b3bff0ac_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI4LTQtMS0xLTA_c47bdc03-291d-4c8a-a3d1-b422c267b08e"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i317a97ccb069420ab772ab1f52d977ba_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI4LTYtMS0xLTA_c203f429-6d7e-413c-85c9-69776532e2b7"
      unitRef="number">0.170</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2ac2702e3294ccc936243e7e77b3337_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI5LTItMS0xLTA_c0b8286b-3982-444d-9cc0-e46a825282a4"
      unitRef="usd">288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d9f04a32215495f8fb5d9251c0b8172_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI5LTQtMS0xLTA_cfa52845-6ecc-440e-a5e8-788a6abaae08"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib2ac2702e3294ccc936243e7e77b3337_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjI5LTYtMS0xLTA_83ad7795-7be0-4fdb-9970-1a266f1ec182"
      unitRef="number">0.137</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0effaa8d4d19429294ebb6baadb91fe8_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMyLTItMS0xLTA_4a858202-0c88-4918-a62a-73695dac3765"
      unitRef="usd">3054000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5dba1ed2af8443a0a29e304aa9362c9e_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMyLTQtMS0xLTA_c7b15005-59bf-4a28-b192-0c5990369dbc"
      unitRef="usd">2898000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0effaa8d4d19429294ebb6baadb91fe8_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMyLTYtMS0xLTA_ee3c17af-2eda-4626-95ce-6348e0640988"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27ba1a98c3ed46fea5a3c71020abc7e5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMzLTItMS0xLTA_fe2794aa-da4b-46dc-8833-ddd2c6b38c6b"
      unitRef="usd">3525000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1eeba07dc96844578537afa4da1d4909_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMzLTQtMS0xLTA_c07eff77-901a-440b-ae26-d48f8bde57d4"
      unitRef="usd">3034000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i27ba1a98c3ed46fea5a3c71020abc7e5_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjMzLTYtMS0xLTA_e63172de-d1a8-496c-9b3d-7ad6b577b224"
      unitRef="number">0.162</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i765e60a738e846889a642c75a5734d75_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM0LTItMS0xLTA_85cb9114-e3c8-46b1-8e0a-be72133b80d2"
      unitRef="usd">6579000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88511d277635488580602c5f2d2efbe9_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM0LTQtMS0xLTA_23ef43ec-f92a-4460-a266-3420484e9fbb"
      unitRef="usd">5932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i765e60a738e846889a642c75a5734d75_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM0LTYtMS0xLTA_908b3e8a-6ec1-41b1-ae7c-3346e4036cc0"
      unitRef="number">0.109</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc1d3ef8e82b4cab9d2f209a70930bad_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM3LTItMS0xLTA_d1dc9425-5faf-4154-a829-67f8821e7a42"
      unitRef="usd">11111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia49cb056ac9642fab13eb3c45dd7beb7_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM3LTQtMS0xLTA_00d42dcb-c971-49ed-a8ac-19de20222efe"
      unitRef="usd">10699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibc1d3ef8e82b4cab9d2f209a70930bad_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM3LTYtMS0xLTA_95332d47-7e09-4332-ba56-cf077f28d452"
      unitRef="number">0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61df9a2348d5485696295a61a5f0b0ba_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM4LTItMS0xLTA_819649b4-84c6-43bf-80ca-cec14d625d52"
      unitRef="usd">11210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7dc14d98635140cf98a64f0c2425a440_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM4LTQtMS0xLTA_c77c5d18-1c52-44fc-8b38-3ee4fe899c9a"
      unitRef="usd">9992000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i61df9a2348d5485696295a61a5f0b0ba_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM4LTYtMS0xLTA_224bab76-2bd5-4c6d-a282-b1f3ddd079b1"
      unitRef="number">0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM5LTItMS0xLTA_fab7d022-83eb-4095-bfe2-67a825cca2b3"
      unitRef="usd">22321000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM5LTQtMS0xLTA_b8ce28c9-a574-40de-9116-55ceace52ebc"
      unitRef="usd">20691000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmIwODk3ODU2ZDFlYTRkNmU5YmYyMmY4NjgyYzFiNmQzL3RhYmxlcmFuZ2U6YjA4OTc4NTZkMWVhNGQ2ZTliZjIyZjg2ODJjMWI2ZDNfMjM5LTYtMS0xLTA_d3cd8a5d-2602-42a6-8bd5-7f6aedd92efa"
      unitRef="number">0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzg5Nw_5c21e8fb-647e-4150-be28-42c8dae8dd05">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.045%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 29,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt"&gt;Includes amortization expense of  $0.1 billion in both the fiscal first quarter of 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes divestiture gains of $0.6&#160;billion in the fiscal first quarter of 2021 related to two brands outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes an unrealized loss on securities of $0.3&#160;billion in the fiscal first quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes litigation expense of $0.1&#160;billion in the fiscal first quarter of 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes amortization expense of $0.9&#160;billion and  $0.8 billion in the fiscal first quarter of 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In fiscal 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.0&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical Devices &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a contingent consideration reversal of $1.0&#160;billion in the fiscal first quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes a restructuring related charge of $0.1 billion in both the fiscal first quarter of 2021 and 2020, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes amortization expense of $0.3&#160;billion and $0.2&#160;billion in the fiscal first quarter of 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8774a60d6f6649268ae5cf40efca6063_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfMi0yLTEtMS0w_768341d6-65e9-4c38-a47e-2a719b12b0c5"
      unitRef="usd">788000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6f824bef77534b77acea435e4bcf50ed_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfMi00LTEtMS0w_210038f7-d99e-430e-b290-469f1fee8f4c"
      unitRef="usd">770000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i8774a60d6f6649268ae5cf40efca6063_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfMi02LTEtMS0w_b7ce9e8e-563c-4867-b0a1-556146baab30"
      unitRef="number">0.023</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id645f8a91fb54b40adfd453cef0dbd05_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfMy0yLTEtMS0w_8f0c80b6-e658-4794-8cf9-7268b5a28514"
      unitRef="usd">5223000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia347c7ffc8b448789de799026384d1b8_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfMy00LTEtMS0w_487e5f7a-0cf7-4b42-9be3-383ce9e077a9"
      unitRef="usd">3834000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="id645f8a91fb54b40adfd453cef0dbd05_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfMy02LTEtMS0yMjUy_91765323-107c-46c8-af00-caad9da4aa11"
      unitRef="number">0.362</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i46b22e45743641e680c31d8beb794e56_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNC0yLTEtMS0w_132f707c-6b76-4bdf-93f6-11deb7a97605"
      unitRef="usd">1629000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idfce5280afb34c08b7d2df0de5af45e1_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNC00LTEtMS0w_d995db81-3fcc-4562-bd64-97b50c8c6f4d"
      unitRef="usd">2025000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i46b22e45743641e680c31d8beb794e56_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNC02LTEtMS0w_1efd70d2-44ec-47c2-82b5-8b06a49fabf3"
      unitRef="number">-0.196</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if4237eb3d9454518b7d9808794278432_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNS0yLTEtMS0w_81264be2-0a9c-48a5-b9b3-36d4254768d0"
      unitRef="usd">7640000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia6730cd63c2644e6b98a2fca79af18d2_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNS00LTEtMS0w_4c105f9d-ba85-4dac-819d-36aeeadf0793"
      unitRef="usd">6629000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="if4237eb3d9454518b7d9808794278432_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNS02LTEtMS0w_1e1915bd-c3f7-46e3-95e5-1e5c2bff9d14"
      unitRef="number">0.153</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7090787364da465d986409e41cdb9e8e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNi0yLTEtMS0w_121699f2-dedd-4998-befd-f30159655bf6"
      unitRef="usd">211000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic00b4438aac54f08b9632ab4416202d2_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNi00LTEtMS0w_c63ac93d-3129-4cb3-ac22-5c7fc78d6f26"
      unitRef="usd">120000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNy0yLTEtMS0w_2a569d01-e538-4b12-88d5-8b33d7971df1"
      unitRef="usd">7429000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNy00LTEtMS0w_e7e27b85-8e0b-4cab-8186-232be6136181"
      unitRef="usd">6509000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmQ5ZDAzM2VlNGI4ZjRkZTFhZjgxMDlhOTQ2MTBiYWFiL3RhYmxlcmFuZ2U6ZDlkMDMzZWU0YjhmNGRlMWFmODEwOWE5NDYxMGJhYWJfNy02LTEtMS0w_9e845fbf-2b9a-4431-8e83-4d70fa68af36"
      unitRef="number">0.141</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="i8774a60d6f6649268ae5cf40efca6063_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfNzM1_384461aa-4ffd-4633-9e35-6f00f44b881d"
      unitRef="usd">100000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i6f824bef77534b77acea435e4bcf50ed_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfNzM1_efaefded-8439-45ae-a038-1242cabf91dd"
      unitRef="usd">100000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="id645f8a91fb54b40adfd453cef0dbd05_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMTA5OTUxMTYzNTg5OA_9b1c0938-5e0b-474b-8aa4-f8842920ead9"
      unitRef="usd">600000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:UnrealizedGainLossOnSecurities
      contextRef="ia347c7ffc8b448789de799026384d1b8_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMTQ0OA_12b9148d-b5c8-41c4-823b-2f7ed1d1b21c"
      unitRef="usd">-300000000</us-gaap:UnrealizedGainLossOnSecurities>
    <us-gaap:LitigationSettlementExpense
      contextRef="ibdca448a11c64bc48442f40fa88d4ce3_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMTA5OTUxMTYzNjA0NA_30138cc7-9900-4fc5-a7e8-88baf1157627"
      unitRef="usd">100000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:AdjustmentForAmortization
      contextRef="id645f8a91fb54b40adfd453cef0dbd05_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMjc0ODc3OTA3NjUxNQ_4cfabfec-fbd9-4685-add6-bee28cff7443"
      unitRef="usd">900000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="ia347c7ffc8b448789de799026384d1b8_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMTc2MQ_146d8c3c-7e86-402e-8eb5-6e522a5921f2"
      unitRef="usd">800000000</us-gaap:AdjustmentForAmortization>
    <jnj:AmountPrepaidAndDueToManufacturers
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMTA5OTUxMTYzNzc4MQ_29b0a5d5-5dbe-48bc-893a-594346a368e3"
      unitRef="usd">1000000000.0</jnj:AmountPrepaidAndDueToManufacturers>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i67972ac0db9340ad9d3acaa558c457e3_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzAwNw_29ff644b-9a1b-40e2-909f-6e01bef3932d"
      unitRef="usd">-1000000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCharges
      contextRef="i88511d277635488580602c5f2d2efbe9_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzQwNA_69d2dfaa-0279-4978-8b3a-1ac0fe40e70e"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i765e60a738e846889a642c75a5734d75_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzQwNA_c92668be-58ea-4d34-bd73-e5e794d0f9bd"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:AdjustmentForAmortization
      contextRef="i46b22e45743641e680c31d8beb794e56_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMjc0ODc3OTA3NjgxMg_fc45bde2-7951-4ca4-adcd-f67083e91478"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="idfce5280afb34c08b7d2df0de5af45e1_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzU2Ng_73dbd80a-eef2-4139-b91f-432e421fb8c0"
      unitRef="usd">200000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RleHRyZWdpb246NjJhMjVjNjlhZmY4NGZmMzkwNjBhOTIyZjRiNTcyMDVfMzkxMA_2c5cc55c-1431-4f0a-be44-1398ee490bd2">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY GEOGRAPHIC AREA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere, excluding U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc1d3ef8e82b4cab9d2f209a70930bad_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfMi0yLTEtMS0w_1bd461ee-4cc4-4f8a-a0b2-7ad3863118a8"
      unitRef="usd">11111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia49cb056ac9642fab13eb3c45dd7beb7_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfMi00LTEtMS0w_9aafb702-8253-4e78-a972-07a725322ac2"
      unitRef="usd">10699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ibc1d3ef8e82b4cab9d2f209a70930bad_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfMi02LTEtMS0w_743418e8-088e-4414-8832-60f36c1fdd76"
      unitRef="number">0.039</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4aeec3665cb149868af31f13c90e99f3_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfMy0yLTEtMS0w_83223f9e-6382-49f2-93d6-89a674d5a92d"
      unitRef="usd">5414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cff44da9a7a458490003f90a4b032fa_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfMy00LTEtMS0w_66189946-eb52-40eb-9693-1a1ef7868657"
      unitRef="usd">4827000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i4aeec3665cb149868af31f13c90e99f3_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfMy02LTEtMS0w_6ddf5933-ec76-403a-a32e-675390254d34"
      unitRef="number">0.121</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e19dfed28af47909fc2e122d61ba3e1_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNC0yLTEtMS0w_51180c91-4373-48d4-9307-6f2f3fc850c8"
      unitRef="usd">1424000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3d17e0cdb3e4dc9a51f76c0b873f000_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNC00LTEtMS0w_e299f838-cee6-47bd-8a19-d2d055ec4b7c"
      unitRef="usd">1502000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i5e19dfed28af47909fc2e122d61ba3e1_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNC02LTEtMS0w_75f751c7-f6d9-483c-85de-ffdf07364681"
      unitRef="number">-0.051</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia707285795354a909320047e9adde65b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNS0yLTEtMS0w_a5c23579-d94e-4415-92fc-05177fdee8a3"
      unitRef="usd">4372000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d72ee63d68e465c9fb647ef821fca86_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNS00LTEtMS0w_1aad9ba9-528e-45ab-862f-a6a09710a482"
      unitRef="usd">3663000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ia707285795354a909320047e9adde65b_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNS02LTEtMS0w_b2f799ce-dbb4-4c53-b514-a4810fd59757"
      unitRef="number">0.194</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNi0yLTEtMS0w_4b57aa85-3a47-454e-920c-35a2390d71cd"
      unitRef="usd">22321000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNi00LTEtMS0w_95b7e7dd-3eec-4b20-ac26-58b373f76d08"
      unitRef="usd">20691000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84NS9mcmFnOjYyYTI1YzY5YWZmODRmZjM5MDYwYTkyMmY0YjU3MjA1L3RhYmxlOmZiN2M2ODExZjk0ZDQ0NDU4ZjQwNjE5Mjg0YjZjMjlkL3RhYmxlcmFuZ2U6ZmI3YzY4MTFmOTRkNDQ0NThmNDA2MTkyODRiNmMyOWRfNi02LTEtMS0w_2228fd15-bc2b-4025-a11b-f7cd01ba8030"
      unitRef="number">0.079</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfNjMzMg_a29ad2c8-4208-47e7-a596-ad52121d78b0">ACQUISITIONS AND DIVESTITURESIn the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6&#160;billion. During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;amp;D, for $0.8 billion. XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. Additionally, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with world-class robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;amp;D, for $0.4 billion, goodwill for $0.2 billion, other assets of $0.2 billion and liabilities assumed of $0.3 billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4 billion.</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i6f4c6a54630d423ab63d36db8db32449_D20210104-20210404"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMTA5OTUxMTY0MDIwOA_5ed6353c-f493-48ad-b96d-03790ae0507f"
      unitRef="usd">600000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i5d9f14bc65a147d0b6ffd1245515b56e_D20191230-20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMTM4OQ_7e9b6b7f-2c40-4c47-b1a1-a7a60dc2beb9"
      unitRef="usd">800000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i8daceaf8ad2943238f7e0666635677be_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMTUxMA_ec5431d6-f2eb-4055-a46f-be7b18617192"
      unitRef="usd">800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i0ebc13e73dd24d8bbb4f49c2c087c1ff_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMjE3Ng_ff246757-6319-4bed-a13c-e1caf1021a94"
      unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i0ebc13e73dd24d8bbb4f49c2c087c1ff_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMjE5Mw_3a4a8126-597d-4c3a-a319-3426c2a68f40"
      unitRef="usd">200000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i0ebc13e73dd24d8bbb4f49c2c087c1ff_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMjIxMw_4f628d65-904d-4767-a177-c7358360a04b"
      unitRef="usd">200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i0ebc13e73dd24d8bbb4f49c2c087c1ff_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMjI0Mw_cd3d5408-4da4-4a2d-8ad1-a261dcf57ecd"
      unitRef="usd">300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="i0ebc13e73dd24d8bbb4f49c2c087c1ff_I20200329"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV84OC9mcmFnOmE1M2RiZDUwMjFlNzRhMmFiZjQ3ZjhkNjc4YTYyYzU1L3RleHRyZWdpb246YTUzZGJkNTAyMWU3NGEyYWJmNDdmOGQ2NzhhNjJjNTVfMjMzOQ_79369c52-3f6b-4cf2-8c54-892d2c8272e5"
      unitRef="usd">400000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfODc5ODI_28403b38-8c43-44e9-b9eb-d0e748582664">LEGAL PROCEEDINGS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed.  The Company continues to monitor its legal proceedings as the situation evolves.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of April&#160;4, 2021, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;PRODUCT LIABILITY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The most significant of these cases include: the DePuy ASR&#x2122; XL Acetabular System and DePuy ASR&#x2122; Hip Resurfacing System; the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acetabular Cup System; pelvic meshes; RISPERDAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; body powders containing talc, primarily JOHNSONS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Baby Powder; INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; and ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Flexible Composite Mesh. As of April&#160;4, 2021, in the United States there were approximately 300 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR&#x2122; XL Acetabular System and DePuy ASR&#x2122; Hip Resurfacing System; 7,000 with respect to the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acetabular Cup System; 12,200 with respect to pelvic meshes; 9,200 with respect to RISPERDAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; 10,200 with respect to XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; 28,900 with respect to body powders containing talc; 300 with respect to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 4,400 with respect to ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Flexible Composite Mesh.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; XL Acetabular System and DePuy ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp;amp; Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle &lt;/span&gt;&lt;span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the class actions filed in that country&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Hip-related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp;amp; Johnson (collectively, DePuy) relating to the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acetabular Cup System and the related settlement program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and class actions in Israel, Australia and Canada,.  In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021. With respect to class members other than the Lead Applicants, the Federal Court will conduct an individual case assessment process that will require proof of use and causally related loss, although the form of that process has not yet been decided. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson alleging personal injury arising out of the use of this hernia mesh device.&#160; Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. Discovery is proceeding in these cases and certain of the cases are in preparation for trials.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Claims have also been filed against Ethicon and Johnson &amp;amp; Johnson alleging personal injuries arising from the PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; Mesh and PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; Ventral Patch hernia mesh products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. Discovery is underway in these cases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Ethicon and Johnson &amp;amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE&#x2122; Polypropylene Hernia System (PHS). In September 2019, plaintiffs&#x2019; attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PHS cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those cases have also been transferred to an MCL in Atlantic County Superior Court. There are now approximately 304 cases pending in the MCL and discovery is underway in a subset of these cases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Flexible Composite Mesh, PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Mesh and PROCEED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Ventral Patch, and PROLENE&#x2122; Polypropylene Hernia System products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson arising out of the use of RISPERDAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff which the trial judge reduced to $6.8&#160;million in January 2020. The Company and plaintiff each are appealing this judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury arising out of the use of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp;amp; Johnson; and JPI&#x2019;s collaboration partner for XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson  &amp;amp; Johnson announced an agreement in principle to settle the XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Personal injury claims alleging that talc causes cancer have been made against Johnson &amp;amp; Johnson Consumer Inc. and Johnson &amp;amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Baby Powder. The number of pending personal injury lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits primarily have been filed in state courts in Missouri, New Jersey and California, and suits have also been filed outside the United States. The majority of cases are pending in federal court, organized into a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, the parties sought to exclude experts through Daubert motions. In April 2020, the Court issued rulings that limit the scope of testimony, including some theories and testing methods, for certain plaintiff expert witnesses and denied  plaintiffs&#x2019; attempt to limit the scope of testimony of certain of the Company&#x2019;s witnesses. With this ruling made, case-specific discovery has begun per the Court&#x2019;s directive. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Ingham v. Johnson &amp;amp; Johnson, et al., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion and, with additional interest as of April 4, 2021, as the Company pursues further appeal, is approximately $2.5&#160;billion (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Ingham &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;decision). An application for transfer of the case to the Missouri Supreme Court was subsequently denied. In March 2021, the Company filed a petition for certiorari, seeking a review of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Ingham &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;decision by the United States Supreme Court. In April 2021, the Plaintiffs filed their opposition to the petition. The Company continues to believe that it has strong legal grounds for the appeal of this verdict, as well as other talc verdicts that it has appealed. Notwithstanding the Company&#x2019;s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. The Company has established an accrual for defense costs and reserves for the resolution of certain cases and claims, including the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Ingham&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; decision currently on appeal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; in connection with product liability litigation associated with body powders containing talc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2019, the Company&#x2019;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#x2019; potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it alleges it has against the Company for indemnification and rights to joint insurance proceeds. The Company previously proposed to resolve Imerys' (and the Company&#x2019;s) obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, waiving the Company&#x2019;s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. In May 2020, Imerys and the asbestos claimants&#x2019; committee (Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto agreeing to put its North American operations up for auction which was subsequently amended. The Company has objected to the Disclosure Statement and intends to object to the Plan of Reorganization as currently structured. Additionally, in June 2020, Cyprus Mines Corporation and its parent (Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company as well as Imerys seeking a declaration of indemnity under certain contractual agreements.  The Company denies such indemnification is owed and filed a motion to dismiss the adversary complaint arguing, among other things, that the Court does not have subject matter jurisdiction over Cyprus&#x2019;s claims against the Company. The Plan Proponents filed numerous amendments to the Plan and Disclosure Statement to which the Company objected. A hearing on the Plan Proponent&#x2019;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement for the Ninth Amended Joint Chapter 11 Plan of Reorganization of Imerys Talc America, Inc. and its Debtor Affiliates, allowing Debtors Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Debtors&#x2019; Plan and opted out of the consensual releases in the Plan. Discovery with respect to the Debtors&#x2019; Plan is ongoing and the Confirmation Hearing is set for August 2021. Relatedly, in February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and Cyprus filed its Disclosure Statement and Plan.  Also, in February 2021, several of the Company&#x2019;s insurers involved in coverage litigation in New Jersey State Court (the &#x201c;Coverage Action&#x201d;) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action.  In March 2021, the Company filed a limited response and reservation of rights with respect to the motion.  The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;In February 2018, a securities class action lawsuit was filed against Johnson &amp;amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp;amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt; Baby Powder, and that purchasers of Johnson &amp;amp; Johnson&#x2019;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. In March 2021 briefing on Plaintiffs&#x2019; motion for class certification was completed.  Discovery is ongoing.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp;amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp;amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;Baby Powder, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:99%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;In July 2020, a report was delivered to the Company&#x2019;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues. Four of the shareholders who sent demands are plaintiffs in th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;e &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:99%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp;amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp;amp; Johnson&#x2019;s motion to dismiss pending a decision on Plaintiff&#x2019;s motion for discovery.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp;amp; Johnson Savings Plan against Johnson &amp;amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp;amp; Johnson stock as a Johnson &amp;amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt; Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#x2019; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#x2019; motion was complete. In February 2021, the Court granted Defendants&#x2019; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#x2019;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp;amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings.  In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#x2019;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2020, the Abtahi Law Group filed an action under Proposition 65 against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Inc. as well as a number of other alleged talcum powder manufacturers and distributors, including one California company. In that action, the plaintiff alleges contamination of talcum powder products with unsafe levels of arsenic, hexavalent chromium and lead. The plaintiff seeks civil penalties and injunctive relief. Defendants filed a motion for summary judgment in January 2021, and a hearing on the motion was held in April 2021. Limited informal discovery is continuing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding talc matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company produced documents as required in response and will continue to cooperate with government inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, a prescription medication  indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including two putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;INTELLECTUAL PROPERTY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain subsidiaries of Johnson &amp;amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#x2019;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medical Devices&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent&#x2019;s RELIEVA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Spin and RELIEVEA SpinPlus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products infringe U.S. Patent No. 9,011,412.  Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent&#x2019;s U.S. Patent No. 8,414,473. Trial is scheduled to begin in October 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC (collectively, Ethicon) alleging the manufacture and sale of VICRYL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Plus Antibacterial Sutures, MONOCRYL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Plus Antibacterial Sutures, PDS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Plus Antibacterial Sutures, STRATAFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; PDS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Antibacterial Sutures and STRATAFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; MONOCRYL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plus Antibacterial Sutures infringe plaintiffs&#x2019; United States Patent Nos. 6,596,296 (&#x2019;296) and 7,033,603 (&#x2019;603) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UT is seeking damages and an injunction.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the USPTO denied institution of the &#x2019;296 patent IPR and granted institution of the &#x2019;603 patent IPR.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UT dismissed the &#x2019;603 patent from the suit and no longer accuses PDS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Plus Antibacterial Sutures or STRATAFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; PDS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Plus Antibacterial Sutures of infringement. The previously scheduled district court trial has been postponed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#x2019;200); 6,491,701 (&#x2019;701); 6,522,906 (&#x2019;906); 6,800,056 (&#x2019;056); 8,142,447 (&#x2019;447); 8,620,473 (&#x2019;473); 8,801,601 (&#x2019;601); and 9,452,276 (&#x2019;276) based on Auris&#x2019; Monarch&#x2122; Platform.  Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#x2019;200, &#x2019;056, &#x2019;601 &#x2019;701, &#x2019;447, &#x2019;276 and &#x2019;906 patents. Intuitive subsequently dropped the &#x2019;200, &#x2019;473 and &#x2019;701 patents from the suit.  In December 2019, the USPTO instituted review of the &#x2019;601 patent and denied review of the &#x2019;056 patent. In February and March 2020, the USPTO instituted review of the &#x2019;200, &#x2019;447, &#x2019;701 and &#x2019;906 patents and denied review of the &#x2019;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#x2019;601 patent to be invalid.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intuitive has appealed that decision. In March 2021, the USPTO ruled that the challenged claims of the &#x2019;447 and &#x2019;906 patents are not invalid. Auris has appealed that decision. The District Court postponed trial until the appeal of the invalidity decision on the &#x2019;601 patent is complete. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA&#x2122; Spacer, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ZERO-P&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Spacer, ZERO-P NATURAL&#x2122; Plate, SYNFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; LR Spacer and SYNFIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. In June 2020, the case was stayed pending IPR proceedings filed by the Consolidated Defendants involving the asserted patents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and Synthes, Inc. (collectively, DePuy Synthes) in the United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and 9,275,191 based on the PROPLAN CMF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Virtual Surgical Planning Services and the TruMatch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. 9,292,920 for U.S. Patent No. 9,929,920.  Osteoplastics seeks monetary damages and injunctive relief. In June 2020, DePuy Synthes filed a motion to dismiss the complaint. In October 2020, the Court dismissed Medical Device Business Services, Inc. from the case but otherwise denied the motion.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trial is scheduled for October 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes lawsuits pending against generic companies that have filed ANDAs with the FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp;amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the third-party companies involved would have the ability, upon approval of the FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, Janssen Inc. and Janssen Oncology Inc. (collectively, Janssen) initiated a Notice of Application under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) and the Minister of Health in Canada in response to Apotex&#x2019;s filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of Canadian Patent No. 2,661,422 (&#x2019;422). The final hearing concluded in May 2019.  In October 2019, the Court issued an order prohibiting the Canadian Minister of Health from approving Apotex&#x2019;s ANDS until the expiration of the &#x2019;422 patent. In November 2019, Apotex filed an appeal, which was dismissed in March 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in January 2019, Janssen initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex, Pharmascience Inc. (Pharmascience) and Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, DRL) in response to those parties&#x2019; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the &#x2019;422 patent. The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#x2019;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;In August 2020, Janssen initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (Jamp) in Canada in response to Jamp&#x2019;s filing of an ANDS seeking approval to market a generic version of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; before the expiration of the &#x2019;422 patent. In March 2021, the parties entered into a confidential settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian actions, Janssen is seeking an order enjoining the defendants from marketing their generic versions of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the &#x2019;422 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin) which filed an ANDA seeking approval to market a generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before expiration of U.S. Patent No. 10,828,310 (&#x2019;310). In this lawsuit, JPI and Bayer are seeking an order enjoining Lupin from marketing their generic version of XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;310 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;/INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;/INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning in July 2017, Janssen Pharmaceuticals, Inc., Janssen Research &amp;amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and/or INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; XR before expiration of MTPC&#x2019;s United States Patent Nos. 7,943,582 (&#x2019;582) and/or 8,513,202 (&#x2019;202) relating to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and/or INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; XR. Janssen is the exclusive licensee of the asserted patents. Named defendants include MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc. (MSN); Zydus Pharmaceuticals (USA) Inc. (Zydus). These cases were consolidated into one action (Polymorph Main Action), which has been scheduled for trial starting in July 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;In July 2017, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus which filed ANDAs seeking approval to market generic versions of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;and INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;before expiration of MTPC&#x2019;s United States Patent No. 7,943,788 (&#x2019;788), 8,222,219 (&#x2019;219) and/or 8,785,403 (&#x2019;403) relating to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt;and INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"&gt; (Compounds Main Action). Janssen is the exclusive licensee of the asserted patents. Trial concluded in October 2020. The Court issued a decision holding that the patents are not invalid and would be infringed by Zydus&#x2019; generic products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2019, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed an ANDA seeking approval to market a generic version of INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;582 patent and &#x2019;202 patent relating to INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed ANDAs seeking approval to market generic versions of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;788 patent. In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;788 patent. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of the &#x2019;582 patent and &#x2019;202 patent relating to INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. In February 2021, Janssen filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before expiration of United States Patent No. 10,617,668 relating to INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. These lawsuits have not been consolidated with the Polymorph Main Action or Compound Main Action.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;In each of these U.S. lawsuits, Janssen and MTPC are seeking an order enjoining the defendant from marketing their generic versions of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;, INVOKAMET&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt; and/or, INVOKAMET XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the Canadian Patent Nos. 2,799,204, 2,534,024 and 2,671,357. Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an order enjoining Sandoz from marketing its generic version of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the relevant patents. The trial is scheduled to begin in August 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2020, Janssen Inc. (Janssen) and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before the expiration of Canadian Patent No. 2,659,770 (&#x2019;770). Trial is scheduled to begin in January 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the &#x2019;770 patent. Trial is scheduled to begin in February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10 mg before the expiration of the &#x2019;770 patent and Canadian Patent No. 2,621,273 (&#x2019;273). Trial is scheduled to begin in April 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of United States Patent No. 9,439,906 (&#x2019;906).  Trial concluded in October 2020, and closing arguments were made in March 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;906 patent. In February 2020, Mylan filed a Petition for Inter Partes Review with the USPTO seeking to invalidate the &#x2019;906 patent. The USPTO denied the Petition in September 2020, and Mylan appealed. Janssen filed a motion to dismiss the appeal, which was granted in March 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of Canadian Patent Nos. 2,309,629 (&#x2019;629) and 2,655,335 (&#x2019;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#x2019;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#x2019;s generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if approved, would infringe claims of the &#x2019;335 patent and that the claims of the &#x2019;335 patent are not invalid for obviousness. Teva Canada appealed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.'s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement is scheduled for November 2021. The trial is scheduled to begin in July 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;in response to Apotex's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement is scheduled for December 2021. The trial is scheduled to begin in September 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp;amp; Development, LCC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before expiration of United States Patent No. 10,143,693 relating to INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before the expiration of the relevant patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Beginning in January 2018, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies that filed ANDAs seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; 140 mg capsules before expiration of Pharmacyclics&#x2019;  United States Patent Nos. 8,008,309, 7,514,444, 8,697,711, 8,735,403, 8,957,079, 9,181,257, 8,754,091, 8,497,277, 8,925,015, 8,476,284, 8,754,090, 8,999,999, 9,125,889, 9,801,881, 9,801,883, 9,814,721, 9,795,604, 9,296,753, 9,540,382, 9,713,617 and/or 9,725,455 relating to IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;. JBI is the exclusive licensee of the asserted patents. The named defendants include the following generic companies: Cipla Limited and Cipla USA Inc. (collectively, Cipla); Sandoz Inc. and Lek Pharmaceuticals d.d. (collectively, Sandoz).  In January 2019 and February 2019, Pharmacyclics and JBI amended their complaint against Sandoz and Cipla, respectively, to allege infringement of United States Patent Nos. 10,125,140 and 10,106,548. In May 2019, Pharmacyclics and JBI amended their complaint against Cipla to further allege infringement of United States Patent No. 10,016,435. In August 2019, Pharmacyclics and JBI amended their complaints against Cipla and Sandoz to further allege infringement of U.S. Patent Nos. 10,294,231 and 10,294,232. In August 2019, the Court granted a joint stipulation to stay the litigation against Cipla.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,003,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trial in the foregoing actions against Sandoz and Alvogen took place in October 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen asserting infringement of United States Patent No. 10,478,439. In October 2020, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of U.S. Patent No. 10,653,696. In April 2021, the court entered a joint stipulation dismissing the complaint against Alvogen.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Zydus Worldwide DMCC and Cadila Healthcare Limited (collectively, Zydus), which filed an ANDA seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,008,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, 10,125,140, 10,213,386 and 10,478,439. In March 2021, JBI, Pharmacyclics and Zydus entered into a confidential settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of the lawsuits, Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2020, Actelion Pharmaceuticals Ltd (Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before expiration of Nippon Shinyaku&#x2019;s United States Patent Nos. 7,205,302; 8,791,122; and 9,284,280 relating to UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Actelion is the exclusive licensee of the asserted patents. The defendants include Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals Inc. (collectively, Alembic); and Zydus Pharmaceuticals (USA), Inc. and Zydus Worldwide DMCC (collectively, Zydus). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Actelion and Nippon Shinyaku are seeking an order enjoining the defendants from marketing generic versions of UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GOVERNMENT PROCEEDINGS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp;amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Average Wholesale Price (AWP) Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;amp;J AWP Defendants were ultimately dismissed. The J&amp;amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial.  In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp;amp; Johnson and ALZA Corporation. All other cases have been resolved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Opioid Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2014 and continuing to the present, Johnson &amp;amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in more than 3,200 lawsuits related to the marketing of opioids, including DURAGESIC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, NUCYNTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and NUCYNTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp;amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia and Wisconsin. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are more than 380 cases pending in various state&#160;courts. There are over 2,800 federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio.&#160;In addition, the Province of British Columbia filed suit in Canada. In October 2019, an anti-trust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp;amp; Johnson and JPI in the amount of $465&#160;million. Johnson &amp;amp; Johnson and JPI have appealed the judgment. The Company believes that it has strong grounds to overturn this judgment. In October 2019 Johnson &amp;amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp;amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial is scheduled to last up to three months. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Johnson &amp;amp; Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp;amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#x2019;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing and would resolve opioid lawsuits filed &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and future claims by states, cities and counties. The Company has made progress towards negotiating a final settlement with a coalition of state Attorneys General. The Company cannot predict if or when the agreement will be finalized and individual cases are ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Johnson &amp;amp; Johnson received a grand jury subpoena from the United States Attorney&#x2019;s Office for the Eastern District of New York for documents related to the Company&#x2019;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#x2019; and distributors&#x2019; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson &amp;amp; Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums.&#160;In September 2020, the Company learned that NYDFS filed a statement of charges related to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From June 2017 through December 2019, the Company&#x2019;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp;amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. In May 2020, the shareholder filed an amended complaint challenging the Board&#x2019;s rejection of his demand. In August 2020, Johnson &amp;amp; Johnson moved to dismiss the amended complaint. In February 2021, the Court held oral argument on Johnson &amp;amp; Johnson's motion. In August 2020, another shareholder who sent a demand filed a separate derivative complaint in the same court making similar allegations. In October 2020, the Court granted defendants&#x2019; request to reassign the second-filed case to the division where the first-filed case is pending. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2019, two additional shareholders who sent demands filed two separate derivative complaints making similar allegations against Johnson &amp;amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. In April 2020, the two federal cases were consolidated into a single action captioned&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; In re Johnson &amp;amp; Johnson Opioid Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. In July 2020, the shareholders filed a consolidated complaint. In September 2020, Johnson &amp;amp; Johnson moved to dismiss the consolidated complaint, and in December 2020, the shareholders opposed Johnson &amp;amp; Johnson&#x2019;s motion. Johnson &amp;amp; Johnson filed its reply in February 2021. In July 2020, an additional shareholder who sent a demand filed a derivative complaint in the same federal court making similar allegations against the same defendants named in the consolidated action. In January 2021, pursuant to an order in the consolidated action, the third case was consolidated into the consolidated action. In February 2021, the Court granted the shareholders motion to voluntarily dismiss the consolidated action without prejudice. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp;amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney's Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR&#x2122; XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#x2019; motion to dismiss with prejudice, unsealed the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; complaint, and denied the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; relators&#x2019; request for leave to file a further amended complaint. The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#x2019;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#x2019; request to file a third amended complaint. The relators&#x2019; remaining claims are now pending before the District Court. In July 2020, the Court ordered the relators to complete discovery by August 2020; the Relators have requested an extension of the August 2020 deadline that DePuy opposed and additional discovery-related motions have been filed by both parties since. In March 2021, DePuy filed its motion to strike and dismiss the relators&#x2019; second amended complaint. In March 2021, the District Court issued an order stating that if DePuy&#x2019;s motion to strike and dismiss is denied, the court will hold a conference at which a limited period for remaining discovery will be established.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2012, Johnson &amp;amp; Johnson was contacted by the California Attorney General's office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp;amp; Johnson's subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp;amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp;amp; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Johnson and Ethicon settled the Washington case. The California case started trial in July 2019 and concluded in September 2019. The trial date for the Kentucky case was scheduled for September 2019 but has been adjourned and no new trial date has been scheduled. In October 2019, Johnson &amp;amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company's motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#x2019;s request for injunctive relief. The Company is appealing the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;penalty judgment. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon.  In November 2020, the Company settled with the Attorney General of Mississippi. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp;amp; Johnson Consumer Inc.) (JJCI).&#160;The complaint alleges that defendants violated the Mississippi Consumer Protection Act by &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;failing to disclose alleged health risks associated with female consumers' use of talc contained in JOHNSON'S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Baby Powder and JOHNSON'S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The matter is stayed pending interlocutory appeal of a December 2018 denial of Johnson &amp;amp; Johnson and JJCI's motion for summary judgment. The Mississippi Supreme Court granted Johnson &amp;amp; Johnson and JJCI's request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. In April 2021, the Mississippi Supreme Court dismissed the Company&#x2019;s interlocutory appeal and remanded the case back to the Hinds County Chancery Court. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. The New Mexico Attorney General has issued requests for documents and the Company anticipates the document production will commence in mid-2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forty-two states have commenced a joint investigation into the Company&#x2019;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has entered into a tolling agreement with the States and has begun to produce responsive documents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Attorney&#x2019;s Office for the Southern District of New York related to JPI&#x2019;s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI's pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act. The Company has provided documents in response to the demand. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2016, Johnson &amp;amp; Johnson and Janssen Products LP were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and INTELENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and anti-kickback violations in connection with the promotion of these products.&#160;The complaint was filed under seal in December 2012.&#160;The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators.&#160; In February 2021, the Court stayed the case and ordered mediation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or SIMPONI ARIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April and September 2017, Johnson &amp;amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, OLYSIO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, STELARA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&#160;The subpoenas also seek documents relating to&#160;Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, Johnson &amp;amp; Johnson received a subpoena from the United States Attorney's Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc.(DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hospitals. Johnson &amp;amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2018 the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp;amp; Johnson do Brasil Ind&#xfa;stria e Com&#xe9;rcio de Produtos para Sa&#xfa;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp;amp; Johnson to cooperate with these inquiries by producing the requested information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GENERAL LITIGATION&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2018, a purported class action was filed in the Circuit Court Third Judicial District Madison County, Illinois against Johnson &amp;amp; Johnson Consumer, Inc. (JJCI), alleging violations of state consumer fraud statutes based on nondisclosure of alleged health risks associated with talc contained in JOHNSON'S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Baby Powder. The complaint seeks damages but does not allege personal injury. In October 2020, JJCI moved to dismiss the complaint.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2013, Janssen Ortho LLC (Janssen Ortho) sued the United States in the United States Court of International Trade (the Classification Litigation) seeking a determination that darunavir ethanolate (the active pharmaceutical ingredient in PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;) is exempt from duties upon importation into the United States.  In August 2014, United States Customs and Border Protection (US CBP) issued a Penalty Notice against Janssen Ortho LLC (Janssen Ortho), assessing penalties for the alleged improper classification of darunavir ethanolate (the active pharmaceutical ingredient in PREZISTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;) in connection with its importation into the United States. In February 2020, the Court in the Classification Litigation ruled that darunavir ethanolate is eligible for duty free treatment. In April 2020, the United States appealed that ruling to the United States Court of Appeals for the Federal Circuit. In August 2020, US CBP formally rejected Janssen&#x2019;s Supplemental Petition challenging the penalties assessment and demanded payment of the mitigated penalty. In October 2020, US CBP agreed to not refer the matter to the Office of Chief Counsel, pending resolution of the related Classification Litigation. In April 2021, the Federal Circuit denied the United States&#x2019; appeal in the Classification Litigation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp;amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. Discovery and pre-trial motion practice are complete. No trial date has been set.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2015, two third-party payors filed a purported class action in the United States District Court for the Eastern District of Louisiana against Janssen Research &amp;amp; Development, LLC, Janssen Ortho LLC, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson (as well as certain Bayer entities), alleging that the defendants improperly marketed and promoted XARELTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; as safer and more effective than less expensive alternative medications while failing to fully disclose its risks. The complaint seeks damages. In November 2020, Defendants moved to dismiss the complaint. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, Pfizer, Inc. (Pfizer) filed an antitrust complaint against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in United States District Court for the Eastern District of Pennsylvania.  Pfizer alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The complaint seeks damages and injunctive relief. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The cases were consolidated for pre-trial purposes as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; In re REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Antitrust Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in United States District Court for the Eastern District of Pennsylvania. The consolidated complaint seeks damages and injunctive relief.  Discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania.  The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decision. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp;amp; Johnson in connection with its investigation of whether Janssen&#x2019;s REMICADE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp;amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act.  The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2021, plaintiffs appealed the District Court&#x2019;s decision to the United States Court of Appeals for the District of Columbia Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia.&#160;The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160; TRACLEER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product.&#160; In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.&#160; In October 2019, the Court granted Actelion&#x2019;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp;amp; Development, LLC, and Johnson &amp;amp; Johnson (collectively, Janssen) were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; complaint filed on behalf of the United States, 28 states, and the District of Columbia.&#160;The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to the government in connection with direct government sales and government-funded drug reimbursement programs.&#160;At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. In September 2019, Janssen moved to dismiss the complaint. In February 2021, the judge has set a renewed schedule for the Company's motion to dismiss, with briefs to be fully submitted by early July 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, Blue Cross &amp;amp; Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research &amp;amp; Development, LLC (collectively, Janssen) and BTG International Limited in the United States District Court for the Eastern District of Virginia on behalf of indirect purchasers of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Several additional complaints were filed thereafter in Virginia and New Jersey.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The indirect purchaser complaints generally allege that the defendants violated the antitrust and consumer protections laws of several states and the Sherman Act by pursuing patent litigation relating to ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in order to delay generic entry and seek damages. The Virginia cases have been transferred to the United States District Court for the District of New Jersey and consolidated with the New Jersey case. A consolidated amended complaint was filed in February 2021. In April 2021, Janssen moved to dismiss the Indirect Purchaser Action. In May 2020, a class action complaint was filed against Janssen Biotech Inc., Janssen Oncology, Inc., Janssen Research &amp;amp; Development LLC and BTG International Limited in the United States District Court for the District of New Jersey, on behalf of direct purchasers of ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The direct purchaser complaint alleges that defendants violated the Sherman Act by pursuing patent litigation relating to ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in order to delay generic entry, and seek damages and injunctive relief. In April 2021, Janssen moved to compel arbitration of the Direct Purchaser Action.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2019, a class action antitrust complaint was filed against Janssen R&amp;amp;D Ireland (Janssen) and Johnson &amp;amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#x2019; motions to dismiss.  Plaintiffs filed an amended complaint in April 2020. Defendants moved to &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;dismiss the amended complaint.  In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#x2019;s&#160;business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;In August 2020, the Court granted in part and denied in part BWI&#x2019;s motion to dismiss. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, Johnson &amp;amp; Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp;amp; Johnson, Inc. received a demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between J&amp;amp;J, Inc. and Sanofi. In January 2020, Johnson &amp;amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim.  The notices seek indemnification for legal claims related to over-the-counter ZANTAC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp;amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#x2019;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2020, Ethicon moved to dismiss certain causes of action in the complaint. Oral argument on the motion to dismiss is scheduled for June 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ic5b57e148881429fbffa7b15c1969483_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDU3NQ_cc46594a-91e6-4652-943b-b13ca3f87853"
      unitRef="claimant">300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i32c65ab8cb634ad9bd5a0e2f7d30a359_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDczOQ_57dc9e0d-065f-4ea3-a69b-6fe372c1b221"
      unitRef="claimant">7000</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="icd5cde0149284609a90fe89bccf88fe6_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDc5NQ_cd22959a-1aca-44ad-847f-14531c7e3729"
      unitRef="claimant">12200</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i08582f9cef4d4567a55ffdc339dd9b58_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDgyOQ_4cafa555-3418-4bb5-9359-cc343e91a314"
      unitRef="claimant">9200</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i4720b5ba970c4ae58eeca3720feaa0b3_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDg2MA_d769b5ce-5e42-453c-8486-1b9ea256f607"
      unitRef="claimant">10200</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ibaeacf387226456196518be5d4285e6c_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDg4OQ_62208040-52e4-4dc0-a82c-9b3e28bbb48b"
      unitRef="claimant">28900</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="if6fb78dabc7c431c8db3fa456cae770d_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDkzOA_beca68ed-2dcd-4400-9050-e1985be5dc94"
      unitRef="claimant">300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i41413d437f794ec3a9f045f6a27f2722_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNDk3Mw_1d36cbec-18b5-499a-b009-01df2a984bad"
      unitRef="claimant">4400</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:Numberofpatientsinsettlement
      contextRef="ifd2cd7a8594949e083f88b8b79935b39_I20210404"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODUyOA_c2e1ec14-93f4-4def-8fca-36528c1bb86e"
      unitRef="patient">10000</jnj:Numberofpatientsinsettlement>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i9b1fe073177c4b3ab83e3d3452139524_D20191001-20191031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODQ4MA_80f6839f-b504-465b-8bac-f0acc568b365"
      unitRef="usd">8000000000.0</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i13f02d9a0d3b4b66a1c40f110cbc1e1e_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODUwNw_59cfde30-6395-4f39-b489-89815b81c04b"
      unitRef="usd">6800000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i6d9b48d0973f493eb3ab6b9a6476c385_D20180701-20180731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODU0OQ_a4d6a48f-e302-4409-9a47-f8a4a3281c7a"
      unitRef="usd">4700000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i709811f027d74897b86c8f1d12b504ed_D20200601-20200628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODU3Ng_b6b8bb25-4bda-4cdf-bb6a-2a789bffa15a"
      unitRef="usd">2100000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i62bf76445bd948c38790ffcd119476a4_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODYwMw_018f0965-e04e-40d4-a9c8-36c825de337e"
      unitRef="usd">2500000000</us-gaap:LossContingencyDamagesSoughtValue>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i5db493405e0444d89bf7eaab26517bde_I20210404"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfNjA0NzMxNDI2Mzg4Ng_05c5045e-705b-45be-8424-e908137b0735"
      unitRef="claimant">3200</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i6e04dd168b1041b3919b1a56f47b4ecf_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODYzNg_8d7638d4-e871-45a5-964c-d2aab6501091"
      unitRef="usd">465000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i2f0753d19d5149c091394208cbea890d_I20191031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODY2MQ_84b1c0d2-5f67-4ba3-a631-35b8e3b20bc8"
      unitRef="usd">4000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <jnj:LossContingencyEstimateOfAdditionalPossibleLoss
      contextRef="i851c9cc374994813ad167606b1ea44ed_I20201031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODY4NA_b480c3db-cffe-4c1c-8bee-1529f476dea7"
      unitRef="usd">1000000000</jnj:LossContingencyEstimateOfAdditionalPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i851c9cc374994813ad167606b1ea44ed_I20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODcwNw_4d6c4f1c-51c4-4137-b898-2c0adc600dcc"
      unitRef="usd">5000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="id807403c46b245c9bd8b6055a4d42cef_D20200120-20200120"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODczMg_76b0567d-cd88-418d-9693-960e5251ae8b"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="id807403c46b245c9bd8b6055a4d42cef_D20200120-20200120"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85MS9mcmFnOmI3ZjYwNTJiYTk5ZjRmM2U4ZTU3ZGY2Y2Q1NTA5YTAyL3RleHRyZWdpb246YjdmNjA1MmJhOTlmNGYzZThlNTdkZjZjZDU1MDlhMDJfMTA5OTUxMTkzODc1OQ_c372c557-7e19-42f4-beac-c4a8f7c06de9"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMjgzMw_bd3d20fb-fe90-4cb3-b6f7-3da7fb5e6536">RESTRUCTURING&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal first quarter of 2021, the Company recorded a pre-tax charge of $104 million, which is included on the following lines of the Consolidated Statement of Earnings, $53 million in restructuring, $27 million in cost of products sold and $24 million in other (income) expense, net.  Total project costs of approximately $1.4 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal first quarter of 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, April 4, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash outlays for severance are expected to be substantially paid out over the next 18 months in accordance with the Company's plans and local laws. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="ic02f715544ff4105bfd2a3c2d151ac0c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfNzg0_651cfae2-98e2-4909-a8d3-29297b2d9042"
      unitRef="usd">104000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i3b908089cc6a4f068612a9b2d5d34ca1_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfODcy_2ccb7632-7b59-4d81-9ddd-4c769f6bca80"
      unitRef="usd">53000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i96add54e896749258f1ad0c9536687a7_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfODkz_c5bc46f9-ad98-42c6-93f4-6bc87d4f3643"
      unitRef="usd">27000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i8a22a8f09eac408299c442ea44cab0af_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfOTI1_d910f022-b0e3-4dcc-83e3-4733740240a1"
      unitRef="usd">24000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i1552e8f8c0724beea6478ac55c3106db_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTIzOQ_3ce8ce0f-b9c2-486b-bc83-18d07be9c704"
      unitRef="usd">1400000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="i95abcc6431244e8a90f59ff7792cfc79_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTQ2Nw_096036c5-86c8-4445-859f-02dfccee0ba4"
      unitRef="usd">600000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="i2e03a943b1aa425496029ce0733bd863_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTQ3Mw_0db62e5d-1fcb-42b6-8e84-5428632e5a9f"
      unitRef="usd">800000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i95abcc6431244e8a90f59ff7792cfc79_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTYzMA_1df48cce-d2da-4a5a-9e9e-3958c95f68b7"
      unitRef="usd">1900000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i2e03a943b1aa425496029ce0733bd863_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTYzNg_e1d59b39-3e6e-4307-bb27-a02459687fbe"
      unitRef="usd">2300000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <jnj:RestructuringandRelatedCostDurationofRestructuringPlan
      contextRef="i0290e1c992b748a9908d71498dc82a4e_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTY0OQ_3eed4464-20b3-497f-bab4-6c0b75a9dd5b">P4Y</jnj:RestructuringandRelatedCostDurationofRestructuringPlan>
    <jnj:RestructuringandRelatedCostDurationofRestructuringPlan
      contextRef="i3aabc22a7d5a4aa597cd7da431d465a3_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMTY1NQ_4a7aeb8a-cf09-4ce6-a5db-ca65e0f37a7f">P5Y</jnj:RestructuringandRelatedCostDurationofRestructuringPlan>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="if3112eec8604498ba5d3696f0c29928c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMjgzNg_38006719-e87e-4112-a76c-7c9be5b73aae">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal first quarter of 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, April 4, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash outlays for severance are expected to be substantially paid out over the next 18 months in accordance with the Company's plans and local laws. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i8f3ba126d47a4b5a846574f6d9d31fa6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfMS0xLTEtMS0w_29876180-da8d-40a9-8ca0-6dd6a8c35ac9"
      unitRef="usd">135000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib0b5e6d446af4a1ca2c03a629dbf4eae_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfMS0yLTEtMS0w_888b1133-368d-4cf9-a6ca-db5f4708d9c4"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i009c62493dd242ae928d25a27ed97197_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfMS0zLTEtMS0w_d798b258-1383-462d-9d8a-595e17379cd7"
      unitRef="usd">9000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i36ee9965a40148bda5e997a88d5d4930_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfMS01LTEtMS0w_2578bfb7-7c92-4762-b327-31ba8831035a"
      unitRef="usd">144000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i52afe008fb4f4c819028d3daabd32602_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNC0xLTEtMS0w_fe517f03-b112-44dd-94ed-65b175bef25c"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i50377f6db9174c48a6ce24be02ba8d60_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNC0yLTEtMS0w_46415dfc-5002-4cb9-a8f7-bb15fbb11413"
      unitRef="usd">14000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="idca084b4733440fcbbf545f29821a06d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNC0zLTEtMS0w_7948963f-6cc2-4ac6-8b65-25810ebd3276"
      unitRef="usd">90000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i0856470384d143029d8218bb9189e71f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNC01LTEtMS0w_6d763948-c60d-400d-8ef5-7fc28763f570"
      unitRef="usd">104000000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i52afe008fb4f4c819028d3daabd32602_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNS0xLTEtMS0w_5bd6b2b5-9933-4756-a226-ccea840cc7f7"
      unitRef="usd">5000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i50377f6db9174c48a6ce24be02ba8d60_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNS0yLTEtMS0w_62415707-f853-4019-983c-6c48cf93e0be"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="idca084b4733440fcbbf545f29821a06d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNS0zLTEtMS0w_bf9f4a6a-39ba-4be1-b574-53b36270552b"
      unitRef="usd">91000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i0856470384d143029d8218bb9189e71f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNS01LTEtMS0w_39117638-9452-4d30-97e9-cb4538e19ad5"
      unitRef="usd">96000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i52afe008fb4f4c819028d3daabd32602_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNi0xLTEtMS0w_29011527-8cc9-4e9a-9a14-e7be16b2c7be"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i50377f6db9174c48a6ce24be02ba8d60_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNi0yLTEtMS0w_8619354f-74b4-4499-8685-4a5fc6968fe4"
      unitRef="usd">14000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="idca084b4733440fcbbf545f29821a06d_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNi0zLTEtMS0w_9fde788d-8e51-4a20-b5d7-2c568dc54fbc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i0856470384d143029d8218bb9189e71f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfNi01LTEtMS0w_e8e70170-d0b6-4d62-905b-40d87b06b93f"
      unitRef="usd">14000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserve
      contextRef="ic1cbff6b8f7d426ab49cc6dad88e6c0f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfOS0xLTEtMS0w_4a8781e1-ac47-4a69-b1bf-f58ac604c15b"
      unitRef="usd">130000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i378ddce2634145fcb6a28fcfb5b8592e_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfOS0yLTEtMS0w_9fa6c446-95bf-4914-8410-2cbaea64703e"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ia10eefa077224d8094f6feb17315c535_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfOS0zLTEtMS0w_2901b60b-c59b-48bb-b4ce-4c6242be10a0"
      unitRef="usd">8000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i9d58eb1fecdb4c148121d9d91c2a78c6_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RhYmxlOjJjMzdhMmMyMDVkNTRlNWM4NWJhZWQxMzlkYzc4YWFhL3RhYmxlcmFuZ2U6MmMzN2EyYzIwNWQ1NGU1Yzg1YmFlZDEzOWRjNzhhYWFfOS01LTEtMS0w_9bac5f5e-bf1b-4220-b31e-4557e349e741"
      unitRef="usd">138000000</us-gaap:RestructuringReserve>
    <jnj:RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid
      contextRef="i0856470384d143029d8218bb9189e71f_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2OTlkNzAyNTNiNDRiOWZiYzIwYWU1NjEwZGY0ZTY5L3NlYzowNjk5ZDcwMjUzYjQ0YjlmYmMyMGFlNTYxMGRmNGU2OV85NC9mcmFnOjJiMWNlM2E3N2NmYzQwNjdhYTc1YjdhY2ZmYTQ2NWU1L3RleHRyZWdpb246MmIxY2UzYTc3Y2ZjNDA2N2FhNzViN2FjZmZhNDY1ZTVfMjAyMg_2df13f9e-9075-414b-8804-dd06c4e493db">P18M</jnj:RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429625682968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Apr. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  04,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Johnson & Johnson<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1024240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Johnson & Johnson Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Brunswick<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">524-0400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,633,396,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000200406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, Par Value $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.250NotesDue2022Member', window );">0.250% Notes Due January 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.250% Notes Due January 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes Due May 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.650% Notes Due May 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes Due November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">5.50% Notes Due November 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24BP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes Due November 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.150% Notes Due November 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes Due May 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.650% Notes Due May 2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.250NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.250NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429618703432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,671<span></span>
</td>
<td class="nump">$ 13,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">11,948<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, trade, less allowances for doubtful accounts and credit losses $270 (2020, $293)</a></td>
<td class="nump">14,938<span></span>
</td>
<td class="nump">13,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Note 2)</a></td>
<td class="nump">9,952<span></span>
</td>
<td class="nump">9,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">3,024<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">52,533<span></span>
</td>
<td class="nump">51,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment at cost</a></td>
<td class="nump">46,430<span></span>
</td>
<td class="nump">46,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(28,063)<span></span>
</td>
<td class="num">(28,038)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">18,367<span></span>
</td>
<td class="nump">18,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (Note 3)</a></td>
<td class="nump">51,110<span></span>
</td>
<td class="nump">53,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 3)</a></td>
<td class="nump">35,688<span></span>
</td>
<td class="nump">36,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred taxes on income (Note 5)</a></td>
<td class="nump">8,321<span></span>
</td>
<td class="nump">8,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,538<span></span>
</td>
<td class="nump">6,562<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">172,557<span></span>
</td>
<td class="nump">174,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">3,350<span></span>
</td>
<td class="nump">2,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,503<span></span>
</td>
<td class="nump">9,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">13,223<span></span>
</td>
<td class="nump">13,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued rebates, returns and promotions</a></td>
<td class="nump">11,919<span></span>
</td>
<td class="nump">11,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee related obligations</a></td>
<td class="nump">2,060<span></span>
</td>
<td class="nump">3,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes on income (Note 5)</a></td>
<td class="nump">1,877<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">40,932<span></span>
</td>
<td class="nump">42,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note 4)</a></td>
<td class="nump">30,263<span></span>
</td>
<td class="nump">32,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred taxes on income (Note 5)</a></td>
<td class="nump">6,507<span></span>
</td>
<td class="nump">7,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Employee related obligations (Note 6)</a></td>
<td class="nump">10,512<span></span>
</td>
<td class="nump">10,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term taxes payable (Note 5)</a></td>
<td class="nump">6,568<span></span>
</td>
<td class="nump">6,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">11,941<span></span>
</td>
<td class="nump">11,944<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">106,723<span></span>
</td>
<td class="nump">111,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock &#8212; par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)</a></td>
<td class="nump">3,120<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss) (Note 7)</a></td>
<td class="num">(15,328)<span></span>
</td>
<td class="num">(15,242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">116,508<span></span>
</td>
<td class="nump">113,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: common stock held in treasury, at cost (487,141,000 and 487,331,000 shares)</a></td>
<td class="nump">38,466<span></span>
</td>
<td class="nump">38,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">65,834<span></span>
</td>
<td class="nump">63,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 172,557<span></span>
</td>
<td class="nump">$ 174,894<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429625920088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">4,320,000,000<span></span>
</td>
<td class="nump">4,320,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,119,843,000<span></span>
</td>
<td class="nump">3,119,843,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">487,141,000<span></span>
</td>
<td class="nump">487,331,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429626392952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 22,321<span></span>
</td>
<td class="nump">$ 20,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SalesRevenueGoodsNetPercentToSales', window );">Sales to customers percent to sales</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">$ 7,063<span></span>
</td>
<td class="nump">$ 7,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CostOfGoodsSoldPercentToSales', window );">Cost of products sold percent to sales</a></td>
<td class="nump">31.70%<span></span>
</td>
<td class="nump">34.10%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 15,258<span></span>
</td>
<td class="nump">$ 13,629<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_GrossProfitPercentToSales', window );">Gross Profit Percent To Sales</a></td>
<td class="nump">68.30%<span></span>
</td>
<td class="nump">65.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">$ 5,432<span></span>
</td>
<td class="nump">$ 5,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SellingGeneralAndAdministrativeExpensePercentToSales', window );">Selling marketing and administrative expenses percent to sales</a></td>
<td class="nump">24.30%<span></span>
</td>
<td class="nump">25.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">$ 3,178<span></span>
</td>
<td class="nump">$ 2,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales', window );">Research and development expense percent to sales</a></td>
<td class="nump">14.20%<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (15)<span></span>
</td>
<td class="num">$ (67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_InvestmentIncomeInterestPercentToSales', window );">Interest income percent to sales</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net of portion capitalized</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_InterestExpensePercentToSales', window );">Interest expense, net of portion capitalized percent to sales</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">$ (882)<span></span>
</td>
<td class="num">$ (679)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherNonOperatingIncomeExpensePercentToSales', window );">Other (income) expense, net percent to sales</a></td>
<td class="num">(3.90%)<span></span>
</td>
<td class="num">(3.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring (Note 12)</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_Restructuringchargepercenttosales', window );">Restructuring charge percent to sales</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 7,429<span></span>
</td>
<td class="nump">$ 6,509<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales', window );">Earnings before provision for taxes on income percent to sales</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">31.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income</a></td>
<td class="nump">$ 1,232<span></span>
</td>
<td class="nump">$ 713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeTaxExpenseBenefitPercentToSales', window );">Provision for taxes on income (Note 5)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 6,197<span></span>
</td>
<td class="nump">$ 5,796<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_NetIncomeAttributableToParentPercentToSales', window );">Net earnings percent to sales</a></td>
<td class="nump">27.80%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (per share)</a></td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">$ 2.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net earnings per share</a></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>AVG. SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">2,631.6<span></span>
</td>
<td class="nump">2,633.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">2,672.7<span></span>
</td>
<td class="nump">2,671.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CostOfGoodsSoldPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of goods sold percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CostOfGoodsSoldPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_GrossProfitPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross profit percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_GrossProfitPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeTaxExpenseBenefitPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax expense benefit percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeTaxExpenseBenefitPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InterestExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InterestExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InvestmentIncomeInterestPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment income interest percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InvestmentIncomeInterestPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NetIncomeAttributableToParentPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income Attributable to Parent Percent to Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NetIncomeAttributableToParentPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherNonOperatingIncomeExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other non operating income expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherNonOperatingIncomeExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense excluding acquired in process cost percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Restructuringchargepercenttosales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring charge percent to sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Restructuringchargepercenttosales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesRevenueGoodsNetPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales revenue goods net percentage to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesRevenueGoodsNetPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SellingGeneralAndAdministrativeExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling general and administrative expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SellingGeneralAndAdministrativeExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429625463096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 6,197<span></span>
</td>
<td class="nump">$ 5,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation</a></td>
<td class="nump">276<span></span>
</td>
<td class="num">(1,519)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) arising during period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Employee benefit plans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax', window );">Prior service cost amortization during period</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax', window );">Gain (loss) amortization during period</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Derivatives &amp; hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) arising during period</a></td>
<td class="num">(522)<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to earnings</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="num">(595)<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(352)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 6,111<span></span>
</td>
<td class="nump">$ 5,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118948100&amp;loc=d3e30304-110892<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429626059112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Common Stock Issued Amount</div></th>
<th class="th"><div>Treasury Stock Amount</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 29, 2019</a></td>
<td class="nump">$ 59,471<span></span>
</td>
<td class="nump">$ 110,659<span></span>
</td>
<td class="num">$ (15,891)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (38,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">5,796<span></span>
</td>
<td class="nump">5,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(2,505)<span></span>
</td>
<td class="num">(2,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">595<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(1,711)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 29, 2020</a></td>
<td class="nump">61,294<span></span>
</td>
<td class="nump">112,901<span></span>
</td>
<td class="num">(16,243)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,484)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jan. 03, 2021</a></td>
<td class="nump">63,278<span></span>
</td>
<td class="nump">113,890<span></span>
</td>
<td class="num">(15,242)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">6,197<span></span>
</td>
<td class="nump">6,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(2,659)<span></span>
</td>
<td class="num">(2,659)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">542<span></span>
</td>
<td class="num">(920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(1,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Apr. 04, 2021</a></td>
<td class="nump">$ 65,834<span></span>
</td>
<td class="nump">$ 116,508<span></span>
</td>
<td class="num">$ (15,328)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (38,466)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429626655720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429626266312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 6,197<span></span>
</td>
<td class="nump">$ 5,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and intangibles</a></td>
<td class="nump">1,894<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset write-downs</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(983)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Net gain on sale of assets/businesses</a></td>
<td class="num">(580)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision</a></td>
<td class="num">(730)<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit losses and accounts receivable allowances</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">(1,604)<span></span>
</td>
<td class="num">(812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(695)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accrued liabilities</a></td>
<td class="num">(2,336)<span></span>
</td>
<td class="num">(2,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease in other current and non-current assets</a></td>
<td class="nump">2,522<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in other current and non-current liabilities</a></td>
<td class="num">(902)<span></span>
</td>
<td class="num">(329)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH FLOWS FROM OPERATING ACTIVITIES</a></td>
<td class="nump">4,074<span></span>
</td>
<td class="nump">3,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="num">(677)<span></span>
</td>
<td class="num">(625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from the disposal of assets/businesses, net (Note 10)</a></td>
<td class="nump">603<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired (Note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(5,994)<span></span>
</td>
<td class="num">(2,064)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales of investments</a></td>
<td class="nump">5,233<span></span>
</td>
<td class="nump">1,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities', window );">Credit support agreements activity, net</a></td>
<td class="nump">751<span></span>
</td>
<td class="nump">1,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other (primarily licenses and milestones)</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(257)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED BY INVESTING ACTIVITIES</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Dividends to shareholders</a></td>
<td class="num">(2,659)<span></span>
</td>
<td class="num">(2,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(1,438)<span></span>
</td>
<td class="num">(1,711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term debt</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term debt</a></td>
<td class="num">(475)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(1,001)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits', window );">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities', window );">Credit support agreements activity, net</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED BY FINANCING ACTIVITIES</a></td>
<td class="num">(5,125)<span></span>
</td>
<td class="num">(4,315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Decrease in cash and cash equivalents</a></td>
<td class="num">(1,314)<span></span>
</td>
<td class="num">(1,775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash equivalents, beginning of period</a></td>
<td class="nump">13,985<span></span>
</td>
<td class="nump">17,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">12,671<span></span>
</td>
<td class="nump">15,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of assets acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed and noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net cash paid for acquisitions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429617652248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign Currency Translation</a></td>
<td class="num">$ (319)<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Employee Benefit Plans</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives &amp; Hedges</a></td>
<td class="num">$ (157)<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429616157016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April 4, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#8217;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended April 4, 2021, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in the fiscal first quarter of 2021 that impacted the Company.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal first quarter of 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429617631272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">INVENTORIES <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.070%"><tr><td style="width:1.0%"/><td style="width:51.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429616087240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2020. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"/><td style="width:61.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,990&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,912&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,402&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of April&#160;4, 2021 was allocated by segment of business as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"/><td style="width:39.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions and divestitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at April 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.2 billion and $1.1&#160;billion for the fiscal first quarters ended April&#160;4, 2021 and March&#160;29, 2020, respectively. Intangible asset write-downs are included in Other (income) expense, net. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429617632952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTSThe Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges.  Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of April&#160;4, 2021, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $102 million net, primarily related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April&#160;4, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $41.2&#160;billion and $31.2&#160;billion, respectively. As of January&#160;3, 2021, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $37.8 billion and $30.6 billion, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;4, 2021, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $57&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investment hedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2021 and 2020, net of tax:</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters 2021 and 2020: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.532%"><tr><td style="width:1.0%"/><td style="width:34.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.896%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal first quarters ended in 2021 and 2020</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.961%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.791%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"/><td style="width:25.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.464%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity investments without readily determinable market values, $55 million of the decrease in the fair value reflected in net income were the result of impairments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Significant unobservable inputs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of April&#160;4, 2021 and January&#160;3, 2021 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.807%"><tr><td style="width:1.0%"/><td style="width:41.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(977)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,481 million, which are classified as Level 1 and contingent consideration of $633 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $589 million and $594 million, classified as non-current other liabilities as of April&#160;4, 2021 and January&#160;3, 2021, respectively.  Includes $11 million and $39 million classified as current liabilities as of April&#160;4, 2021 and January&#160;3, 2021, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a contingent consideration reversal of $983 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense, net. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of April&#160;4, 2021 comprised:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td style="width:1.0%"/><td style="width:22.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other reverse repurchase agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other sovereign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal year ended January&#160;3, 2021 the carrying amount was approximately the same as the estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of April&#160;4, 2021 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.415%"><tr><td style="width:1.0%"/><td style="width:43.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;4, 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 (750MM Euro 1.1757)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Notes due 2024 (500 MM GBP 1.3799)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028 (750MM Euro 1.1757)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035 (1.5B Euro 1.1757)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2050</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2060</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average effective interest rate on non-current debt is 2.98%.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the estimated fair value over the carrying value of debt was $5.4 billion at January 4, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current debt balance as of April 4, 2021 includes $0.3&#160;billion of commercial paper which has a weighted average interest rate of 0.12% and a weighted average maturity of two months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429704251032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rates for the fiscal first quarters of 2021 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2020 were 16.6% an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">d 11.0%, respectively. In 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF), which became effective on January 1, 2020. More information on the provisions of TRAF can be found in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. During the fiscal first quarter of 2020, the final canton where the Company maintains significant operations enacted TRAF legislation and, accordingly, the Company recorded an estimated deferred tax benefit of approximately $0.3 billion for the remeasurement of existing deferred tax liabilities offset by a related $0.2 billion increase in U.S. GILTI deferred taxes (1.3% net benefit to the effective tax rate).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the first fiscal quarter of 2020, the Company reversed a contingent consideration liability related to the 2019 Auris Health acquisition that benefited the effective tax rate by 1.9% (for additional details see Note 18 to the Consolidated Financial Statements in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January 3, 2021). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additionally, the Company had more income in higher tax jurisdictions relative to lower tax jurisdictions, as compared to the same period in the prior fiscal year. The Company also had additional tax benefits received from stock-based compensation that were either exercised or vested during each of the fiscal first quarters. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;4, 2021, the Company had approximately $3.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429704116664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pensions and Other Benefit Plans</a></td>
<td class="text">PENSIONS AND OTHER BENEFIT PLANS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.187%"><tr><td style="width:1.0%"/><td style="width:43.891%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.035%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company Contributions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Three Months Ended April&#160;4, 2021, the Company contributed $24 million and $10 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429615771464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE INCOME<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"/><td style="width:34.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.991%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429616057880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">EARNINGS PER SHARE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.344%"><tr><td style="width:1.0%"/><td style="width:63.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.645%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The diluted net earnings per share calculation for the fiscal first quarter ended April&#160;4, 2021 excluded 9 million shares related to stock options, as the exercise price of these options was greater than their average market value. In the fiscal first quarter ended April&#160;4, 2021, the Company did not have convertible debt.</span></div>The diluted net earnings per share calculation for the fiscal first quarter ended March&#160;29, 2020 excluded 10&#160;million shares related to stock options, as the exercise price of these options was greater than their average market value. The diluted net earnings per share calculation for the fiscal first quarter ended March&#160;29, 2020 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429617638776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 29, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments of Business and Geographic Areas</a></td>
<td class="text">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 vaccine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> /  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                         </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">                     REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVEGA   TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT  </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.415%"><tr><td style="width:1.0%"/><td style="width:55.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.785%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Includes amortization expense of  $0.1 billion in both the fiscal first quarter of 2021 and 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes divestiture gains of $0.6&#160;billion in the fiscal first quarter of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes an unrealized loss on securities of $0.3&#160;billion in the fiscal first quarter of 2020. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes litigation expense of $0.1&#160;billion in the fiscal first quarter of 2020.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes amortization expense of $0.9&#160;billion and  $0.8 billion in the fiscal first quarter of 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.0&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a contingent consideration reversal of $1.0&#160;billion in the fiscal first quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a restructuring related charge of $0.1 billion in both the fiscal first quarter of 2021 and 2020, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes amortization expense of $0.3&#160;billion and $0.2&#160;billion in the fiscal first quarter of 2021 and 2020, respectively. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts not allocated to segments include interest income/expense and general corporate income/expense. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.684%"><tr><td style="width:1.0%"/><td style="width:47.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.190%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429618834024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">ACQUISITIONS AND DIVESTITURESIn the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6&#160;billion. During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $0.8 billion. XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. Additionally, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with world-class robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $0.4 billion, goodwill for $0.2 billion, other assets of $0.2 billion and liabilities assumed of $0.3 billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4 billion.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429616162056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text">LEGAL PROCEEDINGS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed.  The Company continues to monitor its legal proceedings as the situation evolves.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of April&#160;4, 2021, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant of these cases include: the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System; pelvic meshes; RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; body powders containing talc, primarily JOHNSONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Baby Powder; INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flexible Composite Mesh. As of April&#160;4, 2021, in the United States there were approximately 300 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR&#8482; XL Acetabular System and DePuy ASR&#8482; Hip Resurfacing System; 7,000 with respect to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System; 12,200 with respect to pelvic meshes; 9,200 with respect to RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; 10,200 with respect to XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; 28,900 with respect to body powders containing talc; 300 with respect to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 4,400 with respect to ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Flexible Composite Mesh.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> XL Acetabular System and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle </span><span style="color:#201f1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the class actions filed in that country</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and class actions in Israel, Australia and Canada,.  In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021. With respect to class members other than the Lead Applicants, the Federal Court will conduct an individual case assessment process that will require proof of use and causally related loss, although the form of that process has not yet been decided. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device.&#160; Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. Discovery is proceeding in these cases and certain of the cases are in preparation for trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Ventral Patch hernia mesh products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. Discovery is underway in these cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Ethicon and Johnson &amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE&#8482; Polypropylene Hernia System (PHS). In September 2019, plaintiffs&#8217; attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PHS cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those cases have also been transferred to an MCL in Atlantic County Superior Court. There are now approximately 304 cases pending in the MCL and discovery is underway in a subset of these cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Flexible Composite Mesh, PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Mesh and PROCEED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Ventral Patch, and PROLENE&#8482; Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff which the trial judge reduced to $6.8&#160;million in January 2020. The Company and plaintiff each are appealing this judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson; and JPI&#8217;s collaboration partner for XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson  &amp; Johnson announced an agreement in principle to settle the XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Personal injury claims alleging that talc causes cancer have been made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder. The number of pending personal injury lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits primarily have been filed in state courts in Missouri, New Jersey and California, and suits have also been filed outside the United States. The majority of cases are pending in federal court, organized into a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, the parties sought to exclude experts through Daubert motions. In April 2020, the Court issued rulings that limit the scope of testimony, including some theories and testing methods, for certain plaintiff expert witnesses and denied  plaintiffs&#8217; attempt to limit the scope of testimony of certain of the Company&#8217;s witnesses. With this ruling made, case-specific discovery has begun per the Court&#8217;s directive. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion and, with additional interest as of April 4, 2021, as the Company pursues further appeal, is approximately $2.5&#160;billion (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decision). An application for transfer of the case to the Missouri Supreme Court was subsequently denied. In March 2021, the Company filed a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decision by the United States Supreme Court. In April 2021, the Plaintiffs filed their opposition to the petition. The Company continues to believe that it has strong legal grounds for the appeal of this verdict, as well as other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. The Company has established an accrual for defense costs and reserves for the resolution of certain cases and claims, including the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decision currently on appeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in connection with product liability litigation associated with body powders containing talc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217; potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it alleges it has against the Company for indemnification and rights to joint insurance proceeds. The Company previously proposed to resolve Imerys' (and the Company&#8217;s) obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, waiving the Company&#8217;s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. In May 2020, Imerys and the asbestos claimants&#8217; committee (Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto agreeing to put its North American operations up for auction which was subsequently amended. The Company has objected to the Disclosure Statement and intends to object to the Plan of Reorganization as currently structured. Additionally, in June 2020, Cyprus Mines Corporation and its parent (Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company as well as Imerys seeking a declaration of indemnity under certain contractual agreements.  The Company denies such indemnification is owed and filed a motion to dismiss the adversary complaint arguing, among other things, that the Court does not have subject matter jurisdiction over Cyprus&#8217;s claims against the Company. The Plan Proponents filed numerous amendments to the Plan and Disclosure Statement to which the Company objected. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement for the Ninth Amended Joint Chapter 11 Plan of Reorganization of Imerys Talc America, Inc. and its Debtor Affiliates, allowing Debtors Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Debtors&#8217; Plan and opted out of the consensual releases in the Plan. Discovery with respect to the Debtors&#8217; Plan is ongoing and the Confirmation Hearing is set for August 2021. Relatedly, in February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and Cyprus filed its Disclosure Statement and Plan.  Also, in February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the &#8220;Coverage Action&#8221;) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action.  In March 2021, the Company filed a limited response and reservation of rights with respect to the motion.  The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"> Baby Powder, and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. In March 2021 briefing on Plaintiffs&#8217; motion for class certification was completed.  Discovery is ongoing.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:99%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:99%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp; Johnson&#8217;s motion to dismiss pending a decision on Plaintiff&#8217;s motion for discovery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"> Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete. In February 2021, the Court granted Defendants&#8217; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings.  In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the Abtahi Law Group filed an action under Proposition 65 against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Inc. as well as a number of other alleged talcum powder manufacturers and distributors, including one California company. In that action, the plaintiff alleges contamination of talcum powder products with unsafe levels of arsenic, hexavalent chromium and lead. The plaintiff seeks civil penalties and injunctive relief. Defendants filed a motion for summary judgment in January 2021, and a hearing on the motion was held in April 2021. Limited informal discovery is continuing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding talc matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company produced documents as required in response and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a prescription medication  indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including two putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Devices</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent&#8217;s RELIEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Spin and RELIEVEA SpinPlus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products infringe U.S. Patent No. 9,011,412.  Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent&#8217;s U.S. Patent No. 8,414,473. Trial is scheduled to begin in October 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC (collectively, Ethicon) alleging the manufacture and sale of VICRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures, MONOCRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures, PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures, STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Antibacterial Sutures and STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> MONOCRYL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plus Antibacterial Sutures infringe plaintiffs&#8217; United States Patent Nos. 6,596,296 (&#8217;296) and 7,033,603 (&#8217;603) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UT is seeking damages and an injunction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the USPTO denied institution of the &#8217;296 patent IPR and granted institution of the &#8217;603 patent IPR.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UT dismissed the &#8217;603 patent from the suit and no longer accuses PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures or STRATAFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> PDS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Plus Antibacterial Sutures of infringement. The previously scheduled district court trial has been postponed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#8217;200); 6,491,701 (&#8217;701); 6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447); 8,620,473 (&#8217;473); 8,801,601 (&#8217;601); and 9,452,276 (&#8217;276) based on Auris&#8217; Monarch&#8482; Platform.  Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#8217;200, &#8217;056, &#8217;601 &#8217;701, &#8217;447, &#8217;276 and &#8217;906 patents. Intuitive subsequently dropped the &#8217;200, &#8217;473 and &#8217;701 patents from the suit.  In December 2019, the USPTO instituted review of the &#8217;601 patent and denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the &#8217;200, &#8217;447, &#8217;701 and &#8217;906 patents and denied review of the &#8217;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#8217;601 patent to be invalid.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intuitive has appealed that decision. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris has appealed that decision. The District Court postponed trial until the appeal of the invalidity decision on the &#8217;601 patent is complete. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA&#8482; Spacer, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ZERO-P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Spacer, ZERO-P NATURAL&#8482; Plate, SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> LR Spacer and SYNFIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. In June 2020, the case was stayed pending IPR proceedings filed by the Consolidated Defendants involving the asserted patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, Osteoplastics, LLC filed a patent infringement suit against DePuy Synthes, Inc., DePuy Synthes Products, Inc., Medical Device Business Services, Inc., and Synthes, Inc. (collectively, DePuy Synthes) in the United States District Court for the District of Delaware. In the suit, Osteoplastics alleges willful infringement of U.S. Patent Nos. 8,781,557; 9,929,920; 9,330,206; 9,626,756; 9,672,617; 9,672,302; and 9,275,191 based on the PROPLAN CMF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Virtual Surgical Planning Services and the TruMatch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CMF Personalize Solutions. In April 2020, Osteoplastics filed an amended complaint to substitute U.S. Patent No. 9,292,920 for U.S. Patent No. 9,929,920.  Osteoplastics seeks monetary damages and injunctive relief. In June 2020, DePuy Synthes filed a motion to dismiss the complaint. In October 2020, the Court dismissed Medical Device Business Services, Inc. from the case but otherwise denied the motion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trial is scheduled for October 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits pending against generic companies that have filed ANDAs with the FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the third-party companies involved would have the ability, upon approval of the FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Janssen Inc. and Janssen Oncology Inc. (collectively, Janssen) initiated a Notice of Application under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) and the Minister of Health in Canada in response to Apotex&#8217;s filing of an Abbreviated New Drug Submission (ANDS) seeking approval to market a generic version of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of Canadian Patent No. 2,661,422 (&#8217;422). The final hearing concluded in May 2019.  In October 2019, the Court issued an order prohibiting the Canadian Minister of Health from approving Apotex&#8217;s ANDS until the expiration of the &#8217;422 patent. In November 2019, Apotex filed an appeal, which was dismissed in March 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in January 2019, Janssen initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex, Pharmascience Inc. (Pharmascience) and Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;422 patent. The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In August 2020, Janssen initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (Jamp) in Canada in response to Jamp&#8217;s filing of an ANDS seeking approval to market a generic version of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> before the expiration of the &#8217;422 patent. In March 2021, the parties entered into a confidential settlement agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen is seeking an order enjoining the defendants from marketing their generic versions of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;422 patent.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin) which filed an ANDA seeking approval to market a generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before expiration of U.S. Patent No. 10,828,310 (&#8217;310). In this lawsuit, JPI and Bayer are seeking an order enjoining Lupin from marketing their generic version of XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;310 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in July 2017, Janssen Pharmaceuticals, Inc., Janssen Research &amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR before expiration of MTPC&#8217;s United States Patent Nos. 7,943,582 (&#8217;582) and/or 8,513,202 (&#8217;202) relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and/or INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> XR. Janssen is the exclusive licensee of the asserted patents. Named defendants include MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc. (MSN); Zydus Pharmaceuticals (USA) Inc. (Zydus). These cases were consolidated into one action (Polymorph Main Action), which has been scheduled for trial starting in July 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">In July 2017, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Zydus which filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">and INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">before expiration of MTPC&#8217;s United States Patent No. 7,943,788 (&#8217;788), 8,222,219 (&#8217;219) and/or 8,785,403 (&#8217;403) relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">and INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:99%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%"> (Compounds Main Action). Janssen is the exclusive licensee of the asserted patents. Trial concluded in October 2020. The Court issued a decision holding that the patents are not invalid and would be infringed by Zydus&#8217; generic products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2019, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;582 patent and &#8217;202 patent relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against MSN, which filed ANDAs seeking approval to market generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;788 patent. In October 2019, Janssen and MTPC initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;788 patent. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of the &#8217;582 patent and &#8217;202 patent relating to INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In February 2021, Janssen filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before expiration of United States Patent No. 10,617,668 relating to INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. These lawsuits have not been consolidated with the Polymorph Main Action or Compound Main Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">In each of these U.S. lawsuits, Janssen and MTPC are seeking an order enjoining the defendant from marketing their generic versions of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">, INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"> and/or, INVOKAMET XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:102%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the Canadian Patent Nos. 2,799,204, 2,534,024 and 2,671,357. Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an order enjoining Sandoz from marketing its generic version of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents. The trial is scheduled to begin in August 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Trial is scheduled to begin in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Trial is scheduled to begin in February 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg before the expiration of the &#8217;770 patent and Canadian Patent No. 2,621,273 (&#8217;273). Trial is scheduled to begin in April 2022.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of United States Patent No. 9,439,906 (&#8217;906).  Trial concluded in October 2020, and closing arguments were made in March 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;906 patent. In February 2020, Mylan filed a Petition for Inter Partes Review with the USPTO seeking to invalidate the &#8217;906 patent. The USPTO denied the Petition in September 2020, and Mylan appealed. Janssen filed a motion to dismiss the appeal, which was granted in March 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, would infringe claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid for obviousness. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.'s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement is scheduled for November 2021. The trial is scheduled to begin in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in response to Apotex's filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement is scheduled for December 2021. The trial is scheduled to begin in September 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LCC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before expiration of United States Patent No. 10,143,693 relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Janssen is seeking an order enjoining Mylan from marketing a generic version of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before the expiration of the relevant patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Beginning in January 2018, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies that filed ANDAs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> 140 mg capsules before expiration of Pharmacyclics&#8217;  United States Patent Nos. 8,008,309, 7,514,444, 8,697,711, 8,735,403, 8,957,079, 9,181,257, 8,754,091, 8,497,277, 8,925,015, 8,476,284, 8,754,090, 8,999,999, 9,125,889, 9,801,881, 9,801,883, 9,814,721, 9,795,604, 9,296,753, 9,540,382, 9,713,617 and/or 9,725,455 relating to IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:103%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">. JBI is the exclusive licensee of the asserted patents. The named defendants include the following generic companies: Cipla Limited and Cipla USA Inc. (collectively, Cipla); Sandoz Inc. and Lek Pharmaceuticals d.d. (collectively, Sandoz).  In January 2019 and February 2019, Pharmacyclics and JBI amended their complaint against Sandoz and Cipla, respectively, to allege infringement of United States Patent Nos. 10,125,140 and 10,106,548. In May 2019, Pharmacyclics and JBI amended their complaint against Cipla to further allege infringement of United States Patent No. 10,016,435. In August 2019, Pharmacyclics and JBI amended their complaints against Cipla and Sandoz to further allege infringement of U.S. Patent Nos. 10,294,231 and 10,294,232. In August 2019, the Court granted a joint stipulation to stay the litigation against Cipla.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,003,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trial in the foregoing actions against Sandoz and Alvogen took place in October 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen asserting infringement of United States Patent No. 10,478,439. In October 2020, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of U.S. Patent No. 10,653,696. In April 2021, the court entered a joint stipulation dismissing the complaint against Alvogen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, Pharmacyclics and JBI filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Zydus Worldwide DMCC and Cadila Healthcare Limited (collectively, Zydus), which filed an ANDA seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tablets, asserting infringement of United States Patent Nos. 7,514,444, 8,008,309, 8,476,284, 8,497,277, 8,697,711, 8,753,403, 8,754,090, 8,754,091, 8,952,015, 8,957,079, 9,181,257, 9,296,753,  9,655,857, 9,725,455, 10,010,507, 10,106,548, 10,125,140, 10,213,386 and 10,478,439. In March 2021, JBI, Pharmacyclics and Zydus entered into a confidential settlement agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of the lawsuits, Pharmacyclics and JBI are seeking an order enjoining the defendants from marketing generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, Actelion Pharmaceuticals Ltd (Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against a number of generic companies that filed ANDAs seeking approval to market generic versions of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before expiration of Nippon Shinyaku&#8217;s United States Patent Nos. 7,205,302; 8,791,122; and 9,284,280 relating to UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actelion is the exclusive licensee of the asserted patents. The defendants include Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals Inc. (collectively, Alembic); and Zydus Pharmaceuticals (USA), Inc. and Zydus Worldwide DMCC (collectively, Zydus). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actelion and Nippon Shinyaku are seeking an order enjoining the defendants from marketing generic versions of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial.  In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in more than 3,200 lawsuits related to the marketing of opioids, including DURAGESIC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NUCYNTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia and Wisconsin. The Government of Puerto Rico filed suit in Superior Court of San Juan. There are more than 380 cases pending in various state&#160;courts. There are over 2,800 federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio.&#160;In addition, the Province of British Columbia filed suit in Canada. In October 2019, an anti-trust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $465&#160;million. Johnson &amp; Johnson and JPI have appealed the judgment. The Company believes that it has strong grounds to overturn this judgment. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial is scheduled to last up to three months. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson, JPI and other pharmaceutical companies have also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement in principle is not an admission of liability or wrong-doing and would resolve opioid lawsuits filed </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and future claims by states, cities and counties. The Company has made progress towards negotiating a final settlement with a coalition of state Attorneys General. The Company cannot predict if or when the agreement will be finalized and individual cases are ongoing. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Johnson &amp; Johnson received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums.&#160;In September 2020, the Company learned that NYDFS filed a statement of charges related to this investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In May 2020, the shareholder filed an amended complaint challenging the Board&#8217;s rejection of his demand. In August 2020, Johnson &amp; Johnson moved to dismiss the amended complaint. In February 2021, the Court held oral argument on Johnson &amp; Johnson's motion. In August 2020, another shareholder who sent a demand filed a separate derivative complaint in the same court making similar allegations. In October 2020, the Court granted defendants&#8217; request to reassign the second-filed case to the division where the first-filed case is pending. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, two additional shareholders who sent demands filed two separate derivative complaints making similar allegations against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the United States District for the District of New Jersey. In April 2020, the two federal cases were consolidated into a single action captioned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> In re Johnson &amp; Johnson Opioid Stockholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In July 2020, the shareholders filed a consolidated complaint. In September 2020, Johnson &amp; Johnson moved to dismiss the consolidated complaint, and in December 2020, the shareholders opposed Johnson &amp; Johnson&#8217;s motion. Johnson &amp; Johnson filed its reply in February 2021. In July 2020, an additional shareholder who sent a demand filed a derivative complaint in the same federal court making similar allegations against the same defendants named in the consolidated action. In January 2021, pursuant to an order in the consolidated action, the third case was consolidated into the consolidated action. In February 2021, the Court granted the shareholders motion to voluntarily dismiss the consolidated action without prejudice. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney's Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR&#8482; XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. The relators&#8217; remaining claims are now pending before the District Court. In July 2020, the Court ordered the relators to complete discovery by August 2020; the Relators have requested an extension of the August 2020 deadline that DePuy opposed and additional discovery-related motions have been filed by both parties since. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint. In March 2021, the District Court issued an order stating that if DePuy&#8217;s motion to strike and dismiss is denied, the court will hold a conference at which a limited period for remaining discovery will be established.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General's office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson's subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson and Ethicon settled the Washington case. The California case started trial in July 2019 and concluded in September 2019. The trial date for the Kentucky case was scheduled for September 2019 but has been adjourned and no new trial date has been scheduled. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company's motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company is appealing the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">penalty judgment. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon.  In November 2020, the Company settled with the Attorney General of Mississippi. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (JJCI).&#160;The complaint alleges that defendants violated the Mississippi Consumer Protection Act by </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">failing to disclose alleged health risks associated with female consumers' use of talc contained in JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Baby Powder and JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The matter is stayed pending interlocutory appeal of a December 2018 denial of Johnson &amp; Johnson and JJCI's motion for summary judgment. The Mississippi Supreme Court granted Johnson &amp; Johnson and JJCI's request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. In April 2021, the Mississippi Supreme Court dismissed the Company&#8217;s interlocutory appeal and remanded the case back to the Hinds County Chancery Court. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. The New Mexico Attorney General has issued requests for documents and the Company anticipates the document production will commence in mid-2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-two states have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has entered into a tolling agreement with the States and has begun to produce responsive documents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, Janssen Pharmaceuticals, Inc. (JPI) received a Civil Investigative Demand from the United States Attorney&#8217;s Office for the Southern District of New York related to JPI&#8217;s contractual relationships with pharmacy benefit managers over the period from January 1, 2006 to the present with regard to certain of JPI's pharmaceutical products. The demand was issued in connection with an investigation under the False Claims Act. The Company has provided documents in response to the demand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, Johnson &amp; Johnson and Janssen Products LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and INTELENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and anti-kickback violations in connection with the promotion of these products.&#160;The complaint was filed under seal in December 2012.&#160;The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators.&#160; In February 2021, the Court stayed the case and ordered mediation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, OLYSIO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, SIMPONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#160;The subpoenas also seek documents relating to&#160;Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney's Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc.(DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospitals. Johnson &amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018 the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2018, a purported class action was filed in the Circuit Court Third Judicial District Madison County, Illinois against Johnson &amp; Johnson Consumer, Inc. (JJCI), alleging violations of state consumer fraud statutes based on nondisclosure of alleged health risks associated with talc contained in JOHNSON'S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Baby Powder. The complaint seeks damages but does not allege personal injury. In October 2020, JJCI moved to dismiss the complaint.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2013, Janssen Ortho LLC (Janssen Ortho) sued the United States in the United States Court of International Trade (the Classification Litigation) seeking a determination that darunavir ethanolate (the active pharmaceutical ingredient in PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) is exempt from duties upon importation into the United States.  In August 2014, United States Customs and Border Protection (US CBP) issued a Penalty Notice against Janssen Ortho LLC (Janssen Ortho), assessing penalties for the alleged improper classification of darunavir ethanolate (the active pharmaceutical ingredient in PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) in connection with its importation into the United States. In February 2020, the Court in the Classification Litigation ruled that darunavir ethanolate is eligible for duty free treatment. In April 2020, the United States appealed that ruling to the United States Court of Appeals for the Federal Circuit. In August 2020, US CBP formally rejected Janssen&#8217;s Supplemental Petition challenging the penalties assessment and demanded payment of the mitigated penalty. In October 2020, US CBP agreed to not refer the matter to the Office of Chief Counsel, pending resolution of the related Classification Litigation. In April 2021, the Federal Circuit denied the United States&#8217; appeal in the Classification Litigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. Discovery and pre-trial motion practice are complete. No trial date has been set.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2015, two third-party payors filed a purported class action in the United States District Court for the Eastern District of Louisiana against Janssen Research &amp; Development, LLC, Janssen Ortho LLC, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson (as well as certain Bayer entities), alleging that the defendants improperly marketed and promoted XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as safer and more effective than less expensive alternative medications while failing to fully disclose its risks. The complaint seeks damages. In November 2020, Defendants moved to dismiss the complaint. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Pfizer, Inc. (Pfizer) filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in United States District Court for the Eastern District of Pennsylvania.  Pfizer alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The complaint seeks damages and injunctive relief. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. The consolidated complaint seeks damages and injunctive relief.  Discovery is ongoing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania.  The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson in connection with its investigation of whether Janssen&#8217;s REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act.  The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2021, plaintiffs appealed the District Court&#8217;s decision to the United States Court of Appeals for the District of Columbia Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia.&#160;The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160; TRACLEER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product.&#160; In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland.&#160; In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed on behalf of the United States, 28 states, and the District of Columbia.&#160;The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the government in connection with direct government sales and government-funded drug reimbursement programs.&#160;At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. In September 2019, Janssen moved to dismiss the complaint. In February 2021, the judge has set a renewed schedule for the Company's motion to dismiss, with briefs to be fully submitted by early July 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Blue Cross &amp; Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research &amp; Development, LLC (collectively, Janssen) and BTG International Limited in the United States District Court for the Eastern District of Virginia on behalf of indirect purchasers of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Several additional complaints were filed thereafter in Virginia and New Jersey.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indirect purchaser complaints generally allege that the defendants violated the antitrust and consumer protections laws of several states and the Sherman Act by pursuing patent litigation relating to ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to delay generic entry and seek damages. The Virginia cases have been transferred to the United States District Court for the District of New Jersey and consolidated with the New Jersey case. A consolidated amended complaint was filed in February 2021. In April 2021, Janssen moved to dismiss the Indirect Purchaser Action. In May 2020, a class action complaint was filed against Janssen Biotech Inc., Janssen Oncology, Inc., Janssen Research &amp; Development LLC and BTG International Limited in the United States District Court for the District of New Jersey, on behalf of direct purchasers of ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The direct purchaser complaint alleges that defendants violated the Sherman Act by pursuing patent litigation relating to ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in order to delay generic entry, and seek damages and injunctive relief. In April 2021, Janssen moved to compel arbitration of the Direct Purchaser Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss.  Plaintiffs filed an amended complaint in April 2020. Defendants moved to </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">dismiss the amended complaint.  In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s&#160;business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc., pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson, Inc. received a demand for indemnification from Sanofi Consumer Health, Inc., pursuant to the 2016 Asset Purchase Agreement between J&amp;J, Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc., pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim.  The notices seek indemnification for legal claims related to over-the-counter ZANTAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2020, Ethicon moved to dismiss certain causes of action in the complaint. Oral argument on the motion to dismiss is scheduled for June 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson or its subsidiaries are also parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429618294280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">RESTRUCTURING<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal first quarter of 2021, the Company recorded a pre-tax charge of $104 million, which is included on the following lines of the Consolidated Statement of Earnings, $53 million in restructuring, $27 million in cost of products sold and $24 million in other (income) expense, net.  Total project costs of approximately $1.4 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal first quarter of 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:33.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, April 4, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out over the next 18 months in accordance with the Company's plans and local laws. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429620815480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April 4, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#8217;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended April 4, 2021, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standards Recently Adopted</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;3, 2021. There were no new material accounting standards issued in the fiscal first quarter of 2021 that impacted the Company.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal first quarter of 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy</a></td>
<td class="text">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429616024408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.070%"><tr><td style="width:1.0%"/><td style="width:51.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429617681224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"/><td style="width:61.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,990&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,912&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,402&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*The majority is comprised of customer relationships</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of April&#160;4, 2021 was allocated by segment of business as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"/><td style="width:39.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions and divestitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at April 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Intangible Asset Amortization Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429622120792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivative Activity</a></td>
<td class="text">The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2021 and 2020, net of tax:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal first quarters ended in 2021 and 2020</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Effect of Derivatives not Designated as Hedging Instruments</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.532%"><tr><td style="width:1.0%"/><td style="width:34.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.896%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Activity Related to Equity Investments</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"/><td style="width:25.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.464%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Financial Assets and Liabilities at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of April&#160;4, 2021 and January&#160;3, 2021 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.807%"><tr><td style="width:1.0%"/><td style="width:41.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(977)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2020 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,481 million, which are classified as Level 1 and contingent consideration of $633 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $589 million and $594 million, classified as non-current other liabilities as of April&#160;4, 2021 and January&#160;3, 2021, respectively.  Includes $11 million and $39 million classified as current liabilities as of April&#160;4, 2021 and January&#160;3, 2021, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. </span></div>The Company recorded a contingent consideration reversal of $983 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense, net.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of April&#160;4, 2021 comprised:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td style="width:1.0%"/><td style="width:22.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other reverse repurchase agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other sovereign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available for Sale Securities Maturities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of April&#160;4, 2021 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.415%"><tr><td style="width:1.0%"/><td style="width:43.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Financial Liabilities not Measured at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;4, 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 (750MM Euro 1.1757)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Notes due 2024 (500 MM GBP 1.3799)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028 (750MM Euro 1.1757)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035 (1.5B Euro 1.1757)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2050</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2060</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429626378696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.187%"><tr><td style="width:1.0%"/><td style="width:43.891%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.035%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429617377784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"/><td style="width:34.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.991%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429616151656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.344%"><tr><td style="width:1.0%"/><td style="width:63.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.645%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429626065144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas (Tables)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SalesBySegmentOfBusinessTableTextBlock', window );">Sales By Segment Of Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 vaccine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> /  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                         </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">                     REZOLSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / XEPLION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVEGA   TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / TREVICTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / INVOKAMET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;PROCRIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDICAL DEVICES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of VELCADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Operating Profit by Segment of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT  </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.415%"><tr><td style="width:1.0%"/><td style="width:55.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.785%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Includes amortization expense of  $0.1 billion in both the fiscal first quarter of 2021 and 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes divestiture gains of $0.6&#160;billion in the fiscal first quarter of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes an unrealized loss on securities of $0.3&#160;billion in the fiscal first quarter of 2020. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes litigation expense of $0.1&#160;billion in the fiscal first quarter of 2020.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes amortization expense of $0.9&#160;billion and  $0.8 billion in the fiscal first quarter of 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.0&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Devices </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a contingent consideration reversal of $1.0&#160;billion in the fiscal first quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes a restructuring related charge of $0.1 billion in both the fiscal first quarter of 2021 and 2020, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes amortization expense of $0.3&#160;billion and $0.2&#160;billion in the fiscal first quarter of 2021 and 2020, respectively. </span></div>(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.684%"><tr><td style="width:1.0%"/><td style="width:47.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.190%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesBySegmentOfBusinessTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesBySegmentOfBusinessTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8721-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429617485864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 04, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal first quarter of 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:33.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, April 4, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out over the next 18 months in accordance with the Company's plans and local laws. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429617634632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 1,557<span></span>
</td>
<td class="nump">$ 1,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Goods in process</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">6,361<span></span>
</td>
<td class="nump">5,894<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 9,952<span></span>
</td>
<td class="nump">$ 9,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429618355800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="nump">$ 17,849<span></span>
</td>
<td class="nump">$ 19,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets - net</a></td>
<td class="nump">51,110<span></span>
</td>
<td class="nump">53,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="nump">7,061<span></span>
</td>
<td class="nump">7,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember', window );">Purchased In-Process Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="nump">10,788<span></span>
</td>
<td class="nump">11,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">39,505<span></span>
</td>
<td class="nump">39,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="nump">18,006<span></span>
</td>
<td class="nump">17,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">21,499<span></span>
</td>
<td class="nump">22,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">22,793<span></span>
</td>
<td class="nump">22,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="nump">11,031<span></span>
</td>
<td class="nump">10,912<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 11,762<span></span>
</td>
<td class="nump">$ 11,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429625217992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Goodwill By Segment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">$ 36,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions and divestitures</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(705)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">35,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">10,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions and divestitures</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">10,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">11,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions and divestitures</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">10,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">15,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions and divestitures</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">$ 14,915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429618353064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of amortizable intangible assets</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429622146264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">4,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429625617384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">Accumulated other comprehensive income on derivatives, after tax</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss', window );">Reclassification of foreign exchange contracts into earnings, period</a></td>
<td class="text">next 12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Maximum length of time for hedge exposure</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate on non-current debt</a></td>
<td class="nump">2.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt', window );">Excess of the estimated fair value over the carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 3,350<span></span>
</td>
<td class="nump">2,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="nump">0.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">41,200<span></span>
</td>
<td class="nump">37,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">31,200<span></span>
</td>
<td class="nump">$ 30,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember', window );">Equity Investments without readily determinable value | Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentImpairmentLoss', window );">Equity, Fair Value Adjustment, Impairment Loss</a></td>
<td class="num">$ (55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of fair value over carrying value of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExcessOfFairValueOverCarryingValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429622304488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(193)<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(307)<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109974929&amp;loc=SL110061172-113977<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109974929&amp;loc=SL110061190-113977<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429618352792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Forward foreign exchange contracts | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain/(Loss) Recognized In Income on Derivative</a></td>
<td class="num">$ (16)<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429626814136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross Currency Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross Currency Interest Rate Contract | Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109974929&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429622292136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">$ 6,538<span></span>
</td>
<td class="nump">$ 6,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Equity Investments with readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, beginning of period</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Sales/ Purchases/Other</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, end of period</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Equity Investments without readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying value, beginning of period</a></td>
<td class="nump">738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Sales/ Purchases/Other</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying value, end of period</a></td>
<td class="nump">764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">$ 764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investment [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429621575864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">$ 1,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">14,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total Gross Assets</a></td>
<td class="nump">1,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(1,028)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,107)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total Net Asset</a></td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total Gross Liabilities</a></td>
<td class="nump">1,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(1,130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,172)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total Net Liabilities</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">$ 1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue', window );">Changes in estimated fair value (6)</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">14,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429620946024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">$ 14,493<span></span>
</td>
<td class="nump">$ 14,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">12,671<span></span>
</td>
<td class="nump">13,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">11,948<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and current marketable securities, Carrying Amount</a></td>
<td class="nump">24,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain', window );">Total cash, cash equivalents and current marketable securities, Unrecognized Gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss', window );">Total cash, cash equivalents and current marketable securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue', window );">Total cash, cash equivalents and current marketable securities, Estimated Fair Value</a></td>
<td class="nump">24,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">10,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">10,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">8,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Non-U.S. sovereign securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | U.S. reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Other reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">3,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">3,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">2,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">2,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Time deposits(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">14,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Unrecognized Gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">14,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">4,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">10,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Non-U.S. sovereign securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Unrecognized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov't securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">14,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale Securities, Unrecognized Gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">14,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">4,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 9,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments, Accumulated Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=jnj_OtherReverseRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=jnj_OtherReverseRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429626624136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Cost Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 14,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total debt securities</a></td>
<td class="nump">14,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">14,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total debt securities</a></td>
<td class="nump">$ 14,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth fiscal year through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429624425000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 3,350<span></span>
</td>
<td class="nump">$ 2,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">30,263<span></span>
</td>
<td class="nump">$ 32,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">3,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">30,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">3,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 33,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member', window );">2.05% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member', window );">2.05% Notes due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member', window );">2.05% Notes due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.1757)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.1757) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.1757) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500 MM GBP 1.3799)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500 MM GBP 1.3799) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500 MM GBP 1.3799) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 2,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.1757)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.1757) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.1757) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.1757)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.1757) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.1757) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 2,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 2,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember', window );">Other | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember', window );">Other | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429617868376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeTaxTextualsAbstract', window );"><strong>Income Tax (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Worldwide effective income tax rate (as a percent)</a></td>
<td class="nump">16.60%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset', window );">Deferred tax benefit related to TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit', window );">Deferred tax liability related to TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent', window );">Deferred tax benefit related to TRAF, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeTaxTextualsAbstract', window );"><strong>Income Tax (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent', window );">Net impact to tax rate due to change in contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change In Contingent Consideration Liability, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeTaxTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Textuals Abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeTaxTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429626765816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 353<span></span>
</td>
<td class="nump">$ 326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(680)<span></span>
</td>
<td class="num">(614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost/(credit)</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost/(credit)</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429626293112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International retirement plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429620806824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">$ 63,278<span></span>
</td>
<td class="nump">$ 59,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">65,834<span></span>
</td>
<td class="nump">61,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Foreign Currency Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(8,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(8,662)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Investment Gain (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(6,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(6,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(15,242)<span></span>
</td>
<td class="num">(15,891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">$ (15,328)<span></span>
</td>
<td class="num">$ (16,243)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429627142808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Reconciliation of basic net earnings per share to diluted net earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net earnings per share</a></td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">$ 2.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average shares outstanding &#8212; basic</a></td>
<td class="nump">2,631,600<span></span>
</td>
<td class="nump">2,633,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Potential shares exercisable under stock option plans</a></td>
<td class="nump">128,400<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod', window );">Less: shares which could be repurchased under treasury stock method</a></td>
<td class="num">(87,300)<span></span>
</td>
<td class="num">(89,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Convertible debt shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average shares outstanding &#8212; diluted</a></td>
<td class="nump">2,672,700<span></span>
</td>
<td class="nump">2,671,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net earnings per share</a></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1930-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429605393560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 22,321<span></span>
</td>
<td class="nump">$ 20,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 11,111<span></span>
</td>
<td class="nump">10,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 11,210<span></span>
</td>
<td class="nump">9,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,543<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,611<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,932<span></span>
</td>
<td class="nump">1,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,175<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | OTC | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 599<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | OTC | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Skin Health/Beauty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,163<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Skin Health/Beauty | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 634<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Skin Health/Beauty | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 529<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">15.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Oral Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Oral Care | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Oral Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Baby Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 389<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Baby Care | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Baby Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Women's Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Women's Health | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(25.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Women's Health | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 219<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Wound Care/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Wound Care/Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | Wound Care/Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 12,199<span></span>
</td>
<td class="nump">11,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6,446<span></span>
</td>
<td class="nump">6,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 5,753<span></span>
</td>
<td class="nump">5,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,914<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,413<span></span>
</td>
<td class="nump">2,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,501<span></span>
</td>
<td class="nump">1,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">22.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 777<span></span>
</td>
<td class="nump">990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(21.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(21.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE&#174; | U.S. Exports</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(48.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 255<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 307<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">18.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | STELARA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,148<span></span>
</td>
<td class="nump">1,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">18.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | STELARA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,331<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | STELARA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 817<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">35.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | TREMFYA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 418<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | TREMFYA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">46.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | TREMFYA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(38.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,007<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 512<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 494<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | COVID-19 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | COVID-19 | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | EDURANT&#174; / rilpivirine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | EDURANT&#174; / rilpivirine | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | EDURANT&#174; / rilpivirine | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | PREZISTA&#174; / PREZCOBIX&#174; / REZOLSTA&#174; / SYMTUZA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 546<span></span>
</td>
<td class="nump">579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | PREZISTA&#174; / PREZCOBIX&#174; / REZOLSTA&#174; / SYMTUZA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | PREZISTA&#174; / PREZCOBIX&#174; / REZOLSTA&#174; / SYMTUZA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(27.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,721<span></span>
</td>
<td class="nump">1,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 771<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 949<span></span>
</td>
<td class="nump">910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | CONCERTA&#174; / methylphenidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | CONCERTA&#174; / methylphenidate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | CONCERTA&#174; / methylphenidate | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA&#174; / XEPLION&#174; / INVEGA TRINZA&#174; / TREVICTA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 965<span></span>
</td>
<td class="nump">883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA&#174; / XEPLION&#174; / INVEGA TRINZA&#174; / TREVICTA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 589<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA&#174; / XEPLION&#174; / INVEGA TRINZA&#174; / TREVICTA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(11.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 428<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,570<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">18.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,377<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,193<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">19.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | DARZALEX&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,365<span></span>
</td>
<td class="nump">937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">45.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | DARZALEX&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 691<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">49.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | DARZALEX&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 674<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">42.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ERLEADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 261<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">82.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ERLEADA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ERLEADA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | IMBRUVICA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | IMBRUVICA&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | IMBRUVICA&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 680<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ZYTIGA&#174; / abiraterone acetate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 638<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ZYTIGA&#174; / abiraterone acetate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(64.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ZYTIGA&#174; / abiraterone acetate | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 588<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1) | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1) | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(15.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 861<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 573<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">15.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">18.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">21.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 799<span></span>
</td>
<td class="nump">806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 328<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 589<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 589<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA&#174; / INVOKAMET&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA&#174; / INVOKAMET&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(26.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA&#174; / INVOKAMET&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT&#174; / EPREX&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(18.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT&#174; / EPREX&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(18.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT&#174; / EPREX&#174; | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(18.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 261<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(13.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(28.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6,579<span></span>
</td>
<td class="nump">5,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,054<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,525<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">16.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 949<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">30.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Interventional Solutions | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 434<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Interventional Solutions | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 514<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,113<span></span>
</td>
<td class="nump">2,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,249<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 864<span></span>
</td>
<td class="nump">788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | HIPS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | HIPS | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | HIPS | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | KNEES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | KNEES | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(13.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | KNEES | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | TRAUMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 733<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | TRAUMA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS &amp; OTHER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 706<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS &amp; OTHER | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 403<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS &amp; OTHER | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,372<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 898<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,474<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | ADVANCED</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,118<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | ADVANCED | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 405<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | ADVANCED | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 713<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">25.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | GENERAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,254<span></span>
</td>
<td class="nump">1,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | GENERAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 493<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Surgery | GENERAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 761<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,145<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 472<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 673<span></span>
</td>
<td class="nump">628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 857<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 371<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | SURGICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | SURGICAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDICAL DEVICES | Vision | SURGICAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesBySegmentOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesBySegmentOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BeautyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BeautyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OralCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OralCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BabyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BabyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WomensHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WomensHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_StelaraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_StelaraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_DARZALEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ERLEADAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ERLEADAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_IMBRUVICAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ZYTIGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_UPTRAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_HIPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_HIPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_KNEESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_KNEESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TRAUMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SPINEOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SPINEOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_SurgeryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_SurgeryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ADVANCEDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_GENERALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_GENERALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_VisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_VisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SURGICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SURGICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429622181208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="nump">14.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 7,429<span></span>
</td>
<td class="nump">$ 6,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AmountPrepaidAndDueToManufacturers', window );">Amount prepaid and due to manufacturers</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Reversal of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 7,640<span></span>
</td>
<td class="nump">6,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="nump">15.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 788<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 5,223<span></span>
</td>
<td class="nump">3,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="nump">36.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (Loss) on Disposition of Assets</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnSecurities', window );">Unrealized Gain (Loss) on Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 1,629<span></span>
</td>
<td class="nump">2,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(19.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 211<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Reversal of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember', window );">Other Income | Auris Health | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Reversal of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AmountPrepaidAndDueToManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount Prepaid and Due to Manufacturers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AmountPrepaidAndDueToManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in operating income loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in the income statement on unsold other securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429717630280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 22,321<span></span>
</td>
<td class="nump">$ 20,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 11,111<span></span>
</td>
<td class="nump">10,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 5,414<span></span>
</td>
<td class="nump">4,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">12.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember', window );">Western Hemisphere, excluding U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 1,424<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="num">(5.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember', window );">Asia-Pacific, Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 4,372<span></span>
</td>
<td class="nump">$ 3,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">19.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesByGeographicArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by geographic area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesByGeographicArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentsGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentsGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429622799080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 3)</a></td>
<td class="nump">$ 35,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember', window );">bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business acquisition cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalInc.Member', window );">Verb Surgical Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Fair value of previously held equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember', window );">Evra and Doxil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (Loss) on Disposition of Assets</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117311354&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429736312328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 20, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($) </div>
<div>claimant </div>
<div>patient</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_AsrMember', window );">ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember', window );">Pinnacle Acetabular Cup System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember', window );">Pelvic Meshes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RisperdalMember', window );">Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_XareltoMember', window );">XARELTO&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_InvokanaMember', window );">Invokana</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember', window );">Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OpioidMember', window );">Opioid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="nump">$ 344.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss', window );">Loss contingency, estimate of additional possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member', window );">DePuy ASR U.S. | settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_Numberofpatientsinsettlement', window );">Number of patients in settlement | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Judicial Ruling | Damages from Product Defects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Litigation contingency | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700.0<span></span>
</td>
<td class="nump">$ 2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember', window );">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI | settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalProceedingTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal Proceeding Textuals Abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalProceedingTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Additional Possible Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyEstimateOfAdditionalPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Numberofpatientsinsettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients in settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Numberofpatientsinsettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityContingencyNumberOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product liability contingency number of claimant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityContingencyNumberOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_AsrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_AsrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PelvicMeshesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_InvokanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_InvokanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PhysiomeshMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OpioidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OpioidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_BabyPowderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_BabyPowderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429626418216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring charges recorded to date</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Cost savings expected</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring estimated cost</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Cost savings expected</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring estimated cost</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Supply Chain | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostDurationofRestructuringPlan', window );">Period for activity</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Supply Chain | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostDurationofRestructuringPlan', window );">Period for activity</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringandRelatedCostDurationofRestructuringPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Duration of Restructuring Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringandRelatedCostDurationofRestructuringPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringandRelatedCostExpectedFutureSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Future Savings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringandRelatedCostExpectedFutureSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140429625570056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of Restructuring Reserve (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for Restructuring</a></td>
<td class="num">(96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Restructuring Reserve, Settled without Cash</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid', window );">Period of cash outlays for severance expected to be paid out</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for Restructuring</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Restructuring Reserve, Settled without Cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Asset Write-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for Restructuring</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Restructuring Reserve, Settled without Cash</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">Medical Devices | Other Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for Restructuring</a></td>
<td class="num">(91)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Restructuring Reserve, Settled without Cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MV;\%ZV^TV'<ODK9":U%WESO.0+8Q@-^O!2S<X<:\FSJ\B[SX!U!+ P04
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MF4](#!NV2\VC//P"=4%A$2^2J2Y_R:&RG7D3$NVTD5GMC @R+JHG>ZV).'+
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M?1"L:#[/'IF C[WF]DA)3,L: +_O&1-O#_477_]/A]5_4$L#!!0    ( 'N
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MC6QNXG/CT1@-DZZ*<ZOQ+T.<':=*&L593BWD9&YQP!)90]22I$K@P2A<Q39
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MF#5===AJ857IF]1"66QY?EK@HP3:&>#_I5)VMW .FF=N_ ]02P,$%     @
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M6NY:EB.C_(70Y[QM.F*)1OBD#L"K,J8BGC.3T6Z-O]SNQ?/0R\E43>AF5-]
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MSE[1!H+-BB^M'FM,^Z\J(PXY!Q72P&87$9\69AH,=NB@D=&TG?7&X4>ZX X
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MXYN'O0C@_<)A3'<;<=!_19W\"U!+ P04    " ![@)Y2$64I:U8$  "W"0
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M;\F/+5IOP/M;PS>@F_@##L_W[!M02P,$%     @ >X">4J@90>EH#@  \B(
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M;(,!UM<&3:$9! ?M%73Z-U!+ P04    " ![@)Y2'"*8EODF  #CA@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6S=?7ESVTB2[U=!>#=FK B:EN1[
MY'8$+:G;ZI4MA:3NV8D7[X\B4"1A@RA, 1#-_?2;5QTX*$MNS[R9%[$[;9%
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MA!N =_'].E^RAH)'%X3[,"(LJFK];%EK8018S.<6]$V6DS'II)@'B\;?"D?
M_/BH.S/!Q+)=SX&D\%=E&J0&\B2IW:/X> $R<N OVK?5*[2 X:\UL&G^I%*@
M<8$]FZ;0=-1'CF=E'L<\J04Y>2)*G= .I0*TM)NOS)XR" @M8'':(H/@%,C)
MSF( ]F,=J;_BH@&UX,00.0"B,N"4P'4P'GR%&^_J1> $H$>BED"BNHD1H L'
MF=%\XJS58(T.&X&D#:B) #.Q7C#(ZO=']K,RGO3/L.PJ+^%0)P%I42/KKXIX
M%_&0SR]@_D2>J! F$&-A#1E"%TXN*$GBS3H)* ]^".\53Y%0#L $3HXAK:_\
M)X#UI$D[JD[P+.^O?ZX* GKR B9.:G!U)/NP-CH,A:O7:+7X(]2$#[CC[H@+
MV'B)]ASB<(XDF"8?S :8TO(N0+Q,T0IM)BSN*9);B_+QQ@A\69(R6!NK!X2D
MI\F,J8QMR.J$%9H,OM\^>-4,Y83::)FR(2G\4*^2!:BL6O0W8#1/-$7S^N2W
MXYOD_&SV_NS\[.9O/\C(#O+4MZ.32"J]"<ZO(@5(T$&BW8N _\?X@A+5S@2$
M+2$J:_TE"=!;$!@ 8+#>A@D(R%'";U5>*%+ 50NF"2**0/LT^>LJ+W1'$D&_
M(P35: XB-,=3@,\+,V@2 L=L"SCZ7/2X8-]N;O=V!M@A?>M]0IHUR1=WS]QT
M;6HX!6(F8$H"OP@?@U K4H&:83+-;=JN<>2T;U+CK  70*P<)"KKFM;W/4Q&
MY7S,  LK(@NZ; ">_/'$!MY$C"L8K4;:\9&C9,S1" :?MF^H,D3@8H(UY>QQ
M5KA,05A=#<LL 6X8(.CSC*U5%DWV!IJ5\4\_S'Y&"S,2EQY\]LU\AVTJRW)1
ML,ZN(SN'CX3'=LOI6?[1F4^\U1)9MZ X\*0O!P?HSQ?W T DI@-L]3,#Z/#,
M&41 N&%\PAO'!"#P8I9NC"U ^HBB9%0 :%DR28*9K<O;W)HR1"9H(^%1-$E
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M0>1^ /?(:;K$!7R8YA4=13!'R,?ZM[$-;O1757>, V(+Y.NN<4 !C!HG<'M
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M'PV$2U]5:1%L$[]D,AOP713_5O@0)<<"V"^M#?V"#]A\VE[\"U!+ P04
M" ![@)Y2\UKV_C$&  "7$   &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6R=6&UOVS80_BN$!^P%<&+'29JN2P(X68MU0[<@6=L/PS[0XLDB0I$J2=GU
MO]]SI*0XF6.T_1*3%'GWW-US=V3.U\[?AXHHBL^UL>%B5,78O)I,0E%1+<.A
M:\CB2^E\+2.F?CD)C2>ITJ':3&;3Z8M)+;4=79ZGM1M_>>[::+2E&R]"6]?2
M;Z[(N/7%Z&C4+]SJ915Y87)YWL@EW5%\W]QXS":#%*5KLD$[*SR5%Z/YT:NK
M,]Z?-GS0M Y;8\&6+)R[Y\E;=3&:,B R5$26(/&SHFLRA@4!QJ=.YFA0R0>W
MQ[WT-\EVV+*0@:Z=^:A5K"Y&+T="42E;$V_=^C?J[#EE>84S(?T5Z[SW]&0D
MBC9$5W>'@:#6-O_*SYT?M@Z\G#YS8-8=F"7<65%"^:N,\O+<N[7PO!O2>)!,
M3:<!3EL.REWT^*IQ+E[>Y6 (5XH[O;2ZU(6T4<R+PK4V:KL4-\[H0E,0/_:C
MG\XG$:I9P*3HU%QE-;-GU!R+=\[&*HC75I%Z?'X"R /N68_[:K97X+SQAV)Z
M,A:SZ>QHC[SCP0_'2=[Q<_)V&/S/?!&B!V_^W:/@9%!PDA2</*/@?2!V\NL0
M-;A$89</OTZ"^+LB09\C(5[1B76EBTI<__7A[:\'1S\+73= 'D3$IFN'B=U\
M_]W+V='9+T$LV@#9(0AIE2BUE;;0TB#' K@<P$!CP&SDO1)('-O6Y%T;!*V<
M6;&'2DAV/@AM"],JK(PA,@KKHC"ZUI$4 +U*JFL)4L564=*E6B]3,L*.'NDX
M[7MJAXX91C:#4]LH9 8+++RCPEE7ZT+@5VF6N 4&HTBP)0K/;AH+JAOC-C7+
M3RL)2D721.BQ 9AL01"U(H\ZE/&$AF %8/($&0%&-)(-\Y0V;L9)RI+'ED7#
M?[PPN!85LLC 8!,+0004 ?-ABEL7$B%#P&[(+<A'U%"4J8&(B#(,X1#**)9D
M <^8#21_:K5GP"B-BAX\BA)-A0R,\B&HVN;*S7L@'H<B? WGPGB&M?T=F(.S
M<@$E<B6UP8AZ^ -@&,GSUMY;M[:B;&,+,#W=!O[)P)"0IMJ(+DV[L^#2,NM6
M\&CVL6:'-<['[)T=3A@<E>-,*G-NC4@_(=YX)^?A.K=.@8:]0KEV$<O6])HR
M)PI/8),PCG6-H6F%P#J?C?9D.@($\BO^CK.^32N+@5: Z>#W)QL[GQ72^PT;
MM9*FI9Y=2^=4XCIO<UCQ0&"7!P;M*@DDAL=+#U%[:IVS!TN7)1<%"(CT7:'A
M-HGT*?,T2IF&QSC.5,('Z.7B8Z4YPA4[<8V(L2,ENYQ\XDY.OL<,&'0R_U J
ME7Q,N!"QP'I#QX%49.!SEO&IE1["!7$;>,R.W6'KZ)6CGZSIO/8EA07ZU\2.
M#9U?N\(U!O;6J*[@<5H\,3E\N\UZ2(E,: Y* ]E.A<,];>1T:".G>YO G[CG
M;/6JNPCKI5=!W%(!_<C<N7)-?-IC<W_Y1M$[ZE7N*Y)5I<+2>0W>]ST.'0(G
MQU8JAT'B8I/.OQD<N%/OE<,/=Z"M2/P0GJ5:'^HAEFVC4EXBEKBPKC3WL <B
M<8(S.5')2^_JG>&>6]M"T&V*)"/AFZ XFA[\,3"ZU*' E@W)GM6_2QQ"T3C.
MO$X5C?,K5RIAX>8!XD[O=)[3=EM!J3TZ6I\_<'2JJ*DU9.^3VC;A\'^$>#:V
M7X5-=L*^ -P^NK\8Z/YB+R=AA$'(TK64F;:+U5\G05QWC1:U!R',J2EDG;M
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M,$JI64N%9E* HNN9MXC.+W+[WCWX@]&MWOL&:\E*RL]V\Z&>>:$%1#FMC)5
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MY+0 \\L,ART_$(/Z1X;G_P502P,$%     @ >X">4F6>RY,Y P  UP8  !D
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MR)UR67"+IUK^$(4K)]$H@@*7O)'N1J\O<)-/YOER+6WXPKJUS=((\L8Z76W
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M +KNG_7"JM+WK+6RU ']9TZ_'-3.@,XWBLK7+%R [B<V_P-02P,$%     @
M>X">4O47Y_/:#@  720  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
MM5IK<]O(L?TK4[IV(J6P%#!X>VU7020LLR(^0E):VZG[ 0*')&I!@(N'9.77
MY_0 I/"0M;OW)A]$D<!,=\_I[M,] [Q_3+-?\YT0!?N^CY/\P]FN* [O+B_S
M<"?V03Y(#R+!G4V:[8,"/[/M97[(1+"6D_;Q)5=5ZW(?1,G9Q_?RVCS[^#XM
MBSA*Q#QC>;G?!]G3E8C3QP]GVMGQPB+:[@JZ</GQ_2'8BJ4H;@_S#+\N3U+6
MT5XD>90F+!.;#V>>]FYHT7@YX"X2CWGC.Z.5W*?IK_1CO/YPII)!(A9A01("
M_'L00Q'') AF_%;+/#NII(G-[T?IG^3:L9;[(!?#-/XE6A>[#V?.&5N+35#&
MQ2)]_"SJ]9@D+TSC7'ZRQWJL>L;",B_2?3T9%NRCI/H??*]Q^",3>#V!_]$)
M>CU!EPNM+)/+&@5%\/%]ECZRC$9#&GV1V,C96$V4D!>718:[$>85'Y=B"Y\4
M.4LW[*K,<3?/69"LV;5(MUEPV$4A\Q >.3M?!?>QR"_>7Q;02[,OPUK'5:6#
M_T"'SB9I4NQRYB=KL6[/OX2])Z/YT>@K_JI [Y -F&HHC*M<>\&>X>O3)P&F
M<U=.5U\Q1S]AJ$MY^NL8LH4XI%D1)5OV3^\^+S*$Z/^^(MXXB3>D>.-'X@/
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M8H\>*VD6('8,2H 6*YF&A<1Q*9PQIW;X]),_7(UGMTLV&B]];XGJ5863AMA
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M&?RT%5644Z(<#]>0/NNR>ACX&,F8B[(U QT63S^2E69;$&^%1#Y@JQVXJ*U
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MS]!Z!3YOC*&3X!V,+^3Z'U!+ P04    " ![@)Y2V23B%FH"   Y!@  &0
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M8 F<YTB6Q_<*U*ESYH&'XQ?TWXK%V\4\4@U+R?]FL4FFSLA!,6QHQLV=W-]
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;*U766_;.!#^*X31!5K
MB43*5PK'@..DV"R:(DAZ/"SV@9'&%K<2Z9*4#V!__ XE17(2F2W0O-CB,3/?
M'/S(F6Z5_FY2 $MV>2;->2^U=OT^"$R<0L[-J5J#Q)6ETCFW.-2KP*PU\*04
MRK. A>$HR+F0O=FTG+O5LZDJ;"8DW&IBBCSG>G\!F=J>]VCO<>).K%+K)H+9
M=,U7< _VR_I6XRAHM"0B!VF$DD3#\KPWI^\7;. $RAU?!6S-P3=QKCPH]=T-
MKI/S7N@000:Q=2HX_FU@ 5GF-"&.'[727F/3"1Y^/VK_4#J/SCQP PN5?1.)
M3<][DQY)8,F+S-ZI[9]0.S1T^F*5F?*7;*N]XT&/Q(6Q*J^%$4$N9/7/=W4@
M#@103[< JP78<X'1$8&H%HA*1RMDI5N7W/+95*LMT6XW:G,?96Q*:?1&2)?&
M>ZMQ5:"<G7W@0I.O/"N W  WA0;,D37DA'SB6G,78_+V$BP7F7F'LU_N+\G;
M-^_(&R(DN1%9AKDPT\ B%*<PB&NS%Y59=L1L1&Z4M*DA5S*!I$-^X9>GS*,@
MP!@T@6"/@;A@7HWSM3XEX:!/6,AH%R"_^%]<HGC4)?X$3M3D)2KU14?T78(6
MFRK\?W_$-7)M(3?_>#0/&LV#4O/@F*-Q7.1%QBTD1-D4-(E5CA20NK.)YH3$
M,1 \8DF#P?0)7UK<:OFN*]F5Q5%IT1''9C8<3X--!\IA@W+H17D'<<:-$4L1
M\_*\JR5!TL)3*0GLXI3+%2!P:342@4'05A'@6@JY0K!K1*ZZRNK";U7"SA*L
MK;RL+4^P1XT;(Z_"&[X3>9&3#.3*ILX)BR3H/"$I).@"[-;*G;HNK'[5=/)S
MF.,&YMBKZUO)=E@0? ,:V=O%$S082Y "REJ02I[$A=9(#E@7#[8+K]\&.SV;
M_.'!.FFP3KQZKG8Q&%.&,L7X&0QH6<M+QV2;DLG4QI4JKL;(87LLB<?YY3'L
MB\G+"AZ$87<-GS5(S[Q(%W6\+H_$Z^R%S2@:MC8K8-6FX<$F-HIH-S :MJP?
M^J&I/ <="YZ16XZGQ9,7>G"5T%?F+,I:W>RW8EF+/PGFL?S1EH1I]!OGHA.'
M7V%X2IGO$-"6Q:F?QC^#SCL!^,5^@=MHR]'43Y?XD-IRG7B(V6>FY5 Z>NVZ
M:HF/^ED)GW_N*M1X$.:9>P?OR:TRF/(^F:]6&E:._]I'4F?$QR]*CX;L2.FU
M+$?]--<ZW2>?E+L"'<1<%;*[_B<O>&) 6?B<33JV1>/)T8/2,AW]"=5IA9Q<
M71#Q_MGU8;9\[:L$UM(6"U^Y$EC+7HR^9L!K;4\BV1'P>MM37AH="SAK^9#Y
M^?#J1R'LGEQ+?)S9ZLF^%3;%1HVX*A;9'J\Z3 *V#/PA@_H"_(_4<O> N1)6
M@#<O+4^RUWZMLI;HF)^Q*L3]@T-(YLF_1>5UGUSG:UQPW^0CUF!GJEX^3T^&
MPV<9" YZ*+P:5V5KB27M\E^U4\ULT[[.RZ8M:+=7O>\-URLA#3[ZEB@:GHZQ
M2'353E8#J]9E1_:@+/9WY6>*20/M-N#Z4BG[.' &FJ9^]C]02P,$%     @
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MQP!L2+NW:EQ?M2VD6#4\[!W[T[XY6<=<IF@7@@?+B19CR2.;'#J@$TYK0N&
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MM)OC;QUW:\W4^* 6_DE-C5]V+%W2WS7<>Z)\[%4T%:3$;]79K&?;/L XQ+M
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M    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;+5748_:.!#^*U;4AU9J-W&
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M@+&ES>M;L(P+\P:M/Z]OR>M7;\@KPB6YYT)@S<S4MTC9.?;CBMY-22^\0&]
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M*%"6=HP(]+0[$)7V]UB= $?5<(#)%D!=VINZKG1SCM &P-Q@+.::Z!8X,S<
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MPR9; H?94R8:,. M&S'1@&FJ*@R* -"RD1(-F I9@[?&@+#,3MC[ -<S6LZ
ML*QCBD%ON$D5"P,\5$>XJ8%6$ICRDSVY*&$ =UVSS3WGQUYBCY1$&X^]QI1S
MSQF^V)-*%;P!^.V2=^YI<F_-9I5*&[RGS#K GE3+X(V8=W#;V:X^3.J02A>\
MD1(/;CO:$< W$!=[4IF"9V?N?=AK?;IWQ>6OM5'".V-+10C>\%B!H]VEB@-O
MB"/K5E_C:8K'*"$&3P![4BV"-X#(SMC3I'Z9JJPD(M]3)S8*]C1%8";L[52
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M%PJI,[AA1KT8M%U WU.E<!_8]N"[^_@O4$L#!!0    ( 'N GE)L\_D6,P\
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M*>1-E>53V3 RMQ7(BS10S]C' Y2<3!4&\'XGI3DWB@'J(G;U+U!+ P04
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MX-=XM2@!*ZWC1G@N7!8+'M5*0AD#OLM2&=\-_):E++Z; K[;.ZN0 K8[YI"
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MFHIO38V?1,3WIM'=C2U@75;!NO;0RG# 2DLB '-9#>;Z2JTDU!V@MZR4,:2
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M26ZD3 M(R@HH :),%*)L6 MZ$1'@R*0,1R; D4D6CDQ"')GU/(:$0+(HPBQ
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M3)( F;0V#9ZW")!)QDAL^ +(),E-)FD!&VW!%X!),AI,\@214$< 3)(R8)(
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M( /4^DO&^L3(K/@8<"^-D4EQN.0,QI8W@/MS*<WS2=Y!]3UI\C]02P,$%
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M<6<[+?S['2<A"9!&3!,OK>WX^[YSL8_/>"_DG4H -+E/>:8F5J+U]LRV591
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MB".8 M" (5'4G(,'YU'8G5/A]I>5Z6]02P,$%     @ >X">4I>*NQS
M$P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B
M#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z1
M0J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ
M0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?V
MD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " ![@)Y2
MS0H7,%P$  !>)0  #P   'AL+W=O<FMB;V]K+GAM;,6:6V_;-A2 _PJAIPQ8
M9^N6MD%=()>E,]"U1ESDM6"D8YLH17HDY;3]]2/EN"47^V OIWJ21<G2I\/+
M=TCIS:,V7QZT_L*^=E+96;9Q;GLQF=AF QVW?^@M*']DI4W'G=\UZXG=&N"M
MW0"X3DZ*Z?1\TG&ALK=O#M=:F$F\HQTT3FCE"T/!O8!'^_-XV&4[8<6#D,)]
MFV7#;PD9ZX02G?@.[2R;9LQN].-?VHCO6CDNEXW14LZR?'_@'HP3S;/B98#\
MQ!_L4.+XPQWW(+/L?.HON!+&NN&,X?K<,^[ G[S?ZYV^%=*!N>$.WAG=;X5:
MA\OXIYA$CS'$X;#=!_'"_)\PZM5*-'"CF[X#Y?9Q-" #H+(;L;494[R#67:M
M=V#"\_@;S-O]LSD/%47*7 A_P,S; 8\215DM1>OOWK(K+KEJ@ TAM!%@@0 6
MHP&RLP6/($L$LOR%D,L $?Y@F5ZQ/[E1$62%0%:C05[K;AM!U@AD/5XD_^E%
M!'F.0)Z/"/FYB"!?(I OQZMN;C<1Y"L$\M6(;3*)Y&L$\C4MY++O.FZ^!:BE
M6"OA_\:58Y=-HWOEXC:93[&1?$J+.5<[?X+W*<1#=X[*A=@N<R]VM0XW99?6
MAB&;JY:]T[I]%%+&E)AA<F+%W')AV#V7/;"_@=O>[!MAC(>Y)2>6RUPUN@/V
MB7]-*Q9324[LD@4H&\J&^OSH-F#8%2A8"<<67M$Q)B:3G-@FOHOV72^'T65/
M&4QG8!/P=Q!C8CK)B7T2<@2?BUJV\(3+#3<)&>:0G%@B2UC_&)"O>BL4V*<^
M#'IMXNPKQRR2$VODLO&Y@17N1Y.\\;5KG7"^+R=]!K-(3JR1][#FDOG)4P/0
MANJ.$VQ,' 6Q..Y\J$S?^&!YJA@*4T=!K Y4NDEF4*"S$V)W1-)E9WZJ*<'^
M%K-AXBC(Q8'9E\68F$L*8I><T.\AG#$FYI*"V"6H\M(&B;FD('8)JKP4$Q-+
M02R6Y\H[VGTPJ13$4D'=ET82TTI!K)5D]#X6Q!)S2_GK)B7L[ 8<%S*%PQQ3
MCCD]26JXQ!Q3DCL&PRQC3'0-;$S=?*YB3$PW);%N<,PZQL1T4Q+KYI057[ /
MW"29=XGIIB36S6G,(8&+,3'=E,2Z03#]U=L8$U-.2:P<%#,=D##EE,3*02L]
MP:PP]U3$[CF->2M4LDA181:JB"UT&C.LT_X>8V(6JL99)7MJF[&%*LQ"%;&%
MT$I/VR;Z+H;<0C\7]8XF1A4FGVK4N4Y2UYA\*F+YX)AQQE%A\JF(Y8-/R9)H
M8O*IB.5S;$IVK&%BYJFH7\6@<[(XE#5FGIK8/#AFW#!KS#PU]1H;BAFGPC5F
MGIK8/.CJ+GL18V+FJ8G-\VQ]]VCWJ3'KU,362=<*GJ82X2.9/6J,B7X#0*R?
M_V(..7KO)VR^G=XE*X(UII]ZT,_D\#U/Z\6@H/W@;V%]><-ELS L;/9O(*LZ
MO!Y8]5)>^[*/ZKWF[>'SH,.G36__!5!+ P04    " ![@)Y2##^0_.4!  !_
M(0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=H[3L- %(7AK41>
M )/[F/!00D5#B]B %28/D<269Q#)[HE"$8Y%08/F5-;8\O7?^)-E>_Z2=FW9
M=H>\V?9Y<MSO#GG1;$KI'T+(RTW:M_FFZ]/A?&35#?NVG)?#.O3M\KU=IZ#3
MZ2P,/V<TC_.?,R>OIS[]96*W6FV7Z:E;?NS3H?PR.'QVPWO>I%2:R6L[K%-9
M-.&XN^[.X;*1F_/D9O+\MFB&YS=I0NT@A2"M'V009/6#'(*\?E"$H%@_: 9!
ML_I!MQ!T6S_H#H+NZ@?=0]!]_2"9HHQ3@J01U@1:"W(M!%X+@BT$8@N2+01F
M"Z(M!&H+LBT$;@O"+01R"](M!'8+XBT$>BOJK01Z*^JM!'KKZ&&;0&]%O95
M;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 ;T.]C4!O0[V-0&]#O8U
M;QN]+"'0VU!O(]#;4&\CT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU%O)]#;46\G
MT-M1;R?0VU%O)]#;1R^["?1VU-L)]';4VPGT=M3;"?1VU-L)]';4VPGTCJAW
M)- [HMZ10.^(>D<"O2/J'0GTCJAW)- [CCY6$N@=4>_XGWKG<MJE?.WY7N/U
M_Y/J<CXW72]_67[O'-WC%YP#_&_Q^ 502P,$%     @ >X">4H_AMVG3 0
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M2P$"% ,4    " ![@)Y2!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( 'N GE)%%V8S[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M 'N GE*97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ >X">4C&B"79I!@  ]B(  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M 'N GE)?Y($E#P<  )<<   8              " @:P.  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " ![@)Y24V3X7ZX"  "&!P  &
M            @('Q%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ >X">4@2H.>[*!0  51H  !@              ("!U1@  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( 'N GE*/JY\_$@0  )<.
M   8              " @=4>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " ![@)Y2[ =__EL$  " $   &               @($=(P
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ >X">4D:&*,U3
M @  -04  !@              ("!KB<  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( 'N GE*]L&!M9@@  %PB   8              "
M@3<J  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " ![@)Y2
M9+![*K<"  #R!@  &               @('3,@  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ >X">4D0K59]4!@  O@\  !D
M     ("!P#4  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'N GE(192EK5@0  +<)   9              "
M@75A  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ >X">
M4GWL-5,1!   * D  !D              ("! F8  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " ![@)Y24J"9-' #  #*!P  &0
M        @(%*:@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( 'N GE*H&4'I: X  /(B   9              " @?%M  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ >X">4N:#P@E\!   C@H
M !D              ("!D'P  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " ![@)Y2'"*8EODF  #CA@  &0              @(%#@0
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( 'N GE)@4W:6
MCP8  .8.   9              " @7.H  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ >X">4O-:]OXQ!@  EQ   !D
M ("!.:\  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " ![
M@)Y2=IV( 6X"   4!0  &0              @(&AM0  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( 'N GE(;OBF;: 0  ,0*   9
M          " @4:X  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#
M%     @ >X">4N< MI.4#   <"@  !D              ("!Y;P  'AL+W=O
M<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " ![@)Y299[+DSD#  #7
M!@  &0              @(&PR0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM
M;%!+ 0(4 Q0    ( 'N GE)<I:!DUP(   ,&   9              " @2#-
M  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ >X">4B,:
M#@ ( P  T 8  !D              ("!+M   'AL+W=O<FMS:&5E=',O<VAE
M970R."YX;6Q02P$"% ,4    " ![@)Y2]1?G\]H.  !=)   &0
M    @(%MTP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M 'N GE(F+Y/S= ,  "T'   9              " @7[B  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ >X">4MDDXA9J @  .08  !D
M             ("!*>8  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " ![@)Y2KV%!JI\#   1#@  &0              @('*Z   >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( 'N GE) H:W1IP,
M )H.   9              " @:#L  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ >X">4C^;Q,G9 @  :P@  !D              ("!
M?O   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " ![@)Y2
MT66<WSL"  "U!0  &0              @(&.\P  >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( 'N GE+FD<GYE@0  . /   9
M      " @0#V  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ >X">4M?;DS.&!@  H"X  !D              ("!S?H  'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " ![@)Y2Q_2EQ;0"   D!@
M&0              @(&* 0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( 'N GE*0.47;/P,  $(*   9              " @74$ 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ >X">4L G=TB'
M P  7PP  !D              ("!ZP<! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " ![@)Y2WRUH86\(  " .   &0
M@(&I"P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( 'N
MGE)Q:8O*A0@  +U!   9              " @4\4 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ >X">4@$SX<R7 @  Z0<  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( 'N GE(JAA\I0P0  ),3   9
M  " @2HY 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
M>X">4AM6@NU_ P  C H  !D              ("!I#T! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " ![@)Y2FA&RT$(D  #94P$ &0
M            @(%:00$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( 'N GE(*B;('H 4  %L:   9              " @=-E 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ >X">4@L+8U*N P
MV@T  !D              ("!JFL! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " ![@)Y2+;'O28$#  "^"P  &0              @(&/
M;P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( 'N GE*.
MY!"C,@4  ((9   9              " @4=S 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ >X">4O($'38'!   S!(  !D
M     ("!L'@! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
M" ![@)Y2SI_7NE0$  "*$P  &0              @('N? $ >&PO=V]R:W-H
M965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( 'N GE(.8)5M&@,  &81   -
M              "  7F! 0!X;"]S='EL97,N>&UL4$L! A0#%     @ >X">
M4I>*NQS     $P(   L              ( !OH0! %]R96QS+RYR96QS4$L!
M A0#%     @ >X">4LT*%S!<!   7B4   \              ( !IX4! 'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( 'N GE(,/Y#\Y0$  '\A   :
M          "  3"* 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( 'N GE*/X;=ITP$  #8A   3              "  4V, 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !  $  =Q$  %&. 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>628</ContextCount>
  <ElementCount>372</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>173</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEarnings</Role>
      <ShortName>Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006006 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007007 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1405401 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2123105 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125106 - Disclosure - Pensions and Other Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlans</Role>
      <ShortName>Pensions and Other Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - Accumulated Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome</Role>
      <ShortName>Accumulated Other Comprehensive Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Segments of Business and Geographic Areas</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</Role>
      <ShortName>Segments of Business and Geographic Areas</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140110 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2143111 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2145112 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Inventories</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2326304 - Disclosure - Pensions and Other Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</Role>
      <ShortName>Pensions and Other Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Accumulated Other Comprehensive Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Segments of Business and Geographic Areas (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables</Role>
      <ShortName>Segments of Business and Geographic Areas (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2346308 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Restructuring</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/InventoriesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Goodwill By Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Derivative Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2420413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2421414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2422415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2424416 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IncomeTaxes</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2427417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2428418 - Disclosure - Pensions and Other Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails</Role>
      <ShortName>Pensions and Other Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2431419 - Disclosure - Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShareTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2444426 - Disclosure - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedingsDetails</Role>
      <ShortName>Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/LegalProceedings</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="jnj-20210404.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails</Role>
      <ShortName>Restructuring - Schedule of Restructuring Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="jnj-20210404.htm">jnj-20210404.htm</File>
    <File>a20211qex311ceocertificati.htm</File>
    <File>a20211qex312cfocertificati.htm</File>
    <File>a20211qex321ceocertificati.htm</File>
    <File>a20211qex322cfocertificati.htm</File>
    <File>jnj-20210404.xsd</File>
    <File>jnj-20210404_cal.xml</File>
    <File>jnj-20210404_def.xml</File>
    <File>jnj-20210404_lab.xml</File>
    <File>jnj-20210404_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>jnj-20210404_g1.jpg</File>
    <File>jnj-20210404_g2.jpg</File>
    <File>jnj-20210404_g3.jpg</File>
    <File>jnj-20210404_g4.jpg</File>
    <File>jnj-20210404_g5.jpg</File>
    <File>jnj-20210404_g6.jpg</File>
    <File>jnj-20210404_g7.jpg</File>
    <File>jnj-20210404_g8.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>81
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "jnj-20210404.htm": {
   "axisCustom": 0,
   "axisStandard": 32,
   "contextCount": 628,
   "dts": {
    "calculationLink": {
     "local": [
      "jnj-20210404_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "jnj-20210404_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "jnj-20210404.htm"
     ]
    },
    "labelLink": {
     "local": [
      "jnj-20210404_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jnj-20210404_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "jnj-20210404.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 632,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 42,
   "keyStandard": 330,
   "memberCustom": 111,
   "memberStandard": 55,
   "nsprefix": "jnj",
   "nsuri": "http://www.jnj.com/20210404",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.jnj.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Inventories",
     "role": "http://www.jnj.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Fair Value Measurements",
     "role": "http://www.jnj.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123105 - Disclosure - Income Taxes",
     "role": "http://www.jnj.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125106 - Disclosure - Pensions and Other Benefit Plans",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlans",
     "shortName": "Pensions and Other Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - Accumulated Other Comprehensive Income",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome",
     "shortName": "Accumulated Other Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - Earnings Per Share",
     "role": "http://www.jnj.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Segments of Business and Geographic Areas",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas",
     "shortName": "Segments of Business and Geographic Areas",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "id0cec34735fd4353b95e73a94998d0eb_D20191230-20200329",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140110 - Disclosure - Acquisitions and Divestitures",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestitures",
     "shortName": "Acquisitions and Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143111 - Disclosure - Legal Proceedings",
     "role": "http://www.jnj.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145112 - Disclosure - Restructuring",
     "role": "http://www.jnj.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Inventories (Tables)",
     "role": "http://www.jnj.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326304 - Disclosure - Pensions and Other Benefit Plans (Tables)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables",
     "shortName": "Pensions and Other Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Accumulated Other Comprehensive Income (Tables)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables",
     "shortName": "Accumulated Other Comprehensive Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.jnj.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Segments of Business and Geographic Areas (Tables)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables",
     "shortName": "Segments of Business and Geographic Areas (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2346308 - Disclosure - Restructuring (Tables)",
     "role": "http://www.jnj.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Inventories (Details)",
     "role": "http://www.jnj.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "iabd737cfbcd54bdbbcb2e9240b76d431_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
     "shortName": "Intangible Assets and Goodwill - Goodwill By Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails",
     "shortName": "Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "i8d3a64af1b114e0faba3662a1c101141_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
     "shortName": "Fair Value Measurements - Summary of Derivative Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ie01d964788264049a7b9adb01bd01ac5_D20210104-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "i9b228055f3cd41bb8574ba5091b477ab_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "i9b228055f3cd41bb8574ba5091b477ab_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Earnings",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
     "shortName": "Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:SalesRevenueGoodsNetPercentToSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
     "shortName": "Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "i232b3bcc9db9455c814fc452f8315a6d_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails",
     "shortName": "Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ia551774380104d5a9cb2e81ed84e5fbc_I20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424416 - Disclosure - Income Taxes (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ia9ff91fc5b854a42940dee7c48a7c2c2_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ib4d8262305ed4a808270a6d930b2b201_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428418 - Disclosure - Pensions and Other Benefit Plans (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails",
     "shortName": "Pensions and Other Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ib4d8262305ed4a808270a6d930b2b201_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "iabd737cfbcd54bdbbcb2e9240b76d431_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431419 - Disclosure - Accumulated Other Comprehensive Income (Details)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "i1d76493e48f94dcba8cc74f15393b857_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.jnj.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesBySegmentOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "jnj:PercentageChangeInOperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "jnj:PercentageChangeInOperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
     "shortName": "Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesByGeographicArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic8bf9ed56e84446385347cf261ab52e6_I20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
     "shortName": "Acquisitions and Divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "i5d9f14bc65a147d0b6ffd1245515b56e_D20191230-20200329",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic5b57e148881429fbffa7b15c1969483_I20210404",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "jnj:ProductLiabilityContingencyNumberOfClaimant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claimant",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444426 - Disclosure - Legal Proceedings (Details)",
     "role": "http://www.jnj.com/role/LegalProceedingsDetails",
     "shortName": "Legal Proceedings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic5b57e148881429fbffa7b15c1969483_I20210404",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "jnj:ProductLiabilityContingencyNumberOfClaimant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claimant",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Restructuring - Narrative (Details)",
     "role": "http://www.jnj.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "ic02f715544ff4105bfd2a3c2d151ac0c_D20210104-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)",
     "role": "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
     "shortName": "Restructuring - Schedule of Restructuring Reserve (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "i36ee9965a40148bda5e997a88d5d4930_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "i57b90fcac8194c0c83439d028eb794fa_I20191229",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006006 - Statement - Consolidated Statements of Equity",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "i81a1c011ad384c69babb9ebc86eb4a3a_I20191229",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007007 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1405401 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20210404.htm",
      "contextRef": "if3112eec8604498ba5d3696f0c29928c_D20210104-20210404",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 173,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "jnj_A0.250NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.250% Notes Due 2022 [Member]",
        "label": "0.250% Notes Due 2022 [Member]",
        "verboseLabel": "0.250% Notes Due January 2022"
       }
      }
     },
     "localname": "A0.250NotesDue2022Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A0.650NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.650% Notes Due 2024 [Member]",
        "label": "0.650% Notes Due 2024 [Member]",
        "terseLabel": "0.650% Notes due 2024 (750MM Euro 1.1757)",
        "verboseLabel": "0.650% Notes Due May 2024"
       }
      }
     },
     "localname": "A0.650NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A0550NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.550 Notes due 2025",
        "label": "0.550 Notes due 2025 [Member]",
        "terseLabel": "0.55% Notes due 2025"
       }
      }
     },
     "localname": "A0550NotesDue2025Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A095NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.95% Notes due 2027",
        "label": "0.95% Notes due 2027 [Member]",
        "terseLabel": "0.95% Notes due 2027"
       }
      }
     },
     "localname": "A095NotesDue2027Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.150NotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.150% Notes Due 2028 [Member]",
        "label": "1.150% Notes Due 2028 [Member]",
        "terseLabel": "1.150% Notes due 2028 (750MM Euro 1.1757)",
        "verboseLabel": "1.150% Notes Due November 2028"
       }
      }
     },
     "localname": "A1.150NotesDue2028Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.650NotesDue2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.650% Notes Due 2035 [Member]",
        "label": "1.650% Notes Due 2035 [Member]",
        "terseLabel": "1.650% Notes due 2035 (1.5B Euro 1.1757)",
        "verboseLabel": "1.650% Notes Due May 2035"
       }
      }
     },
     "localname": "A1.650NotesDue2035Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1300NotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.300% Notes due 2030",
        "label": "1.300% Notes due 2030 [Member]",
        "terseLabel": "1.30% Notes due 2030"
       }
      }
     },
     "localname": "A1300NotesDue2030Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.05Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.05% Notes due 2023 [Member]",
        "label": "2.05% Notes due 2023 [Member]",
        "terseLabel": "2.05% Notes due 2023"
       }
      }
     },
     "localname": "A2.05Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.45Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes due 2026 [Member]",
        "label": "2.45% Notes due 2026 [Member]",
        "terseLabel": "2.45% Notes due 2026"
       }
      }
     },
     "localname": "A2.45Notesdue2026Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.625Notesdue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.625 Notes due 2025 [Member]",
        "label": "2.625 Notes due 2025 [Member]",
        "terseLabel": "2.625% Notes due 2025"
       }
      }
     },
     "localname": "A2.625Notesdue2025Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.900Notesdue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.900% Notes due 2028 [Member]",
        "label": "2.900% Notes due 2028 [Member]",
        "terseLabel": "2.90%\u00a0Notes due 2028"
       }
      }
     },
     "localname": "A2.900Notesdue2028Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.95Notesdue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Notes due 2027 [Member]",
        "label": "2.95% Notes due 2027 [Member]",
        "terseLabel": "2.95% Notes due 2027"
       }
      }
     },
     "localname": "A2.95Notesdue2027Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A210NotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.10% Notes due 2040",
        "label": "2.10% Notes due 2040 [Member]",
        "terseLabel": "2.10% Notes due 2040"
       }
      }
     },
     "localname": "A210NotesDue2040Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2250NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.250% Notes due 2050",
        "label": "2.250% Notes due 2050 [Member]",
        "terseLabel": "2.25% Notes due 2050"
       }
      }
     },
     "localname": "A2250NotesDue2050Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2450NotesDue2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.450% Notes due 2060",
        "label": "2.450% Notes due 2060 [Member]",
        "terseLabel": "2.45% Notes due 2060"
       }
      }
     },
     "localname": "A2450NotesDue2060Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.375Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes due 2023 [Member]",
        "label": "3.375% Notes due 2023 [Member]",
        "terseLabel": "3.375% Notes due 2023"
       }
      }
     },
     "localname": "A3.375Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.400Notesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.400% Notes due 2038 [Member]",
        "label": "3.400% Notes due 2038 [Member]",
        "terseLabel": "3.40%\u00a0Notes due 2038"
       }
      }
     },
     "localname": "A3.400Notesdue2038Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.500Notesdue2048Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.500% Notes due 2048 [Member]",
        "label": "3.500% Notes due 2048 [Member]",
        "terseLabel": "3.50% Notes due 2048"
       }
      }
     },
     "localname": "A3.500Notesdue2048Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.55Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.55% Notes due 2036 [Member]",
        "label": "3.55% Notes due 2036 [Member]",
        "terseLabel": "3.55% Notes due 2036"
       }
      }
     },
     "localname": "A3.55Notesdue2036Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.625Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.625% Notes due 2037 [Member]",
        "label": "3.625% Notes due 2037 [Member]",
        "terseLabel": "3.625% Notes due 2037"
       }
      }
     },
     "localname": "A3.625Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.70Notesdue2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Notes due 2046 [Member]",
        "label": "3.70% Notes due 2046 [Member]",
        "terseLabel": "3.70% Notes due 2046"
       }
      }
     },
     "localname": "A3.70Notesdue2046Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.75Notesdue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.75% Notes due 2047 [Member]",
        "label": "3.75% Notes due 2047 [Member]",
        "terseLabel": "3.75% Notes due 2047"
       }
      }
     },
     "localname": "A3.75Notesdue2047Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.375Notesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Notes due 2033 [Member]",
        "label": "4.375% Notes due 2033 [Member]",
        "terseLabel": "4.375% Notes due 2033"
       }
      }
     },
     "localname": "A4.375Notesdue2033Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Debenturesdue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Debentures due 2040 [Member]",
        "label": "4.50% Debentures due 2040 [Member]",
        "terseLabel": "4.50% Debentures due 2040"
       }
      }
     },
     "localname": "A4.50Debenturesdue2040Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Notesdue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Notes due 2043 [Member]",
        "label": "4.50% Notes due 2043 [Member]",
        "terseLabel": "4.50% Notes due 2043"
       }
      }
     },
     "localname": "A4.50Notesdue2043Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.85Notesdue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.85% Notes due 2041 [Member]",
        "label": "4.85% Notes due 2041 [Member]",
        "terseLabel": "4.85% Notes due 2041"
       }
      }
     },
     "localname": "A4.85Notesdue2041Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.95Debenturesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.95% Debentures due 2033 [Member]",
        "label": "4.95% Debentures due 2033 [Member]",
        "terseLabel": "4.95% Debentures due 2033"
       }
      }
     },
     "localname": "A4.95Debenturesdue2033Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.50NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Notes Due 2024 [Member]",
        "label": "5.50% Notes Due 2024 [Member]",
        "terseLabel": "5.50% Notes due 2024 (500 MM GBP 1.3799)",
        "verboseLabel": "5.50% Notes Due November 2024"
       }
      }
     },
     "localname": "A5.50NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.85Debenturesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.85% Debentures due 2038 [Member]",
        "label": "5.85% Debentures due 2038 [Member]",
        "terseLabel": "5.85% Debentures due 2038"
       }
      }
     },
     "localname": "A5.85Debenturesdue2038Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.95Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.95% Notes due 2037 [Member]",
        "label": "5.95% Notes due 2037 [Member]",
        "terseLabel": "5.95% Notes due 2037"
       }
      }
     },
     "localname": "A5.95Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.73Debenturesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.73% Debentures due 2023 [Member]",
        "label": "6.73% Debentures due 2023 [Member]",
        "terseLabel": "6.73% Debentures due 2023"
       }
      }
     },
     "localname": "A6.73Debenturesdue2023Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.95Notesdue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.95% Notes due 2029 [Member]",
        "label": "6.95% Notes due 2029 [Member]",
        "terseLabel": "6.95% Notes due 2029"
       }
      }
     },
     "localname": "A6.95Notesdue2029Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ADVANCEDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADVANCED [Member]",
        "label": "ADVANCED [Member]",
        "terseLabel": "ADVANCED"
       }
      }
     },
     "localname": "ADVANCEDMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AccruedRebatesReturnsAndPromotions": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.",
        "label": "Accrued Rebates Returns And Promotions",
        "verboseLabel": "Accrued rebates, returns and promotions"
       }
      }
     },
     "localname": "AccruedRebatesReturnsAndPromotions",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AmountPrepaidAndDueToManufacturers": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Prepaid and Due to Manufacturers",
        "label": "Amount Prepaid and Due to Manufacturers",
        "terseLabel": "Amount prepaid and due to manufacturers"
       }
      }
     },
     "localname": "AmountPrepaidAndDueToManufacturers",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AsiaPacificAfricaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asia-Pacific, Africa [Member]",
        "label": "Asia-Pacific, Africa [Member]",
        "terseLabel": "Asia-Pacific, Africa"
       }
      }
     },
     "localname": "AsiaPacificAfricaMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AsrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASR.",
        "label": "ASR [Member]",
        "terseLabel": "ASR"
       }
      }
     },
     "localname": "AsrMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AssetWriteoffMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Write-off [Member]",
        "label": "Asset Write-off [Member]",
        "terseLabel": "Asset Write-off"
       }
      }
     },
     "localname": "AssetWriteoffMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AurisHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auris Health",
        "label": "Auris Health [Member]",
        "terseLabel": "Auris Health"
       }
      }
     },
     "localname": "AurisHealthMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Care [Member]",
        "label": "Baby Care [Member]",
        "terseLabel": "Baby Care"
       }
      }
     },
     "localname": "BabyCareMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyPowderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Powder [Member]",
        "label": "Baby Powder [Member]",
        "terseLabel": "Baby Powder"
       }
      }
     },
     "localname": "BabyPowderMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BeautyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beauty [Member]",
        "label": "Beauty [Member]",
        "terseLabel": "Skin Health/Beauty"
       }
      }
     },
     "localname": "BeautyMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BermekimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bermekimab [Member]",
        "label": "bermekimab [Member]",
        "terseLabel": "bermekimab"
       }
      }
     },
     "localname": "BermekimabMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONCERTAMethylphenidateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONCERTA/Methylphenidate [Member]",
        "label": "CONCERTA/Methylphenidate [Member]",
        "terseLabel": "CONCERTA\u00ae / methylphenidate"
       }
      }
     },
     "localname": "CONCERTAMethylphenidateMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONTACTLENSESOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONTACT LENSES/OTHER [Member]",
        "label": "CONTACT LENSES/OTHER [Member]",
        "terseLabel": "CONTACT LENSES / OTHER"
       }
      }
     },
     "localname": "CONTACTLENSESOTHERMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CardiovascularMetabolismOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular/Metabolism/Other [Member]",
        "label": "Cardiovascular/Metabolism/Other [Member]",
        "terseLabel": "Cardiovascular / Metabolism / Other"
       }
      }
     },
     "localname": "CardiovascularMetabolismOtherMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss",
        "negatedTerseLabel": "Total cash, cash equivalents and current marketable securities, Unrecognized Loss"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value",
        "label": "Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Estimated Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Short-term Investments, Accumulated Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, and Short-term Investments, Accumulated Gross Unrealized Gain",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Unrecognized Gain"
       }
      }
     },
     "localname": "CashCashEquivalentsandShorttermInvestmentsAccumulatedGrossUnrealizedGain",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ConsumerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer.",
        "label": "Consumer [Member]",
        "terseLabel": "Consumer Health"
       }
      }
     },
     "localname": "ConsumerMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CostOfGoodsSoldPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_GrossProfitPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of goods sold percent to sales.",
        "label": "Cost Of Goods Sold Percent To Sales",
        "terseLabel": "Cost of products sold percent to sales"
       }
      }
     },
     "localname": "CostOfGoodsSoldPercentToSales",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_DARZALEXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DARZALEX [Member]",
        "label": "DARZALEX [Member]",
        "terseLabel": "DARZALEX\u00ae"
       }
      }
     },
     "localname": "DARZALEXMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DePuyASRU.S.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DePuy ASR U.S. [Member]",
        "label": "DePuy ASR U.S. [Member]",
        "terseLabel": "DePuy ASR U.S."
       }
      }
     },
     "localname": "DePuyASRU.S.Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EDURANTrilpivirineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EDURANT/rilpivirine [Member]",
        "label": "EDURANT/rilpivirine [Member]",
        "terseLabel": "EDURANT\u00ae / rilpivirine"
       }
      }
     },
     "localname": "EDURANTrilpivirineMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ERLEADAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ERLEADA",
        "label": "ERLEADA [Member]",
        "terseLabel": "ERLEADA"
       }
      }
     },
     "localname": "ERLEADAMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change In Contingent Consideration Liability, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Change In Contingent Consideration Liability, Percent",
        "terseLabel": "Net impact to tax rate due to change in contingent consideration liability"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInContingentConsiderationLiabilityPercent",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EquityFairValueAdjustmentImpairmentLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity, Fair Value Adjustment, Impairment Loss",
        "label": "Equity, Fair Value Adjustment, Impairment Loss",
        "terseLabel": "Equity, Fair Value Adjustment, Impairment Loss"
       }
      }
     },
     "localname": "EquityFairValueAdjustmentImpairmentLoss",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment [Roll Forward]",
        "label": "Equity Investment [Roll Forward]",
        "terseLabel": "Equity Investment [Roll Forward]"
       }
      }
     },
     "localname": "EquityInvestmentRollForward",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "label": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "terseLabel": "Sales/ Purchases/Other"
       }
      }
     },
     "localname": "EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentswithReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments with Readily Determinable Value [Member]",
        "label": "Equity Investments with Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments with readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityInvestmentswithoutReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments without Readily Determinable Value [Member]",
        "label": "Equity Investments without Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments without readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithoutReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EvraAndDoxilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evra and Doxil",
        "label": "Evra and Doxil [Member]",
        "terseLabel": "Evra and Doxil"
       }
      }
     },
     "localname": "EvraAndDoxilMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExcessOfFairValueOverCarryingValueOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of fair value over carrying value of debt.",
        "label": "Excess Of Fair Value Over Carrying Value Of Debt",
        "terseLabel": "Excess of the estimated fair value over the carrying value of debt"
       }
      }
     },
     "localname": "ExcessOfFairValueOverCarryingValueOfDebt",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "terseLabel": "Changes in estimated fair value (6)"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset",
        "label": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset",
        "terseLabel": "Deferred tax benefit related to TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset, Percent",
        "label": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset, Percent",
        "terseLabel": "Deferred tax benefit related to TRAF, percent"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingDeferredTaxAssetPercent",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)",
        "label": "Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax liability related to TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_GENERALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GENERAL [Member]",
        "label": "GENERAL [Member]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "GENERALMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_GrossProfitPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross profit percent to sales.",
        "label": "Gross Profit Percent To Sales",
        "totalLabel": "Gross Profit Percent To Sales"
       }
      }
     },
     "localname": "GrossProfitPercentToSales",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_HIPSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIPS [Member]",
        "label": "HIPS [Member]",
        "terseLabel": "HIPS"
       }
      }
     },
     "localname": "HIPSMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IMBRUVICAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMBRUVICA [Member]",
        "label": "IMBRUVICA [Member]",
        "terseLabel": "IMBRUVICA\u00ae"
       }
      }
     },
     "localname": "IMBRUVICAMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "label": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "terseLabel": "INVEGA SUSTENNA\u00ae / XEPLION\u00ae / INVEGA TRINZA\u00ae / TREVICTA\u00ae"
       }
      }
     },
     "localname": "INVEGASUSTENNAXEPLIONTRINZATREVICTAMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVOKANAINVOKAMETMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVOKANA/INVOKAMET [Member]",
        "label": "INVOKANA/INVOKAMET [Member]",
        "terseLabel": "INVOKANA\u00ae / INVOKAMET\u00ae"
       }
      }
     },
     "localname": "INVOKANAINVOKAMETMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_NetIncomeAttributableToParentPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments Percent To Sales",
        "totalLabel": "Earnings before provision for taxes on income percent to sales"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_IncomeTaxExpenseBenefitPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_NetIncomeAttributableToParentPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax expense benefit percent to sales.",
        "label": "Income Tax Expense Benefit Percent To Sales",
        "terseLabel": "Provision for taxes on income (Note 5)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitPercentToSales",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_IncomeTaxTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Textuals Abstract.",
        "label": "Income Tax (Textuals) [Abstract]",
        "verboseLabel": "Income Tax (Textuals)"
       }
      }
     },
     "localname": "IncomeTaxTextualsAbstract",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_InfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infectious Diseases [Member]",
        "label": "Infectious Diseases [Member]",
        "terseLabel": "Infectious Diseases"
       }
      }
     },
     "localname": "InfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterestExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense percent to sales.",
        "label": "Interest Expense Percent To Sales",
        "terseLabel": "Interest expense, net of portion capitalized percent to sales"
       }
      }
     },
     "localname": "InterestExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InterestIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Income Expense Net Member.",
        "label": "Interest Income Expense Net Member",
        "verboseLabel": "Interest (income)/Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterventionalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interventional Solutions [Member]",
        "label": "Interventional Solutions [Member]",
        "verboseLabel": "Interventional Solutions"
       }
      }
     },
     "localname": "InterventionalSolutionsMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InvestmentIncomeInterestPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment income interest percent to sales.",
        "label": "Investment Income Interest Percent To Sales",
        "terseLabel": "Interest income percent to sales"
       }
      }
     },
     "localname": "InvestmentIncomeInterestPercentToSales",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InvokanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invokana [Member]",
        "label": "Invokana [Member]",
        "terseLabel": "Invokana"
       }
      }
     },
     "localname": "InvokanaMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_KNEESMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KNEES [Member]",
        "label": "KNEES [Member]",
        "terseLabel": "KNEES"
       }
      }
     },
     "localname": "KNEESMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LegalProceedingTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Proceeding Textuals Abstract.",
        "label": "Legal Proceeding (Textuals) [Abstract]",
        "terseLabel": "Legal Proceeding (Textuals)"
       }
      }
     },
     "localname": "LegalProceedingTextualsAbstract",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Axis]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesAxis",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Domain]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesDomain",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LossContingencyEstimateOfAdditionalPossibleLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Additional Possible Loss",
        "label": "Loss Contingency, Estimate of Additional Possible Loss",
        "terseLabel": "Loss contingency, estimate of additional possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfAdditionalPossibleLoss",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_MedicalDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Devices [Member]",
        "label": "Medical Devices [Member]",
        "terseLabel": "MEDICAL DEVICES",
        "verboseLabel": "Medical Devices"
       }
      }
     },
     "localname": "MedicalDevicesMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NetIncomeAttributableToParentPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income Attributable to Parent Percent to Sales",
        "label": "Net Income Attributable to Parent Percent to Sales",
        "totalLabel": "Net earnings percent to sales"
       }
      }
     },
     "localname": "NetIncomeAttributableToParentPercentToSales",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neuroscience [Member]",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NotesDuePeriodFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes due period fifteen.",
        "label": "Notes Due Period Fifteen Member",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "NotesDuePeriodFifteenMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Numberofpatientsinsettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients in settlement",
        "label": "Number of patients in settlement",
        "terseLabel": "Number of patients in settlement"
       }
      }
     },
     "localname": "Numberofpatientsinsettlement",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_OPSUMITMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPSUMIT [Member]",
        "label": "OPSUMIT [Member]",
        "terseLabel": "OPSUMIT\u00ae"
       }
      }
     },
     "localname": "OPSUMITMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTC [Member]",
        "label": "OTC [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OTCMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTHERNEUROSCIENCEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTHER NEUROSCIENCE [Member]",
        "label": "OTHER NEUROSCIENCE [Member]",
        "terseLabel": "OTHER NEUROSCIENCE"
       }
      }
     },
     "localname": "OTHERNEUROSCIENCEMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "label": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "terseLabel": "Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI"
       }
      }
     },
     "localname": "OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OpioidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid",
        "label": "opioid [Member]",
        "terseLabel": "Opioid"
       }
      }
     },
     "localname": "OpioidMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OralCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Care [Member]",
        "label": "Oral Care [Member]",
        "terseLabel": "Oral Care"
       }
      }
     },
     "localname": "OralCareMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OrthopaedicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orthopaedics [Member]",
        "label": "Orthopaedics [Member]",
        "terseLabel": "Orthopaedics"
       }
      }
     },
     "localname": "OrthopaedicsMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "negatedTerseLabel": "Prior service cost amortization during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "negatedTerseLabel": "Gain (loss) amortization during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "OTHER IMMUNOLOGY"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Expense Net [Member]",
        "label": "Other Income Expense Net [Member]",
        "terseLabel": "Other (income) expense",
        "verboseLabel": "Other Income Expense Net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Infectious Diseases [Member]",
        "label": "Other Infectious Diseases [Member]",
        "terseLabel": "OTHER INFECTIOUS DISEASES"
       }
      }
     },
     "localname": "OtherInfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherNonOperatingIncomeExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non operating income expense percent to sales.",
        "label": "Other Non Operating Income Expense Percent To Sales",
        "terseLabel": "Other (income) expense, net percent to sales"
       }
      }
     },
     "localname": "OtherNonOperatingIncomeExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "OTHER ONCOLOGY(1)"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherReverseRepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Reverse Repurchase Agreements [Member]",
        "label": "Other Reverse Repurchase Agreements [Member]",
        "terseLabel": "Other reverse repurchase agreements"
       }
      }
     },
     "localname": "OtherReverseRepurchaseAgreementsMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "label": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "terseLabel": "PREZISTA\u00ae / PREZCOBIX\u00ae / REZOLSTA\u00ae / SYMTUZA\u00ae"
       }
      }
     },
     "localname": "PREZISTAPREZCOBIXREZOLSTASYMTUZAMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PROCRITEPREXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PROCRIT/EPREX [Member]",
        "label": "PROCRIT/EPREX [Member]",
        "terseLabel": "PROCRIT\u00ae / EPREX\u00ae"
       }
      }
     },
     "localname": "PROCRITEPREXMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents And Trademarks [Member]",
        "label": "Patents And Trademarks [Member]",
        "terseLabel": "Patents And Trademarks"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PelvicMeshesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pelvic meshes.",
        "label": "Pelvic Meshes [Member]",
        "terseLabel": "Pelvic Meshes"
       }
      }
     },
     "localname": "PelvicMeshesMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PercentageChangeInOperatingIncomeLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in operating income loss.",
        "label": "Percentage Change in Operating Income Loss",
        "terseLabel": "Percentage Change in Operating Income Loss"
       }
      }
     },
     "localname": "PercentageChangeInOperatingIncomeLoss",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageChangeInSalesByGeographicArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by geographic area.",
        "label": "Percentage Change In Sales By Geographic Area",
        "terseLabel": "Percentage Change In Sales By Geographic Area"
       }
      }
     },
     "localname": "PercentageChangeInSalesByGeographicArea",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageChangeInSalesBySegmentOfBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by segment of business.",
        "label": "Percentage Change In Sales By Segment Of Business",
        "terseLabel": "Percent Change (as a percent)"
       }
      }
     },
     "localname": "PercentageChangeInSalesBySegmentOfBusiness",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical.",
        "label": "Pharmaceutical [Member]",
        "terseLabel": "PHARMACEUTICAL"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PhysiomeshMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physiomesh [Member]",
        "label": "Physiomesh [Member]",
        "terseLabel": "Physiomesh"
       }
      }
     },
     "localname": "PhysiomeshMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PinnacleAcetabularCupSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Acetabular cup system.",
        "label": "Pinnacle Acetabular Cup System [Member]",
        "terseLabel": "Pinnacle Acetabular Cup System"
       }
      }
     },
     "localname": "PinnacleAcetabularCupSystemMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "label": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "verboseLabel": "Proceeds from the exercise of stock options/employee withholding tax on stock awards, net"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProductLiabilityContingencyNumberOfClaimant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability contingency number of claimant.",
        "label": "Product Liability Contingency Number Of Claimant",
        "terseLabel": "Product liability contingency, number of claimants"
       }
      }
     },
     "localname": "ProductLiabilityContingencyNumberOfClaimant",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_PulmonaryHypertensionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pulmonary Hypertension [Member]",
        "label": "Pulmonary Hypertension [Member]",
        "terseLabel": "Pulmonary Hypertension"
       }
      }
     },
     "localname": "PulmonaryHypertensionMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PurchasedInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased In-Process Research And Development [Member]",
        "label": "Purchased In-Process Research And Development [Member]",
        "terseLabel": "Purchased In-Process Research And Development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RISPERDALCONSTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RISPERDAL CONSTA [Member]",
        "label": "RISPERDAL CONSTA [Member]",
        "terseLabel": "RISPERDAL CONSTA\u00ae"
       }
      }
     },
     "localname": "RISPERDALCONSTAMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member]",
        "label": "Remicade [Member]",
        "terseLabel": "REMICADE\u00ae"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense excluding acquired in process cost percent to sales.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost Percent To Sales",
        "terseLabel": "Research and development expense percent to sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid",
        "label": "Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid",
        "terseLabel": "Period of cash outlays for severance expected to be paid out"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedPeriodOfCashOutlaysForSeverancePaid",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "jnj_RestructuringandRelatedCostDurationofRestructuringPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Duration of Restructuring Plan",
        "label": "Restructuring and Related Cost, Duration of Restructuring Plan",
        "terseLabel": "Period for activity"
       }
      }
     },
     "localname": "RestructuringandRelatedCostDurationofRestructuringPlan",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "jnj_RestructuringandRelatedCostExpectedFutureSavings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Expected Future Savings",
        "label": "Restructuring and Related Cost, Expected Future Savings",
        "terseLabel": "Cost savings expected"
       }
      }
     },
     "localname": "RestructuringandRelatedCostExpectedFutureSavings",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_Restructuringchargepercenttosales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring charge percent to sales",
        "label": "Restructuring charge percent to sales",
        "terseLabel": "Restructuring charge percent to sales"
       }
      }
     },
     "localname": "Restructuringchargepercenttosales",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_RisperdalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risperdal.",
        "label": "Risperdal [Member]",
        "terseLabel": "Risperdal"
       }
      }
     },
     "localname": "RisperdalMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SPINEOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINE &amp; OTHER [Member]",
        "label": "SPINE &amp; OTHER [Member]",
        "terseLabel": "SPINE, SPORTS &amp; OTHER"
       }
      }
     },
     "localname": "SPINEOTHERMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SURGICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SURGICAL [Member]",
        "label": "SURGICAL [Member]",
        "terseLabel": "SURGICAL"
       }
      }
     },
     "localname": "SURGICALMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SalesBySegmentOfBusinessTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales by segment of business.",
        "label": "Sales By Segment Of Business [Table Text Block]",
        "terseLabel": "Sales By Segment Of Business"
       }
      }
     },
     "localname": "SalesBySegmentOfBusinessTableTextBlock",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_SalesRevenueGoodsNetPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_GrossProfitPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales revenue goods net percentage to sales.",
        "label": "Sales Revenue Goods Net Percent To Sales",
        "terseLabel": "Sales to customers percent to sales"
       }
      }
     },
     "localname": "SalesRevenueGoodsNetPercentToSales",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "label": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "label": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "terseLabel": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_SellingGeneralAndAdministrativeExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling general and administrative expense percent to sales.",
        "label": "Selling General And Administrative Expense Percent To Sales",
        "terseLabel": "Selling marketing and administrative expenses percent to sales"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.",
        "label": "Shares Which Could Be Repurchased Under Treasury Stock Method",
        "negatedTerseLabel": "Less: shares which could be repurchased under treasury stock method"
       }
      }
     },
     "localname": "SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_SimponiSimponiAriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi/Simponi Aria [Member]",
        "label": "Simponi/Simponi Aria [Member]",
        "terseLabel": "SIMPONI / SIMPONI ARIA\u00ae"
       }
      }
     },
     "localname": "SimponiSimponiAriaMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_StelaraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stelara [Member]",
        "label": "Stelara [Member]",
        "terseLabel": "STELARA\u00ae"
       }
      }
     },
     "localname": "StelaraMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SupplyChainMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Chain",
        "label": "Supply Chain [Member]",
        "terseLabel": "Supply Chain"
       }
      }
     },
     "localname": "SupplyChainMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgeryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgery [Member]",
        "label": "Surgery [Member]",
        "terseLabel": "Surgery"
       }
      }
     },
     "localname": "SurgeryMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TRAUMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRAUMA [Member]",
        "label": "TRAUMA [Member]",
        "terseLabel": "TRAUMA"
       }
      }
     },
     "localname": "TRAUMAMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TalcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Talc [Member]",
        "label": "Talc [Member]",
        "terseLabel": "Talc"
       }
      }
     },
     "localname": "TalcMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TremfyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tremfaya",
        "label": "Tremfya [Member]",
        "terseLabel": "TREMFYA\u00ae"
       }
      }
     },
     "localname": "TremfyaMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UNITEDSTATESExportsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UNITED STATES Exports [Member]",
        "label": "UNITED STATES Exports [Member]",
        "terseLabel": "U.S. Exports"
       }
      }
     },
     "localname": "UNITEDSTATESExportsMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UPTRAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPTRAVI [Member]",
        "label": "UPTRAVI [Member]",
        "terseLabel": "UPTRAVI\u00ae"
       }
      }
     },
     "localname": "UPTRAVIMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_VerbSurgicalInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verb Surgical Inc. [Member]",
        "label": "Verb Surgical Inc. [Member]",
        "terseLabel": "Verb Surgical Inc."
       }
      }
     },
     "localname": "VerbSurgicalInc.Member",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_VisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision[Member]",
        "label": "Vision [Member]",
        "terseLabel": "Vision"
       }
      }
     },
     "localname": "VisionMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WesternHemisphereExcludingUSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Western Hemisphere, excluding U.S. [Member]",
        "label": "Western Hemisphere, excluding U.S. [Member]",
        "terseLabel": "Western Hemisphere, excluding U.S."
       }
      }
     },
     "localname": "WesternHemisphereExcludingUSMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WomensHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Women's Health [Member]",
        "label": "Women's Health [Member]",
        "terseLabel": "Women's Health"
       }
      }
     },
     "localname": "WomensHealthMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WoundCareandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wound Care and Other [Member]",
        "label": "Wound Care and Other [Member]",
        "terseLabel": "Wound Care/Other"
       }
      }
     },
     "localname": "WoundCareandOtherMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_XareltoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xarelto [Member]",
        "label": "Xarelto [Member]",
        "terseLabel": "XARELTO\u00ae"
       }
      }
     },
     "localname": "XareltoMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ZYTIGAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZYTIGA [Member]",
        "label": "ZYTIGA [Member]",
        "terseLabel": "ZYTIGA\u00ae / abiraterone acetate"
       }
      }
     },
     "localname": "ZYTIGAMember",
     "nsuri": "http://www.jnj.com/20210404",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r149",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r159",
      "r255",
      "r257",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r160",
      "r255",
      "r258",
      "r413",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r23",
      "r162",
      "r163",
      "r256"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, trade, less allowances for doubtful accounts and credit losses $270 (2020, $293)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r17",
      "r383",
      "r402"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Accrued taxes on income (Note 5)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r19",
      "r383",
      "r402"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term taxes payable (Note 5)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r68",
      "r74",
      "r77",
      "r272",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r39",
      "r213"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r74",
      "r84",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r74",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Accumulated Net Investment Gain (Loss) Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss) (Note 7)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r70",
      "r74",
      "r77",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r62",
      "r74",
      "r77",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r113",
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net earnings to cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r26",
      "r164",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r113",
      "r199",
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense of amortizable intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "negatedTerseLabel": "Accumulated other comprehensive income on derivatives, after tax"
       }
      }
     },
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r113",
      "r211"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset write-downs"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r154",
      "r381",
      "r401"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r54"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale Securities, Unrecognized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale Securities, Unrecognized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r166",
      "r187"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale Securities - Carrying Amount"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth fiscal year through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r170",
      "r173",
      "r397"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r170",
      "r172",
      "r396"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r170",
      "r174",
      "r398"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r170",
      "r174",
      "r398"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r170",
      "r171",
      "r395"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r165",
      "r167",
      "r187"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale Securities",
        "verboseLabel": "Available-for-sale Securities - Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r325",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits(1)"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r304",
      "r305",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business acquisition cost"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r112",
      "r309"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedTerseLabel": "Reversal of contingent consideration",
        "terseLabel": "Contingent consideration reversal"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r303",
      "r306",
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "terseLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "verboseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r36",
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r116",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Carrying Amount"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r109",
      "r115",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "periodStartLabel": "Cash and Cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r109",
      "r369"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral Already Posted, Aggregate Fair Value"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r50",
      "r234",
      "r390",
      "r407"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock Issued Amount",
        "verboseLabel": "Common Stock, Par Value $1.00"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock \u2014 par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r80",
      "r82",
      "r83"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "verboseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r263",
      "r284",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities(1)"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate, Non-Segment"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r263",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross Currency Interest Rate Contract",
        "verboseLabel": "Cross currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DamagesFromProductDefectsMember": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk of loss arises with respect to product defects and recalls, or improperly performed services which actually or allegedly resulted in damages suffered by the injured party, excluding major product liability matters.",
        "label": "Damages from Product Defects [Member]",
        "terseLabel": "Damages from Product Defects"
       }
      }
     },
     "localname": "DamagesFromProductDefectsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r17",
      "r18",
      "r382",
      "r384",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale and Held-to-maturity [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale and Held-to-maturity [Abstract]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Available for Sale Securities Maturities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred taxes on income (Note 5)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r122",
      "r295",
      "r296"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r289",
      "r293"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred taxes on income (Note 5)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Abstract]",
        "verboseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r269",
      "r281",
      "r284"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Recognized actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r270",
      "r282",
      "r284"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Amortization of prior service cost/(credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r268",
      "r280",
      "r284"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r262",
      "r267",
      "r279",
      "r284"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "verboseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r265",
      "r277",
      "r284"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": {
     "auth_ref": [
      "r271",
      "r283"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment",
        "negatedLabel": "Curtailments and settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r261",
      "r266",
      "r278",
      "r284"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r113",
      "r152"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization of property and intangibles"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r56",
      "r60",
      "r328"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r57",
      "r58",
      "r365"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "totalLabel": "Total Net Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "auth_ref": [
      "r334",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "terseLabel": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r55",
      "r59",
      "r328",
      "r378"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Total Gross Assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r55",
      "r59",
      "r328",
      "r378"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Total Gross Liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Gain/(Loss) Recognized In Income on Derivative"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Detail [Abstract]",
        "verboseLabel": "Financial assets and liabilities at fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentDetailAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r326",
      "r329",
      "r336",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r323",
      "r326",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r323",
      "r326",
      "r336",
      "r343",
      "r344",
      "r349",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "terseLabel": "Amount of gain or (loss) reclassified from AOCI into income"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Assets, at Fair Value",
        "verboseLabel": "Derivatives designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value",
        "verboseLabel": "Derivatives designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r57",
      "r58",
      "r365"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "totalLabel": "Total Net Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r56",
      "r60",
      "r328"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Fair Value, Gross Asset",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r318",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r125",
      "r317",
      "r319",
      "r320",
      "r323",
      "r324",
      "r332",
      "r336",
      "r347",
      "r348",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.",
        "label": "Description of Reclassification of Cash Flow Hedge Gain (Loss)",
        "verboseLabel": "Reclassification of foreign exchange contracts into earnings, period"
       }
      }
     },
     "localname": "DescriptionOfReclassificationOfCashFlowHedgeGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "NET EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r89",
      "r127",
      "r131",
      "r134",
      "r135",
      "r136",
      "r139",
      "r392",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (per share)",
        "verboseLabel": "Basic net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r89",
      "r127",
      "r131",
      "r134",
      "r135",
      "r136",
      "r139",
      "r392",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "verboseLabel": "Reconciliation of basic net earnings per share to diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r124",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Worldwide effective income tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and employee related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r389",
      "r408"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Employee-related Liabilities",
        "verboseLabel": "Employee related obligations (Note 6)"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.",
        "label": "Equity, Fair Value Adjustment",
        "terseLabel": "Changes in Fair Value Reflected in Net Income"
       }
      }
     },
     "localname": "EquityFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Fair value of previously held equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Available-for-sale Securities, Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r11",
      "r16",
      "r182",
      "r387",
      "r400",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "periodEndLabel": "Carrying value, end of period",
        "periodStartLabel": "Carrying value, beginning of period"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r356",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r356",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r356",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "verboseLabel": "Financial Liabilities not Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r263",
      "r264",
      "r284",
      "r357",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Fair Value, Hierarchy"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r356",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r263",
      "r264",
      "r284",
      "r357",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted prices in active markets for identical assets and liabilities Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r263",
      "r264",
      "r284",
      "r357",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant other observable inputs Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r263",
      "r264",
      "r284",
      "r357",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant unobservable inputs Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r325",
      "r332",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Liabilities"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Finite-Lived Intangible Assets, Weighted-Average Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "verboseLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Intangible Asset Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r200",
      "r202",
      "r205",
      "r209",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r205",
      "r379"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r200",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Intangible assets with definite lives:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value",
        "verboseLabel": "Derivatives not designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value",
        "verboseLabel": "Derivatives not designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r263",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Forward foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "verboseLabel": "International retirement plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Gain (Loss) on Disposition of Assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Net gain on sale of assets/businesses"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill End of Period",
        "periodStartLabel": "Goodwill Beginning of Period",
        "terseLabel": "Goodwill (Note 3)"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, related to acquisitions and divestitures"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Currency translation/Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r323",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r165",
      "r175"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity",
        "totalLabel": "Held-to-maturity Securities - Carrying Amount"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain",
        "terseLabel": "Held-to-maturity Securities, Unrecognized Gain"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss",
        "negatedLabel": "Held-to-maturity Securities, Unrecognized Loss"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesClassifiedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-maturity [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesClassifiedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Fair Value",
        "terseLabel": "Held-to-maturity Securities - Estimated Fair Value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldtomaturitySecuritiesMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as held-to-maturity.",
        "label": "Held-to-maturity Securities [Member]",
        "terseLabel": "Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Earnings before provision for taxes on income",
        "totalLabel": "Earnings before provision for taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "verboseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r153",
      "r297"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Decrease in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Decrease in other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Decrease in other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r133",
      "r138"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "verboseLabel": "Convertible debt shares"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r132",
      "r138"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Potential shares exercisable under stock option plans"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r201",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets with indefinite lives:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r201",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r198",
      "r203"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Total intangible assets - net",
        "verboseLabel": "Intangible assets, net (Note 3)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets and Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r86",
      "r151",
      "r372",
      "r373",
      "r393"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net of portion capitalized"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r263",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r190"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r53",
      "r189"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories (Note 2)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r29",
      "r30",
      "r190"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "verboseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r28",
      "r190"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Goods in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r95",
      "r150"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_JudicialRulingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.",
        "label": "Judicial Ruling [Member]",
        "terseLabel": "Judicial Ruling"
       }
      }
     },
     "localname": "JudicialRulingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r385",
      "r405"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Non-Current Debt",
        "verboseLabel": "Long-term debt (Note 4)"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Excluding Current Maturities [Abstract]",
        "terseLabel": "Non-Current Debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted average interest rate on non-current debt"
       }
      }
     },
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r244",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r244",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "verboseLabel": "Product Liability Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r234",
      "r237",
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r234",
      "r237",
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Litigation contingency"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r238",
      "r243",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss contingency, estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r244",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r6",
      "r44"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "periodEndLabel": "Carrying value, end of period",
        "periodStartLabel": "Carrying value, beginning of period"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "terseLabel": "Maximum length of time for hedge exposure"
       }
      }
     },
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r2",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "verboseLabel": "Acquisitions and Divestitures"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "NET CASH USED BY FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "NET CASH USED BY INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r109",
      "r111",
      "r114"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "NET CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r78",
      "r81",
      "r88",
      "r114",
      "r138",
      "r391",
      "r409"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net earnings",
        "terseLabel": "Net earnings",
        "totalLabel": "Net earnings"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Standards Recently Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r117",
      "r118",
      "r119"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "totalLabel": "Net cash paid for acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r117",
      "r118",
      "r119"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "verboseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r117",
      "r118",
      "r119"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedLabel": "Fair value of liabilities assumed and noncontrolling interests"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "verboseLabel": "Total Segment Operating Income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r149",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Non Current Other Assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]",
        "terseLabel": "Employee benefit plans:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]",
        "terseLabel": "Derivatives &amp; hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r61",
      "r71",
      "r368",
      "r370",
      "r371"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r65",
      "r66",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r63",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Derivatives &amp; Hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r63",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Unrealized gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r71",
      "r75"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": {
     "auth_ref": [
      "r64",
      "r71",
      "r333",
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax",
        "verboseLabel": "Amount of gain or (loss) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r64",
      "r71",
      "r333",
      "r338",
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain/(Loss) Recognized In Accumulated OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r61",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r79",
      "r82",
      "r84",
      "r250"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Net change",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTotalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r69",
      "r72",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r71",
      "r75",
      "r76",
      "r181"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r65",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r66",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeMember": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other revenue.",
        "label": "Other Income [Member]",
        "terseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Customer relationships and other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableAxis": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group of items that represent other investments not readily marketable, including description of investment, fair value, and value as measured by quoted value method.",
        "label": "Other Investment Not Readily Marketable [Axis]",
        "terseLabel": "Other Investment Not Readily Marketable [Axis]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Investment Not Readily Marketable [Line Items]",
        "terseLabel": "Other Investment Not Readily Marketable [Line Items]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the investment category or actual investment title.",
        "label": "Other Investment Not Readily Marketable, Name [Domain]",
        "terseLabel": "Other Investment Not Readily Marketable, Name [Domain]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableTable": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the information about other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price.",
        "label": "Other Investment Not Readily Marketable [Table]",
        "terseLabel": "Other Investment Not Readily Marketable [Table]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r260",
      "r273",
      "r274",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "verboseLabel": "Other Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other Restructuring"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r99",
      "r102",
      "r126"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other (primarily licenses and milestones)"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r108",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payments for Restructuring"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash acquired (Note 10)"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Pensions and Other Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Payment for Pension Benefits",
        "terseLabel": "Contribution to pension plans"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r259",
      "r273",
      "r274",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "verboseLabel": "Retirement Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r34",
      "r35"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.",
        "label": "Reclassification, Policy [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r104",
      "r107",
      "r126"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "verboseLabel": "Proceeds from the disposal of assets/businesses, net (Note 10)"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "verboseLabel": "Proceeds from short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r38",
      "r212"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r214",
      "r406"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r90",
      "r186"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "verboseLabel": "Credit losses and accounts receivable allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayment of short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r218",
      "r221",
      "r228",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring charges recorded to date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r218",
      "r221",
      "r228",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Restructuring estimated cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r113",
      "r217",
      "r224",
      "r230"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring (Note 12)",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r220",
      "r224",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r219",
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Reserve balance ending",
        "periodStartLabel": "Reserve balance beginning"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "auth_ref": [
      "r217",
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
        "label": "Restructuring Reserve, Settled without Cash",
        "negatedTerseLabel": "Restructuring Reserve, Settled without Cash"
       }
      }
     },
     "localname": "RestructuringReserveSettledWithoutCash2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r251",
      "r404"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r274",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r274",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r259",
      "r260",
      "r273",
      "r274",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r259",
      "r260",
      "r273",
      "r274",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r254",
      "r255"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Sales",
        "terseLabel": "Sales to customers",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Components of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Equity Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r326",
      "r336",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Derivative Activity"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Financial Assets and Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r200",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "verboseLabel": "Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r335",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule of Effect of Derivatives not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r222",
      "r223",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r219",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r91",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r85",
      "r87",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r148",
      "r154",
      "r155",
      "r156",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r148",
      "r154",
      "r155",
      "r156",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Operating Profit by Segment of Business"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of securities that an institution sells and agrees to repurchase at a specified date for a specified price, net of any reductions or offsets.",
        "label": "Securities Loaned or Sold under Agreements to Repurchase [Member]",
        "terseLabel": "U.S. reverse repurchase agreements"
       }
      }
     },
     "localname": "SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]",
        "verboseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segments of Business and Geographic Areas"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingInformationRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]",
        "verboseLabel": "Sales by segment of business"
       }
      }
     },
     "localname": "SegmentReportingInformationRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentsGeographicalAreasAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments, Geographical Areas [Abstract]",
        "verboseLabel": "Sales by geographic area"
       }
      }
     },
     "localname": "SegmentsGeographicalAreasAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r94",
      "r188"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, marketing and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r14",
      "r382",
      "r403"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Current Debt",
        "verboseLabel": "Loans and notes payable"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity).",
        "label": "Sovereign Debt Securities [Member]",
        "terseLabel": "Non-U.S. sovereign securities(1)"
       }
      }
     },
     "localname": "SovereignDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r1",
      "r154",
      "r196",
      "r216",
      "r221",
      "r232",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Statement, Business Segments"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r52",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r21",
      "r22",
      "r250",
      "r251",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Employee compensation and stock option plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r311",
      "r312",
      "r316"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r51",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock Amount"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r51",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "verboseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r51",
      "r252",
      "r253"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "verboseLabel": "Less: common stock held in treasury, at cost (487,141,000 and 487,331,000 shares)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r250",
      "r251",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r263",
      "r386",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Gov't securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnSecurities": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in the income statement on unsold other securities.",
        "label": "Unrealized Gain (Loss) on Securities",
        "terseLabel": "Unrealized Gain (Loss) on Securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r288",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r130",
      "r136"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Average shares outstanding \u2014 diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "AVG. SHARES OUTSTANDING"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r129",
      "r136"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Average shares outstanding \u2014 basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1930-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=SL6284393-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e14981-108350"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624186-113959"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624258-113959"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061172-113977"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80845-113994"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118948100&loc=d3e30304-110892"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "820",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r422": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r423": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r424": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r425": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r426": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r427": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-03(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0000200406-21-000036-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000200406-21-000036-xbrl.zip
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M'<X,M]ZC+Q4G.LMTTJVO5<3$:I5GVRJ?>/5>?/I_!'#_DG#Z?U!+ P04
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M1T>#_3&,#V#D#\U.M)V&WHWQ2Q]&@\,7@WU_5#EX_]K_ (/A^%=NQ@4V=['
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M7?;^36(3\R*1S+ID@&A$,0+'9<B'5:7G1<+9;?+Y(SYYS.KG9P?*AY-8IB8
M%?$1IAJT$-A9X]#'P#D'YIGV"?ZR9>ZX+2897'8PZ&T2RY!*+< 58QLF4F63
M)+U(KLPAQC1C-_X:A+9^N[V%H;B@=O"AD(N,/)$SIPC61C[/U?;+DF^;!M>W
M9ZO%:^"6T1$J(HT$,6DK7%H>1BW[9<^W39[KVS,[M"ZIEESCQ?S\&+FI4,IA
M:<;EW5=O.Y0Q7I(6LYHZ8D*L+,,FE1)U\^2* FPI[X5-WFW&>$F648M-2TP*
M(4)8FCFY%(222K/8RP2K8#M >F]KVUALW&,V- BY<:Z (U5LG,Q&BC]17-K1
MI:_U8Q5)D ZZ[ ,D"#U(#AISP%BH]Y%9[JN-W_'JR_J&]C:LUR1U&$;$&A:7
MEI)Z0TBL\ X'B/U1^]X<7_8[/KOHCCH].[F8;W__X/0G0XO_=GSB!U\?W?I!
M'PV;^G(@RPGK+"7C2#X"8=+01^KH)$,*5"A>:@(>MIM@;^%OL]*-D^/3TV='
MB^C3X7Y^XJ=G]P>T)[-7M5Q&^M**:H8^_(M=8\5LI7 3FZ#$O]->=4FE+]0J
M6;-*#QV:.GE1L4R8>L#.;5^LM+I77=:$GQ"-*K0AV.J@.AJN1&P2HEB(K#,5
M1-Z-X?[4QSG]E ^./AL?X).G?W?[^N#HZ_M^>'&&V^FC@R<_X0$^./D''Y[[
M\T=>UN=ZUN_\4DA]=JP7'^#U-W_ A_M9,(J9PXCY/#*Q!DA5>A,'M"PQI.9Q
MP_M;Q=6-X].S>_VWH&M7_6Q*U&.#GH,OI\X@  I6Z*:</29"CC/-]]\QU$_-
M\C_?+'+KAR?CU?9R>I97E#RRFI(&PI?!'<ING1(!>"MYIC%IFQ_\>3]8JH\O
M+LJS!S['_EU_"_G[^O O3)P*]11: JTC\Y$L(_67T%,)9:9S)#;X7P[\GQ=E
M]Q_[&1)$[% *18!2.5$O:-@$2M1GG1R3[+O?L#^5T%UI=(A$<2U&M460[,*P
M'+O0F&IA:[3A?1.Z^X?ZE@2UZS*]4Z!Y9 J8J;7E1)_$.-/ G!U#_=0LOZ+0
M7<</J"N#16B5E]-6.Y; F5(*=6C=@F'S@ROE!^L)W97@7R-IM\;5ZLCZE_$V
M')MR'?!,K?L&_RL'_Q6$[CK8-]%0!Q2KAPHBRE02V#+B*7O->?85W=\#MAM\
M^NAOA\??[ZJPO&02>&>=(^M7<[QQQ!Q+EQJ!*$GQ8KD4#LTIUYGZ96<&^3M2
MN5<:ZH%"%6ZY4<F0-7'RB"'5V .E@C-M)MQ1J+]-R.V-CEWIN*,Z\G4%%#:'
MWAMK+RD7D+P<M!-FVG^YH^!_6[IQ)[QO2LPOYV"60-QB[: #\R8$$@UCQ-CJ
MEL#O-.2F5JSK )ZS:@N"&;5!*(V#VS*&>-DD5;6ER:LU.P#X3;&N7I;!AKD$
M;LD]0F5!#.P08L;*N>39^P]F ?G54JPK03TE;3D">&; U@BM($$MW'-$+QO4
M=QER>Z-8UP$_")GFT!G1H%"5Z#DWY"6E\9C[!OY-L>X;YGM&3$&EA(#0+3!2
M0H'>>R"-LB7P.PVYJ17K.H!GRY*XQ23!@5!)N8N-&TU#'="?O$0S<7_!K@OH
M*0LT$8+%#LLF$8/D#27'9<9)YD"<E#:X7T6X_W8I/27H8? Y4N_:8H14C"U5
M@A9J)Z?89V\QV$ _FYY=:0)NS[%@P0ZUP$CNN8EGYABS0O?BFQM<)3>X:CMF
MQVM5Q^PU1@36PA2%I2DYTH#GAOXKA_XKLRJ; N12K!DQ 7KA6A(3.G*&X0XP
M>5%G@_ZN:MR5]LLFZ<D86ES.QEMF([=<1Z+#TBGG.-.Y[!O<Y].X:]4QE8O5
MMNA<B+%*,/4Z"-^&[$VU;:"_BJ"_<FNVEE)I#+&"+ENE  /VY=#&ULA-:M[<
MX"JYP57;+,L]:ZJD,<K(?-AY,'\V1)#H$M,6!*X<^J_,.BY)2AA*&1Y@$$6P
M-! N@9;I(8UG6L=]CI&;?GKP]='/!/6[QT?V_#ZWK2UA+TLVZIQ+RCZR]P)"
MC<K(ZE-.V 5UW#01DV]PWB4XK]1';)DK<(\2(WCH+)QK31QU4'*$F69U[Z)1
M5UI6#^XQ>*Y<$6HGCLM)J0Q-!ETEXHDX:A>-NHZG1NC>.L9\<9$QB0KETE-/
MX]9:9M^RN!/'?ZSONKF(*5%ELPP&%3EF2=V)#(E\$XI[X<O8((4N K4Z&/9E
MHQI!J9%3= A;W]->978K'84(U:6P2TX)2J_BH9@NJ\RU=@ZR,<D^86RE!=V<
M)(LJ+>,32E$<28I"27V9&[4<W;[S)Y&]G)7WR=.+PS)_YDS-6_\Z'Y_X@>OY
MR<'9P>7M:7V.DN\&2I</???X[+ZS'1P^O<,GW_H9+^=WOH34LP_QXZ-/OS\X
M>_3\\3=]8/WQP='RC(OO<OE0>ROGHE71R&'\&2Q!$,22..G(>KA%:SC322$;
MC":)BMK$:C-"40"-(*U*)(&"N6/)$YQ(ND'M#S#6)9V/RA%U_),:>X-.F2.4
MD4I):=5H_+S%N[>*GN/SL\E#GK&V"M@O)I28&P423D4(6UB.C]M"WAXB:?VH
MY]D$JH$V&@HP!PG.41JX0VP1?(MZ^X.VMQ+X=(@[\425D*#'(!8'2R7*326K
MV50 ^G$^^GC%I0GOZ6=+"]XO#%&_??3D_.STXA%QAD7078&,F84RXAL[ V3+
M4IV"EI"J+^.*VM6 3-H@\]LATTIP2Z46K@1*BI&XTU!G$$15PNY#9B>Z&RX#
MMWD2R.2$L512AIA 6(A#44H60$(LDJ=29!O+O L-YHY#LB_J2PD2):R@N5(+
M'0MAP-UGF0ESF7>SLOMV<M\$U;6;9$"H(4G.U$9*H\ ><DA7 R_OF&(FQDO4
M9<,7EY8'2H9&0C?RAE$!0%G@:N#E30G$AI>7S2!:$( H@F5( 4A<(E%I$JJI
M38"7O3=1C3'5U#QU;U"J2(\A061TIR3H6Y:Y)RY]62O;:6A6Z@D\(@2..("R
M;/J2.M+.HF7W7?I=I)B[XMT!&Z604S51""%3SLKN-7J/-FZ_&M9ZDW?OBK4H
M8.RI!QMV&AEXD]27)ME6'10+Z-6PUBSUF>%!F2K&C*G"D$V40#"A-FXY2]HB
MYT[%+9"2>Q?*!$/=+F<AC:0GQN7F*-C3U;#66X];EV0M[-Y)/4I4@D&$S%:*
MH0YR#"."X=6PUEMGPDNR5J<8T$,D[!$*=-&4>M-H4!E8)R@[?L*'?*3^X)'[
M+TPUN5@JOWM\I!==V&>?'; <'%[J8OPGYZ<'1WYZ>EW_=7YP>O!ZW_7U\Y.#
MT[\['YX]FB0\>J@NF'6D,@FZ9E3L;?ARI1R(7ZYX[; +;Z"X=*98FL.*DV?Q
M &60^V %*-7-\V#[,D%!Z#>"XL;O1<2NN*U6S3T6=6"!U(Q&JE1K"95[:,$G
M6'7<60M=D@])HUBDJR?M4$TY$9<6,G?"NNB.>78_K<=NZV\PTFY=),8>-("F
MP(VLI\QA9+O%=0*Q_V,KX,.G3_P_9P]=5@R\?=2/3QY?^/$G3V^,R_WU\<G3
M>_VFR]GSELBGK[_YW_W0SH[',R[N^\UMD[M"P4',:T H@0-X'.[=2^_9#4I&
M*1-T)/X:,AX<?^<7/1:OV.\2$Z:K!I;E"*%EX5YYQ&OCAB%Q;;'%VJI"GZ"Q
M[%U9['+0^_+=/COF([=[)P^.#^V+(_.3ZU^?^,6NV=.'Q_?]R?D0^OPV!EZ^
MI4X09@\N7K5 &@*->DN96M"+D0T3;![[.:N]W+%\WP?IG/J/9OG16!OQ_$$I
M%VU0#;;!.P@YN^0HK2:VCE2T3%#T^=7\Y?CDR?')L.(6I2X#+"67E(QC-8C
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M@LW=EYSKL+0#"M4J0WD*Q-2((/;FJ&[:,,XPAVR#_S[ ?QWVYX(YM2$O4^M
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M@ 2U%B3,I8TD.?>01_Z\\>F&S=7R4RLMC,PT0R* UJ2W@1M.9< QEKRM0TZ
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MWKI[]_K_W/K\L]OW[CZ\?_ON5]<?WK_UC]LW'O[I$017PUVN8)N$@)A[\-B
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M9(:-HU7ICGGCRW>B7=Z)#TQ)G%A!J4!5C@A%!T";><&4<RV4^PQ]?1M WPU
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ML6DTU0C),@G)@K)9K& 1,7"6D6'.*,45XB*$J%!@X$0WEJ1AW*74[MA%'K5
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M V.1PDX2S9QFWCA+(_5&8RR5!'>R_JFU#>_7@/<7U/]3 ,M'(H'I!7.*&QM
M$#".Q+ HF6WT?N.6/OFM1A,"DAR#=Z@"<+U5!/"Y\D1'1XW"]3\_I1&".@G!
M@G+<D/8&4VL()0R8WUK/;(C>R^ 0PJZQ!/5'0;74SISX=,@;0SHX1K#6P'S&
M4$ K4D2G=:.=GSUC+BAF$JD+ED7!G6.6 &*(+$'I& (#+%&'F,G"W*T?,NO?
MG711[3VZ!8%99 (7PJ 04S/:8%&T(ACL' E8H%K%F!NN?"JZT@-31ANI(AB4
M8TKKI-9&4)X82T">=>F/7'?/Y!$DH)9*$T7#@"TQ$EXR#EH2_E*$4M*$(<+5
M(7&B8<_'8,\%Y35+ZBA75B,%OKGTQCF13FK2#+- 9*WJSYX=RRQ&HT7F"=.:
M&14B8X19X7"4TF C,66F5B5ASXYE%J-E&#,A>(*\2L=8.&ZY8<$&$X-CT@1?
M RWSXT#+ZYWV_OKK_7>;[;W-O?MM7E$_%EU^3V5!X4:L%%A;QR('':JUTEX%
MHP3BD5#LZ]+ O)&")R(%"^K!ZY%F$46G+6$X*FVTP 3^8Q(S%NOBKS^F%#0.
MV--%TX8:&[BUR&O' JA\%0!*6ZJ#I4'S.M36->+P%,5A0?T<L.9@%E@$]X Y
M1 S32A).E>12VM*Y;*Q#PZ(+U-B8Q-1O1%N-/>-66J8,?&"BQQ3;1F,W++IP
M+>H55]QA%#D7S"( $TP)A:03A'-@S-IKT;V/NV^W7M]C9DO]&'/Y_<L%=?<)
M2'B::HVL951+8U(S/1T4,I0@$VNOGAO>KP'O+RC3%DNCI7,6"<V V:V4Q%@<
M.?$ZP>>:Z/W'<NX:.7N*^#QXH7 Z&MU*S@(S&A$? L.6VAB1:3(N&B%X^AZ
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M0N M4&6,XRR"J=:"$@,?80'W>3*2^>C47-!>@M22&(= $FF*(FA/C3.&<^4
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M 'S]^7B;'!ROXYT-?[2]\7?O('W_?;?W^4)G0DHYH\'XC'%%,D:IR13%(4,
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M4B??!WR=(R#895Z[TG5J^7$1DP"6[0/3NE0@Z8'-3XJK[-@?AE%BWR1BP)
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ML,@(&YX-1Z'71!L>L4*W@B%E [9I[ CX85J6 @L)9!U>#,4.QJ,B!6ZBC/I
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MSCPPPST.P<>,>Q0R9B7/C# JBTY38@56#D= <&Q5TSM[8$U$>'D%^!$\L$:
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M\_+T?6F<_O#30:?],3W/]N'FZ:>#C]__]_3]M\\.2>N=8X!EU/D@  'E<;)
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M3P;?;'WEY$=/T-EQ]K.OJU?FN5&)BDUY"YO238:UF#=&*FV!1RZ!14S *(S
M"QZLQUJG'\FF7*%-2B]X0GH_#SIHBBV^Z.OGK:^G= L6??T@^GK"@X^XD\XK
M"28* \P%!)IF:5##@D<<$>.SOB93^P"+OIXG ^,G'MLY,# VVIWCX3W[^98
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MER3B5@MW=R3;]73A>C_X=F9TO;@V(>3K8\&]POKNS/K>3]IT$6N/B$"@.,;
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MRY@45E&TS,.P"L]M%"HPHC!E6&.EO?8\1J8Q2_I&%58Q[_J&G^L;G/0)(28
M<E3G2A<1E%$8",<2":19U,F.H6J976/&/ FK> X%A'+5]ZF:XSR+\AR/66@G
M2>0B9[>HF[NHF_:$=U9QRCEC 12NO;-1@+&.0K)M(E&""B1'A77TU7SNII7C
M*(5U[HW<("72&DNB.6:26FLL%XZ2P+BBUK."W(8@=\+A29W5B2T 5B09)B1X
M,)11$!1YIQA5PA7DSBER__O_*(+)RR*F(J8BIOD7TV.G\CQ9^9]\=JY*W][V
MH>L'U9%I^^J7GY[T>Q/ZN_NF'V9K29!KBOD=]KJU;V/C;'AG7YT'_2:-])R*
MH$)%_IF*G-Q\EN_3WGYZMD_M[=?;I+61OG<C?>[UYO?M@[>GG_:^\-;&1_;Q
MPR9KG>[G(Z6?@_%*T\"!:&&!&81!8R?S47RL*:<T_6-I%:^@:TI&'(5^-<A2
M_/<UI_D6R8O8B$84M^;XYR"; %[&6:'[=\/8A:'.G(B86 M.A @,FP02&PUX
M([3%*@;-PM(J61;\:OFI$FQ<"  _II%> #P; %_8Z]H2+Y-P@%*.@2$B08=@
MD[TNK)1:*&4*@.</P/<S+HJ8BIB*F!HHIN<0S#ROJI>+\H;NH"YF4Q?E&>1M
MONH=U2\<Y8)@)=CY@.;4-9D7HW-RDX4M_S*=XW!V;*R^YEUHUU<5+G8'+M9:
MGS"FG!?2.17 ^J@3%[,*K!41>"0$,<6T)WIIE5^3MUE\O<T&\"/;4S>4N2M0
M?F H7YA52CKM/8I <0C &":@L' @N2'64I=[=RZMZFNR,QO4ZJ^@N&$1FR*F
M(J:%$=,=MD1K)4*<!R>%85)%*ZP7BBIO'3'!F%FZ&,LF^<";Y$52,<+64V\D
M.,1\3BK&H!5#@&S:,+E.=%CG"-LR$TUBO(M5 >-Z;+X+1\=]MV\&=2%%-RJ;
M4IOA][*\Y]?ST]1(YB5-5.NF-?>?XW8_^/7>8+@=AON]HICNI)@FBT,(KQ'#
M2H+&.K'W$ ,8F?04E@(S'AVEGM:*B5ZM#;$009&FW&,QE<J3NY.+F(J8%D9,
M=]FB'].0*%OT[+?H"]N!6<$IX0ZX]0B8B0:4,,EVB(1Z1#SAF#5JB[Y'\?UR
MY5-=^1SBK3LW=T#]I=,;#/Z]7'7#,-M_0_/]F05<']GLNT=;HJ8U?9^/'60R
M==5)'1DC'CA6%A@F%#0U%'R2'Q$$16W0TJJZVJEE(2(T3;E'T1\:"9U[_(EH
M%,.)KT1-D25(4JTM4;?AI$5_/)K^N"BTQ;"0RBD-RCD#C)((5CH.Q@I!*=5*
M<[JX^F,Q<5M"AT5,SR\&] ]5T.M6/!4K-="?50UTIVS4P7,1%&-,4,4IDRX2
M@8WE)(AQ=:^I0^VEJ-=C,IB=R7Q3RYBW2#D@,2>I29;("Q8,@O$8:YK-([6T
M*OBRHJQ4$2PN^8=0,\0);[!#1'#!J+>*!F2B\\8PI3R21<W,J9JYR(45BE(E
M.08B<C$O%2+DC04"UCCM,<)94]= %\L<E5X+1<\\3+52BHCVC!J#O6#2.&L1
M\8X['P.U7JJ;%4VI5CH?&N?"-4.M2[N(-I!(K %F$Z<QDM'TPTEO;1(S=W4-
M=$H:$ATL>)]U;Q5*990F6"4UTP0;(XBA,2,\6R^L\(HY1?E%#71DB$8T2@A(
M8F!.>] R\0KOD9)&F1"3<$L-]*)E'I!5&.T3ES ^*9K L!9&*<LQ<S)JC[FS
MA57,N[ZY2#F*(FJIC08J, ,6L ,KA0+FM5;"<XNB'-5 %],$?4K.T?.\LA;6
MKS5V5Z_VN+^NA?UH0>5&K9>KS#W9QPY-_TN["Z-%^((G;3M^9=@[JO]YW7WK
M)SZ'0Z^?U%N&0L<<#<*+LS]>GLU8NULK[/I#/R[^]"TOQVW$]0H7=:_P\>H?
MW_Z?&Y!3M8+1[3J0W^6V\]3<?I[&BO&*(O/4W'Z>QGH[&(PWF;,+QE2*UHSQ
M>NUWCR[:Y=)'N/0>=*$PC#FZL@AKCJXLPIJC*XNPYNC*(JPYNK((:XZN+,*:
MHRN+L.;HRB*L.;JR"&N.KKR?V_WL_=G')*_$C$EVTKUJYZA=]:K='PRKM\>F
MGX92;79]\-6VZ;O]44R9Z#I)'U5SX:''(\?MG3WT<D7?TS_]<Z^W5 _BG,4/
M$4W01,_)6+.'7L[+8/4*DF)^QJIN-YY_V(_NX3:^)H]CI"T>)Y%#WRJ/8Z\W
M-)T;"Q<L_O._"T.37O1US';SG]J$+_Y\K#EW?'C<,</QE-3'H^N_+IV1KE\9
M'91^QI,U:K!4U3E'HQFIBYU6:X>]X^[P&4_,65FG>E(NIN>:>7E6AT0W@@N'
M-I'2$0?%NAP4?28'1;FT&D5GG,*:.>04951[1%2P4K-H<@HDUHGLZY)I/8/,
MQX/W)Q\//^*/']ZB3Q\VZ:>]MVAG;Y.W#K=//WW88FD,^-/!?OO3ZRW^8^9C
M:^^/]J>#O_8_;;SK?-SSG=;&6[Z]]Y5\/$W/<+"?GO>OPYW7?WQ-8X_;D_50
M&:+6&*N!,TV!!4/ :D& >$X(YDP2%)=6N5YF\FHSU))J?0>=_\Q2K>^@9A3.
MQT0Q-IXJYH2VQEH=K%,B6&9H43/SJF8N#HH&ZZUR+("(7@&C#H/A%.>R1]+C
M]**.)!\41==VHRQZINB9F1SI$)9I0E1NX<,,#UJR*)E%DBE/)!8W*YIRI&,^
M-,[%05&=NTQ$EE8X=@&85PBLXAJ4$=)+2CV2L3XHJO158E,.BC86[W<J":V-
M,30WY<()X8G;4AZI83B2Q#.*^3*W*+\X*(J=X-(P!,HBG% >/>3J?! 8"8(8
M[I7%Y:!HT3(/R2H<DL&I@&RVEQ'SFB.EM1,6H\BB=855S+N^N3@H2@G5,28:
MP52,P)*!"H92!$@J)0QUVI,P.BB*93-81<E8F:,KGT-Q^E885N&?0I:+6=ST
M#IN*1RXXRF1BK)Y13JWF05*CF=;*HV!SZ>B\J23=D]."$)V"Q":)7%2/+GO#
M7?:&R:KSFAMIN$LT-%F8P(R,8"RC$*R1WD<L/"%+JWQ9ZJLU!$I9XH5!;I ,
M)4/3>\X\,R@8Y:S7V!)B55H)HB"W(<B=:.G-(\8BX=5K1( Q*\'HP(!PZCCW
MQ";M6Y [G\A]\H+B14Q%3$5,\UJ>O\ZR?XJ97C>#_2I]>]N'KA]41Z;MJU_^
M]3,>\B;T=_=-/\S6DB _<HY1^F#MB-HX&][95^=!OTDC/:<BJ%"1?Z0BK77T
M[8R*I/MTPN_O3CY]\$>6,+&3[OUIXV.:@VWZ\2!71O,''T^_HD\'+LU;ZV!G
MX\OW3QO[AY]>_Q'3LWUF%G%#A8=@L@V"< !%L0&B*74)LURP9(.@%<VO$)GJ
M*/2K09;BOR^?,5DXE^_TC9T>TSH_!]D$\#+."MV_&\8FVL-%8YC)W1 $99!D
M9D%K8T#Q@+&-V!@>EE;),D=745(BPPL!X,<TT@N 9P/@B;8#WFF1S'30R I@
MBFFP)EGN7M$8@A(*4U\ /'< +EW9BYB*F!9&3,\AF+EY>-3IG810Y6;;H3LP
M-?$PW3S#:9NO>D?U"T>=]!TEV/F YM0U:3*C8XT;Q_V<').>H>?_,IWC<';*
MK[[F76C75Q4N=A<N-GF "$L7A6 <D$/)F%+"@W(^0C"8"!0(XT;F T17F5CQ
M]38;P(]L3]TS&:Z@_.%0?F%QL8 Y$IP <U0!0UZ!#28 C=AXEG0V80GE>!FQ
MJZ=W%JPI]APB^394L-F3ODAZ]<EC:$5,,^:O)')IK-#:LL"8)-I@:8ESCI @
M!5.S]":63>^!-[V+9&^KJ2!:(O !8V"&Z!&U1<@)C;@DP=N\Z0EVM8?R\XF0
M/P4VWX6CX[[;-X-0]6*VO7-!F]KBOI>1/;].GJ8&+2]IHEHWK;G_'+?[P:_W
M!L/M,-SO%<5T)\74GBS:88(R6!D0N?\I,RJ (<A#=)@;RG+I!)P5D\3E:.L<
M@?G)/;9%3$5,14Q%3$UE,(]I9Q4&,WL&<V%:24*XT]H#<KGL6#*EDFFE,=A$
M107*R1VYP7.#&$PY1CM'5SZ'R'-=XK8..Y^7MZW:]5FPZI=.;S#X]W+5#<-L
M'@_-]V<6>GYDJ_@\<G5Y!ZDE=*G^\,59O588[L0]\[WL('?8078FDW@Y\@11
M(8 D-@!,80Z:^V0(8QJX"I9)D2LQ<++H\:A% FX)C<R%F.ZB7R7S*OCLKD*.
M>1&M3M1/:A&#]=I95_1KD_3K1?T\&I*,N"$@G/' +#*@D]$%2>L:(U!02LBB
M7^<,N$6_%C$]OQCB/_0WJ+ML56<-MDIS@V?2W""0J".C5"B!&7=$IY$YA*44
M)/ H=2[;-XM<C5*M[U$YS&1N,@DR:F$51.UCLA$]!Z-)XC#8D(!DC KCI56!
MEXF^FL%1RH.6H,4,U$PR?Q0*7*MDX3 IG!9.!*N]54@%35Q1,W.J9BZ2HY$0
MVC/,P)D@@&EE06&/02JBL49&Q<!S<P.RK%%IHE+TS,.4(::!*$,0S<E!S&JJ
M#.+!6^><5(BKGRB:4H9X/C3.A7/&:6VYEAJX4 Z8-PRT"Q:\ET$:XXU'/FD<
ML4P8;4;\M.!]UKW9(O<XDH1YHQDA5%&+!4/IA2 Y)ZSPBCE%^45S Z$E1C%1
M"DYH754V@M::@I9">>D=)8R5Y@9%RSPDJTA&BM?&6!.23J'!6,21Q%*'I&,P
M0Z*PBGG7-WS"CC$A:,22X1(I,*PM6&\HV"3TD/87Z="XN8&ZZBYYRJRLL^\Z
M6^6\1O.L8PWE'N4>#W&/>A'_6NNTLY*+Z<?9O:YTS!YO&JMU;^K+E1H?_6-I
M O*PSY^[UT^Z.S]SQQP-PHNS/UZ>)>FUN_5N5'_H1V0/>T<OO[7]</^%UBN8
MD$R'QR&H\>U'[^*5FBG_H&9&[U&YHA6_\6VT@F]\[V>W52M2D7O=]>??F#;2
M!QBK)GI.QHKQBI+S,EB]@J28G[&JVXWG^AV4_F0#O8,>+)<^XJ7WR% O2>US
M=&41UAQ=680U1U<68<W1E458<W1E$=8<75F$-4=7%F'-T95%6'-T91'6'%U9
MA#5'5S8IT'%H^E_:71CVCEY@>CE@?^DV9]>[A\^=(-F?NQM"U>H-TPV'O6J]
MUQWT.FUOAL%7K]I=TW5MTZEVA^F%PS3*P8V/-[XG(RN2I^\]Z@W:.4K[HA\Z
M9MC^.XPC+>.LHXD/CN*K+]#%1XQ-8S@>WOR1IDP=^Z%MV<3//-HZ%P )K;U$
MA%/+F-71.H),X (C'UD0^C,32V<?VC_WBA^9+P%L/YBO8&)ZP!>F\\V<#)9^
MO;RDTGH:#XC(-.(?Y^MI9F6O#M#U8EY,PR2>ZR:I@<+\8^?WUNY.J_IO<WCT
MLCK[UUIKH]I]_]ONUL;6VKNMS=T[:X7'?HSUG33N/[<VUO8VT\CWTJ_MS=;>
M;K7SJEI?V_V]>O7GSH?F/\4O[[OFV+>3%GI9;>28;G]0M;O5=KO321IB\.]_
MTK)CI9(UT83>Y3>HW0<**4M4Q]GN&E*68H7BV<<HT0JG]%Z?_'G<C_'[11.?
M9JSJ5G?]!Y+7B$.G:HK,R/L$ _5M'G\$J29-P*MV3LZK]O;[B>=LI\OW!]5F
MUP=_:4YN*?"'":K.Q3RN'?7;G8HMUR27(()GL:;F="[.SV^?30:ZRV*:L[/L
M-S2+/N<2U:MW.]O5SIO-=VM[6ZW7U=KZWM9?6WN37.EFL=\_47K!YO/6>KK,
MV,TS]ARJ\+7"L JFWTWC'53W6B__D%UZE\EJ6OF)ZZ?L]N4GKGO$IIRLF+IG
M2*08DQ"<$HCE(\.&>RJTB,@1K8FJZV(1C#!B4/^1"Z+>]R!76J47I;&6FG(^
MHM4^.Q^QS3_MO6IO[ZV=?-I[RSX=O/W6(N_V/^UMH];I_O[VZT]?6Q\V3UNG
MG_8OSD?4UZ'6QOMOGPZWOWW<>XNV]S;9-GE/M@^VV?:!(ZV]M7SNX>KYB(W]
MP]9&^NS>;X<?3W_;3W]_W][[<IJ>XV3[],M)Z_0CWM[X^CT]>]P^02?GYR,B
MHR02IR%2+8$Y)$$9*B RHKD61FC)EE;%,M:R0?U 9J2(SN^QF"67&MI'HR!W
M"N2BB_/2TG.+0UJG%A-(HK.@7<(PY9P2I#C67B^M\F6I18.0^QPLES5_<#P8
MUL&,'/'HAP0UU^Z$NGCQ.;-*[S@SV*]BI_=M4,5^[[#J'86^&:9WJRRGO]O#
M=AB\*(R]V#CS:./4ZD&.8G5-GH&-<)00VK[H<FT.\\'<T]$+O5@=]3,NAR?U
MF^WNT'2_M&TGW-S[NC"2.;,E)I= ^KL3ZG/97;\VL1(*4;D#46GM3I@8-A)!
M@DHF!G(,F)8!K&$"@O,$8^H]B75?#'5-P;IB8BP,H!_3Q"B GCV@+RP/1@42
MC&K0PN7&V51 $J.%J((Q4GGAN:X;W; F^0QF9'G,"ZVI"X]4U@Q"?MS#H] =
MU,O^0<GQO->6:0)K^:%^S+[IA]^R%-<GA%ATUUUT5WN2C CD(N48@D(!F&<(
M-(X*C"!&$D&ITVAIE:*I-5>I -5<E,Z BA24SAZE%PQ#,(*%CA2<(A(8L0PT
M-1R8L\$HD^B']4NK":X-0ND"I^T_WT=;-&?7VF 0AM6W?GL8P/>^=8L3:[[H
M8"V_K<,CT^[G^,)ZVG>^A!)$N\M&LW/)-X6P1#%@B!CYM-$$GXQ:H8 ++;E'
MA$=BDRE;'%,+#-*9L\$"TEF ]((->A0CMHX""UH X]B 84&!4E);'K7QAN9>
M! T"Z7,(<X]F=_0S'\1*XTZK/6-KT/9U(#OAKA_2D >F4]Q.#><9D[[UT]#O
M>3/8_U&Q_78\2*,<#)*1:]O=6L 7@E^?E/M:OV_2JW4.1-)_Z<^M[MIADLMP
M)][PD3_;QK8[[>$)+IKR+CE!>VO#[?:X0=3:9V&CITXR"-%&8,@Y,)(A" 93
MP86TSJGS9GP-LIZ+2IB?)N!%#313#;36S]6 Q$()ZQE(;B0PRC@H%QA0(A#U
MW@:APM*J5@WII/+,O##YA,47T^Y6"<&)&]5'V4TV&@:_VC&V2GK1 ZO'F;MF
M7B>!YHSFG>YN$NE@)]9FX"!G'11[<'KUMCG)<E#TGF$1P,1(@"D<01-- 5--
MB676)+:SM,K5U1XRI9%W8]'[=+E$-]D[!=(/#.D)QJ((=\1'#=('#<Q:#)81
M <X*'P63V@@R,\/E\3P]S8MX/6!L;+XSIC9"#/U^\-70?,])WW^W!R5?:@YH
MV U6ZIDX1V?-]LSWS>\Y,R/\%KHAMIO34FL^=/7V)/W23)J0^18S22XLV9-@
MD;80=:0L4"6#YTNKDDY#OXIO::'I5\'J0V)UDE?%9 L1PL'EK$<6; #-HX(@
MK$&)6%'&LJDT=82[>(/N7>@F+?SVL.KTLM=G= +-N>PC'>2CHZ']=UT[SG0Z
MO6^FZ\+#U.18<-NR&93DS1FI?-7K;_2.[3 >=];&LBXZ[DXZ[NTD'_%)#MPC
M"I@+E&Q'34!A[8%CATD^&1]SDT\\C;.[>(.>$1TI.)TA3B>XB):.*X<"4(,4
M,"PLF%RW@M*D0VFTRN"<UDWFQ[VS$(D\H\AL7?YV%(6J24AG'(AMA\%R7;FB
M%ZOT9,$-Q]4JC/O/<7M44'OT"=_^.PR&[>%QOY2M*&4K2MF*!YV!9"KW@QF$
M&K57[85B(S3=1KCU8?8S26^$T>^M[AD7>7<N[L)*[L1*/DY:#X%'00WC8+V)
MP*2VH"5G(+BBD@HEN3/Y.'L2=3$@%A/.,[<@"F8? +,3EH1 A& 1'009#3!D
M!"AJ$>@HD)&$1\[XTJK"5TV))T'L,XND3G*3=O?OT!WV^NU[9K0][Z#,DV:T
M755B6Q?"+-KK3MK+33(.9[# GGF0*F?G>BO ,.O "VZH-0)'F;27T+S$3Q<3
MJH_ -PI4[P_5R?"I8"I-?TPF@4? B")@N$@_)%=8.^NUQ<DXX+H94'UF3I"S
MY7[)"7)D3D81TU$DM7\<+CDSBV>DZ2SD/'HZ Q?)F]%BR"F[HZ7PY\5**'KQ
M3GKQRR2%(5X'*B('08@'1BD&R[4"&2,QF-)@:-*+9)G2J]7'B]-D(9 ^RP.&
M!>G-0OH$ S)4RV X TV$2$BWB0M9HL 8Y;D3SD4E,](Y:4A^Q3-SMDQRH-YP
M/_0K=]SOYTH,F0 E:<#YO^O@;O'"-+P2PRR4XDY>"#MG[21&QY:*$KR3$OPZ
M27>BUE(CR@ +F\Q QQVD74X!3]N:L-QYK?5("4Z=O%(<-\U%]\/55"@0?A (
M3_ 8CJ7BV"D@7ICL=)5@J'/ A<BZ6HA 0H*PG+J,5''G/#R5*?Z<>?3GW$WE
M%?OMGGKOX%)%*!PP#I)P("ZGMU@EZL)YR7YCRK,L.$J65C5J2*B\(+C)?IJ"
MX,="\ 1S(8HIS1D'0;T&1B,#ZX,"'9"0GDNI,G-)8FL&@L>DY>R[QNN6UO!\
MPK3FA;W'L^A)OKE7K:_M_EZ]^G/GPV[UZMW.=K7S9O/=VMY6ZW6UMKZW]=?6
MWM;F;B&##7=NW:5+\+H9[-='L7SPOYV\'^3SX1<&\7F'U+*UW&EKV9HDAY1*
MKA$W8+&UP*1)1C'1&()&@D0EG(QH:94M(UE*H"\PL!^Y_7<!]L, >[( J,**
MZ"#!RT0<F:$<K"86<BUUIPS5FOG$&9<I5PT"=J&.A3K._'3K#[1QJ_77YNYC
MTL8%F\\I#JN6&;OW8=4Y/*.[EH8Z.AP^[)TW45^NCCIF[- /_SEN'^7RF24E
MH>DN_!_J8YB3NJ3[7F\MUP#HAS=CZ;[)LEWK^LTSR18*=R<*]W[2-K-::>YY
M .6C3Q0.8]!<&W#($\F"E9+(I54AK[8J+:=$%@*WLZ]K4W#[4+B=,+VLXTPR
M&4"KW+-*"P_6:PE:2R<)<@BIF'!+&G*ZZSG8 &F=IPGSX\(UP_U0Y7K'O8'I
M7-MZ853OYI=6;Q@JC*Y(I?B>&N94OE*]JQ;VJR3K7+=])Z97_'%V*X621G4/
M[?;Q\L$/%C&Q"H)1$9A+*DXIBR%XRU#:IPQW^>PJFKHU<_$7-Q>S#U%QKV!V
MMIB=/,(A#;=<.V"(!& 8&5#2>J#!<Z1,,(;XI55\U9!X<D_P8CM()@KHG9?8
M<V:P/RJMEUL13,=!GK>IU;S^F5?LK]_.*6<KY)9XZ3/C=WS1=W?2=Y?K:RAL
MB:44J,X)4]@QL#8I/<F%X@I39XPL33#G%=?-<J$4",\.PI,%OBS14F@"A#H/
MC#,!1@@$ 0>-,=*2!K>TJNEBU=UH-%UY<]QW^R;W*$@T)9?U&@QK*!3W2-.C
M-[?.S;FBW;8NQ%RTV9VTV:5J&8HP3JA2@'"(P)0T8'6RQ]*>))&-RGEOEU;Y
MLM:EQ.B"PO@Q4^P*C&<(XTD_2L1&):V;# FB$BEQ"A2B DA$/C)%HE(DGP)'
MHB$P?@Y>E+HUZRPHR?.VJIK*2'YP#&^;X7&_/3Q9Z_KU7J<3ZL$.=F+1</?5
M<)?J7 CBC4;"@2#.Y6YQ2<-Y'Q);P=)$3KR,+A,50J>.[Q2_27,1_JADI2#\
MP1$^608#!<(Y(H!1YC !,]"<:/ XD1=/ S*&YFX'G"U@2\A&$YEQ'\C!\=%1
MKS^LS)=^"/5RK\SH2,Q)'20J[I:&<YN1>COH'IRKMC-[+*NXO=Y(SKLC,:^=
M2WFDW\H!J'OKN=-+92^$$=Z*X,"Q7*!48 Z64@T1<>HITLJ0I.<DG[K<3_&Z
M-!?-C\%C"M"? .B3324)4D@[!((:D@A-7=^&,XC$>LNB8BXWE<3+DC4I)>TY
M>&;J8C#5+T?]!)=^NGW5:;O<U7W4+3)]88)!KQL&);FE\1&DZ_W+KWK]2>NM
MEG?1;M-JM\U+K:VCU]*8"#%R!XSD3A2:8&#82)_^4T*BI-W051I3#@$M!'@?
M+(.E@/=AP#M!39 Q+$JL@/GL:Y$VV2!&2HC8(">4QX*SI57"&W*";Q;5%Q[@
MB/?"WN,Y<,#SPEWO=S<WJM\^SJ[\0ME"GKZ$ZPVU?,HV,NTVLGTI>XAAQ7R0
M('"PD.S9 %K&",$@K3FCQJF0.*!JR('2 N &<L "X,<&\.2)<,U50":Q/X1R
MZ?F$8LN<!4J8)%2PI(_5TBI7#3'B"@\L//"AJW"]VFJMM=8?D08NV'Q.486K
MS-B]JW#-85;!1COO[%U?5^$:[)M^V.]U?.B78QN--[KNG.^]$W?Z:4Y-_^1<
MZH6VW8FV72IU$9W! >52%TAA8)9HL%)3\-S0Q+JC#,SD=&\Q5??GDC_08!0_
MQ:F-@N+I43R9'X ],E9%<%1:8,$$4#:H!&5G/7',2CEJW8>F\9^4U( [8?!=
M.!J?)JUK7O0.#WMY##WWM?B"%XZ6O.KU+^2]$]=K:>]F81>]=B>]=JG(A<(A
MC@['&R^!4<9 (44@AB"Y9#YM174B-Z-7*[P7O_!"@/DIV$D!\\S /$%2O K4
M,VP!64F!<4U .^T@1!J"54*$@.HD1MPL'_%"NTXN5PT=[/?Z0QB&_F&"D"W'
M,.;C&,:UI\RR)/>2(#>2'(O6NI/6NE36@B,D%=4>O SYM&A,5I6Q&I1/@HL1
M2>H3!2%-RKLN2&W>$8N"U(=!ZJ03A'D?.39@G4K&@O0!%(X,),X'O85'U*N<
M1MP@I#X3-\B(5F<OR"P(1K&=GHQAG,MRL!.+WKJ_WKI4CX(EP\=I[H%0DAB&
M"!JT) :H4TPA*:FPN3^E+*EO"PK3F=.+ M-9P?12M4XC)+$>I HDT0N"P0K+
M@3+EC25""89SAFHS4/K\?!>=7O?+!;,XKS7>'@R.3=>%- N#4L=SCCT:6V-!
M[L0_DZ2+1KN'1FMM7"H?H943R6B*8%!-/"0&S3@'&W62C(X!*9TT6H/LI8+8
MYGDV;M44H.!XUCB>[(/M8Z06!;#$<6".>5"$90/"6YI8"8Y6S*P50/%^W-_[
M<9FB%.='TYT?MPX<3QI<1:O=6ZM=J@K!F&?:8 ;(!YJT&E>@8N0@HJ8H8DM,
MS.[<953J0BPJA!_4,5)P.@5.)]F'4,X(82#I5P])Z B,#!*"$AX+HI!&^>1N
M0T#Z_/PBN1-L^![ZKCU*1*TS4*O>45UR]M=P>-3IG810?6L/]_.IF?20U=!\
MK\YR52OSS?3]H)3EG!_OR62UOFQQ;8ZEOQ/K'+:=D>AS*^SO+@P&>^;[;Z$;
M8KL4';ZC'MRZ=))&6YDV+ 9:<P',8PDF, ?:&,68H5KJ.E%$-,@"*QANGC^E
M8/B1,3S!90@C&L5( 3/&@"D306/$(5D;E+E :<P]C"@E#<+P<_"B/&39\.=M
MCCTU/[E5->%7[:[INE*JY?Y:;J+6TL$7U%K[S *-QB5-)Y% R6K3&%1T% 17
MZ/^S]Z9-;279VNA?47!/G+?[#9+*>:@^UQ&4P3[T+8FRC<MA?W'D",)"HC48
MPZ^_*_>6D)C,8(:-R.IS,$BIK1S6LZ9<@XM$6^MRFR?RRYRN.%B:B^@'OOTI
M.'\"G)]J,S7.DW5",D40,&:'N!$868XU\DXZZB6ADMHFMHE^"7Z:JAQM\:DT
M_1;HBK)RB];90N)@=:B%D=VCPK+^5<!Q,18(8DPIQ+W%2&.CD A2*R$MEYJ
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M_'NP!Z/ZK?^V!X?_.OTK?W<7!HPF;M0-73O,EUC_R ]_72_JGY=,SXZJ;;.
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M6Y-1S 42<A6"4<OF'/R#G,Y^DLMB@/S):8/=(6QP710EG!E?5W'(]1)&N?Q
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MDX"!+;8_;1Y_WO^CEY_3WM@$(_LCV]YYDS.ZC^9U&91SPDN+L#*Y*P^-R,9
MD0DR&N<LEI2NO.*K$E],Q7O0I-:E ]QSQMOG:(<[1X,"L]O!;!Y;*C4AE-J
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MCD O&ZVU_AB,]UKCX\-ZG@%F^=WF4+$Z%BS$7):B#I\9S3>QM1<#;$D. ;O
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M-Q1QP2S2P@<DF#0!%++DN2[.K :#]7'"TPJ$&P;AQ3@VRIGR)AADD[9@!>.
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M,3":K&?\*:IK'R390J'%1>Y\Q&W/RG,VT,X!M#,[$UB,$(@,E"Z%0(L(EJD
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MDQ3.&18$=Y%EQ5E13\[X'%%\,9FY%$U!;ZS/*'V.*G)Z8Q3LY.<4491+2>=
M]\7I8SSGN61ED$?ZJ=SE!+[;W][V(WI#Z@UW)LF)^IP^[.[O]>*&W_F8N\;C
MK:FKK3F,PR<\19QW..[Y^I*MK=TOXU\67Q##B"7+S)7T,/B2T&[N>AAB"?G9
M'WIEB0FUI)F^ ?$.O.)5?WJS%QO9GV1%OJ\%\E3Y?(=XO5=>4);C$LH,]T?$
MX8*1PL-7L[C@0/3]*&[TA.M&@CT<-8N+YMF;G,5\B^;NT^2_R.3C=^AN>R_\
MEM^)^1J&X)3'O]^IVH>9D9U7VN=H]ZN?_7A_U)4L?!CN;;S?V0WT%']5FO=Z
MY_/^WOBX@%3]<7\THH%]X<?#:4M8=ZT'DC9Z2Y_7_S98_OW3RO*+[?75M_0Y
M[]7ZZA_#E>6(ZZ_>?EI;?;&YLOSZR\FTT>#5'YO];WW6WWZ#_5?K6X-7Z\/U
MU:VMP8?7./BV\8G>N]%_U<?^YHOCW9TE<"XR0U"T:@%=+! ,JST8RBE=E$G<
M7D' [^8RM\V,W&LSHDQPK$0?+7<86;02I4M,V!R,P^*K&>&."^&NO.7>+,P"
M6)AI8CJE%)@M"91(!I E!)N9 U6G7(6(V74*-X:KV[<QC^<4IFD.*(_W"#9[
M.?4*(:7W5UW>]_$P)OWWWHD\9:N2N@&+761E"#E:S1"=#5XEJ9TNK"8]A8U_
M+A\2/X3S]^0W=S9/M<U?+F";CYOFR6)^O?/;]Y5\=-EFIB]AIH\UXUK'>716
M55T/64^]9&!1!$@ZVFR$YKIV_5W61K>"R#N'^F4*(A.+.4HT4A6*Z90,3F4C
MO4/G;&(Y5*Q7=B99Q3IC\D>:-J8'IN\:Z!<7]#-% U&C3,J#LS(":F\AU/-N
M&47XNH@BG#%/GM&7>U$[>9\R:,_I5KN@8QXI=''J$-P3^W2[5.0BAZ]=-8 \
M(W[\S_XH;A!M?2C%3;=DI][-D)-H:%)+))NBL@?R3XG(2?$0'/)D?68:^17/
M9[O]3-6C@^T<6$4#Z"("=$HDI(U<,!4A!E-JHS<#)Q*#Q&TNB2<1L[J"E,]]
M3/'<!1C_XP\J!J[68]'"HUM/A=R0(7N7]_:VNHLT4W8I4S:K7J&$XG6?$U)B
M"A!C )LY!\M<2<$69U \>7:*=$5K"GT0(%]TMM) ?F60S\BA"I-T]@I"9($"
M"J$(W\R!%,;PXDORH=1#)Q<#Y \H[_';3FIE0X]HOW]>C9QM4__.[>=LV9 I
M+&=5!5LYEX":"[*DNN[Q.RFLREP8?X5#>UO94#,CIYJ1+(HK**6VFJ.B<(ON
M+#)NC!99%>,Z,W*#7*R9D3F:D1D:9JS355LV9\,!;2H0A ^04Y!(CB,2Y7[R
MS-A+GGUUQZ<$'WX\5)OQ"[??#<EP)]%J^P7J;^:-N M4VHBK5]KPO]](>="%
M>MO^>7PTV1+*.GP5[CW?*3WW_$XZUMCF1[GGM[9Z<8M>,"S#G&HOV[_S7WFK
M)WIUY[FWMY%[^6O,GSO#LUMZ^7_W"<Z]X<Y?>;S7!5?UM_]U"1.%0<E2@I,.
M(WK.+?G S'G]-0^VB#F("?W6W>2[:HJZ)WWYUV!XWXW/5O[7VX/U#^ES$*C7
M7_U&KW]_L$+7'*R^W!XL;VVO?/CMZV#Y$]W7RXW!YFM>_[NVN5Y6EC_RE>=_
M4HS.T!@%IFIY(<8$+DH+&K503A#Q9+J6%Z+]4;"ZMSUI7'G:^[(QC!O=PCEM
MT?!NB9W9*WG)A6)+)LN6>>#183;!^Z14LE$4<F#1VW;6_4TLED\'@X]_1E.\
M*C( \5=&_J8H<(Z63=&1."L&:;TXO=I]NE1.6R!RZ?$X _'W7OW?W7F$)\]Z
MKW?BUGZB"\9.GKM2L[P3J_G>RR,RX#U:][DW_N(_3[S#*;__<<;NTRSTIO_[
MF_S[A S]^/4NY^C78S A*,%DEO9ZN^1\1X>^>ZEWKZ?A;WB'S.C)L[/F?6;L
M*]L9[O2B'V]T'.<O,O\[AYSI^X1L^]&G?-B4?\0M'I%%4PLYB4<V[C+<HCC.
M;&;<V4)Q,I801=7FX@FU1Q_M1=-MC5M<@EM4J:>/?V(IRLH8P%NE "4F")P'
M"-EEGZI.98Y/GBG[HT[V=V[1@?(RLTW4-@?Z3"=18"'6&VTQ1"FUD\SYP!J3
MO)'99H,O?_+DM$8?0"2;B$DR#T$5#IHF0TLG=,8ZV^['S,593/)'%WDLINWB
MT4Y\86(>#A48NC7SN]_9]Z.#R1_DY ]/>T1X/N=8S>#6P5*O=R5[(G+FBA:P
M#)FAHH"%; =23)6RI A&8;,G-['"WGSIO_G3"2.-)GMBN'& BA5PO@307(A0
MN)0\AHD\U;S,2=11%JYBIG6-PB3'N=5:,>T+,RS+9DYN9+*_4F!JO&>V,(2H
M3 2"F !7;( B2Q(T*\EZ_N29/,=W'#<FWPW)/$W(O6;JLP&3OE.^5V]A9>?C
M;MT&GVG ]&ES?Y)Y[/GMW?V.HX]RCV:K"GMM'=!<Q"J558/9WML\SIW\3)VZ
MY9J"V/W<O35__9QWQOED6'6NJM\/?/Z.E/9.5VG[N>K:ZD;ND:FA.YX9)']V
MNFY$XS4:^ZW+YNV"<5R%$K.(!76*7CBO#).^.*N#R)=ICKIPRO?BMO3Y:%0;
MI+K<]?=>J>?=2EHI/S.__!';WS6Q\N9/(V,*7"0HPA&=T\6#%2Q"]@*EBC86
M[9\\<_;LQ&"%9;<IT9DE6H%[N]TNP]YPNR*=UEHDV^3I56F*5UJ$]/8\WMO=
MZ0ST>#<.NS<?;5(\IW!\W/M7]EOT"Q\I@I]8OZ5>7?:S2[F^^LPU_X6,_ZP!
M6>D(YG G[F[GSH@<&HZGO9V\M_2CO;B,/7F4*J&BJ83^?(_T5 /_4_G.$S*<
M1) X3PJ3,@ZU3"$J6W5!D^3,"\./Z@H.-6WG4,)]W"2_BQLY[6]E,JM^O%'_
M_39-K#W?2>\V=D=[JWFT_7JZF=@-W2K=Q8NMW?CID=G8_NKK+W0/?Z; N%"Y
M0*;8$5 & ;8X"3(*3:M )L["DUXF3_2Y0GNTG^]TM4]IQ?\==PG4IU=(HY[-
MNLGTTB_'.5U=7?6&M%2=61)"7$5+58@EP>S<A43=DA'F!D1/N9)SOU?.EY2\
MV@W=R<U*>U]N]J96 2J<_\"R)317 \(=K )ZHQ7ST.E=B$IT>Z/ZI?=+I/97
M/QH=U/AC$@D^9KW>]SLU /JXTXFDOZ) K W&X6#\>W<\%QF*^SH81XHRO5H>
MW.MJ>A_S>-20IO=__/;G?_:Z;V?"FT<]+(<\OS_E^=-2S.OI?]_#,_[JRKC6
M677WNLOBL1W'5U()@?/"(L,HF#<N%2$],\&K'.,<CCO^5]Y*J[M]OU<!-5/C
M?-\STT?-%2NK_2]]NK_^J\$&W=OV8/7%L+^Y)OJO^F)]]??ARJLW2/>[]6-S
MQ7O5__;\Z\J'-U_6Q&]L\(H^^]7K@\'FVI>U;^M;_>W7N+[\4:UO_U'Z[]C7
MZ=&H)6>E? :350&,3($SS$!MI&$Q89'9U*-1!2[2F6#MO+Z%Q.Y96EEGP?9Y
MC/O;^]U.R"S7_-?N5AWJ2K\;L"\'[&_34SB+9PXM!Q7JF<?".PA.&?#*V\)I
MF2=,5U3#:M!NT+X>M&LPV:!].6CS:4.D%4+FP,$6:0&SD^!X="!3<)H' K3$
M!NT&[9MDW ]/5_>68"RG9QXHGX06'F+0 6@Q& @V&6#!,'+0G$O'&O5N(+X^
MB&L:YOE..EF%L/<]\=^ ? 4@JZD_SIHA31D8"I<!*6B&8$H"IZ640DDM:\')
M0P?R5:^Q(*=ZME?>U2L?S?$Z@]T=>+_T;JDWWJ5[H[_LS-0 W<.S=::*'V<<
MK?,P=2(OX=M92.0;+"KF&68NG"^J%)D3*FF#2A?MC&IY[WGX[(.9O+<4KA01
M/:3B'&!,2#Z;HNGDM'<F>ZND>O(,+ZM-UF1<'P<\6]9[D6 ]S7HK:90NO #G
MNK9HI B>%P&TC&V,AD4NS-Q28PW:#=HMZWVST)YFO6NK1_+)@"RA;FCE ,ZJ
M!($F.1?%O;*N0;M!^]JDNJ6VKXA5.7,4DT": 0=%UTYU9CU8$QA(PS06HS-*
MU]AUP^DU7'#+:=\ @J<Y;6NUE8[BXY(L @8;P3$K093$ Y/&J7K2:_.V#<47
M]+;3@NBIISTLEFXHO606ZZB"\_F?G(!:8E"0?=: OB2*=;,%$;A---E(KGC1
M/.UCJ'SO\OP3Y86JP/#Y\/3 GO\XROG\8]@>_8YX8!F9"#)Z'S!Y8YGPVG##
MM=$1"VN%Y(MAB@:_SB34K36HBR*&H) H?Q"Q]NUG,)JB\]JUGYVM$MO<_:A/
M]7 VP1MVYX+=EE*_:V!/4^K9%"T\1V#9,D">%=C &>1HC=3>!9U#JS9MT+X3
M:+>4^N6A/4VI>X&1&1Z !RT 73) 0;\&ARYR3%'ZH!NT&[1ODG&W;/L583S-
MMA<EN%$I !."U4UO!S;;J@G,0PA&E2)*H]X-Q*V0?"&!/$VZ,\NUU#E#*$8#
M)B/I.X60HI)"",D-L@;D!N1K$>V6B)]?]FLF$>^XE,S+"+K(6I[B+ 21!.@8
M"]'LDJ4LB\BE;[OZ_BZP-Q$RGG\V_E%L $;A?68Y9!T5"N:\*T9(9UB,]5B\
M<#-A?S-%ES%%LXHNT;B84D;PVLL:U!.=$,Z R%ZD;$PQ:7["#VWGO@&WI>)O
M%MK35+S$9$MQ'(2.'-"; CYR!B(PH0U-K;*R0;M!^TZ@W5+QEX?V-!5?/$LI
M% XY2@K]<XD0G(C E0TE*ZM$/72X0;M!^T:@W;+P5T3P- OOM40MF:>(/RC
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M=H1A8$A3:NO!7(G8-T%9MVBZ0;EMRR\&@/N3JAH"\?,_=7(91:KNEZ)FY**
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MJ$P=R@6G6G$'F7M;>T:W!KNS::U))^6<(L)IA_8Q*N)M$"2J(*6.T46AFLP
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MV;BBFJ-+R3*Q*EG"61).)EM.KET>8?H>LC\!QC#M)5=X>W'8B[RD;WV4*<3
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MR1CJ>2:"2D] \4"<DYQ0@R0)#:\+I0SIQ1WLBMHG@=HY!%,J:N\+M:>A%6E
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MJ(+0;.X<C-V@,^-)GIF+:VK^7V.#'L7\O3H<#M-^.'K&(K3^G,W)-'7B&<_
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MEGHVB:F%)6DO%A2\OJ=?@=MFX%)E 5]>96> @3"YJ5U$-6IOS\UUK&T%[MR
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M"+[[G";Q^[7]JS*)OB.8\ KAZT"8GU;UBD9Y&U/)K[<$+)7$<<.(4-)GXVG
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M/74A&1NRMB)<PR.K^&X/OD^=-17!*94DR9XY DE)8@TWA-*4J$A445>ZUKY
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M29-0I?&M<!&B$E;GQ)1AB#C-HO?5ZVJ9ON]N+(^[??JMT?G+GV(4*FO+2<A
MD;1%( 8$NF&6129ES"Z$A27):PKB$P8Q4XHK&JV.E*/G%9VTN.)&,DVIQT^J
MW]5"$/=>?0=QD)QS;Q3)EJ'GE80F7C-.$N7)\^QXBFQA">2=-Z8KB-L"XDL=
MKSL:8U']K3E!]]3^^N"$3:"("S$0,-P1JSGJ64@0J(W><(0NDXMW[C;98NRV
MV9NJFUPUB;A]A,U+(Z.!E*B'8)*Q-J.Z0!X '()G-8GX,1F$U5F'3#E+>3:6
ML.P3 :L=,2X#D9(J9[20R=$FC5B)&D=_N@C7T2;)-4\L*HB6([%7$KC,VC$M
M%:MIQ(\+X3/>6K(I6(;@=JBR"0@FB:'4D)A]%KC<C&G3(/Q)=QA_9@B_U%^[
MHQFO_MJ\P'MJGG4227 .A J%_EI*@.994:(",,0SDS:44,LB>\+0;;,3]ERW
MR:XHXSQT@\XK-[Q.OXZVY+G69]2P2@VKU-SAN28>QIQ<# %"(6 ,/),TR11I
MS"S%8.HN=NM867<V:.(BR&2R(TIG2R#P0)RSCCB1M996<"8LNE0U9/*406RI
MRM$DJ;PQ8%5TT6;\F49N'4!T=1>[A2">B8OXD UWH GG)2[")1"GN2.^)*C(
MS&5D@"#6JH+XD8'XIM6P[F:-:_[PW$%\:HFY98QR&P@PX0A05+:6>4629,EQ
M)Z(6:F%)+_*:0=S>*Y]6:*1F$+>:M@DC(23K8HX*F;LR7$JJD<@G835J_NI[
MM4[COYWUO7*4%(SR1!NI"7@-Q&>-:C\S$ZT0$2 L+"&;>\()3,\>Q%XIEEG0
MBJ(K#LEZ*;4$;GAV4J=K5;VJ()XWB&=\+Q&"C(%ZPB&*DD$LB GHA3GE#$L0
M*55(VSBKQP">#(@O=;WN:(SKCO2\H'MJ?R5HCO!-)(I02EJE0'Q2BC"94DD8
M"BR'$ON\I.O,T\%NF[VINM55,XA;1]A,=DX:*B0D"B)FE[G(+ //WABKJM?5
M/JW_8=;KHD%J%E(FVHM,0"1/K/&)<.9!*\NCXZA6H*80/F40"XY\35*3G(J@
MI/&4X4Q0)CA%YTO5':\V@GC&ZP)MG?=)$U2]BH#G2-U$EL1&(Y-@%C@MY39L
M+1C^9$!\J==U1V-<O:YY07?FF$X.:'2U)]Z4C).8*''@!'$I>*^4H2K$A:5[
M.+;98NBVV95ZKIM=E^<!_^;\4<T#KL]H'_IJ<*3F ;?'H;(\^1"ITSIJ<,C*
MP*5LDA":(B'SO$9%6L?*PFQ4Q#@;)+I.)( NW?@\)RXH2[A/C$657"YYP+9F
M$#YA# =P$C%,<_0<+%.. _6*(5Z59VE2?;0&15J&X9F@2)0B2<B9,!&! $N<
M6*T941"RD(DRGPUB^&("8<7P(\7P%3V6[F2*:TQD7LB=V9/(/!O*452YRVA]
MJ2+."$N,9L!QZ9)AMIR-?LK0;;,']5QC(C4!N$7*_B)A4QKU!;42H@ (X+VT
MU)O$5+)>6&:KT]4ZM?]YUNEB$:1G8 B77A* <OA2&D\\<&N!!HYD;F&)VSL?
MOFQQ_M&S![&W5!IG: [1HCA$A#.W# 1W,0-X4[VN%H)XQNO*2I75RB0IKQ'$
ME!'/E"0"US/;K$P0'$&L:@+PDP'QI6[7'8UQ=;OF!=U3^UNZ4/,@(^$N> )"
M)F)UY@12#MI3JF2$A25S2=.6IP/=-CM3=8NKYO^VCJ\9[Y)F)N;2\"$S825:
M>^D#L*A]MJHZ7:U3^KMG=KJX5(%&1X#G3,"6_"/% O%:!*FXXB['A25A:K.]
M)PQB:P1ZURXYJST4;UL@@T\T&X=8SII7IZN%()ZM> /1YY@],9&6[6H7B&$*
M"$LL)TT9M]$@B-53+B;ZS$!\>?[OW8QQ=;KF!=V9J@= <]0&" U"HZO%2AU@
MFM <!R.H1J]+IU+GIN;_MOW*I[77=7G^[T>TWOO_[ZCS>W*#\79- G[6SV@?
M!&N$I"8!M\>K M!&<Q#9(Q=/C'K@'*07./O2ZAAK:*1MU&SG3 <E0XUV@4DB
M#>4$HK'H595VYJ X%3:;+!QZ54^8F#U["%OIM*34J)@LX"_&Y:"U<LRZJ)VM
M!Z/;".'9P @SCDD+1$+V!"AWQ 0(1%"G#*69L5*.ZLX5Y2J$YPSA&Q8"OJ,E
MKH6 YP[AV49)*G(:*8F.EVK>INQ*JU1J0RJKC/#@2D*)7+S8E+I6 F[-E4\K
M.%(3@5O-VH#[;&)PJ.@]&&&-Y[E41A$I K,^5\>K=2I_;=;Q"IY!9#02HQBZ
M6[B6Q&OEB= \R\2Y5Y35(J)/',0V.T6%L8QJ"2P)$Q,Z8DQQ;4'"!,35]6H9
MB&=<+P. #"<J(BQC".+LB.?"$)-MYCH: 1+9 ><7:5L%<;M!?%/GZV[6N#I?
M<P?QJ26."%4(FA%6$L. .B".QDA4!.VU<-P&O; D+DD)OK[OU6+\MMFCJGM=
M-1NX=:1-".:%M]Q3+\"[[*Q1UF:ME+%<FEH-N'WZ_DS_2YVTLU);HF-02-H$
M(P:7DSAG4C(6N'/E""9_RB?OGSV(;:F0 C)&%CU(KDS*UC*=) 4%,.G=4#VO
MEH%XQO-"]:I0]P))KF0#QV1(.;U%(CA!@]7".(,@%A7$CPW$-_2\[FB-J^<U
M=Q#/U,#A+H 6B?#,3=GV4L1#E(3'#(HQY5,YC F+%]-/ZJY7:ZY\6KM>5Z4$
MX_B;FL#_6A]OIV%-"G[6SV@?"&N@I"8%M\>Y4C0B)=/2,Y7 &^%,U([R% 6G
M":BL$9+6\;(S_9)BI$H8*XG-I2]Y!$F,%9& UEYYPTV,<6&)L=IJY0F#&#DX
M5=8X"-X@9H--WOO"RR.W%IWL&B%I(8AG(B0R:@B,E3Q@0PG(H(E1D9&DP01G
MC N.%1#7H@>/#<0WC)#<T1K7",G<03S3KS9F!\9RHHU#$.<@B8M.D2 -I\:D
M'$PN>],7V]76"$EKKGQ:$9*:%]QJVI8M:G?/-3<0"FUS7"MN#&IUD4RTJ?I>
MK=/XF[.^EZ7:"V$<D1(T >X#<4998AE3(BJ61' +2W>O<M/BC*1GC^&@&2+8
M:B4I@)'<4AI*E5DA-3BTG=7U:B&&9URO@-PZA20)]S822)P3PZ0B66;MM! I
M1;ZP).^\-UTQW!8,7^IXW=$4UTI5\T+NJ?5-TH( ]+*B$XR HHYX&S("N11K
M!V&D@X4EIA?OW!6MQ=AMLR]5-[IJ1G#K^%J*REJCN&3!@779RF!0\2>D\2$'
MJ/M=[=/Z9SIAJH K%G0DFME,@"%I,P(,\0K5O>,JV^R+UG_*]0F?/8BY\CD:
MB;#T%B :)W,VUF;(QAMG9'6Z6@CB&:=+V^#!(U?ST@H""%QB'8O$,9,=Y5JJ
MY J(:WW@)P/B2[VN.QKCZG7-"[HSNUPY4N.M)%DJA*Z-@A@)@3AN@4F*\&WJ
M\U^2!_QTH-MF5ZJ]6UVQ__<]ZR1[K83@C?6-Y?]\]ZH>(B49*<7H$&G$^3+%
MS8P\@AS:^HP:KJGAFIJ7/$\7C[+D8P@B>2W!I.@<=]KJB._.3?+L&G&:?##<
M<V-\UK?Q2Z2?\6 \_;QZ?_.FD&=;/ EJM&"4F%#Z/)7HC9&XCB)#8*7!JE 2
MO;\7BE7_[PDC7):6,!:"B>@ZF*0,3TYK25VR"5RZ3M)R17B+$#X3WP$E(5OP
M1$H?":A@B94B(> =:%QHXU(J"-=P,1FR(KS="+]A1O,=[7C-:)X[C$\--:3L
MF1."*'!EK\50X@NJE0M9J.@,9%IZ05VL5UXSFEMS9<UHKAG-\]N8,U8+[9#.
M.PF1!N\U3<9[QY.5$5SUVAZ1,3A>/N.U.9%L\=42NFD$M!/$N6"(9BPZ6\ZW
M*%LXG;U['9\6YUL]>X13$#QXEIW*"73V/F07J:%(YF@(FE6O[7$A?,9KXUJ$
M#$")T)H1H%H19U,@FALII,A93A!NS)T/DU>$MP7AESIM=S3C=5]^7N"=R8;F
M"LIA82)9$L57<\2)4NU<QPA,&0/>+RSQQ:<,W3:[875WK29#MX[,V>"5!*<,
MTP A!!<]]UEZH9RCC/'JKCTF>W"F66@6-)=>[832DF+IJ2?>"D<BYUEH9CUS
M: _$"PE/.5/KV2,\!Q-EY R$=8#_8W.B3FN-3EJR(:GJKCTNA,_V$G4)US9X
MDE+I2J6\)BYKB2+'A?,NAIA40;CBM?;78T/X#3?9[FC'ZR;;W&$\L\G&N=9)
M&^(9_@/ -3%94^*]TEHQ*-WEBN-6"RNW^,JISW9RR0F69?/.[4Y$K<]HYS/:
M)^1WAH,R/\###::F7OJ<Y.A?8^<'Z?MQB8D1[)7S%/TP^;UPH?[^8;/#WYPS
M.2=XP!<UJN)_?SD8]<LU+X=I@!?_G?[]M1_'VR=>U<R-$YOWDI[>XOSH8' X
MOOJ6&3-::!-RM+E31U[&Q,RY\R4S_VX/3P7H<R)^F-PN.@TXV)=N\-4=C1;^
M=>:=]OK[Y-P<GG_]AWG)C2(2G8/<*8XFSO9EKSS['F[X&5]ENJKE-:9_&1]\
M>3DQTN?$:$)C?>;:21N#]!:<SMY0[9R ')RF&=VKSO2>%)>+ARRM1F FGAD5
MP!/XJ'A(%*36-F<FK_H>FE+TRH)!#H\7*\^M02*H8A1&X7_.?X^@/E.;2KZL
MAXQ>O<<!1:VRI9Y:5?#3@.94G(<Q#8LM&K@OH_3RY(=_GX"NO]_,<7/3>?Z'
M<S1==2T7&:BR\-/P]/3Q4YE8;&3B'!F=? 9V46ESY<=TD=WR,ZWYK>[\T6"9
M6#3_/WMOVUO9<:.+_I6&+G Q<Q J]<)BD0X@H(_39]* [<ZTVX/)?#D@ZR7Q
M'<=M='=FDOGUMTJVHRVW/*/.CK=+6Q4@LJ2]M'KMO=9#\B$?DOSC+R]VL>G2
M87XH%QLOO?O;3OL_7>R]/X('X?@>B;SO?@V<O_W-TY>?/OWXV1>OGG_\]).]
MS^51GV,]!#[6RN[=8'W^QS_^Z>OQ;_W^+S]IZ7:?8_5SK >_1^)4?]X&YRVS
MNV]EMB?**H2(%9V._[666D)K)4>']QG^O2NSRY1T;LT%1\_,P0G$P=(!B^%L
M=6[@8DL4![FOI!=7X1?HC]9>+*S&>_0(M[GVN!"JRP&K-"5),3>K,9#5&K?V
MXF$A_%![$3GWZ@EJZ@AHQ4!#-;#JJF3,9K5\B_"C&YPWPE=!^-V#PX]SXULJ
M?RKPWKCGZ+U0F],GO4N P@DDQ@9]BF:*&E&UBRMW><Y[.U9F7X\UH?+S]#8_
M;J'=!X1S6"FDWJRC&687#5VL,B68C4O*M@G;0_((MX:*QXBMS/B-,HUP3I*?
M^S<C5&VN9N>+,,W.Q^3V1*HS1KART!9JU*0!Q9J6X#"V[D(+'>,F; \,X0>$
MC7)IF0."2"IS55L#SBF"=[E4[8&+#Q/A(?!&^+D@_$["=J0;WX3M5."]<<\Z
M>'7S?H"W)C?!RR TOE.' 2FERGZXYW"71OY\L+LR#]N5M=,U-^_DW#VC.?+9
M=U9+M>H<8B%=-4<.)?00O<7-UQZ20_C]K0);SB[4TB$.OP!8Q8,X-5!F*8I1
M?.;9^BC^_=&$YY/#>_0(3]7WD+N4/ A\B5VT!FZU6\^UJ.Y95 \,X0=\;=CM
MB+4U\'WR-<PV@C\-X\=ARWVM1$FOFYOCT7QM(WP5A-_)UXYTXYNOG0J\!Z,B
M\_C\J1.02P3H:@.SE %33>.6=2VB<V[P7LR[^I&G+K#]]#NB/HRR_21;H^YS
M2=]^8@-&K]]<%_<^&I]Q>S./^OYB7S[[]/G'3W_][">YQ'3)Z3Y7^7Y'Y>RH
M@W@Y6]_?N\OZMOWU'63\U1%[L!ZN+'J?8W6;MY-96R:^#L<E:<IM,-V8,LK<
MO)E*TZB46G:*]QG1MXGL*6/ASW[]]/8</BK:VHB%"^.(@ E!&S)@8 G)<O)E
MV!-D.>-8>(/85_8U(<?NL(2!:';<NW@4ETJZSZJK#>)3@_B6>B!Y9*K0>G6
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M A(S05)1U!A*GIN9_M__AX,/OSIC>']XO'-]V7'UP.=__:1QS<IA[;ID>[T
M>$M+3R<ME5AZ87&^9!1?U6'MU2L7YXI(WI'P<@[S]X>1<.M(87A'Z/YZE;!W
MH*X5J+7Y7+(Y'_S%U=&+#!?6M3QZ"%<MV5$O5-ECJ=%<B..1T")*<\#H+G$N
M".&#F%=2#E53 -04 2TFX&0!0I&>"YDK+EU<;6WX0X/P/WR@KO0X3SSOPWC+
M \^[U'DB"!_,@)R+E!P:A(@5D&L$T]S&E\BA.$.794"8[UC&\H_G ."5Z=2N
M/&QMZ7(Q6VC)5\:4M0<,7"5T\TH]5O1D8=.N]0S^[=V8XLNX'06B-0/LCD"Z
M1IB2PM;,.L=P<;65I6<,8<N8\YSZV1B1XR1;@W%3#$X]BM--NQ:$\ 'M&A:X
M, E"2R-<0RI^SO=-X)+XN?XP6ZA_!]JU,(1WD>'1%QF^/^3[SP^OW_/:XJ9]
MCC7/L=Y#_EBI7[[3+#[_NK?IPO[T]LFOOWS;=$01)S*4^QQKGF,]'.XJ^0ED
MHH\[+?\A61IKS8DYU["ASV2HP<6DFCJQB>PLS6H4[_][?JLX'FNLF1AJ5YS%
M<01+?>9K:D4O&$+J%U?)[_+X&8,8.W/7%#H;C9O.&G*UE&OA'A&I[CS-@B ^
MR-,4H=R8#;17!QA+ LD409VR>22R7BZN,)[SOLU'!N([Z^-'.N/= 7PJZ!ZN
M1F2GRA5:HRE.JP8<>;KCD'(*-4K7BRN?[RB+GP]V5R91CS5!\O.(DG=I[;XA
M6XPJE4>0UA"#J9(:$V8LXK)*V[QK.;M_:\](3-'5Y 6BS'FW@3+P')I9 WI6
ME& 21\@F>\_(&8.X:,])L@771KR64"/7F#IKRAS1;UGRBB ^X%U!NA](9?#C
M 1[!FQF(-()"4YC:Q5*1 6(^YPKY(P/QG;SK2&>\>=>IH'LP^7 0Y31N%KA@
M#A";!\.Y K?[W@*FDJU?7(6]9F3Y(W>5ZUA)\DZQW;>-S#<RJN*]8Y2D5LB;
MCXUB:#6U= _2=3A08?B2^OK==Z_O4.[4_N#6_A&'J2?+!!)D\#%S%5BS@4EI
MXFKLJ>:+*_\+YXX>F;)P(N[1(UQ[J^QCK\[&$Q%%0G-AA'>I>X_4=R5L11@?
M,#)R!<=]0VBNCF .?09.04981]'W@>5*X>)*PCEO,7AD(+Z3D1WIJ3<C.Q5T
M#S8_)I%",0%E"8 -&6S0:G Z"]HU&L]9]'*9SABZ*_.L=0MA>Q3NO4?A?OSB
M7Y[_&KP\^0\M9?SFB%&X#U?3N\^QN@79V9^M<5Z'%+(;I# PY=([:E!QJIVI
MJE7J.>U1N.M%EK^[R>V\>NH_^\__6S%14V((M2%@8@*)H8 .HL"YQ&H=YVK*
M30S/&,B1NDM6V5HMR+%)0T^U278]-_9I#\1],/#^:\[GU=/PV>__K^]Y@-AH
ML,7: 8>-!NLA04_JN*L,XM__;D-Q%X;XAT<^W_:KY\5#H+^M7WW3[JT_W:J7
MG\252L<6.'OA:MC<W-CN(F>T5 IWNL]TINU*5W"EY8>1LHM%FKD.EL.(E,<]
M!BLM0T5BX9A":_08YLL_>HBG,L)DB8RQ#?@FU=@U$#;O.;24=[3\<"#^@VBY
M>'5!9JM@4P;,4D%+]- L9!$,L9L]!HC_K=.=5H^6_WKG3C*Z9+U(>*>/_P;Q
MX,XA_Z2M'APR6;-2(^'X1EQR5 D[A2(IA9U#7LYM_OZ'D?%<S<L- \12PXB,
MQW=BPL!6G8;>*&K>.>0S![*:T]2"*$:'4@>0LR/O<M%6+5+;4?&#@?</HN(>
M^K#.":%+KX ^$9BW -4JNA!:*5. M'/(#S4JWCGD]7+(6[IU;^G6LU]_\?+I
M9Z]^DFM+EYSN<WG?O'[[Y?5UO6E?C0O\C_:K=Z^_^0CBI9]__L.;K&_;MY<^
M/M6,:WZJ3W[YY,V77WWSY7]\^6;+X?8YUK3*.Y^QY7#K,*!(ODOFEJ48IM*D
M!8?M6AY'%$/=J8SEN,[O#EL=/<74LV9P>0[ZC#6"]MB@1TIFQ2=O;:8QSICB
M/'H,.ZVDSF(6;.@X6G#=/%6SB"5$O_L<%\3P09]CCD0ISQUZ0@$0L8.DA)#(
MHJ6*+&%B>$_M?6@8_L"-F$?ZXGD?]D;,DV+XQ@_72.*J=5"N"J@U@QJ/&]6E
M->]2[S0EZ7?-H-D;,9<Y<JLNM^KR9&%;U\KLJP0EC]I0<VBU]=QBY!9#W-1K
M.9-?#JF7!1G$*PI$AR-LBW/J9VLXJ!</+U[4NVGR0SSGJ6./'L1AD*_:B.=F
M1:R.=*Y:X)RFEEI-]HR9%4%\P+U&C!V;LP2^E0Q($8%S,]"$UEQO/LYM"^%X
M\K5!O J([^1>1SKC/6/F5-"]\;]<\LQ\5>BI%L#!E\%X(#G7@)9SS[7.\5"7
MY[R5>F4RM0M=>^KG<O%:DBXI]FP\HG8_HG>)=5@.7P)19'*;="UG]']_BW1A
M8)?#B*:#C7BMSCU9K>+XSB7V0CY4&?$:'DVZ%LZU/7H05U^00IQ9<AUA.K-$
M*@/0I2C[F#?I6A'$!Z1+>=K>)',Z( _210D4JT'QI6KH2G'N2PGAG-=D/3(0
MWTFZCG3&FW2="KHW_E<].JI>H2HFP% (S)D#26W<2ZE"F2ZN^/*<MU.N3*76
MK75M=?B]=<R_??GLWYY__NKI:O+P'[OB<Q".S\_\XQ?_^_F_[@_]=!_ZDY_M
MPL8__V/_6_/#NNM_XY%]\<FV$R=]9#__W:>OOOBWL_[(=\/,(S['>H'JKB/L
MAIEU<H_DU-764W.LJ)6%?%<KJI%*2_X^:\-V[O&D"8S_>GI80, 0+?54H::4
M *W%.5RV@;:.GBG7YOO%5>3=,7/&(&Z^U#IU6N%Z[H<7<F+.=94J+J:]JWE%
M$!]N!@MS]5/P4$++ \1B8)89)'+UFL0U<0/$<LY9R/,$\0>VS!SIC7?+S,E!
M?%!**,.LSMH?C5L(V&("9F^0>\F"P6KW98#X#OW6[IA9YLC=,;,[9DZWNR=Z
M3]E*=9210V2M3H;Q$*9B6?;<Q?4L_K-;W,OW$+(+0,$\()(;W,MUH&9FD7**
M,KB7IZ/#MH45NX\>Q!I<RS'[I)EP!&OL?4L4&B>69+BYUXH@/NR8P=#(F*!%
MCW,K,X-F96CJNK$H"L<!8CY:O+5!O#;W.M(;;^YU<A ?],[48K&W*=X*@WO%
MC,#4*GC1H#Z1AHJS=T:.X%X+XW=E1K7+7;MM9KF@C;OF4@I3;@Z3KUPBYI B
M:BE.>]O,:SE[__S6F+BF5 (C1&ES'+9T$(T**%U;"*1.AKU/N!/FYPQB:[ZD
MD%)!0_7,44*1DDE*&HQ+-_-:$,2'<^*XQ5(+@S4:05NV ((M01^A&^9K\A4&
MB//[0=L&\=H@_E#F=9PWWLSKY" ^J'JU85?)1\C!=T!U.F>-(%3I<W]U)TI^
M@'A7O58^\COF]?TAWV,Y7[_GM?6=^QQKGF.]A_QH.*0/@L.'6Y!]CO,]QWH/
M^0?"X9?OU+YJ5]=>? 9O7W[]IVN-P)V_N6ZX&%]^@" ,EWGV;;S?[_&?7]9W
M?_B> 1[\X;?.^R-W\R=J;U]_]:=W/_XG!_' C/]&L'GR&#C,:_+R@_Z3@Z]_
M^*MM^6;$IV!OFOX[:!\7^Y%^]9_ZE[<7O[SUGO[XY=?P@\_PAV__YWF3K^9#
M\>1U?S+Y\OBT[WK+A^]#W_Q^O)7O[NI\&]_]9G;U?&M>?_ P?1N/)\ES+&'H
MWD4,#:U2*),KY"R]^_0MGQA_T^K3N;O.,[?>A'WIXV!I:J;C+[*21J$0?NS?
MB<ZZD]8T9\..*%8TUTQ=G#FA]L-_)Y28DZ99_U7T+FGN$OJ(@3D&*2Y.=W']
M"?WU<7Y3VYMI1;[2;]ZVC[[_YE??P^[+KZ\_X^L_^F$@.SZC[^YZ3I<>:=[X
M[[+EWYW^NV?B\OJ9^$%4_>UK*)>4^4=?=I?^;WPMY_ W_>5_=[$^7C+_^,N+
M76RZ=)@?RL7&2^_^MM/^3Q=[[X_@0;B^=86#>_S O;M<7[SZS;.73YY_]G^>
M??SJ^8LO/G_RZ^>?/WOZ^;//=X/H/L>"IF17S'>#Z#I5-E%71^0<$,G0A<HL
MB5L.-03F$/HNE2^7H/_GPU+YN'-)2LW0>XJ DA248@9SFB74WDK3.1%\%]G.
M%\.3UEIK&8T(O>],:3P'7 /[ =@6=J5\00P?5,I;K10L(#12&A@F L[C2XH!
MJ?BB,IN\PRZ4/S0,?V"A_$A?O OE)\?PP48U'VV8WP9N.%[ I@ZXB4'HWE.5
M5MUL#PWY\OU)#;M2OLR1NS]T]X>>,&SS;GC\1EPKHB55WT.N)7).UB5OZK6<
MR?_BD'I58L&N""3.#Y,_YX*+]V"QZ&PV:I$&]3I^JL?"G2F/'L/" ZRQ)M<R
MX0C4-9<1 +!+P?7HD#?U6A##!]3+M]AK'A86$PX,:VK [ *8^A&+UU =C;"-
M\\;PN6#X3N9UI"O>H_U/A=P;[ULLHMJPJ]5[!8PQ@=6$,+M%>L;8>ZNS)_2<
MH;LRE=IEKMT8NERX1BHM#</ E3Q2=ARH(@F3=D2G?E.NY8S^[VZ-Y&FM$).'
MW!(!XERBF6H8/@"UUR;)DUQ<>7^TT5\XT_;H0=P;2PJ<$I:$O12KG5()?H1M
M&'W9G&M%$!\VAN;J8R8'/3B9FW 9=&["M5Q;*EG'#>,)XMW=?38@OGL:ZG'.
M>).N4T'WQO_&..PI=P7OJ,^1>!DD! +?7(BAI-@:7ERYO4]M^2/O;H*3W1*Z
MS[%3$ \\!9'O=,Z?M3^]>?VV?-F^+NTGS3+L<ZQ^CO4 N"4:)Q#%[XK0?3,,
MG!.6*!@&%>E414IQ:(Y-LNN>=YIP.9KR[[?FQ^D@(DDR)$L.L$8&\Z8@S2&6
M&C@A7USE?+0J?N':T*,'L<]DJDSD,"!18N&8LK*+W47FO-.$"X+X($T8/%LG
M9X"J!= U#UIR@Q1+,$E3&1T'B/']T5,;Q \4Q'>F"8]TQCM->"KHWOA?\=4B
M60#+%&#.\0!CUV#\1"&%G$MJ<U=2.&/HKLRA'FMBY.<1Q.^:T'W5&35EYY$B
M!D',V7IV+FA((TCS*>ZQW:N9_1>_OK6L5GSDQ$D@5/9S;'>;PT(C1$O:1IR=
MNLXU#;@;&<\8Q"%0FIV+W@V6G6-DXQ@L.";&JKENVK4@B ]H%QNER-B@E3)B
MMU8S:(@1<C-?@@X#;1/$?F^</AL0WZW..,X9;]IU*NC>^%_JXUZYKD!Y6-=!
MD0?M0A- J8E['^;8N8LKO(QG#-V5R=0N<IU.$K\S;/>,UW()XLT-.R\!-:7Q
M,90<(I>440O_3SO)9[S67[_YH\Z!J7]^]]'P)?7UN^]>WZ'<J?W!K06V,8P[
MZ6TN*N<*PX<S:*L$#F/(J==BJ5Y<^5_DX\=#+9R(>_0(#\&(*0WV-7L;N9@*
MQ_$<4"T])KJ/7GXC?"&$'Y UI%D,:08]#7!C0P^#;P=0[*0A^$QM;K?]!:5=
M)3L;A-])UXYTXYNNG0J\-^XYE4(Q]PP5HP&B:R#L":I8-1\&HL-UE>R<H;LR
M"5NW2K:G@]][.OC'+S[[^-G+5T]_DHM+EYSN<WWO;T29&S$@7LZE0^_=97W;
MOKWV\;%F7/-C??++)W]L[_[PEZ^^^4/[^LNJ[]H1T]8?KI!ZGV-UT[QS;EM8
MO@X5%Q?,1;+!Q FI1"W=5$EI!.3!2MT*A^5"]D]O"<M[Q2[1@?=S'>J4N/'X
M&=H@7=@HMMSYX@K/>>;0H\<P8754DW%RBB&(<M.:HDH14VE[_,2*&#[(F16,
MU"H9Q&8)L F#H"N@KKO4W&#?/5]<I7/6IIXGAC]TVOIQOGA/6S\YAF_\<.@M
M)(T$WJ6I;R 'BABABW.62D2FZ^%_[\^AN/^P]87QNS*-6C=KMA[AVMKRTS&O
MXJ/KFDJSACD4\9DPNUJ8JYG=1^:PH[;36OQ;>ZY"'A&U%00O/0(Z/YB70X*<
ME:CYC-SZQ=4XYHRU;8\>Q+&XZ+35$:\3JI%F,E?5<Q).6F13KP5!?$"]8@VY
M6"L@O2A@[V%\9X-_D?K>:LYU3EOW_NB*YP;Q*B"^FWH=YXRW6.%4T#U8=J+5
M%_05G)N]724@:-4.,4??8XR]N32UY>F,H;LRF=IUKJTM7RY>DX9-AGD?;CVC
M66!)Q8B2:&^HK6S2M9S1O[7AJJLGKHTA!F9 2@96LX?J4E9?O??51KRVYRB=
M,X@=IQ&L(4?G"5T+*CSN>'3"C7RO;9.N!4%\0+I&<&WJBX..50:(2_UV&$M/
M*3;"1#GH!O%9@?ANTG6<,]ZDZU30O?&_ZKU:38-E%3; 2!6X, UWG&JCW%QC
MF^/6S[E6O3*56K?6M17B]Y8R/__L7Y[]T],GGW_Q^:MGGWVVA>)_=Z'XOS[[
M[2?/7WRV/]B_]P?[W9/[Y,FKE\\_^[?]Y/[=/^!7+Y_]R_./SZ%Y9'=E/.)S
MK!<.[6SU[LI8)\.5+.* E!8.B"X2(R:4/!4G :/_G[8_[PS7Z6ER.4Q35TQ:
M<JK@A12PI@C:FT*+I-W[6(L->Y+XZ+F3"]/D1P]B0ZNMN2D%4R1UQL5%KH@L
M6@JZG:9>$,0':6K%2NB5@9*?:6KN8-495,&"-21O(0X0(VX0GPN([TQ3'^F,
M=YKZ5- ]\+_,CJQE:,XW0&\"(M0&=)N8B[[Z//PO'S]W<F'HKLRAUDU3K\>V
M=DO&Z1IIF;H%L299T(4DZKQ/O=80->6&FW8M9_9_?TB[-(2<#1G$STGASA>0
M6 /D%GIO83@#YHNKF,]Y&?0&<6Q-F]!P\3@BM20C:$N$.,(W0VUATZX%07Q
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M9MNY\K,!<<]%,EOP.3DT;))+TEA51M">K>UZUXH@/FPD32YGH02E]!&YE="
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M@A:42R(6%44R)5>P5F4'S+[F+@;:03QL]C6G-N[L:_$@GK(O*75%J$'80"3
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M7X^>[OYKZUE/;>[7&* HZ=Z>GMH\(((8L22+SO,O\"X%(EV+\9I,586ZFV>
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MT:]:WL_S'I6S WI:+W3T,SH^XB$_?/'D\-Q\YSM\J\!W^:O_>7"4?U].I7U
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MC%-!M5B.E:LL%^Y[+.>S=N+HL9SY 3N-Y40*8&NJ0J>( L HAFXP HJ7%5W
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MF56#LE7+@/5#-:J[6?Q$C&BUJW^R-$/R^Y=^$VLBQF*)0-9_WJ9%S_*-;(R
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MC:Y66'7_0R\(>Z+?&?CPO[+9;T?]_J@_Z@T&[<ZHO2)5W'RB@<Y6>!)IZH"
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M=825E-,A4;] '-BBMA 1L0AQG]0!:EMP'4 )S,D9P@.-(0 <1(6RG!!2*$K
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M#)1&Q7(=KOR4ASC=:[,5%@^Z&);2DZ.4N^'K:IF4'BC/5*!PN@$2,'I S5^
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M,.B&93L&N^7[NE:$)K+),)0@3=]PB#Y],M/.%!QS> KWV<]C>RH3G,$[+F+
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M,<[^WT_-GU":@<"!._PU_QDLCS"9JZ]_HF7]OY\^33_]?,':_"06HQBDY>*
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MJ'@$I&PP4I@JS=(Y'J*11EK=AYO4 XK)^3>:4_9$X)=MD5:%I=GAL3F$KMO
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MCAJ8^+WXX%FKVV3.>"Z9A^9X6B'4=7+OU[.86!?7S8U\FF*NU\Q/*(Y\TKC
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MFP1TD(K:?Y[D!W83J]UF-A!(=/BH<*"W8[3*S-3U]V$.D$AB@"[7.NR#BU%
M0W\F"1<(Y]\G9]4GPD$L+:OY"=VSN;MUM?E8K;DX%P:+X"X_SM1/'@?C(%NQ
MU_^\ Z=R!.8R.5)2<C[\>.@"[5246;X?"!S.KXA!94G9P30BM\0/DD%-UFPH
M\7\Z5KR1XV_6_'F6/.NP'/)A5.'-K8*91<'2Z?C)G'EF*8^@8!, @<:9V>H7
M@+0Q*0=RLB@GLT$('M$K8:U\L-;G5?+35I(@AO9943(J68!;%3H#7(O:'MX+
ML,B.1Z*=&C8LK)1Y%LB#?/?ZZ!9!PF5DH R=UR[B X_[TQ?><M.GS?\I^^26
M!W^GH7-4,.RGDF'[7EE=>4**H/U"S5LM9($.OLMS59=1PDP'/YVNG8^<UK2:
ME4KV:97LSDHDE"^+5>)RLZ:E"EMWY/IN-=*ZI4?NR"*Z4Q*SDR"P/!,W$ 'M
M(F!TL$ J-]SYJ\K0BVCZC.*8E^JW6(6<,V5PH!PA!0&(]Z9\KX69/$OK@GLB
M8+-5/7?'PV['/NZU7JOC/\R2%(Q+?WAAG@97V,>0Q<S28DH6YBS,%I%_#'!.
M[&QEN%]3G^STOCZ;%#;D%OUZ<(D)S? UN':$!IE@.L2>US^_?,W,'FR.@?/D
M;H,CC:=A(A8S-1XT!1T=DN36PM]CAD(<MD]N4+U>_#</7%?D=2+-7L8N\;QX
M*A-ONA_(_8,Q:A*UZ/? @S!IS0S" KM;5>31'),KJ'<&4>=64<K^N7=G@?=D
M%O@=6>#-S.IF(OV>,\,Y&3Y+\RCOM\&CI[="I%N:SJJ9MW)P''1XHOB*)][P
MS"@>7JP.C6>CF>!!I=C%0_F3NA@@+))EWO]YM%I"^YR>&DMJN5K&'+RU.$WF
MX7\7\U2PF+U*(A-ZKAPJC*WAJDS.Z8A.$;B9TS*FB-T4P]VKQ:*R+ _Y6;_2
M*I=&0 3/-%CV&> "I'24HB(](9,)7K]/X)*L2$S\',)*4]:XIOQB-ND,Z!EV
MOGA6T\QYP88\'49QF_)T"G*?ZF&UDA"HT=:+$0+%04B]TXRSQ 0#,>H:>3<
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MKM_KF)( UD8 Y@D0@.]V#&K[;7W@N6#/N9UVC_:LMFT9@ SXAC@#)(#>8@)
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M2ER0:OV*NMI#'9]PLP@6J<W? 5\NW/:+H:G=8K&J<A0ML6ON2F:UEQ/OOWG
M=2NW(GRT5+, I_JR,=T5H.J[Y*L0>V6CP.&Y0Z;,%9"1OV['#&_.A>Z-\EF]
M4#G\HZ D!EU7]?I<WB6(BI%%@D/P4K0] //1%/680#VSJ&86(1B$"6OV^'R(
MQ%O8/N_$(V 1;*< K3]%*>$3H"$5%3?- 91Q-]?HAFHLRS9=U?QU":ZQ )3/
M"ZSI32]/_<Z64/]2L$L+$JB0#JQPF"< #P#C"-TFOX8]P+2^+*8MM;L,IKL@
M']6*%J<6@AOX$S 'B%+^3<=!.@'GG>*,2GRS\,(9V;>8NPT>.[AR^$:?>@@2
M+JCG++F&TCEKPEON6E,_#4C[$_$"<!);2G\ CCQ!SY3-Q9R!FN[ !EOBS<SM
MG0LMW5P.7#9<ICZ$_NXQCF^/7*J;QGIO62-[GH,6C,'13CP6<2SCDW\/=?7;
M9/A*(6&VX)MI_]+H6),?[VZ/4YP=@8@+X%\+-\JTM<D/]+D6K,-8N [C:=>A
MBW7<[9GH/>U!'LU#[W-0GA2?L-,#_M&SN]JS<_[FR['3.*-O%8PYP2/'Y$89
M$<P3I#12V/D(]65@HAZ8T&5@8E/LM7FWK519[_,4+DQ3Y8(.IQMB-<)DN358
MCQ^J8? <O&70]2",1\]^TK$D@&>7E7*0"N-I"==!&-*F:M?M:#!12@O:8%;Q
M;<\A)>,RH$Q$N_AA7+<F !QU@Z)F]YC+6=HX6%;EKL/=&Q6/]I&\N-%V-&5"
MWP<FOEMVNP$^Y/TF$7J:2SG8VC.["HMVMKS38&V)TW!"OH&G.KO?#WA",@J
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MD76#N^W+R,A:PQ'T@@9B/TXVK;-H>TG<_/-9!8X$EP37(THJMK # !=U1]&
M=53-4^4@P(E;SS-5^\68I@LF^;4TK;MSI4^20)8F$,?8O5&/DCR6)X\=+.J5
MY+%"/X+=JZN5Y+%"V?6.=N^10;FR<?P5\3RX5P;E5D\"T61M:L-1)#I%OQPT
MO?#PB0371L$EA8!,!GL^D^/PX/-Y__1RVY/!-@'8-TD03H*K(*E;:C(I;<6,
M)VO54SKID*X;1<:J:=421>M.15!EWF##4:3):N*FHZBW<OW(%D>_GMX>=9[
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MST_3O8PS$BJ?1B09$X_F;%W*!0EI^AQ%V_?=Y\:)3Y,VA\A;$_#FQ[D;4J4
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M&M%0&0<_[J)1WK9UYO7#,';AJGD"*Y]DY#N=%:)W;G!A [,E-CU(XG&U;5P
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M.( ;X)G )QEP,8B$"$RF5'$I6*(H*>(KH9[0,"4_X+WP1Q"!2*&EL3I7B*
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MD""G>?8)&<:8!A2D\W-]X*FYQT)]8A7B^3->4QA?P^)!F5$6WJO63)((4V1
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M^9#(8K USJ)-@W2V01U6!;<I;#1G+;UQ/&75T=LK&K+QYX8!P,3'8;+ 2H-
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MX=_?SN[:!F/#X@!^P?W0JG6\7<_.SLSNS#P/WIG$C8-#P/:_M[)KF&@/)87
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MNLC[GH%^FQ W@6]>LJ\GP(<)^)_>GQEH^G?5QHM+)FC-K)D)'*."!'21YP?
ML]=TO7"Q&]H)R&6P6L)+"@$)LM<(V%/ P5YE"X\!.<$:+\W5U67TY84!@H"@
M21C !TP6;3@%H4M10N^O$+AHBJ!#'<:%S"4R *FO T!F,.B!!?27P(9BG7WZ
MQ3"8$=%BB4E@>#FL*? GG$N?!!2M?E>IU2O-^H41F?T1VR#@OIR6*H=T"=W
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M6SZ>=@#QD#<KVY5VDA";JEFKF2)3;4@:>&HD1,\FFK;P@@HVAYZ/7F'7H_:
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M];2;H987Q=]9?IM$;@W/.$5);7GYPY+  B<L2\6H!"5,DS7C,6 5!9\X31F
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M<0M[/"Y=Z6#13[O^HF"U5%N\ZB%-EW<$?=E/%QBAO!YV$]X#_E*ZDETQR1E
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M&BXT-\99=[#6/L8OH*^FJ>T&J:F^/<1:U^E%4J?\$?P"_O*'_P502P,$%
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M7B?A.7@E';!HN:IQ)J:;A- ? K9_S6E!Z/8ZLSL;^]66&Z=$)V<UU^Q?RVJ
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MF/T$]^A&!?>-UD"(6S0G$$XYS45,3$8EE8Q)H_).ZT1KH&:\6Y0]VA)TCC?
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M((,SH)36X KY0"S'; *]1HU2QYK,YNC4]/"<-ZA"/<BD5N_HUYL3<U;&+&,
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M,BT'(J_!K94K9X]>S_FM,^$5/D2O;/; 8UP6#TD04TA@,)*=+EU]+YN>TF\
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M,,9SAZ4TZD.[(\[]*U4SSN]T%VQ'6(/%ZJ?Y8GP6%OBV;"$7YR7Y[X6<#$V
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M--D3\]L(MW(X]VAZ&Z!T7$H='>$BEP$KS.)YDRP)GEH:#+4VKP1Y-LRX>)8
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MY%$3<WT/E27QY<; *YT%USQ;UV2$U!YX?\+4V!OM6TBX\KG_/L4R_O=-6M0
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M!B6D,[+7/N<:A-4T%IX.J^0BS S@*1?1B1!>=J;4(RFV(W.EI(&UH8H?P.;
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MLOHUYZ<7X@X^28QZ^N4ZK^\/5(/ECWY?BO7J%I6'IL-&M%/FVK_Q#7X1Q.)
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MZC]Y1DMN4<M9Y./;XI'W/KZ=^VEZ_N'PDUVIH=MT0(]JM<'M2C^(/M2\"RZ
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MDW5II9=E"/.&9H3H5&=)UC3-,10[M15F3'Y 8NW49/_'452IK/Z<DA@*PCT
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M,288D>X39:AQ6S$#L\(,)M!Q 1L7SC6/7\#93=J9;F!<M3?\,HS)3+0 5'=
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MP,3\@A]B@934'W2 ,!UP[6]IH/D?3+FF>!-!Y$-T@!]6Y/(@'7!?/ZZV=CR
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M7\;;>[^U/01JX&ZY7$M4C*\\ES6=,D'RZ['C2*!H..&&63WXCEYFE]OV!I5
M9@;%7ZZ<.:?^O(A=P-;FFEC$::5.5#^"X>0"-%&804PG#3Q:/P0\L;"1+TP8
M[+SH,B:WO1TY;V>:VBW^O.#A]6OS(5/)B$YV13H Z([ ZWO/K SA[G]OR:%<
M&\M1:CZA.L,(TB=$;_%] # _/ D(L_Y?U% PI\!_0)@8"VY$R&MH)>AA8XB3
M!7QO7FD'4.L#/&LXQ1.YG\F6^WQ=%7=;Z7=Z($>Y[K852@?<8:8#9*NTZ8#D
MJ6J*!1V0^A)XM NALFUFHUJ&_-0GDT^]O8)[VG?E28;!^W:N-*-?\("<Y4/7
M!WWO-YS*#(TWE@USO2>:&FC/$%MD/!BCTFTJ\',3S=IQ'O%H@VL]Y<049,[:
M6@U[7;=7^>M6D73I\U/P!T%*6TJ?*:"_C7D?[7I3V4 =J-SO%3CY\ZNJ$Q(W
M;3VNW 1W&-=NU+ H2KD.\KCW<;:.RIM!_.]#7ICI\/[*G_Z;:<Q]?>UVM[C+
MV;WXJJ""M9SHX3GO/Z&V*V2USI5O7I4+YF%KN[J!^9L_IAA8O.U-]E^C U@9
M^%/4<8S:*(UPKP) .1@LA;,:SD)JQ6[!Q>L59+/A(_W!N#,R!X>?<L.>LX8&
MGUK<5X7Z[C8K$:VW \C^4#^B(ZD3?X#Y4!6$-;Y,!^"4DE&RT=4D.J GY;T[
MMZ--_1MC:0=IKNB69K+MDVZ.5N\KK&(GDUYH+.]K7&>[+2-H?/M$:SY_)JM5
MQITTW6CMFNKGED;OQ'U49$/BG^7()BE7B+;+IC^=&KGS*'[_G?G5B]\M-*\S
M2R8NY1PF@Y/3GD(:2SHA3!1K:JJ_C%J?XQ622/7FI*.<I[M7@!S[P-D<_7'_
M.Y!:*2G7ED@%Z<\JJ0>G/.0P_7\%4KX<];TFD (@]>/M]?#1JST09H^<':(=
M])MLO3>SP0=JFK9KE7VP5.;ND'=@340:IY#NFG:BX2T-#LS4EBL"/TSL)J')
M5M"4_B/=5F#O3?\KGG5 TIVOU]=2BF?JW]_-,@Z0S'$0SKPD]=TWD1TT5R\"
M-)CD$Y^H:_4H.+&I>'SE)$)6AUS=&M[-WO,<] M,NHKJ1<[,+1U0N(J(:9'8
MU9[ADZ1)!V;, KKTV4A A;%!W6;4V&]!UL0[OYU\-@S!)WAOW.3=V]DJP^OU
MII"-X/T,@@AV0H0?'813KA3!)/+03[X]YV#YAJ7R]_@8%\V%1<P7Y-^PMF@C
M/UZWPHF'Q3\?3=U]P3'^%,1@J-%(O(5QJ!6)BD$P8I*()KN[*%MZO^.I*8J>
M)A*8T+M2A>DNEJD<=JNRB^5]F&GO42 UO?VI$(I?XLKOQJ1LIY)O49Y[1X.Y
M81+D*U7#771  @W8-/$'P3T'+39>C=D6'-[.<3G*J^TJCPL]8]G# ;(?'$Q:
M.27]#GAG?;8ZN]*^?B&U3"N RUA<1J)N<$-<3VK-,$T%!+HBHG5"5,=L1#T
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M7;+!&]KX5)MY9^ V;CH:H')<0D;/[.LG+HV-F RV[+/,ZSA<=#Y-+??$M>2
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MU7#VLME0&_?[QKPNBDP$-)4]!"\"28+A'X.W/>G1=9LZV@1[+B/L9'QUQ"!
MM4L^_X./C%-)2&#W8VBNBC8>>R]1[DXC_->/G<9%<(,H66J"'LQ[P#\JPYN^
MI-Z'>0[A:XM<@,6$9_7C(28_M[:F;J+NR#ZDRK=8Y"=@'6.HU:/:-QS[N.;_
MO#\-7N>]/MK0SGLSWG1$<R9"W\*KRQ&+[:KM%TA+^OB.1::K\A9K%'VDFR'Q
M&&_8KY N3#-K[Z"3.NY'\I*8OY8RIQ_2-DFH;@PQI3>MN3_0:3#5F'86QJSH
M>?\SD\(>*Y6K%RC#3_8OA6S;X:J,^UM,FDH7(QV[[0REQG:"V990=^+.'@R?
M7TA-\+X2AM_!\AB,_]#AH)"+HCC(XP"$0**RTVDORWO*BVVJ*++3]*\Z"PW4
MY8_K;:N;? @/)'AA\\3D0Y%-3UKCSGUJ?NMB?Z.I:J7BPM7?:EB*<B6$GZP!
M^"U)RX]=)H1T;_/:U(Q]R^=4M3"/"_5+BA(=-+U='@428Q(38@">T7UH!>@O
MS@/RNUW#,S/$=$ ?1X$MQF^1"AV=RKKR(Z^ -7AED!ZE^P8C#[3O.2:\/9FS
M*7=^2$>(2Q:+8:;.@AN:<DG>R$X1\EE"TD;PTN+VA:7ZWNI0TRY#MM:1-E8\
M#63AZV?F\.N7,;-YV5%]KGG>[='9^@LJ:2 G&F@RN+U-Y,69JDIV(:N39DNI
M5SXJBH$8?C)@*Y!=E]XAW<"\--"#:4I4-'?Z=-;7DV_G@R3#]\?0F@SD?7H$
M3Z'$#<7AUO2HC*#V'U)9")&-:\0X5, '^QE=KT=R]226RM/+1HKV!CE/[M?Y
M_0*^9;(IU-*//O!Q\-R:I3NXD?(&N5".Y'\W12?I47K#SRO_^NZ*ADHZML9L
M#=PL%.[J#BNSD$I"?(<W*PK87/CP^L0*C_+A$.@$Z&/>:DPAD&^1:TR03_;^
M8'\35/#C>-H]Z3+/M>7'1LM, ]N7P:^;M"'XJWX61%?@B'2;? (0_@CLXZ82
MVTZQI/?!$@)\\E9^3E5YM*1Z1(LWLLOXM@[>'<;:%TD6!R<:]&8D0.G*92$7
M4_]/C<@/DT7F<;M?H( "[_9K;P**" >Z<3.[?$ 6=#38;%?P^JAKM)74<>;E
M&^?NF9Y[=OHSH_;+VH2BG?.H^8I+K,9C?U\]D>26&.64?&(=_4TR^&ZQS<D/
MUDP@QA,@*9>B$?(9'(P7YNP3SAKWA"3Y]AKLPJU/]75F!1M'1R7NH,_+>X%A
MF@PH@B?5'):(V8*UTT CO+#A8;+D/.DJ69;R"K*0B&F,CZ-> D:[N\*KB+GE
M?UI$,A8YL^M;)BO1FNIUV$%/H5:'#?=/SW#74LYY=JUI402^2@5=&[&0J--X
M\:W[9,PXO[U#?!29M^*W]V$X.D8SO_S)&Z2[14#9U6W/%-=O9\S3)4UG^XTV
MZ&Y%X1_RD@5W^\',D(47>O/=&&PK[B^QANQ%D"FO= ZU<&CR*G$2V>G"=KH6
M:'>?RE,.R6)E'7RMP? =3N?Q)TB(K^!&UJTE$H),5P?1WG"SL.H.?C(KD.6_
M%*%<4?IPWL=.I'YF0QS\I/]2<>\'/L/EXX>ZF[Y_EZ@<Y>^0G=>UZ'("(4P_
MU39TK+M%IV<0*GSW]V]Z@)JSU/='E)[,&FY*^=U'D*U_Q>[!=.BM5*&LD?>7
M=SH$ATQK4_==1"8CQ9_XZ77W0_@.>B>T*#H6'3J/O<^9^ M7%;R5[DSEZA([
M9?L4*UQ6@!MG";@L4PXK*&"D5&+NHX&S#,!G$@>RT]Q "\=9Y=@)%H/;%WFU
M('LLS"I/3OX==+J]JNSX76F%7#-F=&+&6V;.2$^3Y7>ZIN"QZ%WJ*2!R 2SJ
MY8]+%P9D32<TIQ6\E\<:I37.+GC;OYX>>E1J(>+A$I!YMV U"L+UGQ9M\#?8
M#<%T_,$\]#]!CS<(0G[>!UG?5(H/N8WWB%T\\J>./0A:Y 14"_1U'V4MM_FR
M<V,U-SX7,<MFCI[W%Z&[2!*@8UGC@G_4O !RX14$;[?+"70;$YJREC8<>$$^
M><.)ME/.MB3#&9;1OQMMY;NRK<US'UW4U?/9T\-NH/^FOO<.]T@LZRY9QSX1
MR<DA/&]N:HQU33LC+6QSF>-2K'5^9P??)X(<0@/5E>>[B>]=Z?[8GN*Q(LCL
M)Y#QB0<*6LJZ#$ZAVW''GQG1.5\/_L=PU(!X'$1F \5@J!"J_&6R_^:8X>F+
M2&YOJG!-DEO,C7$U$=O0G4/S %^AC+:8E<BMI]V8.>3"2P@;Y@&4_Q]KZ]!
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MF<WCNW3F(%O)A;H3Q?J3 T0)PZ.WD20U8(D8.X5QFV>#A^+[B@G*W2*<$6A
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M488+C\A&.X566.#?Y_M]A*FI!RM'B(TN+@1T#YQ86]?+^FF;#4+P(#O].B[
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MPK_!3I,+#<SAJW;.RGCCQ5VRT!AQ YA2Z>Z=;PA)4/7SD).&=!\RW8A2/^3
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M"*:=L(0\_QXDVV^_EK$U+GS] [73!@90ZJ":T=_-BZ"IS=TN=")" NC$DRR
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M[<][O>W[%,.,T8-.R-#3T,<0N$(.R#]$<^0%:T+"D0.J+ZYB2?V!OD&J?N:
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MOBJ%VF^V?B%)?QY:HHR9ESB@1V^A_F)B3'N:7$*+ -?1Y% 'D:>H*.Q[SPG
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MM8+-\^S0_F-@]V\A,O=/?)G)N\<46S1-$=N\FB=F6Z.*]M!BJW"CR>/[;?\
M?+>AFF /U^PO@W_&5Q4;X@_^V)DK#9NP;H/+!>[C!OB#G\5@1G9]V[IH)ZWB
M.HA( EMMD-VT7_K.DW?65.)LKP/>.Z.\P#BA%B_N0(]6M,LE/=Q.AGS!.R'
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MI,(2WOWQE)RPGEH,#A;L5*:SC8\\JU9V2]+,/K7?\W_#I/_M@\OOQ5L$D/N
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MK]4NREM[_<G2.S JG@-:<N* /G- [#%/Q"U1+3G91:O%R-+M:HP4IOW:SYP
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MCS#A0RU:@!:1*X=(-&>O[UY?T+%>8.Y#/H89=_7J[%)OJ*VD!NTCF'4<Y>.
M+.12;OA>N(5P.GNDQTVLG#W2 F6EM8"1_'A6"=X;([TDA^8UM6:<1H2ZL)XU
M7R:*%)0E$(=0W8:U7^D?]OVN0US_F&*;NWDC;B[X&S@J20($M7LQ9F";ILE
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M 643W=[7@Y3$3S]4B9<63'QV[=#N!Z"5(^?_&UKE__>.W9SQ_P]02P,$%
M  @ ?(">4O+29ZMY/   U5@  !,   !J;FHM,C R,3 T,#1?9S,N:G!G[;P)
M/%3]VS]^9 M%]C53EE)"65)9I@U)UC!9IY+$A&3/F!'9MR*$F I)8B)+V29[
M$;)$1I89(=EF+&.8[7_<W^_S>[YW]_V[G^7_O'[/\_K]OJ?7=9ISYISK7-?G
MVM[7YW,,ZRMK MAUWM#8$&#;Q@9<!O\!K$6 _]0U[ZNN@"L ;FRL$> ,L(UM
M:]O:;]O:.-BW]IP<'.P<7)Q<7+\1-\]VD+BYN+;S;>?AW=K 3SOX>'=L'6PQ
M^=NMVSC9V3EYN;FX>?_#&^L](+B=[<:VP^QL<L V039V0396"P !9>3\33PV
MX.\;VS9V#DXN;E ,/O""REV@^.SLH-"<H,3@MZ'@]P"'(*?0WB.GN(0MKW#+
M^8BHWWWP=+O\Z;)&4:M>DH+&U=OA/+QBXA*24HK[]BL=.*BI=53[V/$39\X:
M&!J=,SY_T=K&%G;)SM[EFNMUMQON'KY^_@&!0<%W(NY%1D7'Q,:EI#Y,2\]X
ME)GU+"^_X'GABZ*7Y6\J*JNJW[ZK:6IN:6UK__"QHZ]_X,O@T-=A/($X^7UJ
M>N;'[$_R\LKJ&F6=NK&YI1<;P,[V+]N?ZB4(ZK5MRP;<6WJQ;0O<ND"0@W/O
M$2ZA4Y;<5WR$Y=3O;A<Y_>!I62./O(852?3J[5Y>,05-@B)Y2[7?-/OW*1;^
MG]+L?RGVKWKA@1WL;*#QV 4!*,"@/XM3 OZG$O8Q"R#@<#]3T5,A+* "UINV
MT0,/;+0[ZI!-0Y?T3T]-5978TX>&2S]098]UO]'%_&0!UD6=73VA<DM>#EZ8
MP+)5-[KV.L/*FXY%4^*@_\BKVP\VBBZJTV8!^M!E=Q:P;-2(+JTS90%0\/,E
M]/+^7@QI?'S-&+=<SP+P2BP@BLD"7H+?IRTQ>^''>XTVLYO1*Y,L8!^&!2A
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M0XA60XIYGNU(S<^*?M\TQFNF!IP.,#+K7,CF9R*Z!P_YI4<T5SW9YN7O$.6
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MU$QR-%$LE@#GG_4)SDJO):I8*2OKV.P'/FJ^>O%.@2WUXQ[^&^QWXLB8*!9
MLAC_FDT<2EH%PTN6BY%?IP6-\;^G]O3'4+6IF\_+%S\]A:9<M(-DF#-HF=7I
M^D?WN8S!3O.[O@CJ,X2=J>-(#1^:J&[%"%!?46&73L!B,,WX_$#WPO'M?895
M#XB*9U^6%J0>=YR8^ Z#G^04)<"ET!.%<)(Y=+B'^!W*QCS!'$8+Z"H3-^KJ
M-_DKB3?V9HU\8DM=D+SIX&4E$5R@+B'8R%7?H&=DGFWN9*_\P_[+4V&5CHX=
MU]6UN7?V>QWON6#!,0![1%=@5*!=(<FR:MYL2%DJC8#=]7/\>OKT8(_I@$W7
M6IV9D-V"0V1MI,S+NM<9!M<M6H0T( NG:)[,#RR@S#GR"A&*KZ9$D[!A"_YV
M62I*0=$VYUSK7=O *%.]]E!UZIO-.:?.Q]<LN(LL'=L;QQ/AV]$WX-%5$#$4
M)]+T<QV<D&-Y:79S*5KK6.F"&S[@M9!A:Z#RME?UUN';.:X6(W 5 N^7=M"=
M/[, -T8(L2=ZH<Z7:!*\J*FVW?BE$:,@F.-(1?FG](F-7/MG1U1/.A]Y?%^)
M_?5_Z+=HZB*(V(4UFC12A%P_WFP>PP(JH-$WZ4:%(Z\V"Z,75*66U\UCHVQ-
M'JFD&ZOTABEH/CW%OB=K$25(=Z,:D6GOJS#"#=Q(L\](.&%D/M[4N_G.*UAZ
MN3JI0R$V,_  (>/XQ4;@,[>I@<_6>Q$W('?'@875>$PB7 P))?@0=SKO5#YE
MZFV=-&9Z?M-=[%A)26^,>_YU?VD+X6XS8%\M+Z!4&DAL;QV/Q+ Q(1YP4:86
MTJ 7>8"0(RNH6H0-BK!*ZNL;-N&4GKH?R5'&RW7[TWO >-M;[#":,L-(1GN:
MZEB P,55#0]M<M8U54SSOX2$%N?W#WLI[$V7B96WQ8_8/>3"WS+;"=RI%VU$
M(A@OT&[CPWVF1T<F8:VA^T_6#.KVY\^N:XC7UET*<\^/&SO<5^<3SO?6ZL7V
M0X8&_K+\Y*%PU%[JB68B)*P._AQQAZOX6D;6]>K\<2,?]T"OYMN=,F4I2?=N
M2P@=.2E5 ;N'!%-F^!,PK>J@=.@N&10459MV WF"O#\A!1:GPFY,/BO4Y?>#
MQZ]Z;]6W\LBK9PT^\!I/2*VAXZ"B3$FZ$,E@J04;S]3M0VH]<6]$#1?/P3YZ
M<Q@\DE.=V2-VW=7&,OWZY9<\>RRX3QGXC'/A;@B$@^:430PII4M2$Y_/D68S
M<"Y?KKYY&+M*2WQ*SXYQY%'YKM1!4+"Y6OJ*2T+XZ^>_G&?ZT[FG="GM)"QT
MXBF&=!L;Q^1 PN#5="U&*IV=JYA@SON-/ACH?*#61)Y1I*NRW'GH0+"FCP;[
MU"/!?O?K^]?T<6HH5:3R()B,'T%)3HEP)J\+L4O]!YV'RIBX5*=-%FZU)6G@
MJ1#'NYYB^&46<'D?W_'(APA*.@-O['O@P7W.0VQK2W31,Y1+).@"FL9%/T>%
M$4=/0*M'@JZNV)*27N,4V^)+\*=7AN&GE)H-%'SE7.^'6]2D1LG593"W[Z5=
M"<IC\AJ!"#B'!&_QQDOIH'=1HT3K2>T)TP,E?=>^?*^XW_+F0@)OK8G7YXI,
M"3>W8XVB@^C&T^B))V@NY%Z:,A73!'DSDU2!CH6*Z 83BKOD">BP.H&BYI<>
M4H-Y_NQG=CQ3DHS#M_3Q7'\;6F8D)71)Z$D7^+P@1M00D\<7_#1,@LW/D:5;
M[(,&_4*4<US:[9^\LZF,8TX;OGV[S;!IPZ+XD-R9L$[ -^$S=S3H.#A]"=),
M.%...=(@3(J*="^8O1.XD$P,TF2<:!J]$HY7O'2Z74J)-R8O[,G6KWIQHI*&
MI@/ITC1R(,$<]!S42)9:I+[B#ZFTZ0*: S7#MK_DIE;0]90E<[2*U:*B[;YS
M$L5L!Z?X^7>BTD>=[+_B/X:&^LH<;I8,?I[6]%))\I#Q!'!<X3/W!TPE-UVX
MG<DS.P'_*DY,CR6/3,Q$^N_<3=__:J[A!+FM.F^DJC@4=3F=. E+)V$?J=*[
M^I2+MT5[[+&QL02M95S*!".S7(TN-442H+A0H[$_:\R3&E004@+-#$.B7:::
MWZB:]=NZ>I-]*A'2JCD[ KP2UZUK9%R2KU*_L #.>3"0]%!@8I11TY=$^C/*
M-3VA!.\PY"F9Q&=&A 7;#:1_\<BY<@-=+,)=P;3 H>/EK"S1:R;1*;R1EZ\T
MGLF;&)H/#J<;=")%&UH!G^?+]QA3 1LW?_+!GC;XSC&G?0A;LLN//EV889^D
MC=N>5]6?VTJDZE)&TFSV?HGA[*$>JR%V4K1!*4*01QF%#9RSMW[<Z9E?)YLW
MPYC<3KK!I_FT1J^H/M[. C+</?.7\Y,7:UZ&\W.&9OK29)A=F%T-AQ"8"F@+
M+A(/20 ADI![0)581NZAWB<-)YQ39>3%Q#K5#\>)I\WDG@34=6=\+L>($U@
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MDW/KPQ:3?[MU&RLS,^M.MNUL._^/#\9;@)>=R7G;,68F"6 ;+Q,S+Q.C&4#
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MNW/Z_$:$FT4=JT=%'M8;^H^V3SH%2N1'CKRRNKKY[5A.DMQ'Y%7Y!'SI%"3
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MH+5FU-I.)!F7N"$?B5@^5D)G7<\I@-UG^=(/RL_.F/('MEQ3_U/6^E'"@YQ
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MA)LK[G @IHJ,R>WMI;3%0MAZ+C# A\H5)%(R2Q[\<'1[5+9+/39'=8%0<RZ
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MGV_B;@<+\QNG6';IL8BZYIW0;U'QJYXWR#<^9NPR,+^!/&TII]2DI42IC&4
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MR);Z:_3^-5O<PO\=AJF]UX(!\)QC &%!<-+MPVP5M%+_%IE_3AF"L[B_884
MQJD%#1[TG!<CHR*JER*_HP<3&DMM1F<N-;GS# X$U.P''.XS=7EKER3C_F]L
M4/"[A1J_W;*Z8OYI!=<+2P_5)C^?6^]<BC@F\L/Y<O-Y_18+[[+:C1;\?XM+
M!2+_TJ<P^/_73O6O*/=/%N7^-2#_9P/R'3^ 7NVA)6/%H/,9S7N5:4\@.0?G
MP<LOBXB#SP]8U]ISZII_O_11H26XZN^+T0<TXDJML7R86_?"8E,>WR]9KL5/
M^(UAQ YV4.\U]SP:?K+X8MSS<39!Z;\-2I<D:'4N=_T2M_5^310EE_X.L/N'
M(-^?R$)PPP^4KB;TRI>A0@F[?1/X;68JYDY^%[T>^X'S^M 9U<LW4((UOW:(
M:5H$'8'A:"CM\"/QL+B(7B[=9Y';X_OUB8N >$B+@+W3JR=<M_YT:JX($440
MU!()$J3HP/RZ8I&[RE [P0"#F,XOY41>UT0+B\'GQ[?KYSGHO-_'F:D/^&B+
M?3&+A=3@]!%!;R8*U0;D0\<H:@O2I.>PL>T/YM&MJW;3B#/1N^2<)B=2\W9J
M30.<RE>9;PY1- 0$S/93<E9#0 1U<*I9B,!:?QC$M3@U5C=\KCU+W]LK66.H
M!>HFJ90E\!Z2-O$[_+!]BHU-HGH#D"W9"?8P %;8@<)NTC_BA/>#/-3^U0[P
M)@DM_&%RZ9-?"?\ISK[1*YQXYXYK0][WFCX<O/<VGEUE@3JK'C1X:[8;?;JO
MF/VAA^E%.X7$-\<],KP^WKH6<B"[MHTDLY"S*0MAJ($8CK&U-B(7)M)T4[E2
MM>*61_8+SV+RC:0NU^$CP[*3)I-WJN44(_8E/F  KCQ#GJMZM.CO<CR\]%Y"
M&3(\B,VMH+/;Y4RS>L&9(W-'U=85?*2R HZ2"TXO6H]+A)P\'_U-BQMR!<]L
MGH9.O@1+*7)DCW R ^"<C6Y#]0>=>-X2X*;54QZ2I"I792[H,)N[2UM2T,J&
M]@3+AG$BKT9N(N>(0D%(]W$\GU675Q;FM*$Q<D'NW?ZXO%3[2K;.Y5[>*.]M
MU-B)4.T]?W->\R])< (AB/,L^3HTEA^W2!<-TJ-E01I.Y)-:(TZ]FDB7&_UI
MU4&_*;ZV;KC^6M\CEFE_WDYV$99^'TK".+(1F3#*6@8^IFB0_6_#JG 3[2W=
ML&*]UVK+$],BC*1^ZZA"<5:U9[)O#U%WE4L :S:U(6Z0S3/7&NZ'4A(#X$C8
MY4IQL=SI=BO7?]G5K.?<JQ9WC]@SAI)*SP9#,KUO,*E\O<BDXT,0TCH*'09Y
M*)O&8 FUD'PTAH3BG*9$^1D&-HO>]T]-;3>7)1Z^(RM]]Z)2JB.P[9Q@"[:#
M 50BYP,W75T&(_(W#V*[Z7Q4LLOAPH(F$LWF0&:'UW[.EQ/ZHA5]@YU/5'O"
M;C@S]TZ_X!A'+YS9U*)_3'*I((K6R\VHL_:]^O98!E7UH&Z$W,QL*&5*C4@9
MC]UETYBB?>J:HMPS2D!\+3^5IZ$/L0MB)=.4K#ZI6$G5]JC4'=C0B#&H\1=+
M-9^,O>\K>>]M8C30FUTK29*'!-GH.X:HQ'%Q0NE: V'H#*D_2M,^J=;(6105
MO2_5+5_;(*^*JV+ROAR?Q%%M8Q307P@9@264KK&T,'FL=!":^BV95,Q\@6/U
M ]JRW@ C<;B!-^ $4*ITJ""V5(GUHOZVK9WT\:#*IG:0,.W)=[>1@+&N9G<U
M=.1O=9M["P4?Y:+RA]UY)H9/C^E[[M<UVR%1*.AWY=C;S-8_G[__(X)>=M?Z
MW83]DA..]RE!9A1)<C6-0"J9QX_M5D'OQ)A.?2NMIAH.6B 6]$F>J197#=[G
M1#U ''X;GV&@@'S^8SV0ZD.RA;,6"YS?PN9=&0#E$D+()4UO#-6VM*V%1+B;
M>:@R-+/_[<8$AW-%?]HFTS&+SL,YZ++*Q<\&#W^+#3EXA:<$-U: >-T6R@#<
M&,!7-;)>(T%HIIM6/]0DG%YYQR]\_:BRC<=GX<SVC1VZH@<E'_(?OL,7_N61
M@N $@7**9XBC!4$Q1H)22V%T2>RG[B$PLOE8\5*$II-JGD?R@1+IW CI=/LK
M)H-6_N&Y[YHT3K2RORBE[^2'=68&E4@\ ^AF^BX:7M,O!]('L\:[N&Q=$!P0
MZUCPA3V7+O:5BST3W>W J]UIVG?@GH%*TT+T\4]);U.V>X*2;?.J!(H!'CS0
M%49P0M\=E>AI+<T9L)[;J][+VEY<9+:FJ-+RED]5N#W<XBJ?^'9SYD>.(9I(
M.M<ZI2U24Y@JO#I"P=]1EC.4-^@A7,?Q-^3/] G-<0IU'VH4.MZM?5E'G/7W
M1QO*??<G*!'&B,08PD[8=,97A[N##E+EM;^4J,@/$INK*QZ[72UL4DZ[%;CN
MFN9UZ)6B=HOY#C/9&S?<OE?,SO:U]AG,S3T@1>SN^*#\0M!(^_TU%,#T_D"(
MUEG:,^18)I*"0FVCOR4(E*'BB6R:<L^<ET@GG6RH_?$J=7M'RJWF5E@JA45K
M*\.#&@*^>23:F MH&&TK*$B !\O5,& UGY:(&^N7#\&5(II/XDP^!_E1W<P_
M81&S:GR=[P.?SMS*:YF<M5"XOGO =]JNU->S.N_3N'B@<&L)*.\$\<ZM1H*D
MFY2.\9*%Q!P7.)H$,9/9)]SYD#RNE1WCQ;:#.DD')P.M]"7<#XV:F)U;XP_0
M=)T78K]HXXNF7'9;D*%SG( -+[&*ELT KMA(FE(](;F2*%.L(NBQ/*-D61F#
MT$TD5ZO>:R\\P>I0'Z'BW#N1.ESPG+M(^RBNH:5?"/V* /$/D2H73E+D#2+/
M].&<"-%840)%?6:\?9?%B[D=OF-Z4(V!NTR*%,ZO]_*N&W+S'?BO4ZO7P7"J
MG34MBRX-'?T$.92 R0;E+\MJJ8YQK-3/WQ^0=K^LL$B\<[&V1',98$J<THAA
MT2;PP'@6#7E2VN@[5S:/!NVG11'LT7M=Z(<)8 >5^4QO[1FA./_D#Z02#LO%
M*L(7^3[5 UWM5P7$I <7--;/<X2Q!<(&"X/>L#YL$[%4ON4-X2J*']MOZ=E4
MYS_[%AFO:6:7/T)$D6Q.AL%EKI7T(W[WW@-Q!+]O0.H[[*?-NQ$[WBHBQ\+Q
MI?$/*6*K8;172U@V<YQC$,\7^G'IM"8;H=Z[K\/H[2/DOLQNK>D0FVK+YZC[
MP7=:D;U7'.E?D-P0,PD!GM!8-:+JA6ORY\ZDI]91>MH4YP(&L7AQQ5D^Z9R4
MFP\!Q9>*R,X!I,*WNB'ZCD)8XAVPQ-[T+T+%FRIP!Z@&:6^LA6-%0<?A6>%;
M3I&>166T/?;WVMRO+P4+&!MZ:74\#)#U#HH2U1MN"NA"5%2V(<.J$9"XS^:!
M03>D<)""RX$$RE)K176U]5P%-4-DJNPJRR4/KTG-\-T2%1R\(5P ]M'?^Q0]
ML_<$BC5J"-F&>"D/\:V1\0N2E HOGNBBLB%WI28UW6-$^]KZFH@/1[7WA7V*
M2G?@W)D:=8I%W*S/9"4!$JQ<W?<&5BT&UZ!)E\:^5]?-9TTM)9\\<!!2N^GK
M)6[Y.*_9S#]KB*7(\S"'V$N6.XEWV?* B_ =&M@/MORTAX2QQSB.[^X'AKM*
MP/Q&4RU9ZM3=H[E*MF[IBSD>:0%I 4H5M@&*[>TB[_?S"A\W0N^'_*@M1(@_
M@,ZM"9KD09+W7/"P2;EY<ANZ4(4;_7.E<T<E*Q1SU:O/'GM^HWE0\@WPQJ7#
MP^G=!@]]A\ZF+W0"]Y78 .>K!12Y6(.$;^6Y0Q<LI70U>S)CEHPC+Q J4QL%
M*VQ."3D:G<QK]CH\X\.+L>K<=^*0-A6L%WR_]8 :6/BAH).TBOJ]I_MQ3 S
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MJ>E?,[-S\PODM?6-S:UM<&?WMUY, #/3?SO^H5Z\D%Y[?ON [;=>3'L"?E_
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MNR>C=SK_%FS]/9JZ$IA$1V&F?S" Z<<T/R)NYS<,2H0P5()N[#\=$MX[)LT
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M>;QSX.1X]\VQ^'+0NLO<>>#&!2O",T?_#K?T+Y^F3V%V^*DQG\](3SO#?G?
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M/#2L.Q)1Z,8^=7>2<EC-WN#C;LZSE*HN-C ^:YN$H]'(FS%>O#Q($]<. T$
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MHS+:1%_E=/D(M#D,"4:/'QT/J^==/_S2I4J+U!9G\R#OZ,7G_55]F^)>RPJ
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M@YG,W,ISWH&-3B$7PY=<JT>.+;=^ :Y=GVY] *D?A$48EP\\\>VB@BY(/J"
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M8XW\=[@W&OW_K>*Q]2#;WDU8;#7%/V/\)GL?^(2C";JSK5G%"6\BEMIPQ=1
M:GP]5LWX_9>TYN_;I\T\8H>CT1(!$%3;'/L_4$L#!!0    ( 'R GE)O9FBJ
MI6\  **$   3    :FYJ+3(P,C$P-# T7V<W+FIP9^R[!U137[LW&&JHAEZ%
M*$50JE0+$E%I(J*"%"D1Z2"B(A UY @HO0@("/PE""@J(%("2 L=Q8)T2)2$
M(* (DHB&HRE\AW?FF^_][ON_LV:^N7?-S%KWL/8)D+//?MI^GM]OGWTVIS>I
M,(GC-O8V,!Y>'MAYZ >V^1VVS<H_XD( +  &'3R;9-A1&"_/UK%UYMTZ^/FV
MS@+\_'S\@@*"@O]H<&$AJ,$%!85$A81%M@[H-S%1$;&M/[9N\K]UY17@XQ,0
M@0O"1?YO'YM=,$DAGLL\=_EXU&"\DCQ\DCR;?3 D)*/ /\3C@?WO!P\O'[^
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MW5>A4@3J7Q\*U78A01,R]TPARWL31A[DXK5J*<O_TQC_VCJWV,-G;#3G(1
MH:I-6!^"U,P, 'LCYYQD0)'1R1^3J!5/T6^.5@%$0C/FNWI;O$V7O=?3E/*=
MR7KMXHT\OS[)_IZ [)[':41%#)/7N4)QU=Q1N1*=$=.LS#\9^)15"Q7@^B.R
MQTQ3.9^#2C(FVU6"[[:B;R.>.! V1J0F.T"ES ,]H[0)XZI^N0 E'N@7J6_E
MI;\?]ZX29RQ=#EJ.<?"LC-D8? /2\ET;,?&6Y>"_69*&E1$M4=3/*+(6\P6D
M#@[7JP2L.K TL/X1XM^B<:9UHQ$_61V\/=Q1)FEQ_^M S_LJHV<Q\Z17RVT.
M\=7'\_YH<85]&4LT]"I43?F_@0=91]C^DSO'+9QIFS#>F>5SJRMR5\@54T:[
M=7OV=1V#CQR6X5D;/VT-DW';6J:XG,66Y:/9LJ4JF>).Z42!1E'E846PMC^?
MJTC_-/D441S^V$&OXUWOK,5UWC/9Y'W'M"YM'.G.\W"2AT9C?B!2&TIV@RPZ
MFIG*P*]:/\9,,:^#<71C&P8\ZR+6+:+R<:4<\?HCX8_N@P%^/''6XW?SSJQ*
MW'JU;4GX%F)D2+OLELB_U]A0O4V8!3Y/XN";L)G#X\#/VVZKOW [H.F_AOH1
MAH)8^TII*.K/D7^LZO_+VG\5'?XW3PG^_>&@9@D!W(2[P*7:%.(+)%N* I5K
M*4N1L+%@KB'#AQ TYX3XEC_<Y+WW>U^]XQ7)Y?H:0D>7[?;R^GT+8>OH?C3]
M9.TM557H%JZF*'+H2-0KKCZFLN<%)JU_=G]:GSPZE($@$5[=G4%7[7>HBLHH
M)V567GQ179KT!CEI .HML:6KW*  * 6Z#V'/LDQ 8U="'</?/)JT%/\]2EB$
M_.#X>)W[H_/"+OE:12J;L*X \7B9A-_$,BS$D>+?8-:X0DB: :A10H <,SW1
M2)3%>#HY:H"UK@S7!TQOM).WC\Z3'2\R][\N^LPK^: P?%1;]>CNJR_NBD.U
M-2:!C:*M@2:VM-M_9DOJAQ]B#M)V-9=]VJ99-ZX[UUXRNRB/-+FJD2P4L(.:
M_9>TEQM;8GT0W>24!E!GB*0$'TYQNS/-T8^6CI3X-=V^-U)\94HIQ\8D7.A]
M4[K]W9,[PA*3M=XMYLVL2Z*/<;LH4*"S9=29$9"MKG?N ;I1G6K<P0T*O1Z2
M710LMZ%/9CS&C!V[[Z,22EHTS;?W^;%OA[O2Z79%]^SXN/<NYX%N.:(?$MRS
MP9;.X@KO9A0S@39.082%.2..C>4:@%>#&#XI-WVK7GT(,4S3NNGP]<3-SMX]
MKQ?YCVXG8K=3^180H!IBU1XRU!=.U3QHP#($&WI<*?Q ,(4'>^P#P0%0.N>D
MX8J6G1P^G4D+.^38RW<E=D_5_=&E:'WU.P_O7C+[!4DJ,#?2?K0,"L<A8@.E
M)^LV7A)"MCQD#'>]JS[,'"<Y7C)QYQ<E15_/GRB9L$ 8Z$O_'K"SR-#=?#\3
M38:@T\YY/*B]M/J-;CL_W(,$M6+2@""*XE>N;H(KIY2-?AIZX_A70>U=\0'Y
M[QUTGJ(:(SQ&3^7V;[_(^C#<F+  $MG;C:_/>Z.XVZYP"@RXRL'Y2@7)U*0Y
M=I'@@V>S!$+-Q#+XC-XM,[;GH+6RG:Q'S]ZS&G<NGK^U11D^@4[6T,?62LTI
M')P[17SA4TY#B$^#O8[Y\X-<%7R_/.DV3IVE\C$L6G_V1X@_?E7"2ZV)N2]G
M[Y[5W,7:<*CS&FZ:(@4$.X&Z4RM+D"F3ZQBFG*2><+^^684VL+#BZU2])]!S
MJOG/+4K(Y5='#]63=O1=)_G$!/(/*GH2Z5")F!9E?H5N] WHMNM$6#$03 ,&
MJIN2@!:]V.=C-HF-K?J:XX#]X:TQ]<%#+^,M;<X_4^%AJO7!ZT&Q"4*Q"5Q1
M4VC48I U/PQJ$[MJ01W\2AS5C%'23!_K.V# UD4E3<9,,J=(SXM] 69>2WU8
M0:86_O7UA_Y!9X[TG-HKILVW!)"1\QA(!$.@>Q 0Y$IQ!TG'?"1 !T96KX]R
MUB!%%'M(B/#A4?XFS+5SM.B'J )#3'I C_J7Q?$[#[RDCM5?6D>!>^"KCRJY
MK]#TRZ@,4SRX9VWE*:K?*4%I,+'Z)R5)KNB>H N=F\_PW#]A@OFLIGZY6?AR
M?7UC)#R(O"=<A.*./0.-'X3[0*&?=0+U8WHW8: VNK\V;FLU$IV @C>JR!W:
M0Q[4"]]62_/D6'Y?.I6Z;X5:Y!K/$W75O+T_1N.8-E1X#)YR*2AAKBYW= H%
M)8? 6G(D5[@2J@#I*)&ER3/K5(/,=O&8"L=G(6Y27R9]_.VW3YWZZ+'2N<[T
MNC7RPLC6Z'>H19< ?;C'((.K 0DDA4GH N@V!J0BI/PR5WLB*M9IKC+S%T+"
M0;74Y TGVI.<YF&@GPD2%!Z6W/33):OX'W$?U'I+S 'HK@_0<^@5%DL2]QZ0
MZ!1V?/@5:%SJ79, _+%>8#,]]6:*;^[9S _$F>]17U+23HTGY<DT['FG<VS1
M:\5>PIQ,%(.2>2:*[H*8(7+%&QA)*Y[T-!<)MC]C.)W2=P.JL=?6)(YN?_$U
MDI.OG*&J/+S75\K$K$KC_EWUW[E]B@D+[=+,HJV'#D!W"!<%98I.,>X;(VZ_
MCQ"=0^E!RKS1597\P':[^.=[@VR/U]IXI>#I$&'Q/4D9@?DAYYQW2O)K=R&=
M@.XABB3V* /@BH^#$8RP_@;=HMI4@W;9JN6K:@+B5R(K[4UN"\!@WN1;L-H6
M@'J'^"-I;8;,?8U[L DK50+)7)$"EC0TN^R(841P9T0W%.SX+G2=UP^VPVA2
MDK//2#5N1W!-> 7Y:[[!I1-3YFYF0^MVW4*9/$;:%RS&FK56UT#UVIZU#*B$
MHZC%1!$<#W<$#?^%$,"T=7$5DJPG&JM6W9PZ/,YMC[,X,^TUK&S3%6]NU+)?
MP);_%A8B2?!HH-NF<Q^$)>N3;G%YN<.S$#M_7\=(<AFG3;1;5[S_\*GW40B#
MK+@ZER<4?,[#(+P[:F=[8_:-_;4/4-1F2[X1R MI2%[ 'R"]X0JO/2)C]S$6
M4KR-^UL3XY YG4;6=4TMP.J=(X(5YZP+(M^]3'[0Z7N;O(%F;X^%9F4"@\*6
MC6&>^6#;=7V%.!>(-9NX9(H0F5YVT^$_4$-X&UP0;1EV]\4KKF-;^4OA5EBU
MR_YKOWNY(FB6%.X3D>Y9*\A]"^'%#;91<UJGU-<2?N<H!G[ YU"N4^;4R1:S
MR<DUN;_N>@W]2<-]_URN5AV$/5AHQ()9K'&W44=P$EBHL,1?Q,(Y1!.DD%,(
M#:T21A*[XF/_S,LPZWCK2)2*E5ZZ95#V2Y_#V&Z%R/1+Y'[<(\A7VW%"V+T@
M-'OX1T'C 'IO;WW("*9@KCF);56C6Y37/TPR5:Y1>SML:/QJT;!??B.DR71P
MJ'Q7YV&HC&5#I!]BS4FK=U@26"U.*G >-1/APK FQK4[^N(,AE--/$4/ZEF.
MG6BM2R6;3[UXH]%29/QCP"T47VSA]FF+M#B)8T_1$2N[Z05S00-9=Y3P"1:G
MJ92D&UI)A YYE_&+^J]>UH]1F_/M%NI:2K122LRF'01W!&3?. 4GC%C+P$[_
M.^WO=E 0(ZK^#J\?5@4V88+%P) S*HS(@M+BV.=?+ [Z%HH>TLQ^9,R$V$ES
M%L?2"4T<_W>'.VUMI5KY^,U3A_+^)X>G+EMM'R-5E[[>?E7>)=KKLX["9UB)
M<,8M5B5,^A\RHTU UM8#3AZV#D2<,BR"&%KS>HM9<YNPI$V8Q"4+25JME..<
MRIGP V]\XO>5>.YJB9^9%^N\%I9S)%_3):<:7L_F 3GT!&8%:%6&Q8+P^6 +
MVSF$9+<&29\0SE^G.:I1*VWH<7:[[WS4[WNQE..PE; ?PUP12&=^<T[U)BS<
M -2!]Q+!W>@[.#/LP0_G00]@[K?%_KF;+,_?)5P]+9?<4^D?AU)Y36K5=?C/
M2%Z)[Y,"G+5+15IEBCZ2]"HZ-1L(S>/G/HG_E#/7,]G[KC'"_?,UFRCXO@O/
M[);AQPG_4!*%]87BL0+70^%!743 N5 RD.T\0 I!2[.OZFW"YE3IK) -(]VL
M*^JVX3(%PHJ)BKNB=)0.5NTE#[XO[HPKY4W5_C]I>T0/.9\8#WS9//9+02OG
M/:#&V%GHWJW?'YO)\]O3K_S\>I+SAU18R3_W(4H U W\;U-\W":,><H4R=DI
MRXK]F\<^,"AN_I64L7G^9DO?/\N$R$=12Z%R1HFCO$#U9242&[XW5#YN8^C0
MOC<6Q<2W[[>L52WV+WYLAYL 8M5:&IO754X99GJHU,N9D?JQ!50\6_[ 32*X
M1V"0+17)[./D.\\5]'DFGV8;5X$Q@WY]YRRKAP.8XT[[JZL_WVK?V?0]>>'#
M0Y+=,,3]N_LW84WP%0#B(W=!!#W2FY/?#I_/RBIZ7Q6"@DJK(M;V^H61=D28
M9>E=ZR<^OT\F?M]Y1;DE;CB_\UC.WNVZ>%DPOR>6C[MM#71Z%$9LO$V4^17F
M6;/;=$W1RS3G^D:E]?TW4KW^5>*-P78NMWA?/3QJW+1T'C$)U5FH\+%83J V
M9Y@M]8WI#,J68=9I)Y.H:Z =VTTK#:>6)>X^TW=&V*^A^4K =<V%^:-79&;=
M,R3]8@<.RPXYU #=_A9P>@,3!A:P8KBC>!X+!ZHL&$1CK8DMXW@Z.N._N>#/
M)&+":7'G+(Z)C;Z]X^&1.Z3F_?9Q)\1:XI<AW14M_%BAW(G.?1QHIE+O [+/
M5SL/8?>VC#X$TZAIX=8K$=^?JX^N5KX@CEV2S2MO8>U,-!1VN4=^8>NA%A5K
M,(UDYM WV'(0"PZ8A\HLA>Z\ZL>5_-;-,#]!/T3I^X0ZF3GK^2[0X]K$*$%X
MG/_HU0)I$OFMY5E,3Z+V]CP8RX\*L&6EF8F,V1JZT@:M=N6@;QG&EAG?DH$U
MF,^"8\]F]9DIG7E=\2ET[U& &W=QY&-+\X\)=:G>7*VU==7!C^ &A*F=1]AZ
MK)A@(OT$929R[E!S'S[=K4BC:"I%SQ0EHZ)L36_ZJT[8U8$UO7IIP</?-<U_
MK^<KIP>2%^+&\8,1TZYON"(0!13\#72[<&6![H.=YLM[,5/4M0&$"NDK5Z79
MQOQ P##I4CF!.S765QAKN?QI*>.[FH* O7B[B;.PI6S8!EX8H*[BTWT$P'76
M84SMW$4H$Q'"G>Q&L,ZEGV;(;[_&J#Q:++PTBO8<ED@-?ABOV</KOU?;-T<(
M_@VU DUM@=0Z3C5. !LZ@5/@OE-J)RI9\H69W]#*[!1!RGAH/'W2:_(B,>GT
M7_VB)/GX>>/ZJKAP;8F&ZV%:2\-L90@]"!SD=&XE)E(O,QZB ;8LDX]L>\L#
M#//;X5C[9U]Q1B]&5]H%'MF0<JQDS)JS%C_V;C]S8F[GQQ7?Z NCCODL,O,J
M% ^!N$%\G?RJ,*.7%M&#2(?ZH_J!%$OAC@G<#A)8[!Z_]M:A<"'/0".3-*H1
M;Q\DG=RMTZ[+DDC^6+L4Q%;@5']5,D@@ACC4!)UM:DPA ()'ZKU/UCW-=ZZR
ME@I(5BZQ<3D]41B?GB, P\5C+: !1S##S$)P@U$U%[%BS5([QSX^TLD76GZ2
M$?N9(KUS]%>-S]RY:_=#E/QFA@J"ZSV'4M<_>>K>%J_X++*AC""O]P1QA7.(
M]#. +'C<$7YB$W;'#AL>,T=N:]!HRF!*1S+E<B_(Y^)VON]R4(7OJ^U#@;N7
MV%(LR$39.'W,,%?T#I32_<&U)T"/:25(]&YG+!94?!(B& A3R*'&1ZML+NS/
M7'?R?!*XON-R]"YSC6P^-0[ 4&>V,]!LV0BN< Q+A3M\;BU^U0)5RYU$28:O
MM,>4?C54V E-A)C>J3'OL +7KW\-;B_KD7=YK:S/S#_499'&%7&@P_LV83 4
M=<S;")G"@Q_HW,\PRYK'JWJ?* [$NTT2K)XX+F:ME0UOU^*V9':$0:!\*\@#
M.66H+;Q /X)*P"LUKH&[AE,L(NA5/=%G9C#-@Z,@<_!X,)832-M[Z%%6GL6&
MH? NNQ,Y0CQW[QKA.VJA&DY=U?9MVEI7!EMG9S4S][$]YQ:.67>=,K@+@WW1
MZ;(PK@X^X,96=-1<;--%!P&)YOF,0@6_X=R^>FNA);!]\C#<:[X#%OL58J Z
MPSU/B=1\J! )H#D/V *H3+9\6$6&D_.'2Z918Z:B[E)^$5&2@OOO?NPV)(U(
MR>9YY]C\YB]QHT: !HMI#'6NL!X-JJ*VMU$!>C9.VT"'OOJ0HHW;E]J]96+>
M\ Y'P$D[[WHV7L4;+1OYA=\__'GO#G7L(98P5A7,HJ]QQ;Z (\"\BM&R!B.J
M(-G"JI3\OL+HZV-/=]?#E7?3)QN.(XX\5[C<-57$?>VC2?^> LWM(&Q$DOO4
MQ56?]<%FL^B4*U>?!+X,=[ /N,.#,LX3B,^\+#P 164=5A"R#Q4K"%9!D?%@
M"J#6=!X"(ZM!AVX23Z=#+8+P,:8@YXTX::97[.)#B?;U]M./HY\8B??![,HA
MI"0RQ3K,/DYWZUI++S'FW%ZY:,'#6/,:7;$PI5&$L>Y97HYB:!V3HZYI+,M/
M-8&_L41]]0/"#3(Y?1 &J075G7JR9AKFB6REN1BZ&_,E0X-D< OK1FOC:+E.
M[<@^W=B6PK;BCW8KQB^<%I_W/.[!/:RNV7DJ;"%B!LKC*+IS+6A&W(JN*:8+
M8Z"UQ!)48:31Q//QCV:./(XU\%PW"']H'CWY0XJ$>WIIS//56=SZ'O$?I6XP
M9#!N%M6XM *?0X/[=*A+/402%'(=^LV,?,>8WLD2&%A>B?F#KGO4,<&RK9S]
MZ/[[2D6NYY#_^>?/3]\-S^X9Z(6P*/4QA8[>A(D"W?J;L(M.PK@AHAP$$FO\
MT 3&HXP,;@8-V ;>/MXS>?,QX2KSPO10@+UZKJ2-OY'^N\I(&?0P!!ITE]@U
M#UCZP/11",MQ\<^U(<A01ES8#]2[<1+8AS9A3TW&>38DH/\FFSHEX>G.2'Y(
M<0L@# %J#:=QI2O[FE^H"C LV^9%==ZTW2,^6*W6>/F"8.MP-I]F=J=@U<CB
MI- UA8NQ\E#4BD!^+F?OY=S&HNE+5%<\-6U8A7T.[* )7<M* A"-;WX2S/77
M-6R6OR],]#]XUIXJUJ:2\HF@H'$'I4&DTI"_/0:9EINP%T#O&L?1=,]#B#PA
M,$2W?^P*4N8. ZHX7<R:#QT?[]9;HNH0H? E<:=9=F#K@Q6W^IZQ?ET??\N;
M)X;\@'SK@[B 4L1DUDP"5Z2XDNW">=D.\1#^"4Y9IZ0G]B#83^6HJ00.]1YG
MV$\V A)?KUK+E,3F?2.1[$;5WA;/Y<R:*5QXU+,?O1.T@K2:9>!73U,CTC9A
MC8B5$):,%@2DD'!"6X>Y<V<#6"Q>FT*X$T\9#GNCIUA=Z#,QM<LL9U7SGL[M
ME,\VR5%<4<@FY[G]LP+09R)['W1.P&0QGX)9\^BT/TT/HH*H;9\B^J+ES?Z\
M2Q[]+G7$MZXN1?63WN- Z8!3![O,\S$31.4MWX-:S:N'MM9V)O6(U$8\W28K
MR\U\$\;W:T9]7$5W41! D#Y^Y.>^&P]WO[]V,3]:XJIHW[*<M5OZ\2YD P3%
MT&RYF+F-E<HYIQF6PZBE(AF31(.O(O7B,>H]?PK2G.W'JG/F]-(^HD,-^$N.
M:4]=+E6#7Q<^Z+RPXP:PTLL*P :"=2P[D,QTYY0" <+<[9BT;IS<**'[*0DD
MF&;H>,4S;[Z*F?XHBE&U*S=K"<S7KIA]6R-UQS47@JY<$466-!9*; D0SO6E
MS#2@Q[!6C[$ZX$8->V<+(ZGW@<CW3U/V'?62(>6GQC)'7I[WT->=590Q'E3^
M/CTTG*4.F4T)-P%%Y^[VTRP;*$"5@; :]3/CW!U84W!O]6OJNYMN=[V6BW2'
M7GCV/B[NOW IO,*\:9W<M'XG:^'"'5Y8[$N(8PE,X6D%B=S]V  .E+X"7,"'
M]#;F]=2C\\3M:,S/X-4J$\G&C;0R<IIR-G9'<\:"GDG3L_F(?*\#N1TL6VC0
M6*(_(AZ@.]8* MVV;-F 6-H[=9I-^;9<*B!&^'@NMN]/N>*QR>9(2W!E\F/W
MOB+G#I?!'VO;;G-=@>ZG7 $PG'46RP<N023+BO,,MP.CN@ES;LM9.T-')D:I
M&$U$<?;\>.4^6^=9I?@X*/U8W>NZJ0OO%+LT"+%/6<> ;CD4M4CU(&2)R\%H
M^@FG!%2C9<>CP9N,\C,093*8^EYPR@%0.%KI[1!562BE[5?RL3<\1KG"?_6!
MRE'%"WMO(>H[Q;@?@4;+-I8SZ,?T@ J?7Q4:_HY&X5OVV35B$3'GE)Q&4Q'\
M<=!>]RZI?W]]X[WA)OI!>(K,GH<V]_?O_KF*XP6Z12SUM[8: M1B)/ULC2A7
M*)=U<1HO@0D[-4)0'A9\'7F%^:51X4+=R]94ED.K;X?N);E)=R5>&=UT2_=/
M_JX<3\Y=**W5(^E.!N1*"-NF H%.,Y7S?>?6TMB[&E['^.TJO!*A\M-P2*TH
MS#[@<,'>\CS^A_O%%'CQIK#8O55OJJPJ/CF63I,_4C3;"'F$3V-6,O5W#DI^
M=HE4RN_2E1R*MW,=0"QLK(Q!*6//-Q2A8- @&55/[$: NVJS+(XRC+OEFF=M
M$QOQ\M/*-\EI#@\C]A4QHU)%]\GD8)<TZK13E-N>32T[ I8H>E@MN])@:_OT
M"R 9^+4K\1;*'J"FX>E>J*W%6O1%;,S<)"C[A&W*:.XEMT5-61C<K'G^2)G\
M=K3,0;8KGM?#/_'8M>![#W?'DUOPYR"_#2YOT4T4U@^$LV#<MTR*?" H4-XQ
MU??NYED&A2F>2N$S5'(M>>V'F2KP)WMIO7]QM!.N&G$$,$51/S1M;=K?R7EV
M:F_WBPLV-Z&4X.@#)37!ER%3;@!A:E68)8N]R'G:?I,^./CG(WV(%)1DT/CM
MNNF;=Y:T/RHVL[Y T&7_(N/+*F<.932OBAT5&(+A'K&WQ%HB@1#1(#\'ND^C
MSE/B8RP-6\9J*ILF&KV!,TV-:*'98[ 21ZL3#Y_+J3$.]$>\7/0H0[6Y!CEM
MU0P/(,R);#R?M#(3!3!0S)L3[-,/P4$:/OD77I9]I9WQ_*]G1>EUMCI'2%=\
MK\YD^Z4K?+ I.]LE<AM*BXU+;&D6TPR2 (+)W6*01@:WD'5 )M:^9MHZR&16
M+PD],0E^_=,\L])\N-Y6S.ZY'O?]^X1(_85/F0(A4)=2I8'L2NA335?7X)=#
ML%8G6/N\.T!L[%E'7YF"IO:MO]J$1C[&Y1(4?O)_@"]WR)P^+/#?V]\\N])A
M_OE7-B[#LP1APW^[Z#*Q59'^97GF?]P=:DASW$>HIQU4@;4VV#))?5PEJ(S<
MH<L9R(1VRF24CD;,3=9>U#1[RR*1W!J+C'4]?W2[/WAT_ZGW:ELN8XHM$<85
M-F6(TBH3.@W#T'6#2:M13KQ?)YE*XH\SHB)]?9D8Q1*9DM%9E_BEL(-2_C9&
ME]2.S*?^8:;"?I-I!6RI=:8W6,QHZ$,UUF1,9;)5&(A^,U>FTE*Z)1)K/6'B
M656E'3X??]#6(612/L755/U:0%YG0,"^G4PB_7CM](%>IE8N5WB^DBW4U S:
M1UX/BWD"AHJ?_*K*Q1B4=DH-7]-@':NW8#+D(W<MGIUYT,+W)52;;PEQAT(_
M3IDY.%<PZ(3 C11<P8P-6.ZANSXP3;H5@5,#-V%GIJ9Z)D>?STCU1P3>M7E;
MNCNO^4VC "53!\D5@2HD_];RS V@V]'TG?D FN#6'=C)V)4;K*?;[EP6VA"R
M01LW-FS.L7,7+A=[>];?==JC:?7CS)^25-B/K.D-IAJG$#@_?*=R#K[201]%
M(D*<O6.K3A<YO'R^9JKS(+4D]MW;E1_O66==+EV0==ESYQ3L!R4.2;=&@;L*
M5D98-LLH@GDW:J:>?)3A6A[+7,P4O_K[)_EF=8/PP[%9OS#EJH-&DLCO*;L,
M]#N?EMVR=& DL24=F(J,4 S%J;D.C'OX%27-M@9JL"?I2XG<W6%F!X)2OT?H
M^[>TL+RK8]3TJD=E+,\,G/#UTRB[4^M$IZQ(LXPQYO-!MW ',+;=XH_1;'VZ
M^& "FZ=\>GCA:Y%^\<%C 3_"NWJ&7HM=*31^D*"R[O/&&G8=OQK VHGEY31W
M2F?%X1N;XS=A<VKT\C#7<P\FTZ>N'E49;VH0+K,7NU@]LG;ZI1'?MFU6.T @
M&45-0M&=\%+@1:PND>Z66@8&6AR)ZJ9?'1YLO:<J);_H9/*J]6*DT"C*I-#R
M_:/SLWV_L5-3]T[!435L;3"(9G"G&<UOBN?Y:HRQW+"*E5KJ1?E:U\7NGS,T
MK<PIU4X;.F@&@_D(8(/H9*XX!#CB46P3.C'5 A'&,IE=_F.06ICQON Y9NIL
MB0[L;46QD;YL3<5.6;$OQQ8-_8QD8EQ9]5#H-G0AZ7;#TPB(N1;34--A76C!
MB)5.&;!^>?^O8;@72';O:,[+QRSY*GM_&F(NKRD52-1?6KZ^^!#<6NK.Y62V
M"S!N=E.4#$RV]E36G@'#9>K81G6,M3X]9Z]Z>O+=/75UB<SKO&;C&6<I-W=D
M&MZ)UK<LA)SI 4)8F=\3$OL*[@/0.$%<S6;$4/-?5F$=Z\?U(JY1Y&K[$5*>
M3KZFC?$.D1=?A JKU ]0C32./ZN\*^B(8D)$,'XOT+T?"#=(5XH8'"9%4#,;
M:'CYX$G7R2++!O.^84E/T]N&>S'Y_,WCZG9V5_UU4Q4?I-7IVJ-.CQQ&ZK"Q
MT UTH)RT#Q6*S"2A5\T92]3''30#U2^7I_O+,"7S-'S*A9:QR7?L-[[PW"=E
M?6>.C/*62JLW_-5FK/J&"7&%^##< )%^&G7G7$0/@D2>4\+@G3Y\?%T::O#4
MR_K)UQS9LT&)C.TG1 4<YPKSCZ1Z[3V=%0UI?F5K-^P]Y-9S8&GGD\0TIBMX
M5A__-#2_*NP)F'9NHG(\2K@F;R,MJB@Z8I<*&"EC)7E?<(\[GY<CE*0J(1*-
MBM.W1'A^43U$H L^?;:KDH9.,B/*_'KT(8H\<=]QZ9-';,6 QZ.ST>[LQFAK
MW<K@P6DHJ))P'_#TDUDSMLS[$YU($(*B\;\.'3P#.OM>#Z%/G:%'I*PU[F:;
M->L$UYM6A:P??7&[/DYF^Y/#KYO#7I@! >AI9>953A;6FD9)1HHV.GJ>8F1E
M1:B]9#1GLCUKO4);)QL9^J_RPZH2 R4'6EQ2S 9*+[]<["A+A8$1\Q2V<B'D
M[$).&3'8H984-$!I^/0=3_-V.A6V>AF#[G<C>3^OO/JY4#-?Y[J+^DN-MJ,+
M!9J%*8$78L?FT6SI-*8YR*$?[48U %F="%MX/&[[-]?6YOA& _'EYAL'OLKG
M3S;+-:U;::;7.2@?*SA3GW?YZ"K07CK5<OJPJCC+<LO)0&#M#&4>]Y3E&"(!
MEO>CI4R]94U"+*(8HOU318N5X8_*(SP5-%NC?^S\M"YQRSBW(-!B:@A?1V%+
M23-]P:,0$O#!,]]RLHE!WLYSPPD6.G.<2V/.XZ;V$7.J.@S!<MW0;WY!F,^]
ME:0CN307N_E\AQ<[U]62#3D:9;=TEEO#.QL>??RRD>.EX1:])E8;$J,A]:P^
M3U,S)6_^HJJ*@M%?$E:PJ3>;L(8LMJ0G5YC(4F>[37;NY[Y'"YA";!33UG<C
M8"&QK78&Z\+0+9#_X&T8TO?8V[KWX#X/_ML1]K+^KFZG>I=3M?D6#:997"$(
MYO&O<.(Z=U.PP9R<3L%EG"1#]6DPL[5F!9 T94VOT2);JNG>% <( YB_%2V7
MC;@O<?VY#K,3 A@X(K4 U30U:,NIZ-R+%6YO9.2-,]Y5AZG*,E1F\Z-L#_.V
M?^6[;71>;.AAP$6QEUV#))=3\ >@%O,$IQBG@GL/T%]QMX&F91YLLW"E^>/X
M'D'RV\:6QK_V/=@E)1>2WNE7J/+&(GWE;7^*Z2*R#L&6,F;R;>WA#_M3F8KR
MI\2?"98G/;QGL3&K/FYJ4%]1;-'7[/EZ04+P1YG8*[Z6#+X&_E.6N?^O;Y?Y
M?]S^$T76>6_AP/+FONO<-HZ->HRIHLT65KZFOW'@CC#8!1>.)5DU&6KV=+Q]
M%&W;*N\AZW I:O^I,&6F!:>=&%!+'NMNQAWD%'2J.SZ?=K_O.(H.-B<%]%@;
M1@ITQ3,5 H(U)5\OO'WF!^@?KCZ^[Q3B_+_LZ/H/:'_SP@V.\A_Q.C3?>B]7
M)(BU%Q-&6\J( (*R,I'T4Q&W*>)<$;8-8Z!P'I%2(L%0^>BJNFOJ0D/B>^G'
MO5&FR[;,W<5.S8&Y0^L23T^]397J:&.:@;G435@ZDI#4MR8)ZLS7]D1(?_D#
MCV>;5F#">O$B!,*X_.$QW$B522 SN"O]S<&=,U("[CG3L,HKV5QSSL.HB.FI
MN0*V3/,\9W@P E1##Z!)GBZ3OQ"(6;P"A+1YK@W+>WRM9"F1)/U"]#Z-N#0)
MBQPWK'N]Y'@YO5@]H_A+%JA!R00"T8K8<+"%V)#$EIH?0#>(G ,]>P"R$CH=
M)^L!VCAB".\[%AQE'Q6;7*WV]7?>?S EUQ=F4W$KMO??OOCT']'^LUZ>DNV!
MLE@9EH^N[D6W36*'5WY;'X;ZR'?/=0@WHA%>%%O9SW6OU0AO>M+U'O8Y%OKW
MU)XYS'\+D<\]B!7@M$ A@"(Y#-[0ZB62I]Q!!'UJ;I(04MK]F+UO)+QB"@*0
MG <A@-ZGA97?9B]*.^UHS=;GEQ_;#/R2_4JL2WS*2)A+&C!0Q WBE3=A(4*=
M^LM<:7IGVG,/S.3:T::Z2;6&CB*NPDJ4":'/0$W9+&=W_,!HQ?!+8\4<=#8T
M<9\BY0!JH:49YRG[*'V0ADI!A6;QL%WI"WEYE:D6CJS](>=^5;1F_'57K[\Q
MQFBZ7X] $UKL:2L_@'VE(+#G$)HKE$5;FQ;IM]3$BG 2<=)LV]& #^HC4415
M3#-M(!<(?P[F;\).AQ_9][DEUDHNI+UQ[+T"C\1ZLK5S^POX[+6MS8[_P4WV
M;W>VUI*7_R:GG8+C_\:I;E3$WP4 3):&;M8:0)*EJ5-Q[?N?<OLI#8*Y#+>^
M \14]3&"GK([X_0([45CV/4%\XS]B=9"M5(V5H/&^L:C'4WMMLQ%<"_+&1M!
M=TK$&K"TN-,%: $"IMUM>^M:<KB%N>^SU]<?<XJHAZHO^PR\\C?ZO4U!=J<?
MT#%ZRT*)PH3X9_R7<Z'F!SHJV5+%U':WF#B!3V\!I-GK?8>/P'TK YKB#P^?
M^,NMDMN+EX+<6HJ2[#3&6N<R:9Q<M@%]:':X%[<=+>PT!TCO(LA5O[-\?JEW
M5N@"MC\MXJ-A'RZ:P6U9>H^:^TBDNV3]<4+U(=A&)7*;L,\WUC9AOEDS4\R[
M( ]CC>8%-":Q97A9\QG,JCF4F(J9"KK7[(#C;(),S(%9V@?W9WTC[T>Q]9+M
MQ==EZ&F'D:?^_;T(_^OM/VG;A%LV=XH+YV1KT7$IK*/<Z;JO9JU:W1G7+8+*
M(=@[OMB4<)38G#'OT+#0FF+GX>%JODWQP>$CY+ IG<]KH,Y:'VHF:ZZRVRFI
M<R>GD7!3U.F.*"/)#E &PCSL(X-,+GO.>I,T^_:6%Y:Q8CNRM4_?6_V=:'P8
MN0TW2I0&J.,4TH5A&I(M*SHO,%G .+-^=JKQ@;1;4WWSY"K!/FIG\(BGE>!?
MCE6YNG*9LV&E-BR3I+>_+UL^A<)"!:/.%=9\ L('\)!SI")ZC, (.\;%UNB,
M>;R8]R&:5TAK8M&ESQE:\=\]E!130_5RTOVB7/;8BX4M(62AX#\#4#^1B>#N
MK%XT:=T>_$:U>]Z^G][;UR2/4VND>_^TWU8V563TM9IZ3C!D<N;7G8R>!T\U
MNNH7>/ZD<85?LWQP_4!3T.H45-QH^!6K^0[COE;=61A=%%/K,7KM6YK[]R@\
M 5-B'B*'F0^Z?^ZH_^/#%3+N4QJ/87#RO\Y>GS!6$#9H@AB$F-Z@$5<1I23-
M_HU;G4K?.M7JXZT%_//?.)4LR"2,RR4C!F[M8"!6ZUB:&"=:,WLW4I+[H42^
M@7%D6>X/]H\7J8PO_.8^P=GW(:B)[DCM@!_4['Q[\^<3X;V6Y>A"] NWE8U2
M[ DH'P098 \R-(#09:*LI32([R_1FS+(*HQ\$J:4TMZA=+M>U6=N>]?04IZA
M+6<$#260;E$@!+\=-[4)H]MGQ0.JG9K+N>AO?Y(2=XT18FT6WCC<M'QP\\IC
M0E_Z]1 -LQ(_\^BK-S_ )W6'4KVG88+V6K=TDD TRP$K#)*?HX-1@EQ-=\R3
MKS5JZ&55%<1U7_ZZ%ML[M1=<F]?S,L5\@NZ+-+DM7,1":$L X#QM/\JH9((@
M%-K\ /TOR[VY/24[/P0P*@>#VWDJ/PX_"_TC%J$;35(R[11O-X_L\WN9/:LI
MZ:@0(NN1$.O $L?-$NN!0:(<)HMY!+2B>D?,-:=;2L^0NZO8ZHR(1&F;SM%K
M/YY 3(7_(OUU\-ER$7J;-D+ULD;Z"_BHR__WDG'<//$.EP?\ZUK<?VOONZ.:
M^KX]@Z(TD=Y+D"(@3:DB)2A?FA$!$6E"5#J(41",$'(1E%X4!:Q$I(DTZ18@
M= 1$I$M/@@@B)4&-5W,3YO)]OYGUYLW,F[7>>O-;:]9Z?]Q_*.>>L_<^G_W9
MY^R]+_PS/O=@^K+'R]$?TS'')OU33/(Y/VH^DA4\7KCID\'#&;8+.V0A"[OU
M ]A;P ][4Q2\;P)18$H5!16/Y(-X%IH#J#;QIB(E05&D)/VW_"C7UR.KP\BZ
MM@"5T1Q*'$=6>O25N&AS$]=.E+0OZQ4<^4QM(<2:>$*V+XQ'@  B+TYWP2ZQ
M35YX"))YNB(AW9S>3=Q3L^(J<21G:>X2>X(K*Q]??;$PS;:2G0]K;P,,I0=0
M)GJ E$-X=W@NV49K0N'7*2@^LP+[PJ!Q75R,^-)93LDZLL*TL:G1G_;03T8<
M:CN_!?];EDXAP60LK@%3E[LZ0A=@1(S6BP1@%S9V!L_)OGJ+N+L#X]X?/-AC
MRF,':;Q^%HM2AX%Q<.K12=8CV$7$2\^O9M(OX*[.9Q+WXB4J\09(7LZ5/^/Y
M57?"0XLL@P))+6\R5HQ#]V>X9=]Y%GGY>('0.K(&D]RRW7F%%R#G K4]K0*P
M'+HV W,G&AN\);"K+-WHSUN(FW==<KZPH_'39>RU_5F?KY<L*IIFN/$R+V'V
MXJ)"(W5$[9].FI?LV<T=(5YO:7I%)"MUO]$NU2R.+KO2Y3?F=;=[RK\:3H1@
MPW+%OT7L>*?X8.\IJYF]X\[OSK];LT ^(<J9JA&KB9"L# 4UW4.MZ_6A]2Q(
MM/YND>ZE?OO*&>DAD$0E)6S.R91Z?F[TO%^1==B]+S'[R9&%(R0!@K@['O8(
M\0D1F&D'<NC/BE\WFG8R3:S(\Y)@F=UMNX!2,"/F5-"$@YWCZJLL/B>1]Z<;
M[^%OX@\A8K80+X(\O%^7V!>&1(4V+Q:UB[ZJ?W/+-\/%S"7[QAZS=&GO[*+E
MJ*M'K).+IR>G/)^BHSW=SARF.@VYG$84?'+<E?+O15O@!IOO 1,+V;!NP?Y6
M@R@*[6U*&*$B,R'W8E"F5?HF73/9IW1%<V'-1%)P353HK&ULW-LAHQVON5:/
M0U1X04\@E2H'YEZ\$4CQN? ]",D-!))XP,&N4%F_M".^6N%!RO=E*;[-27<_
M^?Z0>LJ-(C\+%8"$,ELQN[<0%S/CV,9TK[E'Q9#=,%Z+WJ(C#+[X=4I>>TAG
MV';=0*8Z7*-T]/P3I8?&$R'\F]8.]^:\"%FN7QHAN5T4]'PFZJ51![R#@=;Y
MKV]^=6UDS$G1-A(5ZO9-N=Z;.3&R!^C7M^W78XUQ*=_ %/)7!'XKUTE\=*9!
M8N/B)?'.#RU7;AYT5CBQ?D#RQEO)WAVQ*!-X_:%1/6P^'GHM(Q-<HI=AZ&(]
M\ LX\$YOP2!:;L>448K.U?X8 _UEI9#F\_R/JW.:7V5]41>F)&=QNMCVX:>;
M-=C<V<SSD .KB,T)'06-Z<S.X1! D, !G9TPE\4]PCP1\Q^_Z_#(KQ[*MY#W
MO2.7@9M5W@O*E/6AR-,DKF 4!R3&=&3W>NNED^DZL:3@&()G_W7<]8LZ6A?S
M^C;D(D_>,<GOT8C_@2+/P "P\J8.59^Y=D[AZD>"#F&L16/,5.D04F6=*/8Y
MULL:2)9V]\\T_K:3H( L'/TG4E6@$5A;A!D2SR2MQ ;<8%JO&)V1%VBBN[2D
MOE@9CQ3Q:KZ1QY>8@MDO%J2\V^T.MY4RC]$Y:G--;?T\-XCMG/ASLJ0J2,C+
M(3]X_Q;"+NOL%J+@[/W]C=]/!TAMEF1?_V"T])P303#&!VV',.018,IRH209
M")R?VFF%D<35=EUX'_PFH9%&[*S:0LB/?\-*632@Z^X/'XQ:.E=5!)"3MQ#"
M /GVO&"+'A2, 96)'9U#^H\$]H)6IJ%F><DQQ=-GO?3_T&^(3S'T;]LFR=;%
MAIY7/A>6B,HWR T@5_%]PHTX@LD!!3WR]2^^YD1%YA/XL'E3X^@'6@M*A]O-
M%GLY][!_?'Z\!Q'\-V>\2YC"U&<F A<V;OQ"RIHZ44P&@H?GG1KK0F1XAHUY
M[MV6T>G>K3$>LN  ZG"KLGF8I0AC<]41X(=AA;JU7IED[Z1AVDJ?8Y&ZE5?A
MX($M1-)MPBY@J F$D73W^!:"8@/]%4_38*<O=<Z#AHU;"%[H!GNP>0M!C"Q@
MFO]BQTR1PN!_"F\E_=#;0O3=([V#D&Q%5_DMQ,=:6'EC6PB]GTRVXE$09F36
MWZE82,9S"W$+21<6:*WZ8T2$&>+4/*2QR?4O8V6N,N=__PI&465I.JP]6XC-
M(IU- 3#Y;/06XM@@5.(*#4YL@,E<9%>6S& RB1:*98L"G;:H':3EN>T$]/@0
M@%;U#OF/06HW@*79Y__SY%!4E2L;+#[4YA/,=Q2&1%5&WL#\P)KOWR[O)&WS
M#R$%B!<VB.MT(S9_Q1:BG:0 _,LX_WW1['V#.^#%#6XA#IS:0BC PV?WD'YH
MPL-' .]9A/^  #/!1%.^+80E"BI%0_'_WPKO5 DD&T/3M>8FUO8D)YLAQBI(
ML/3^9: 7GAH:S]?OS.U&&"E/[$?%'M;@OU'FD>,SH-9MKQT55?<(;16#\:G5
MH0NDT]W^Z <O-KV\]^S1YQ?EC^R:O>H\5@ G^;UT6?F#M(QLZK>0@ 0S5_NX
MS<.^"C6:U66WE",4##6L7P-QR$VKIGU;B LM,)X4#DTX85*0K_[U3>4N?]Q(
M&T$(3*?(.;3*F]/&,FKSOYT1G@S^8UURL=9SSO/X+>4$MQFQJW[*8DJ<TB//
M8DW1Y.W;@B7&15!K 24 _CHV#%F5K\CO&5$9P>_&GU^0LW3/;&\(4TBGC QO
M!HG/U 572UGH2;:FO7/<5:'ES)!G/8X@3MO ?#PN=L5\[VL@^8]-'+&]0?K=
M6"6G>G'=\'''Z<3-!XUHG0^NA\.7"Z-F13D6B!+ >9W)+<0"LA/67>K#(E(R
M'D4UPUJE6M/-*\B9DBO2LE.,)U(^<O7?W.V1>2+1-^]1 W-LW#Y;71 H@/3!
M !J3/-'!0E)<VXF[O\[)T^9NG)?+27T69%C&W_SDS1[-P-16!"% ^?/#F7_>
M">GO$3:O"CV:NM2Q)D,AP8[O9M"""4]3-%V87\.%;A2G]2-9IX[I%GH):]^D
M=.9.:.>$?7!#WX?R'?WJF+G?,#)936C0:\F)[9@I$TI"&<UG(3>V;@LA@L-X
MWO(9_1%S4FOHN-C8T U.W2-'R@I*]V:\Z+-$6'!]V5B#J<<N+E8Y$+R%R) .
MV,Z41M"(75C^$+:LF\X6(A"3U(#YY/QM3GJ(UN)27] 3P[#]R5=\6*703M'1
MW4?IBL-3$CF/H -^I1$7,I,!G\RD"4#&%)/OC@NPITLDXAWH#[]9OAVON_DJ
MYP]/:)7V#V;6I?PL],'Q]2$IRYA\N08;*?DEIC*A@UAS;56)'#*?B*K!M&EI
MM#T\4T+ 1EC57/?/^T-.NWYWYJSIW1,6[V1F&^(LND/"*:ZKDS2 3$J'W.D:
MK5'BSUH4Z)T-5=1T'U>Z"KOD"DXKQZHQR6QU\_ZS)'OM=P73TK_3;TGI<\QN
MUSFXF$5WY,G33^9=)8HLG_%(+[W</<4>VY_V<CGRE9)BI9.%+ E2%XB;_V&[
MW6(LC@_+5LP$3R%WD99O@QB8R8O/0U81HHY<\"]Y+<F-+&$DC%'DN&D8$@K8
MHHEMV#_*YA*P2>R"(4W(RTJ4HQ]&R]N@UA;BK\3V+02HT #'S6K;#99HGNQD
M 5@'M*.P.^]TA=D![#%HA>9\P- ^&HG-K44"4U 4V^V2TF>6%  2] 3H8J/_
M'TR0/XY;ZQPZ)/#4X06+ZNZ4'2]NQ"+D$*(K_U[EQ+]Y_A]71?RG/_^4^6KH
M=>?!\68,A=^Y=6X?T^&3P1/S$ U*P#65IF(IQX*;.;I5,F(7=N;O:3[*N=-"
M'D7&@.I5D,@"]5K/ \!?()'48-,QZ],S=+87UB=W5V+RN2RJ9]+W+T?E92[6
M5([/2HM'3$WN#.IY/;&(@L1:4* *[ ^#YB>C&3+#^&C:+TIF)X8?\AVJ;]9S
M&Z[+KCZR.]>G^<,CN8&F8X?WO[GO>51T[TI^^[M6R057EMM3 ;UQX.+&I%('
M(+6*"M 18@_/<8U P(L/^X8AJ1AJ2&"$22_/.7&-@"O*-[//&<9G%496G:CJ
M!<##_0QK&![74/3!5GDM4"#ZFA_=B"+1.B^%MP5C(DIV+K44%7R;$[[CXVA\
M[:!#I)(W$/6U*Z:,J;:=E\;F8W\DT4X,B+!Y[2M67@;-R<ES/O*DXP_*]9QX
M4YO>Q7I1:NQO1\W1ESM[46DC!?&#*$R81-9@X]EZJJM+U,PIFS9#<U26Y!<'
MSADP9S+"6:;R!U"S\3TR^_>-Z;3PX>8#)%$2^<$\/WL_B&+O=:<C,\S-K/0!
M0?-][+Y-<+ [TD@XE]W;3!HK]S ST!NZ6&%5G]3C%/(63"=D?4/!FRNM10&Z
M3I]?76+*X<6'(: "TD[XB-M"N- ETJ8MA\NQE?E!3T<4\C1,>K6QID_EK3:S
MU&XFR3M^?HKXHY@"?J?\@L25*#V=F9^8U)XU#<H6(E9>[VX7:L=Z!%HG%>!I
M&2GI*0.CUMO5_5[-*D\(=1BTO//U?;@_\L[IU?0G'H<6V<8P;GP'^ULQ-5RQ
M)/+3/R1(I*-;B9S7?+[@+#C?/8QK^*!N:FK HYAD5I_Z]-7H^0SW+*5#Z(A(
MA9YF[B@$2Z1*&YCV9+AL(1+RZEAIH6RCY4:4J([^ZY^BM-#4YJY1PX]I[[Y+
MCF7-[WS6]VX 4ICHQ="<YZ=#&!T@:CM+F'6/%"!P ^"].F#33A3$N[R8[[^,
M]]9<HFLV2)_-N"CY^V3#^+M+SQZ_Y=)MLLUWW*=[&56/Z1R4PFFP]W*R\DPC
MHFDA+F-XEPCFP9"G.-6.:T)GWT_=S-UC__3-W;Y;/C::_.^+U>)*?=)N*2"?
MWW/M0U5?@T2IOQB)8 4]EW&-]6P+$8"&]]P60I#-792]D:(O0Q*V+)\^&^2:
MLW$%&X.-P$IKQCX3?B>A_GHW6MS%(0%#<P)2,6($*;P.J[!)@WG ?0ZO =96
M?37TD$C2A[%5P["T<'+%B(^_>;W(A[%/=&>X8IWC[,E>S629M=^3"/.J?WVA
M6 XDH02A7;1';1[$3F**O/XP9$)9$Q^JK(\)]R1EC _WB3&'T9HW#ZC]5#[3
M%484)XC@#X!5Q4%E],2.G",-N90U%X/[%W_B#6Z_3C#F#+<78:\[B7]73.8X
M?4?I'H)>H,:%9.JPYS#5)6NE\L_G:W+7U"E(N9:D/H-HK,!*KR;C1C+OIE7'
MBT.<&ME3G8(\;55G6IKK1C2+1^OY;B;PX1[:+=ZF.(GZ5IO'[@CY+L*PI]M
M(O.,-%AF\4U!]!*&+=A!L=?SI*':?"A$$3#@:%V(5!.F%!WS90 GT6^[3JZ[
MI;40=+I6KRY&6#2 9?%4X#"(8IYC]P%UR+3ZJD3,3E3@!B?XME->UFM.X2-D
M0O4,>3N@C]WLS9.<:7(#[JWOY._Q^!$%'62]*('#!?(3@.:J(P.T^4/:O]3)
M:R:,>XD4H,<$?7E &G?-D0;<6C_7Y.L]Y&5OVKF%$"V[V/R;=1(V\YOXLW3_
M.S09>]"*IM09)R /!8V?HV%CZTW4=]8G-Z5_;AK[6+IXL6ZY2L=R3]PXO8J>
M%AL)A^C Q<Q)(T8"?7\!12"65)<9AP]Z$22B?Z0B\U83.A10>9QBZWOOV-KB
MRZD90P&N;510(Y''!/A '7+/:A<3#3H<SS%#':55K5E2T6JJS:\D&VOJ:ZK_
MTK6=S='O]3<OG!CVJ(+$G*G>U4RM8*!QHPW[:?Q[-Y)3_U7E1G<5,BUGI/-A
M<7J(<O*5,O<@@< ANTOBZBKI^YOB@A2]YDXM'D4PM5/ ?D8AO,9AO"S(PS2'
M)%BE!!E(D:[:B4% H?1+J?G+Y@<^KFLM--;<=;S&X1\?/E>W?/O#":%I0V\E
MH:MA'*\IF> !UTY^'0:#AEIU8MH2.EM4P  L/>3$6&6+"*[6F>Y-)$0DZR];
M=0TTSU;D R^/*^QK?^"W.'223_ ITGO6R^/35&],3+CLP0ZIZ\79[2_4I#3M
MR ACY8F'[ _;.>>K)*9'<)[6,. _GS;ED$9L?=/^U5N-^)>N'38 U^?VE^H!
MQ?MDV?L/6I4XX[OP$4P#P@RFT;4+"VJI]A G%SJ)'%>K0"N"W+*W\,B%X:?T
MJ6?+#(D*L^F5#WLXO6;M1=]YB'X2"EU(,I%]-P?C$2<;7*._)6^L76'B/=D#
M\S67:NDA73I,R]ZK;U0JFT.>35KQ3LD^P*Y_E[PSO6A;X*Y\(:Q-1!N!\E"K
MRB1(P@[$E\ %;1M.*(AE\^X+((<Z.R1VOF%5)51 4J7>5GL8<PK$TU[J%TM>
M759*47D=NG:Y=5>LE.$EUFS4/$R?IB06QHN85L3)^07BZGP)[OP7VD6VPC#D
M3!F4;JDNQG!?JEC[7&>=TSWL]\#\8P:E@%=L86KP=0,BVNR?EIGZ]Q..DFHY
MA#=B$<U%<8D+0+> <&4Z!<O[U3G8@_UBO.:]EM:%4\.V/K?D;1 [+K]P>%KY
M\)&FDX.(I7[P\HK+4(+ESE&A&4>N+R60V%NJP.IV0M+VE674 !-%Z)T7;1*C
M^U"-TG[*'6*+38$^3BG?G8:JS*<Y'CD]<-8+:J!-)Z=WUFJ>=S[T^-UR^A^K
MIT$3TN:W_ J]5H2]^D."9'5G^W\5^SD6#:IF63N,EX$!;82]-)>FACQ^6MZ#
MPBZ3C8=:NNV'Q:W9WSD1(NLA)V/-S<$'S&,0UPB*7$?BP^]\@?>A-;?4<JTR
M%U+5ZWI_3D<\T*XT&.0U%5_D^XQ6=)_5[;;^(FB,N'487&"<W3Z$#43>(-%.
M8Y-AD:+ED!W1@-^ 3_<4IL?S>M+Y/>)E&O=H?_:(;7X>JUCCLW8PG/HK-IZ1
MT+,*T^??*F12YA9BQV<8&^OQ#GBBE*GV^'=V/WW9<88_:J9G?PDK/PCU*;N1
M/+BH#JC)31\]3'V3">XG=<8(L'E^PX([PJH"_(C3?%T-\@*OP3+Z\24JT#XH
M!#YDA6KBT47>3>GZXA,BNMV;4[L3#)/D.B[>Y*^^BWE>_X2*X0+1W9'5GW =
M[5.199RZR1<23U5G7+61D^3BW#GH7<?Q&_D41%D-M\@";4XPB.9G@1D]:#"
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M<IYL7@>:GCPON$;3#G$0Q/E0)1+'0JO6M4Y1#U=J5OJ>C7DFLB=C)>L2Q]T
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MRCP_IE8+))%WZL7SJL9P1.)=V+IV &W&;+5MC+@07:'$2'R3@$E!"C=Y7EM
M(KLX^P]\\IHI#,RY\-?OLSVRYQ]7N@[D.);WB67.G';DZH<]H',F>("TNMWY
MO@>\7K2"DB(H!C+,U>A^O;4T0NKS7F-WI(+98M^TC>;0Y-%7^C7*EWINIGM;
MNYBK;KL+^/W5L-#4\4YT&7L6$?#7F?+_1=U"=#NDS*F$;"'$@QO,>4<KM"-2
MNQIUKL3HS7IV\=<_J2B748RUQ3]7R%#KS,R:S[_GR/5E:54HB$P"]Z,@41-&
M ZC'M 9';&C8!,(!\#W>'0RE8H56#KF[!8\W$H+&SF5<?^ C//G!QS4UDB*;
MO-_0,$2&S=-,)25BJK&Q0 @&U 36KE$E:#9Q; .\QYMQZ-#^UUAE5U=OJ9HL
M*O]^E\;+*GI>OS?K''?-] V)25[!%/V93S0UH[HI-M#EX_V>V^QJ'^2\UE!Z
MH.< :U+TX.'SDXF*E1^Y%@7:-L## FSNQ2J\!9'1SLI'A?2CB4B[PH$24*?M
M"! ?\;:6(J=]QC5$4NHB_G4]7[%M^NC*-)^R8_<7M;^R6+^8Y_#.M-Q;P/DJ
M>>@8F%_J"1Z;^D9I*/S>0359/A=B5SA2A*TUP:KY<6G4N]><7AN(EA/EH&U
M,JD+F-U@"9M[DF9C1QM,U1^PWK"AO6^8:JY(A\+M?(RF+SGDZI;N5^TQ\>02
M^R7VK[?<710MTJ$3$__09I7%- >Q700]VNJ1@>UH;/;DDD-S<^*:XU?U@.>I
MCQ+2,WXV[OG(=<'0MSC:]9N!*(=-!T&5-I]69X(5 5&=AD<J'UR79YK9V+^U
M(S\)L_Y\A^>,%*>O_!B]"I(]2I=HW?YB9IPY_O)PD]^"EP;Z[82IE$I>:@@
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M$ L[Y+R]Q+8YY3>CE9<B!D[.77UE%]IY5/0O76XE8WV.K<G_!E!+ P04
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MQ-E_8^R_\T4"-O#S(<KCEP+0 +3"0G'C>,!E1TB'0'_/)%-MV]+&&CI4U_.
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M$/[8WW:CI&\$\R:';L#F@Y;@C>)0#F/A  ^(#B;>0?L_4!O6XS@P1=&HGN*
MS-.>.\HZ:EA31H=)/P[./SB4(>E6$1O!#^!:^S&/B,)$"N750CS(./F.2,G$
M[>,FADH(0LO&[#(S'G#R:U28V$CI%8\F:OZZFH9IZ3'MA^NHYGV[=QZ-3,"4
M$(B!F.1:5*T6@:T(H5G!@\LZ-]6IOU5UZYF-XWMVDCRMKAGW5N<5=NB<7[0.
M-NXL[%JW@-'2S@SV78P70%=B.'(&+#GN:Q[@OZ "OR=73G<'8B3#%ZBCCV!I
M+]7]9E-RIV)#:_(/:V8;I_Y0S\LV\7]XZX+W85_M\="4$V-6 _K5#2.OO97W
M^>6?KZS,IETX>:)#PTG'3N?,E?C2CU< C=N8="+#BD!RAD7&F)&P:"L3,4D>
M4-G'D:E?H-IVOC7J]9ZF"2=>8+Z:S1Z6$*K$"OZH+M40J$WU+)'W^?'R581]
M"]^!E0@TI:Y^I8L\-M&%>H/AR/2PC.J@WF*.<?7;3)I"X@)NBV<X>*PB0R1#
MY$QU0-"TPE41S'N^Y!T#ZI35B[X RA+^A&*<)(_HL&HA:BG<BZE<H?-A7T-+
M[34YKF8+,86?0Y5U&@1J\O=%WM[Q?:RS?"+W9,J]/&KJKM;NS\8<)MC:/*Z?
M1!/FJ-#9CM B6GAV7-5L_-'$H]40/=R0Y<VB]Z8)ES0B(^._/-!X]_$#Q1!H
MH:3WXEZ'+\&BU=J)Q,MEUV"10;94E-0;J)"IT(K;E',:NAWY.OSS3R756TD_
M=*\'16S.F\STWM<KNFJW<6C)(H#/[M 9U)E^C!*N!V2XD>/(->@Y%).?U0QI
M,E(9$)YZ.HP)L:D7FLH*RZ;RPGRE<FG?+Y_8+GV@7[UJ]R4Q=?VN79)LB_/0
M7L0[K7Z1J[KGRI@&K$QN+DC)&;=@.D'.ETEIR4&:S*RL;/R+&:>6P9XPO=_I
M*O4O#ULW2O9M=\L;4;OEQK^<6[>0B)>-0C%\6CS2.OI0O<76!0&2BLN*OWLW
M+CAE;XK3VQH[L-UW6X'N1\F8XV[W^(R7^CC2[;!H'0,#B\:Q%1W99\(#VP<A
M?;+5T((16<F?]/5)QNNDT* -8=(\X'F,=39*S?^Y=-:Q3=$O3R:N]E&U.0I)
MW>A:0AQL$%[),D5<*A)ZU(47LE#M#"X*!*5X '5W3=70PC6LNIUF;(JN\NL:
MZX3&@F"5%Z8'9#X&2P%LU#]&)>,Z\8SC]EC)<5PWJ(I$9N5NJKN><X>$3]'W
M5I;)6^D'5C>?;5JY+&F?4M?5_C@8?XG0@H9VVW;DHN[@%'%#XP9,F\+-V0\+
M36,-C)7?)XP*2%F5-F:8[-M1HCV#"8#X83$V4WO"=2Z&*0R+2C%D6.NP"E&J
M#/V"8E*/<5SG'H6.J7V'7$US/&Q'CGAX!EVA)Y5<.%RY+6;H_"W<_2&E%R4O
M_&_X=E677=SI/CK:LO3]^_>CY9T"APL??G]PZR6@D8'XSQ E>K<X3@5QFC$>
MP#A!( U3RHBQQ#,\((XH?ME\%P6,OZAOC%'>?&[TM?DI 0E^AR+/3MD4S<+Z
MQO[G93MM'T0GFM_K.B/Q[:+.#W0",H7SJ[11998!TX^>AF0L.>ZC:L<[5\*O
MG93W\+O;G63T_0;;.T(]N:6FS%<[:\I._7"TJ2]I:X1*Z9DWC#XYA Q<E",2
MS#=#IFQWF$0L-X3$*'U=JV<PXN'M!Z!8XUXK6_L'%H-^^B5%>18C!RO&^-%K
MYBNZQ:FB"WR;^'_C$LL*?BDYQH<D>8&60T^:RIMK[)-T>MP/I3O*%)]/5PSW
M]=T2O6?+'1=_X%GBMK\TPCTTA8A:C.TCR<#O.>0ULQUK</.?F,L!/RBC_1W9
MVDO@SY_%_% ;TIM_A0V+F_" ^R]PPR +B3M%[W^MK!$!D#*(73WB1T<"/Q:U
M%I6/Y/F_7>S/%$P0EO /0;UQ; OO2>FF,;9>>\]OW_2>:SN-P2#"V 3KA/-3
M,!S), JY"Y/8K%G3WVA*!6/$2W[=*/QVVZ>F)N9%V%5';[Z6V6/ 9.)RVI@M
M+.+ %@-;K;"Z^N E;(S9<(K:0%% 5:\9&%^_G)?RO$RI:\ V(."F[/H?Q]>U
M\NWU>5PI\RZ R#C( R M&SR#;0>A@QFV'6OXZ*J]A^H=;YM;,I,Z;^3?OCC6
M\R.DI^F8O6.S_9G.Y(P;N0#G(E*$.!-]'1/QU;8<.>TN,L.9'MB6DXN-YA@'
MO_Y&NGCMD(M.+_;4;NU1M4N"F1]JZO(F=?+NMJU7/3<,(DF4S .R.F#$ET:L
M.LEK J'L'Q14+&9CLVRX4C<UK:V//\!"D3'_,(AUT]"*L7SWNDM-\+7%3I6M
M+KO>H[>I/%XF/(:5P%8Y(N41$H1XP$5M;A6L&B4[7&JQW;[DVT4%[]U@8KYF
M_M1LQ-*TXEU2DL8L-=Y_TL5&6#"X$\#Y(!(FH2O]TL +$B04A<"1CV1=NS/G
ML1)GS-93[ZB]TG6];/EY["_[M_<-QEU/OJV]5\/G1DG+&R%\04-:N>&/:'Y_
MO&;,AV8;HV_D*!,5WAS7Z?!L_)UJ$,J:;7[%?RU24DC4W59V41]04,C1;G9\
M@1LB5TRWHL?V42Y4L_? _:H2#F%MWEM,IIT'O5T.3HG%SZN=^?4A7>/PU?V[
MQAL"FV2.-7PN9)"Z-:N?UZ1<DFZCTO.W?:!W8*5<XV^ON(M64.2VW/+G7^4@
M>K@(_CA+)BW K? N'C!4\^D5PMWC6B5".T)A'^LQ9,@,3;:P<-#B+_'T;M8_
M^M4CK\-TU/F]6@3M6Z3T_L#E0=8%Q-!W@ZU[B3[$-%-BU<+<!,/6G3&=NGSH
MK0.F@Y_F%_^:[&3WP_V%YX/Y4!'U.M<L:1OI5^M^E@WQN_$ 5037Q)(9Q[ D
M;18>7:.0!,O^4K)-TV_U"CO%P"8;B\L&7G3N\:WWW%M ;K)P]1T9,-CH=ESX
M!\B1;.\PDXA'AL^")*(W ZX.O.D#HM+.ES=6O757>VM%\Y165+3;N%X@>O?Z
MJ;<82%.^,(+2!^WI8SWDYC7O@0>\#:%3-$=4>$/'YQDE8AQ65V_JRS)?Z:-B
M/?<%^F79YZP%C7Y!T=.E9Z3=+;D/($'$\HX@O/K!'\$JO6FZ,\.5A4TZQ/P^
M7A8,JE8&T,0/[IG[^,G]2?07;?G/+895A\H%1];=.]#I!X^C&%82D%8?1]:/
MYD#L DEHRGWZQ*8SB2*-CM2FRQ,.#8VQY@+V:9K1QTX=.!7FK%8LN@D @,6%
M&#+#@3S2#HM\8>QC-7T&+Z 3QG<.-SK3%F)KS8HZDC ROZ2\Q0)([2X9HZVQ
MI&VT7$<S*LD\>_VY<R\)BMA>(F2ZR0,/;<70&09W<8Z<K;D+>5,3E\F0C8'A
M8V9R:"]N(EP!%J&RMT;MYMX/-1AY1%UIJPMQC//X7LH(K/=.H^D='%APEBGV
MC'M+C UIR+8[*1"A=.[3G;.:%AY+Y#L@XU :I(6?6V&$=>,K5UK!VV;DN$9E
MIJFCO+?99UV+;= ]JY>MT87*UY]Y['_7J_S@0TY*KHEN\LE;. >PE:]Q[T2:
M F)PE>0:; RLU&I.^KZ\D'2NO*9:H&>OA<*;[])\[\,<W@&S;J++(&2$IJ%N
M&^$A]>EN.NH44SPK[]-MIH3[E^HZ_:+#7P>Z,!(CNM<.?[1YMQ1P;<D$6!S+
M%\<]PW6 # >)D098I.=YH/=F;@I.%A..=F"*MWV[N.83WN<V%'0A[^0V).>&
M[;;5^G)*_[;;RUMV@.CB?@58G(6HVP/RF8BM8W:WX==A?S^,LC?((X0['F6>
M^FV!:GX4D>[M9>PK>?C5UO$W%0_DWKCLNGT ]0#)9[Z3WI)O(3GV:4_.@<'F
MT2=-.7&NIRM'//LJ3>H_/]RY7CLD,E98VYB"0@"0%SL D4'SN,X 2'F.4,L#
M4DLF\*,]W;1/]H'OOSD&@B_&MV:3CWV=2Q"YMB&]0>WT$Y5R];G%W7?8PVQ%
ML%4%3<D'&8[LFSZPHBLE"E9I9&[,)N&()7:TO"/S00?7;3IG&7QEIFMJK/K
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M<X_;PGC@^0A14H^?V:MN@T>*ZA4E[[XG_@8A[==$]@VP#3.!CL-4=\^5,7@
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M:=S'-9?L[/Z+C$H[4+Y$-NTB@,WUM=W@@]HIK.$Z$R/+M^J I#4C;B$L'*4
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M/R[".PXY= RG?W46^GTW>-C0P"M_09@-/TL3<TO98[E8M5WJVFA;2#?TU>H
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M7Z96QO[LPKRDAE%3FM&:9K6?LMN^[&1:^2:-)R#%0R&HMCGY;U!+ P04
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M0JP4A7HZ*B#E$5>Q)"RAR+JN[I%&IJ8(-4Y0 07O0(G5H<;L,3)/[SOW0='
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M,4RB*( B1DQ2213WJ)N#9-GR]+RD$CC@-?+M6ET@_YT^.6ZEV79!+*,DDDS
MD)N,(5AZD'$D(3$G"!4EH>3(96%L@ X8YQA\>;:CH7^KT->JDO0P/6#GH [
MZ\ #DQ6E X1\.3+5I\=JV_2H;JLC'[N^J^OM[@[LIV?S@$P]:7? G)Y.%WJ:
M6,S+8)&99,Q/1$RACT*NAPC]/RQ( F@R'BNS<*]?0UMGMJVAJ0E2A=5LX3=H
MS4[7&J^]C]=*[VG7MR_2!E:;D?BR]X_[XFTD7[DS?TZ.LPTI+4YTZ^VC.=0V
M1FPZUU;7=W.T;^5]>71:FOP3Z>+^.LWY/,N?E_).?B_>:\2_S3#U62 C#X;4
M4Q 'S(=)0K2@BI"&L4<2GSIN7%BT.CT'NP9=9D9?92TS2Y$_R>Q^29\>4@XN
MS=ZTFY=GTP-V'E[/K ZLMS5:L((+UGC!KP8Q*"'WZ-@Y$-2G4V?3[*@.G0,/
MN\Z<RZT=,_&661U6J^]>G$@>*&P*Y880FV5(JG@ $^1QQ)C'D'3*L[#]^*DY
M;76J$(LE>!ON[&2C.R,#*X0]&>ZY; _:W&O.VNT6QLU->]"ZO1RTAZ_J]M5^
M+A[D<IV*Y5.F)8**=/[R,UW^)@L3+G17AA7B $N/)A@2+O1TS!>1=B:\$!(L
M Y4$@F+I5!G"MN&I?>DE[LV<0!HYJ*&#-78]$IK_..J =6_8*<00' ^L'7W1
MZZPLKESUJ3G6;8^J1JZ,[.J4\_W]S(1N%BI;/I:3YJ_RFUP\RW45 (8%\_5<
MB";$1')IGX3QD$#B2Q3Y@1?$Q#$SBWWC$YP7T;G, 7O1<_W[ILH6J^='YTV%
M6KJ@VXRH'UI'GQAMP+X -7"@?U5?4@I9<]<0WI([C4-.GUI:?]59U&E63DVF
M+)[0H5YU]):$96E284J3^J3>-0HX5DJ&"+(D9A '*H(L4@FD41S&02(B(GWK
MTLJ'VYB:SV50;A=6]HE#?> C1)Y> >^!GH$UYQ S74HH'Z'(H8+R^52-M-[=
MC3*W^LGM9+253SYRYWC5D]NA;Q5//G%I-W>N2;=LTBS?/FA]717K1+&G,(XC
M* ),(1:)#XGGZ[DH2GCLQP01D;AY;T?;FIZSMLH\7J8;SPW8KM50CS-LYYSU
MPMK NKA-U^V:KGX+HIZDHD]_ZGACH[I/)VW>]99.W]#[Q._CJAIX&)H2( &%
MR%1_PUZ M*.D72:/\D0%0B)$G>HBV30Z-?>I=6)R1A%VJPXX>\+7B=;7G.H-
M5*/=A:*1IG$?7Z=NNPL3#E.W_7O/6%*_RAZ?EO)!+O(R]M\<6"Q3$M/\X<=Y
M]OO?I+B7337-]U)CD+LU-2^5UH8[^GV&$DF1V<;W(J3]'F42A0:$0XFYXE(P
M1D*K"=] ^*:F=K\LEI+.T_^2HJJ]7!=>ILLT-Q^J>%Z:_SS)99HYYC[ONV,=
M%O%?I[M&6>O?,JTY<EW53;X QD!@+ 2EB5M5E2\ *RW=JZY\ :@QUIS;[GE_
MH/]NZ'T;H4>(X^\V],_OP4V) 9KI>%PB>WQ,R]V1_'(AUOGJ3:$MQ97 *I!0
MA%&D/=>8P$1%# 9,$L2C4,]]0Z?X_.-M34W"-Z"6@5I;8.OL%0@YIJ]HX]I.
MB7MB<&!5;26OQV#[TV3T&F#?TMRX0?6G[=X+I+>XI6O6BB*]+P7IMJ#%<UXG
M_TQ"% 8TY##F2D*,/0J9B@B43)$HD"(BH=.D]W S4U.--4I0P71-4W&02SMI
M.)^A@55ACYP!DJ6VD]!O5HJ#+8V<D:+-VOUL%*U7=W0?M,-B_L]$A'VC<UDF
MU<J+9<H+*<P?M-QL_V+CREFBE,<\P2#BQ(,X3@(]K_0#R!%1*/!4P F;5?,D
MC7E96+H9YV!R^6!VD0TXHII)2#F4FG_(-5PS [E/%Z8B?'E^HL.<\LPN1 HQ
M+A*8\""!6%(.":.1=AE%[%,/>UZLZB[\L+#,LSAR!S:X!NR^R]N_@<M/UZ#\
MQX=_^>7F[Y<?/WRZN[T '_1O/_\(OGSX>O/Y>LR.LW0XQ^J*H5U2C:R>RW_8
M_'K6V,'J&]O]W<8-/3JO?1#;JWM[%J!Q'> ^N-MSD7MY:,=Z)>DB+>3'])O)
M+%?H]S9E<WE99BSZ)->YRF+&8X7T^!C21$!L5F 3AJ@6W"AAF!'.(\><3G8-
M3V\O>@VV2>ST>UH\ "%5:1"8:XM<D\19=H*=;O9/[, "60&&)6*P06^%^0)H
MU(,$"+H1U6OE%+N6QRVGXL3&7HT5M[O= P)O%M^RW^B"UK%9(0\"CXG0>'S:
M]Z/<@\PG B;:DZ>!J5^06->/VW[TU";V#3K[>+8=JMI5XSP"!E:&!EB'H+X=
M$NQC^;J3,5((GSTI3F%[A^UNB=;;N6&T(+W#0#=C\XY<X2XZN[6Z<S/4U^<X
MKJ4)J4H7)HZ]K#;0)'?2;A%% 8(")>:81>1#HD0 61AC0:(@QL3JJ%C']J<F
M7WMEY&M_:5F?:A(;9KBDPNS:/:?5<&#2!Y;,8WPWI\@V+:CKI;B+:Q?B[15X
MX X82::'Z @G03^#QA;5[_+4T8:&,TS>'#_.>4S'M6RSO_Y9W189_ZW>>L&8
MQ)3B  H<A1 +AB'S]&"BN!<%U/<"%;GM@.\U,;6AHD1HEI)+C!W+ QY@TG*Y
M\2Q^AEY#=*3&?4WPJ/6]+O3MMS+NZMU1*_>6Y(Y?Z>Y&_D/KB%PN_B8?T_SI
M02[EA^]\_BS2Q?TOMTT]]#B.J20(2B\0$'.<F,KH LH $?VMBR 0Q-9K/-W<
MU+[\&C%80[X L@$-?GE[^];>-[$@^[0/V"^% XO#:?8ZN'@6--I[=/W2.9(#
MUP>M3@Z;/4LM_IG%0T9SQ^P-VO2^'.YRD^)\6<RN3 '6>2K*=Z>,=Z^=!(:8
M(-@G$(5Q G$@0TB\T(?"YR'F?IQX=AF;VAJ9FNQNX:R.;#AZ7:V4MLML7T0-
M[7EUX<CZL[<AH<4!T[=O.%_ZIUW'J_7YH^B C87-UV]U;?=@(1-^N+UW^D6W
MQ%_6&0L1]CS/)QX,E2\A5A&'E 98_\AEQ&7((V7EA3FU.CE5V KXV0I9J)"[
MAXJ<9MYRCM8WGT.+QRDJP:_U?P?)'.E$5]\!':<;'CUPPYJ+0P$:]C=WK./Y
MC:9SLZKT8[8TR8EN)7]>EI6BS&GAGVE1__2/M'A(%Y\7\M\D79HJY>4JU$RR
M6 @OB6%"1 !QA"FDBD60H 0EB3DQ(9P*&IP'9VJ:=OTLR]77= &RA00O&JMC
M^<_S>L=.WL;C?&#=,W#!&OT%6%D&5;:$N;;M M3VO.B_SDLMDZ+4REOMZ<_E
MZL_@6O_EHND];30P5E\ 8W>U;MYC0=)>.J#7DJ7G(1JWJ&DO[.V5/>WGJ=U$
M^6>M%G7&OA^?%R)O5NN(2#P6)M#'@D&<) )2KO_'PT'HHSCQ!1$N8GNXF:F)
M:(D2/)8P@3(XW33T")EVVG@^10-K7L5.A1"4$ <H\M+.0I_"<Z2E406EW=I=
MH3AQ=<?PV$9(JEBVGR4U6</%Y\57(T/F,/U[FJ?Y+XN,Y7)9UG._63P]%_K/
MVL9TGI;SV/<OY>WEID*].*+],IG(0$&%F ^Q22M,/>VYQ10G7"8"JSARD9"A
M@$Y-A$I\H-H/Z[9#.%B7V@G9%#IJ8"ETZB/WL-V!">PUT'<HK..&!@_,^%XP
M\=#M=0H_KH-!JHP)346P+U)_,XOB+BOS"<\XU@YAY&'H(R_4JAY(2%F"8!32
MQ,,D\D4B'<*2+9J<FCZOZMVE52Z3IPHM*#)@IGV6+J,#Y:<W<_LG<F#]W$@
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MQ%Z@!QV?(R@02CRJ(A9BIS((!UN9VOBP!@E*E&Z#P&$B[?3Z;'J&7M;;86:
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MCF?\6YJ;FA?8'&LO(5?GXBX.9.AR/O_?QGB[^O3/X\#"<RZ%71(%6#!S?M:
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M#^>VF#[)--1"<Y:PB)'8RZ Z-LC8>.2PL.!.Q9Q2A<Z<<A1F-R8Y%[R>^>,
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MT=KK34_/1%CI8CXE6]AX!=;_KBE7Q+^"FGY5U<@U<4KPIJ8CJ)3\)6#/IU[
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M6BB O5G-&ZR0E.8^^*!\YHW)/IGY/Z"C,58U@_JJ%K??6:TH(TIC;>C)$)?
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M,N19R]EU:)^/<YB8RMOGQT>V>+'1?6O1IZYU&KV!=V.]/L#LF>GJ09(;H2]
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M\7(F[]C/21[9C3B/H. "01S;2DTB9X8ND.9:<JZQ5Z_(D,)Y6; #=);\K%9
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MJ0EG>9)&10XSIBC$JBA,1UIA*IK&1$4L9RIR+JI\;#:7QVF8"E"5L&!EI+T
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ME%-3$[RL#]2R5Z:5O5)J )"GQ7D <T>[\3P<![3^*D$O&L!Z"$>QP*07,^S
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M>J9*(SG8*G(!-DI"M5C"U4Y)3/WIK*3!VL-UK^WBF=Q6S+S6GUS4RVST!S4
M0"-0)OCJ\;>-+,,1;_"%"<G.X80;E,*#8_J6Y\-/X%F:<U-DQ]1$,!N[!SU0
M7>:QB#"B5%-[D0@!<4$-OQ,"C1,J9HP+1:RB9FPF&QUE;V0%C;"^13:[(+;C
MWE# ]4ZG'IBYE\NT "-H3<RN^88M?&FA^5YU2YM[O%OTFL!D>2VK?S?=DU9W
M]+5TN<^%_LOR9:?;>%GZ"A640<(4@QAG"61$[V\%35B.!2.)=/0N^ DR/G]#
M([_I8$9K#<!SI4)I<M!*B4V!(8_&G%Y+9L=2_2]#S_S5* #>-2K\M=5,;@7N
M6DM1*](^YPS:3_@,) -W&O:19.@>Q&>@=: [\3FC>03NH9^B=!L&@Y(Z@BJ3
M&1+Z?Y"FJ;:^&(\AB;#>7<L$99&*$(VM(DTZYAB;T66DW VO0HE#+-H1(+O9
M*Q \/5/3(61\PO6.0.00K7<^5 ,%Z_E!YA:KUPU&5ZC>D3N'B]3K%GTG4._$
MI>Z4]U'JZ^CLDJ]OYP_T^Q?3B.?)\.HOOV^.''^^^?1P\T4^:0Y^69:U73>-
MZ#Y\?Y;SE7POYU)-UQ-M.)*BP"FDDF!37R^!>GN*8!KIO\H(D4@B6Z(,*MG8
MZ/5:*KDT 5IK^KU5I'(I9Z53:[T #U\N/]JS2=AE/$W3/VQQ>B;W6B\35 %N
MYV7CRDHW<&DLS5]^WP9>7(!20;"CX45SOF/NK+4$[VH]'5JJ!GXLK=\I/VQ=
M!WH3_:#U=7J5];(&'2_ L/,-]MKL!:;VR[:?"?P</'K"Z5J6:>EO\S<OGTPE
MJO^4#TX]9U5?\T5O7'*<Y:;D)4E+M[%Q\&02098RSC/,<D6LZMV>)\;87K[Z
M"<!NSAI/^.V<-?V#VO=+LU2@+N5Q('F\K45#FA=-H=V7@%'GYR$9TEGC*<F@
MSIKST'KKK#ES- ]GS<MRNOI%TMGZ:[UUUF^UI) 9ACQ&.<19S&"1)P(R$E$I
M1)+GB%F[:=Z./C82*P4$E80.7H<]T"Q<,N= T3/UM%'P<<+LP>'@?CD'EH',
M7:LOB9N?Y9C671Z6O7N&\ZT<$W?'JW+T(D]CK8D(^'5K%F[#!'Z9:JMRR;^^
MUN?.DB1("I1!D3*J;32509IS"@7*"\8*)KA0;H=P3O./[^QM&YES =H:M&-V
MP$8+1T/.:6DL[;>^X.[;;#N 9GF@]OGR]QZ"!;Q@"FJ3.0DPK"GF@\V>!>8U
MB&=7=?I:#O^PJ-/X[I:+9[E<O][IK]A:;Y)-T?1G<\DDRS*>9FD!DYPPB&-&
MJIIEB*@\+6C&*>.3N7PTCD\[?K.?W.II*ZJGK2U"CV]D(<J69ROCXWVNY;X
MST;R\N&3C>R.G=7M%\2.U0*#/%"3K5IH VXM-KC;@%Q*?K%IS="-LGO_=&?
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M-%-6$84=<XSMT3=2[IYUX\SAT/8(D!;GVN?#T_/S?@@9GW/M(Q YG&N?#]5
MQHL?9&[GVMU@=)UK'[ESN'/M;M%WSK5/7.J;#E'Y$3<M35MY_)_E>E*PB,8R
M,:VJ.(&8Z'U808L,4EJD".541"EV2[XZ,:/+5WB88*KV>93^$NM7_+2N*F=6
M Z26,3^VB-L91@%1[-O!U<#7ZJK<$O;"I**$3+JPPB5L#D;WE .G9%CIOY^A
M87>;'\E<+9Z>%O/[]8+_^WKZ;2KD7*SNY/+^*UW**[KZ>D>G8H(%$T4B$!0"
M<XB1$K H8@4S4:"$"HH1LCH-=YET;):7D0N(1EKPK$4$[Z9S(!:S&5VNS*$W
M6!D%'#G':@'LB"<TK#VS3R4N*.6] !N)RS-04 I] 4K4C=SA:,@%I9!<9#7O
MH(3D@L1;5G*ZUXV:RE23Y>ODM_L)40*EF;9N&#;%/QC1/^41AIPI)&(:QR2-
M[4R<[:#CLV)^^^G^N/OP&#1<&WAY)".("I,EDZL",H&T,9AQF29%4I#$ZJ#6
M#Y@A&/<WT]%:5 60+-U:+7RZ*=-/ZYX)\;?/-P\?KL']P^7#A_OS"6]?QXX<
MEOIB0V=Y\XMALKS%9*T!!^&I?04:%CKPR9F]@K=G:C=K^515=U_5I6A3'.D]
M7:&AH%D*<9IDD- TARJE/%=)(@KLU!3)9M*Q/8RM*F.M_J:>17^M4+>S>4)C
MV?,C[@NC?[M?"UQZZ?+;->^/:>YK@<31GKXV]P9JY=M4\2EW=[?*&%/U)V*2
MY2A).)<0)<J<=D4%)#R-8"KR3*),QBQE9S;S[9C>ZCD:MIVOD:RJ3;?:-&?C
M9L] :YEK3U <.6[+G);%\L L--0_KJGO5O+21V10+W=JC?@]MO6U *W7QKY=
M\__8UKX6R)QL[FLSAOL!WJ]23#F=7<MO4RY7]8F*,D7"),/FO%[O[53*(:-2
MP#@ITIAEK&"(V>?_'IIB?#N]6DI0BVE_+'40P3A1A!0)AYE,31N\@D.J*(*1
M0AP53,J\L,[U/1>_(6S07S]<WUQ=?@+7'WZ_N>K8(=FA=_K0\UQ,>B;F-U\F
MC\/.@[C8GW2>B\] QYS..#F=<':!T'&\>?"VP<XVNX1N'VQV7N=[JLG6VX+#
M39K?%VTLEHX>46=+T$<YX3(F(L-"OY-E!'&>"DBUH0LQB>(<I3(1B5-LE_W4
M8V.^2CXP;5)YE_I7\(ZN &V2[9Q/.JU7P?;0LP]L>S__9.M6O?5MYB\P@E^
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M02(2Y3A/$IAJ(P[B#$E8*"9AQM*,\C@B1*;G%EX<X6[Z4)5 K_W=,5SMV"T
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M!:6\Y]?\V^+L=I!S+GI#'=PX Q>B!N >(CT7 MS.]Z.K >YI;E$2</\>S[J
MG!M+:W5'7\U.M8ZWF5")6)00"8DQ7S$K$D@+FL),HL@8L5&:.':%.#S1""W/
M6D[P7 GJ6*KO,)QV-'$^1#T3Q :;6D*]!Z]D#%CVKA.#H 7L#L\T;"FZ3FWW
MBLIU7^U;_D1_T4N[Y%9M=MNF2-TD5SQ.M+4 ,Q9K&R+GJ0F)(S M$B5$A$26
M)TT/-3L..#J7U7=\MQU:WP<>C:AF#[K:^I1,(4_7"A[' +9CA?- &RIOLI'1
MP-5RP5UWP>51T^,$%&$+>QR;;.#J'B=TWB_Q<>H&CR8PWY;T<BZN%]^GL_J
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M2-_M"EC:6H%Q[=OD"@!IR"C>/8P&"MW=SCN6>-T])!R"=/?O]2ALHO>W9=F
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MP,CYEUQ*>^>U"<1N1[X': :FG ,JN3E8G,9U]^^;(++W]'N :B2?WP\RIP!
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MK8-BBY.2T8_TCC#8^OR=8"!/ P:'"W!\&.@_;V7"F8+"64/@E86<,*O!*^>
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MT[C3-X='U5#B[V!N[XN4:F_LZBTFI.5!+/V*ZYNJ/2N]1XHC.$E&A6 A)A_
M^IPQV128W-(#-L!N]P11XX[P'!Y+@RF@"\/T>OZ9Z%XLOQ(3$RLR19(V@"+I
M@$+ZRF=A2$#>1U,\YVV<I=M$C#OL<WBX/%O 7<#CMR5^"M/\XY=/.%\A;<QO
MUA]Q>4=*$YL8.HP"T-I,08<QX$+RH(N)0D63K-S2['$X:G:@;=R9H<.#:6AU
M=(&QN^1G$VA%) F"2W+MK,P0'-? M/(9?6 Z-_&V]\=-LR&C#?:L9XOX^1[/
M8AUF ]F@Q2=<KK_^-@LDCGFN<<&GF@GYRW*Q6DVXL)H7ID$ZEFO-L0=OL38N
M)),<HA=^R\G4$.;G*;)Z\* '"?4'E'X?WO/YV?FLIG%?(1&1IAN=T-<SW"AG
MGE^<U?:I_]I\_BCS$^_0<F\", H60"GFP'$;P;'(?.:6N= $=4,QT(-7/DPJ
M:@R-[H]D?X'D.7ZHE+X?#-"/\E/=32DR5X4G<-G7='!D$"))6#,=!&K!PDV[
M_%%,8R?^?5O#N*_D.]AB7Y,*YA^F%,M>"(A8^/%+FIW70KB_+!;Y]^EL-HE.
M9F9S'3=<;V03-5$B58)L6<S%"!U<DU.878CKP=$?!%6#:Z(+%_^:\JR+12T5
M^,V=6R9ZB**>6"<G=;"V3HUL@:&]<-+8L1\$)\^2: <.V*O+U]:1?V?X/GRY
MAGGM!$O,2XI472U_RME63C(4VGY-U!Z]:>)2/4[2.*,6&Z!E(*EW84MNI3Q^
M7<S394PK"C=6ZP+$#IG$@K3UJJ0@<56K_H4)9<N<O,/!LY6:<88L-L#-X;+N
M C(7'$QT#(+'7)M"7"2GS#-RSVR"PGD,K@1E<<O\S:%22^-,4FQV^+^7-#MP
M<7^>ACB=;4[^R%G?]'Q\7,Q(Z*OJN*^_7HL&A<W!QP2"<P:J[JK><%63;<PP
MIYTN35"R*X'C9I::ER$UT5,75N@69_=SNTZK(FP=EBUS=>A9 E^4!,U]U"(:
M%;')$<KC)(U;5](&!(\C[1!]=(&M=Q\7R_5[7)[]L%@N%[]3L+B:J.#1)I*(
M+8QLO!$>G),%<@PVH$\\A2V]/0,4B#ZDI1LT':3H^[>''RCS+H!S5<WP6_A:
M2QFNCH@P<BN*(3X4UB,BZR"FK('"@Z*9E4CA0<M"DKODC+OE-8+/ )+O!4'+
M<WKO RE-;#+:E+2Y%:2VJ(A:%D/Q93;!H39!"K>ESWT0$&VG:-Q#CW8X&D#^
MX]\G>L'&6XSD8*[>XOI\.:^;_V\DQT55$44<(B?/R*066>^[8S*01YD+B*)<
M$CYXG[_5(;+;F\8]HQ@8)PV$VX7=^?'LTVSQ%?$M;@[_MN!?<$$VDX+3@K6#
M7W #H=@"R!E#5U*]G+6%_?DF9>.>5C2R0\/JHPN(72Z;ZZSI#2N<-N<8+0,?
M:H2K>83H:+58+8RTOD1O6_E'VRD:]V"C[=9VH/R[@-*6Y2"5RQJ3!L<-;<_:
MD&0810W,JNPU8Y[,[W&"_G'/.1J!YT")]Y"R7,P_U/CR%<;UK?1[=CHY5A)D
M&64MWV/@BN/ 8T'R[)CEIHE;O9V<;F*SAHFBP_70A0UZ< IX2WKU*%#1@D(C
M)!@9:W5ZB.0"6@L6B;><:/6H)HU(WZ"KFZBM'<*&U$P74/NF,TBRO+64.$JR
MY%F#48F"#TX;>W V =EX7UBVFMS#43SU.V1V$Q:V V)#O76!RX<>Y2UN+$F'
MW T&)J0:GQ@.3@@-FCZTL5B64ILQ T\0U4VHV YS@^FD@_*F3<'$;>-]PPGJ
MVDQJR/F4DGS96J_GLZNE$RX$9Q(3L<GN^CA)W<2,[; UD#ZZL%VWV)B$$(NV
M%+_89"-%,H[8,'4 80B6Q&2L;5.+>XN&;H+&HYP0[R7Q#F+'.MITNJZ%&E4^
M+Q?S>B,0SE-EQ?)HI2;W441>[VU7 H+*%+T([E1AQ0G7I"W@"9K&K9@["IB&
MTD@'N]P3$C+299FCA22Q#FE7NO862L"8HV%12&;:%!T<5B_5K.[N*- :2!]=
M['*W9C)?S'J11=K @B=)"#*\) L(/@<@S\_D&!7+I4G+P'U"QA[_-8R*MQBE
M9TN["[S<ZO_;.'OU_I E?L3Y:OH9+V**GQ>KFD5Y4RBXF"0;4"E:7?4^(E!%
M>/#*1-#!*L<=1FF:' KN2>?859Y-T-925UV \2VNPW2.^<>PG-=ZL#O-J66:
MIC5E$HJR*D(VG,(.YNIUC*Q6B&EZ'CD!N&WB]N'X^S9IX^99&T%N8(UT@;+W
M2PRK\^776V8[B&"U*@9*O5U<:2[ L:0@>^9BY%$%T>1,Z"$IXR9)&Z'H0(EW
M@9J'HB&+>]%8^EOMCR<%K=?+:3S?S$E[OZBI$@I2B YZXH?--:&X6D\"R8LB
MX () _FIJ"3X.KF8>2XX*]S9-D4UPY _;CJU$3I'T&P'&8YO15:3[(2,"160
M!3>UDC:"XSQ#\BQ*Z85(;<I/OT78;H'$X%?WC94Y.UPY@X'M"%/+?]OHX".N
MIRG,[C)PV CSNP]N-L_\"?J/.=Q<9%&8K-.MG*P),>/J@;>A,-1ZJT/V6FZY
M)."4AIO?+W7RD6'6J4#<7#<51(; 602KO4U<I9)-P^;4KKJ_!D?(;N.K]]%
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MU8$EK=<\KS;=W1<BO:ZJ3Q0&8]89>/">=@2?(1:IP1N,EL>4@VJ20'^,H-T
M=U)I\D%D/_Z5CG7]/,;*O<6AD8AGQ EWQ8)*=5BO(+F%HF5 YSW>CRVV6K'=
MWK8;8DXF-]Y Q%W8GPLNKL*<)#,R410(76=_,T<NJ3/UCF?FT+ALHM-MS,X=
M.G;#SDFEP@^1],ANU#W2[R'>28,ZVPA9*8J,B^+@70Z 6@?/10J2[^(:/?F2
MW?!P,@GPX03:@0G9M.3_NIC7:VW#>M,96*5UA7/BIA0=,MC(*5R(*H+GJ@Y
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MO0)CI-*.H66IR94;WR:MRVQX:]@-I*D^T'<[<_"1HK+WN#Q[A7$]B9:8X:I
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M) -F2X@NH7&NR62;NV1T:ZWVT?]]:W6 I+LHG7G4UFZD]/7BSQN[FE7*2H@
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M >>)(G1"+,7H;\/Z/F,J*&9]2( NDLCJ:G2JII^,-XRY5#1K$D7L2%\O >W
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M+_[^ <MB>:N_^F9:25%1(OH(V1H.2EL&/A@#Q6%(3";E;)/ M#5CO1Q=-5L
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MM62BB"81R2Y$#EL@,!8_<#^=C<P2?IQ=7OXZF_\SS/,%\X*VD2C HC*@F Q
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MIXSREC_H_K&UJU5K.CO!W)\.S$>GVQ'XJ?MN^2=V_(>K>?H2%G3J,1]KP_4
M3B620Y8)? B&3CT;@V-1T/_&9/!_QE"WPCEV.KMA5 CX]]L)Y[A<7EX_-*!
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M.,F P&QU*87\IRY5Z,]]QI@ L:\&9PW$.30LY"_2ZG>SY4,>9##))Q('!L%
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ML^BD\$8TJ;U_GJQA3_Z1PW%O_8T4C[7:-BVQ9EROYM/W*TE?]\ZYB)YD@R6
M4%*0X'SM:*LDD#!3$NAX3DT>5N]"Y+ =B$:.U9YTNSMR_35RI_BYMD)JA-RS
MK[6C^+]6RGY?/LPGL_F=L^(E$3E97J@0)#<4&5BGR9=*:&LG<0U%^\!*SN1G
M-4E3[D?N,"78)X+FWO4]4HM\G\_?PF2ZJ(\=<7&1<TBR9N>\B'4DMU*URQ '
M7SB/=!*YX!HUA.M,XS UVB>)X'TU.U)S_/&FJO@=+BMOE;575_AI=H[+Y>5*
MS%4-+Z_FM4QA]4=^(;F*L@@+3&9;F]PH\,Q92(*S+*-SPA[)Q]B+_F&*PT\$
M[NT1,=*ML+T\YP*=S]Y% ]HJ ZK8##Z7#)(5$FV4TK=IJ=>5P$Y@;CB]?-1@
M[D&G^^>%9\MP>?1RNS;%=,<HE1M+(5SB2MM<#$55LCJCDET7M6L;>999&"V:
M%-Z,MA!.*.5,L0R$#0R4*))LN^=@'$>6BM;!-+EY_3<MA-L%7X<5PNVBN!%<
M?]V_N#[_1G9B-G];_]JF9YF)2<>2(V3A2'32:@C1(42&*4E$6[1I@<2?4G9*
MY7$[H>+9\J9#531VS*WK)A23T9#0P-0YZ"I&12Y)*:"+M-:A%,B:O*7H0-N8
MJIT.1L,N6-M#-0.B+=4AF_,?%W^>7TB;B@^,D?6OW>NC8>"%C^"YX<K8R(K:
MXETL-FA:8/KE\^S[?ZQ7K&"RFS]4'-D[.+K]U!'#9!]%S@Z2ZB@2B+_.YCCY
MO(J4-I-6C6:8M0:?B@"EHX,HF02TT3C%N0ZE24[E$25CJE[K#RS]"'X4V.E6
MCR*D\K:.Z@TF(2CK:$L8YB )A]IGEIDX4H[NQ,O4#O&7^E?5"'RF=1!?&YS,
M)_'JNN==85Y:YAV@JR,/C/'@6/(0E0K>9.6Y;%D/?H^8457F]*'S[07A^RM@
MA,_BSU*Z^GIU6?.[J\Q0C:CG^*5RNFFWLT=.J\NJA^:T=J:\IYS6Z_^YFBQ_
MW*05BM2,%ZX $](QYKV!&)$ )8,B;&@7VMR9WR?C4-NR17CO9LL[;Z5E;7D8
M*R769%"E( 3,1)5!DY,NRK4)QGY&V+ VYP L/#0NO6I@E*_5.VS8O1MQ=%_[
M"&:G85N.AX KAF,1 A*O\9>NAX]B"61MGN#(@_)M@I=^C<^M7]A!N/5:]$$?
M!Z$MX\;I&I?$6IYEP2L*3FS*B05,+&&3].2!=(_+=.V I*>SX^WU=ZJ6;?_[
MP1T6/X)M:WE;^ "2J(WA(41PA9LZ<-*"<UQ#U)'7HA^A8I,*@'Z-VRY;XB*B
ME 3Z!%G4QRQ%T1EO!(?,??0\TNJFM&!Y%R)'9;9VP<A#L]5,,R/(%:S&JM9L
MWK6\;MOAK*X'L!0M51TLG+6OQ1X(D0>$(IWV&%C0;5Y2/$O5L+AJ!X:'AV5O
MFAD!S![PL,X3.XLY.5)_BG7>C.<%O#$2F [,.)6L<0T-]P-J!KXB[D_;#^=B
M'"SZ$>#GSJ[[- _3Q>6U8O+_N5HLJ]365P7!84Q%&N"Y[C>C&'CD%JS2-FC,
M5MLF75:[D3>& _$@'#Q]+O:EE'%![1TN:U_G<%FK;=],O^,U7YNBVS5_RDO&
M(L^0+&>@D@X0K0RUB[1BTN>@VL36NQ(Z[)U.4_CUKZAQ 7'+-=BC;18SSXYI
M!AA4 J5JFU]5&.1B$_HHD*+DQC#L0.:P+PN;@K!O)8T+@IN]1%OM95A\^?5R
M]L_?,7_&#RO!WW24B;59?NV^6OT4VE3@LBH0) ]*%$Q.-&F]LB.=PSX(; K"
MWM4T+A0^%7*M&?,)T7ER,!P/ILZSK(UZ60*;O>',<R]5:_P]3^&P#_F:(J]'
MU8RBBJ=CH/_VIF+ .Q^$M0XL&@M*Z]5,W5KZY!R6^OY*-)EOO2NAP_J!1\N?
M--7?"*SB1TR78;&8E,EU[=VO).H./+^\FE<U7;^ZHE/B?:F3NC9I4@K4BK%,
M@I=:U6[J$;S&!"PF[E)AB<4F3F0+9DXB3[@G_!Z58@^,A1'LA_/E+/WCR^R2
MU+JX/NB(R<NK/)E^_E ?B)/:E]?E6*M+Q=F[&<E@NB0J:,7/FP8T%]Y2D,B<
M ZE354.)X**0$*.D@U!:9W.3FY5^R!^ZD'QH&#[*H1\=$WOOA&\K]L^78;[L
MKX?K$U9G(^0+B2%SZ2Q(BQ%4KJV6ZE!O#"4Z1]]AN4FU5A?BAJYS'QF6>]?G
MOX_-9BBCX%A 1AGJB,8,T:(&;I*SHB@1L$EM\Q%M=K.4V.AP/@ F#K39KZ=W
M6U[T5RWT.LRGQ-*"A'S^A92Y1TW0HR4.K?QYGJ:^ZGL>?,@-KJ3)$BT2KG+%
M%68$Q[,'"@RE#IY.XS9]1I\BZ.!K\0?KWBGB+3)%'P5H0:!5DLCR6 H@83?G
M@-RUF0_V)$4#7U[V@8A'-^.]2'^4A8:/6-NW7OJ)A?HV(RTKH9^"#O,Q.Q\3
M),L<*%X=>C0:F,@<E91&Y2;5P*V,R6UU[<-/>!$6DU3[_4PNK^IE_?VJVJ!B
MSDXA",5TG<P>(9C((&1R%CV=HCDT;A^R$[TC-42[H.GINNAVFCL),[5_\?-3
M*_5MJ)J6-3^%K:""]9S+>D,C027C:NK!@XA.<T=:3J?M]M26=M,TN9Q<;^.;
MT9Z"G/12%&A?'WY']! =IU.>:Z&CMLF7)JFX;N2-U [M@I6?.40]Z&445WE;
MK>H%(Y.=7,F05K486G,(C%' R+PI+G!C>9/+XJW4C M-?2C^)]C:70>C@-+?
M<?+Y"YW$9[1H^(SOKNKE]ONR8FGQ_FJY6(9I355<LU=TX"E)01!('!0KQ!XO
M 5@L)AK' V_S&'8G*@>N"VP/O78Z&P4DWTS3=4.6</ER]O7K;'K-V/TLV6;/
M8?X0?M0?/IO/P_3S=;?8B\*1BV0R:.E)NB)G<$524"VR\#DSQG*3$M;#21^X
MGK ]>(^LW0$O!<COOKAF[N]?)NG+R]G597Y!(OUV-4]?*F]_DH\]_S3'L+B:
M_UBEB?_ Y9=9OO#6>LE$A"A%G<_.Z"NM*0ISY/#8H#-*_I/X8>\/'[B6L!T
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M97)T:69I8V%T:2YH=&U02P$"% ,4    " !\@)Y2^8S,Q  &  "U)P  '@
M            @ '##P  83(P,C$Q<65X,S(Q8V5O8V5R=&EF:6-A=&DN:'1M
M4$L! A0#%     @ ?(">4H-J:]'W!0  B2<  !X              ( !_Q4
M &$R,#(Q,7%E>#,R,F-F;V-E<G1I9FEC871I+FAT;5!+ 0(4 Q0    ( 'R
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M+3(P,C$P-# T7V1E9BYX;6Q02P$"% ,4    " !\@)Y2@,I\54^/  ""H0
M$P              @ &1^ , :FYJ+3(P,C$P-# T7V<Q+FIP9U!+ 0(4 Q0
M   ( 'R GE)$W?<WS'L  %J,   3              "  1&(! !J;FHM,C R
M,3 T,#1?9S(N:G!G4$L! A0#%     @ ?(">4O+29ZMY/   U5@  !,
M         ( !#@0% &IN:BTR,#(Q,#0P-%]G,RYJ<&=02P$"% ,4    " !\
M@)Y2YP;3 P9!  #670  $P              @ &X0 4 :FYJ+3(P,C$P-# T
M7V<T+FIP9U!+ 0(4 Q0    ( 'R GE([;.UZ;#X  $]8   3
M  "  >^!!0!J;FHM,C R,3 T,#1?9S4N:G!G4$L! A0#%     @ ?(">4A=U
MA1WN70  W7(  !,              ( !C, % &IN:BTR,#(Q,#0P-%]G-BYJ
M<&=02P$"% ,4    " !\@)Y2;V9HJJ5O  "BA   $P              @ &K
M'@8 :FYJ+3(P,C$P-# T7V<W+FIP9U!+ 0(4 Q0    ( 'R GE+P'U!L_U8
M .IN   3              "  8&.!@!J;FHM,C R,3 T,#1?9S@N:G!G4$L!
M A0#%     @ ?(">4L4QE*C2+@$ E#X, !0              ( !L>4& &IN
M:BTR,#(Q,#0P-%]L86(N>&UL4$L! A0#%     @ ?(">4F%T!2J8JP  -I,'
M !0              ( !M10( &IN:BTR,#(Q,#0P-%]P<F4N>&UL4$L%!@
0   2 !( O 0  '_ "     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
